


(b) (4)

FULLY REDACTED PAGES WITHHELD IN FULL FOLLOWING THIS PAGE. SEE BATES-NUMBERS ON BOTTOM OF PAGES TO IDENTIFY RANGE OF PAGES WITHHELD IN FULL.


FDACDER\_SAR\_0017110

Sarepta, Inc  
 4658-us-201 & 4658-us-202  
 Week 168 Analysis

Figure 14.2.5.2.2.1  
 LS Mean +/- SEM Change from Baseline in 6 Minute Walk Test by Week of Assessment  
 ITT Population



(b) (4)



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.1.3.1  
 Summary of Eteplirsen Exposure  
 Safety Population

		Placebo to Eteplirsen (N=4)	Eteplirsen		Eteplirsen for 185 Weeks (N=8)
			30 mg/kg (N=4)	50 mg/kg (N=4)	
Total Number of Infusions Received During the Eteplirsen Treatment Period	n	4	4	4	8
	Mean	159.3	181.5	184.0	182.8
	Median	160.5	181.0	184.5	183.0
	SD	2.87	2.65	1.41	2.38
	Min, Max	155, 161	179, 185	182, 185	179, 185
Total Volume Administered (mL) During the Eteplirsen Treatment Period	n	4	4	4	8
	Mean	23098.26	26660.26	27245.21	26952.74
	Median	23217.40	26658.55	27232.75	26992.15
	SD	500.289	192.292	126.483	347.083
	Min, Max	22398.5, 23559.8	26444.2, 26879.7	27104.6, 27410.8	26444.2, 27410.8
Total Eteplirsen Drug Exposure (mg) During 185 Week Treatment Period <sup>1</sup>	n	4	4	4	8
	Mean	229390.8	254016.2	342613.8	298315.0
	Median	210851.7	267889.9	314222.5	306506.0
	SD	45404.69	71098.74	97408.58	92063.21
	Min, Max	200080, 295780	166995, 313290	259315, 482695	166995, 482695

<sup>1</sup>Total Eteplirsen drug exposure is calculated by adding up the dose received at each visit. For each visit, if the actual amount of drug in the IV bag is not available then dose received in mg is calculated as the planned dose multiplied by the subject's weight recorded at the previous visit. If a subject did not receive the full infusion, the amount received at that visit was calculated by multiplying the fraction of the infusion that was received by the amount of drug in the IV bag (or planned dose when amount of drug in the IV bag is not available (201 study)).

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_exp.sas, Date/time of run: 06APR2015: 9:23

Reference listing: L.16.2.5.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.1.3.2  
 Summary of Eteplirsen Exposure  
 Active Dosing Only  
 Safety Population

		Eteplirsen		
		30 mg/kg (N=6)	50 mg/kg (N=6)	Eteplirsen (N=12)
Total Number of Infusions Received During the Eteplirsen Treatment Period	n	6	6	12
	Mean	174.5	175.3	174.9
	Median	179.5	183.0	181.0
	SD	11.04	13.60	11.82
	Min, Max	160, 185	155, 185	155, 185
Total Volume Administered (mL) During the Eteplirsen Treatment Period	n	6	6	12
	Mean	25512.64	25823.18	25667.91
	Median	26506.53	27160.70	26658.55
	SD	1785.224	2235.542	1935.616
	Min, Max	23117.8, 26879.7	22398.5, 27410.8	22398.5, 27410.8
Total Eteplirsen Drug Exposure (mg) During the Eteplirsen Treatment Period <sup>1</sup>	n	6	6	12
	Mean	239622.8	311057.7	275340.3
	Median	223252.4	298962.5	277547.5
	SD	59803.87	94858.78	84305.88
	Min, Max	166995, 313290	200111, 482695	166995, 482695

Note: Two subjects under each treatment were exposed to Eteplirsen for 161 weeks and four subjects were exposed to Eteplirsen for 185 weeks.  
<sup>1</sup>Total Eteplirsen drug exposure is calculated by adding up the dose received at each visit. For each visit, if the actual amount of drug in the IV bag is not available then dose received in mg is calculated as the planned dose multiplied by the subject's weight recorded at the previous visit. If a subject did not receive the full infusion, the amount received at that visit was calculated by multiplying the fraction of the infusion that was received by the amount of drug in the IV bag (or planned dose when amount of drug in the IV bag is not available (201 study)).

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_exp2.sas, Date/time of run: 06APR2015: 9:23

Reference listing: L.1b.2.5.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsen		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 185 Weeks (N=8)
At Least One TEAE		2 (100.0%)	2 (100.0%)	4 (100.0%)	4 (100.0%)	4 (100.0%)	8 (100.0%)
Injury, poisoning and procedural complications	Overall	2 (100.0%)	2 (100.0%)	4 (100.0%)	4 (100.0%)	4 (100.0%)	8 (100.0%)
	Procedural pain	2 (100.0%)	2 (100.0%)	4 (100.0%)	3 ( 75.0%)	4 (100.0%)	7 ( 87.5%)
	Contusion	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
	Arthropod bite	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	1 ( 25.0%)	0	1 ( 12.5%)
	Excoriation	0	1 ( 50.0%)	1 ( 25.0%)	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
	Joint injury	0	1 ( 50.0%)	1 ( 25.0%)	2 ( 50.0%)	0	2 ( 25.0%)
	Foot fracture	1 ( 50.0%)	0	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Incision site haemorrhage	1 ( 50.0%)	0	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Muscle strain	0	0	0	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
	Arthropod sting	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Back injury	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Burns first degree	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Fall	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Femur fracture	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Head injury	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Incision site pain	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Joint sprain	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Laceration	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Limb injury	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Lip injury	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Lower limb fracture	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Nail injury	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Post procedural haematoma	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsen		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 185 Weeks (N=8)
	Radius fracture	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Thermal burn	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
Nervous system disorders	Overall	2 (100.0%)	2 (100.0%)	4 (100.0%)	4 (100.0%)	4 (100.0%)	8 (100.0%)
	Headache	2 (100.0%)	2 (100.0%)	4 (100.0%)	2 ( 50.0%)	3 ( 75.0%)	5 ( 62.5%)
	Balance disorder	0	0	0	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)
	Psychomotor hyperactivity	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Somnolence	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
Respiratory, thoracic and mediastinal disorders	Overall	2 (100.0%)	2 (100.0%)	4 (100.0%)	4 (100.0%)	4 (100.0%)	8 (100.0%)
	Oropharyngeal pain	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)	3 ( 75.0%)	2 ( 50.0%)	5 ( 62.5%)
	Nasal congestion	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	3 ( 75.0%)	1 ( 25.0%)	4 ( 50.0%)
	Cough	0	2 (100.0%)	2 ( 50.0%)	1 ( 25.0%)	2 ( 50.0%)	3 ( 37.5%)
	Epistaxis	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	0	0	0
	Pharyngeal erythema	0	0	0	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
	Rhinorrhoea	0	1 ( 50.0%)	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Upper respiratory tract congestion	0	0	0	2 ( 50.0%)	0	2 ( 25.0%)
	Productive cough	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Respiratory disorder	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Sinus congestion	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Sneezing	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Upper-airway cough syndrome	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsen		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 185 Weeks (N=8)
General disorders and administration site conditions	Overall	2 (100.0%)	1 ( 50.0%)	3 ( 75.0%)	4 (100.0%)	4 (100.0%)	8 (100.0%)
	Catheter site pain	0	0	0	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)
	Infusion site extravasation	1 ( 50.0%)	0	1 ( 25.0%)	1 ( 25.0%)	2 ( 50.0%)	3 ( 37.5%)
	Device occlusion	0	0	0	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
	Infusion site haematoma	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	0	0	0
	Oedema peripheral	0	0	0	2 ( 50.0%)	0	2 ( 25.0%)
	Pyrexia	0	1 ( 50.0%)	1 ( 25.0%)	1 ( 25.0%)	0	1 ( 12.5%)
	Thrombosis in device	0	0	0	2 ( 50.0%)	0	2 ( 25.0%)
	Catheter site haematoma	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Catheter site inflammation	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Catheter site related reaction	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Chest pain	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Influenza like illness	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Infusion site pain	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Infusion site rash	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Injection site pain	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Irritability	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Malaise	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Non-cardiac chest pain	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsen		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 185 Weeks (N=8)
	Pain	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
Musculoskeletal and connective tissue disorders	Overall	2 (100.0%)	2 (100.0%)	4 (100.0%)	3 ( 75.0%)	4 (100.0%)	7 ( 87.5%)
	Back pain	2 (100.0%)	1 ( 50.0%)	3 ( 75.0%)	3 ( 75.0%)	1 ( 25.0%)	4 ( 50.0%)
	Pain in extremity	1 ( 50.0%)	0	1 ( 25.0%)	2 ( 50.0%)	3 ( 75.0%)	5 ( 62.5%)
	Arthralgia	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	1 ( 25.0%)	2 ( 50.0%)	3 ( 37.5%)
	Muscle spasms	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Myalgia	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Muscular weakness	0	2 (100.0%)	2 ( 50.0%)	0	0	0
	Musculoskeletal pain	0	1 ( 50.0%)	1 ( 25.0%)	1 ( 25.0%)	0	1 ( 12.5%)
	Bone pain	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Neck pain	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Tendon disorder	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Tendonitis	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
Gastrointestinal disorders	Overall	2 (100.0%)	2 (100.0%)	4 (100.0%)	3 ( 75.0%)	3 ( 75.0%)	6 ( 75.0%)
	Vomiting	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)
	Abdominal pain upper	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	0	2 ( 50.0%)	2 ( 25.0%)
	Diarrhoea	0	1 ( 50.0%)	1 ( 25.0%)	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
	Dyspepsia	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	1 ( 25.0%)	0	1 ( 12.5%)
	Nausea	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Abdominal pain	0	1 ( 50.0%)	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Abdominal discomfort	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsen		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 185 Weeks (N=8)
	Dental caries	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Dysphagia	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Flatulence	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Food poisoning	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Lip swelling	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Oral pain	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Retained deciduous tooth	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Tooth impacted	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Toothache	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
Infections and infestations	Overall	2 (100.0%)	2 (100.0%)	4 (100.0%)	2 ( 50.0%)	4 (100.0%)	6 ( 75.0%)
	Nasopharyngitis	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)
	Upper respiratory tract infection	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	1 ( 25.0%)	3 ( 75.0%)	4 ( 50.0%)
	Hordeolum	0	1 ( 50.0%)	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Influenza	0	1 ( 50.0%)	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Gastroenteritis viral	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Incision site infection	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Pharyngitis streptococcal	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Rhinitis	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Tinea pedis	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Viral infection	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsen		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 185 Weeks (N=8)
	Viral upper respiratory tract infection	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
Investigations	Overall	2 (100.0%)	2 (100.0%)	4 (100.0%)	2 ( 50.0%)	4 (100.0%)	6 ( 75.0%)
	C-reactive protein increased	2 (100.0%)	0	2 ( 50.0%)	0	2 ( 50.0%)	2 ( 25.0%)
	Activated partial thromboplastin time prolonged	0	1 ( 50.0%)	1 ( 25.0%)	0	2 ( 50.0%)	2 ( 25.0%)
	Blood creatine phosphokinase increased	0	0	0	2 ( 50.0%)	0	2 ( 25.0%)
	Blood glucose increased	1 ( 50.0%)	0	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Blood creatinine increased	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Blood urea increased	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Lymphocyte count decreased	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Neutrophil count increased	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Red blood cells urine positive	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	White blood cell count decreased	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Wound healing normal	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsen		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 185 Weeks (N=8)
Skin and subcutaneous tissue disorders	Overall	2 (100.0%)	2 (100.0%)	4 (100.0%)	3 ( 75.0%)	3 ( 75.0%)	6 ( 75.0%)
	Dermatitis contact	0	0	0	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
	Rash	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)	1 ( 25.0%)	0	1 ( 12.5%)
	Ecchymosis	0	1 ( 50.0%)	1 ( 25.0%)	1 ( 25.0%)	0	1 ( 12.5%)
	Erythema	0	0	0	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
	Intertrigo	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Keloid scar	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Nail discolouration	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Nail dystrophy	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Papule	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Petechiae	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Pruritus	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Rash papular	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Skin erosion	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
Urticaria	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)	
Urticaria thermal	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)	
Metabolism and nutrition disorders	Overall	1 ( 50.0%)	0	1 ( 25.0%)	3 ( 75.0%)	2 ( 50.0%)	5 ( 62.5%)
	Hypokalaemia	0	0	0	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)
	Obesity	0	0	0	2 ( 50.0%)	0	2 ( 25.0%)
	Vitamin D deficiency	0	0	0	2 ( 50.0%)	0	2 ( 25.0%)
	Dehydration	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsen		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 185 Weeks (N=8)
Renal and urinary disorders	Overall	0	1 ( 50.0%)	1 ( 25.0%)	2 ( 50.0%)	3 ( 75.0%)	5 ( 62.5%)
	Proteinuria	0	1 ( 50.0%)	1 ( 25.0%)	2 ( 50.0%)	3 ( 75.0%)	5 ( 62.5%)
	Glycosuria	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Polyuria	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
Ear and labyrinth disorders	Overall	0	0	0	0	2 ( 50.0%)	2 ( 25.0%)
	Motion sickness	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Tympanic membrane disorder	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
Eye disorders	Overall	1 ( 50.0%)	0	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Cataract	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
	Cataract subcapsular	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Conjunctivitis	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Hypermetropia	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
Psychiatric disorders	Overall	1 ( 50.0%)	0	1 ( 25.0%)	0	1 ( 25.0%)	1 ( 12.5%)
	Anxiety disorder	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Insomnia	0	0	0	0	1 ( 25.0%)	1 ( 12.5%)
Reproductive system and breast disorders	Overall	0	0	0	2 ( 50.0%)	0	2 ( 25.0%)
	Pelvic pain	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Testicular pain	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1.A  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo to			Eteplirsén		
		30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsén for 161 Weeks (N=4)	30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsén for 185 Weeks (N=8)
Vascular disorders	Overall	0	0	0	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
	Haematoma	0	0	0	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
Cardiac disorders	Overall	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
	Tachycardia	0	0	0	1 ( 25.0%)	0	1 ( 12.5%)
Congenital, familial and genetic disorders	Overall	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
	Cryptorchism	1 ( 50.0%)	0	1 ( 25.0%)	0	0	0
Endocrine disorders	Overall	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Growth hormone deficiency	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
Immune system disorders	Overall	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Hypersensitivity	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Overall	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0
	Skin papilloma	0	1 ( 50.0%)	1 ( 25.0%)	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae2.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsen		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
At Least One TEAE		4 (100.0%)	6 (100.0%)	6 (100.0%)	12 (100.0%)
Injury, poisoning and procedural complications	Overall	4 (100.0%)	6 (100.0%)	6 (100.0%)	12 (100.0%)
	Procedural pain	3 ( 75.0%)	5 ( 83.3%)	6 (100.0%)	11 ( 91.7%)
	Contusion	0	3 ( 50.0%)	3 ( 50.0%)	6 ( 50.0%)
	Arthropod bite	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
	Excoriation	0	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
	Joint injury	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
	Fall	1 ( 25.0%)	1 ( 16.7%)	0	1 ( 8.3%)
	Foot fracture	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Incision site haemorrhage	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Incision site pain	1 ( 25.0%)	1 ( 16.7%)	0	1 ( 8.3%)
	Muscle strain	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Arthropod sting	0	1 ( 16.7%)	0	1 ( 8.3%)
	Back injury	0	1 ( 16.7%)	0	1 ( 8.3%)
	Burns first degree	0	0	1 ( 16.7%)	1 ( 8.3%)
	Femur fracture	0	1 ( 16.7%)	0	1 ( 8.3%)
	Head injury	0	0	1 ( 16.7%)	1 ( 8.3%)
	Joint sprain	0	0	1 ( 16.7%)	1 ( 8.3%)
	Laceration	0	1 ( 16.7%)	0	1 ( 8.3%)
	Limb injury	0	1 ( 16.7%)	0	1 ( 8.3%)
	Lip injury	0	0	1 ( 16.7%)	1 ( 8.3%)
	Lower limb fracture	0	1 ( 16.7%)	0	1 ( 8.3%)
	Nail injury	0	1 ( 16.7%)	0	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsen		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
	Post procedural haematoma	0	0	1 ( 16.7%)	1 ( 8.3%)
	Radius fracture	0	1 ( 16.7%)	0	1 ( 8.3%)
	Thermal burn	0	0	1 ( 16.7%)	1 ( 8.3%)
	Wound dehiscence	1 ( 25.0%)	0	0	0
Nervous system disorders	Overall	2 ( 50.0%)	6 (100.0%)	6 (100.0%)	12 (100.0%)
	Headache	2 ( 50.0%)	4 ( 66.7%)	5 ( 83.3%)	9 ( 75.0%)
	Balance disorder	0	2 ( 33.3%)	2 ( 33.3%)	4 ( 33.3%)
	Dizziness	1 ( 25.0%)	0	0	0
	Psychomotor hyperactivity	0	0	1 ( 16.7%)	1 ( 8.3%)
	Somnolence	0	1 ( 16.7%)	0	1 ( 8.3%)
Respiratory, thoracic and mediastinal disorders	Overall	3 ( 75.0%)	6 (100.0%)	6 (100.0%)	12 (100.0%)
	Oropharyngeal pain	3 ( 75.0%)	4 ( 66.7%)	4 ( 66.7%)	8 ( 66.7%)
	Nasal congestion	1 ( 25.0%)	4 ( 66.7%)	2 ( 33.3%)	6 ( 50.0%)
	Cough	2 ( 50.0%)	1 ( 16.7%)	4 ( 66.7%)	5 ( 41.7%)
	Epistaxis	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Pharyngeal erythema	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Rhinorrhoea	0	0	2 ( 33.3%)	2 ( 16.7%)
	Upper respiratory tract congestion	0	2 ( 33.3%)	0	2 ( 16.7%)
	Productive cough	0	0	1 ( 16.7%)	1 ( 8.3%)
	Respiratory disorder	0	1 ( 16.7%)	0	1 ( 8.3%)
	Sinus congestion	0	1 ( 16.7%)	0	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsén		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsén (N=12)
	Sneezing	0	1 ( 16.7%)	0	1 ( 8.3%)
	Upper-airway cough syndrome	0	0	1 ( 16.7%)	1 ( 8.3%)
General disorders and administration site conditions	Overall	2 ( 50.0%)	6 (100.0%)	5 ( 83.3%)	11 ( 91.7%)
	Catheter site pain	0	2 ( 33.3%)	2 ( 33.3%)	4 ( 33.3%)
	Infusion site extravasation	0	2 ( 33.3%)	2 ( 33.3%)	4 ( 33.3%)
	Pyrexia	2 ( 50.0%)	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Device occlusion	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Infusion site haematoma	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Oedema peripheral	0	2 ( 33.3%)	0	2 ( 16.7%)
	Thrombosis in device	0	2 ( 33.3%)	0	2 ( 16.7%)
	Catheter site haematoma	0	0	1 ( 16.7%)	1 ( 8.3%)
	Catheter site inflammation	0	0	1 ( 16.7%)	1 ( 8.3%)
	Catheter site related reaction	0	0	1 ( 16.7%)	1 ( 8.3%)
	Chest pain	0	1 ( 16.7%)	0	1 ( 8.3%)
	Influenza like illness	0	1 ( 16.7%)	0	1 ( 8.3%)
	Infusion site pain	0	0	1 ( 16.7%)	1 ( 8.3%)
	Infusion site rash	0	1 ( 16.7%)	0	1 ( 8.3%)
	Injection site pain	0	0	1 ( 16.7%)	1 ( 8.3%)
	Irritability	0	1 ( 16.7%)	0	1 ( 8.3%)
	Malaise	0	0	1 ( 16.7%)	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsien		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsien (N=12)
Musculoskeletal and connective tissue disorders	Non-cardiac chest pain	0	1 ( 16.7%)	0	1 ( 8.3%)
	Pain	0	0	1 ( 16.7%)	1 ( 8.3%)
	Overall	4 (100.0%)	5 ( 83.3%)	6 (100.0%)	11 ( 91.7%)
	Pain in extremity	4 (100.0%)	3 ( 50.0%)	3 ( 50.0%)	6 ( 50.0%)
	Back pain	2 ( 50.0%)	5 ( 83.3%)	2 ( 33.3%)	7 ( 58.3%)
	Arthralgia	0	2 ( 33.3%)	3 ( 50.0%)	5 ( 41.7%)
	Muscle spasms	0	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
	Myalgia	0	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
	Muscular weakness	0	0	2 ( 33.3%)	2 ( 16.7%)
	Musculoskeletal pain	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Bone pain	0	1 ( 16.7%)	0	1 ( 8.3%)
	Neck pain	0	0	1 ( 16.7%)	1 ( 8.3%)
	Tendon disorder	0	0	1 ( 16.7%)	1 ( 8.3%)
	Tendonitis	0	0	1 ( 16.7%)	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsen		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Gastrointestinal disorders	Overall	1 ( 25.0%)	5 ( 83.3%)	5 ( 83.3%)	10 ( 83.3%)
	Vomiting	0	3 ( 50.0%)	3 ( 50.0%)	6 ( 50.0%)
	Abdominal pain upper	0	1 ( 16.7%)	3 ( 50.0%)	4 ( 33.3%)
	Abdominal pain	1 ( 25.0%)	0	2 ( 33.3%)	2 ( 16.7%)
	Diarrhoea	0	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
	Dyspepsia	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
	Nausea	1 ( 25.0%)	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
	Abdominal discomfort	0	1 ( 16.7%)	0	1 ( 8.3%)
	Dental caries	0	1 ( 16.7%)	0	1 ( 8.3%)
	Dysphagia	0	1 ( 16.7%)	0	1 ( 8.3%)
	Flatulence	0	1 ( 16.7%)	0	1 ( 8.3%)
	Food poisoning	0	0	1 ( 16.7%)	1 ( 8.3%)
	Lip swelling	0	0	1 ( 16.7%)	1 ( 8.3%)
	Oral pain	0	1 ( 16.7%)	0	1 ( 8.3%)
	Retained deciduous tooth	0	1 ( 16.7%)	0	1 ( 8.3%)
	Tooth impacted	0	0	1 ( 16.7%)	1 ( 8.3%)
	Toothache	0	1 ( 16.7%)	0	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsien		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsien (N=12)
Infections and infestations	Overall	3 ( 75.0%)	4 ( 66.7%)	6 (100.0%)	10 ( 83.3%)
	Nasopharyngitis	1 ( 25.0%)	3 ( 50.0%)	4 ( 66.7%)	7 ( 58.3%)
	Upper respiratory tract infection	0	2 ( 33.3%)	4 ( 66.7%)	6 ( 50.0%)
	Hordeolum	0	0	2 ( 33.3%)	2 ( 16.7%)
	Influenza	0	0	2 ( 33.3%)	2 ( 16.7%)
	Rhinitis	1 ( 25.0%)	0	1 ( 16.7%)	1 ( 8.3%)
	Enterobiasis	1 ( 25.0%)	0	0	0
	Gastroenteritis viral	0	0	1 ( 16.7%)	1 ( 8.3%)
	Incision site infection	0	0	1 ( 16.7%)	1 ( 8.3%)
	Pharyngitis streptococcal	0	1 ( 16.7%)	0	1 ( 8.3%)
	Soft tissue infection	1 ( 25.0%)	0	0	0
	Tinea pedis	0	1 ( 16.7%)	0	1 ( 8.3%)
	Viral infection	0	1 ( 16.7%)	0	1 ( 8.3%)
	Viral upper respiratory tract infection	0	1 ( 16.7%)	0	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsen		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Investigations	Overall	0	4 ( 66.7%)	6 (100.0%)	10 ( 83.3%)
	C-reactive protein increased	0	2 ( 33.3%)	2 ( 33.3%)	4 ( 33.3%)
	Activated partial thromboplastin time prolonged	0	0	3 ( 50.0%)	3 ( 25.0%)
	Blood creatine phosphokinase increased	0	2 ( 33.3%)	0	2 ( 16.7%)
	Blood glucose increased	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Blood creatinine increased	0	0	1 ( 16.7%)	1 ( 8.3%)
	Blood urea increased	0	0	1 ( 16.7%)	1 ( 8.3%)
	Lymphocyte count decreased	0	0	1 ( 16.7%)	1 ( 8.3%)
	Neutrophil count increased	0	0	1 ( 16.7%)	1 ( 8.3%)
	Red blood cells urine positive	0	0	1 ( 16.7%)	1 ( 8.3%)
	White blood cell count decreased	0	0	1 ( 16.7%)	1 ( 8.3%)
	Wound healing normal	0	0	1 ( 16.7%)	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsen		All Eteplirsen (N=12)
			30 mg/kg (N=6)	50 mg/kg (N=6)	
Skin and subcutaneous tissue disorders	Overall	0	5 ( 83.3%)	5 ( 83.3%)	10 ( 83.3%)
	Dermatitis contact	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
	Rash	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
	Ecchymosis	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Erythema	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Intertrigo	0	1 ( 16.7%)	0	1 ( 8.3%)
	Keloid scar	0	0	1 ( 16.7%)	1 ( 8.3%)
	Nail discolouration	0	1 ( 16.7%)	0	1 ( 8.3%)
	Nail dystrophy	0	1 ( 16.7%)	0	1 ( 8.3%)
	Papule	0	1 ( 16.7%)	0	1 ( 8.3%)
	Petechiae	0	1 ( 16.7%)	0	1 ( 8.3%)
	Pruritus	0	0	1 ( 16.7%)	1 ( 8.3%)
	Rash papular	0	1 ( 16.7%)	0	1 ( 8.3%)
	Skin erosion	0	1 ( 16.7%)	0	1 ( 8.3%)
	Urticaria	0	0	1 ( 16.7%)	1 ( 8.3%)
	Urticaria thermal	0	1 ( 16.7%)	0	1 ( 8.3%)
Metabolism and nutrition disorders	Overall	2 ( 50.0%)	4 ( 66.7%)	2 ( 33.3%)	6 ( 50.0%)
	Hypokalaemia	2 ( 50.0%)	2 ( 33.3%)	2 ( 33.3%)	4 ( 33.3%)
	Obesity	0	2 ( 33.3%)	0	2 ( 16.7%)
	Vitamin D deficiency	0	2 ( 33.3%)	0	2 ( 16.7%)
	Dehydration	0	1 ( 16.7%)	0	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsen		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Renal and urinary disorders	Overall	1 ( 25.0%)	2 ( 33.3%)	4 ( 66.7%)	6 ( 50.0%)
	Proteinuria	1 ( 25.0%)	2 ( 33.3%)	4 ( 66.7%)	6 ( 50.0%)
	Glycosuria	0	0	1 ( 16.7%)	1 ( 8.3%)
	Polyuria	0	1 ( 16.7%)	0	1 ( 8.3%)
Vascular disorders	Overall	1 ( 25.0%)	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Haematoma	1 ( 25.0%)	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
Ear and labyrinth disorders	Overall	0	0	2 ( 33.3%)	2 ( 16.7%)
	Motion sickness	0	0	1 ( 16.7%)	1 ( 8.3%)
	Tympanic membrane disorder	0	0	1 ( 16.7%)	1 ( 8.3%)
Eye disorders	Overall	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Cataract	0	0	1 ( 16.7%)	1 ( 8.3%)
	Cataract subcapsular	0	1 ( 16.7%)	0	1 ( 8.3%)
	Conjunctivitis	0	1 ( 16.7%)	0	1 ( 8.3%)
	Hypermetropia	0	1 ( 16.7%)	0	1 ( 8.3%)
Psychiatric disorders	Overall	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Anxiety disorder	0	1 ( 16.7%)	0	1 ( 8.3%)
	Insomnia	0	0	1 ( 16.7%)	1 ( 8.3%)
Reproductive system and breast disorders	Overall	0	2 ( 33.3%)	0	2 ( 16.7%)
	Pelvic pain	0	1 ( 16.7%)	0	1 ( 8.3%)
	Testicular pain	0	1 ( 16.7%)	0	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.1  
 Summary of Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsen		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Cardiac disorders	Overall	0	1 ( 16.7%)	0	1 ( 8.3%)
	Tachycardia	0	1 ( 16.7%)	0	1 ( 8.3%)
Congenital, familial and genetic disorders	Overall	0	1 ( 16.7%)	0	1 ( 8.3%)
	Cryptorchism	0	1 ( 16.7%)	0	1 ( 8.3%)
Endocrine disorders	Overall	0	0	1 ( 16.7%)	1 ( 8.3%)
	Growth hormone deficiency	0	0	1 ( 16.7%)	1 ( 8.3%)
Immune system disorders	Overall	0	0	1 ( 16.7%)	1 ( 8.3%)
	Hypersensitivity	0	0	1 ( 16.7%)	1 ( 8.3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Overall	0	0	1 ( 16.7%)	1 ( 8.3%)
	Skin papilloma	0	0	1 ( 16.7%)	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.7.2



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.2  
 Summary of Treatment Related Treatment Emergent Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	Eteplirsen		
			30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
At Least One Treatment Related TEAE		1 ( 25.0%)	3 ( 50.0%)	3 ( 50.0%)	6 ( 50.0%)
General disorders and administration site conditions	Overall	0	2 ( 33.3%)	0	2 ( 16.7%)
	Thrombosis in device	0	2 ( 33.3%)	0	2 ( 16.7%)
	Device occlusion	0	1 ( 16.7%)	0	1 ( 8.3%)
Renal and urinary disorders	Overall	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Proteinuria	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
Gastrointestinal disorders	Overall	1 ( 25.0%)	0	0	0
	Nausea	1 ( 25.0%)	0	0	0
Investigations	Overall	0	0	1 ( 16.7%)	1 ( 8.3%)
	White blood cell count decreased	0	0	1 ( 16.7%)	1 ( 8.3%)
Skin and subcutaneous tissue disorders	Overall	0	0	1 ( 16.7%)	1 ( 8.3%)
	Erythema	0	0	1 ( 16.7%)	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen				
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)		
At Least One TEAE	Overall		4 (100.0%)	6 (100.0%)	6 (100.0%)	12 (100.0%)		
		Mild	3 ( 75.0%)	0	2 ( 33.3%)	2 ( 16.7%)		
		Moderate	1 ( 25.0%)	4 ( 66.7%)	4 ( 66.7%)	8 ( 66.7%)		
		Severe	0	2 ( 33.3%)	0	2 ( 16.7%)		
Injury, poisoning and procedural complications	Overall		4 (100.0%)	6 (100.0%)	6 (100.0%)	12 (100.0%)		
		Procedural pain	Mild	2 ( 50.0%)	4 ( 66.7%)	5 ( 83.3%)	9 ( 75.0%)	
			Moderate	1 ( 25.0%)	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)	
			Severe	0	0	0	0	
			Contusion	Mild	0	2 ( 33.3%)	2 ( 33.3%)	4 ( 33.3%)
				Moderate	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
				Severe	0	0	0	0
			Arthropod bite	Mild	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
				Moderate	0	0	0	0
				Severe	0	0	0	0
			Excoriation	Mild	0	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
				Moderate	0	0	0	0
				Severe	0	0	0	0
			Joint injury	Mild	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
				Moderate	0	0	0	0
				Severe	0	0	0	0
			Fall	Mild	1 ( 25.0%)	1 ( 16.7%)	0	1 ( 8.3%)
				Moderate	0	0	0	0
				Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.1.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Foot fracture		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Incision site haemorrhage		Mild	0	0	0	0
		Moderate	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Severe	0	0	0	0
Incision site pain		Mild	1 ( 25.0%)	0	0	0
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Muscle strain		Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Arthropod sting		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Back injury		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Burns first degree		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Femur fracture		Mild	0	0	0	0
		Moderate	0	0	0	0
		Severe	0	1 ( 16.7%)	0	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesv.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Head injury		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Joint sprain		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Laceration		Mild	0	0	0	0
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Limb injury		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Lip injury		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Lower limb fracture		Mild	0	0	0	0
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Nail injury		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Post procedural haematoma		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
	Radius fracture	Mild	0	0	0	0
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
	Thermal burn	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Wound dehiscence	Mild	1 ( 25.0%)	0	0	0
		Moderate	0	0	0	0
		Severe	0	0	0	0
Nervous system disorders	Overall		2 ( 50.0%)	6 (100.0%)	6 (100.0%)	12 (100.0%)
	Headache	Mild	2 ( 50.0%)	3 ( 50.0%)	5 ( 83.3%)	8 ( 66.7%)
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
	Balance disorder	Mild	0	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
		Moderate	0	0	0	0
		Severe	0	1 ( 16.7%)	0	1 ( 8.3%)
	Dizziness	Mild	1 ( 25.0%)	0	0	0
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Psychomotor hyperactivity	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Respiratory, thoracic and mediastinal disorders	Somnolence	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Overall		3 ( 75.0%)	6 (100.0%)	6 (100.0%)	12 (100.0%)
	Oropharyngeal pain	Mild	3 ( 75.0%)	4 ( 66.7%)	3 ( 50.0%)	7 ( 58.3%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
	Nasal congestion	Mild	1 ( 25.0%)	3 ( 50.0%)	2 ( 33.3%)	5 ( 41.7%)
		Moderate	0	0	0	0
		Severe	0	1 ( 16.7%)	0	1 ( 8.3%)
	Cough	Mild	2 ( 50.0%)	1 ( 16.7%)	3 ( 50.0%)	4 ( 33.3%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
	Epistaxis	Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Pharyngeal erythema	Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
Severe		0	0	0	0	
Rhinorrhoea	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)	
	Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)	
	Severe	0	0	0	0	

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>2</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Upper respiratory tract congestion		Mild	0	2 ( 33.3%)	0	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Productive cough		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Respiratory disorder		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Sinus congestion		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Sneezing		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Upper-airway cough syndrome		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
General disorders and administration site conditions	Overall		2 ( 50.0%)	6 (100.0%)	5 ( 83.3%)	11 ( 91.7%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Catheter site pain		Mild	0	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Infusion site extravasation		Mild	0	2 ( 33.3%)	2 ( 33.3%)	4 ( 33.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Pyrexia		Mild	2 ( 50.0%)	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Device occlusion		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Infusion site haematoma		Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Oedema peripheral		Mild	0	0	0	0
		Moderate	0	2 ( 33.3%)	0	2 ( 16.7%)
		Severe	0	0	0	0
Thrombosis in device		Mild	0	0	0	0
		Moderate	0	2 ( 33.3%)	0	2 ( 16.7%)
		Severe	0	0	0	0
Catheter site haematoma		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Catheter site inflammation		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Catheter site related reaction		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Chest pain		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Influenza like illness		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Infusion site pain		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Infusion site rash		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Injection site pain		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Musculoskeletal and connective tissue disorders	Irritability	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Malaise	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Non-cardiac chest pain	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Pain	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Overall		4 (100.0%)	5 ( 83.3%)	6 (100.0%)	11 ( 91.7%)
	Pain in extremity	Mild	4 (100.0%)	2 ( 33.3%)	2 ( 33.3%)	4 ( 33.3%)
		Moderate	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
Severe		0	0	0	0	
Back pain	Mild	2 ( 50.0%)	3 ( 50.0%)	2 ( 33.3%)	5 ( 41.7%)	
	Moderate	0	2 ( 33.3%)	0	2 ( 16.7%)	
	Severe	0	0	0	0	
Arthralgia	Mild	0	1 ( 16.7%)	3 ( 50.0%)	4 ( 33.3%)	
	Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)	
	Severe	0	0	0	0	

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesv.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Muscle spasms		Mild	0	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Myalgia		Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
Muscular weakness		Mild	0	0	2 ( 33.3%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Musculoskeletal pain		Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Bone pain		Mild	0	0	0	0
		Moderate	0	0	0	0
		Severe	0	1 ( 16.7%)	0	1 ( 8.3%)
Neck pain		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Tendon disorder		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Tendonitis		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen			
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)	
Gastrointestinal disorders	Overall		1 ( 25.0%)	5 ( 83.3%)	5 ( 83.3%)	10 ( 83.3%)	
	Vomiting	Mild	0	3 ( 50.0%)	3 ( 50.0%)	6 ( 50.0%)	
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
		Abdominal pain upper	Mild	0	1 ( 16.7%)	3 ( 50.0%)	4 ( 33.3%)
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
		Abdominal pain	Mild	1 ( 25.0%)	0	2 ( 33.3%)	2 ( 16.7%)
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
		Diarrhoea	Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)	
		Severe	0	0	0	0	
		Dyspepsia	Mild	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
		Nausea	Mild	1 ( 25.0%)	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
		Abdominal discomfort	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
	Moderate	0	0	0	0		
	Severe	0	0	0	0		
	Dental caries	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)	
	Moderate	0	0	0	0		
	Severe	0	0	0	0		

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Dysphagia		Mild	0	0	0	0
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Flatulence		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Food poisoning		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Lip swelling		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Oral pain		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Retained deciduous tooth		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Tooth impacted		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Toothache		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Infections and infestations	Overall		3 ( 75.0%)	4 ( 66.7%)	6 (100.0%)	10 ( 83.3%)
	Nasopharyngitis	Mild	1 ( 25.0%)	3 ( 50.0%)	4 ( 66.7%)	7 ( 58.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Upper respiratory tract infection	Mild	0	2 ( 33.3%)	3 ( 50.0%)	5 ( 41.7%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
	Hordeolum	Mild	0	0	2 ( 33.3%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Influenza	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
	Rhinitis	Mild	1 ( 25.0%)	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Enterobiasis	Mild	1 ( 25.0%)	0	0	0
	Moderate	0	0	0	0	
	Severe	0	0	0	0	
Gastroenteritis viral	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)	
	Moderate	0	0	0	0	
	Severe	0	0	0	0	

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Incision site infection		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Pharyngitis streptococcal		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Soft tissue infection		Mild	1 ( 25.0%)	0	0	0
		Moderate	0	0	0	0
		Severe	0	0	0	0
Tinea pedis		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Viral infection		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Viral upper respiratory tract infection		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Investigations	Overall		0	4 ( 66.7%)	6 (100.0%)	10 ( 83.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
C-reactive protein increased		Mild	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
Activated partial thromboplastin time prolonged		Mild	0	0	3 ( 50.0%)	3 ( 25.0%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Blood creatine phosphokinase increased		Mild	0	2 ( 33.3%)	0	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Blood glucose increased		Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Blood creatinine increased		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Blood urea increased		Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Skin and subcutaneous tissue disorders	Lymphocyte count decreased	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Neutrophil count increased	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Red blood cells urine positive	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	White blood cell count decreased	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Wound healing normal	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)	
	Moderate	0	0	0	0	
	Severe	0	0	0	0	
Overall			0	5 ( 83.3%)	5 ( 83.3%)	10 ( 83.3%)
	Dermatitis contact	Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Rash		Mild	0	2 ( 33.3%)	1 ( 16.7%)	3 ( 25.0%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Ecchymosis		Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Erythema		Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Intertrigo		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Keloid scar		Mild	0	0	0	0
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
Nail discolouration		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Nail dystrophy		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Papule		Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
	Petechiae	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Pruritus	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Rash papular	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Skin erosion	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)	
	Moderate	0	0	0	0	
	Severe	0	0	0	0	
Urticaria	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)	
	Moderate	0	0	0	0	
	Severe	0	0	0	0	
Urticaria thermal	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)	
	Moderate	0	0	0	0	
	Severe	0	0	0	0	
Metabolism and nutrition disorders	Overall		2 ( 50.0%)	4 ( 66.7%)	2 ( 33.3%)	6 ( 50.0%)
	Hypokalaemia	Mild	2 ( 50.0%)	1 ( 16.7%)	2 ( 33.3%)	3 ( 25.0%)
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen			
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)	
	Obesity	Mild	0	0	0	0	
		Moderate	0	2 ( 33.3%)	0	2 ( 16.7%)	
		Severe	0	0	0	0	
	Vitamin D deficiency	Mild	0	2 ( 33.3%)	0	2 ( 16.7%)	
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
	Dehydration	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)	
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
Renal and urinary disorders	Overall		1 ( 25.0%)	2 ( 33.3%)	4 ( 66.7%)	6 ( 50.0%)	
	Proteinuria	Mild	1 ( 25.0%)	2 ( 33.3%)	4 ( 66.7%)	6 ( 50.0%)	
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
	Glycosuria	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)	
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
	Polyuria	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)	
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
	Vascular disorders	Overall		1 ( 25.0%)	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
		Haematoma	Mild	1 ( 25.0%)	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
Moderate			0	0	0	0	
Severe			0	0	0	0	

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Ear and labyrinth disorders	Overall		0	0	2 ( 33.3%)	2 ( 16.7%)
	Motion sickness	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Tympanic membrane disorder	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
Severe		0	0	0	0	
Eye disorders	Overall		0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)
	Cataract	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Cataract subcapsular	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Conjunctivitis	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Hypermetropia	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
Severe		0	0	0	0	
Psychiatric disorders	Overall		0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
	Anxiety disorder	Mild	0	0	0	0
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
	Insomnia	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Reproductive system and breast disorders	Overall		0	2 ( 33.3%)	0	2 ( 16.7%)
	Pelvic pain	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
	Testicular pain	Mild	0	1 ( 16.7%)	0	1 ( 8.3%)
		Moderate	0	0	0	0
Severe		0	0	0	0	
Cardiac disorders	Overall		0	1 ( 16.7%)	0	1 ( 8.3%)
	Tachycardia	Mild	0	0	0	0
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Congenital, familial and genetic disorders	Overall		0	1 ( 16.7%)	0	1 ( 8.3%)

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.3  
 Summary of Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
	Cryptorchism	Mild	0	0	0	0
		Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
		Severe	0	0	0	0
Endocrine disorders	Overall Growth hormone deficiency	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
Immune system disorders	Overall Hypersensitivity	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	1 ( 16.7%)	1 ( 8.3%)
		Severe	0	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Overall Skin papilloma	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.4  
 Summary of Treatment Related Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen			
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)	
At Least One TEAE	Overall		1 ( 25.0%)	3 ( 50.0%)	3 ( 50.0%)	6 ( 50.0%)	
		Mild	1 ( 25.0%)	1 ( 16.7%)	3 ( 50.0%)	4 ( 33.3%)	
		Moderate	0	2 ( 33.3%)	0	2 ( 16.7%)	
		Severe	0	0	0	0	
General disorders and administration site conditions	Overall		0	2 ( 33.3%)	0	2 ( 16.7%)	
		Thrombosis in device	Mild	0	0	0	0
			Moderate	0	2 ( 33.3%)	0	2 ( 16.7%)
			Severe	0	0	0	0
		Device occlusion	Mild	0	0	0	0
			Moderate	0	1 ( 16.7%)	0	1 ( 8.3%)
			Severe	0	0	0	0
Renal and urinary disorders	Overall Proteinuria		0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)	
		Mild	0	1 ( 16.7%)	1 ( 16.7%)	2 ( 16.7%)	
		Moderate	0	0	0	0	
		Severe	0	0	0	0	
Gastrointestinal disorders	Overall Nausea		1 ( 25.0%)	0	0	0	
		Mild	1 ( 25.0%)	0	0	0	
		Moderate	0	0	0	0	
		Severe	0	0	0	0	

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.4  
 Summary of Treatment Related Treatment Emergent Adverse Events by Severity  
 Safety Population

Body System	Preferred Term	Severity <sup>1</sup>	Placebo <sup>3</sup> (N=4)	Eteplirsen		
				30 mg/kg (N=6)	50 mg/kg (N=6)	All Eteplirsen (N=12)
Investigations	Overall		0	0	1 ( 16.7%)	1 ( 8.3%)
	White blood cell count decreased	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0
Skin and subcutaneous tissue disorders	Overall		0	0	1 ( 16.7%)	1 ( 8.3%)
	Erythema	Mild	0	0	1 ( 16.7%)	1 ( 8.3%)
		Moderate	0	0	0	0
		Severe	0	0	0	0

Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>Worst severity in case of multiple occurrences per preferred term.

<sup>2</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>3</sup>Placebo is from Week 1 to Week 24 of the 201 Study.


Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumaesev.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.2

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.1.5  
 Summary of Serious Adverse Events  
 Safety Population

Body System	Preferred Term	Placebo <sup>2</sup> (N=4)	30 mg/kg (N=6)	Eteplirsen	
				50 mg/kg (N=6)	All Eteplirsen (N=12)
At Least One Serious AE		0	1 ( 16.7%)	0	1 ( 8.3%)
Injury, poisoning and procedural complications	Overall	0	1 ( 16.7%)	0	1 ( 8.3%)
	Femur fracture	0	1 ( 16.7%)	0	1 ( 8.3%)



Note: Adverse events were attributed to the treatment being received at start of adverse event.

Note: Adverse events through study day 1296 are included.

<sup>1</sup>All Subjects = Subjects who took any study medication (counted only once). Subjects were counted once in each body system and preferred term.

<sup>2</sup>Placebo is from Week 1 to Week 24 of the 201 Study.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sumae.sas, Date/time of run: 06APR2015: 9:27

Reference listing: L.16.2.7.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Sodium (mmol/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	141.0		140.0		140.5	
	Median	141.0		140.0		140.0	
	SD	1.15		0.82		1.07	
	(SE)	( 0.58)		( 0.41)		( 0.38)	
	Min,	140,		139,		139,	
	Max	142		141		142	
Week 2	n	4	4	4	4	8	
	Mean	140.5	-0.5	140.3	0.3	140.4	-0.1
	Median	141.0	-1.0	141.0	0.5	141.0	-0.5
	SD	1.00	1.00	1.50	0.96	1.19	0.99
	(SE)	( 0.50)	( 0.50)	( 0.75)	( 0.48)	( 0.42)	( 0.35)
	Min,	139,	-1,	138,	-1,	138,	-1,
	Max	141	1	141	1	141	1
Week 4	n	4	4	4	4	8	
	Mean	138.5	-2.5	140.5	0.5	139.5	-1.0
	Median	139.0	-2.0	140.5	0.0	139.5	0.0
	SD	1.73	2.65	1.29	1.00	1.77	2.45
	(SE)	( 0.87)	( 1.32)	( 0.65)	( 0.50)	( 0.63)	( 0.87)
	Min,	136,	-6,	139,	0,	136,	-6,
	Max	140	0	142	2	142	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	142.0	1.0	142.5	2.5	142.3	1.8
	Median	142.0	1.0	141.5	1.5	142.0	1.5
	SD	1.63	1.15	3.11	2.38	2.31	1.91
	(SE)	( 0.82)	( 0.58)	( 1.55)	( 1.19)	( 0.82)	( 0.67)
	Min,	140,	0,	140,	1,	140,	0,
	Max	144	2	147	6	147	6
Week 8	n	4	4	4	4	8	8
	Mean	140.8	-0.3	141.3	1.3	141.0	0.5
	Median	140.0	-0.5	141.5	1.5	140.5	0.5
	SD	2.22	1.71	1.71	1.71	1.85	1.77
	(SE)	( 1.11)	( 0.85)	( 0.85)	( 0.85)	( 0.65)	( 0.63)
	Min,	139,	-2,	139,	-1,	139,	-2,
	Max	144	2	143	3	144	3
Week 10	n	4	4	4	4	8	8
	Mean	139.5	-1.5	140.5	0.5	140.0	-0.5
	Median	139.5	-2.0	140.5	0.5	140.0	-0.5
	SD	1.29	1.73	1.29	1.29	1.31	1.77
	(SE)	( 0.65)	( 0.87)	( 0.65)	( 0.65)	( 0.46)	( 0.63)
	Min,	138,	-3,	139,	-1,	138,	-3,
	Max	141	1	142	2	142	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	140.3	-0.8	139.0	-1.0	139.6	-0.9
	Median	140.5	-0.5	138.5	-2.0	139.5	-1.5
	SD	1.71	0.96	1.41	2.00	1.60	1.46
	(SE)	( 0.85)	( 0.48)	( 0.71)	( 1.00)	( 0.56)	( 0.52)
	Min,	138,	-2,	138,	-2,	138,	-2,
	Max	142	0	141	2	142	2
Week 15	n	4	4	4	4	8	8
	Mean	139.8	-1.3	140.0	0.0	139.9	-0.6
	Median	139.0	-1.0	140.0	0.0	139.5	-0.5
	SD	2.22	2.06	0.82	0.82	1.55	1.60
	(SE)	( 1.11)	( 1.03)	( 0.41)	( 0.41)	( 0.55)	( 0.56)
	Min,	138,	-4,	139,	-1,	138,	-4,
	Max	143	1	141	1	143	1
Week 18	n	4	4	4	4	8	8
	Mean	140.0	-1.0	139.0	-1.0	139.5	-1.0
	Median	140.5	-1.5	139.0	-1.0	139.5	-1.5
	SD	1.41	1.41	1.63	1.83	1.51	1.51
	(SE)	( 0.71)	( 0.71)	( 0.82)	( 0.91)	( 0.53)	( 0.53)
	Min,	138,	-2,	137,	-3,	137,	-3,
	Max	141	1	141	1	141	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	142.3	1.3	141.3	1.3	141.8	1.3
	Median	142.0	1.5	141.0	1.0	142.0	1.0
	SD	0.50	0.96	1.26	0.50	1.04	0.71
	(SE)	( 0.25)	( 0.48)	( 0.63)	( 0.25)	( 0.37)	( 0.25)
	Min,	142,	0,	140,	1,	140,	0,
	Max	143	2	143	2	143	2
Week 24	n	4	4	4	4	8	8
	Mean	141.5	0.5	140.5	0.5	141.0	0.5
	Median	142.0	1.0	141.0	0.5	141.0	1.0
	SD	1.91	1.00	1.73	1.29	1.77	1.07
	(SE)	( 0.96)	( 0.50)	( 0.87)	( 0.65)	( 0.63)	( 0.38)
	Min,	139,	-1,	138,	-1,	138,	-1,
	Max	143	1	142	2	143	2
Week 25	n	4	4	4	4	8	8
	Mean	141.8	0.8	141.3	1.3	141.5	1.0
	Median	141.5	1.0	142.0	1.5	142.0	1.0
	SD	0.96	1.26	1.50	1.71	1.20	1.41
	(SE)	( 0.48)	( 0.63)	( 0.75)	( 0.85)	( 0.42)	( 0.50)
	Min,	141,	-1,	139,	-1,	139,	-1,
	Max	143	2	142	3	143	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	138.0	-3.0	139.8	-0.3	138.9	-1.6
	Median	138.0	-3.0	140.0	0.5	139.0	-2.0
	SD	2.58	1.63	3.77	3.59	3.14	2.97
	(SE)	( 1.29)	( 0.82)	( 1.89)	( 1.80)	( 1.11)	( 1.05)
	Min,	135,	-5,	135,	-5,	135,	-5,
	Max	141	-1	144	3	144	3
Week 32	n	4	4	3	3	7	7
	Mean	140.5	-0.5	140.0	-0.3	140.3	-0.4
	Median	140.5	-1.0	140.0	-1.0	140.0	-1.0
	SD	1.29	1.73	1.00	1.15	1.11	1.40
	(SE)	( 0.65)	( 0.87)	( 0.58)	( 0.67)	( 0.42)	( 0.53)
	Min,	139,	-2,	139,	-1,	139,	-2,
	Max	142	2	141	1	142	2
Week 36	n	4	4	4	4	8	8
	Mean	139.0	-2.0	139.0	-1.0	139.0	-1.5
	Median	139.0	-2.0	139.5	-0.5	139.5	-1.5
	SD	1.83	2.45	1.41	1.41	1.51	1.93
	(SE)	( 0.91)	( 1.22)	( 0.71)	( 0.71)	( 0.53)	( 0.68)
	Min,	137,	-5,	137,	-3,	137,	-5,
	Max	141	1	140	0	141	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	140.5	-0.5	140.8	0.8	140.6	0.1
	Median	140.5	-0.5	141.0	1.0	141.0	0.0
	SD	0.58	0.58	1.26	0.50	0.92	0.83
	(SE)	( 0.29)	( 0.29)	( 0.63)	( 0.25)	( 0.32)	( 0.30)
	Min,	140,	-1,	139,	0,	139,	-1,
	Max	141	0	142	1	142	1
Week 44	n	4	4	4	4	8	8
	Mean	140.5	-0.5	139.3	-0.8	139.9	-0.6
	Median	141.5	0.5	139.0	-1.0	139.5	-1.0
	SD	3.11	4.04	0.50	1.26	2.17	2.77
	(SE)	( 1.55)	( 2.02)	( 0.25)	( 0.63)	( 0.77)	( 0.98)
	Min,	136,	-6,	139,	-2,	136,	-6,
	Max	143	3	140	1	143	3
Week 48	n	4	4	4	4	8	8
	Mean	139.5	-1.5	139.5	-0.5	139.5	-1.0
	Median	139.5	-1.5	139.5	-0.5	139.5	-0.5
	SD	1.29	2.38	1.29	1.29	1.20	1.85
	(SE)	( 0.65)	( 1.19)	( 0.65)	( 0.65)	( 0.42)	( 0.65)
	Min,	138,	-4,	138,	-2,	138,	-4,
	Max	141	1	141	1	141	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	138.8	-2.3	138.5	-1.5	138.6	-1.9
	Median	138.5	-2.0	138.5	-1.5	138.5	-2.0
	SD	0.96	1.26	1.29	0.58	1.06	0.99
	(SE)	( 0.48)	( 0.63)	( 0.65)	( 0.29)	( 0.38)	( 0.35)
	Min,	138,	-4,	137,	-2,	137,	-4,
	Max	140	-1	140	-1	140	-1
Week 56	n	4	4	3	3	7	7
	Mean	138.8	-2.3	140.0	0.3	139.3	-1.1
	Median	138.5	-2.0	139.0	0.0	139.0	-1.0
	SD	0.96	1.26	1.73	1.53	1.38	1.86
	(SE)	( 0.48)	( 0.63)	( 1.00)	( 0.88)	( 0.52)	( 0.70)
	Min,	138,	-4,	139,	-1,	138,	-4,
	Max	140	-1	142	2	142	2
Week 60	n	4	4	4	4	8	8
	Mean	138.8	-2.3	139.5	-0.5	139.1	-1.4
	Median	138.5	-2.0	139.5	-1.0	139.0	-1.0
	SD	1.71	1.50	1.29	1.00	1.46	1.51
	(SE)	( 0.85)	( 0.75)	( 0.65)	( 0.50)	( 0.52)	( 0.53)
	Min,	137,	-4,	138,	-1,	137,	-4,
	Max	141	-1	141	1	141	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	139.5	-1.5	139.3	-0.8	139.4	-1.1
	Median	140.5	-1.5	139.5	-0.5	140.0	-1.0
	SD	2.38	2.08	0.96	0.96	1.69	1.55
	(SE)	( 1.19)	( 1.04)	( 0.48)	( 0.48)	( 0.60)	( 0.55)
	Min,	136,	-4,	138,	-2,	136,	-4,
	Max	141	1	140	0	141	1
Week 68	n	4	4	4	4	8	8
	Mean	137.8	-3.3	139.5	-0.5	138.6	-1.9
	Median	138.0	-3.5	139.5	-1.0	139.0	-1.0
	SD	1.50	1.71	0.58	1.00	1.41	1.96
	(SE)	( 0.75)	( 0.85)	( 0.29)	( 0.50)	( 0.50)	( 0.69)
	Min,	136,	-5,	139,	-1,	136,	-5,
	Max	139	-1	140	1	140	1
Week 72	n	3	3	4	4	7	7
	Mean	138.3	-2.3	139.3	-0.8	138.9	-1.4
	Median	140.0	-2.0	139.5	-0.5	140.0	-1.0
	SD	2.89	2.52	1.71	0.96	2.12	1.81
	(SE)	( 1.67)	( 1.45)	( 0.85)	( 0.48)	( 0.80)	( 0.69)
	Min,	135,	-5,	137,	-2,	135,	-5,
	Max	140	0	141	0	141	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	139.0	-2.0			139.0	-2.0
	Median	139.0	-2.0			139.0	-2.0
	SD	0.00	1.41			0.00	1.41
	(SE)	( 0.00)	( 1.00)			( 0.00)	( 1.00)
	Min,	139,	-3,			139,	-3,
	Max	139	-1			139	-1
Week 76	n	4	4	4	4	8	8
	Mean	140.0	-1.0	139.3	-0.8	139.6	-0.9
	Median	139.5	-1.0	139.0	-1.0	139.0	-1.0
	SD	1.41	0.82	2.06	2.87	1.69	1.96
	(SE)	( 0.71)	( 0.41)	( 1.03)	( 1.44)	( 0.60)	( 0.69)
	Min,	139,	-2,	137,	-4,	137,	-4,
	Max	142	0	142	3	142	3
Week 80	n	4	4	4	4	8	8
	Mean	138.0	-3.0	139.0	-1.0	138.5	-2.0
	Median	137.5	-3.5	139.5	-0.5	138.0	-2.0
	SD	2.94	2.45	2.45	3.16	2.56	2.83
	(SE)	( 1.47)	( 1.22)	( 1.22)	( 1.58)	( 0.91)	( 1.00)
	Min,	135,	-5,	136,	-5,	135,	-5,
	Max	142	0	141	2	142	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	140.0	-1.0	139.0	-1.0	139.5	-1.0
	Median	139.0	-1.0	139.0	-0.5	139.0	-1.0
	SD	2.00	1.63	0.82	1.41	1.51	1.41
	(SE)	( 1.00)	( 0.82)	( 0.41)	( 0.71)	( 0.53)	( 0.50)
	Min,	139,	-3,	138,	-3,	138,	-3,
	Max	143	1	140	0	143	1
Week 88	n	4	4	4	4	8	8
	Mean	139.3	-1.8	138.8	-1.3	139.0	-1.5
	Median	139.5	-1.5	139.0	-1.5	139.0	-1.5
	SD	3.50	2.50	2.22	1.71	2.73	2.00
	(SE)	( 1.75)	( 1.25)	( 1.11)	( 0.85)	( 0.96)	( 0.71)
	Min,	135,	-5,	136,	-3,	135,	-5,
	Max	143	1	141	1	143	1
Week 92	n	4	4	4	4	8	8
	Mean	141.0	0.0	138.8	-1.3	139.9	-0.6
	Median	142.0	1.0	138.5	-1.0	140.0	-0.5
	SD	3.46	2.83	1.71	2.06	2.80	2.39
	(SE)	( 1.73)	( 1.41)	( 0.85)	( 1.03)	( 0.99)	( 0.84)
	Min,	136,	-4,	137,	-4,	136,	-4,
	Max	144	2	141	1	144	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	141.0	0.0	138.3	-1.8	139.6	-0.9
	Median	140.0	0.0	138.0	-2.5	139.0	-1.5
	SD	2.83	2.58	2.22	1.89	2.77	2.30
	(SE)	( 1.41)	( 1.29)	( 1.11)	( 0.95)	( 0.98)	( 0.81)
	Min,	139,	-3,	136,	-3,	136,	-3,
	Max	145	3	141	1	145	3
Week 100	n	4	4	4	4	8	8
	Mean	138.5	-2.5	139.8	-0.3	139.1	-1.4
	Median	138.0	-2.0	139.5	-1.0	138.5	-2.0
	SD	1.00	1.00	1.71	2.36	1.46	2.07
	(SE)	( 0.50)	( 0.50)	( 0.85)	( 1.18)	( 0.52)	( 0.73)
	Min,	138,	-4,	138,	-2,	138,	-4,
	Max	140	-2	142	3	142	3
Week 104	n	4	4	4	4	8	8
	Mean	140.0	-1.0	138.0	-2.0	139.0	-1.5
	Median	140.0	-1.5	137.5	-2.0	138.5	-2.0
	SD	1.83	2.16	2.16	1.63	2.14	1.85
	(SE)	( 0.91)	( 1.08)	( 1.08)	( 0.82)	( 0.76)	( 0.65)
	Min,	138,	-3,	136,	-4,	136,	-4,
	Max	142	2	141	0	142	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	139.5	-1.5	140.0	0.0	139.8	-0.8
	Median	139.5	-1.5	140.0	0.0	139.5	-1.5
	SD	1.29	0.58	2.31	2.94	1.75	2.12
	(SE)	( 0.65)	( 0.29)	( 1.15)	( 1.47)	( 0.62)	( 0.75)
	Min,	138,	-2,	138,	-3,	138,	-3,
	Max	141	-1	142	3	142	3
Week 112	n	4	4	4	4	8	8
	Mean	139.3	-1.8	140.0	0.0	139.6	-0.9
	Median	139.5	-1.5	140.0	-0.5	139.5	-1.5
	SD	2.50	2.06	2.94	3.56	2.56	2.85
	(SE)	( 1.25)	( 1.03)	( 1.47)	( 1.78)	( 0.91)	( 1.01)
	Min,	136,	-4,	137,	-3,	136,	-4,
	Max	142	0	143	4	143	4
Week 116	n	4	4	4	4	8	8
	Mean	140.3	-0.8	138.0	-2.0	139.1	-1.4
	Median	139.0	-2.0	138.0	-2.0	138.5	-2.0
	SD	3.95	3.30	1.63	1.83	3.04	2.56
	(SE)	( 1.97)	( 1.65)	( 0.82)	( 0.91)	( 1.08)	( 0.91)
	Min,	137,	-3,	136,	-4,	136,	-4,
	Max	146	4	140	0	146	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	139.0	-1.7	139.0	-1.0	139.0	-1.3
	Median	140.0	0.0	139.0	-0.5	140.0	0.0
	SD	1.73	2.89	1.83	2.45	1.63	2.43
	(SE)	( 1.00)	( 1.67)	( 0.91)	( 1.22)	( 0.62)	( 0.92)
	Min,	137,	-5,	137,	-4,	137,	-5,
	Max	140	0	141	1	141	1
Week 124	n	3	3	4	4	7	7
	Mean	139.3	-1.3	139.3	-0.8	139.3	-1.0
	Median	139.0	-1.0	139.0	-1.0	139.0	-1.0
	SD	0.58	0.58	1.50	2.22	1.11	1.63
	(SE)	( 0.33)	( 0.33)	( 0.75)	( 1.11)	( 0.42)	( 0.62)
	Min,	139,	-2,	138,	-3,	138,	-3,
	Max	140	-1	141	2	141	2
Week 128	n	4	4	4	4	8	8
	Mean	139.3	-1.8	140.3	0.3	139.8	-0.8
	Median	139.0	-1.5	140.0	0.0	139.5	-1.0
	SD	0.50	0.96	1.26	1.50	1.04	1.58
	(SE)	( 0.25)	( 0.48)	( 0.63)	( 0.75)	( 0.37)	( 0.56)
	Min,	139,	-3,	139,	-1,	139,	-3,
	Max	140	-1	142	2	142	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	137.5	-3.5	139.3	-0.8	138.4	-2.1
	Median	137.0	-3.5	139.0	-0.5	137.5	-2.5
	SD	1.73	1.29	2.22	2.06	2.07	2.17
	(SE)	( 0.87)	( 0.65)	( 1.11)	( 1.03)	( 0.73)	( 0.77)
	Min,	136,	-5,	137,	-3,	136,	-5,
	Max	140	-2	142	1	142	1
Week 136	n	4	4	4	4	8	8
	Mean	137.5	-3.5	140.5	0.5	139.0	-1.5
	Median	137.5	-3.5	141.0	0.5	138.5	-1.5
	SD	0.58	1.29	1.00	1.29	1.77	2.45
	(SE)	( 0.29)	( 0.65)	( 0.50)	( 0.65)	( 0.63)	( 0.87)
	Min,	137,	-5,	139,	-1,	137,	-5,
	Max	138	-2	141	2	141	2
Week 140	n	4	4	4	4	8	8
	Mean	139.8	-1.3	139.5	-0.5	139.6	-0.9
	Median	139.5	-1.0	139.0	-0.5	139.0	-1.0
	SD	0.96	0.50	1.00	0.58	0.92	0.64
	(SE)	( 0.48)	( 0.25)	( 0.50)	( 0.29)	( 0.32)	( 0.23)
	Min,	139,	-2,	139,	-1,	139,	-2,
	Max	141	-1	141	0	141	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	137.5	-3.5	141.5	1.5	139.5	-1.0
	Median	137.5	-3.5	141.0	1.0	139.5	-1.5
	SD	1.29	0.58	1.91	1.73	2.62	2.93
	(SE)	( 0.65)	( 0.29)	( 0.96)	( 0.87)	( 0.93)	( 1.04)
	Min,	136,	-4,	140,	0,	136,	-4,
	Max	139	-3	144	4	144	4
Week 148	n	4	4	4	4	8	8
	Mean	138.5	-2.5	138.5	-1.5	138.5	-2.0
	Median	139.0	-3.0	138.0	-1.5	138.5	-2.5
	SD	1.00	1.00	1.00	1.29	0.93	1.20
	(SE)	( 0.50)	( 0.50)	( 0.50)	( 0.65)	( 0.33)	( 0.42)
	Min,	137,	-3,	138,	-3,	137,	-3,
	Max	139	-1	140	0	140	0
Week 152	n	4	4	3	3	7	7
	Mean	137.5	-3.5	138.0	-2.3	137.7	-3.0
	Median	138.0	-3.0	137.0	-3.0	138.0	-3.0
	SD	1.00	1.91	1.73	1.15	1.25	1.63
	(SE)	( 0.50)	( 0.96)	( 1.00)	( 0.67)	( 0.47)	( 0.62)
	Min,	136,	-6,	137,	-3,	136,	-6,
	Max	138	-2	140	-1	140	-1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 156	n	4	4	4	4	8	8
	Mean	138.8	-2.3	138.0	-2.0	138.4	-2.1
	Median	139.0	-2.5	138.0	-1.5	139.0	-2.0
	SD	0.50	0.96	1.15	1.41	0.92	1.13
	(SE)	( 0.25)	( 0.48)	( 0.58)	( 0.71)	( 0.32)	( 0.40)
	Min,	138,	-3,	137,	-4,	137,	-4,
	Max	139	-1	139	-1	139	-1
Week 160	n	4	4	4	4	8	8
	Mean	138.0	-3.0	138.0	-2.0	138.0	-2.5
	Median	137.0	-3.0	138.0	-2.5	137.0	-3.0
	SD	2.00	1.63	1.83	2.16	1.77	1.85
	(SE)	( 1.00)	( 0.82)	( 0.91)	( 1.08)	( 0.63)	( 0.65)
	Min,	137,	-5,	136,	-4,	136,	-5,
	Max	141	-1	140	1	141	1
Week 164	n	4	4	4	4	8	8
	Mean	139.0	-2.0	139.3	-0.8	139.1	-1.4
	Median	139.5	-2.5	139.5	-0.5	139.5	-1.5
	SD	1.41	1.41	0.96	1.71	1.13	1.60
	(SE)	( 0.71)	( 0.71)	( 0.48)	( 0.85)	( 0.40)	( 0.56)
	Min,	137,	-3,	138,	-3,	137,	-3,
	Max	140	0	140	1	140	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 168	n	4	4	4	4	8	8
	Mean	139.0	-2.0	139.5	-0.5	139.3	-1.3
	Median	138.0	-2.0	139.5	0.0	138.5	-1.0
	SD	2.71	2.45	2.08	1.73	2.25	2.12
	(SE)	( 1.35)	( 1.22)	( 1.04)	( 0.87)	( 0.80)	( 0.75)
	Min,	137,	-5,	137,	-3,	137,	-5,
	Max	143	1	142	1	143	1
Week 172	n	4	4	4	4	8	8
	Mean	139.3	-1.8	139.0	-1.0	139.1	-1.4
	Median	139.5	-1.5	139.5	-1.0	139.5	-1.0
	SD	1.71	0.96	2.16	1.63	1.81	1.30
	(SE)	( 0.85)	( 0.48)	( 1.08)	( 0.82)	( 0.64)	( 0.46)
	Min,	137,	-3,	136,	-3,	136,	-3,
	Max	141	-1	141	1	141	1
Week 176	n	4	4	4	4	8	8
	Mean	139.3	-1.8	140.0	0.0	139.6	-0.9
	Median	139.0	-1.5	140.0	-0.5	139.0	-1.0
	SD	1.26	0.96	1.15	1.41	1.19	1.46
	(SE)	( 0.63)	( 0.48)	( 0.58)	( 0.71)	( 0.42)	( 0.52)
	Min,	138,	-3,	139,	-1,	138,	-3,
	Max	141	-1	141	2	141	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	4	4	3	3	7	7
	Mean	138.0	-3.0	139.3	-1.0	138.6	-2.1
	Median	138.0	-3.0	140.0	0.0	138.0	-3.0
	SD	0.82	0.82	2.08	1.73	1.51	1.57
	(SE)	( 0.41)	( 0.41)	( 1.20)	( 1.00)	( 0.57)	( 0.59)
	Min,	137,	-4,	137,	-3,	137,	-4,
	Max	139	-2	141	0	141	0
Week 184	n	4	4	4	4	8	8
	Mean	139.0	-2.0	140.0	0.0	139.5	-1.0
	Median	139.5	-2.5	138.5	-1.5	138.5	-1.5
	SD	2.45	2.45	4.83	4.08	3.59	3.30
	(SE)	( 1.22)	( 1.22)	( 2.42)	( 2.04)	( 1.27)	( 1.16)
	Min,	136,	-4,	136,	-3,	136,	-4,
	Max	141	1	147	6	147	6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Potassium (mmol/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	4.25		3.85		4.05	
	Median	4.20		3.90		4.00	
	SD	0.300		0.173		0.312	
	(SE)	( 0.150)		( 0.087)		( 0.110)	
	Min, Max	4.0, 4.6		3.6, 4.0		3.6, 4.6	
Week 2	n	4	4	4	4	8	8
	Mean	4.00	-0.25	3.60	-0.25	3.80	-0.25
	Median	3.95	-0.25	3.65	-0.15	3.85	-0.15
	SD	0.216	0.465	0.392	0.387	0.363	0.396
	(SE)	( 0.108)	( 0.233)	( 0.196)	( 0.194)	( 0.128)	( 0.140)
	Min, Max	3.8, 4.3	-0.8, 0.3	3.1, 4.0	-0.8, 0.1	3.1, 4.3	-0.8, 0.3
Week 4	n	4	4	4	4	8	8
	Mean	3.93	-0.33	4.05	0.20	3.99	-0.06
	Median	3.90	-0.35	4.20	0.25	4.05	-0.05
	SD	0.222	0.411	0.451	0.535	0.336	0.524
	(SE)	( 0.111)	( 0.206)	( 0.225)	( 0.268)	( 0.119)	( 0.185)
	Min, Max	3.7, 4.2	-0.8, 0.2	3.4, 4.4	-0.5, 0.8	3.4, 4.4	-0.8, 0.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	3.63	-0.63	3.88	0.03	3.75	-0.30
	Median	3.60	-0.65	3.90	0.05	3.80	-0.05
	SD	0.330	0.492	0.222	0.096	0.293	0.478
	(SE)	( 0.165)	( 0.246)	( 0.111)	( 0.048)	( 0.104)	( 0.169)
	Min,	3.3,	-1.2,	3.6,	-0.1,	3.3,	-1.2,
	Max	4.0	0.0	4.1	0.1	4.1	0.1
Week 8	n	4	4	4	4	8	8
	Mean	4.08	-0.18	3.95	0.10	4.01	-0.04
	Median	4.05	-0.20	4.20	0.40	4.05	0.05
	SD	0.171	0.377	0.926	0.902	0.620	0.657
	(SE)	( 0.085)	( 0.189)	( 0.463)	( 0.451)	( 0.219)	( 0.232)
	Min,	3.9,	-0.6,	2.7,	-1.2,	2.7,	-1.2,
	Max	4.3	0.3	4.7	0.8	4.7	0.8
Week 10	n	4	4	4	4	8	8
	Mean	3.88	-0.38	3.68	-0.18	3.78	-0.28
	Median	3.95	-0.25	3.80	0.00	3.90	-0.10
	SD	0.189	0.450	0.403	0.427	0.311	0.420
	(SE)	( 0.095)	( 0.225)	( 0.202)	( 0.214)	( 0.110)	( 0.149)
	Min,	3.6,	-1.0,	3.1,	-0.8,	3.1,	-1.0,
	Max	4.0	0.0	4.0	0.1	4.0	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	4.08	-0.18	3.90	0.05	3.99	-0.06
	Median	4.10	-0.15	3.75	0.00	4.00	0.00
	SD	0.126	0.320	0.337	0.265	0.253	0.297
	(SE)	( 0.063)	( 0.160)	( 0.168)	( 0.132)	( 0.090)	( 0.105)
	Min,	3.9,	-0.5,	3.7,	-0.2,	3.7,	-0.5,
	Max	4.2	0.1	4.4	0.4	4.4	0.4
Week 15	n	4	4	4	4	8	8
	Mean	3.73	-0.53	3.50	-0.35	3.61	-0.44
	Median	3.75	-0.45	3.40	-0.40	3.65	-0.40
	SD	0.096	0.359	0.271	0.191	0.223	0.283
	(SE)	( 0.048)	( 0.180)	( 0.135)	( 0.096)	( 0.079)	( 0.100)
	Min,	3.6,	-1.0,	3.3,	-0.5,	3.3,	-1.0,
	Max	3.8	-0.2	3.9	-0.1	3.9	-0.1
Week 18	n	4	4	4	4	8	8
	Mean	4.05	-0.20	3.98	0.13	4.01	-0.04
	Median	4.00	-0.20	4.05	0.10	4.00	0.00
	SD	0.173	0.440	0.263	0.377	0.210	0.417
	(SE)	( 0.087)	( 0.220)	( 0.131)	( 0.189)	( 0.074)	( 0.148)
	Min,	3.9,	-0.7,	3.6,	-0.3,	3.6,	-0.7,
	Max	4.3	0.3	4.2	0.6	4.3	0.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	3.68	-0.58	3.75	-0.10	3.71	-0.34
	Median	3.70	-0.50	3.75	-0.15	3.70	-0.25
	SD	0.150	0.386	0.311	0.216	0.230	0.385
	(SE)	( 0.075)	( 0.193)	( 0.155)	( 0.108)	( 0.081)	( 0.136)
	Min, Max	3.5, 3.8	-1.1, -0.2	3.4, 4.1	-0.3, 0.2	3.4, 4.1	-1.1, 0.2
Week 24	n	4	4	4	4	8	8
	Mean	3.95	-0.30	3.58	-0.28	3.76	-0.29
	Median	4.00	-0.40	3.60	-0.30	3.75	-0.35
	SD	0.252	0.346	0.222	0.126	0.297	0.242
	(SE)	( 0.126)	( 0.173)	( 0.111)	( 0.063)	( 0.105)	( 0.085)
	Min, Max	3.6, 4.2	-0.6, 0.2	3.3, 3.8	-0.4, -0.1	3.3, 4.2	-0.6, 0.2
Week 25	n	4	4	4	4	8	8
	Mean	3.73	-0.53	3.60	-0.25	3.66	-0.39
	Median	3.80	-0.70	3.60	-0.30	3.70	-0.45
	SD	0.310	0.350	0.183	0.265	0.245	0.323
	(SE)	( 0.155)	( 0.175)	( 0.091)	( 0.132)	( 0.086)	( 0.114)
	Min, Max	3.3, 4.0	-0.7, 0.0	3.4, 3.8	-0.5, 0.1	3.3, 4.0	-0.7, 0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	3.80	-0.45	3.50	-0.35	3.65	-0.40
	Median	3.80	-0.50	3.45	-0.35	3.70	-0.40
	SD	0.163	0.342	0.216	0.129	0.239	0.245
	(SE)	( 0.082)	( 0.171)	( 0.108)	( 0.065)	( 0.085)	( 0.087)
	Min,	3.6,	-0.8,	3.3,	-0.5,	3.3,	-0.8,
	Max	4.0	0.0	3.8	-0.2	4.0	0.0
Week 32	n	4	4	3	3	7	7
	Mean	4.10	-0.15	3.97	0.17	4.04	-0.01
	Median	4.10	-0.10	4.00	0.20	4.10	0.00
	SD	0.082	0.265	0.153	0.252	0.127	0.291
	(SE)	( 0.041)	( 0.132)	( 0.088)	( 0.145)	( 0.048)	( 0.110)
	Min,	4.0,	-0.5,	3.8,	-0.1,	3.8,	-0.5,
	Max	4.2	0.1	4.1	0.4	4.2	0.4
Week 36	n	4	4	4	4	8	8
	Mean	4.08	-0.18	4.00	0.15	4.04	-0.01
	Median	4.15	-0.05	4.00	0.15	4.00	0.15
	SD	0.506	0.806	0.183	0.311	0.354	0.591
	(SE)	( 0.253)	( 0.403)	( 0.091)	( 0.155)	( 0.125)	( 0.209)
	Min,	3.5,	-1.1,	3.8,	-0.2,	3.5,	-1.1,
	Max	4.5	0.5	4.2	0.5	4.5	0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	4.20	-0.05	3.88	0.03	4.04	-0.01
	Median	4.15	-0.15	3.90	0.05	4.10	0.05
	SD	0.455	0.656	0.263	0.171	0.385	0.445
	(SE)	( 0.227)	( 0.328)	( 0.131)	( 0.085)	( 0.136)	( 0.157)
	Min,	3.7,	-0.7,	3.6,	-0.2,	3.6,	-0.7,
	Max	4.8	0.8	4.1	0.2	4.8	0.8
Week 44	n	4	4	4	4	8	8
	Mean	3.93	-0.33	4.05	0.20	3.99	-0.06
	Median	3.85	-0.25	4.10	0.30	4.00	0.15
	SD	0.538	0.574	0.443	0.424	0.461	0.545
	(SE)	( 0.269)	( 0.287)	( 0.222)	( 0.212)	( 0.163)	( 0.193)
	Min,	3.4,	-1.0,	3.5,	-0.4,	3.4,	-1.0,
	Max	4.6	0.2	4.5	0.6	4.6	0.6
Week 48	n	4	4	4	4	8	8
	Mean	4.05	-0.20	4.05	0.20	4.05	0.00
	Median	4.00	-0.10	4.00	0.10	4.00	0.10
	SD	0.661	0.712	0.100	0.271	0.438	0.542
	(SE)	( 0.330)	( 0.356)	( 0.050)	( 0.135)	( 0.155)	( 0.192)
	Min,	3.4,	-1.0,	4.0,	0.0,	3.4,	-1.0,
	Max	4.8	0.4	4.2	0.6	4.8	0.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	4.23	-0.03	4.18	0.33	4.20	0.15
	Median	4.20	0.00	4.20	0.30	4.20	0.10
	SD	0.492	0.634	0.330	0.443	0.389	0.540
	(SE)	( 0.246)	( 0.317)	( 0.165)	( 0.221)	( 0.138)	( 0.191)
	Min,	3.8,	-0.8,	3.8,	-0.1,	3.8,	-0.8,
	Max	4.7	0.7	4.5	0.8	4.7	0.8
Week 56	n	4	4	3	3	7	7
	Mean	4.08	-0.18	4.03	0.10	4.06	-0.06
	Median	4.10	-0.10	4.10	0.20	4.10	0.20
	SD	0.222	0.519	0.306	0.265	0.237	0.424
	(SE)	( 0.111)	( 0.259)	( 0.176)	( 0.153)	( 0.090)	( 0.160)
	Min,	3.8,	-0.8,	3.7,	-0.2,	3.7,	-0.8,
	Max	4.3	0.3	4.3	0.3	4.3	0.3
Week 60	n	4	4	4	4	8	8
	Mean	4.23	-0.03	4.05	0.20	4.14	0.09
	Median	4.30	-0.10	4.10	0.15	4.30	-0.05
	SD	0.222	0.299	0.370	0.469	0.297	0.383
	(SE)	( 0.111)	( 0.149)	( 0.185)	( 0.235)	( 0.105)	( 0.136)
	Min,	3.9,	-0.3,	3.6,	-0.3,	3.6,	-0.3,
	Max	4.4	0.4	4.4	0.8	4.4	0.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	4.10	-0.15	4.13	0.28	4.11	0.06
	Median	4.00	-0.20	4.20	0.25	4.05	0.10
	SD	0.200	0.443	0.236	0.330	0.203	0.427
	(SE)	( 0.100)	( 0.222)	( 0.118)	( 0.165)	( 0.072)	( 0.151)
	Min,	4.0,	-0.6,	3.8,	-0.1,	3.8,	-0.6,
	Max	4.4	0.4	4.3	0.7	4.4	0.7
Week 68	n	4	4	4	4	8	8
	Mean	3.88	-0.38	4.25	0.40	4.06	0.01
	Median	3.95	-0.35	4.20	0.35	4.10	0.15
	SD	0.189	0.386	0.100	0.141	0.245	0.494
	(SE)	( 0.095)	( 0.193)	( 0.050)	( 0.071)	( 0.086)	( 0.175)
	Min,	3.6,	-0.8,	4.2,	0.3,	3.6,	-0.8,
	Max	4.0	0.0	4.4	0.6	4.4	0.6
Week 72	n	3	3	4	4	7	7
	Mean	4.53	0.33	4.03	0.18	4.24	0.24
	Median	3.80	-0.20	4.05	0.15	4.00	0.10
	SD	1.358	1.570	0.171	0.330	0.838	0.940
	(SE)	( 0.784)	( 0.906)	( 0.085)	( 0.165)	( 0.317)	( 0.355)
	Min,	3.7,	-0.9,	3.8,	-0.2,	3.7,	-0.9,
	Max	6.1	2.1	4.2	0.6	6.1	2.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	4.55	0.35			4.55	0.35
	Median	4.55	0.35			4.55	0.35
	SD	0.212	0.495			0.212	0.495
	(SE)	( 0.150)	( 0.350)			( 0.150)	( 0.350)
	Min,	4.4,	0.0,			4.4,	0.0,
	Max	4.7	0.7			4.7	0.7
Week 76	n	4	4	4	4	8	8
	Mean	4.08	-0.18	3.88	0.03	3.98	-0.08
	Median	4.05	-0.15	3.90	0.05	4.00	0.00
	SD	0.250	0.506	0.222	0.096	0.243	0.354
	(SE)	( 0.125)	( 0.253)	( 0.111)	( 0.048)	( 0.086)	( 0.125)
	Min,	3.8,	-0.8,	3.6,	-0.1,	3.6,	-0.8,
	Max	4.4	0.4	4.1	0.1	4.4	0.4
Week 80	n	4	4	4	4	8	8
	Mean	4.15	-0.10	3.83	-0.03	3.99	-0.06
	Median	4.05	-0.15	3.80	-0.05	3.85	-0.05
	SD	0.387	0.627	0.050	0.171	0.309	0.427
	(SE)	( 0.194)	( 0.314)	( 0.025)	( 0.085)	( 0.109)	( 0.151)
	Min,	3.8,	-0.8,	3.8,	-0.2,	3.8,	-0.8,
	Max	4.7	0.7	3.9	0.2	4.7	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	4.20	-0.05	3.88	0.02	4.04	-0.01
	Median	4.15	-0.05	3.95	0.00	4.00	-0.05
	SD	0.245	0.451	0.340	0.222	0.325	0.331
	(SE)	( 0.122)	( 0.225)	( 0.170)	( 0.111)	( 0.115)	( 0.117)
	Min,	4.0,	-0.6,	3.4,	-0.2,	3.4,	-0.6,
	Max	4.5	0.5	4.2	0.3	4.5	0.5
Week 88	n	4	4	4	4	8	8
	Mean	4.18	-0.08	4.45	0.60	4.31	0.26
	Median	4.10	-0.10	4.20	0.45	4.15	0.30
	SD	0.310	0.585	0.574	0.483	0.452	0.614
	(SE)	( 0.155)	( 0.293)	( 0.287)	( 0.242)	( 0.160)	( 0.217)
	Min,	3.9,	-0.7,	4.1,	0.2,	3.9,	-0.7,
	Max	4.6	0.6	5.3	1.3	5.3	1.3
Week 92	n	4	4	4	4	8	8
	Mean	4.28	0.03	4.00	0.15	4.14	0.09
	Median	4.30	0.15	4.00	0.05	4.00	0.05
	SD	0.443	0.602	0.245	0.387	0.362	0.473
	(SE)	( 0.221)	( 0.301)	( 0.122)	( 0.194)	( 0.128)	( 0.167)
	Min,	3.8,	-0.8,	3.7,	-0.2,	3.7,	-0.8,
	Max	4.7	0.6	4.3	0.7	4.7	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	4.20	-0.05	4.00	0.15	4.10	0.05
	Median	4.00	-0.25	4.10	0.25	4.05	0.10
	SD	0.469	0.686	0.271	0.387	0.370	0.526
	(SE)	( 0.235)	( 0.343)	( 0.135)	( 0.194)	( 0.131)	( 0.186)
	Min,	3.9,	-0.6,	3.6,	-0.4,	3.6,	-0.6,
	Max	4.9	0.9	4.2	0.5	4.9	0.9
Week 100	n	4	4	4	4	8	8
	Mean	4.18	-0.08	4.15	0.30	4.16	0.11
	Median	4.10	0.00	4.15	0.20	4.15	0.20
	SD	0.486	0.519	0.208	0.346	0.346	0.455
	(SE)	( 0.243)	( 0.259)	( 0.104)	( 0.173)	( 0.122)	( 0.161)
	Min,	3.7,	-0.7,	3.9,	0.0,	3.7,	-0.7,
	Max	4.8	0.4	4.4	0.8	4.8	0.8
Week 104	n	4	4	4	4	8	8
	Mean	4.00	-0.25	4.20	0.35	4.10	0.05
	Median	4.00	-0.20	4.05	0.10	4.00	-0.05
	SD	0.183	0.332	0.497	0.645	0.363	0.573
	(SE)	( 0.091)	( 0.166)	( 0.248)	( 0.323)	( 0.128)	( 0.203)
	Min,	3.8,	-0.7,	3.8,	-0.1,	3.8,	-0.7,
	Max	4.2	0.1	4.9	1.3	4.9	1.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	4	4	4	4	8	8
	Mean	3.88	-0.38	3.93	0.08	3.90	-0.15
	Median	3.80	-0.40	3.95	0.00	3.95	-0.15
	SD	0.340	0.532	0.250	0.377	0.278	0.490
	(SE)	( 0.170)	( 0.266)	( 0.125)	( 0.189)	( 0.098)	( 0.173)
	Min,	3.6,	-1.0,	3.6,	-0.3,	3.6,	-1.0,
	Max	4.3	0.3	4.2	0.6	4.3	0.6
Week 112	n	4	4	4	4	8	8
	Mean	3.95	-0.30	3.95	0.10	3.95	-0.10
	Median	3.95	-0.30	4.05	0.20	4.05	-0.10
	SD	0.238	0.408	0.311	0.432	0.256	0.444
	(SE)	( 0.119)	( 0.204)	( 0.155)	( 0.216)	( 0.091)	( 0.157)
	Min,	3.7,	-0.8,	3.5,	-0.5,	3.5,	-0.8,
	Max	4.2	0.2	4.2	0.5	4.2	0.5
Week 116	n	4	4	4	4	8	8
	Mean	4.28	0.03	4.13	0.28	4.20	0.15
	Median	4.25	0.00	4.10	0.30	4.10	0.20
	SD	0.386	0.538	0.150	0.126	0.283	0.385
	(SE)	( 0.193)	( 0.269)	( 0.075)	( 0.063)	( 0.100)	( 0.136)
	Min,	3.9,	-0.6,	4.0,	0.1,	3.9,	-0.6,
	Max	4.7	0.7	4.3	0.4	4.7	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	4.00	-0.20	4.20	0.35	4.11	0.11
	Median	3.90	-0.10	4.20	0.30	4.10	0.10
	SD	0.265	0.557	0.183	0.300	0.227	0.485
	(SE)	( 0.153)	( 0.321)	( 0.091)	( 0.150)	( 0.086)	( 0.183)
	Min,	3.8,	-0.8,	4.0,	0.1,	3.8,	-0.8,
	Max	4.3	0.3	4.4	0.7	4.4	0.7
Week 124	n	3	3	4	4	7	7
	Mean	3.93	-0.27	4.10	0.25	4.03	0.03
	Median	3.70	-0.40	4.15	0.35	4.10	0.20
	SD	0.493	0.709	0.294	0.404	0.364	0.571
	(SE)	( 0.285)	( 0.410)	( 0.147)	( 0.202)	( 0.138)	( 0.216)
	Min,	3.6,	-0.9,	3.7,	-0.3,	3.6,	-0.9,
	Max	4.5	0.5	4.4	0.6	4.5	0.6
Week 128	n	4	4	4	4	8	8
	Mean	4.20	-0.05	3.70	-0.15	3.95	-0.10
	Median	4.10	-0.20	3.85	-0.10	3.90	-0.10
	SD	0.346	0.526	0.337	0.412	0.414	0.441
	(SE)	( 0.173)	( 0.263)	( 0.168)	( 0.206)	( 0.146)	( 0.156)
	Min,	3.9,	-0.5,	3.2,	-0.7,	3.2,	-0.7,
	Max	4.7	0.7	3.9	0.3	4.7	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	4.25	0.00	4.05	0.20	4.15	0.10
	Median	4.05	-0.20	4.05	0.20	4.05	0.10
	SD	0.507	0.735	0.129	0.183	0.359	0.507
	(SE)	( 0.253)	( 0.367)	( 0.065)	( 0.091)	( 0.127)	( 0.179)
	Min,	3.9,	-0.6,	3.9,	0.0,	3.9,	-0.6,
	Max	5.0	1.0	4.2	0.4	5.0	1.0
Week 136	n	4	4	4	4	8	8
	Mean	3.98	-0.28	3.95	0.10	3.96	-0.09
	Median	4.00	-0.45	3.90	0.15	4.00	0.00
	SD	0.369	0.457	0.191	0.141	0.272	0.372
	(SE)	( 0.184)	( 0.229)	( 0.096)	( 0.071)	( 0.096)	( 0.132)
	Min,	3.5,	-0.6,	3.8,	-0.1,	3.5,	-0.6,
	Max	4.4	0.4	4.2	0.2	4.4	0.4
Week 140	n	4	4	4	4	8	8
	Mean	4.20	-0.05	3.75	-0.10	3.98	-0.08
	Median	4.05	-0.20	3.75	-0.15	3.90	-0.15
	SD	0.337	0.545	0.058	0.141	0.328	0.369
	(SE)	( 0.168)	( 0.272)	( 0.029)	( 0.071)	( 0.116)	( 0.131)
	Min,	4.0,	-0.5,	3.7,	-0.2,	3.7,	-0.5,
	Max	4.7	0.7	3.8	0.1	4.7	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	3.95	-0.30	3.83	-0.03	3.89	-0.16
	Median	4.10	-0.20	3.90	0.05	4.00	0.00
	SD	0.451	0.668	0.386	0.465	0.394	0.553
	(SE)	( 0.225)	( 0.334)	( 0.193)	( 0.232)	( 0.139)	( 0.195)
	Min,	3.3,	-1.1,	3.3,	-0.6,	3.3,	-1.1,
	Max	4.3	0.3	4.2	0.4	4.3	0.4
Week 148	n	4	4	4	4	8	8
	Mean	3.93	-0.33	3.90	0.05	3.91	-0.14
	Median	3.90	-0.20	3.85	0.00	3.90	-0.10
	SD	0.330	0.479	0.424	0.342	0.352	0.434
	(SE)	( 0.165)	( 0.239)	( 0.212)	( 0.171)	( 0.125)	( 0.153)
	Min,	3.6,	-1.0,	3.5,	-0.3,	3.5,	-1.0,
	Max	4.3	0.1	4.4	0.5	4.4	0.5
Week 152	n	4	4	3	3	7	7
	Mean	4.18	-0.08	3.90	0.10	4.06	0.00
	Median	4.20	-0.05	3.90	0.10	4.10	0.10
	SD	0.369	0.320	0.200	0.100	0.321	0.252
	(SE)	( 0.184)	( 0.160)	( 0.115)	( 0.058)	( 0.121)	( 0.095)
	Min,	3.7,	-0.4,	3.7,	0.0,	3.7,	-0.4,
	Max	4.6	0.2	4.1	0.2	4.6	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	4.28	0.03	4.00	0.15	4.14	0.09
	Median	4.25	-0.10	4.00	0.10	4.05	0.05
	SD	0.427	0.556	0.082	0.173	0.320	0.387
	(SE)	( 0.214)	( 0.278)	( 0.041)	( 0.087)	( 0.113)	( 0.137)
	Min,	3.8,	-0.5,	3.9,	0.0,	3.8,	-0.5,
	Max	4.8	0.8	4.1	0.4	4.8	0.8
Week 160	n	4	4	4	4	8	8
	Mean	4.18	-0.08	4.13	0.28	4.15	0.10
	Median	4.20	-0.10	4.15	0.30	4.15	0.20
	SD	0.222	0.369	0.171	0.126	0.185	0.316
	(SE)	( 0.111)	( 0.184)	( 0.085)	( 0.063)	( 0.065)	( 0.112)
	Min,	3.9,	-0.5,	3.9,	0.1,	3.9,	-0.5,
	Max	4.4	0.4	4.3	0.4	4.4	0.4
Week 164	n	4	4	4	4	8	8
	Mean	3.98	-0.28	4.03	0.18	4.00	-0.05
	Median	4.00	-0.25	4.05	0.25	4.05	0.10
	SD	0.556	0.640	0.250	0.287	0.400	0.518
	(SE)	( 0.278)	( 0.320)	( 0.125)	( 0.144)	( 0.141)	( 0.183)
	Min,	3.4,	-1.0,	3.7,	-0.2,	3.4,	-1.0,
	Max	4.5	0.4	4.3	0.4	4.5	0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	3.98	-0.28	3.93	0.08	3.95	-0.10
	Median	3.95	-0.20	3.90	0.05	3.95	-0.10
	SD	0.171	0.299	0.330	0.250	0.245	0.316
	(SE)	( 0.085)	( 0.149)	( 0.165)	( 0.125)	( 0.087)	( 0.112)
	Min,	3.8,	-0.7,	3.6,	-0.2,	3.6,	-0.7,
	Max	4.2	0.0	4.3	0.4	4.3	0.4
Week 172	n	4	4	4	4	8	8
	Mean	4.08	-0.17	3.90	0.05	3.99	-0.06
	Median	4.20	0.05	3.85	0.05	3.95	0.05
	SD	0.499	0.704	0.216	0.238	0.368	0.501
	(SE)	( 0.250)	( 0.352)	( 0.108)	( 0.119)	( 0.130)	( 0.177)
	Min,	3.4,	-1.2,	3.7,	-0.2,	3.4,	-1.2,
	Max	4.5	0.4	4.2	0.3	4.5	0.4
Week 176	n	4	4	4	4	8	8
	Mean	4.40	0.15	4.00	0.15	4.20	0.15
	Median	4.55	0.20	4.00	0.20	4.15	0.20
	SD	0.424	0.265	0.183	0.173	0.370	0.207
	(SE)	( 0.212)	( 0.132)	( 0.091)	( 0.087)	( 0.131)	( 0.073)
	Min,	3.8,	-0.2,	3.8,	-0.1,	3.8,	-0.2,
	Max	4.7	0.4	4.2	0.3	4.7	0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	4	4	3	3	7	7
	Mean	4.13	-0.13	3.87	0.07	4.01	-0.04
	Median	4.10	-0.05	3.90	0.10	3.90	0.10
	SD	0.443	0.538	0.153	0.252	0.353	0.420
	(SE)	( 0.221)	( 0.269)	( 0.088)	( 0.145)	( 0.134)	( 0.159)
	Min,	3.7,	-0.8,	3.7,	-0.2,	3.7,	-0.8,
	Max	4.6	0.4	4.0	0.3	4.6	0.4
Week 184	n	4	4	4	4	8	8
	Mean	3.88	-0.38	4.00	0.15	3.94	-0.11
	Median	3.85	-0.30	4.00	0.15	4.00	0.10
	SD	0.665	0.772	0.183	0.129	0.457	0.584
	(SE)	( 0.333)	( 0.386)	( 0.091)	( 0.065)	( 0.161)	( 0.207)
	Min,	3.3,	-1.3,	3.8,	0.0,	3.3,	-1.3,
	Max	4.5	0.4	4.2	0.3	4.5	0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Chloride (mmol/L)						
Baseline <sup>1</sup>	n	4		4		8
	Mean	102.5		102.8		102.6
	Median	102.5		103.0		103.0
	SD	1.29		2.06		1.60
	(SE)	( 0.65)		( 1.03)		( 0.56)
	Min,	101,		100,		100,
	Max	104		105		105
Week 2	n	4	4	4	4	8
	Mean	103.3	0.8	104.3	1.5	103.8
	Median	104.0	0.5	105.0	2.0	105.0
	SD	2.36	2.50	1.50	3.32	1.91
	(SE)	( 1.18)	( 1.25)	( 0.75)	( 1.66)	( 0.67)
	Min,	100,	-2,	102,	-3,	100,
	Max	105	4	105	5	105
Week 4	n	4	4	4	4	8
	Mean	102.5	0.0	102.3	-0.5	102.4
	Median	102.5	0.0	102.0	-0.5	102.0
	SD	1.29	2.45	0.50	2.08	0.92
	(SE)	( 0.65)	( 1.22)	( 0.25)	( 1.04)	( 0.32)
	Min,	101,	-3,	102,	-3,	101,
	Max	104	3	103	2	104

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	105.3	2.8	101.8	-1.0	103.5	0.9
	Median	105.0	2.5	102.5	-1.5	104.5	2.0
	SD	0.50	0.96	2.63	3.74	2.56	3.23
	(SE)	( 0.25)	( 0.48)	( 1.31)	( 1.87)	( 0.91)	( 1.14)
	Min,	105,	2,	98,	-5,	98,	-5,
	Max	106	4	104	4	106	4
Week 8	n	4	4	4	4	8	8
	Mean	103.0	0.5	103.8	1.0	103.4	0.8
	Median	102.0	0.5	104.0	2.5	102.5	1.5
	SD	2.71	2.08	2.22	3.37	2.33	2.60
	(SE)	( 1.35)	( 1.04)	( 1.11)	( 1.68)	( 0.82)	( 0.92)
	Min,	101,	-2,	101,	-4,	101,	-4,
	Max	107	3	106	3	107	3
Week 10	n	4	4	4	4	8	8
	Mean	102.3	-0.3	103.3	0.5	102.8	0.1
	Median	101.5	0.0	103.5	0.5	102.5	0.5
	SD	2.63	2.22	0.96	2.89	1.91	2.42
	(SE)	( 1.31)	( 1.11)	( 0.48)	( 1.44)	( 0.67)	( 0.85)
	Min,	100,	-3,	102,	-3,	100,	-3,
	Max	106	2	104	4	106	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 12	n	4	4	4	4	8	8
	Mean	102.5	0.0	101.3	-1.5	101.9	-0.8
	Median	102.0	0.0	101.5	-1.5	102.0	0.0
	SD	1.00	0.82	1.71	2.38	1.46	1.83
	(SE)	( 0.50)	( 0.41)	( 0.85)	( 1.19)	( 0.52)	( 0.65)
	Min,	102,	-1,	99,	-4,	99,	-4,
	Max	104	1	103	1	104	1
Week 15	n	4	4	4	4	8	8
	Mean	103.5	1.0	103.5	0.8	103.5	0.9
	Median	103.5	1.0	103.0	0.0	103.0	0.0
	SD	2.38	2.58	1.00	1.50	1.69	1.96
	(SE)	( 1.19)	( 1.29)	( 0.50)	( 0.75)	( 0.60)	( 0.69)
	Min,	101,	-2,	103,	0,	101,	-2,
	Max	106	4	105	3	106	4
Week 18	n	4	4	4	4	8	8
	Mean	103.5	1.0	102.0	-0.8	102.8	0.1
	Median	103.0	1.0	102.0	-0.5	103.0	1.0
	SD	1.73	0.82	2.58	2.75	2.19	2.10
	(SE)	( 0.87)	( 0.41)	( 1.29)	( 1.38)	( 0.77)	( 0.74)
	Min,	102,	0,	99,	-4,	99,	-4,
	Max	106	2	105	2	106	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	106.0	3.5	106.8	4.0	106.4	3.8
	Median	106.0	3.5	107.0	4.0	106.5	3.5
	SD	1.83	0.58	1.50	1.83	1.60	1.28
	(SE)	( 0.91)	( 0.29)	( 0.75)	( 0.91)	( 0.56)	( 0.45)
	Min,	104,	3,	105,	2,	104,	2,
	Max	108	4	108	6	108	6
Week 24	n	4	4	4	4	8	8
	Mean	104.5	2.0	103.8	1.0	104.1	1.5
	Median	105.0	2.0	104.0	1.0	104.0	1.5
	SD	1.73	0.82	0.50	1.63	1.25	1.31
	(SE)	( 0.87)	( 0.41)	( 0.25)	( 0.82)	( 0.44)	( 0.46)
	Min,	102,	1,	103,	-1,	102,	-1,
	Max	106	3	104	3	106	3
Week 25	n	4	4	4	4	8	8
	Mean	104.0	1.5	104.3	1.5	104.1	1.5
	Median	103.5	2.0	104.5	1.0	104.0	1.5
	SD	2.16	1.91	0.96	2.65	1.55	2.14
	(SE)	( 1.08)	( 0.96)	( 0.48)	( 1.32)	( 0.55)	( 0.76)
	Min,	102,	-1,	103,	-1,	102,	-1,
	Max	107	3	105	5	107	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	105.5	3.0	104.5	1.8	105.0	2.4
	Median	105.5	3.0	104.5	1.0	105.0	2.5
	SD	0.58	0.82	1.29	3.10	1.07	2.20
	(SE)	( 0.29)	( 0.41)	( 0.65)	( 1.55)	( 0.38)	( 0.78)
	Min,	105,	2,	103,	-1,	103,	-1,
	Max	106	4	106	6	106	6
Week 32	n	4	4	3	3	7	7
	Mean	102.3	-0.3	102.3	-1.3	102.3	-0.7
	Median	102.5	-0.5	102.0	-2.0	102.0	-1.0
	SD	0.96	0.96	1.53	2.08	1.11	1.50
	(SE)	( 0.48)	( 0.48)	( 0.88)	( 1.20)	( 0.42)	( 0.57)
	Min,	101,	-1,	101,	-3,	101,	-3,
	Max	103	1	104	1	104	1
Week 36	n	4	4	4	4	8	8
	Mean	101.8	-0.8	101.3	-1.5	101.5	-1.1
	Median	101.5	-0.5	101.5	-1.5	101.5	-1.0
	SD	1.71	1.71	0.96	2.89	1.31	2.23
	(SE)	( 0.85)	( 0.85)	( 0.48)	( 1.44)	( 0.46)	( 0.79)
	Min,	100,	-3,	100,	-5,	100,	-5,
	Max	104	1	102	2	104	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	102.5	0.0	102.5	-0.3	102.5	-0.1
	Median	102.0	0.0	102.5	-0.5	102.5	-0.5
	SD	1.91	1.83	2.08	1.71	1.85	1.64
	(SE)	( 0.96)	( 0.91)	( 1.04)	( 0.85)	( 0.65)	( 0.58)
	Min,	101,	-2,	100,	-2,	100,	-2,
	Max	105	2	105	2	105	2
Week 44	n	4	4	4	4	8	8
	Mean	101.8	-0.8	102.8	0.0	102.3	-0.4
	Median	102.0	-0.5	103.0	-0.5	103.0	-0.5
	SD	1.50	2.50	0.50	2.16	1.16	2.20
	(SE)	( 0.75)	( 1.25)	( 0.25)	( 1.08)	( 0.41)	( 0.78)
	Min,	100,	-4,	102,	-2,	100,	-4,
	Max	103	2	103	3	103	3
Week 48	n	4	4	4	4	8	8
	Mean	102.3	-0.3	101.5	-1.3	101.9	-0.8
	Median	102.0	-0.5	101.5	-2.0	102.0	-1.0
	SD	0.50	1.71	1.29	3.10	0.99	2.38
	(SE)	( 0.25)	( 0.85)	( 0.65)	( 1.55)	( 0.35)	( 0.84)
	Min,	102,	-2,	100,	-4,	100,	-4,
	Max	103	2	103	3	103	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	101.5	-1.0	101.5	-1.3	101.5	-1.1
	Median	101.5	-1.5	101.5	-0.5	101.5	-1.0
	SD	1.29	2.16	1.29	1.89	1.20	1.89
	(SE)	( 0.65)	( 1.08)	( 0.65)	( 0.95)	( 0.42)	( 0.67)
	Min,	100,	-3,	100,	-4,	100,	-4,
	Max	103	2	103	0	103	2
Week 56	n	4	4	3	3	7	7
	Mean	101.3	-1.3	103.0	0.3	102.0	-0.6
	Median	101.0	-1.5	103.0	1.0	102.0	-1.0
	SD	0.50	1.71	1.00	3.06	1.15	2.30
	(SE)	( 0.25)	( 0.85)	( 0.58)	( 1.76)	( 0.44)	( 0.87)
	Min,	101,	-3,	102,	-3,	101,	-3,
	Max	102	1	104	3	104	3
Week 60	n	4	4	4	4	8	8
	Mean	101.0	-1.5	103.8	1.0	102.4	-0.3
	Median	101.0	-1.5	104.0	1.0	102.0	-0.5
	SD	0.82	1.29	1.50	3.37	1.85	2.71
	(SE)	( 0.41)	( 0.65)	( 0.75)	( 1.68)	( 0.65)	( 0.96)
	Min,	100,	-3,	102,	-3,	100,	-3,
	Max	102	0	105	5	105	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	100.5	-2.0	101.8	-1.0	101.1	-1.5
	Median	100.0	-2.0	101.5	-0.5	101.0	-1.0
	SD	1.00	1.83	0.96	2.16	1.13	1.93
	(SE)	( 0.50)	( 0.91)	( 0.48)	( 1.08)	( 0.40)	( 0.68)
	Min,	100,	-4,	101,	-4,	100,	-4,
	Max	102	0	103	1	103	1
Week 68	n	4	4	4	4	8	8
	Mean	100.5	-2.0	102.0	-0.8	101.3	-1.4
	Median	100.5	-2.5	102.0	-0.5	101.5	-1.5
	SD	1.29	2.16	0.82	1.71	1.28	1.92
	(SE)	( 0.65)	( 1.08)	( 0.41)	( 0.85)	( 0.45)	( 0.68)
	Min,	99,	-4,	101,	-3,	99,	-4,
	Max	102	1	103	1	103	1
Week 72	n	3	3	4	4	7	7
	Mean	100.7	-1.3	102.0	-0.8	101.4	-1.0
	Median	101.0	-1.0	102.0	-1.0	101.0	-1.0
	SD	0.58	1.53	0.82	1.26	0.98	1.29
	(SE)	( 0.33)	( 0.88)	( 0.41)	( 0.63)	( 0.37)	( 0.49)
	Min,	100,	-3,	101,	-2,	100,	-3,
	Max	101	0	103	1	103	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	102.5	0.0			102.5	0.0
	Median	102.5	0.0			102.5	0.0
	SD	0.71	2.83			0.71	2.83
	(SE)	( 0.50)	( 2.00)			( 0.50)	( 2.00)
	Min,	102,	-2,			102,	-2,
	Max	103	2			103	2
Week 76	n	4	4	4	4	8	8
	Mean	101.0	-1.5	101.8	-1.0	101.4	-1.3
	Median	101.0	-1.5	102.0	-2.0	101.5	-1.5
	SD	1.63	1.29	1.26	2.83	1.41	2.05
	(SE)	( 0.82)	( 0.65)	( 0.63)	( 1.41)	( 0.50)	( 0.73)
	Min,	99,	-3,	100,	-3,	99,	-3,
	Max	103	0	103	3	103	3
Week 80	n	4	4	4	4	8	8
	Mean	101.0	-1.5	102.5	-0.3	101.8	-0.9
	Median	101.0	-1.0	103.0	-1.0	101.5	-1.0
	SD	0.82	1.00	1.91	3.40	1.58	2.42
	(SE)	( 0.41)	( 0.50)	( 0.96)	( 1.70)	( 0.56)	( 0.85)
	Min,	100,	-3,	100,	-3,	100,	-3,
	Max	102	-1	104	4	104	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	101.3	-1.3	100.5	-2.3	100.9	-1.8
	Median	101.0	-1.0	100.5	-3.5	100.5	-2.5
	SD	1.50	2.22	1.29	2.87	1.36	2.43
	(SE)	( 0.75)	( 1.11)	( 0.65)	( 1.44)	( 0.48)	( 0.86)
	Min,	100,	-4,	99,	-4,	99,	-4,
	Max	103	1	102	2	103	2
Week 88	n	4	4	4	4	8	8
	Mean	102.0	-0.5	102.5	-0.3	102.3	-0.4
	Median	101.5	-0.5	102.5	1.0	102.0	0.0
	SD	2.16	1.73	2.89	4.27	2.38	3.02
	(SE)	( 1.08)	( 0.87)	( 1.44)	( 2.14)	( 0.84)	( 1.07)
	Min,	100,	-2,	99,	-6,	99,	-6,
	Max	105	1	106	3	106	3
Week 92	n	4	4	4	4	8	8
	Mean	104.0	1.5	103.0	0.3	103.5	0.9
	Median	104.5	1.5	102.5	0.5	103.5	1.5
	SD	2.16	1.29	1.41	2.75	1.77	2.10
	(SE)	( 1.08)	( 0.65)	( 0.71)	( 1.38)	( 0.63)	( 0.74)
	Min,	101,	0,	102,	-3,	101,	-3,
	Max	106	3	105	3	106	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	101.8	-0.8	102.8	0.0	102.3	-0.4
	Median	102.0	-1.0	102.5	1.0	102.0	0.0
	SD	0.50	1.26	2.06	2.71	1.49	2.00
	(SE)	( 0.25)	( 0.63)	( 1.03)	( 1.35)	( 0.53)	( 0.71)
	Min,	101,	-2,	101,	-4,	101,	-4,
	Max	102	1	105	2	105	2
Week 100	n	4	4	4	4	8	8
	Mean	100.5	-2.0	101.8	-1.0	101.1	-1.5
	Median	100.5	-2.5	101.5	-0.5	101.5	-1.5
	SD	1.73	2.16	0.96	2.16	1.46	2.07
	(SE)	( 0.87)	( 1.08)	( 0.48)	( 1.08)	( 0.52)	( 0.73)
	Min,	99,	-4,	101,	-4,	99,	-4,
	Max	102	1	103	1	103	1
Week 104	n	4	4	4	4	8	8
	Mean	102.3	-0.3	102.5	-0.3	102.4	-0.3
	Median	102.5	-0.5	103.0	-1.0	103.0	-0.5
	SD	0.96	1.71	1.00	2.36	0.92	1.91
	(SE)	( 0.48)	( 0.85)	( 0.50)	( 1.18)	( 0.32)	( 0.67)
	Min,	101,	-2,	101,	-2,	101,	-2,
	Max	103	2	103	3	103	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	102.0	-0.5	102.5	-0.3	102.3	-0.4
	Median	102.0	-1.0	102.5	0.0	102.5	-1.0
	SD	1.15	1.73	2.08	2.63	1.58	2.07
	(SE)	( 0.58)	( 0.87)	( 1.04)	( 1.31)	( 0.56)	( 0.73)
	Min,	101,	-2,	100,	-3,	100,	-3,
	Max	103	2	105	2	105	2
Week 112	n	4	4	4	4	8	8
	Mean	102.8	0.3	103.5	0.8	103.1	0.5
	Median	102.5	0.0	104.0	1.0	102.5	0.0
	SD	1.71	0.50	3.00	4.79	2.30	3.16
	(SE)	( 0.85)	( 0.25)	( 1.50)	( 2.39)	( 0.81)	( 1.12)
	Min,	101,	0,	100,	-5,	100,	-5,
	Max	105	1	106	6	106	6
Week 116	n	4	4	4	4	8	8
	Mean	103.5	1.0	102.0	-0.8	102.8	0.1
	Median	102.0	0.0	101.5	-0.5	102.0	0.0
	SD	3.70	2.71	2.16	2.50	2.92	2.59
	(SE)	( 1.85)	( 1.35)	( 1.08)	( 1.25)	( 1.03)	( 0.91)
	Min,	101,	-1,	100,	-4,	100,	-4,
	Max	109	5	105	2	109	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	103.0	1.0	103.0	0.3	103.0	0.6
	Median	103.0	1.0	103.0	0.0	103.0	1.0
	SD	1.00	2.00	0.82	2.22	0.82	1.99
	(SE)	( 0.58)	( 1.15)	( 0.41)	( 1.11)	( 0.31)	( 0.75)
	Min,	102,	-1,	102,	-2,	102,	-2,
	Max	104	3	104	3	104	3
Week 124	n	3	3	4	4	7	7
	Mean	101.7	-0.3	103.0	0.3	102.4	0.0
	Median	101.0	0.0	102.5	1.0	102.0	0.0
	SD	1.15	0.58	2.16	3.40	1.81	2.45
	(SE)	( 0.67)	( 0.33)	( 1.08)	( 1.70)	( 0.69)	( 0.93)
	Min,	101,	-1,	101,	-4,	101,	-4,
	Max	103	0	106	3	106	3
Week 128	n	4	4	4	4	8	8
	Mean	102.5	0.0	103.5	0.8	103.0	0.4
	Median	102.5	0.0	103.0	1.0	103.0	0.0
	SD	0.58	0.82	1.73	2.63	1.31	1.85
	(SE)	( 0.29)	( 0.41)	( 0.87)	( 1.31)	( 0.46)	( 0.65)
	Min,	102,	-1,	102,	-2,	102,	-2,
	Max	103	1	106	3	106	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	101.3	-1.3	102.0	-0.8	101.6	-1.0
	Median	100.5	-1.0	101.5	0.0	101.0	-1.0
	SD	1.89	1.50	2.16	3.40	1.92	2.45
	(SE)	( 0.95)	( 0.75)	( 1.08)	( 1.70)	( 0.68)	( 0.87)
	Min,	100,	-3,	100,	-5,	100,	-5,
	Max	104	0	105	2	105	2
Week 136	n	4	4	4	4	8	8
	Mean	100.8	-1.8	103.3	0.5	102.0	-0.6
	Median	100.0	-2.0	103.5	0.5	102.0	-1.0
	SD	2.22	1.50	1.71	2.38	2.27	2.20
	(SE)	( 1.11)	( 0.75)	( 0.85)	( 1.19)	( 0.80)	( 0.78)
	Min,	99,	-3,	101,	-2,	99,	-3,
	Max	104	0	105	3	105	3
Week 140	n	4	4	4	4	8	8
	Mean	102.5	0.0	101.8	-1.0	102.1	-0.5
	Median	103.0	0.0	101.5	-0.5	102.0	0.0
	SD	1.91	0.82	1.71	2.16	1.73	1.60
	(SE)	( 0.96)	( 0.41)	( 0.85)	( 1.08)	( 0.61)	( 0.57)
	Min,	100,	-1,	100,	-4,	100,	-4,
	Max	104	1	104	1	104	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	102.5	0.0	104.0	1.3	103.3	0.6
	Median	101.0	-0.5	104.0	0.5	103.5	0.0
	SD	3.70	2.94	0.82	1.89	2.60	2.39
	(SE)	( 1.85)	( 1.47)	( 0.41)	( 0.95)	( 0.92)	( 0.84)
	Min,	100,	-3,	103,	0,	100,	-3,
	Max	108	4	105	4	108	4
Week 148	n	4	4	4	4	8	8
	Mean	102.0	-0.5	102.3	-0.5	102.1	-0.5
	Median	102.0	-0.5	102.5	-0.5	102.0	-0.5
	SD	1.63	0.58	0.96	1.29	1.25	0.93
	(SE)	( 0.82)	( 0.29)	( 0.48)	( 0.65)	( 0.44)	( 0.33)
	Min,	100,	-1,	101,	-2,	100,	-2,
	Max	104	0	103	1	104	1
Week 152	n	4	4	3	3	7	7
	Mean	101.5	-1.0	102.3	-1.3	101.9	-1.1
	Median	101.0	-1.0	103.0	0.0	101.0	-1.0
	SD	1.00	0.82	1.15	2.31	1.07	1.46
	(SE)	( 0.50)	( 0.41)	( 0.67)	( 1.33)	( 0.40)	( 0.55)
	Min,	101,	-2,	101,	-4,	101,	-4,
	Max	103	0	103	0	103	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	102.3	-0.3	102.3	-0.5	102.3	-0.4
	Median	101.5	0.0	102.5	-0.5	102.0	-0.5
	SD	1.89	1.50	1.71	1.29	1.67	1.30
	(SE)	( 0.95)	( 0.75)	( 0.85)	( 0.65)	( 0.59)	( 0.46)
	Min,	101,	-2,	100,	-2,	100,	-2,
	Max	105	1	104	1	105	1
Week 160	n	4	4	4	4	8	8
	Mean	101.8	-0.8	101.5	-1.3	101.6	-1.0
	Median	101.5	-1.0	101.5	-1.5	101.5	-1.0
	SD	0.96	0.50	1.29	3.30	1.06	2.20
	(SE)	( 0.48)	( 0.25)	( 0.65)	( 1.65)	( 0.37)	( 0.78)
	Min,	101,	-1,	100,	-5,	100,	-5,
	Max	103	0	103	3	103	3
Week 164	n	4	4	4	4	8	8
	Mean	103.0	0.5	103.8	1.0	103.4	0.8
	Median	103.0	0.5	103.5	1.0	103.0	0.5
	SD	1.63	1.29	1.71	2.94	1.60	2.12
	(SE)	( 0.82)	( 0.65)	( 0.85)	( 1.47)	( 0.56)	( 0.75)
	Min,	101,	-1,	102,	-2,	101,	-2,
	Max	105	2	106	4	106	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 168	n	4	4	4	4	8	8
	Mean	103.5	1.0	102.5	-0.3	103.0	0.4
	Median	103.0	0.5	102.5	0.0	103.0	0.5
	SD	2.52	1.41	1.29	2.99	1.93	2.26
	(SE)	( 1.26)	( 0.71)	( 0.65)	( 1.49)	( 0.68)	( 0.80)
	Min,	101,	0,	101,	-4,	101,	-4,
	Max	107	3	104	3	107	3
Week 172	n	4	4	4	4	8	8
	Mean	102.3	-0.3	102.0	-0.8	102.1	-0.5
	Median	102.0	0.0	101.5	-0.5	101.5	0.0
	SD	1.50	0.50	1.41	2.06	1.36	1.41
	(SE)	( 0.75)	( 0.25)	( 0.71)	( 1.03)	( 0.48)	( 0.50)
	Min,	101,	-1,	101,	-3,	101,	-3,
	Max	104	0	104	1	104	1
Week 176	n	4	4	4	4	8	8
	Mean	103.8	1.3	103.8	1.0	103.8	1.1
	Median	103.5	1.0	104.0	0.5	104.0	1.0
	SD	0.96	1.26	0.50	2.16	0.71	1.64
	(SE)	( 0.48)	( 0.63)	( 0.25)	( 1.08)	( 0.25)	( 0.58)
	Min,	103,	0,	103,	-1,	103,	-1,
	Max	105	3	104	4	105	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	101.5	-1.0	101.7	-2.0	101.6	-1.4
	Median	102.0	-1.0	101.0	-2.0	102.0	-1.0
	SD	1.00	0.82	2.08	3.00	1.40	1.90
	(SE)	( 0.50)	( 0.41)	( 1.20)	( 1.73)	( 0.53)	( 0.72)
	Min,	100,	-2,	100,	-5,	100,	-5,
	Max	102	0	104	1	104	1
Week 184	n	4	4	4	4	8	8
	Mean	101.5	-1.0	103.3	0.5	102.4	-0.3
	Median	102.5	-0.5	103.0	1.0	102.5	0.0
	SD	2.38	1.41	2.22	2.52	2.33	2.05
	(SE)	( 1.19)	( 0.71)	( 1.11)	( 1.26)	( 0.82)	( 0.73)
	Min,	98,	-3,	101,	-3,	98,	-3,
	Max	103	0	106	3	106	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Calcium (mmol/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	2.2875		2.3438		2.3156	
	Median	2.3125		2.3500		2.3375	
	SD	0.09682		0.05154		0.07785	
	(SE)	( 0.04841)		( 0.02577)		( 0.02752)	
	Min,	2.150,		2.275,		2.150,	
	Max	2.375		2.400		2.400	
Week 2	n	4	4	4	4	8	8
	Mean	2.3250	0.0375	2.2938	-0.0500	2.3094	-0.0063
	Median	2.3125	0.0625	2.3000	-0.0375	2.3000	-0.0250
	SD	0.07906	0.10104	0.03146	0.03536	0.05815	0.08425
	(SE)	( 0.03953)	( 0.05052)	( 0.01573)	( 0.01768)	( 0.02056)	( 0.02979)
	Min,	2.250,	-0.100,	2.250,	-0.100,	2.250,	-0.100,
	Max	2.425	0.125	2.325	-0.025	2.425	0.125
Week 4	n	4	4	4	4	8	8
	Mean	2.3063	0.0188	2.4125	0.0688	2.3594	0.0438
	Median	2.3125	0.0000	2.4375	0.0625	2.3250	0.0000
	SD	0.02394	0.11434	0.11990	0.09656	0.09814	0.10155
	(SE)	( 0.01197)	( 0.05717)	( 0.05995)	( 0.04828)	( 0.03470)	( 0.03590)
	Min,	2.275,	-0.100,	2.250,	-0.025,	2.250,	-0.100,
	Max	2.325	0.175	2.525	0.175	2.525	0.175

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	2.2813	-0.0063	2.2188	-0.1250	2.2500	-0.0656
	Median	2.2750	-0.0125	2.3250	0.0000	2.2750	0.0000
	SD	0.03146	0.10680	0.26800	0.26693	0.17978	0.19863
	(SE)	( 0.01573)	( 0.05340)	( 0.13400)	( 0.13346)	( 0.06356)	( 0.07023)
	Min,	2.250,	-0.125,	1.825,	-0.525,	1.825,	-0.525,
	Max	2.325	0.125	2.400	0.025	2.400	0.125
Week 8	n	4	4	4	4	8	8
	Mean	2.3250	0.0375	2.3125	-0.0313	2.3187	0.0031
	Median	2.3250	0.0500	2.3500	-0.0125	2.3250	0.0000
	SD	0.06124	0.12990	0.11273	0.06575	0.08425	0.10215
	(SE)	( 0.03062)	( 0.06495)	( 0.05637)	( 0.03287)	( 0.02979)	( 0.03612)
	Min,	2.250,	-0.125,	2.150,	-0.125,	2.150,	-0.125,
	Max	2.400	0.175	2.400	0.025	2.400	0.175
Week 10	n	4	4	4	4	8	8
	Mean	2.2938	0.0063	2.2875	-0.0563	2.2906	-0.0250
	Median	2.2875	-0.0625	2.3125	-0.0500	2.2875	-0.0625
	SD	0.08750	0.16378	0.10897	0.09437	0.09155	0.12817
	(SE)	( 0.04375)	( 0.08189)	( 0.05449)	( 0.04719)	( 0.03237)	( 0.04532)
	Min,	2.200,	-0.100,	2.150,	-0.150,	2.150,	-0.150,
	Max	2.400	0.250	2.375	0.025	2.400	0.250

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	2.3125	0.0250	2.3500	0.0063	2.3313	0.0156
	Median	2.2875	0.0250	2.3250	0.0000	2.2875	0.0000
	SD	0.05951	0.10206	0.11365	0.07465	0.08634	0.08339
	(SE)	( 0.02976)	( 0.05103)	( 0.05683)	( 0.03733)	( 0.03053)	( 0.02948)
	Min,	2.275,	-0.075,	2.250,	-0.075,	2.250,	-0.075,
	Max	2.400	0.125	2.500	0.100	2.500	0.125
Week 15	n	4	4	4	4	8	8
	Mean	2.3000	0.0125	2.3188	-0.0250	2.3094	-0.0062
	Median	2.3000	0.0000	2.3000	-0.0375	2.3000	-0.0125
	SD	0.06124	0.10308	0.09656	0.05401	0.07552	0.07877
	(SE)	( 0.03062)	( 0.05154)	( 0.04828)	( 0.02700)	( 0.02670)	( 0.02785)
	Min,	2.225,	-0.100,	2.225,	-0.075,	2.225,	-0.100,
	Max	2.375	0.150	2.450	0.050	2.450	0.150
Week 18	n	4	4	4	4	8	8
	Mean	2.2938	0.0063	2.3375	-0.0063	2.3156	0.0000
	Median	2.3000	-0.0250	2.3500	-0.0125	2.3250	-0.0125
	SD	0.03750	0.12479	0.06614	0.02394	0.05500	0.08345
	(SE)	( 0.01875)	( 0.06240)	( 0.03307)	( 0.01197)	( 0.01944)	( 0.02950)
	Min,	2.250,	-0.100,	2.250,	-0.025,	2.250,	-0.100,
	Max	2.325	0.175	2.400	0.025	2.400	0.175

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	2.2875	0.0000	2.2875	-0.0563	2.2875	-0.0281
	Median	2.2750	0.0000	2.2500	-0.1000	2.2625	-0.0750
	SD	0.06614	0.08660	0.11273	0.10680	0.08557	0.09490
	(SE)	( 0.03307)	( 0.04330)	( 0.05637)	( 0.05340)	( 0.03025)	( 0.03355)
	Min,	2.225,	-0.075,	2.200,	-0.125,	2.200,	-0.125,
	Max	2.375	0.075	2.450	0.100	2.450	0.100
Week 24	n	4	4	4	4	8	8
	Mean	2.3063	0.0188	2.2813	-0.0625	2.2938	-0.0219
	Median	2.3000	0.0500	2.2750	-0.0500	2.2750	-0.0250
	SD	0.07465	0.12479	0.03146	0.04787	0.05469	0.09769
	(SE)	( 0.03733)	( 0.06240)	( 0.01573)	( 0.02394)	( 0.01934)	( 0.03454)
	Min,	2.225,	-0.150,	2.250,	-0.125,	2.225,	-0.150,
	Max	2.400	0.125	2.325	-0.025	2.400	0.125
Week 25	n	4	4	4	4	8	8
	Mean	2.3000	0.0125	2.2875	-0.0563	2.2938	-0.0219
	Median	2.2875	-0.0500	2.2875	-0.0500	2.2875	-0.0500
	SD	0.06124	0.14216	0.08780	0.05543	0.07039	0.10643
	(SE)	( 0.03062)	( 0.07108)	( 0.04390)	( 0.02772)	( 0.02489)	( 0.03763)
	Min,	2.250,	-0.075,	2.200,	-0.125,	2.200,	-0.125,
	Max	2.375	0.225	2.375	0.000	2.375	0.225

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	2.2375	-0.0500	2.2375	-0.1063	2.2375	-0.0781
	Median	2.2375	-0.1000	2.2375	-0.1000	2.2375	-0.1000
	SD	0.03227	0.10000	0.04330	0.03750	0.03536	0.07611
	(SE)	( 0.01614)	( 0.05000)	( 0.02165)	( 0.01875)	( 0.01250)	( 0.02691)
	Min,	2.200,	-0.100,	2.200,	-0.150,	2.200,	-0.150,
	Max	2.275	0.100	2.275	-0.075	2.275	0.100
Week 32	n	4	4	3	3	7	7
	Mean	2.3563	0.0688	2.3167	-0.0083	2.3393	0.0357
	Median	2.3500	0.0625	2.2750	0.0000	2.3250	0.0000
	SD	0.05543	0.09656	0.07217	0.06292	0.06099	0.08763
	(SE)	( 0.02772)	( 0.04828)	( 0.04167)	( 0.03632)	( 0.02305)	( 0.02312)
	Min,	2.300,	-0.025,	2.275,	-0.075,	2.275,	-0.075,
	Max	2.425	0.175	2.400	0.050	2.425	0.175
Week 36	n	4	4	4	4	8	8
	Mean	2.3563	0.0688	2.3375	-0.0063	2.3469	0.0313
	Median	2.3625	0.0500	2.3375	0.0250	2.3625	0.0250
	SD	0.04270	0.05543	0.04330	0.06250	0.04105	0.06781
	(SE)	( 0.02135)	( 0.02772)	( 0.02165)	( 0.03125)	( 0.01451)	( 0.02397)
	Min,	2.300,	0.025,	2.300,	-0.100,	2.300,	-0.100,
	Max	2.400	0.150	2.375	0.025	2.400	0.150

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	2.3125	0.0250	2.3438	0.0000	2.3281	0.0125
	Median	2.3125	0.0000	2.3375	0.0000	2.3125	0.0000
	SD	0.07217	0.10801	0.08750	0.04564	0.07611	0.07792
	(SE)	( 0.03608)	( 0.05401)	( 0.04375)	( 0.02282)	( 0.02691)	( 0.02755)
	Min,	2.225,	-0.075,	2.250,	-0.050,	2.225,	-0.075,
	Max	2.400	0.175	2.450	0.050	2.450	0.175
Week 44	n	4	4	4	4	8	8
	Mean	2.3250	0.0375	2.3438	0.0000	2.3344	0.0188
	Median	2.3125	0.0250	2.3375	0.0000	2.3125	0.0000
	SD	0.03536	0.09242	0.08004	0.06124	0.05815	0.07530
	(SE)	( 0.01768)	( 0.04621)	( 0.04002)	( 0.03062)	( 0.02056)	( 0.02662)
	Min,	2.300,	-0.050,	2.275,	-0.075,	2.275,	-0.075,
	Max	2.375	0.150	2.425	0.075	2.425	0.150
Week 48	n	4	4	4	4	8	8
	Mean	2.3375	0.0500	2.3375	-0.0063	2.3375	0.0219
	Median	2.3375	0.0625	2.3375	0.0000	2.3375	0.0375
	SD	0.05204	0.07906	0.07217	0.08260	0.05825	0.08066
	(SE)	( 0.02602)	( 0.03953)	( 0.03608)	( 0.04130)	( 0.02059)	( 0.02852)
	Min,	2.275,	-0.050,	2.250,	-0.100,	2.250,	-0.100,
	Max	2.400	0.125	2.425	0.075	2.425	0.125

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	2.3688	0.0813	2.3813	0.0375	2.3750	0.0594
	Median	2.3750	0.0750	2.3875	0.0125	2.3875	0.0250
	SD	0.05543	0.13901	0.08260	0.05951	0.06547	0.10172
	(SE)	( 0.02772)	( 0.06950)	( 0.04130)	( 0.02976)	( 0.02315)	( 0.03596)
	Min,	2.300,	-0.075,	2.275,	0.000,	2.275,	-0.075,
	Max	2.425	0.250	2.475	0.125	2.475	0.250
Week 56	n	4	4	3	3	7	7
	Mean	2.4063	0.1188	2.2500	-0.0917	2.3393	0.0286
	Median	2.3875	0.1250	2.2750	-0.1000	2.3250	0.0000
	SD	0.08985	0.11063	0.06614	0.03819	0.11167	0.13877
	(SE)	( 0.04492)	( 0.05532)	( 0.03819)	( 0.02205)	( 0.04221)	( 0.05245)
	Min,	2.325,	0.000,	2.175,	-0.125,	2.175,	-0.125,
	Max	2.525	0.225	2.300	-0.050	2.525	0.225
Week 60	n	4	4	4	4	8	8
	Mean	2.3813	0.0938	2.2938	-0.0500	2.3375	0.0219
	Median	2.3750	0.0750	2.2625	-0.0500	2.3375	-0.0125
	SD	0.05543	0.12970	0.11250	0.12247	0.09449	0.13979
	(SE)	( 0.02772)	( 0.06485)	( 0.05625)	( 0.06124)	( 0.03341)	( 0.04942)
	Min,	2.325,	-0.025,	2.200,	-0.200,	2.200,	-0.200,
	Max	2.450	0.250	2.450	0.100	2.450	0.250

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	2.3812	0.0938	2.3750	0.0313	2.3781	0.0625
	Median	2.3750	0.1375	2.3625	0.0125	2.3750	0.0625
	SD	0.10078	0.13598	0.10607	0.08509	0.09584	0.11019
	(SE)	( 0.05039)	( 0.06799)	( 0.05303)	( 0.04254)	( 0.03388)	( 0.03896)
	Min,	2.275,	-0.100,	2.275,	-0.050,	2.275,	-0.100,
	Max	2.500	0.200	2.500	0.150	2.500	0.200
Week 68	n	4	4	4	4	8	8
	Mean	2.3750	0.0875	2.3813	0.0375	2.3781	0.0625
	Median	2.3750	0.0625	2.4000	0.0250	2.3875	0.0500
	SD	0.02887	0.11990	0.09656	0.07500	0.06606	0.09636
	(SE)	( 0.01443)	( 0.05995)	( 0.04828)	( 0.03750)	( 0.02336)	( 0.03407)
	Min,	2.350,	-0.025,	2.250,	-0.025,	2.250,	-0.025,
	Max	2.400	0.250	2.475	0.125	2.475	0.250
Week 72	n	3	3	4	4	7	7
	Mean	2.3417	0.0583	2.3438	0.0000	2.3429	0.0250
	Median	2.3750	0.0000	2.3000	-0.0125	2.3250	0.0000
	SD	0.08036	0.17017	0.10680	0.12416	0.08864	0.13540
	(SE)	( 0.04640)	( 0.09825)	( 0.05340)	( 0.06208)	( 0.03350)	( 0.05118)
	Min,	2.250,	-0.075,	2.275,	-0.125,	2.250,	-0.125,
	Max	2.400	0.250	2.500	0.150	2.500	0.250

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	2.3375	0.0250			2.3375	0.0250
	Median	2.3375	0.0250			2.3375	0.0250
	SD	0.08839	0.10607			0.08839	0.10607
	(SE)	( 0.06250)	( 0.07500)			( 0.06250)	( 0.07500)
	Min,	2.275,	-0.050,			2.275,	-0.050,
	Max	2.400	0.100			2.400	0.100
Week 76	n	4	4	4	4	8	8
	Mean	2.3750	0.0875	2.3438	0.0000	2.3594	0.0438
	Median	2.3625	0.0750	2.3250	0.0125	2.3375	0.0250
	SD	0.05401	0.11990	0.05543	0.07906	0.05335	0.10501
	(SE)	( 0.02700)	( 0.05995)	( 0.02772)	( 0.03953)	( 0.01886)	( 0.03713)
	Min,	2.325,	-0.025,	2.300,	-0.100,	2.300,	-0.100,
	Max	2.450	0.225	2.425	0.075	2.450	0.225
Week 80	n	4	4	4	4	8	8
	Mean	2.3500	0.0625	2.3188	-0.0250	2.3344	0.0188
	Median	2.3375	0.0000	2.3250	0.0000	2.3375	0.0000
	SD	0.05401	0.14216	0.09437	0.09574	0.07312	0.12156
	(SE)	( 0.02700)	( 0.07108)	( 0.04719)	( 0.04787)	( 0.02585)	( 0.04298)
	Min,	2.300,	-0.025,	2.225,	-0.150,	2.225,	-0.150,
	Max	2.425	0.275	2.400	0.050	2.425	0.275

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 84	n	4	4	4	4	8	8
	Mean	2.3813	0.0938	2.3438	0.0000	2.3625	0.0469
	Median	2.3750	0.0875	2.3500	0.0375	2.3500	0.0500
	SD	0.05543	0.09656	0.07181	0.10607	0.06268	0.10643
	(SE)	( 0.02772)	( 0.04828)	( 0.03590)	( 0.05303)	( 0.02216)	( 0.03763)
	Min,	2.325,	0.000,	2.250,	-0.150,	2.250,	-0.150,
	Max	2.450	0.200	2.425	0.075	2.450	0.200
Week 88	n	4	4	4	4	8	8
	Mean	2.3438	0.0563	2.3000	-0.0438	2.3219	0.0063
	Median	2.3250	0.0250	2.3125	-0.0375	2.3250	0.0125
	SD	0.05907	0.10078	0.10607	0.09656	0.08285	0.10586
	(SE)	( 0.02954)	( 0.05039)	( 0.05303)	( 0.04828)	( 0.02929)	( 0.03743)
	Min,	2.300,	-0.025,	2.175,	-0.150,	2.175,	-0.150,
	Max	2.425	0.200	2.400	0.050	2.425	0.200
Week 92	n	4	4	4	4	8	8
	Mean	2.3187	0.0313	2.3313	-0.0125	2.3250	0.0094
	Median	2.3250	0.0500	2.3250	-0.0500	2.3250	-0.0250
	SD	0.09437	0.12970	0.15326	0.13150	0.11802	0.12316
	(SE)	( 0.04719)	( 0.06485)	( 0.07663)	( 0.06575)	( 0.04173)	( 0.04354)
	Min,	2.200,	-0.125,	2.150,	-0.125,	2.150,	-0.125,
	Max	2.425	0.150	2.525	0.175	2.525	0.175

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	2.4063	0.1188	2.3250	-0.0188	2.3656	0.0500
	Median	2.4125	0.0750	2.3125	0.0000	2.3625	0.0375
	SD	0.06250	0.14773	0.05401	0.08509	0.06936	0.13363
	(SE)	( 0.03125)	( 0.07386)	( 0.02700)	( 0.04254)	( 0.02452)	( 0.04725)
	Min,	2.325,	0.000,	2.275,	-0.125,	2.275,	-0.125,
	Max	2.475	0.325	2.400	0.050	2.475	0.325
Week 100	n	4	4	4	4	8	8
	Mean	2.4063	0.1188	2.3375	-0.0063	2.3719	0.0563
	Median	2.4125	0.0875	2.3250	-0.0375	2.3625	0.0000
	SD	0.06884	0.14631	0.08539	0.07181	0.08066	0.12589
	(SE)	( 0.03442)	( 0.07315)	( 0.04270)	( 0.03590)	( 0.02852)	( 0.04451)
	Min,	2.325,	0.000,	2.250,	-0.050,	2.250,	-0.050,
	Max	2.475	0.300	2.450	0.100	2.475	0.300
Week 104	n	4	4	4	4	8	8
	Mean	2.4000	0.1125	2.3000	-0.0438	2.3500	0.0344
	Median	2.4125	0.1000	2.2750	-0.0500	2.3625	0.0250
	SD	0.05401	0.10508	0.06770	0.07465	0.07792	0.11873
	(SE)	( 0.02700)	( 0.05254)	( 0.03385)	( 0.03733)	( 0.02755)	( 0.04198)
	Min,	2.325,	0.000,	2.250,	-0.125,	2.250,	-0.125,
	Max	2.450	0.250	2.400	0.050	2.450	0.250

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	2.4250	0.1375	2.3438	0.0000	2.3844	0.0688
	Median	2.4000	0.1375	2.3250	-0.0375	2.3875	0.0375
	SD	0.06770	0.11637	0.12141	0.10206	0.10083	0.12518
	(SE)	( 0.03385)	( 0.05818)	( 0.06070)	( 0.05103)	( 0.03565)	( 0.04426)
	Min,	2.375,	0.025,	2.225,	-0.075,	2.225,	-0.075,
	Max	2.525	0.250	2.500	0.150	2.525	0.250
Week 112	n	4	4	4	4	8	8
	Mean	2.3875	0.1000	2.3313	-0.0125	2.3594	0.0438
	Median	2.4000	0.0625	2.3500	0.0000	2.4000	0.0500
	SD	0.04330	0.12416	0.11250	0.10308	0.08445	0.12156
	(SE)	( 0.02165)	( 0.06208)	( 0.05625)	( 0.05154)	( 0.02986)	( 0.04298)
	Min,	2.325,	0.000,	2.200,	-0.125,	2.200,	-0.125,
	Max	2.425	0.275	2.425	0.075	2.425	0.275
Week 116	n	4	4	4	4	8	8
	Mean	2.4250	0.1375	2.3563	0.0125	2.3906	0.0750
	Median	2.4250	0.1125	2.3375	0.0000	2.4000	0.0625
	SD	0.04082	0.10104	0.08985	0.08539	0.07433	0.10938
	(SE)	( 0.02041)	( 0.05052)	( 0.04492)	( 0.04270)	( 0.02628)	( 0.03867)
	Min,	2.375,	0.050,	2.275,	-0.075,	2.275,	-0.075,
	Max	2.475	0.275	2.475	0.125	2.475	0.275

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	2.3417	0.0583	2.3750	0.0313	2.3607	0.0429
	Median	2.3500	0.0000	2.3500	0.0250	2.3500	0.0000
	SD	0.03819	0.12332	0.06770	0.08260	0.05563	0.09322
	(SE)	( 0.02205)	( 0.07120)	( 0.03385)	( 0.04130)	( 0.02103)	( 0.03523)
	Min,	2.300,	-0.025,	2.325,	-0.050,	2.300,	-0.050,
	Max	2.375	0.200	2.475	0.125	2.475	0.200
Week 124	n	3	3	4	4	7	7
	Mean	2.4250	0.1417	2.3875	0.0438	2.4036	0.0857
	Median	2.4250	0.1000	2.3375	0.0250	2.4250	0.0500
	SD	0.00000	0.11815	0.10897	0.11614	0.07962	0.11890
	(SE)	( 0.00000)	( 0.06821)	( 0.05449)	( 0.05807)	( 0.03009)	( 0.04494)
	Min,	2.425,	0.050,	2.325,	-0.075,	2.325,	-0.075,
	Max	2.425	0.275	2.550	0.200	2.550	0.275
Week 128	n	4	4	4	4	8	8
	Mean	2.4250	0.1375	2.3375	-0.0063	2.3812	0.0656
	Median	2.4250	0.1750	2.3625	0.0250	2.4000	0.0875
	SD	0.07360	0.11273	0.16394	0.15729	0.12660	0.14817
	(SE)	( 0.03680)	( 0.05637)	( 0.08197)	( 0.07864)	( 0.04476)	( 0.05238)
	Min,	2.350,	-0.025,	2.125,	-0.225,	2.125,	-0.225,
	Max	2.500	0.225	2.500	0.150	2.500	0.225

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	2.3375	0.0500	2.3250	-0.0188	2.3313	0.0156
	Median	2.3375	0.0250	2.3250	-0.0125	2.3250	0.0125
	SD	0.03227	0.12583	0.02041	0.06250	0.02588	0.09905
	(SE)	( 0.01614)	( 0.06292)	( 0.01021)	( 0.03125)	( 0.00915)	( 0.03502)
	Min,	2.300,	-0.075,	2.300,	-0.100,	2.300,	-0.100,
	Max	2.375	0.225	2.350	0.050	2.375	0.225
Week 136	n	4	4	4	4	8	8
	Mean	2.3500	0.0625	2.3063	-0.0375	2.3281	0.0125
	Median	2.3375	0.0375	2.3125	-0.0625	2.3375	-0.0125
	SD	0.07360	0.10104	0.12645	0.09682	0.09860	0.10607
	(SE)	( 0.03680)	( 0.05052)	( 0.06322)	( 0.04841)	( 0.03486)	( 0.03750)
	Min,	2.275,	-0.025,	2.150,	-0.125,	2.150,	-0.125,
	Max	2.450	0.200	2.450	0.100	2.450	0.200
Week 140	n	4	4	4	4	8	8
	Mean	2.3000	0.0125	2.2813	-0.0625	2.2906	-0.0250
	Median	2.3000	0.0625	2.3000	-0.0750	2.3000	-0.0125
	SD	0.08660	0.10897	0.11614	0.08292	0.09537	0.09820
	(SE)	( 0.04330)	( 0.05449)	( 0.05807)	( 0.04146)	( 0.03372)	( 0.03472)
	Min,	2.225,	-0.150,	2.125,	-0.150,	2.125,	-0.150,
	Max	2.375	0.075	2.400	0.050	2.400	0.075

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	2.2813	-0.0063	2.2938	-0.0500	2.2875	-0.0281
	Median	2.3250	0.0000	2.2750	-0.0750	2.3250	-0.0375
	SD	0.14343	0.17485	0.12970	0.10801	0.12677	0.13656
	(SE)	( 0.07172)	( 0.08743)	( 0.06485)	( 0.05401)	( 0.04482)	( 0.04828)
	Min,	2.075,	-0.225,	2.175,	-0.150,	2.075,	-0.225,
	Max	2.400	0.200	2.450	0.100	2.450	0.200
Week 148	n	4	4	4	4	8	8
	Mean	2.3750	0.0875	2.3188	-0.0250	2.3469	0.0313
	Median	2.3750	0.0500	2.3000	-0.0250	2.3375	0.0125
	SD	0.04564	0.13617	0.07739	0.07360	0.06606	0.11783
	(SE)	( 0.02282)	( 0.06808)	( 0.03870)	( 0.03680)	( 0.02336)	( 0.04166)
	Min,	2.325,	-0.025,	2.250,	-0.100,	2.250,	-0.100,
	Max	2.425	0.275	2.425	0.050	2.425	0.275
Week 152	n	4	4	3	3	7	7
	Mean	2.3188	0.0313	2.2250	-0.1000	2.2786	-0.0250
	Median	2.3250	0.0250	2.1750	-0.1000	2.3250	-0.0250
	SD	0.09214	0.07465	0.08660	0.07500	0.09621	0.09789
	(SE)	( 0.04607)	( 0.03733)	( 0.05000)	( 0.04330)	( 0.03636)	( 0.03700)
	Min,	2.200,	-0.050,	2.175,	-0.175,	2.175,	-0.175,
	Max	2.425	0.125	2.325	-0.025	2.425	0.125

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	2.3563	0.0688	2.3500	0.0063	2.3531	0.0375
	Median	2.3500	0.0500	2.3625	-0.0125	2.3500	0.0000
	SD	0.03750	0.12141	0.11726	0.08509	0.08066	0.10264
	(SE)	( 0.01875)	( 0.06070)	( 0.05863)	( 0.04254)	( 0.02852)	( 0.03629)
	Min,	2.325,	-0.050,	2.200,	-0.075,	2.200,	-0.075,
	Max	2.400	0.225	2.475	0.125	2.475	0.225
Week 160	n	4	4	4	4	8	8
	Mean	2.4000	0.1125	2.3438	0.0000	2.3719	0.0563
	Median	2.4000	0.0750	2.3500	0.0125	2.3875	0.0375
	SD	0.02041	0.11273	0.05543	0.05401	0.04899	0.10155
	(SE)	( 0.01021)	( 0.05637)	( 0.02772)	( 0.02700)	( 0.01732)	( 0.03590)
	Min,	2.375,	0.025,	2.275,	-0.075,	2.275,	-0.075,
	Max	2.425	0.275	2.400	0.050	2.425	0.275
Week 164	n	4	4	4	4	8	8
	Mean	2.3688	0.0813	2.3125	-0.0313	2.3406	0.0250
	Median	2.3625	0.0250	2.3250	-0.0500	2.3250	0.0125
	SD	0.05154	0.12970	0.10308	0.07739	0.08122	0.11573
	(SE)	( 0.02577)	( 0.06485)	( 0.05154)	( 0.03870)	( 0.02871)	( 0.04092)
	Min,	2.325,	0.000,	2.175,	-0.100,	2.175,	-0.100,
	Max	2.425	0.275	2.425	0.075	2.425	0.275

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	2.3813	0.0938	2.2813	-0.0625	2.3313	0.0156
	Median	2.3875	0.0625	2.2625	-0.0750	2.3625	0.0250
	SD	0.02394	0.09437	0.06575	0.06614	0.07039	0.11255
	(SE)	( 0.01197)	( 0.04719)	( 0.03287)	( 0.03307)	( 0.02489)	( 0.03979)
	Min,	2.350,	0.025,	2.225,	-0.125,	2.225,	-0.125,
	Max	2.400	0.225	2.375	0.025	2.400	0.225
Week 172	n	4	4	4	4	8	8
	Mean	2.3375	0.0500	2.3313	-0.0125	2.3344	0.0188
	Median	2.3375	0.0375	2.3375	0.0000	2.3375	0.0375
	SD	0.03227	0.11365	0.06884	0.11087	0.04989	0.10918
	(SE)	( 0.01614)	( 0.05683)	( 0.03442)	( 0.05543)	( 0.01764)	( 0.03860)
	Min,	2.300,	-0.075,	2.250,	-0.150,	2.250,	-0.150,
	Max	2.375	0.200	2.400	0.100	2.400	0.200
Week 176	n	4	4	4	4	8	8
	Mean	2.3563	0.0688	2.3313	-0.0125	2.3438	0.0281
	Median	2.3875	0.0375	2.3625	-0.0125	2.3750	0.0250
	SD	0.16755	0.10873	0.08985	0.05951	0.12518	0.09204
	(SE)	( 0.08377)	( 0.05437)	( 0.04492)	( 0.02976)	( 0.04426)	( 0.03254)
	Min,	2.125,	-0.025,	2.200,	-0.075,	2.125,	-0.075,
	Max	2.525	0.225	2.400	0.050	2.525	0.225

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	2.4125	0.1250	2.3417	0.0167	2.3821	0.0786
	Median	2.4000	0.1125	2.4000	0.0500	2.4000	0.0500
	SD	0.06292	0.11726	0.12332	0.08036	0.09210	0.11127
	(SE)	( 0.03146)	( 0.05863)	( 0.07120)	( 0.04640)	( 0.03481)	( 0.04206)
	Min,	2.350,	0.025,	2.200,	-0.075,	2.200,	-0.075,
	Max	2.500	0.250	2.425	0.075	2.500	0.250
Week 184	n	4	4	4	4	8	8
	Mean	2.3813	0.0938	2.3500	0.0063	2.3656	0.0500
	Median	2.3625	0.0875	2.3375	0.0000	2.3625	0.0375
	SD	0.04732	0.11434	0.12416	0.11968	0.08858	0.11802
	(SE)	( 0.02366)	( 0.05717)	( 0.06208)	( 0.05984)	( 0.03132)	( 0.04173)
	Min,	2.350,	-0.025,	2.225,	-0.125,	2.225,	-0.125,
	Max	2.450	0.225	2.500	0.150	2.500	0.225

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	E*teplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Glucose (mmol/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	5.05050		4.70363		4.87706	
	Median	4.93950		4.46775		4.88400	
	SD	0.604585		1.171541		0.882750	
	(SE)	( 0.302292)		( 0.585770)		( 0.312099)	
	Min,	4.4400,		3.6075,		3.6075,	
	Max	5.8830		6.2715		6.2715	
Week 2	n	4	4	4	4	8	8
	Mean	5.31413	0.26363	4.32900	-0.37463	4.82156	-0.05550
	Median	4.71750	0.05550	4.27350	-0.08325	4.35675	-0.02775
	SD	1.608144	1.808298	0.282996	1.097325	1.191612	1.426129
	(SE)	( 0.804072)	( 0.904149)	( 0.141498)	( 0.548662)	( 0.421299)	( 0.504213)
	Min,	4.1625,	-1.7205,	4.0515,	-1.9425,	4.0515,	-1.9425,
	Max	7.6590	2.6640	4.7175	0.6105	7.6590	2.6640
Week 4	n	3	3	4	4	7	7
	Mean	5.99400	0.88800	5.23088	0.52725	5.55793	0.68186
	Median	5.21700	0.77700	5.38350	0.69375	5.21700	0.72150
	SD	1.345803	0.727876	0.704034	1.216366	1.008935	0.976503
	(SE)	( 0.777000)	( 0.420239)	( 0.352017)	( 0.608183)	( 0.381341)	( 0.369083)
	Min,	5.2170,	0.2220,	4.2735,	-1.1100,	4.2735,	-1.1100,
	Max	7.5480	1.6650	5.8830	1.8315	7.5480	1.8315

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	5.88300	0.83250	4.23188	-0.47175	5.05744	0.18038
	Median	5.68875	0.86025	4.30125	-0.19425	4.91175	0.13875
	SD	1.014300	0.522605	0.708395	0.690969	1.197874	0.898713
	(SE)	( 0.507150)	( 0.261302)	( 0.354198)	( 0.345485)	( 0.423512)	( 0.317743)
	Min,	4.9395,	0.2775,	3.4410,	-1.4985,	3.4410,	-1.4985,
	Max	7.2150	1.3320	4.8840	0.0000	7.2150	1.3320
Week 8	n	4	4	4	4	8	8
	Mean	5.50838	0.45788	4.74525	0.04162	5.12681	0.24975
	Median	5.49450	0.41625	4.77300	0.38850	4.96725	0.41625
	SD	0.408783	0.886119	0.146839	1.153880	0.497237	0.978079
	(SE)	( 0.204392)	( 0.443060)	( 0.073420)	( 0.576940)	( 0.175800)	( 0.345803)
	Min,	5.0505,	-0.5550,	4.5510,	-1.5540,	4.5510,	-1.5540,
	Max	5.9940	1.5540	4.8840	0.9435	5.9940	1.5540
Week 10	n	4	4	4	4	8	8
	Mean	5.05050	0.00000	4.20413	-0.49950	4.62731	-0.24975
	Median	5.02275	0.13875	3.85725	0.02775	4.71750	0.11100
	SD	0.481711	0.679733	1.160976	1.766145	0.939030	1.267332
	(SE)	( 0.240856)	( 0.339867)	( 0.580488)	( 0.883072)	( 0.331997)	( 0.448070)
	Min,	4.4955,	-0.9435,	3.2190,	-3.0525,	3.2190,	-3.0525,
	Max	5.6610	0.6660	5.8830	0.9990	5.8830	0.9990

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	6.66000	1.60950	4.78688	0.08325	5.72344	0.84638
	Median	6.68775	1.60950	4.71750	0.24975	5.63325	0.61050
	SD	0.875189	1.317273	0.529194	0.666770	1.204468	1.264812
	(SE)	( 0.437594)	( 0.658636)	( 0.264597)	( 0.333385)	( 0.425844)	( 0.447179)
	Min,	5.7720,	0.1665,	4.2180,	-0.7770,	4.2180,	-0.7770,
	Max	7.4925	3.0525	5.4945	0.6105	7.4925	3.0525
Week 15	n	4	4	4	4	8	8
	Mean	4.20413	-0.84638	3.95438	-0.74925	4.07925	-0.79781
	Median	4.32900	-0.88800	3.94050	-1.05450	4.19025	-0.88800
	SD	0.546377	0.390806	0.649413	1.039792	0.571407	0.729046
	(SE)	( 0.273188)	( 0.195403)	( 0.324707)	( 0.519896)	( 0.202023)	( 0.257757)
	Min,	3.4965,	-1.2765,	3.2745,	-1.6095,	3.2745,	-1.6095,
	Max	4.6620	-0.3330	4.6620	0.7215	4.6620	0.7215
Week 18	n	4	4	4	4	8	8
	Mean	4.91175	-0.13875	5.20313	0.49950	5.05744	0.18038
	Median	4.93950	-0.05550	5.16150	0.49950	4.93950	0.41625
	SD	0.273775	0.675947	0.947708	1.495413	0.664305	1.127210
	(SE)	( 0.136887)	( 0.337973)	( 0.473854)	( 0.747707)	( 0.234867)	( 0.398529)
	Min,	4.5510,	-0.9435,	4.1070,	-1.3320,	4.1070,	-1.3320,
	Max	5.2170	0.4995	6.3825	2.3310	6.3825	2.3310

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	3.92663	-1.12388	4.03763	-0.66600	3.98213	-0.89494
	Median	3.63525	-1.22100	4.13475	-0.33300	4.02375	-0.77700
	SD	1.146739	1.360505	0.315179	1.430853	0.780813	1.315525
	(SE)	( 0.573369)	( 0.680252)	( 0.157590)	( 0.715426)	( 0.276059)	( 0.465108)
	Min,	2.9415,	-2.6640,	3.6075,	-2.6640,	2.9415,	-2.6640,
	Max	5.4945	0.6105	4.2735	0.6660	5.4945	0.6660
Week 24	n	4	4	4	4	8	8
	Mean	5.38350	0.33300	4.45388	-0.24975	4.91869	0.04163
	Median	5.38350	0.22200	4.38450	-0.24975	4.88400	0.00000
	SD	0.801714	0.648820	1.040656	0.346597	0.993230	0.573521
	(SE)	( 0.400857)	( 0.324410)	( 0.520328)	( 0.173299)	( 0.351160)	( 0.202770)
	Min,	4.6620,	-0.3330,	3.4410,	-0.6660,	3.4410,	-0.6660,
	Max	6.1050	1.2210	5.6055	0.1665	6.1050	1.2210
Week 25	n	4	4	4	4	8	8
	Mean	3.84338	-1.20713	3.48263	-1.22100	3.66300	-1.21406
	Median	3.80175	-1.47075	3.66300	-0.94350	3.66300	-1.16550
	SD	0.742367	0.706945	0.577440	0.834348	0.645193	0.715952
	(SE)	( 0.371183)	( 0.353472)	( 0.288720)	( 0.417174)	( 0.228110)	( 0.253127)
	Min,	3.0525,	-1.7205,	2.6640,	-2.4420,	2.6640,	-2.4420,
	Max	4.7175	-0.1665	3.9405	-0.5550	4.7175	-0.1665

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	4.96725	-0.08325	4.20413	-0.49950	4.58569	-0.29138
	Median	4.91175	0.02775	4.19025	-0.77700	4.55100	-0.36075
	SD	0.705673	0.537138	0.816152	0.752839	0.815646	0.645022
	(SE)	( 0.352836)	( 0.268569)	( 0.408076)	( 0.376419)	( 0.288375)	( 0.228050)
	Min,	4.1625,	-0.8325,	3.2190,	-1.0545,	3.2190,	-1.0545,
	Max	5.8830	0.4440	5.2170	0.6105	5.8830	0.6105
Week 32	n	4	4	3	3	7	7
	Mean	5.73038	0.67988	4.36600	0.18500	5.14564	0.46779
	Median	5.63325	0.69375	4.38450	0.05550	4.93950	0.55500
	SD	0.781447	1.364273	0.582970	0.539046	0.974924	1.047592
	(SE)	( 0.390724)	( 0.682137)	( 0.336578)	( 0.311218)	( 0.368487)	( 0.395953)
	Min,	4.8840,	-0.9990,	3.7740,	-0.2775,	3.7740,	-0.9990,
	Max	6.7710	2.3310	4.9395	0.7770	6.7710	2.3310
Week 36	n	4	4	4	4	8	8
	Mean	5.53613	0.48563	4.41225	-0.29138	4.97419	0.09713
	Median	5.49450	0.80475	4.10700	0.27750	5.07825	0.52725
	SD	0.536899	0.868565	0.686497	1.341505	0.828493	1.125648
	(SE)	( 0.268449)	( 0.434282)	( 0.343249)	( 0.670753)	( 0.292917)	( 0.397977)
	Min,	5.0505,	-0.7770,	3.9960,	-2.2755,	3.9960,	-2.2755,
	Max	6.1050	1.1100	5.4390	0.5550	6.1050	1.1100

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	5.42513	0.37463	4.92563	0.22200	5.17538	0.29831
	Median	5.68875	0.24975	5.16150	0.22200	5.60550	0.24975
	SD	0.935714	1.064072	1.050476	1.676676	0.958882	1.302583
	(SE)	( 0.467857)	( 0.532036)	( 0.525238)	( 0.838338)	( 0.339016)	( 0.460533)
	Min,	4.1070,	-0.7770,	3.6075,	-1.7205,	3.6075,	-1.7205,
	Max	6.2160	1.7760	5.7720	2.1645	6.2160	2.1645
Week 44	n	4	4	4	4	8	8
	Mean	5.56388	0.51338	4.45388	-0.24975	5.00888	0.13181
	Median	5.46675	0.52725	4.41225	0.11100	4.99500	0.36075
	SD	0.467377	1.042627	0.340244	1.338536	0.703747	1.183275
	(SE)	( 0.233688)	( 0.521314)	( 0.170122)	( 0.669268)	( 0.248812)	( 0.418351)
	Min,	5.1060,	-0.7770,	4.1070,	-2.1645,	4.1070,	-2.1645,
	Max	6.2160	1.7760	4.8840	0.9435	6.2160	1.7760
Week 48	n	4	4	4	4	8	8
	Mean	5.52225	0.47175	4.67588	-0.02775	5.09906	0.22200
	Median	5.27250	0.33300	4.68975	0.30525	4.91175	0.30525
	SD	0.925925	1.476411	0.294987	0.976653	0.780637	1.189233
	(SE)	( 0.462962)	( 0.738206)	( 0.147493)	( 0.488326)	( 0.275997)	( 0.420457)
	Min,	4.7175,	-1.1655,	4.3290,	-1.4430,	4.3290,	-1.4430,
	Max	6.8265	2.3865	4.9950	0.7215	6.8265	2.3865

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	4.81463	-0.23588	4.62038	-0.08325	4.71750	-0.15956
	Median	4.82850	-0.11100	4.52325	0.27750	4.57875	-0.08325
	SD	0.695228	1.267520	0.559376	1.575327	0.593320	1.326185
	(SE)	( 0.347614)	( 0.633760)	( 0.279688)	( 0.787663)	( 0.209770)	( 0.468877)
	Min,	3.9960,	-1.8870,	4.0515,	-2.2200,	3.9960,	-2.2200,
	Max	5.6055	1.1655	5.3835	1.3320	5.6055	1.3320
Week 56	n	4	4	3	3	7	7
	Mean	6.02175	0.97125	5.03200	0.11100	5.59757	0.60257
	Median	5.71650	0.52725	5.10600	-0.05550	5.38350	0.49950
	SD	0.858009	1.264377	0.178408	1.312197	0.811534	1.258855
	(SE)	( 0.429005)	( 0.632189)	( 0.103004)	( 0.757597)	( 0.306731)	( 0.475802)
	Min,	5.3835,	0.0000,	4.8285,	-1.1100,	4.8285,	-1.1100,
	Max	7.2705	2.8305	5.1615	1.4985	7.2705	2.8305
Week 60	n	4	4	4	4	8	8
	Mean	5.78588	0.73538	4.71750	0.01388	5.25169	0.37463
	Median	5.71650	0.77700	4.52325	0.22200	5.16150	0.61050
	SD	0.774850	1.320678	0.485955	1.389626	0.827430	1.312951
	(SE)	( 0.387425)	( 0.660339)	( 0.242978)	( 0.694813)	( 0.292541)	( 0.464198)
	Min,	4.9950,	-0.8880,	4.3845,	-1.7760,	4.3845,	-1.7760,
	Max	6.7155	2.2755	5.4390	1.3875	6.7155	2.2755

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	6.54900	1.49850	4.75913	0.05550	5.65406	0.77700
	Median	6.21600	1.05450	4.68975	0.36075	5.30025	0.83250
	SD	1.185156	1.283319	0.199466	1.236874	1.238689	1.398713
	(SE)	( 0.592578)	( 0.641659)	( 0.099733)	( 0.618437)	( 0.437943)	( 0.494520)
	Min,	5.5500,	0.5550,	4.6065,	-1.5540,	4.6065,	-1.5540,
	Max	8.2140	3.3300	5.0505	1.0545	8.2140	3.3300
Week 68	n	4	4	4	4	8	8
	Mean	6.97913	1.92863	4.60650	-0.09712	5.79281	0.91575
	Median	6.32700	1.22100	4.52325	0.27750	5.57775	0.97125
	SD	1.616423	2.058432	0.485955	1.546964	1.682075	2.003498
	(SE)	( 0.808211)	( 1.029216)	( 0.242978)	( 0.773482)	( 0.594703)	( 0.708344)
	Min,	5.8830,	0.3330,	4.1070,	-2.1645,	4.1070,	-2.1645,
	Max	9.3795	4.9395	5.2725	1.2210	9.3795	4.9395
Week 72	n	3	3	4	4	7	7
	Mean	7.49250	2.42350	4.57875	-0.12487	5.82750	0.96729
	Median	6.21600	1.11000	4.66200	0.36075	5.27250	1.11000
	SD	2.405783	2.973440	0.680488	1.823001	2.141610	2.542493
	(SE)	( 1.388979)	( 1.716716)	( 0.340244)	( 0.911501)	( 0.809452)	( 0.960972)
	Min,	5.9940,	0.3330,	3.7185,	-2.5530,	3.7185,	-2.5530,
	Max	10.2675	5.8275	5.2725	1.3320	10.2675	5.8275

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	5.32800	0.61050			5.32800	0.61050
	Median	5.32800	0.61050			5.32800	0.61050
	SD	0.784889	0.392444			0.784889	0.392444
	(SE)	( 0.555000)	( 0.277500)			( 0.555000)	( 0.277500)
	Min,	4.7730,	0.3330,			4.7730,	0.3330,
	Max	5.8830	0.8880			5.8830	0.8880
Week 76	n	4	4	4	4	8	8
	Mean	7.29825	2.24775	4.52325	-0.18038	5.91075	1.03369
	Median	6.71550	1.47075	4.55100	0.24975	5.35575	0.74925
	SD	1.728241	2.167818	0.246126	1.312099	1.872486	2.106273
	(SE)	( 0.864120)	( 1.083909)	( 0.123063)	( 0.656049)	( 0.662024)	( 0.744680)
	Min,	5.9385,	0.6660,	4.2180,	-2.0535,	4.2180,	-2.0535,
	Max	9.8235	5.3835	4.7730	0.8325	9.8235	5.3835
Week 80	n	4	4	4	4	8	8
	Mean	6.31313	1.26263	4.56488	-0.13875	5.43900	0.56194
	Median	6.29925	1.49850	4.32900	0.49950	6.07725	0.97125
	SD	0.183374	0.589756	1.056324	1.763527	1.168705	1.429346
	(SE)	( 0.091687)	( 0.294878)	( 0.528162)	( 0.881763)	( 0.413200)	( 0.505350)
	Min,	6.1050,	0.3885,	3.5520,	-2.7195,	3.5520,	-2.7195,
	Max	6.5490	1.6650	6.0495	1.1655	6.5490	1.6650

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	5.92463	0.87413	5.32800	0.62438	5.62631	0.74925
	Median	5.35575	0.19425	5.38350	0.69375	5.35575	0.19425
	SD	1.428968	1.854827	0.470933	1.159206	1.035313	1.438113
	(SE)	( 0.714484)	( 0.927413)	( 0.235467)	( 0.579603)	( 0.366038)	( 0.508450)
	Min,	4.9395,	-0.4995,	4.7730,	-0.6105,	4.7730,	-0.6105,
	Max	8.0475	3.6075	5.7720	1.7205	8.0475	3.6075
Week 88	n	4	4	4	4	8	8
	Mean	5.64713	0.59663	4.55100	-0.15262	5.09906	0.22200
	Median	5.74425	0.47175	4.68975	0.41625	5.05050	0.47175
	SD	0.523341	0.895341	0.636034	1.768106	0.796264	1.357847
	(SE)	( 0.261670)	( 0.447670)	( 0.318017)	( 0.884053)	( 0.281522)	( 0.480072)
	Min,	4.9395,	-0.2775,	3.6630,	-2.6085,	3.6630,	-2.6085,
	Max	6.1605	1.7205	5.1615	1.1655	6.1605	1.7205
Week 92	n	4	4	4	4	8	8
	Mean	7.06238	2.01188	4.98113	0.27750	6.02175	1.14469
	Median	6.35475	1.41525	4.93950	0.44400	5.30025	0.83250
	SD	2.346530	2.838062	0.349180	1.131075	1.910407	2.204473
	(SE)	( 1.173265)	( 1.419031)	( 0.174590)	( 0.565537)	( 0.675431)	( 0.779399)
	Min,	5.2170,	-0.6660,	4.6620,	-1.1100,	4.6620,	-1.1100,
	Max	10.3230	5.8830	5.3835	1.3320	10.3230	5.8830

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	5.50838	0.45788	5.42513	0.72150	5.46675	0.58969
	Median	5.52225	0.47175	5.41125	0.72150	5.41125	0.47175
	SD	0.478235	0.984897	0.868565	1.722587	0.650626	1.306631
	(SE)	( 0.239117)	( 0.492448)	( 0.434282)	( 0.861294)	( 0.230031)	( 0.461964)
	Min,	4.9950,	-0.6660,	4.3845,	-0.9990,	4.3845,	-0.9990,
	Max	5.9940	1.5540	6.4935	2.4420	6.4935	2.4420
Week 100	n	4	4	4	4	8	8
	Mean	5.39738	0.34688	4.63425	-0.06938	5.01581	0.13875
	Median	5.43900	0.33300	4.66200	-0.02775	4.99500	0.33300
	SD	0.171811	0.568480	0.228832	1.154769	0.448867	0.871494
	(SE)	( 0.085906)	( 0.284240)	( 0.114416)	( 0.577385)	( 0.158698)	( 0.308120)
	Min,	5.1615,	-0.3330,	4.3845,	-1.4430,	4.3845,	-1.4430,
	Max	5.5500	1.0545	4.8285	1.2210	5.5500	1.2210
Week 104	n	4	4	4	4	8	8
	Mean	5.66100	0.61050	5.98012	1.27650	5.82056	0.94350
	Median	5.77200	0.83250	5.52225	1.05450	5.71650	0.99900
	SD	0.792699	0.707852	1.904534	2.912913	1.361226	1.994473
	(SE)	( 0.396349)	( 0.353926)	( 0.952267)	( 1.456456)	( 0.481266)	( 0.705153)
	Min,	4.6065,	-0.3885,	4.2180,	-2.0535,	4.2180,	-2.0535,
	Max	6.4935	1.1655	8.6580	5.0505	8.6580	5.0505

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	6.86813	1.81763	4.80075	0.09713	5.83444	0.95738
	Median	6.79875	1.85925	4.68975	0.58275	5.85525	0.94350
	SD	0.643058	1.229693	0.548487	1.430404	1.235843	1.539705
	(SE)	( 0.321529)	( 0.614847)	( 0.274243)	( 0.715202)	( 0.436937)	( 0.544368)
	Min,	6.1605,	0.2775,	4.2735,	-1.9980,	4.2735,	-1.9980,
	Max	7.7145	3.2745	5.5500	1.2210	7.7145	3.2745
Week 112	n	4	4	4	4	8	8
	Mean	7.64513	2.59463	5.24475	0.54113	6.44494	1.56788
	Median	6.41025	1.47075	5.30025	0.55500	5.57775	1.11000
	SD	3.209537	3.681837	0.548487	1.074633	2.487956	2.740334
	(SE)	( 1.604768)	( 1.840918)	( 0.274243)	( 0.537317)	( 0.879625)	( 0.968854)
	Min,	5.4390,	-0.4440,	4.5510,	-0.4440,	4.5510,	-0.4440,
	Max	12.3210	7.8810	5.8275	1.4985	12.3210	7.8810
Week 116	n	4	4	4	4	8	8
	Mean	7.40925	2.35875	5.18925	0.48563	6.29925	1.42219
	Median	6.35475	1.35975	5.24475	1.24875	5.43900	1.24875
	SD	2.932060	3.394889	0.722922	1.662145	2.305756	2.669435
	(SE)	( 1.466030)	( 1.697444)	( 0.361461)	( 0.831073)	( 0.815208)	( 0.943788)
	Min,	5.3280,	-0.4440,	4.2735,	-1.9980,	4.2735,	-1.9980,
	Max	11.5995	7.1595	5.9940	1.4430	11.5995	7.1595

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	5.08750	0.01850	4.80075	0.09712	4.92364	0.06343
	Median	4.82850	-0.05550	4.82850	0.58275	4.82850	0.11100
	SD	0.497440	1.167261	0.474192	1.520183	0.467338	1.269414
	(SE)	( 0.287197)	( 0.673918)	( 0.237096)	( 0.760092)	( 0.176637)	( 0.479793)
	Min,	4.7730,	-1.1100,	4.2180,	-2.0535,	4.2180,	-2.0535,
	Max	5.6610	1.2210	5.3280	1.2765	5.6610	1.2765
Week 124	n	3	3	4	4	7	7
	Mean	7.88100	2.81200	4.81463	0.11100	6.12879	1.26857
	Median	7.99200	2.10900	4.91175	0.66600	5.38350	1.33200
	SD	1.335464	1.669004	0.577440	1.626317	1.856793	2.082157
	(SE)	( 0.771031)	( 0.963600)	( 0.288720)	( 0.813159)	( 0.701802)	( 0.786981)
	Min,	6.4935,	1.6095,	4.0515,	-2.2200,	4.0515,	-2.2200,
	Max	9.1575	4.7175	5.3835	1.3320	9.1575	4.7175
Week 128	n	4	4	4	4	8	8
	Mean	5.49450	0.44400	4.81463	0.11100	5.15456	0.27750
	Median	5.41125	0.33300	4.82850	0.33300	4.91175	0.33300
	SD	0.498471	0.977178	0.027750	1.174714	0.488758	1.016033
	(SE)	( 0.249236)	( 0.488589)	( 0.013875)	( 0.587357)	( 0.172802)	( 0.359222)
	Min,	4.9950,	-0.6105,	4.7730,	-1.4430,	4.7730,	-1.4430,
	Max	6.1605	1.7205	4.8285	1.2210	6.1605	1.7205

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	6.24375	1.19325	4.57875	-0.12488	5.41125	0.53419
	Median	5.43900	0.47175	4.55100	0.08325	4.82850	0.33300
	SD	2.237735	2.709287	0.710024	1.858698	1.776000	2.263369
	(SE)	( 1.118868)	( 1.354643)	( 0.355012)	( 0.929349)	( 0.627911)	( 0.800222)
	Min,	4.6620,	-1.1655,	3.8295,	-2.4420,	3.8295,	-2.4420,
	Max	9.4350	4.9950	5.3835	1.7760	9.4350	4.9950
Week 136	n	4	4	4	4	8	8
	Mean	7.83938	2.78888	5.17538	0.47175	6.50738	1.63031
	Median	7.32600	1.88700	4.85625	0.61050	5.96625	1.24875
	SD	2.672610	2.991985	1.124132	1.980710	2.372863	2.655552
	(SE)	( 1.336305)	( 1.495993)	( 0.562066)	( 0.990355)	( 0.838934)	( 0.938879)
	Min,	5.1615,	0.2775,	4.2180,	-2.0535,	4.2180,	-2.0535,
	Max	11.5440	7.1040	6.7710	2.7195	11.5440	7.1040
Week 140	n	4	4	4	4	8	8
	Mean	6.67388	1.62338	5.43900	0.73538	6.05644	1.17938
	Median	6.18825	1.24875	5.07825	0.58275	5.21700	0.97125
	SD	1.999220	2.496626	1.145507	1.945075	1.646513	2.125574
	(SE)	( 0.999610)	( 1.248313)	( 0.572754)	( 0.972538)	( 0.582130)	( 0.751504)
	Min,	4.9950,	-0.8880,	4.4955,	-1.2765,	4.4955,	-1.2765,
	Max	9.3240	4.8840	7.1040	3.0525	9.3240	4.8840

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	7.40925	2.35875	5.23088	0.52725	6.32006	1.44300
	Median	6.74325	1.80375	5.10600	0.86025	5.77200	1.30425
	SD	2.272339	2.776665	0.542605	1.553009	1.922219	2.301363
	(SE)	( 1.136170)	( 1.388332)	( 0.271303)	( 0.776504)	( 0.679607)	( 0.813655)
	Min,	5.5500,	-0.3330,	4.7175,	-1.5540,	4.7175,	-1.5540,
	Max	10.6005	6.1605	5.9940	1.9425	10.6005	6.1605
Week 148	n	4	4	4	4	8	8
	Mean	6.25763	1.20713	4.91175	0.20813	5.58469	0.70763
	Median	5.27250	0.33300	4.85625	0.61050	5.18925	0.33300
	SD	2.198330	2.667996	0.622161	1.725788	1.659689	2.147611
	(SE)	( 1.099165)	( 1.333998)	( 0.311081)	( 0.862894)	( 0.586789)	( 0.759295)
	Min,	4.9395,	-0.9435,	4.2735,	-1.9980,	4.2735,	-1.9980,
	Max	9.5460	5.1060	5.6610	1.6095	9.5460	5.1060
Week 152	n	4	4	3	3	7	7
	Mean	6.34088	1.29038	5.03200	0.85100	5.77993	1.10207
	Median	6.43800	1.27650	5.05050	0.72150	5.60550	0.72150
	SD	0.712730	0.924676	0.582970	0.539046	0.925608	0.761267
	(SE)	( 0.356365)	( 0.462338)	( 0.336578)	( 0.311218)	( 0.349847)	( 0.287732)
	Min,	5.3835,	0.3885,	4.4400,	0.3885,	4.4400,	0.3885,
	Max	7.1040	2.2200	5.6055	1.4430	7.1040	2.2200

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	5.89688	0.84638	4.63425	-0.06938	5.26556	0.38850
	Median	5.82750	0.83250	4.49550	0.02775	5.27250	0.38850
	SD	0.529194	0.812369	0.396349	1.493610	0.801771	1.215944
	(SE)	( 0.264597)	( 0.406185)	( 0.198175)	( 0.746805)	( 0.283469)	( 0.429901)
	Min,	5.3280,	0.0000,	4.3290,	-1.9425,	4.3290,	-1.9425,
	Max	6.6045	1.7205	5.2170	1.6095	6.6045	1.7205
Week 160	n	4	4	4	4	8	8
	Mean	5.52225	0.47175	6.32700	1.62338	5.92462	1.04756
	Median	5.41125	0.44400	6.18825	1.94250	5.66100	1.19325
	SD	0.435831	0.978753	1.357199	2.232625	1.027553	1.710480
	(SE)	( 0.217916)	( 0.489377)	( 0.678600)	( 1.116313)	( 0.363295)	( 0.604746)
	Min,	5.1615,	-0.6660,	4.8840,	-1.3875,	4.8840,	-1.3875,
	Max	6.1050	1.6650	8.0475	3.9960	8.0475	3.9960
Week 164	n	4	4	4	4	8	8
	Mean	6.85425	1.80375	5.06438	0.36075	5.95931	1.08225
	Median	6.90975	1.55400	4.82850	0.49950	5.96625	1.11000
	SD	0.821325	1.231467	0.724163	1.669619	1.195484	1.561908
	(SE)	( 0.410662)	( 0.615733)	( 0.362082)	( 0.834809)	( 0.422667)	( 0.552218)
	Min,	5.8275,	0.7770,	4.4955,	-1.6095,	4.4955,	-1.6095,
	Max	7.7700	3.3300	6.1050	2.0535	7.7700	3.3300

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	6.32700	1.27650	5.23087	0.52725	5.77894	0.90188
	Median	6.24375	0.80475	4.71750	0.47175	5.66100	0.80475
	SD	1.069486	1.401856	1.271564	2.136330	1.235487	1.720052
	(SE)	( 0.534743)	( 0.700928)	( 0.635782)	( 1.068165)	( 0.436811)	( 0.608130)
	Min,	5.1060,	0.2220,	4.3845,	-1.8870,	4.3845,	-1.8870,
	Max	7.7145	3.2745	7.1040	3.0525	7.7145	3.2745
Week 172	n	4	4	4	4	8	8
	Mean	6.70163	1.65113	4.82850	0.12488	5.76506	0.88800
	Median	6.41025	1.02675	4.68975	0.36075	5.57775	1.02675
	SD	1.298728	1.579151	0.567802	1.575245	1.365099	1.672647
	(SE)	( 0.649364)	( 0.789576)	( 0.283901)	( 0.787623)	( 0.482636)	( 0.591370)
	Min,	5.5500,	0.5550,	4.3290,	-1.7760,	4.3290,	-1.7760,
	Max	8.4360	3.9960	5.6055	1.5540	8.4360	3.9960
Week 176	n	4	4	4	4	8	8
	Mean	6.04950	0.99900	4.93950	0.23588	5.49450	0.61744
	Median	5.71650	1.05450	4.60650	0.36075	5.16150	0.69375
	SD	1.183422	1.524651	1.027375	1.947713	1.185156	1.669866
	(SE)	( 0.591711)	( 0.762326)	( 0.513687)	( 0.973856)	( 0.419016)	( 0.590387)
	Min,	5.1060,	-0.7770,	4.1070,	-2.1645,	4.1070,	-2.1645,
	Max	7.6590	2.6640	6.4380	2.3865	7.6590	2.6640

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsén for 184 Weeks  
 Safety Population

Time Point		Eteplirsén					
		30 mg/kg		50 mg/kg		Eteplirsén for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	6.07725	1.02675	5.69800	1.51700	5.91471	1.23686
	Median	6.07725	1.08225	6.32700	1.44300	6.32700	1.44300
	SD	0.867530	1.329299	1.236459	0.890309	0.962813	1.102908
	(SE)	( 0.433765)	( 0.664650)	( 0.713870)	( 0.514020)	( 0.363909)	( 0.416860)
	Min,	5.2725,	-0.4995,	4.2735,	0.6660,	4.2735,	-0.4995,
	Max	6.8820	2.4420	6.4935	2.4420	6.8820	2.4420
Week 184	n	4	4	4	4	8	8
	Mean	6.13275	1.08225	5.27250	0.56888	5.70263	0.82556
	Median	6.21600	1.22100	5.05050	0.47175	5.71650	1.22100
	SD	0.680488	0.807457	1.344277	2.229404	1.088281	1.576333
	(SE)	( 0.340244)	( 0.403728)	( 0.672138)	( 1.114702)	( 0.384766)	( 0.557318)
	Min,	5.2725,	0.0555,	3.9405,	-1.6650,	3.9405,	-1.6650,
	Max	6.8265	1.8315	7.0485	2.9970	7.0485	2.9970

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsén.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Creatinine (umol/L)							
Baseline <sup>1</sup>	n	4	4	4	8		
	Mean	23.8680		26.5200		25.1940	
	Median	21.6580		26.9620		24.7520	
	SD	5.35289		2.16535		4.03719	
	(SE)	( 2.67644)		( 1.08267)		( 1.42736)	
	Min,	20.332,		23.868,		20.332,	
	Max	31.824		28.288		31.824	
Week 2	n	4	4	4	8	8	
	Mean	27.4040	3.5360	33.3710	6.8510	30.3875	5.1935
	Median	27.4040	3.9780	30.0560	3.0940	29.1720	3.9780
	SD	2.04151	4.73305	11.82436	10.39405	8.47821	7.68387
	(SE)	( 1.02076)	( 2.36652)	( 5.91218)	( 5.19703)	( 2.99750)	( 2.71666)
	Min,	25.636,	-2.652,	22.984,	-0.884,	22.984,	-2.652,
	Max	29.172	8.840	50.388	22.100	50.388	22.100
Week 4	n	4	4	4	8	8	
	Mean	24.0890	0.2210	27.4040	0.8840	25.7465	0.5525
	Median	24.3100	-0.8840	28.2880	0.4420	27.4040	0.4420
	SD	4.69852	4.41263	2.39388	1.25016	3.88033	3.02328
	(SE)	( 2.34926)	( 2.20631)	( 1.19694)	( 0.62508)	( 1.37190)	( 1.06889)
	Min,	18.564,	-3.536,	23.868,	0.000,	18.564,	-3.536,
	Max	29.172	6.188	29.172	2.652	29.172	6.188

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	25.1940	1.3260	28.0670	1.5470	26.6305	1.4365
	Median	25.1940	0.8840	24.7520	0.0000	24.7520	0.0000
	SD	3.10451	5.12923	7.26728	6.38992	5.39659	5.36547
	(SE)	( 1.55225)	( 2.56462)	( 3.63364)	( 3.19496)	( 1.90798)	( 1.89698)
	Min,	22.100,	-4.420,	23.868,	-4.420,	22.100,	-4.420,
	Max	28.288	7.956	38.896	10.608	38.896	10.608
Week 8	n	4	4	4	4	8	8
	Mean	24.7520	0.8840	24.9730	-1.5470	24.8625	-0.3315
	Median	24.3100	0.4420	24.7520	-1.7680	24.7520	-0.4420
	SD	3.14618	5.44934	0.44200	1.96014	2.08324	4.00771
	(SE)	( 1.57309)	( 2.72467)	( 0.22100)	( 0.98007)	( 0.73654)	( 1.41694)
	Min,	22.100,	-5.304,	24.752,	-3.536,	22.100,	-5.304,
	Max	28.288	7.956	25.636	0.884	28.288	7.956
Week 10	n	4	4	4	4	8	8
	Mean	26.2990	2.4310	27.1830	0.6630	26.7410	1.5470
	Median	26.9620	3.5360	27.4040	1.3260	26.9620	2.6520
	SD	1.67338	4.91528	2.63969	3.84481	2.09992	4.19318
	(SE)	( 0.83669)	( 2.45764)	( 1.31985)	( 1.92240)	( 0.74243)	( 1.48251)
	Min,	23.868,	-4.420,	23.868,	-4.420,	23.868,	-4.420,
	Max	27.404	7.072	30.056	4.420	30.056	7.072

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	24.3100	0.4420	26.9620	0.4420	25.6360	0.4420
	Median	22.5420	0.4420	27.4040	0.4420	23.8680	0.4420
	SD	5.88596	2.55189	5.22981	4.70545	5.34593	3.50429
	(SE)	( 2.94298)	( 1.27594)	( 2.61491)	( 2.35272)	( 1.89007)	( 1.23895)
	Min,	19.448,	-2.652,	21.216,	-4.420,	19.448,	-4.420,
	Max	32.708	3.536	31.824	5.304	32.708	5.304
Week 15	n	4	4	4	4	8	8
	Mean	24.7520	0.8840	28.0670	1.5470	26.4095	1.2155
	Median	22.9840	0.0000	28.2880	0.0000	25.6360	0.0000
	SD	5.00066	2.39388	4.91528	4.58630	4.92049	3.40533
	(SE)	( 2.50033)	( 1.19694)	( 2.45764)	( 2.29315)	( 1.73965)	( 1.20396)
	Min,	21.216,	-0.884,	22.100,	-1.768,	21.216,	-1.768,
	Max	31.824	4.420	33.592	7.956	33.592	7.956
Week 18	n	4	4	4	4	8	8
	Mean	24.3100	0.4420	29.1720	2.6520	26.7410	1.5470
	Median	22.9840	0.4420	28.7300	1.7680	26.0780	0.4420
	SD	6.14576	3.26801	4.14633	6.25082	5.50539	4.76634
	(SE)	( 3.07288)	( 1.63401)	( 2.07316)	( 3.12541)	( 1.94645)	( 1.68516)
	Min,	18.564,	-3.536,	24.752,	-3.536,	18.564,	-3.536,
	Max	32.708	4.420	34.476	10.608	34.476	10.608

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	23.6470	-0.2210	24.0890	-2.4310	23.8680	-1.3260
	Median	20.7740	-0.4420	24.3100	-3.0940	22.9840	-3.0940
	SD	8.14608	3.84481	3.09400	3.00863	5.70946	3.40737
	(SE)	( 4.07304)	( 1.92240)	( 1.54700)	( 1.50432)	( 2.01860)	( 1.20469)
	Min,	17.680,	-3.536,	20.332,	-5.304,	17.680,	-5.304,
	Max	35.360	3.536	27.404	1.768	35.360	3.536
Week 24	n	4	4	4	4	8	8
	Mean	22.7630	-1.1050	26.0780	-0.4420	24.4205	-0.7735
	Median	21.2160	-2.2100	27.4040	0.0000	25.1940	-1.3260
	SD	4.58630	2.53910	3.92029	2.33884	4.32909	2.28757
	(SE)	( 2.29315)	( 1.26955)	( 1.96014)	( 1.16942)	( 1.53056)	( 0.80878)
	Min,	19.448,	-2.652,	20.332,	-3.536,	19.448,	-3.536,
	Max	29.172	2.652	29.172	1.768	29.172	2.652
Week 25	n	4	4	4	4	8	8
	Mean	26.2990	2.4310	26.5200	0.0000	26.4095	1.2155
	Median	26.0780	1.3260	27.8460	0.4420	27.8460	1.3260
	SD	5.65461	4.52915	4.27013	2.79545	4.64025	3.71873
	(SE)	( 2.82730)	( 2.26458)	( 2.13506)	( 1.39773)	( 1.64058)	( 1.31477)
	Min,	20.332,	-1.768,	20.332,	-3.536,	20.332,	-3.536,
	Max	32.708	8.840	30.056	2.652	32.708	8.840

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	23.2050	-0.6630	33.1500	6.6300	28.1775	2.9835
	Median	22.5420	-2.6520	32.2660	5.3040	28.7300	0.4420
	SD	6.47094	5.27322	6.31302	8.37082	7.95512	7.55936
	(SE)	( 3.23547)	( 2.63661)	( 3.15651)	( 4.18541)	( 2.81256)	( 2.67264)
	Min,	17.680,	-4.420,	26.520,	-1.768,	17.680,	-4.420,
	Max	30.056	7.072	41.548	17.680	41.548	17.680
Week 32	n	4	4	3	3	7	7
	Mean	16.7960	-7.0720	19.7427	-7.6613	18.0589	-7.3246
	Median	15.0280	-6.6300	20.3320	-7.9560	16.7960	-7.9560
	SD	6.96062	3.46155	2.70066	3.98618	5.39788	3.37445
	(SE)	( 3.48031)	( 1.73077)	( 1.55923)	( 2.30142)	( 2.04021)	( 1.27542)
	Min,	10.608,	-11.492,	16.796,	-11.492,	10.608,	-11.492,
	Max	26.520	-3.536	22.100	-3.536	26.520	-3.536
Week 36	n	4	4	4	4	8	8
	Mean	17.9010	-5.9670	19.0060	-7.5140	18.4535	-6.7405
	Median	16.7960	-5.7460	19.8900	-7.0720	18.1220	-6.6300
	SD	3.56352	2.21000	3.57264	1.53113	3.35579	1.94466
	(SE)	( 1.78176)	( 1.10500)	( 1.78632)	( 0.76557)	( 1.18645)	( 0.68754)
	Min,	15.028,	-8.840,	14.144,	-9.724,	14.144,	-9.724,
	Max	22.984	-3.536	22.100	-6.188	22.984	-3.536

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	20.1110	-3.7570	20.7740	-5.7460	20.4425	-4.7515
	Median	18.5640	-3.5360	20.3320	-6.1880	19.0060	-3.9780
	SD	4.41263	1.32600	5.27939	4.23952	4.51836	3.09625
	(SE)	( 2.20631)	( 0.66300)	( 2.63969)	( 2.11976)	( 1.59748)	( 1.09469)
	Min,	16.796,	-5.304,	15.028,	-9.724,	15.028,	-9.724,
	Max	26.520	-2.652	27.404	-0.884	27.404	-0.884
Week 44	n	4	4	4	4	8	8
	Mean	20.5530	-3.3150	22.1000	-4.4200	21.3265	-3.8675
	Median	17.6800	-3.0940	22.1000	-4.8620	21.2160	-3.9780
	SD	6.97464	2.21000	1.44357	1.90966	4.73550	2.00124
	(SE)	( 3.48732)	( 1.10500)	( 0.72178)	( 0.95483)	( 1.67425)	( 1.07555)
	Min,	15.912,	-6.188,	20.332,	-6.188,	15.912,	-6.188,
	Max	30.940	-0.884	23.868	-1.768	30.940	-0.884
Week 48	n	4	4	4	4	8	8
	Mean	16.7960	-7.0720	23.6470	-2.8730	20.2215	-4.9725
	Median	15.9120	-6.6300	23.4260	-3.5360	19.0060	-5.7460
	SD	5.15456	2.79545	6.59059	5.22358	6.58883	4.48114
	(SE)	( 2.57728)	( 1.39773)	( 3.29530)	( 2.61179)	( 2.32950)	( 1.58432)
	Min,	11.492,	-10.608,	15.912,	-7.956,	11.492,	-10.608,
	Max	23.868	-4.420	31.824	3.536	31.824	3.536

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\c\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	18.3430	-5.5250	23.4260	-3.0940	20.8845	-4.3095
	Median	16.7960	-6.6300	20.7740	-4.4200	19.8900	-5.3040
	SD	5.22358	2.53910	6.22995	5.27939	5.97576	4.04927
	(SE)	( 2.61179)	( 1.26955)	( 3.11498)	( 2.63969)	( 2.11275)	( 1.43163)
	Min,	14.144,	-7.072,	19.448,	-7.956,	14.144,	-7.956,
	Max	25.636	-1.768	32.708	4.420	32.708	4.420
Week 56	n	4	4	3	3	7	7
	Mean	16.5750	-7.2930	27.1093	0.2947	21.0897	-4.0411
	Median	15.0280	-7.9560	20.3320	-5.3040	18.5640	-7.9560
	SD	4.41263	1.96014	13.29923	12.06695	10.01990	8.17970
	(SE)	( 2.20631)	( 0.98007)	( 7.67831)	( 6.96686)	( 3.78717)	( 3.09164)
	Min,	13.260,	-8.840,	18.564,	-7.956,	13.260,	-8.840,
	Max	22.984	-4.420	42.432	14.144	42.432	14.144
Week 60	n	4	4	4	4	8	8
	Mean	16.5750	-7.2930	19.0060	-7.5140	17.7905	-7.4035
	Median	15.4700	-8.8400	18.1220	-6.6300	18.1220	-7.9560
	SD	5.17348	3.70683	2.10434	2.10434	3.88033	2.79296
	(SE)	( 2.58674)	( 1.85342)	( 1.05217)	( 1.05217)	( 1.37190)	( 0.98746)
	Min,	12.376,	-9.724,	17.680,	-10.608,	12.376,	-10.608,
	Max	22.984	-1.768	22.100	-6.188	22.984	-1.768

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	15.2490	-8.6190	15.6910	-10.8290	15.4700	-9.7240
	Median	13.7020	-9.7240	17.2380	-10.6080	16.3540	-9.7240
	SD	5.02015	2.83018	4.04295	2.63969	4.22633	2.79545
	(SE)	( 2.51008)	( 1.41509)	( 2.02148)	( 1.31985)	( 1.49423)	( 0.98834)
	Min,	11.492,	-10.608,	9.724,	-14.144,	9.724,	-14.144,
	Max	22.100	-4.420	18.564	-7.956	22.100	-4.420
Week 68	n	4	4	4	4	8	8
	Mean	17.0170	-6.8510	17.4590	-9.0610	17.2380	-7.9560
	Median	15.9120	-7.5140	16.7960	-8.8400	16.7960	-8.3980
	SD	3.77645	3.00863	2.63969	1.82241	3.02559	2.58809
	(SE)	( 1.88822)	( 1.50432)	( 1.31985)	( 0.91121)	( 1.06971)	( 0.91503)
	Min,	14.144,	-9.724,	15.028,	-11.492,	14.144,	-11.492,
	Max	22.100	-2.652	21.216	-7.072	22.100	-2.652
Week 72	n	3	3	4	4	7	7
	Mean	14.4387	-10.6080	19.4480	-7.0720	17.3011	-8.5874
	Median	11.4920	-10.6080	18.1220	-8.3980	17.6800	-9.7240
	SD	5.88596	0.00000	4.94829	3.60891	5.56422	3.17561
	(SE)	( 3.39826)	( 0.00000)	( 2.47415)	( 1.80446)	( 2.10308)	( 1.20027)
	Min,	10.608,	-10.608,	15.028,	-9.724,	10.608,	-10.608,
	Max	21.216	-10.608	26.520	-1.768	26.520	-1.768

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	21.2160	-4.8620			21.2160	-4.8620
	Median	21.2160	-4.8620			21.2160	-4.8620
	SD	5.00066	3.12541			5.00066	3.12541
	(SE)	( 3.53600)	( 2.21000)			( 3.53600)	( 2.21000)
	Min,	17.680,	-7.072,			17.680,	-7.072,
	Max	24.752	-2.652			24.752	-2.652
Week 76	n	4	4	4	4	8	8
	Mean	18.7850	-5.0830	19.4480	-7.0720	19.1165	-6.0775
	Median	16.3540	-4.4200	19.4480	-7.5140	18.1220	-5.3040
	SD	5.79116	1.32600	2.16535	2.16535	4.06304	1.97315
	(SE)	( 2.89558)	( 0.66300)	( 1.08267)	( 1.08267)	( 1.43650)	( 0.69761)
	Min,	15.028,	-7.072,	16.796,	-8.840,	15.028,	-8.840,
	Max	27.404	-4.420	22.100	-4.420	27.404	-4.420
Week 80	n	4	4	4	4	8	8
	Mean	16.3540	-7.5140	17.6800	-8.8400	17.0170	-8.1770
	Median	15.9120	-7.0720	18.5640	-9.7240	16.7960	-8.3980
	SD	2.93190	3.01943	3.14618	2.50033	2.90320	2.66250
	(SE)	( 1.46595)	( 1.50972)	( 1.57309)	( 1.25016)	( 1.02644)	( 0.94134)
	Min,	13.260,	-11.492,	13.260,	-10.608,	13.260,	-11.492,
	Max	20.332	-4.420	20.332	-5.304	20.332	-4.420

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	18.5640	-5.3040	18.3430	-8.1770	18.4535	-6.7405
	Median	17.6800	-6.1880	20.3320	-7.5140	19.8900	-7.0720
	SD	4.01872	3.14618	4.58630	3.00863	3.99375	3.23726
	(SE)	( 2.00936)	( 1.57309)	( 2.29315)	( 1.50432)	( 1.41201)	( 1.14455)
	Min,	15.028,	-7.956,	11.492,	-12.376,	11.492,	-12.376,
	Max	23.868	-0.884	21.216	-5.304	23.868	-0.884
Week 88	n	4	4	4	4	8	8
	Mean	17.0170	-6.8510	41.5480	15.0280	29.2825	4.0885
	Median	16.7960	-8.3980	22.1000	-4.8620	20.3320	-7.0720
	SD	4.52915	4.16982	40.68962	42.51173	29.83769	30.31097
	(SE)	( 2.26458)	( 2.08491)	( 20.34481)	( 21.25587)	( 10.54922)	( 10.71655)
	Min,	12.376,	-9.724,	19.448,	-8.840,	12.376,	-9.724,
	Max	22.100	-0.884	102.544	78.676	102.544	78.676
Week 92	n	4	4	4	4	8	8
	Mean	17.4590	-6.4090	19.6690	-6.8510	18.5640	-6.6300
	Median	16.3540	-7.0720	20.3320	-6.6300	19.0060	-7.0720
	SD	4.64275	2.73660	3.33703	1.82241	3.92503	2.16535
	(SE)	( 2.32138)	( 1.36830)	( 1.66851)	( 0.91121)	( 1.38771)	( 0.76557)
	Min,	13.260,	-8.840,	15.028,	-8.840,	13.260,	-8.840,
	Max	23.868	-2.652	22.984	-5.304	23.868	-2.652

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	17.6800	-6.1880	20.3320	-6.1880	19.0060	-6.1880
	Median	17.2380	-6.1880	19.8900	-6.1880	19.0060	-6.1880
	SD	2.79545	3.60891	2.60243	1.44357	2.87421	2.54459
	(SE)	( 1.39773)	( 1.80446)	( 1.30121)	( 0.72178)	( 1.01619)	( 0.89965)
	Min,	15.028,	-10.608,	17.680,	-7.956,	15.028,	-10.608,
	Max	21.216	-1.768	23.868	-4.420	23.868	-1.768
Week 100	n	4	4	4	4	8	8
	Mean	16.5750	-7.2930	19.4480	-7.0720	18.0115	-7.1825
	Median	15.4700	-7.9560	18.5640	-7.9560	17.2380	-7.9560
	SD	5.51468	3.33703	4.01872	2.39388	4.72370	2.69117
	(SE)	( 2.75734)	( 1.66851)	( 2.00936)	( 1.19694)	( 1.67008)	( 0.95147)
	Min,	11.492,	-10.608,	15.912,	-8.840,	11.492,	-10.608,
	Max	23.868	-2.652	24.752	-3.536	24.752	-2.652
Week 104	n	4	4	4	4	8	8
	Mean	19.2270	-4.6410	17.9010	-8.6190	18.5640	-6.6300
	Median	18.1220	-6.1880	18.1220	-8.8400	18.1220	-7.0720
	SD	6.14046	4.41263	1.50972	3.56352	4.19983	4.27883
	(SE)	( 3.07023)	( 2.20631)	( 0.75486)	( 1.78176)	( 1.48486)	( 1.51280)
	Min,	14.144,	-7.956,	15.912,	-12.376,	14.144,	-12.376,
	Max	26.520	1.768	19.448	-4.420	26.520	1.768

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	18.1220	-5.7460	17.9010	-8.6190	18.0115	-7.1825
	Median	18.1220	-8.3980	18.5640	-8.8400	18.5640	-8.8400
	SD	7.16349	6.86643	1.96014	1.11234	4.86343	4.80571
	(SE)	( 3.58175)	( 3.43321)	( 0.98007)	( 0.55617)	( 1.71948)	( 1.69907)
	Min,	11.492,	-10.608,	15.028,	-9.724,	11.492,	-10.608,
	Max	24.752	4.420	19.448	-7.072	24.752	4.420
Week 112	n	4	4	4	4	8	8
	Mean	19.2270	-4.6410	20.3320	-6.1880	19.7795	-5.4145
	Median	19.4480	-7.0720	19.4480	-6.6300	19.4480	-7.0720
	SD	6.93719	6.74684	3.75049	2.60243	5.19635	4.80571
	(SE)	( 3.46860)	( 3.37342)	( 1.87525)	( 1.30121)	( 1.83719)	( 1.69907)
	Min,	12.376,	-9.724,	16.796,	-8.840,	12.376,	-9.724,
	Max	25.636	5.304	25.636	-2.652	25.636	5.304
Week 116	n	4	4	4	4	8	8
	Mean	17.4590	-6.4090	16.7960	-9.7240	17.1275	-8.0665
	Median	17.2380	-7.9560	16.7960	-10.1660	16.7960	-8.3980
	SD	6.01185	5.02015	3.60891	2.16535	4.60402	3.99375
	(SE)	( 3.00592)	( 2.51008)	( 1.80446)	( 1.08267)	( 1.62777)	( 1.41201)
	Min,	11.492,	-10.608,	12.376,	-11.492,	11.492,	-11.492,
	Max	23.868	0.884	21.216	-7.072	23.868	0.884

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	15.0280	-10.0187	16.1330	-10.3870	15.6594	-10.2291
	Median	12.3760	-9.7240	16.3540	-10.6080	15.0280	-10.6080
	SD	6.18800	1.35033	2.43435	0.44200	4.00945	0.86270
	(SE)	( 3.57264)	( 0.77961)	( 1.21717)	( 0.22100)	( 1.51543)	( 0.32607)
	Min,	10.608,	-11.492,	13.260,	-10.608,	10.608,	-11.492,
	Max	22.100	-8.840	18.564	-9.724	22.100	-8.840
Week 124	n	3	3	4	4	7	7
	Mean	15.6173	-9.4293	16.5750	-9.9450	16.1646	-9.7240
	Median	12.3760	-8.8400	16.3540	-10.1660	15.9120	-8.8400
	SD	6.39501	1.02076	0.84637	2.83018	3.77522	2.10434
	(SE)	( 3.69216)	( 0.58933)	( 0.42318)	( 1.41509)	( 1.42690)	( 0.79537)
	Min,	11.492,	-10.608,	15.912,	-12.376,	11.492,	-12.376,
	Max	22.984	-8.840	17.680	-7.072	22.984	-7.072
Week 128	n	4	4	4	4	8	8
	Mean	15.4700	-8.3980	17.6800	-8.8400	16.5750	-8.6190
	Median	14.5860	-10.1660	19.0060	-8.3980	18.5640	-8.8400
	SD	6.39501	4.59340	3.60891	1.90966	4.95017	3.26516
	(SE)	( 3.19751)	( 2.29670)	( 1.80446)	( 0.95483)	( 1.75015)	( 1.15441)
	Min,	9.724,	-11.492,	12.376,	-11.492,	9.724,	-11.492,
	Max	22.984	-1.768	20.332	-7.072	22.984	-1.768

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	16.3540	-7.5140	19.2270	-7.2930	17.7905	-7.4035
	Median	16.3540	-10.1660	17.2380	-9.7240	17.2380	-10.1660
	SD	6.14576	6.22995	4.91528	6.89954	5.37586	6.08682
	(SE)	( 3.07288)	( 3.11498)	( 2.45764)	( 3.44977)	( 1.90066)	( 2.15202)
	Min,	10.608,	-11.492,	15.912,	-12.376,	10.608,	-12.376,
	Max	22.100	1.768	26.520	2.652	26.520	2.652
Week 136	n	4	4	4	4	8	8
	Mean	15.6910	-8.1770	16.3540	-10.1660	16.0225	-9.1715
	Median	14.5860	-9.7240	16.7960	-10.1660	16.7960	-9.7240
	SD	5.17348	3.70683	3.01943	1.14124	3.93745	2.75270
	(SE)	( 1.58674)	( 1.85342)	( 1.50972)	( 0.57062)	( 1.39210)	( 0.97322)
	Min,	11.492,	-10.608,	12.376,	-11.492,	11.492,	-11.492,
	Max	22.100	-2.652	19.448	-8.840	22.100	-2.652
Week 140	n	4	4	4	4	8	8
	Mean	14.1440	-9.7240	15.6910	-10.8290	14.9175	-10.2765
	Median	14.1440	-11.9340	15.9120	-11.0500	15.9120	-11.4920
	SD	5.10378	5.35289	2.63969	4.35320	3.85146	4.55527
	(SE)	( 2.55189)	( 2.67644)	( 1.31985)	( 2.17660)	( 1.36170)	( 1.61053)
	Min,	9.724,	-13.260,	12.376,	-15.912,	9.724,	-15.912,
	Max	18.564	-1.768	18.564	-5.304	18.564	-1.768

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	16.5750	-7.2930	19.2270	-7.2930	17.9010	-7.2930
	Median	14.1440	-7.5140	17.6800	-7.9560	15.9120	-7.5140
	SD	5.51468	1.50972	5.07178	4.10688	5.10560	2.86449
	(SE)	( 2.75734)	( 0.75486)	( 2.53589)	( 2.05344)	( 1.80510)	( 1.01275)
	Min,	13.260,	-8.840,	15.028,	-11.492,	13.260,	-11.492,
	Max	24.752	-5.304	26.520	-1.768	26.520	-1.768
Week 148	n	4	4	4	4	8	8
	Mean	16.3540	-7.5140	19.4480	-7.0720	17.9010	-7.2930
	Median	14.5860	-8.3980	18.5640	-7.9560	18.1220	-7.9560
	SD	7.23585	4.47855	3.81932	2.39388	5.60586	3.33284
	(SE)	( 3.61793)	( 2.23927)	( 1.90966)	( 1.19694)	( 1.98197)	( 1.17834)
	Min,	10.608,	-11.492,	15.912,	-8.840,	10.608,	-11.492,
	Max	25.636	-1.768	24.752	-3.536	25.636	-1.768
Week 152	n	4	4	3	3	7	7
	Mean	15.0280	-8.8400	15.0280	-12.3760	15.0280	-10.3554
	Median	13.7020	-9.2820	17.6800	-10.6080	15.0280	-9.7240
	SD	5.05248	2.60243	5.37716	6.37461	4.73305	4.52813
	(SE)	( 2.52624)	( 1.30121)	( 3.10451)	( 3.68039)	( 1.78892)	( 1.71147)
	Min,	10.608,	-11.492,	8.840,	-19.448,	8.840,	-19.448,
	Max	22.100	-5.304	18.564	-7.072	22.100	-5.304

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	15.6910	-8.1770	16.3540	-10.1660	16.0225	-9.1715
	Median	14.5860	-9.2820	17.2380	-10.1660	17.2380	-9.2820
	SD	5.79116	3.84481	3.42372	2.10434	4.41842	3.05999
	(SE)	( 2.89558)	( 1.92240)	( 1.71186)	( 1.05217)	( 1.56215)	( 1.08187)
	Min,	10.608,	-11.492,	11.492,	-12.376,	10.608,	-12.376,
	Max	22.984	-2.652	19.448	-7.956	22.984	-2.652
Week 160	n	4	4	4	4	8	8
	Mean	14.8070	-9.0610	15.4700	-11.0500	15.1385	-10.0555
	Median	14.1440	-10.6080	16.7960	-11.4920	16.3540	-10.6080
	SD	6.55095	5.07178	5.07819	4.23952	5.43781	4.45616
	(SE)	( 3.27548)	( 2.53589)	( 2.53910)	( 2.11976)	( 1.92255)	( 1.57549)
	Min,	8.840,	-13.260,	8.840,	-15.028,	8.840,	-15.028,
	Max	22.100	-1.768	19.448	-6.188	22.100	-1.768
Week 164	n	4	4	4	4	8	8
	Mean	13.4810	-10.3870	15.2490	-11.2710	14.3650	-10.8290
	Median	12.3760	-11.9340	16.3540	-11.4920	15.9120	-11.9340
	SD	5.65461	4.04295	3.17708	1.96014	4.34999	2.97911
	(SE)	( 2.82730)	( 2.02148)	( 1.58854)	( 0.98007)	( 1.53795)	( 1.05328)
	Min,	8.840,	-13.260,	10.608,	-13.260,	8.840,	-13.260,
	Max	20.332	-4.420	17.680	-8.840	20.332	-4.420

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	14.1440	-9.7240	18.7850	-7.7350	16.4645	-8.7295
	Median	13.7020	-11.9340	17.6800	-9.2820	17.6800	-10.6080
	SD	5.72897	4.73305	5.56171	4.16982	5.78593	4.26413
	(SE)	( 2.86449)	( 2.36652)	( 2.78086)	( 2.08491)	( 2.04564)	( 1.50760)
	Min,	8.840,	-12.376,	13.260,	-10.608,	8.840,	-12.376,
	Max	20.332	-2.652	26.520	-1.768	26.520	-1.768
Week 172	n	4	4	4	4	8	8
	Mean	15.0280	-8.8400	16.7960	-9.7240	15.9120	-9.2820
	Median	14.1440	-10.6080	17.6800	-9.2820	17.2380	-10.6080
	SD	4.94829	3.53600	3.75049	2.16535	4.17316	2.75523
	(SE)	( 2.47415)	( 1.76800)	( 1.87525)	( 1.08267)	( 1.47544)	( 0.97412)
	Min,	10.608,	-10.608,	11.492,	-12.376,	10.608,	-12.376,
	Max	21.216	-3.536	20.332	-7.956	21.216	-3.536
Week 176	n	4	4	4	4	8	8
	Mean	13.9230	-9.9450	20.5530	-5.9670	17.2380	-7.9560
	Median	13.2600	-11.4920	22.1000	-4.8620	17.2380	-9.7240
	SD	5.56171	4.35320	7.33862	5.17348	6.99263	4.91055
	(SE)	( 2.78086)	( 2.17660)	( 3.66931)	( 2.58674)	( 2.47227)	( 1.73614)
	Min,	8.840,	-13.260,	11.492,	-12.376,	8.840,	-13.260,
	Max	20.332	-3.536	26.520	-1.768	26.520	-1.768

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	13.9230	-9.9450	19.1533	-8.2507	16.1646	-9.2189
	Median	13.2600	-11.9340	18.5640	-7.0720	16.7960	-11.4920
	SD	5.56171	4.29294	3.57264	3.68039	5.24757	3.81444
	(SE)	( 2.78086)	( 2.14647)	( 2.06267)	( 2.12487)	( 1.98340)	( 1.44172)
	Min,	8.840,	-12.376,	15.912,	-12.376,	8.840,	-12.376,
	Max	20.332	-3.536	22.984	-5.304	22.984	-3.536
Week 184	n	4	4	4	4	8	8
	Mean	13.7020	-10.1660	15.9120	-10.6080	14.8070	-10.3870
	Median	12.3760	-11.4920	15.9120	-10.1660	15.0280	-11.4920
	SD	6.01726	3.98618	3.88692	3.14618	4.83610	3.33284
	(SE)	( 3.00863)	( 1.99309)	( 1.94346)	( 1.57309)	( 1.70982)	( 1.17834)
	Min,	8.840,	-13.260,	11.492,	-14.144,	8.840,	-14.144,
	Max	21.216	-4.420	20.332	-7.956	21.216	-4.420

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Blood Urea Nitrogen (mmol/L)						
Baseline <sup>1</sup>	n	4	4	4	4	8
	Mean	2.9453	0.4463	4.7303	1.6958	2.9899
	Median	2.6775	0.3570	4.4625	1.7850	3.2130
	SD	1.40928	0.44922	0.93889	1.06603	1.00862
	(SE)	( 0.70464)	( 0.22461)	( 0.30917)	( 0.53302)	( 0.35660)
	Min,	1.785,	0.000,	3.927,	0.357,	1.785,
	Max	4.641	1.071	3.570	2.856	4.641
Week 2	n	4	4	4	4	8
	Mean	3.3915	0.4463	4.7303	1.6958	4.0609
	Median	2.8560	0.3570	4.4625	1.7850	4.1055
	SD	1.68712	0.44922	0.93889	1.06603	1.45249
	(SE)	( 0.84356)	( 0.22461)	( 0.46945)	( 0.53302)	( 0.51353)
	Min,	2.142,	0.000,	3.927,	0.357,	2.142,
	Max	5.712	1.071	6.069	2.856	6.069
Week 4	n	4	4	4	4	8
	Mean	3.7485	0.8033	3.9270	0.8925	3.8378
	Median	3.5700	0.7140	3.7485	0.5355	3.5700
	SD	0.94453	0.53550	1.39793	1.10996	1.10859
	(SE)	( 0.47227)	( 0.26775)	( 0.69897)	( 0.55498)	( 0.39195)
	Min,	2.856,	0.357,	2.499,	0.000,	2.499,
	Max	4.998	1.428	5.712	2.499	5.712

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	3.4808	0.5355	3.5700	0.5355	3.5254	0.5355
	Median	3.0345	0.8925	3.3915	0.7140	3.0345	0.8925
	SD	1.60650	1.38266	1.27057	0.94453	1.34172	1.09620
	(SE)	( 0.80325)	( 0.69133)	( 0.63529)	( 0.47227)	( 0.47437)	( 0.38757)
	Min,	2.142,	-1.428,	2.499,	-0.714,	2.142,	-1.428,
	Max	5.712	1.785	4.998	1.428	5.712	1.785
Week 8	n	4	4	4	4	8	8
	Mean	3.3023	0.3570	4.4625	1.4280	3.8824	0.8925
	Median	3.2130	0.1785	4.4625	1.6065	3.9270	0.8925
	SD	0.73597	0.87447	0.74315	0.87447	0.92383	0.99155
	(SE)	( 0.36799)	( 0.43723)	( 0.37158)	( 0.43723)	( 0.32662)	( 0.35057)
	Min,	2.499,	-0.357,	3.570,	0.357,	2.499,	-0.357,
	Max	4.284	1.428	5.355	2.142	5.355	2.142
Week 10	n	4	4	4	4	8	8
	Mean	3.6593	0.7140	4.4625	1.4280	4.0609	1.0710
	Median	3.3915	0.7140	4.6410	1.7850	3.9270	0.8925
	SD	1.28305	0.29149	1.58319	1.51462	1.40146	1.07947
	(SE)	( 0.64152)	( 0.14574)	( 0.79160)	( 0.75731)	( 0.49549)	( 0.38165)
	Min,	2.499,	0.357,	2.499,	-0.714,	2.499,	-0.714,
	Max	5.355	1.071	6.069	2.856	6.069	2.856

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	4.1055	1.1603	4.6410	1.6065	4.3733	1.3834
	Median	4.1055	1.4280	4.6410	1.6065	4.4625	1.6065
	SD	1.03057	1.46834	0.58298	0.84983	0.82629	1.13597
	(SE)	( 0.51529)	( 0.73417)	( 0.29149)	( 0.42491)	( 0.29214)	( 0.40163)
	Min,	2.856,	-0.714,	3.927,	0.714,	2.856,	-0.714,
	Max	5.355	2.499	5.355	2.499	5.355	2.499
Week 15	n	4	4	4	4	8	8
	Mean	3.5700	0.6248	4.7303	1.6958	4.1501	1.1603
	Median	3.5700	0.3570	4.6410	1.7850	4.4625	0.7140
	SD	1.69966	0.84356	1.63273	1.82908	1.66289	1.43753
	(SE)	( 0.84983)	( 0.42178)	( 0.81637)	( 0.91454)	( 0.58792)	( 0.50824)
	Min,	1.785,	0.000,	2.856,	-0.357,	1.785,	-0.357,
	Max	5.355	1.785	6.783	3.570	6.783	3.570
Week 18	n	4	4	4	4	8	8
	Mean	3.7485	0.8033	4.9088	1.8743	4.3286	1.3388
	Median	3.3915	0.8925	4.6410	1.7850	4.2840	1.0710
	SD	1.44280	0.34180	0.84356	0.79160	1.25767	0.80396
	(SE)	( 0.72140)	( 0.17090)	( 0.42178)	( 0.39580)	( 0.44465)	( 0.28424)
	Min,	2.499,	0.357,	4.284,	1.071,	2.499,	0.357,
	Max	5.712	1.071	6.069	2.856	6.069	2.856

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 21	n	4	4	4	4	8	8
	Mean	3.6593	0.7140	5.0873	2.0527	4.3733	1.3834
	Median	3.5700	0.5355	4.6410	1.7850	3.5700	1.0710
	SD	1.02540	0.77121	1.89748	1.65855	1.60508	1.39495
	(SE)	( 0.51270)	( 0.38560)	( 0.94874)	( 0.82927)	( 0.56748)	( 0.49319)
	Min,	2.499,	0.000,	3.570,	0.357,	2.499,	0.000,
	Max	4.998	1.785	7.497	4.284	7.497	4.284
Week 24	n	4	4	4	4	8	8
	Mean	3.3915	0.4463	4.9088	1.8743	4.1501	1.1603
	Median	3.2130	0.5355	4.6410	1.7850	4.2840	0.7140
	SD	1.07100	0.34180	1.34765	1.43911	1.38840	1.23300
	(SE)	( 0.53550)	( 0.17090)	( 0.67382)	( 0.71956)	( 0.49087)	( 0.43593)
	Min,	2.499,	0.000,	3.570,	0.357,	2.499,	0.000,
	Max	4.641	0.714	6.783	3.570	6.783	3.570
Week 25	n	4	4	4	4	8	8
	Mean	3.4808	0.5355	4.9980	1.9635	4.2394	1.2495
	Median	3.2130	0.5355	5.1765	1.9635	4.4625	1.0710
	SD	0.84356	0.61834	0.50487	0.74315	1.03534	0.99155
	(SE)	( 0.42178)	( 0.30917)	( 0.25244)	( 0.37158)	( 0.36605)	( 0.35057)
	Min,	2.856,	0.000,	4.284,	1.071,	2.856,	0.000,
	Max	4.641	1.071	5.355	2.856	5.355	2.856

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	3.4808	0.5355	4.3733	1.3388	3.9270	0.9371
	Median	3.0345	0.5355	4.6410	1.2495	3.9270	0.8925
	SD	1.60650	0.46089	0.84356	1.17954	1.28009	0.93363
	(SE)	( 0.80325)	( 0.23044)	( 0.42178)	( 0.58977)	( 0.45258)	( 0.33009)
	Min,	2.142,	0.000,	3.213,	0.000,	2.142,	0.000,
	Max	5.712	1.071	4.998	2.856	5.712	2.856
Week 32	n	4	4	3	3	7	7
	Mean	3.8378	0.8925	4.2840	1.4280	4.0290	1.1220
	Median	3.7485	0.8925	4.6410	1.4280	3.9270	1.4280
	SD	0.60969	0.84983	0.61834	1.07100	0.60845	0.90851
	(SE)	( 0.30485)	( 0.42491)	( 0.35700)	( 0.61834)	( 0.22997)	( 0.34338)
	Min,	3.213,	0.000,	3.570,	0.357,	3.213,	0.000,
	Max	4.641	1.785	4.641	2.499	4.641	2.499
Week 36	n	4	4	4	4	8	8
	Mean	4.0163	1.0710	5.0873	2.0528	4.5518	1.5619
	Median	4.1055	0.8925	4.9980	1.9635	4.4625	1.6065
	SD	0.60969	1.12893	0.73597	0.60969	0.84804	0.99041
	(SE)	( 0.30485)	( 0.56447)	( 0.36799)	( 0.30485)	( 0.29983)	( 0.35016)
	Min,	3.213,	0.000,	4.284,	1.428,	3.213,	0.000,
	Max	4.641	2.499	6.069	2.856	6.069	2.856

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	4.3733	1.4280	5.0872	2.0527	4.7303	1.7404
	Median	4.1055	1.4280	5.1765	2.3205	4.6410	1.6065
	SD	1.21502	0.87447	1.17954	1.28305	1.17245	1.06994
	(SE)	( 0.60751)	( 0.43723)	( 0.58977)	( 0.64152)	( 0.41452)	( 0.37828)
	Min,	3.213,	0.357,	3.570,	0.357,	3.213,	0.357,
	Max	6.069	2.499	6.426	3.213	6.426	3.213
Week 44	n	4	4	4	4	8	8
	Mean	3.8378	0.8925	5.2658	2.2313	4.5518	1.5619
	Median	3.7485	0.8925	4.8195	1.4280	4.4625	1.0710
	SD	1.37881	0.20611	2.14942	1.87496	1.83777	1.42720
	(SE)	( 0.68940)	( 0.10306)	( 1.07471)	( 0.93748)	( 0.64975)	( 0.50459)
	Min,	2.499,	0.714,	3.213,	1.071,	2.499,	0.714,
	Max	5.355	1.071	8.211	4.998	8.211	4.998
Week 48	n	4	4	4	4	8	8
	Mean	3.8378	0.8925	4.9980	1.9635	4.4179	1.4280
	Median	3.5700	0.8925	4.2840	1.4280	4.1055	1.0710
	SD	1.21502	0.20611	1.69966	1.60980	1.50180	1.20688
	(SE)	( 0.60751)	( 0.10306)	( 0.84983)	( 0.80490)	( 0.53097)	( 0.42670)
	Min,	2.856,	0.714,	3.927,	0.714,	2.856,	0.714,
	Max	5.355	1.071	7.497	4.284	7.497	4.284

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	4.3733	1.4280	4.5518	1.5173	4.4625	1.4726
	Median	3.9270	1.6065	4.1055	0.8925	3.9270	1.2495
	SD	1.17954	0.50487	1.87496	1.63273	1.45328	1.11982
	(SE)	( 0.58977)	( 0.25244)	( 0.93748)	( 0.81637)	( 0.51381)	( 0.39592)
	Min,	3.570,	0.714,	2.856,	0.357,	2.856,	0.357,
	Max	6.069	1.785	7.140	3.927	7.140	3.927
Week 56	n	4	4	3	3	7	7
	Mean	3.9270	0.9818	5.8310	2.4990	4.7430	1.6320
	Median	3.7485	1.0710	5.3550	1.7850	4.6410	1.0710
	SD	1.27057	0.17850	2.88560	2.92217	2.14907	1.87617
	(SE)	( 0.63529)	( 0.08925)	( 1.66600)	( 1.68712)	( 0.81227)	( 0.70913)
	Min,	2.856,	0.714,	3.213,	0.000,	2.856,	0.000,
	Max	5.355	1.071	8.925	5.712	8.925	5.712
Week 60	n	4	4	4	4	8	8
	Mean	4.2840	1.3388	4.6410	1.6065	4.4625	1.4726
	Median	4.1055	1.4280	4.6410	1.7850	4.6410	1.4280
	SD	1.27057	0.17850	1.16596	1.31977	1.14495	0.88353
	(SE)	( 0.63529)	( 0.08925)	( 0.58298)	( 0.65989)	( 0.40480)	( 0.31238)
	Min,	3.213,	1.071,	3.213,	0.000,	3.213,	0.000,
	Max	5.712	1.428	6.069	2.856	6.069	2.856

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	4.4625	1.5173	4.8195	1.7850	4.6410	1.6511
	Median	4.4625	1.6065	4.6410	1.7850	4.6410	1.6065
	SD	1.50053	0.34160	0.94453	0.92177	1.17632	0.65931
	(SE)	( 0.75027)	( 0.17090)	( 0.47227)	( 0.46089)	( 0.41589)	( 0.23310)
	Min,	2.856,	1.071,	3.927,	0.714,	2.856,	0.714,
	Max	6.069	1.785	6.069	2.856	6.069	2.856
Week 68	n	4	4	4	4	8	8
	Mean	4.8195	1.8743	4.9980	1.9635	4.9088	1.9189
	Median	4.4625	1.7850	4.8195	1.9635	4.6410	1.9635
	SD	1.71211	0.53550	1.12893	1.03057	1.34596	0.76181
	(SE)	( 0.85606)	( 0.26775)	( 0.56447)	( 0.51529)	( 0.47587)	( 0.26934)
	Min,	3.213,	1.428,	3.927,	0.714,	3.213,	0.714,
	Max	7.140	2.499	6.426	3.213	7.140	3.213
Week 72	n	3	3	4	4	7	7
	Mean	3.8080	1.4280	4.6410	1.6065	4.2840	1.5300
	Median	3.5700	1.4280	4.4625	1.6065	3.5700	1.4280
	SD	0.74315	0.35700	1.77306	1.60980	1.39793	1.16074
	(SE)	( 0.42906)	( 0.20611)	( 0.88653)	( 0.80490)	( 0.52837)	( 0.43872)
	Min,	3.213,	1.071,	2.856,	-0.357,	2.856,	-0.357,
	Max	4.641	1.785	6.783	3.570	6.783	3.570

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	6.2475	2.1420			6.2475	2.1420
	Median	6.2475	2.1420			6.2475	2.1420
	SD	2.27193	1.51462			2.27193	1.51462
	(SE)	( 1.60650)	( 1.07100)			( 1.60650)	( 1.07100)
	Min,	4.641,	1.071,			4.641,	1.071,
	Max	7.854	3.213			7.854	3.213
Week 76	n	4	4	4	4	8	8
	Mean	4.2840	1.3388	4.9088	1.8743	4.5964	1.6065
	Median	4.1055	1.4280	4.9980	2.1420	4.1055	1.6065
	SD	0.87447	0.53550	1.75802	1.46834	1.32808	1.06247
	(SE)	( 0.43723)	( 0.26775)	( 0.87901)	( 0.73417)	( 0.46955)	( 0.37564)
	Min,	3.570,	0.714,	3.213,	0.000,	3.213,	0.000,
	Max	5.355	1.785	6.426	3.213	6.426	3.213
Week 80	n	4	4	4	4	8	8
	Mean	4.1948	1.2495	4.9088	1.8743	4.5518	1.5619
	Median	4.1055	1.0710	4.9980	2.3205	4.1055	1.6065
	SD	0.89250	0.94453	1.57983	1.34765	1.24768	1.12792
	(SE)	( 0.44625)	( 0.47227)	( 0.78992)	( 0.67382)	( 0.44112)	( 0.39878)
	Min,	3.213,	0.357,	3.213,	0.000,	3.213,	0.000,
	Max	5.355	2.499	6.426	2.856	6.426	2.856

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	4.1948	1.2495	4.6410	1.6065	4.4179	1.4280
	Median	3.9270	1.2495	4.2840	1.4280	4.2840	1.4280
	SD	1.60650	0.20611	1.62294	1.47195	1.51387	0.99155
	(SE)	( 0.80325)	( 0.10306)	( 0.81147)	( 0.73597)	( 0.53523)	( 0.35057)
	Min,	2.856,	1.071,	3.213,	0.000,	2.856,	0.000,
	Max	6.069	1.428	6.783	3.570	6.783	3.570
Week 88	n	4	4	4	4	8	8
	Mean	4.5518	1.6065	8.3003	5.2658	6.4260	3.4361
	Median	4.9980	0.8925	6.9615	3.7485	5.7120	2.4990
	SD	1.52510	1.55613	4.48150	4.04294	3.69037	3.44510
	(SE)	( 0.76255)	( 0.77806)	( 2.24075)	( 2.02147)	( 1.30474)	( 1.21803)
	Min,	2.499,	0.714,	4.641,	2.499,	2.499,	0.714,
	Max	5.712	3.927	14.637	11.067	14.637	11.067
Week 92	n	4	4	4	4	8	8
	Mean	4.6410	1.6958	4.9980	1.9635	4.8195	1.8296
	Median	3.9270	1.4280	4.6410	1.7850	4.6410	1.4280
	SD	2.01950	0.79160	1.23668	1.31977	1.56197	1.01761
	(SE)	( 1.00975)	( 0.39580)	( 0.61834)	( 0.65989)	( 0.55224)	( 0.35978)
	Min,	3.213,	1.071,	3.927,	0.714,	3.213,	0.714,
	Max	7.497	2.856	6.783	3.570	7.497	3.570

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	3.8378	0.8925	5.8013	2.7668	4.8195	1.8296
	Median	3.3915	1.0710	4.9980	2.3205	4.2840	1.6065
	SD	1.02540	0.94453	2.18860	2.10952	1.89868	1.81472
	(SE)	( 0.51270)	( 0.47227)	( 1.09430)	( 1.05476)	( 0.67128)	( 0.64160)
	Min,	3.213,	-0.357,	4.284,	0.714,	3.213,	-0.357,
	Max	5.355	1.785	8.925	5.712	8.925	5.712
Week 100	n	4	4	4	4	8	8
	Mean	3.9270	0.9818	4.3733	1.3388	4.1501	1.1603
	Median	3.3915	0.8925	3.7485	0.7140	3.7485	0.8925
	SD	1.77306	0.60969	1.63273	1.52510	1.59584	1.09204
	(SE)	( 0.88653)	( 0.30485)	( 0.81637)	( 0.76255)	( 0.56421)	( 0.38610)
	Min,	2.499,	0.357,	3.213,	0.357,	2.499,	0.357,
	Max	6.426	1.785	6.783	3.570	6.783	3.570
Week 104	n	4	4	4	4	8	8
	Mean	4.1947	1.2495	4.2840	1.2495	4.2394	1.2495
	Median	4.2840	1.0710	4.2840	1.4280	4.2840	1.2495
	SD	0.73597	0.94453	1.23668	0.94453	0.94333	0.87447
	(SE)	( 0.36799)	( 0.47227)	( 0.61834)	( 0.47227)	( 0.33352)	( 0.30917)
	Min,	3.213,	0.357,	3.213,	0.000,	3.213,	0.000,
	Max	4.998	2.499	5.355	2.142	5.355	2.499

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	4.1948	1.2495	4.7303	1.6958	4.4625	1.4726
	Median	4.1055	1.0710	4.6410	1.7850	4.6410	1.2495
	SD	1.55271	0.35700	1.34765	1.34765	1.37606	0.94333
	(SE)	( 0.77636)	( 0.17850)	( 0.67382)	( 0.67382)	( 0.48651)	( 0.33352)
	Min,	2.856,	1.071,	3.213,	0.000,	2.856,	0.000,
	Max	5.712	1.785	6.426	3.213	6.426	3.213
Week 112	n	4	4	4	4	8	8
	Mean	4.6410	1.6958	5.2658	2.2313	4.9534	1.9635
	Median	3.9270	1.7850	4.8195	1.9635	4.2840	1.7850
	SD	1.69966	0.73597	1.60650	1.49699	1.56706	1.12893
	(SE)	( 0.84983)	( 0.36799)	( 0.80325)	( 0.74849)	( 0.55404)	( 0.39914)
	Min,	3.570,	0.714,	3.927,	0.714,	3.570,	0.714,
	Max	7.140	2.499	7.497	4.284	7.497	4.284
Week 116	n	4	4	4	4	8	8
	Mean	4.6410	1.6958	4.8195	1.7850	4.7303	1.7404
	Median	4.2840	1.6065	4.9980	2.1420	4.9980	2.1420
	SD	2.38594	0.98310	1.58319	1.51462	1.87698	1.18307
	(SE)	( 1.19297)	( 0.49155)	( 0.79160)	( 0.75731)	( 0.66361)	( 0.41828)
	Min,	2.499,	0.714,	2.856,	-0.357,	2.499,	-0.357,
	Max	7.497	2.856	6.426	3.213	7.497	3.213

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	3.3320	0.9520	4.6410	1.6065	4.0800	1.3260
	Median	2.8560	1.0710	4.6410	1.7850	4.2840	1.0710
	SD	0.82446	0.20611	0.65179	0.35700	0.96362	0.44752
	(SE)	( 0.47600)	( 0.11900)	( 0.32589)	( 0.17850)	( 0.36421)	( 0.16915)
	Min,	2.856,	0.714,	3.927,	1.071,	2.856,	0.714,
	Max	4.284	1.071	5.355	1.785	5.355	1.785
Week 124	n	3	3	4	4	7	7
	Mean	3.5700	1.1900	5.3550	2.3205	4.5900	1.8360
	Median	2.8560	1.0710	5.8905	2.6775	5.3550	1.7850
	SD	1.55613	0.54533	1.45745	0.84983	1.66721	0.90851
	(SE)	( 0.89843)	( 0.31484)	( 0.72872)	( 0.42491)	( 0.63015)	( 0.34338)
	Min,	2.499,	0.714,	3.213,	1.071,	2.499,	0.714,
	Max	5.355	1.785	6.426	2.856	6.426	2.856
Week 128	n	4	4	4	4	8	8
	Mean	4.1948	1.2495	5.2657	2.2313	4.7303	1.7404
	Median	3.9270	1.2495	4.4625	1.2495	4.1055	1.2495
	SD	1.10516	0.46089	2.54741	2.33874	1.90586	1.64638
	(SE)	( 0.55258)	( 0.23044)	( 1.27370)	( 1.16937)	( 0.67382)	( 0.58208)
	Min,	3.213,	0.714,	3.213,	0.714,	3.213,	0.714,
	Max	5.712	1.785	8.925	5.712	8.925	5.712

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	3.8378	0.8925	5.3550	2.3205	4.5964	1.6065
	Median	3.3915	0.8925	5.5335	2.6775	4.2840	1.2495
	SD	1.60650	0.46089	1.27057	1.10996	1.56706	1.09620
	(SE)	( 0.80325)	( 0.23044)	( 0.63529)	( 0.55498)	( 0.55404)	( 0.38757)
	Min,	2.499,	0.357,	3.927,	0.714,	2.499,	0.357,
	Max	6.069	1.428	6.426	3.213	6.426	3.213
Week 136	n	4	4	4	4	8	8
	Mean	4.4625	1.5173	5.3550	2.3205	4.9088	1.9189
	Median	3.9270	1.6065	5.3550	2.1420	4.4625	1.7850
	SD	1.60980	0.60969	1.30358	0.94453	1.43753	0.85206
	(SE)	( 0.80490)	( 0.30485)	( 0.65179)	( 0.47227)	( 0.50824)	( 0.30125)
	Min,	3.213,	0.714,	3.927,	1.428,	3.213,	0.714,
	Max	6.783	2.142	6.783	3.570	6.783	3.570
Week 140	n	4	4	4	4	8	8
	Mean	4.1055	1.1603	4.1055	1.0710	4.1055	1.1156
	Median	3.3915	0.7140	4.2840	1.0710	4.2840	0.8925
	SD	2.44747	1.14296	0.61834	0.29149	1.65259	0.77366
	(SE)	( 1.22373)	( 0.57148)	( 0.30917)	( 0.14574)	( 0.58428)	( 0.27353)
	Min,	2.142,	0.357,	3.213,	0.714,	2.142,	0.357,
	Max	7.497	2.856	4.641	1.428	7.497	2.856

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	4.6410	1.6958	4.8195	1.7850	4.7303	1.7404
	Median	4.2840	1.7850	4.2840	1.4280	4.2840	1.7850
	SD	1.36721	1.02540	1.60980	1.74894	1.38594	1.32808
	(SE)	( 0.68360)	( 0.51270)	( 0.80490)	( 0.87447)	( 0.49000)	( 0.46955)
	Min,	3.570,	0.357,	3.570,	0.357,	3.570,	0.357,
	Max	6.426	2.856	7.140	3.927	7.140	3.927
Week 148	n	4	4	4	4	8	8
	Mean	3.4808	0.5355	4.8195	1.7850	4.1501	1.1603
	Median	3.3915	0.8925	5.1765	1.7850	4.1055	1.0710
	SD	0.73597	0.84983	1.18404	0.65179	1.15976	0.96833
	(SE)	( 0.36799)	( 0.42491)	( 0.59202)	( 0.32589)	( 0.41004)	( 0.34236)
	Min,	2.856,	-0.714,	3.213,	1.071,	2.856,	-0.714,
	Max	4.284	1.071	5.712	2.499	5.712	2.499
Week 152	n	4	4	3	3	7	7
	Mean	3.6593	0.7140	4.8790	2.0230	4.1820	1.2750
	Median	3.7485	0.8925	4.2840	2.1420	4.2840	1.0710
	SD	1.14296	0.50487	1.35158	1.25374	1.29892	1.06816
	(SE)	( 0.57148)	( 0.25244)	( 0.78034)	( 0.72385)	( 0.49094)	( 0.40373)
	Min,	2.499,	0.000,	3.927,	0.714,	2.499,	0.000,
	Max	4.641	1.071	6.426	3.213	6.426	3.213

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	3.3023	0.3570	5.4443	2.4098	4.3733	1.3834
	Median	3.2130	0.7140	5.3550	2.4990	4.4625	1.0710
	SD	0.93889	0.71400	0.93889	0.73597	1.43753	1.28630
	(SE)	( 0.46945)	( 0.35700)	( 0.46945)	( 0.36799)	( 0.50824)	( 0.45477)
	Min,	2.499,	-0.714,	4.641,	1.428,	2.499,	-0.714,
	Max	4.284	0.714	6.426	3.213	6.426	3.213
Week 160	n	4	4	4	4	8	8
	Mean	3.2130	0.2678	5.3550	2.3205	4.2840	1.2941
	Median	3.0345	0.7140	5.5335	2.6775	3.9270	1.0710
	SD	0.50487	1.17954	1.27057	1.10996	1.45328	1.52585
	(SE)	( 0.25244)	( 0.58977)	( 0.63529)	( 0.55498)	( 0.51381)	( 0.53947)
	Min,	2.856,	-1.428,	3.927,	0.714,	2.856,	-1.428,
	Max	3.927	1.071	6.426	3.213	6.426	3.213
Week 164	n	4	4	4	4	8	8
	Mean	3.3023	0.3570	5.7120	2.6775	4.5071	1.5173
	Median	3.3915	0.5355	6.0690	3.2130	3.9270	0.8925
	SD	0.73597	0.77121	1.82035	1.87779	1.81972	1.81785
	(SE)	( 0.36799)	( 0.38560)	( 0.91017)	( 0.93889)	( 0.64337)	( 0.64271)
	Min,	2.499,	-0.714,	3.213,	0.000,	2.499,	-0.714,
	Max	3.927	1.071	7.497	4.284	7.497	4.284

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	3.4808	0.5355	5.9798	2.9453	4.7303	1.7404
	Median	3.3915	0.8925	5.7120	2.8560	4.8195	1.4280
	SD	0.98310	0.84983	1.21502	1.02540	1.68261	1.55540
	(SE)	( 0.49155)	( 0.42491)	( 0.60751)	( 0.51270)	( 0.59489)	( 0.54992)
	Min,	2.499,	-0.714,	4.998,	1.785,	2.499,	-0.714,
	Max	4.641	1.071	7.497	4.284	7.497	4.284
Week 172	n	4	4	4	4	8	8
	Mean	3.9270	0.9818	5.2658	2.2313	4.5964	1.6065
	Median	3.7485	1.4280	5.1765	2.3205	4.6410	1.7850
	SD	0.50487	1.17954	0.60969	0.60969	0.88353	1.09620
	(SE)	( 0.25244)	( 0.58977)	( 0.30485)	( 0.30485)	( 0.31237)	( 0.38757)
	Min,	3.570,	-0.714,	4.641,	1.428,	3.570,	-0.714,
	Max	4.641	1.785	6.069	2.856	6.069	2.856
Week 176	n	4	4	4	4	8	8
	Mean	3.3023	0.3570	5.7120	2.6775	4.5071	1.5173
	Median	3.2130	0.7140	5.8905	2.4990	4.1055	1.0710
	SD	0.93889	0.71400	1.67448	1.31977	1.79960	1.58223
	(SE)	( 0.46945)	( 0.35700)	( 0.83724)	( 0.65989)	( 0.63626)	( 0.55940)
	Min,	2.499,	-0.714,	3.570,	1.428,	2.499,	-0.714,
	Max	4.284	0.714	7.497	4.284	7.497	4.284

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	3.5700	0.6248	4.8790	2.0230	4.1310	1.2240
	Median	3.5700	0.5355	4.6410	2.4990	4.6410	0.7140
	SD	1.45745	0.60969	1.09065	1.14759	1.39576	1.08787
	(SE)	( 0.72872)	( 0.30485)	( 0.62969)	( 0.66256)	( 0.52755)	( 0.41118)
	Min,	2.142,	0.000,	3.927,	0.714,	2.142,	0.000,
	Max	4.998	1.428	6.069	2.856	6.069	2.856
Week 184	n	4	4	4	4	8	8
	Mean	4.0163	1.0710	5.3550	2.3205	4.6856	1.6958
	Median	4.1055	1.2495	5.1765	1.7850	4.9980	1.4280
	SD	1.14296	0.50487	1.91142	1.58319	1.62411	1.27653
	(SE)	( 0.57148)	( 0.25244)	( 0.95571)	( 0.79160)	( 0.57421)	( 0.45132)
	Min,	2.856,	0.357,	3.213,	1.071,	2.856,	0.357,
	Max	4.998	1.428	7.854	4.641	7.854	4.641

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg			50 mg/kg		Eteplirsen for 184 Weeks	
	Observed	Change from Baseline		Observed	Change from Baseline	Observed	Change from Baseline
Protein (g/dL)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	6.95		6.90		6.93	
	Median	7.05		6.80		7.00	
	SD	0.387		0.529		0.430	
	(SE)	( 0.194)		( 0.265)		( 0.152)	
	Min,	6.4,		6.4,		6.4,	
	Max	7.3		7.6		7.6	
Week 2	n	4	4	4	4	8	8
	Mean	6.75	-0.20	6.63	-0.28	6.69	-0.24
	Median	6.55	-0.20	6.65	-0.20	6.60	-0.20
	SD	0.580	0.523	0.330	0.486	0.442	0.469
	(SE)	( 0.290)	( 0.261)	( 0.165)	( 0.243)	( 0.156)	( 0.166)
	Min,	6.3,	-0.7,	6.2,	-0.9,	6.2,	-0.9,
	Max	7.6	0.3	7.0	0.2	7.6	0.3
Week 4	n	4	4	4	4	8	8
	Mean	6.63	-0.33	7.13	0.23	6.88	-0.05
	Median	6.65	-0.35	7.20	0.20	6.80	-0.20
	SD	0.250	0.411	0.624	0.512	0.515	0.521
	(SE)	( 0.125)	( 0.206)	( 0.312)	( 0.256)	( 0.182)	( 0.184)
	Min,	6.3,	-0.8,	6.3,	-0.3,	6.3,	-0.8,
	Max	6.9	0.2	7.8	0.8	7.8	0.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	6.25	-0.70	6.68	-0.23	6.46	-0.46
	Median	6.35	-0.70	6.60	-0.30	6.45	-0.55
	SD	0.311	0.183	0.310	0.411	0.366	0.389
	(SE)	( 0.155)	( 0.091)	( 0.155)	( 0.206)	( 0.129)	( 0.138)
	Min,	5.8,	-0.9,	6.4,	-0.6,	5.8,	-0.9,
	Max	6.5	-0.5	7.1	0.3	7.1	0.3
Week 8	n	4	4	4	4	8	8
	Mean	6.60	-0.35	6.75	-0.15	6.68	-0.25
	Median	6.35	-0.40	6.80	-0.05	6.50	-0.05
	SD	0.606	0.526	0.370	0.238	0.471	0.393
	(SE)	( 0.303)	( 0.263)	( 0.185)	( 0.119)	( 0.167)	( 0.139)
	Min,	6.2,	-0.8,	6.3,	-0.5,	6.2,	-0.8,
	Max	7.5	0.2	7.1	0.0	7.5	0.2
Week 10	n	4	4	4	4	8	8
	Mean	6.40	-0.55	6.68	-0.23	6.54	-0.39
	Median	6.50	-0.45	6.70	-0.10	6.70	-0.35
	SD	0.383	0.311	0.450	0.499	0.414	0.422
	(SE)	( 0.191)	( 0.155)	( 0.225)	( 0.250)	( 0.146)	( 0.149)
	Min,	5.9,	-1.0,	6.1,	-0.9,	5.9,	-1.0,
	Max	6.7	-0.3	7.2	0.2	7.2	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	6.63	-0.33	6.95	0.05	6.79	-0.14
	Median	6.55	-0.35	6.70	-0.05	6.55	-0.25
	SD	0.419	0.206	1.028	0.507	0.747	0.410
	(SE)	( 0.210)	( 0.103)	( 0.514)	( 0.253)	( 0.264)	( 0.145)
	Min,	6.2,	-0.5,	6.1,	-0.4,	6.1,	-0.5,
	Max	7.2	-0.1	8.3	0.7	8.3	0.7
Week 15	n	4	4	4	4	8	8
	Mean	6.28	-0.68	6.60	-0.30	6.44	-0.49
	Median	6.35	-0.70	6.60	-0.40	6.35	-0.55
	SD	0.359	0.150	0.808	0.432	0.605	0.360
	(SE)	( 0.180)	( 0.075)	( 0.404)	( 0.216)	( 0.214)	( 0.127)
	Min,	5.8,	-0.8,	5.9,	-0.7,	5.8,	-0.8,
	Max	6.6	-0.5	7.3	0.3	7.3	0.3
Week 18	n	4	4	4	4	8	8
	Mean	6.50	-0.45	6.68	-0.23	6.59	-0.34
	Median	6.65	-0.45	6.55	-0.20	6.65	-0.35
	SD	0.337	0.129	0.655	0.150	0.491	0.177
	(SE)	( 0.168)	( 0.065)	( 0.328)	( 0.075)	( 0.174)	( 0.062)
	Min,	6.0,	-0.6,	6.1,	-0.4,	6.0,	-0.6,
	Max	6.7	-0.3	7.5	-0.1	7.5	-0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	6.35	-0.60	6.60	-0.30	6.48	-0.45
	Median	6.30	-0.60	6.50	-0.40	6.30	-0.60
	SD	0.332	0.183	0.683	0.632	0.515	0.460
	(SE)	( 0.166)	( 0.091)	( 0.342)	( 0.316)	( 0.182)	( 0.163)
	Min,	6.0,	-0.8,	5.9,	-0.9,	5.9,	-0.9,
	Max	6.8	-0.4	7.5	0.5	7.5	0.5
Week 24	n	4	4	4	4	8	8
	Mean	6.73	-0.23	6.60	-0.30	6.66	-0.26
	Median	6.60	-0.20	6.50	-0.05	6.50	-0.05
	SD	0.403	0.330	0.271	0.606	0.325	0.453
	(SE)	( 0.202)	( 0.165)	( 0.135)	( 0.303)	( 0.115)	( 0.160)
	Min,	6.4,	-0.6,	6.4,	-1.2,	6.4,	-1.2,
	Max	7.3	0.1	7.0	0.1	7.3	0.1
Week 25	n	4	4	4	4	8	8
	Mean	6.48	-0.48	6.55	-0.35	6.51	-0.41
	Median	6.50	-0.30	6.55	-0.30	6.50	-0.30
	SD	0.330	0.350	0.569	0.265	0.432	0.295
	(SE)	( 0.165)	( 0.175)	( 0.284)	( 0.132)	( 0.153)	( 0.104)
	Min,	6.1,	-1.0,	5.9,	-0.7,	5.9,	-1.0,
	Max	6.8	-0.3	7.2	-0.1	7.2	-0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 28	n	4	4	4	4	8	8
	Mean	6.48	-0.48	6.40	-0.50	6.44	-0.49
	Median	6.55	-0.45	6.50	-0.50	6.50	-0.50
	SD	0.538	0.427	0.271	0.497	0.396	0.429
	(SE)	( 0.269)	( 0.214)	( 0.135)	( 0.248)	( 0.140)	( 0.152)
	Min,	5.8,	-1.0,	6.0,	-1.1,	5.8,	-1.1,
	Max	7.0	0.0	6.6	0.1	7.0	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Albumin (g/dL)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	4.30		4.25		4.28	
	Median	4.35		4.20		4.25	
	SD	0.141		0.412		0.287	
	(SE)	( 0.071)		( 0.206)		( 0.101)	
	Min,	4.1,		3.8,		3.8,	
	Max	4.4		4.8		4.8	
Week 2	n	4	4	4	4	8	8
	Mean	4.13	-0.18	3.98	-0.28	4.05	-0.23
	Median	4.00	-0.20	4.00	-0.25	4.00	-0.20
	SD	0.403	0.403	0.206	0.457	0.307	0.403
	(SE)	( 0.202)	( 0.202)	( 0.103)	( 0.229)	( 0.109)	( 0.142)
	Min,	3.8,	-0.6,	3.7,	-0.8,	3.7,	-0.8,
	Max	4.7	0.3	4.2	0.2	4.7	0.3
Week 4	n	4	4	4	4	8	8
	Mean	4.05	-0.25	4.30	0.05	4.18	-0.10
	Median	4.00	-0.25	4.40	0.10	4.10	-0.10
	SD	0.100	0.173	0.346	0.342	0.271	0.298
	(SE)	( 0.050)	( 0.087)	( 0.173)	( 0.171)	( 0.096)	( 0.105)
	Min,	4.0,	-0.4,	3.8,	-0.4,	3.8,	-0.4,
	Max	4.2	-0.1	4.6	0.4	4.6	0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	3.83	-0.48	4.13	-0.13	3.98	-0.30
	Median	3.85	-0.50	4.10	-0.10	3.95	-0.35
	SD	0.171	0.126	0.206	0.206	0.238	0.245
	(SE)	( 0.085)	( 0.063)	( 0.103)	( 0.103)	( 0.084)	( 0.087)
	Min,	3.6,	-0.6,	3.9,	-0.4,	3.6,	-0.6,
	Max	4.0	-0.3	4.4	0.1	4.4	0.1
Week 8	n	4	4	4	4	8	8
	Mean	3.98	-0.33	4.10	-0.15	4.04	-0.24
	Median	3.85	-0.35	4.10	-0.10	4.00	-0.15
	SD	0.287	0.275	0.245	0.173	0.256	0.233
	(SE)	( 0.144)	( 0.138)	( 0.122)	( 0.087)	( 0.091)	( 0.082)
	Min,	3.8,	-0.6,	3.8,	-0.4,	3.8,	-0.6,
	Max	4.4	0.0	4.4	0.0	4.4	0.0
Week 10	n	4	4	4	4	8	8
	Mean	3.83	-0.48	4.08	-0.18	3.95	-0.33
	Median	3.85	-0.45	4.15	-0.10	4.00	-0.35
	SD	0.206	0.171	0.263	0.299	0.256	0.276
	(SE)	( 0.103)	( 0.085)	( 0.131)	( 0.149)	( 0.091)	( 0.098)
	Min,	3.6,	-0.7,	3.7,	-0.6,	3.6,	-0.7,
	Max	4.0	-0.3	4.3	0.1	4.3	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	4.10	-0.20	4.38	0.13	4.24	-0.04
	Median	4.05	-0.20	4.20	0.20	4.10	-0.10
	SD	0.216	0.163	0.499	0.236	0.385	0.256
	(SE)	( 0.108)	( 0.082)	( 0.250)	( 0.118)	( 0.136)	( 0.091)
	Min,	3.9,	-0.4,	4.0,	-0.2,	3.9,	-0.4,
	Max	4.4	0.0	5.1	0.3	5.1	0.3
Week 15	n	4	4	4	4	8	8
	Mean	3.83	-0.48	4.00	-0.25	3.91	-0.36
	Median	3.85	-0.50	3.95	-0.20	3.85	-0.35
	SD	0.250	0.150	0.424	0.265	0.336	0.233
	(SE)	( 0.125)	( 0.075)	( 0.212)	( 0.132)	( 0.119)	( 0.082)
	Min,	3.5,	-0.6,	3.6,	-0.6,	3.5,	-0.6,
	Max	4.1	-0.3	4.5	0.0	4.5	0.0
Week 18	n	4	4	4	4	8	8
	Mean	4.00	-0.30	4.08	-0.18	4.04	-0.24
	Median	4.05	-0.35	4.00	-0.20	4.00	-0.20
	SD	0.294	0.216	0.377	0.050	0.316	0.160
	(SE)	( 0.147)	( 0.108)	( 0.189)	( 0.025)	( 0.112)	( 0.056)
	Min,	3.6,	-0.5,	3.7,	-0.2,	3.6,	-0.5,
	Max	4.3	0.0	4.6	-0.1	4.6	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	3.88	-0.43	4.00	-0.25	3.94	-0.34
	Median	3.90	-0.40	4.00	-0.25	3.90	-0.40
	SD	0.126	0.050	0.337	0.465	0.245	0.320
	(SE)	( 0.063)	( 0.025)	( 0.168)	( 0.233)	( 0.086)	( 0.113)
	Min,	3.7,	-0.5,	3.6,	-0.7,	3.6,	-0.7,
	Max	4.0	-0.4	4.4	0.2	4.4	0.2
Week 24	n	4	4	4	4	8	8
	Mean	4.18	-0.13	4.15	-0.10	4.16	-0.11
	Median	4.10	-0.15	4.15	0.05	4.10	0.00
	SD	0.222	0.206	0.129	0.408	0.169	0.300
	(SE)	( 0.111)	( 0.103)	( 0.065)	( 0.204)	( 0.060)	( 0.106)
	Min,	4.0,	-0.3,	4.0,	-0.7,	4.0,	-0.7,
	Max	4.5	0.1	4.3	0.2	4.5	0.2
Week 25	n	4	4	4	4	8	8
	Mean	4.05	-0.25	4.10	-0.15	4.08	-0.20
	Median	4.05	-0.20	4.05	-0.20	4.05	-0.20
	SD	0.289	0.265	0.294	0.265	0.271	0.251
	(SE)	( 0.144)	( 0.132)	( 0.147)	( 0.132)	( 0.096)	( 0.089)
	Min,	3.8,	-0.6,	3.8,	-0.4,	3.8,	-0.6,
	Max	4.3	0.0	4.5	0.2	4.5	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 28	n	4	4	4	4	8	8
	Mean	3.93	-0.38	3.90	-0.35	3.91	-0.36
	Median	3.90	-0.45	3.90	-0.40	3.90	-0.45
	SD	0.206	0.189	0.258	0.300	0.217	0.233
	(SE)	( 0.103)	( 0.095)	( 0.129)	( 0.150)	( 0.077)	( 0.082)
	Min,	3.7,	-0.5,	3.6,	-0.6,	3.6,	-0.6,
	Max	4.2	-0.1	4.2	0.0	4.2	0.0
Week 32	n	4	4	3	3	7	7
	Mean	4.15	-0.15	4.07	0.00	4.11	-0.09
	Median	4.25	-0.10	4.00	0.00	4.20	-0.10
	SD	0.238	0.100	0.115	0.200	0.186	0.157
	(SE)	( 0.119)	( 0.050)	( 0.067)	( 0.115)	( 0.070)	( 0.059)
	Min,	3.8,	-0.3,	4.0,	-0.2,	3.8,	-0.3,
	Max	4.3	-0.1	4.2	0.2	4.3	0.2
Week 36	n	4	4	4	4	8	8
	Mean	4.25	-0.05	4.33	0.08	4.29	0.01
	Median	4.25	-0.05	4.30	0.10	4.25	0.00
	SD	0.129	0.129	0.150	0.299	0.136	0.223
	(SE)	( 0.065)	( 0.065)	( 0.075)	( 0.149)	( 0.048)	( 0.079)
	Min,	4.1,	-0.2,	4.2,	-0.3,	4.1,	-0.3,
	Max	4.4	0.1	4.5	0.4	4.5	0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	4.08	-0.23	4.30	0.05	4.19	-0.09
	Median	4.05	-0.15	4.20	0.10	4.10	-0.05
	SD	0.275	0.263	0.383	0.191	0.331	0.259
	(SE)	( 0.138)	( 0.131)	( 0.191)	( 0.096)	( 0.117)	( 0.091)
	Min,	3.8,	-0.6,	4.0,	-0.2,	3.8,	-0.6,
	Max	4.4	0.0	4.8	0.2	4.8	0.2
Week 44	n	4	4	4	4	8	8
	Mean	4.03	-0.28	4.23	-0.02	4.13	-0.15
	Median	4.00	-0.20	4.20	-0.05	4.05	-0.20
	SD	0.150	0.150	0.330	0.386	0.260	0.302
	(SE)	( 0.075)	( 0.075)	( 0.165)	( 0.193)	( 0.092)	( 0.107)
	Min,	3.9,	-0.5,	3.9,	-0.4,	3.9,	-0.5,
	Max	4.2	-0.2	4.6	0.4	4.6	0.4
Week 48	n	4	4	4	4	8	8
	Mean	4.15	-0.15	4.25	0.00	4.20	-0.08
	Median	4.20	-0.15	4.25	-0.05	4.25	-0.10
	SD	0.191	0.129	0.129	0.374	0.160	0.271
	(SE)	( 0.096)	( 0.065)	( 0.065)	( 0.187)	( 0.057)	( 0.096)
	Min,	3.9,	-0.3,	4.1,	-0.4,	3.9,	-0.4,
	Max	4.3	0.0	4.4	0.5	4.4	0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 52	n	4	4	4	4	8	8
	Mean	4.18	-0.13	4.35	0.10	4.26	-0.01
	Median	4.15	-0.10	4.40	0.10	4.25	-0.05
	SD	0.096	0.126	0.342	0.327	0.250	0.259
	(SE)	( 0.048)	( 0.063)	( 0.171)	( 0.163)	( 0.089)	( 0.091)
	Min,	4.1,	-0.3,	3.9,	-0.3,	3.9,	-0.3,
	Max	4.3	0.0	4.7	0.5	4.7	0.5
Week 56	n	4	4	3	3	7	7
	Mean	4.23	-0.08	3.97	-0.30	4.11	-0.17
	Median	4.25	-0.05	4.00	-0.20	4.00	-0.10
	SD	0.171	0.096	0.058	0.458	0.186	0.298
	(SE)	( 0.085)	( 0.048)	( 0.033)	( 0.265)	( 0.070)	( 0.113)
	Min,	4.0,	-0.2,	3.9,	-0.8,	3.9,	-0.8,
	Max	4.4	0.0	4.0	0.1	4.4	0.1
Week 60	n	4	4	4	4	8	8
	Mean	4.18	-0.13	4.20	-0.05	4.19	-0.09
	Median	4.15	-0.05	4.25	0.15	4.15	0.00
	SD	0.171	0.189	0.245	0.436	0.196	0.314
	(SE)	( 0.085)	( 0.095)	( 0.122)	( 0.218)	( 0.069)	( 0.111)
	Min,	4.0,	-0.4,	3.9,	-0.7,	3.9,	-0.7,
	Max	4.4	0.0	4.4	0.2	4.4	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	4.38	0.08	4.23	-0.02	4.30	0.03
	Median	4.40	0.10	4.20	-0.05	4.35	0.10
	SD	0.150	0.126	0.330	0.386	0.251	0.271
	(SE)	( 0.075)	( 0.063)	( 0.165)	( 0.193)	( 0.089)	( 0.096)
	Min,	4.2,	-0.1,	3.9,	-0.4,	3.9,	-0.4,
	Max	4.5	0.2	4.6	0.4	4.6	0.4
Week 68	n	4	4	4	4	8	8
	Mean	4.43	0.13	4.43	0.18	4.43	0.15
	Median	4.40	0.15	4.45	0.20	4.45	0.15
	SD	0.330	0.330	0.275	0.299	0.282	0.293
	(SE)	( 0.165)	( 0.165)	( 0.138)	( 0.149)	( 0.100)	( 0.104)
	Min,	4.1,	-0.3,	4.1,	-0.2,	4.1,	-0.3,
	Max	4.8	0.5	4.7	0.5	4.8	0.5
Week 72	n	3	3	4	4	7	7
	Mean	4.17	-0.10	4.28	0.02	4.23	-0.03
	Median	4.30	-0.10	4.15	-0.05	4.30	-0.10
	SD	0.321	0.200	0.450	0.538	0.373	0.403
	(SE)	( 0.186)	( 0.115)	( 0.225)	( 0.269)	( 0.141)	( 0.152)
	Min,	3.8,	-0.3,	3.9,	-0.5,	3.8,	-0.5,
	Max	4.4	0.1	4.9	0.7	4.9	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	3.95	-0.30			3.95	-0.30
	Median	3.95	-0.30			3.95	-0.30
	SD	0.071	0.141			0.071	0.141
	(SE)	( 0.050)	( 0.100)			( 0.050)	( 0.100)
	Min,	3.9,	-0.4,			3.9,	-0.4,
	Max	4.0	-0.2			4.0	-0.2
Week 76	n	4	4	4	4	8	8
	Mean	4.25	-0.05	4.23	-0.03	4.24	-0.04
	Median	4.30	-0.05	4.20	-0.05	4.30	-0.05
	SD	0.100	0.058	0.377	0.275	0.256	0.185
	(SE)	( 0.050)	( 0.029)	( 0.189)	( 0.138)	( 0.091)	( 0.065)
	Min,	4.1,	-0.1,	3.9,	-0.3,	3.9,	-0.3,
	Max	4.3	0.0	4.6	0.3	4.6	0.3
Week 80	n	4	4	4	4	8	8
	Mean	4.38	0.08	4.10	-0.15	4.24	-0.04
	Median	4.30	0.05	4.10	0.05	4.20	0.05
	SD	0.310	0.330	0.183	0.436	0.277	0.378
	(SE)	( 0.155)	( 0.165)	( 0.091)	( 0.218)	( 0.098)	( 0.134)
	Min,	4.1,	-0.3,	3.9,	-0.8,	3.9,	-0.8,
	Max	4.8	0.5	4.3	0.1	4.8	0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	4.25	-0.05	4.20	-0.05	4.23	-0.05
	Median	4.20	-0.05	4.20	0.05	4.20	0.00
	SD	0.100	0.129	0.082	0.465	0.089	0.316
	(SE)	( 0.050)	( 0.065)	( 0.041)	( 0.233)	( 0.031)	( 0.112)
	Min,	4.2,	-0.2,	4.1,	-0.7,	4.1,	-0.7,
	Max	4.4	0.1	4.3	0.4	4.4	0.4
Week 88	n	4	4	4	4	8	8
	Mean	4.28	-0.03	4.20	-0.05	4.24	-0.04
	Median	4.25	0.00	4.25	0.05	4.25	0.00
	SD	0.171	0.126	0.294	0.387	0.226	0.267
	(SE)	( 0.085)	( 0.063)	( 0.147)	( 0.194)	( 0.080)	( 0.094)
	Min,	4.1,	-0.2,	3.8,	-0.6,	3.8,	-0.6,
	Max	4.5	0.1	4.5	0.3	4.5	0.3
Week 92	n	4	4	4	4	8	8
	Mean	4.20	-0.10	4.33	0.08	4.26	-0.01
	Median	4.20	-0.10	4.35	-0.05	4.20	-0.10
	SD	0.163	0.082	0.457	0.359	0.325	0.259
	(SE)	( 0.082)	( 0.041)	( 0.229)	( 0.180)	( 0.115)	( 0.091)
	Min,	4.0,	-0.2,	3.8,	-0.2,	3.8,	-0.2,
	Max	4.4	0.0	4.8	0.6	4.8	0.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	4.38	0.08	4.33	0.08	4.35	0.08
	Median	4.35	0.00	4.25	0.20	4.30	0.00
	SD	0.250	0.222	0.189	0.427	0.207	0.315
	(SE)	( 0.125)	( 0.111)	( 0.095)	( 0.214)	( 0.073)	( 0.111)
	Min,	4.1,	-0.1,	4.2,	-0.5,	4.1,	-0.5,
	Max	4.7	0.4	4.6	0.4	4.7	0.4
Week 100	n	4	4	4	4	8	8
	Mean	4.30	0.00	4.38	0.13	4.34	0.06
	Median	4.35	-0.05	4.35	0.10	4.35	0.00
	SD	0.294	0.216	0.386	0.222	0.320	0.213
	(SE)	( 0.147)	( 0.108)	( 0.193)	( 0.111)	( 0.113)	( 0.075)
	Min,	3.9,	-0.2,	4.0,	-0.1,	3.9,	-0.2,
	Max	4.6	0.3	4.8	0.4	4.8	0.4
Week 104	n	4	4	4	4	8	8
	Mean	4.35	0.05	4.33	0.08	4.34	0.06
	Median	4.45	0.05	4.25	0.20	4.35	0.05
	SD	0.238	0.129	0.189	0.427	0.200	0.292
	(SE)	( 0.119)	( 0.065)	( 0.095)	( 0.214)	( 0.071)	( 0.103)
	Min,	4.0,	-0.1,	4.2,	-0.5,	4.0,	-0.5,
	Max	4.5	0.2	4.6	0.4	4.6	0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	4	4	4	4	8	8
	Mean	4.28	-0.03	4.20	-0.05	4.24	-0.04
	Median	4.30	-0.05	4.20	-0.10	4.30	-0.10
	SD	0.050	0.096	0.476	0.252	0.316	0.177
	(SE)	( 0.025)	( 0.048)	( 0.238)	( 0.126)	( 0.112)	( 0.063)
	Min,	4.2,	-0.1,	3.7,	-0.3,	3.7,	-0.3,
	Max	4.3	0.1	4.7	0.3	4.7	0.3
Week 112	n	4	4	4	4	8	8
	Mean	4.20	-0.10	4.25	0.00	4.23	-0.05
	Median	4.20	-0.10	4.30	0.10	4.20	0.00
	SD	0.082	0.183	0.342	0.432	0.231	0.312
	(SE)	( 0.041)	( 0.091)	( 0.171)	( 0.216)	( 0.082)	( 0.110)
	Min,	4.1,	-0.3,	3.8,	-0.6,	3.8,	-0.6,
	Max	4.3	0.1	4.6	0.4	4.6	0.4
Week 116	n	4	4	4	4	8	8
	Mean	4.18	-0.13	4.30	0.05	4.24	-0.04
	Median	4.15	-0.20	4.35	0.00	4.15	-0.15
	SD	0.096	0.222	0.356	0.265	0.250	0.245
	(SE)	( 0.048)	( 0.111)	( 0.178)	( 0.132)	( 0.089)	( 0.086)
	Min,	4.1,	-0.3,	3.9,	-0.2,	3.9,	-0.3,
	Max	4.3	0.2	4.6	0.4	4.6	0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 120	n	3	3	4	4	7	7
	Mean	4.10	-0.17	4.25	0.00	4.19	-0.07
	Median	4.20	-0.20	4.20	-0.05	4.20	-0.20
	SD	0.173	0.058	0.370	0.392	0.291	0.293
	(SE)	( 0.100)	( 0.033)	( 0.185)	( 0.196)	( 0.110)	( 0.111)
	Min,	3.9,	-0.2,	3.9,	-0.4,	3.9,	-0.4,
	Max	4.2	-0.1	4.7	0.5	4.7	0.5
Week 124	n	3	3	4	4	7	7
	Mean	4.20	-0.07	4.25	0.00	4.23	-0.03
	Median	4.20	-0.10	4.20	0.10	4.20	0.00
	SD	0.100	0.058	0.342	0.503	0.250	0.359
	(SE)	( 0.058)	( 0.033)	( 0.171)	( 0.252)	( 0.094)	( 0.136)
	Min,	4.1,	-0.1,	3.9,	-0.7,	3.9,	-0.7,
	Max	4.3	0.0	4.7	0.5	4.7	0.5
Week 128	n	4	4	4	4	8	8
	Mean	4.23	-0.08	4.13	-0.13	4.18	-0.10
	Median	4.25	-0.05	4.15	-0.20	4.20	-0.05
	SD	0.096	0.096	0.250	0.340	0.183	0.233
	(SE)	( 0.048)	( 0.048)	( 0.125)	( 0.170)	( 0.065)	( 0.082)
	Min,	4.1,	-0.2,	3.8,	-0.4,	3.8,	-0.4,
	Max	4.3	0.0	4.4	0.3	4.4	0.3

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	4.13	-0.18	4.13	-0.13	4.13	-0.15
	Median	4.10	-0.15	4.10	-0.10	4.10	-0.10
	SD	0.150	0.171	0.126	0.287	0.128	0.220
	(SE)	( 0.075)	( 0.085)	( 0.063)	( 0.144)	( 0.045)	( 0.078)
	Min,	4.0,	-0.4,	4.0,	-0.5,	4.0,	-0.5,
	Max	4.3	0.0	4.3	0.2	4.3	0.2
Week 136	n	4	4	4	4	8	8
	Mean	4.23	-0.08	4.08	-0.18	4.15	-0.13
	Median	4.25	-0.10	4.10	-0.20	4.25	-0.10
	SD	0.171	0.126	0.330	0.299	0.256	0.219
	(SE)	( 0.085)	( 0.063)	( 0.165)	( 0.149)	( 0.091)	( 0.077)
	Min,	4.0,	-0.2,	3.7,	-0.5,	3.7,	-0.5,
	Max	4.4	0.1	4.4	0.2	4.4	0.2
Week 140	n	4	4	4	4	8	8
	Mean	3.98	-0.33	4.25	0.00	4.11	-0.16
	Median	4.00	-0.35	4.25	0.00	4.15	-0.15
	SD	0.263	0.350	0.311	0.183	0.304	0.311
	(SE)	( 0.131)	( 0.175)	( 0.155)	( 0.091)	( 0.108)	( 0.110)
	Min,	3.7,	-0.7,	3.9,	-0.2,	3.7,	-0.7,
	Max	4.2	0.1	4.6	0.2	4.6	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	4.23	-0.08	4.03	-0.23	4.13	-0.15
	Median	4.25	0.05	4.00	-0.40	4.20	-0.15
	SD	0.275	0.287	0.512	0.427	0.396	0.346
	(SE)	( 0.138)	( 0.144)	( 0.256)	( 0.214)	( 0.140)	( 0.122)
	Min,	3.9,	-0.5,	3.5,	-0.5,	3.5,	-0.5,
	Max	4.5	0.1	4.6	0.4	4.6	0.4
Week 148	n	4	4	4	4	8	8
	Mean	4.08	-0.23	4.30	0.05	4.19	-0.09
	Median	4.15	-0.25	4.25	0.00	4.20	-0.15
	SD	0.189	0.096	0.294	0.265	0.259	0.236
	(SE)	( 0.095)	( 0.048)	( 0.147)	( 0.132)	( 0.091)	( 0.083)
	Min,	3.8,	-0.3,	4.0,	-0.2,	3.8,	-0.3,
	Max	4.2	-0.1	4.7	0.4	4.7	0.4
Week 152	n	4	4	3	3	7	7
	Mean	4.13	-0.18	4.07	0.00	4.10	-0.10
	Median	4.15	-0.20	4.10	0.00	4.10	-0.10
	SD	0.250	0.150	0.153	0.100	0.200	0.153
	(SE)	( 0.125)	( 0.075)	( 0.088)	( 0.058)	( 0.076)	( 0.058)
	Min,	3.8,	-0.3,	3.9,	-0.1,	3.8,	-0.3,
	Max	4.4	0.0	4.2	0.1	4.4	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	4.10	-0.20	4.13	-0.13	4.11	-0.16
	Median	4.10	-0.20	3.95	-0.10	4.05	-0.20
	SD	0.163	0.082	0.457	0.222	0.318	0.160
	(SE)	( 0.082)	( 0.041)	( 0.229)	( 0.111)	( 0.112)	( 0.056)
	Min,	3.9,	-0.3,	3.8,	-0.4,	3.8,	-0.4,
	Max	4.3	-0.1	4.8	0.1	4.8	0.1
Week 160	n	4	4	4	4	8	8
	Mean	4.10	-0.20	4.33	0.08	4.21	-0.06
	Median	4.10	-0.20	4.35	0.10	4.20	-0.15
	SD	0.082	0.082	0.096	0.377	0.146	0.292
	(SE)	( 0.041)	( 0.041)	( 0.048)	( 0.189)	( 0.052)	( 0.103)
	Min,	4.0,	-0.3,	4.2,	-0.4,	4.0,	-0.4,
	Max	4.2	-0.1	4.4	0.5	4.4	0.5
Week 164	n	4	4	4	4	8	8
	Mean	4.15	-0.15	4.15	-0.10	4.15	-0.13
	Median	4.15	-0.15	4.15	-0.10	4.15	-0.15
	SD	0.058	0.129	0.311	0.183	0.207	0.149
	(SE)	( 0.029)	( 0.065)	( 0.155)	( 0.091)	( 0.073)	( 0.053)
	Min,	4.1,	-0.3,	3.8,	-0.3,	3.8,	-0.3,
	Max	4.2	0.0	4.5	0.1	4.5	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	4.20	-0.10	4.08	-0.18	4.14	-0.14
	Median	4.15	-0.10	4.15	-0.20	4.15	-0.10
	SD	0.141	0.115	0.287	0.377	0.220	0.262
	(SE)	( 0.071)	( 0.058)	( 0.144)	( 0.189)	( 0.078)	( 0.092)
	Min,	4.1,	-0.2,	3.7,	-0.5,	3.7,	-0.5,
	Max	4.4	0.0	4.3	0.2	4.4	0.2
Week 172	n	4	4	4	4	8	8
	Mean	4.05	-0.25	4.13	-0.13	4.09	-0.19
	Median	4.05	-0.25	4.15	-0.05	4.05	-0.15
	SD	0.129	0.238	0.206	0.287	0.164	0.253
	(SE)	( 0.065)	( 0.119)	( 0.103)	( 0.144)	( 0.058)	( 0.092)
	Min,	3.9,	-0.5,	3.9,	-0.5,	3.9,	-0.5,
	Max	4.2	0.0	4.3	0.1	4.3	0.1
Week 176	n	4	4	4	4	8	8
	Mean	4.03	-0.28	3.95	-0.30	3.99	-0.29
	Median	4.05	-0.25	3.95	-0.30	4.05	-0.25
	SD	0.096	0.096	0.311	0.183	0.217	0.136
	(SE)	( 0.048)	( 0.048)	( 0.155)	( 0.091)	( 0.077)	( 0.048)
	Min,	3.9,	-0.4,	3.6,	-0.5,	3.6,	-0.5,
	Max	4.1	-0.2	4.3	-0.1	4.3	-0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	4.25	-0.05	4.17	0.10	4.21	0.01
	Median	4.25	-0.05	4.20	0.00	4.20	0.00
	SD	0.058	0.129	0.351	0.173	0.212	0.157
	(SE)	( 0.029)	( 0.065)	( 0.203)	( 0.100)	( 0.080)	( 0.059)
	Min,	4.2,	-0.2,	3.8,	0.0,	3.8,	-0.2,
	Max	4.3	0.1	4.5	0.3	4.5	0.3
Week 184	n	4	4	4	4	8	8
	Mean	4.20	-0.10	4.18	-0.08	4.19	-0.09
	Median	4.25	-0.10	4.15	0.10	4.20	-0.05
	SD	0.141	0.082	0.171	0.499	0.146	0.331
	(SE)	( 0.071)	( 0.041)	( 0.085)	( 0.250)	( 0.052)	( 0.117)
	Min,	4.0,	-0.2,	4.0,	-0.8,	4.0,	-0.8,
	Max	4.3	0.0	4.4	0.3	4.4	0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Uric Acid (mmol/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	0.18880		0.21978		0.20429	
	Median	0.18290		0.22715		0.20650	
	SD	0.029696		0.021204		0.029065	
	(SE)	( 0.014848)		( 0.010602)		( 0.010276)	
	Min,	0.1593,		0.1888,		0.1593,	
	Max	0.2301		0.2360		0.2360	
Week 2	n	4	4	4	4	8	8
	Mean	0.25223	0.06343	0.23600	0.01623	0.24411	0.03983
	Median	0.25665	0.06195	0.21535	0.00590	0.23600	0.02655
	SD	0.045287	0.059660	0.057203	0.059465	0.048544	0.060642
	(SE)	( 0.022643)	( 0.029830)	( 0.028601)	( 0.029733)	( 0.017163)	( 0.021440)
	Min,	0.1947,	0.0118,	0.1947,	-0.0354,	0.1947,	-0.0354,
	Max	0.3009	0.1180	0.3186	0.0885	0.3186	0.1180
Week 4	n	4	4	4	4	8	8
	Mean	0.21683	0.02803	0.20945	-0.01033	0.21314	0.00885
	Median	0.21240	0.01770	0.21240	0.00295	0.21240	0.00885
	SD	0.030610	0.029451	0.043222	0.037120	0.034896	0.037181
	(SE)	( 0.015305)	( 0.014725)	( 0.021611)	( 0.018560)	( 0.012338)	( 0.013146)
	Min,	0.1888,	0.0059,	0.1593,	-0.0649,	0.1593,	-0.0649,
	Max	0.2537	0.0708	0.2537	0.0177	0.2537	0.0708

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	0.24780	0.05900	0.19618	-0.02360	0.22199	0.01770
	Median	0.25075	0.06195	0.20060	-0.02360	0.22125	0.00885
	SD	0.046457	0.065168	0.039247	0.049597	0.048441	0.069453
	(SE)	( 0.023228)	( 0.032584)	( 0.019624)	( 0.024799)	( 0.017127)	( 0.024555)
	Min,	0.1947,	-0.0059,	0.1475,	-0.0767,	0.1475,	-0.0767,
	Max	0.2950	0.1180	0.2360	0.0295	0.2950	0.1180
Week 8	n	4	4	4	4	8	8
	Mean	0.21240	0.02360	0.20208	-0.01770	0.20724	0.00295
	Median	0.21830	0.01475	0.20355	-0.01770	0.21240	-0.00590
	SD	0.025032	0.041159	0.019494	0.025942	0.021491	0.038753
	(SE)	( 0.012516)	( 0.020580)	( 0.009747)	( 0.012971)	( 0.007598)	( 0.013701)
	Min,	0.1770,	-0.0118,	0.1770,	-0.0472,	0.1770,	-0.0472,
	Max	0.2360	0.0767	0.2242	0.0118	0.2360	0.0767
Week 10	n	4	4	4	4	8	8
	Mean	0.23895	0.05015	0.20798	-0.01180	0.22346	0.01918
	Median	0.25665	0.05605	0.22125	-0.00295	0.23305	0.01475
	SD	0.045828	0.053318	0.037740	0.052107	0.042245	0.058979
	(SE)	( 0.022914)	( 0.026659)	( 0.018870)	( 0.026054)	( 0.014936)	( 0.020852)
	Min,	0.1711,	-0.0118,	0.1534,	-0.0826,	0.1534,	-0.0826,
	Max	0.2714	0.1003	0.2360	0.0413	0.2714	0.1003

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	0.23453	0.04573	0.17405	-0.04572	0.20429	0.00000
	Median	0.23600	0.03835	0.18585	-0.02950	0.20650	0.00885
	SD	0.022272	0.026550	0.038689	0.049685	0.043578	0.061233
	(SE)	( 0.011136)	( 0.013275)	( 0.019344)	( 0.024843)	( 0.015407)	( 0.021649)
	Min,	0.2065,	0.0236,	0.1180,	-0.1180,	0.1180,	-0.1180,
	Max	0.2596	0.0826	0.2065	-0.0059	0.2596	0.0826
Week 15	n	4	4	4	4	8	8
	Mean	0.23895	0.05015	0.21093	-0.00885	0.22494	0.02065
	Median	0.24780	0.05015	0.20355	-0.01475	0.23010	0.02360
	SD	0.026605	0.031405	0.036806	0.027463	0.033292	0.041719
	(SE)	( 0.013302)	( 0.015703)	( 0.018403)	( 0.013732)	( 0.011770)	( 0.014750)
	Min,	0.2006,	0.0177,	0.1770,	-0.0354,	0.1770,	-0.0354,
	Max	0.2596	0.0826	0.2596	0.0295	0.2596	0.0826
Week 18	n	4	4	4	4	8	8
	Mean	0.24780	0.05900	0.21830	-0.00148	0.23305	0.02876
	Median	0.25370	0.05605	0.21535	-0.00295	0.23600	0.02655
	SD	0.025032	0.029303	0.026822	0.019494	0.028731	0.039696
	(SE)	( 0.012516)	( 0.014651)	( 0.013411)	( 0.009747)	( 0.010158)	( 0.014035)
	Min,	0.2124,	0.0295,	0.1888,	-0.0236,	0.1888,	-0.0236,
	Max	0.2714	0.0944	0.2537	0.0236	0.2714	0.0944

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	0.23600	0.04720	0.23748	0.01770	0.23674	0.03245
	Median	0.23895	0.04425	0.22420	0.01475	0.22715	0.03245
	SD	0.025032	0.027673	0.035195	0.038236	0.028284	0.034691
	(SE)	( 0.012516)	( 0.013837)	( 0.017597)	( 0.019118)	( 0.010000)	( 0.012265)
	Min,	0.2065,	0.0236,	0.2124,	-0.0177,	0.2065,	-0.0177,
	Max	0.2596	0.0767	0.2891	0.0590	0.2891	0.0767
Week 24	n	4	4	4	4	8	8
	Mean	0.24633	0.05753	0.21830	-0.00147	0.23231	0.02803
	Median	0.23600	0.05310	0.22715	0.00295	0.23600	0.04130
	SD	0.020650	0.013082	0.028500	0.034191	0.027482	0.039610
	(SE)	( 0.010325)	( 0.006541)	( 0.014250)	( 0.017096)	( 0.009716)	( 0.014004)
	Min,	0.2360,	0.0472,	0.1770,	-0.0472,	0.1770,	-0.0472,
	Max	0.2773	0.0767	0.2419	0.0354	0.2773	0.0767
Week 25	n	4	4	4	4	8	8
	Mean	0.25665	0.06785	0.24043	0.02065	0.24854	0.04425
	Median	0.27140	0.09440	0.24190	0.03540	0.25370	0.04425
	SD	0.053100	0.080825	0.032806	0.038084	0.041771	0.063701
	(SE)	( 0.026550)	( 0.040412)	( 0.016403)	( 0.019042)	( 0.014768)	( 0.022522)
	Min,	0.1829,	-0.0472,	0.2006,	-0.0354,	0.1829,	-0.0472,
	Max	0.3009	0.1298	0.2773	0.0472	0.3009	0.1298

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	0.25518	0.06638	0.23748	0.01770	0.24633	0.04204
	Median	0.23600	0.06195	0.23895	0.02065	0.23600	0.04130
	SD	0.046799	0.020080	0.012163	0.017369	0.033038	0.031289
	(SE)	( 0.023399)	( 0.010040)	( 0.006082)	( 0.008685)	( 0.011681)	( 0.011063)
	Min,	0.2242,	0.0472,	0.2242,	-0.0059,	0.2242,	-0.0059,
	Max	0.3245	0.0944	0.2478	0.0354	0.3245	0.0944
Week 32	n	4	4	3	3	7	7
	Mean	0.27288	0.08408	0.23403	0.00393	0.25623	0.04973
	Median	0.26255	0.08260	0.22420	-0.01180	0.25960	0.07080
	SD	0.026983	0.012163	0.027882	0.027251	0.032469	0.046439
	(SE)	( 0.013492)	( 0.006082)	( 0.016098)	( 0.015733)	( 0.012272)	( 0.017552)
	Min,	0.2537,	0.0708,	0.2124,	-0.0118,	0.2124,	-0.0118,
	Max	0.3127	0.1003	0.2655	0.0354	0.3127	0.1003
Week 36	n	4	4	4	4	8	8
	Mean	0.26550	0.07670	0.22420	0.00443	0.24485	0.04056
	Median	0.26255	0.07670	0.22715	0.00295	0.23305	0.03245
	SD	0.038236	0.024087	0.017369	0.012163	0.035259	0.042480
	(SE)	( 0.019118)	( 0.012043)	( 0.008685)	( 0.006082)	( 0.012466)	( 0.015019)
	Min,	0.2301,	0.0472,	0.2006,	-0.0059,	0.2006,	-0.0059,
	Max	0.3068	0.1062	0.2419	0.0177	0.3068	0.1062

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	0.26697	0.07818	0.21683	-0.00295	0.24190	0.03761
	Median	0.25665	0.07375	0.22125	0.00590	0.24485	0.04425
	SD	0.032090	0.021204	0.034191	0.038084	0.040755	0.051910
	(SE)	( 0.016045)	( 0.010602)	( 0.017096)	( 0.019042)	( 0.014409)	( 0.018353)
	Min,	0.2419,	0.0590,	0.1711,	-0.0531,	0.1711,	-0.0531,
	Max	0.3127	0.1062	0.2537	0.0295	0.3127	0.1062
Week 44	n	4	4	4	4	8	8
	Mean	0.26697	0.07818	0.23158	0.01180	0.24928	0.04499
	Median	0.27140	0.08555	0.22125	0.00885	0.25075	0.06195
	SD	0.036806	0.030987	0.060241	0.063727	0.049939	0.058402
	(SE)	( 0.018403)	( 0.015493)	( 0.030120)	( 0.031864)	( 0.017656)	( 0.020648)
	Min,	0.2183,	0.0354,	0.1711,	-0.0531,	0.1711,	-0.0531,
	Max	0.3068	0.1062	0.3127	0.0826	0.3127	0.1062
Week 48	n	4	4	4	4	8	8
	Mean	0.25960	0.07080	0.23158	0.01180	0.24559	0.04130
	Median	0.26255	0.07080	0.23305	0.00295	0.23895	0.04720
	SD	0.020998	0.019862	0.010076	0.025032	0.021375	0.037844
	(SE)	( 0.010499)	( 0.009931)	( 0.005038)	( 0.012516)	( 0.007557)	( 0.013380)
	Min,	0.2360,	0.0472,	0.2183,	-0.0059,	0.2183,	-0.0059,
	Max	0.2773	0.0944	0.2419	0.0472	0.2773	0.0944

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	0.29795	0.10915	0.23895	0.01918	0.26845	0.06416
	Median	0.30090	0.10030	0.22715	0.01770	0.27140	0.07080
	SD	0.032495	0.035236	0.040448	0.046300	0.046349	0.061350
	(SE)	( 0.016247)	( 0.017618)	( 0.020224)	( 0.023150)	( 0.016387)	( 0.021691)
	Min,	0.2596,	0.0767,	0.2065,	-0.0236,	0.2065,	-0.0236,
	Max	0.3304	0.1593	0.2950	0.0649	0.3304	0.1593
Week 56	n	4	4	3	3	7	7
	Mean	0.25813	0.06933	0.24190	0.02360	0.25117	0.04973
	Median	0.25665	0.07080	0.24780	0.05310	0.24780	0.05900
	SD	0.025205	0.019494	0.044544	0.056282	0.032469	0.042933
	(SE)	( 0.012602)	( 0.009747)	( 0.025718)	( 0.032495)	( 0.012272)	( 0.016227)
	Min,	0.2301,	0.0472,	0.1947,	-0.0413,	0.1947,	-0.0413,
	Max	0.2891	0.0885	0.2832	0.0590	0.2891	0.0885
Week 60	n	4	4	4	4	8	8
	Mean	0.27288	0.08408	0.23010	0.01033	0.25149	0.04720
	Median	0.27730	0.08260	0.22715	0.01475	0.25370	0.04720
	SD	0.036806	0.043456	0.051209	0.049918	0.047193	0.058577
	(SE)	( 0.018403)	( 0.021728)	( 0.025604)	( 0.024959)	( 0.016685)	( 0.020710)
	Min,	0.2242,	0.0413,	0.1711,	-0.0531,	0.1711,	-0.0531,
	Max	0.3127	0.1298	0.2950	0.0649	0.3127	0.1298

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 64	n	4	4	4	4	8	8
	Mean	0.25518	0.06638	0.21388	-0.00590	0.23453	0.03024
	Median	0.26550	0.06785	0.20650	-0.00590	0.23305	0.02360
	SD	0.038350	0.049685	0.070368	0.070141	0.056919	0.068256
	(SE)	( 0.019175)	( 0.024843)	( 0.035184)	( 0.035071)	( 0.020124)	( 0.024132)
	Min,	0.2006,	0.0177,	0.1357,	-0.0885,	0.1357,	-0.0885,
	Max	0.2891	0.1121	0.3068	0.0767	0.3068	0.1121
Week 68	n	4	4	4	4	8	8
	Mean	0.24928	0.06048	0.20060	-0.01918	0.22494	0.02065
	Median	0.26255	0.05605	0.21240	0.00000	0.22715	0.02065
	SD	0.032806	0.044511	0.045447	0.056050	0.044981	0.063310
	(SE)	( 0.016403)	( 0.022256)	( 0.022723)	( 0.028025)	( 0.015903)	( 0.022383)
	Min,	0.2006,	0.0177,	0.1357,	-0.1003,	0.1357,	-0.1003,
	Max	0.2714	0.1121	0.2419	0.0236	0.2714	0.1121
Week 72	n	3	3	4	4	7	7
	Mean	0.24780	0.05703	0.21683	-0.00295	0.23010	0.02276
	Median	0.24780	0.05310	0.20355	-0.00885	0.23600	0.02950
	SD	0.011800	0.029696	0.051067	0.053318	0.040305	0.052377
	(SE)	( 0.006813)	( 0.017145)	( 0.025534)	( 0.026659)	( 0.015234)	( 0.019797)
	Min,	0.2360,	0.0295,	0.1711,	-0.0531,	0.1711,	-0.0531,
	Max	0.2596	0.0885	0.2891	0.0590	0.2891	0.0885

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	0.25075	0.04425			0.25075	0.04425
	Median	0.25075	0.04425			0.25075	0.04425
	SD	0.020860	0.012516			0.020860	0.012516
	(SE)	( 0.014750)	( 0.008850)			( 0.014750)	( 0.008850)
	Min,	0.2360,	0.0354,			0.2360,	0.0354,
	Max	0.2655	0.0531			0.2655	0.0531
Week 76	n	4	4	4	4	8	8
	Mean	0.25075	0.06195	0.21535	-0.00443	0.23305	0.02876
	Median	0.25370	0.07375	0.22715	0.01180	0.23895	0.03835
	SD	0.043756	0.034234	0.052440	0.057279	0.048550	0.056277
	(SE)	( 0.021878)	( 0.017117)	( 0.026220)	( 0.028639)	( 0.017165)	( 0.019897)
	Min,	0.1947,	0.0118,	0.1416,	-0.0826,	0.1416,	-0.0826,
	Max	0.3009	0.0885	0.2655	0.0413	0.3009	0.0885
Week 80	n	4	4	4	4	8	8
	Mean	0.24928	0.06048	0.22863	0.00885	0.23895	0.03466
	Median	0.25665	0.05310	0.22420	0.01770	0.23895	0.02950
	SD	0.032450	0.037431	0.028652	0.031033	0.030413	0.042127
	(SE)	( 0.016225)	( 0.018716)	( 0.014326)	( 0.015517)	( 0.010753)	( 0.014894)
	Min,	0.2065,	0.0236,	0.2006,	-0.0354,	0.2006,	-0.0354,
	Max	0.2773	0.1121	0.2655	0.0354	0.2773	0.1121

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	0.25813	0.06933	0.24190	0.02213	0.25001	0.04573
	Median	0.27140	0.06785	0.23895	0.03245	0.25665	0.04720
	SD	0.035195	0.040412	0.037003	0.040983	0.034538	0.045346
	(SE)	( 0.017597)	( 0.020206)	( 0.018501)	( 0.020491)	( 0.012211)	( 0.016032)
	Min,	0.2065,	0.0236,	0.2006,	-0.0354,	0.2006,	-0.0354,
	Max	0.2832	0.1180	0.2891	0.0590	0.2891	0.1180
Week 88	n	4	4	4	4	8	8
	Mean	0.25223	0.06343	0.25813	0.03835	0.25518	0.05089
	Median	0.25960	0.07375	0.25665	0.02360	0.25960	0.07080
	SD	0.051520	0.045030	0.072320	0.087842	0.058215	0.065997
	(SE)	( 0.025760)	( 0.022515)	( 0.036160)	( 0.043921)	( 0.020582)	( 0.023333)
	Min,	0.1829,	0.0000,	0.1829,	-0.0413,	0.1829,	-0.0413,
	Max	0.3068	0.1062	0.3363	0.1475	0.3363	0.1475
Week 92	n	4	4	4	4	8	8
	Mean	0.29647	0.10768	0.23305	0.01328	0.26476	0.06048
	Median	0.30385	0.10915	0.21240	0.00000	0.26845	0.06490
	SD	0.044250	0.050839	0.053967	0.050381	0.056892	0.068859
	(SE)	( 0.022125)	( 0.025420)	( 0.026983)	( 0.025190)	( 0.020114)	( 0.024345)
	Min,	0.2360,	0.0531,	0.1947,	-0.0295,	0.1947,	-0.0295,
	Max	0.3422	0.1593	0.3127	0.0826	0.3422	0.1593

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	0.27140	0.08260	0.25665	0.03688	0.26402	0.05974
	Median	0.28910	0.08260	0.25665	0.04425	0.27140	0.06195
	SD	0.044674	0.056179	0.075017	0.077434	0.057700	0.067229
	(SE)	( 0.022337)	( 0.028090)	( 0.037509)	( 0.038717)	( 0.020400)	( 0.023769)
	Min,	0.2065,	0.0236,	0.1652,	-0.0590,	0.1652,	-0.0590,
	Max	0.3009	0.1416	0.3481	0.1180	0.3481	0.1416
Week 100	n	4	4	4	4	8	8
	Mean	0.29648	0.10768	0.22568	0.00590	0.26107	0.05679
	Median	0.29795	0.11210	0.21830	0.00590	0.27730	0.07080
	SD	0.019494	0.013082	0.042100	0.041159	0.048525	0.061310
	(SE)	( 0.009747)	( 0.006541)	( 0.021050)	( 0.020580)	( 0.017156)	( 0.021676)
	Min,	0.2714,	0.0885,	0.1829,	-0.0413,	0.1829,	-0.0413,
	Max	0.3186	0.1180	0.2832	0.0531	0.3186	0.1180
Week 104	n	4	4	4	4	8	8
	Mean	0.29353	0.10473	0.21388	-0.00590	0.25370	0.04941
	Median	0.31860	0.11210	0.22125	-0.00590	0.23895	0.03245
	SD	0.062695	0.069872	0.032450	0.047445	0.062837	0.080954
	(SE)	( 0.031347)	( 0.034936)	( 0.016225)	( 0.023723)	( 0.022216)	( 0.028622)
	Min,	0.2006,	0.0177,	0.1711,	-0.0590,	0.1711,	-0.0590,
	Max	0.3363	0.1770	0.2419	0.0472	0.3363	0.1770

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	0.28763	0.09883	0.20945	-0.01033	0.24854	0.04425
	Median	0.30680	0.10030	0.20945	-0.00885	0.22420	0.02360
	SD	0.051067	0.060433	0.021811	0.026983	0.055386	0.072672
	(SE)	( 0.025534)	( 0.030217)	( 0.010906)	( 0.013492)	( 0.019582)	( 0.025693)
	Min,	0.2124,	0.0295,	0.1829,	-0.0413,	0.1829,	-0.0413,
	Max	0.3245	0.1652	0.2360	0.0177	0.3245	0.1652
Week 112	n	4	4	4	4	8	8
	Mean	0.28025	0.09145	0.24043	0.02065	0.26034	0.05605
	Median	0.30680	0.10030	0.23010	0.01475	0.25960	0.04130
	SD	0.053100	0.057304	0.033506	0.028295	0.046289	0.056415
	(SE)	( 0.026550)	( 0.028652)	( 0.016753)	( 0.014148)	( 0.016366)	( 0.019946)
	Min,	0.2006,	0.0177,	0.2124,	-0.0059,	0.2006,	-0.0059,
	Max	0.3068	0.1475	0.2891	0.0590	0.3068	0.1475
Week 116	n	4	4	4	4	8	8
	Mean	0.29353	0.10473	0.19470	-0.02508	0.24411	0.03983
	Median	0.28910	0.11800	0.19765	-0.02655	0.22715	0.03245
	SD	0.052854	0.035195	0.022076	0.031359	0.064780	0.075934
	(SE)	( 0.026427)	( 0.017597)	( 0.011038)	( 0.015679)	( 0.022903)	( 0.026847)
	Min,	0.2360,	0.0531,	0.1652,	-0.0590,	0.1652,	-0.0590,
	Max	0.3599	0.1298	0.2183	0.0118	0.3599	0.1298

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	0.30090	0.11013	0.22125	0.00147	0.25539	0.04804
	Median	0.30090	0.12390	0.20945	-0.00295	0.28910	0.05900
	SD	0.005900	0.040160	0.048294	0.045287	0.054684	0.070259
	(SE)	( 0.003406)	( 0.023187)	( 0.024147)	( 0.022643)	( 0.020669)	( 0.026556)
	Min,	0.2950,	0.0649,	0.1770,	-0.0472,	0.1770,	-0.0472,
	Max	0.3068	0.1416	0.2891	0.0590	0.3068	0.1416
Week 124	n	3	3	4	4	7	7
	Mean	0.31663	0.12587	0.22568	0.00590	0.26466	0.05731
	Median	0.31860	0.12390	0.22715	0.00590	0.27730	0.07670
	SD	0.009012	0.032495	0.053508	0.066924	0.061826	0.081874
	(SE)	( 0.005203)	( 0.018761)	( 0.026754)	( 0.033462)	( 0.023368)	( 0.030946)
	Min,	0.3068,	0.0944,	0.1711,	-0.0649,	0.1711,	-0.0649,
	Max	0.3245	0.1593	0.2773	0.0767	0.3245	0.1593
Week 128	n	4	4	4	4	8	8
	Mean	0.27435	0.08555	0.26107	0.04130	0.26771	0.06343
	Median	0.29795	0.11210	0.23010	0.02065	0.25960	0.06785
	SD	0.070882	0.066140	0.065942	0.061504	0.063774	0.063682
	(SE)	( 0.035441)	( 0.033070)	( 0.032971)	( 0.030752)	( 0.022548)	( 0.022515)
	Min,	0.1711,	-0.0118,	0.2242,	-0.0059,	0.1711,	-0.0118,
	Max	0.3304	0.1298	0.3599	0.1298	0.3599	0.1298

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	0.25075	0.06195	0.22273	0.00295	0.23674	0.03245
	Median	0.26845	0.06195	0.22125	0.00590	0.23600	0.02655
	SD	0.050639	0.061409	0.019494	0.032495	0.038552	0.055347
	(SE)	( 0.025320)	( 0.030705)	( 0.009747)	( 0.016247)	( 0.013630)	( 0.019568)
	Min,	0.1770,	-0.0059,	0.2006,	-0.0354,	0.1770,	-0.0354,
	Max	0.2891	0.1298	0.2478	0.0354	0.2891	0.1298
Week 136	n	4	4	4	4	8	8
	Mean	0.26255	0.07375	0.21830	-0.00147	0.24043	0.03614
	Median	0.28025	0.07965	0.20355	-0.00885	0.24190	0.03540
	SD	0.041580	0.046830	0.058008	0.056257	0.052369	0.062554
	(SE)	( 0.020790)	( 0.023415)	( 0.029004)	( 0.028128)	( 0.018515)	( 0.022116)
	Min,	0.2006,	0.0177,	0.1652,	-0.0590,	0.1652,	-0.0590,
	Max	0.2891	0.1180	0.3009	0.0708	0.3009	0.1180
Week 140	n	4	4	4	4	8	8
	Mean	0.25518	0.06638	0.17700	-0.04278	0.21609	0.01180
	Median	0.27730	0.07375	0.16815	-0.03835	0.21535	0.00590
	SD	0.052634	0.059854	0.049831	0.057682	0.063226	0.079783
	(SE)	( 0.026317)	( 0.029927)	( 0.024915)	( 0.028841)	( 0.022354)	( 0.028207)
	Min,	0.1770,	-0.0059,	0.1298,	-0.1062,	0.1298,	-0.1062,
	Max	0.2891	0.1239	0.2419	0.0118	0.2891	0.1239

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	0.25518	0.06638	0.20650	-0.01328	0.23084	0.02655
	Median	0.27730	0.08260	0.19765	-0.01475	0.23305	0.02360
	SD	0.070533	0.067679	0.046954	0.046550	0.061269	0.068588
	(SE)	( 0.035267)	( 0.033839)	( 0.023477)	( 0.023275)	( 0.021662)	( 0.024250)
	Min,	0.1534,	-0.0295,	0.1593,	-0.0649,	0.1534,	-0.0649,
	Max	0.3127	0.1298	0.2714	0.0413	0.3127	0.1298
Week 148	n	4	4	4	4	8	8
	Mean	0.27583	0.08703	0.24928	0.02950	0.26255	0.05826
	Median	0.28320	0.07670	0.23600	0.02950	0.26255	0.05900
	SD	0.028244	0.040699	0.086225	0.089995	0.061071	0.071599
	(SE)	( 0.014122)	( 0.020349)	( 0.043113)	( 0.044998)	( 0.021592)	( 0.025314)
	Min,	0.2360,	0.0531,	0.1593,	-0.0767,	0.1593,	-0.0767,
	Max	0.3009	0.1416	0.3658	0.1357	0.3658	0.1416
Week 152	n	4	4	3	3	7	7
	Mean	0.31123	0.12243	0.24190	0.01180	0.28151	0.07501
	Median	0.33335	0.12685	0.21240	-0.02360	0.31270	0.08260
	SD	0.054582	0.061950	0.061598	0.061315	0.064245	0.081662
	(SE)	( 0.027291)	( 0.030975)	( 0.035564)	( 0.035400)	( 0.024282)	( 0.030865)
	Min,	0.2301,	0.0472,	0.2006,	-0.0236,	0.2006,	-0.0236,
	Max	0.3481	0.1888	0.3127	0.0826	0.3481	0.1888

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	0.28320	0.09440	0.24780	0.02803	0.26550	0.06121
	Median	0.29205	0.09735	0.23895	0.03245	0.27140	0.04425
	SD	0.052107	0.062254	0.049831	0.048503	0.050852	0.062673
	(SE)	( 0.026054)	( 0.031127)	( 0.024915)	( 0.024252)	( 0.017979)	( 0.022158)
	Min,	0.2124,	0.0295,	0.2006,	-0.0354,	0.2006,	-0.0354,
	Max	0.3363	0.1534	0.3127	0.0826	0.3363	0.1534
Week 160	n	4	4	4	4	8	8
	Mean	0.29352	0.10473	0.22568	0.00590	0.25960	0.05531
	Median	0.30090	0.11210	0.23010	0.02360	0.27140	0.06490
	SD	0.046799	0.041823	0.066816	0.076169	0.064554	0.077630
	(SE)	( 0.023399)	( 0.020912)	( 0.033408)	( 0.038084)	( 0.022823)	( 0.027446)
	Min,	0.2301,	0.0472,	0.1416,	-0.0944,	0.1416,	-0.0944,
	Max	0.3422	0.1475	0.3009	0.0708	0.3422	0.1475
Week 164	n	4	4	4	4	8	8
	Mean	0.27583	0.08703	0.21388	-0.00590	0.24485	0.04056
	Median	0.28320	0.07670	0.19470	-0.01475	0.22715	0.01770
	SD	0.068361	0.084869	0.042375	0.041159	0.062200	0.079247
	(SE)	( 0.034181)	( 0.042435)	( 0.021187)	( 0.020580)	( 0.021991)	( 0.028018)
	Min,	0.1888,	0.0059,	0.1888,	-0.0413,	0.1888,	-0.0413,
	Max	0.3481	0.1888	0.2773	0.0472	0.3481	0.1888

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	0.27288	0.08408	0.21830	-0.00147	0.24559	0.04130
	Median	0.27140	0.09145	0.20060	-0.02360	0.26255	0.05310
	SD	0.013082	0.036806	0.056999	0.048503	0.048132	0.060662
	(SE)	( 0.006541)	( 0.018403)	( 0.028500)	( 0.024252)	( 0.017017)	( 0.021447)
	Min,	0.2596,	0.0354,	0.1711,	-0.0295,	0.1711,	-0.0295,
	Max	0.2891	0.1180	0.3009	0.0708	0.3009	0.1180
Week 172	n	4	4	4	4	8	8
	Mean	0.26697	0.07818	0.19618	-0.02360	0.23158	0.02729
	Median	0.27140	0.06785	0.17110	-0.03540	0.23305	0.02655
	SD	0.043722	0.062695	0.069539	0.072420	0.065756	0.083017
	(SE)	( 0.021861)	( 0.031347)	( 0.034770)	( 0.036210)	( 0.023248)	( 0.029351)
	Min,	0.2124,	0.0236,	0.1475,	-0.0885,	0.1475,	-0.0885,
	Max	0.3127	0.1534	0.2950	0.0649	0.3127	0.1534
Week 176	n	4	4	4	4	8	8
	Mean	0.29943	0.11063	0.23600	0.01623	0.26771	0.06343
	Median	0.30385	0.11210	0.23305	0.00295	0.27730	0.07080
	SD	0.027410	0.047537	0.062625	0.050839	0.056144	0.067987
	(SE)	( 0.013705)	( 0.023768)	( 0.031313)	( 0.025420)	( 0.019850)	( 0.024037)
	Min,	0.2655,	0.0590,	0.1652,	-0.0236,	0.1652,	-0.0236,
	Max	0.3245	0.1593	0.3127	0.0826	0.3245	0.1593

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	0.28025	0.09145	0.24977	0.01967	0.26719	0.06069
	Median	0.28615	0.07965	0.22420	-0.01180	0.26550	0.03540
	SD	0.049245	0.067529	0.060265	0.059684	0.051852	0.070283
	(SE)	( 0.024623)	( 0.033764)	( 0.034794)	( 0.034459)	( 0.019598)	( 0.026564)
	Min,	0.2183,	0.0354,	0.2065,	-0.0177,	0.2065,	-0.0177,
	Max	0.3304	0.1711	0.3186	0.0885	0.3304	0.1711
	Week 184	n	4	4	4	4	8
Mean		0.29500	0.10620	0.18585	-0.03393	0.24043	0.03614
Median		0.30090	0.10030	0.15930	-0.04720	0.24780	0.04130
SD		0.056591	0.076473	0.069893	0.067507	0.082885	0.100346
(SE)		( 0.028295)	( 0.038236)	( 0.034946)	( 0.033754)	( 0.029304)	( 0.035478)
Min,		0.2301,	0.0354,	0.1357,	-0.1003,	0.1357,	-0.1003,
Max		0.3481	0.1888	0.2891	0.0590	0.3481	0.1888

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Bilirubin (umol/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	5.985		3.848		4.916	
	Median	4.275		5.130		5.130	
	SD	4.0706		2.5650		3.3506	
	(SE)	( 2.0353)		( 1.2825)		( 1.1846)	
	Min,	3.42,		0.00,		0.00,	
	Max	11.97		5.13		11.97	
Week 2	n	4	4	4	4	8	8
	Mean	6.413	0.428	4.275	0.428	5.344	0.428
	Median	3.420	0.000	5.130	0.000	4.275	0.000
	SD	5.9850	2.1517	2.9618	0.8550	4.5185	1.5158
	(SE)	( 2.9925)	( 1.0759)	( 1.4809)	( 0.4275)	( 1.5975)	( 0.5359)
	Min,	3.42,	-1.71,	0.00,	0.00,	0.00,	-1.71,
	Max	15.39	3.42	6.84	1.71	15.39	3.42
Week 4	n	4	4	4	4	8	8
	Mean	5.985	0.000	4.275	0.428	5.130	0.214
	Median	5.985	0.000	4.275	0.855	4.275	0.000
	SD	2.9618	2.7924	2.2076	2.9204	2.5853	2.6550
	(SE)	( 1.4809)	( 1.3962)	( 1.1038)	( 1.4602)	( 0.9140)	( 0.9387)
	Min,	3.42,	-3.42,	1.71,	-3.42,	1.71,	-3.42,
	Max	8.55	3.42	6.84	3.42	8.55	3.42

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\c\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	7.268	1.283	5.558	1.710	6.413	1.496
	Median	5.130	0.855	5.985	0.855	5.130	0.855
	SD	5.4747	1.6372	4.2750	2.4183	4.6382	1.9254
	(SE)	( 2.7373)	( 0.8186)	( 2.1375)	( 1.2092)	( 1.6399)	( 0.6807)
	Min,	3.42,	0.00,	0.00,	0.00,	0.00,	0.00,
	Max	15.39	3.42	10.26	5.13	15.39	5.13
Week 8	n	4	4	4	4	8	8
	Mean	6.840	0.855	6.840	2.993	6.840	1.924
	Median	5.130	0.855	7.695	3.420	5.985	1.710
	SD	4.8366	0.9873	4.1886	2.5650	4.1886	2.1314
	(SE)	( 2.4183)	( 0.4936)	( 2.0943)	( 1.2825)	( 1.4809)	( 0.7536)
	Min,	3.42,	0.00,	1.71,	0.00,	1.71,	0.00,
	Max	13.68	1.71	10.26	5.13	13.68	5.13
Week 10	n	4	4	4	4	8	8
	Mean	7.268	1.283	4.275	0.428	5.771	0.855
	Median	6.840	1.710	5.130	0.000	5.130	0.855
	SD	2.5650	3.5253	1.7100	0.8550	2.5752	2.4183
	(SE)	( 1.2825)	( 1.7626)	( 0.8550)	( 0.4275)	( 0.9105)	( 0.8550)
	Min,	5.13,	-3.42,	1.71,	0.00,	1.71,	-3.42,
	Max	10.26	5.13	5.13	1.71	10.26	5.13

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	7.268	1.283	5.130	1.283	6.199	1.283
	Median	5.130	0.855	5.130	1.710	5.130	1.710
	SD	5.6499	1.6372	3.1220	2.1517	4.3776	1.7700
	(SE)	( 2.8250)	( 0.8186)	( 1.5610)	( 1.0759)	( 1.5477)	( 0.6258)
	Min,	3.42,	0.00,	1.71,	-1.71,	1.71,	-1.71,
	Max	15.39	3.42	8.55	3.42	15.39	3.42
Week 15	n	4	4	4	4	8	8
	Mean	7.268	1.283	5.130	1.283	6.199	1.283
	Median	6.840	1.710	5.130	0.855	5.985	1.710
	SD	2.1517	2.1517	1.3962	1.6372	2.0310	1.7700
	(SE)	( 1.0759)	( 1.0759)	( 0.6981)	( 0.8186)	( 0.7181)	( 0.6258)
	Min,	5.13,	-1.71,	3.42,	0.00,	3.42,	-1.71,
	Max	10.26	3.42	6.84	3.42	10.26	3.42
Week 18	n	4	4	4	4	8	8
	Mean	6.413	0.428	3.848	0.000	5.130	0.214
	Median	5.985	0.000	4.275	0.000	4.275	0.000
	SD	3.5253	2.1517	2.9204	1.3962	3.2956	1.6947
	(SE)	( 1.7626)	( 1.0759)	( 1.4602)	( 0.6981)	( 1.1652)	( 0.5992)
	Min,	3.42,	-1.71,	0.00,	-1.71,	0.00,	-1.71,
	Max	10.26	3.42	6.84	1.71	10.26	3.42

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	6.413	0.428	4.703	0.855	5.558	0.641
	Median	5.985	0.000	5.130	0.000	5.130	0.000
	SD	3.5253	2.1517	3.5253	1.7100	3.3893	1.8137
	(SE)	( 1.7626)	( 1.0759)	( 1.7626)	( 0.8550)	( 1.1983)	( 0.6413)
	Min,	3.42,	-1.71,	0.00,	0.00,	0.00,	-1.71,
	Max	10.26	3.42	8.55	3.42	10.26	3.42
Week 24	n	4	4	4	4	8	8
	Mean	7.695	1.710	4.703	0.855	6.199	1.283
	Median	6.840	0.855	5.130	0.855	5.130	0.855
	SD	5.1300	2.4183	2.1517	0.9873	3.9776	1.7700
	(SE)	( 2.5650)	( 1.2092)	( 1.0759)	( 0.4936)	( 1.4063)	( 0.6258)
	Min,	3.42,	0.00,	1.71,	0.00,	1.71,	0.00,
	Max	13.68	5.13	6.84	1.71	13.68	5.13
Week 25	n	4	4	4	4	8	8
	Mean	5.558	-0.428	4.275	0.428	4.916	0.000
	Median	5.130	0.000	5.130	0.855	5.130	0.000
	SD	2.1517	2.1517	3.2744	1.6372	2.6550	1.8281
	(SE)	( 1.0759)	( 1.0759)	( 1.6372)	( 0.8186)	( 0.9387)	( 0.6463)
	Min,	3.42,	-3.42,	0.00,	-1.71,	0.00,	-3.42,
	Max	8.55	1.71	6.84	1.71	8.55	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 28	n	4	4	4	4	8	8
	Mean	6.840	0.855	4.703	0.855	5.771	0.855
	Median	6.840	0.855	5.130	0.855	5.130	0.855
	SD	3.1220	2.2076	2.1517	0.9873	2.7326	1.5832
	(SE)	( 1.5610)	( 1.1038)	( 1.0759)	( 0.4936)	( 0.9661)	( 0.5597)
	Min,	3.42,	-1.71,	1.71,	0.00,	1.71,	-1.71,
	Max	10.26	3.42	6.84	1.71	10.26	3.42
Week 32	n	4	4	3	3	7	7
	Mean	5.558	-0.428	2.280	-1.140	4.153	-0.733
	Median	4.275	-0.855	1.710	-1.710	1.710	-1.710
	SD	4.9116	1.6372	0.9873	2.6121	3.9314	1.9390
	(SE)	( 2.4558)	( 0.8186)	( 0.5700)	( 1.5081)	( 1.4859)	( 0.7329)
	Min,	1.71,	-1.71,	1.71,	-3.42,	1.71,	-3.42,
	Max	11.97	1.71	3.42	1.71	11.97	1.71
Week 36	n	4	4	4	4	8	8
	Mean	3.420	-2.565	2.138	-1.710	2.779	-2.138
	Median	3.420	-1.710	1.710	-2.565	2.565	-1.710
	SD	1.3962	2.9618	0.8550	2.4183	1.2723	2.5446
	(SE)	( 0.6981)	( 1.4809)	( 0.4275)	( 1.2092)	( 0.4498)	( 0.8996)
	Min,	1.71,	-6.84,	1.71,	-3.42,	1.71,	-6.84,
	Max	5.13	0.00	3.42	1.71	5.13	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	3.420	-2.565	2.138	-1.710	2.779	-2.138
	Median	3.420	-1.710	1.710	-2.565	1.710	-1.710
	SD	1.9745	2.9618	0.8550	2.4183	1.5666	2.5446
	(SE)	( 0.9873)	( 1.4809)	( 0.4275)	( 1.2092)	( 0.5539)	( 0.8996)
	Min,	1.71,	-6.84,	1.71,	-3.42,	1.71,	-6.84,
	Max	5.13	0.00	3.42	1.71	5.13	1.71
Week 44	n	4	4	4	4	8	8
	Mean	3.848	-2.138	2.565	-1.283	3.206	-1.710
	Median	1.710	-1.710	2.565	-1.710	1.710	-1.710
	SD	4.2750	0.8550	0.9873	2.1517	2.9530	1.5832
	(SE)	( 2.1375)	( 0.4275)	( 0.4936)	( 1.0759)	( 1.0440)	( 0.5597)
	Min,	1.71,	-3.42,	1.71,	-3.42,	1.71,	-3.42,
	Max	10.26	-1.71	3.42	1.71	10.26	1.71
Week 48	n	4	4	4	4	8	8
	Mean	3.848	-2.138	2.565	-1.283	3.206	-1.710
	Median	2.565	-1.710	1.710	-1.710	1.710	-1.710
	SD	3.2370	0.8550	1.7100	2.5650	2.4927	1.8281
	(SE)	( 1.6185)	( 0.4275)	( 0.8550)	( 1.2825)	( 0.8813)	( 0.6463)
	Min,	1.71,	-3.42,	1.71,	-3.42,	1.71,	-3.42,
	Max	8.55	-1.71	5.13	1.71	8.55	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	5.558	-0.428	2.565	-1.283	4.061	-0.855
	Median	3.420	-0.855	2.565	-1.710	2.565	-1.710
	SD	5.6499	1.6372	0.9873	2.1517	4.0813	1.8281
	(SE)	( 2.8250)	( 0.8186)	( 0.4936)	( 1.0759)	( 1.4430)	( 0.6463)
	Min,	1.71,	-1.71,	1.71,	-3.42,	1.71,	-3.42,
	Max	13.68	1.71	3.42	1.71	13.68	1.71
Week 56	n	4	4	3	3	7	7
	Mean	5.130	-0.855	3.420	0.000	4.397	-0.489
	Median	3.420	-0.855	3.420	-1.710	3.420	-1.710
	SD	4.8366	0.9873	0.0000	2.9618	3.5400	1.9027
	(SE)	( 2.4183)	( 0.4936)	( 0.0000)	( 1.7100)	( 1.3380)	( 0.7192)
	Min,	1.71,	-1.71,	3.42,	-1.71,	1.71,	-1.71,
	Max	11.97	0.00	3.42	3.42	11.97	3.42
Week 60	n	4	4	4	4	8	8
	Mean	5.558	-0.428	2.993	-0.855	4.275	-0.641
	Median	3.420	0.000	3.420	-1.710	3.420	-0.855
	SD	4.2750	0.8550	0.8550	1.7100	3.1663	1.2723
	(SE)	( 2.1375)	( 0.4275)	( 0.4275)	( 0.8550)	( 1.1195)	( 0.4498)
	Min,	3.42,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	11.97	0.00	3.42	1.71	11.97	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	4.703	-1.283	3.848	0.000	4.275	-0.641
	Median	4.275	-0.855	3.420	-0.855	3.420	-0.855
	SD	2.9204	1.6372	0.8550	2.4183	2.0438	2.0310
	(SE)	( 1.4602)	( 0.8186)	( 0.4275)	( 1.2092)	( 0.7226)	( 0.7181)
	Min,	1.71,	-3.42,	3.42,	-1.71,	1.71,	-3.42,
	Max	8.55	0.00	5.13	3.42	8.55	3.42
Week 68	n	4	4	4	4	8	8
	Mean	5.558	-0.428	3.848	0.000	4.703	-0.214
	Median	4.275	0.000	3.420	-0.855	3.420	0.000
	SD	3.2370	0.8550	0.8550	2.4183	2.3747	1.6947
	(SE)	( 1.6185)	( 0.4275)	( 0.4275)	( 1.2092)	( 0.8396)	( 0.5992)
	Min,	3.42,	-1.71,	3.42,	-1.71,	3.42,	-1.71,
	Max	10.26	0.00	5.13	3.42	10.26	3.42
Week 72	n	3	3	4	4	7	7
	Mean	3.990	0.000	2.993	-0.855	3.420	-0.489
	Median	3.420	0.000	2.565	-0.855	3.420	0.000
	SD	2.6121	1.7100	1.6372	2.2076	1.9745	1.9027
	(SE)	( 1.5081)	( 0.9873)	( 0.8186)	( 1.1038)	( 0.7463)	( 0.7192)
	Min,	1.71,	-1.71,	1.71,	-3.42,	1.71,	-3.42,
	Max	6.84	1.71	5.13	1.71	6.84	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	6.840	-1.710			6.840	-1.710
	Median	6.840	-1.710			6.840	-1.710
	SD	4.8366	0.0000			4.8366	0.0000
	(SE)	( 3.4200)	( 0.0000)			( 3.4200)	( 0.0000)
	Min,	3.42,	-1.71,			3.42,	-1.71,
	Max	10.26	-1.71			10.26	-1.71
Week 76	n	4	4	4	4	8	8
	Mean	4.275	-1.710	4.275	0.428	4.275	-0.641
	Median	3.420	-1.710	4.275	0.000	3.420	-0.855
	SD	2.9618	1.3962	0.9873	2.1517	2.0438	2.0310
	(SE)	( 1.4809)	( 0.6981)	( 0.4936)	( 1.0759)	( 0.7226)	( 0.7181)
	Min,	1.71,	-3.42,	3.42,	-1.71,	1.71,	-3.42,
	Max	8.55	0.00	5.13	3.42	8.55	3.42
Week 80	n	4	4	4	4	8	8
	Mean	4.703	-1.283	3.420	-0.428	4.061	-0.855
	Median	2.565	-1.710	3.420	-0.855	3.420	-1.710
	SD	4.9116	0.8550	1.3962	1.6372	3.4124	1.2926
	(SE)	( 2.4558)	( 0.4275)	( 0.6981)	( 0.8186)	( 1.2065)	( 0.4570)
	Min,	1.71,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	11.97	0.00	5.13	1.71	11.97	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	4.275	-1.710	3.420	-0.428	3.848	-1.069
	Median	2.565	-1.710	3.420	0.000	2.565	-0.855
	SD	4.0706	1.3962	1.9745	2.1517	2.9969	1.8137
	(SE)	( 2.0353)	( 0.6981)	( 0.9873)	( 1.0759)	( 1.0595)	( 0.6413)
	Min,	1.71,	-3.42,	1.71,	-3.42,	1.71,	-3.42,
	Max	10.26	0.00	5.13	1.71	10.26	1.71
Week 88	n	4	4	4	4	8	8
	Mean	5.130	-0.855	3.420	-0.428	4.275	-0.641
	Median	4.275	-1.710	3.420	-1.710	3.420	-1.710
	SD	3.6940	1.7100	0.0000	2.5650	2.5853	2.0310
	(SE)	( 1.8470)	( 0.8550)	( 0.0000)	( 1.2825)	( 0.9140)	( 0.7181)
	Min,	1.71,	-1.71,	3.42,	-1.71,	1.71,	-1.71,
	Max	10.26	1.71	3.42	3.42	10.26	3.42
Week 92	n	4	4	4	4	8	8
	Mean	6.840	0.855	2.993	-0.855	4.916	0.000
	Median	5.130	0.855	2.565	-0.855	5.130	0.000
	SD	3.4200	0.9873	1.6372	2.2076	3.2235	1.8281
	(SE)	( 1.7100)	( 0.4936)	( 0.8186)	( 1.1038)	( 1.1397)	( 0.6463)
	Min,	5.13,	0.00,	1.71,	-3.42,	1.71,	-3.42,
	Max	11.97	1.71	5.13	1.71	11.97	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	7.695	1.710	3.848	0.000	5.771	0.855
	Median	5.130	1.710	3.420	-0.855	4.275	0.855
	SD	6.3216	2.7924	0.8550	2.4183	4.6551	2.5853
	(SE)	( 3.1608)	( 1.3962)	( 0.4275)	( 1.2092)	( 1.6458)	( 0.9140)
	Min,	3.42,	-1.71,	3.42,	-1.71,	3.42,	-1.71,
	Max	17.10	5.13	5.13	3.42	17.10	5.13
Week 100	n	4	4	4	4	8	8
	Mean	6.413	0.428	2.993	-0.855	4.703	-0.214
	Median	4.275	0.000	3.420	-1.710	3.420	-1.710
	SD	6.4551	2.5650	0.8550	1.7100	4.6382	2.1314
	(SE)	( 3.2276)	( 1.2825)	( 0.4275)	( 0.8550)	( 1.6399)	( 0.7536)
	Min,	1.71,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	15.39	3.42	3.42	1.71	15.39	3.42
Week 104	n	4	4	4	4	8	8
	Mean	6.413	0.428	3.420	-0.428	4.916	0.000
	Median	3.420	-0.855	3.420	-0.855	3.420	-0.855
	SD	7.3051	3.2370	1.3962	1.6372	5.1249	2.4183
	(SE)	( 3.6526)	( 1.6185)	( 0.6981)	( 0.8186)	( 1.8119)	( 0.8550)
	Min,	1.71,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	17.10	5.13	5.13	1.71	17.10	5.13

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	4.275	-1.710	2.565	-1.283	3.420	-1.496
	Median	3.420	-1.710	2.565	-1.710	3.420	-1.710
	SD	2.9618	1.3962	0.9873	2.1517	2.2389	1.6947
	(SE)	( 1.4809)	( 0.6981)	( 0.4936)	( 1.0759)	( 0.7916)	( 0.5992)
	Min,	1.71,	-3.42,	1.71,	-3.42,	1.71,	-3.42,
	Max	8.55	0.00	3.42	1.71	8.55	1.71
Week 112	n	4	4	4	4	8	8
	Mean	4.275	-1.710	3.848	0.000	4.061	-0.855
	Median	3.420	-0.855	3.420	-0.855	3.420	-0.855
	SD	1.7100	2.4183	0.8550	2.4183	1.2723	2.4183
	(SE)	( 0.8550)	( 1.2092)	( 0.4275)	( 1.2092)	( 0.4498)	( 0.8550)
	Min,	3.42,	-5.13,	3.42,	-1.71,	3.42,	-5.13,
	Max	6.84	0.00	5.13	3.42	6.84	3.42
Week 116	n	4	4	4	4	8	8
	Mean	7.695	1.710	3.420	-0.428	5.557	0.641
	Median	6.840	1.710	3.420	-0.855	5.130	0.855
	SD	3.2744	1.3962	1.3962	1.6372	3.2638	1.8137
	(SE)	( 1.6372)	( 0.6981)	( 0.6981)	( 0.8186)	( 1.1539)	( 0.6413)
	Min,	5.13,	0.00,	1.71,	-1.71,	1.71,	-1.71,
	Max	11.97	3.42	5.13	1.71	11.97	3.42

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	4.560	0.570	2.993	-0.855	3.664	-0.244
	Median	5.130	0.000	2.565	-0.855	3.420	0.000
	SD	0.9873	0.9873	1.6372	2.2076	1.5385	1.8281
	(SE)	( 0.5700)	( 0.5700)	( 0.8186)	( 1.1038)	( 0.5815)	( 0.6909)
	Min,	3.42,	0.00,	1.71,	-3.42,	1.71,	-3.42,
	Max	5.13	1.71	5.13	1.71	5.13	1.71
Week 124	n	3	3	4	4	7	7
	Mean	3.420	-0.570	3.420	-0.428	3.420	-0.489
	Median	3.420	0.000	3.420	-0.855	3.420	0.000
	SD	0.0000	0.9873	1.3962	1.6372	0.9873	1.2926
	(SE)	( 0.0000)	( 0.5700)	( 0.6981)	( 0.8186)	( 0.3732)	( 0.4886)
	Min,	3.42,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	3.42	0.00	5.13	1.71	5.13	1.71
Week 128	n	4	4	4	4	8	8
	Mean	5.985	0.000	4.275	0.428	5.130	0.214
	Median	4.275	0.000	4.275	0.855	4.275	0.000
	SD	4.0706	0.0000	2.2076	1.6372	3.1663	1.0959
	(SE)	( 2.0353)	( 0.0000)	( 1.1038)	( 0.8186)	( 1.1195)	( 0.3875)
	Min,	3.42,	0.00,	1.71,	-1.71,	1.71,	-1.71,
	Max	11.97	0.00	6.84	1.71	11.97	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	7.268	1.283	4.703	0.855	5.985	1.069
	Median	5.130	1.710	5.130	0.000	5.130	0.855
	SD	4.2750	0.8550	0.8550	1.7100	3.1663	1.2723
	(SE)	( 2.1375)	( 0.4275)	( 0.4275)	( 0.8550)	( 1.1195)	( 0.4498)
	Min,	5.13,	0.00,	3.42,	0.00,	3.42,	0.00,
	Max	13.68	1.71	5.13	3.42	13.68	3.42
Week 136	n	4	4	4	4	8	8
	Mean	5.558	-0.428	2.138	-1.710	3.848	-1.069
	Median	3.420	0.000	1.710	-2.565	3.420	-0.855
	SD	4.2750	0.8550	0.8550	2.4183	3.3893	1.8137
	(SE)	( 2.1375)	( 0.4275)	( 0.4275)	( 1.2092)	( 1.1983)	( 0.6413)
	Min,	3.42,	-1.71,	1.71,	-3.42,	1.71,	-3.42,
	Max	11.97	0.00	3.42	1.71	11.97	1.71
Week 140	n	4	4	4	4	8	8
	Mean	5.985	0.000	3.420	-0.428	4.703	-0.214
	Median	5.130	0.000	3.420	-0.855	3.420	0.000
	SD	3.2744	1.3962	1.3962	1.6372	2.7037	1.4270
	(SE)	( 1.6372)	( 0.6981)	( 0.6981)	( 0.8186)	( 0.9559)	( 0.5045)
	Min,	3.42,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	10.26	1.71	5.13	1.71	10.26	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 144	n	4	4	4	4	8	8
	Mean	5.130	-0.855	2.993	-0.855	4.061	-0.855
	Median	4.275	0.000	2.565	-0.855	3.420	0.000
	SD	2.4183	1.7100	1.6372	2.2076	2.2272	1.8281
	(SE)	( 1.2092)	( 0.8550)	( 0.8186)	( 1.1038)	( 0.7874)	( 0.6463)
	Min,	3.42,	-3.42,	1.71,	-3.42,	1.71,	-3.42,
	Max	8.55	0.00	5.13	1.71	8.55	1.71
Week 148	n	4	4	4	4	8	8
	Mean	8.123	2.138	3.420	-0.428	5.771	0.855
	Median	5.130	1.710	3.420	-1.710	3.420	0.000
	SD	7.1705	3.5253	0.0000	2.5650	5.3248	3.1663
	(SE)	( 3.5852)	( 1.7626)	( 0.0000)	( 1.2825)	( 1.8826)	( 1.1195)
	Min,	3.42,	-1.71,	3.42,	-1.71,	3.42,	-1.71,
	Max	18.81	6.84	3.42	3.42	18.81	6.84
Week 152	n	4	4	3	3	7	7
	Mean	7.268	1.283	3.990	0.570	5.863	0.977
	Median	3.420	0.000	3.420	0.000	3.420	0.000
	SD	7.6950	3.7917	0.9873	2.6121	5.7446	3.0996
	(SE)	( 3.8475)	( 1.8958)	( 0.5700)	( 1.5081)	( 2.1713)	( 1.1716)
	Min,	3.42,	-1.71,	3.42,	-1.71,	3.42,	-1.71,
	Max	18.81	6.84	5.13	3.42	18.81	6.84

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	5.558	-0.428	4.703	0.855	5.130	0.214
	Median	3.420	0.000	5.130	0.000	4.275	0.000
	SD	4.2750	0.8550	0.8550	1.7100	2.8904	1.4270
	(SE)	( 2.1375)	( 0.4275)	( 0.4275)	( 0.8550)	( 1.0219)	( 0.5045)
	Min,	3.42,	-1.71,	3.42,	0.00,	3.42,	-1.71,
	Max	11.97	0.00	5.13	3.42	11.97	3.42
Week 160	n	4	4	4	4	8	8
	Mean	5.558	-0.428	3.420	-0.428	4.489	-0.428
	Median	5.130	0.000	3.420	-0.855	3.420	0.000
	SD	2.5650	2.1517	1.3962	2.9204	2.2272	2.3747
	(SE)	( 1.2825)	( 1.0759)	( 0.6981)	( 1.4602)	( 0.7874)	( 0.8396)
	Min,	3.42,	-3.42,	1.71,	-3.42,	1.71,	-3.42,
	Max	8.55	1.71	5.13	3.42	8.55	3.42
Week 164	n	4	4	4	4	8	8
	Mean	5.985	0.000	2.565	-1.283	4.275	-0.641
	Median	3.420	0.000	2.565	-1.710	3.420	-0.855
	SD	5.1300	1.3962	0.9873	2.1517	3.8779	1.8137
	(SE)	( 2.5650)	( 0.6981)	( 0.4936)	( 1.0759)	( 1.3711)	( 0.6413)
	Min,	3.42,	-1.71,	1.71,	-3.42,	1.71,	-3.42,
	Max	13.68	1.71	3.42	1.71	13.68	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	5.130	-0.855	2.993	-0.855	4.061	-0.855
	Median	3.420	-0.855	3.420	-1.710	3.420	-1.710
	SD	4.8366	0.9873	0.8550	1.7100	3.4124	1.2926
	(SE)	( 2.4183)	( 0.4936)	( 0.4275)	( 0.8550)	( 1.2065)	( 0.4570)
	Min,	1.71,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	11.97	0.00	3.42	1.71	11.97	1.71
Week 172	n	4	4	4	4	8	8
	Mean	6.413	0.428	3.848	0.000	5.130	0.214
	Median	3.420	0.000	4.275	0.000	3.420	0.000
	SD	7.1705	3.5253	1.6372	1.3962	5.0064	2.4927
	(SE)	( 3.5852)	( 1.7626)	( 0.8186)	( 0.6981)	( 1.7700)	( 0.8813)
	Min,	1.71,	-3.42,	1.71,	-1.71,	1.71,	-3.42,
	Max	17.10	5.13	5.13	1.71	17.10	5.13
Week 176	n	4	4	4	4	8	8
	Mean	8.123	2.138	3.420	-0.428	5.771	0.855
	Median	3.420	-0.855	3.420	-0.855	3.420	-0.855
	SD	10.5758	6.6044	1.3962	1.6372	7.4221	4.6607
	(SE)	( 5.2879)	( 3.3022)	( 0.6981)	( 0.8186)	( 2.6241)	( 1.6478)
	Min,	1.71,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	23.94	11.97	5.13	1.71	23.94	11.97

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	4	4	3	3	7	7
	Mean	5.985	0.000	3.420	0.000	4.886	0.000
	Median	4.275	0.000	3.420	0.000	3.420	0.000
	SD	4.0706	0.0000	1.7100	1.7100	3.3376	0.9873
	(SE)	( 2.0353)	( 0.0000)	( 0.9873)	( 0.9873)	( 1.2615)	( 0.3732)
	Min,	3.42,	0.00,	1.71,	-1.71,	1.71,	-1.71,
	Max	11.97	0.00	5.13	1.71	11.97	1.71
Week 184	n	4	4	4	4	8	8
	Mean	6.413	0.428	2.993	-0.855	4.703	-0.214
	Median	3.420	0.000	3.420	-1.710	3.420	-0.855
	SD	5.9850	2.1517	0.8550	2.9618	4.3597	2.4927
	(SE)	( 2.9925)	( 1.0759)	( 0.4275)	( 1.4809)	( 1.5414)	( 0.8813)
	Min,	3.42,	-1.71,	1.71,	-3.42,	1.71,	-3.42,
	Max	15.39	3.42	3.42	3.42	15.39	3.42

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg			50 mg/kg			
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Alkaline Phosphatase (U/L)							
Baseline <sup>1</sup>	n	4	4	4	4	8	
	Mean	92.0		99.5		95.8	
	Median	93.5		100.0		100.0	
	SD	22.38		10.12		16.57	
	(SE)	( 11.19)		( 5.06)		( 5.86)	
	Min,	68,		87,		68,	
	Max	113		111		113	
Week 2	n	4	4	4	4	8	
	Mean	91.3	-0.8	89.8	-9.8	90.5	-5.3
	Median	91.5	0.5	90.5	-9.5	90.5	-6.0
	SD	16.74	9.32	5.06	5.74	11.48	8.63
	(SE)	( 8.37) <sup>f</sup>	( 4.66)	( 2.53)	( 2.87)	( 4.06)	( 3.05)
	Min,	71,	-13,	84,	-17,	71,	-17,
	Max	111	9	94	-3	111	9
Week 4	n	4	4	4	4	8	
	Mean	95.3	3.3	103.3	3.8	99.3	3.5
	Median	97.0	3.0	105.5	6.0	105.0	5.5
	SD	22.46	5.12	8.06	8.22	16.19	6.35
	(SE)	( 11.23)	( 2.56)	( 4.03)	( 4.11)	( 5.73)	( 2.24)
	Min,	68,	-2,	92,	-8,	68,	-8,
	Max	119	9	110	11	119	11

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	87.3	-4.8	104.0	4.5	95.6	-0.1
	Median	88.5	-4.5	103.5	4.5	99.0	-3.0
	SD	22.53	2.06	15.56	12.40	20.04	9.60
	(SE)	( 11.26)	( 1.03)	( 7.78)	( 6.20)	( 7.08)	( 3.39)
	Min,	62,	-7,	87,	-10,	62,	-10,
	Max	110	-3	122	19	122	19
Week 8	n	4	4	4	4	8	8
	Mean	99.5	7.5	92.5	-7.0	96.0	0.3
	Median	97.0	6.5	93.0	-6.0	95.0	-2.0
	SD	17.41	9.54	11.00	6.32	13.99	10.78
	(SE)	( 8.70)	( 4.77)	( 5.50)	( 3.16)	( 4.95)	( 3.81)
	Min,	83,	-3,	82,	-15,	82,	-15,
	Max	121	20	102	-1	121	20
Week 10	n	4	4	4	4	8	8
	Mean	94.0	2.0	96.5	-3.0	95.3	-0.5
	Median	96.5	2.5	102.0	-2.0	102.0	2.5
	SD	24.97	6.48	19.12	13.64	20.63	10.24
	(SE)	( 12.48)	( 3.24)	( 9.56)	( 6.82)	( 7.29)	( 3.62)
	Min,	63,	-5,	69,	-18,	63,	-18,
	Max	120	8	113	10	120	10

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	103.5	11.5	110.8	11.3	107.1	11.4
	Median	103.5	10.0	112.0	12.0	111.5	10.0
	SD	33.41	11.82	26.51	16.48	28.19	13.28
	(SE)	( 16.71)	( 5.91)	( 13.26)	( 8.24)	( 9.97)	( 4.69)
	Min,	67,	-1,	79,	-8,	67,	-8,
	Max	140	27	140	29	140	29
Week 15	n	4	4	4	4	8	8
	Mean	100.5	8.5	105.0	5.5	102.8	7.0
	Median	103.5	10.0	110.5	6.5	110.5	9.5
	SD	30.45	10.08	14.31	7.23	22.15	8.28
	(SE)	( 15.22)	( 5.04)	( 7.15)	( 3.62)	( 7.83)	( 2.93)
	Min,	63,	-5,	84,	-3,	63,	-5,
	Max	132	19	115	12	132	19
Week 18	n	4	4	4	4	8	8
	Mean	107.8	15.8	105.8	6.3	106.8	11.0
	Median	110.0	16.5	106.5	6.5	106.5	8.0
	SD	42.08	20.32	12.61	2.50	28.78	14.33
	(SE)	( 21.04)	( 10.16)	( 6.30)	( 1.25)	( 10.17)	( 5.07)
	Min,	59,	-9,	90,	3,	59,	-9,
	Max	152	39	120	9	152	39

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	94.8	2.8	95.8	-3.8	95.3	-0.5
	Median	94.0	0.5	101.0	-4.5	101.0	0.5
	SD	28.50	7.80	15.86	11.90	21.36	9.94
	(SE)	( 14.25)	( 3.90)	( 7.93)	( 5.95)	( 7.55)	( 3.52)
	Min,	64,	-4,	73,	-14,	64,	-14,
	Max	127	14	108	8	127	14
	Week 24	n	4	4	4	4	8
Mean		109.8	17.8	108.0	8.5	108.9	13.1
Median		109.0	20.0	102.0	8.0	102.0	13.0
SD		29.76	8.81	18.94	18.86	23.11	14.50
(SE)		( 14.88)	( 4.40)	( 9.47)	( 9.43)	( 8.17)	( 5.13)
Min,		84,	6,	93,	-14,	84,	-14,
Max		137	25	135	32	137	32
Week 25		n	4	4	4	4	8
	Mean	105.3	13.3	105.8	6.3	105.5	9.8
	Median	106.0	10.5	108.0	4.0	108.0	5.5
	SD	35.94	14.43	15.41	9.84	25.60	12.03
	(SE)	( 17.97)	( 7.22)	( 7.71)	( 4.92)	( 9.05)	( 4.25)
	Min,	69,	1,	85,	-2,	69,	-2,
	Max	140	31	122	19	140	31

\*Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 28	n	4	4	4	4	8	8
	Mean	103.3	11.3	106.3	6.8	104.8	9.0
	Median	108.0	13.5	102.0	5.5	102.0	5.5
	SD	36.54	14.31	15.90	14.77	26.14	13.68
	(SE)	( 18.27)	( 7.16)	( 7.95)	( 7.39)	( 9.24)	( 4.84)
	Min,	62,	-6,	92,	-10,	62,	-10,
	Max	135	24	129	26	135	26
Week 32	n	4	4	3	3	7	7
	Mean	98.5	6.5	105.7	10.0	101.6	8.0
	Median	100.5	5.0	116.0	19.0	116.0	6.0
	SD	30.58	10.79	28.92	21.00	27.59	14.45
	(SE)	( 15.29)	( 5.39)	( 16.70)	( 12.12)	( 10.43)	( 5.46)
	Min,	63,	-5,	73,	-14,	63,	-14,
	Max	130	21	128	25	130	25
Week 36	n	4	4	4	4	8	8
	Mean	98.8	6.8	108.0	8.5	103.4	7.6
	Median	100.5	5.0	108.5	4.5	107.0	4.5
	SD	28.61	11.50	19.92	13.48	23.35	11.64
	(SE)	( 14.30)	( 5.75)	( 9.96)	( 6.74)	( 8.25)	( 4.11)
	Min,	64,	-4,	84,	-3,	64,	-4,
	Max	130	21	131	28	131	28

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	91.5	-0.5	110.0	10.5	100.8	5.0
	Median	96.0	0.5	117.5	13.5	113.0	4.5
	SD	26.45	6.56	21.09	13.87	24.25	11.64
	(SE)	( 13.23)	( 3.28)	( 10.54)	( 6.93)	( 8.57)	( 4.11)
	Min,	59,	-9,	79,	-8,	59,	-9,
	Max	115	6	126	23	126	23
Week 44	n	4	4	4	4	8	8
	Mean	93.8	1.8	116.3	16.8	105.0	9.3
	Median	91.5	0.0	129.0	25.0	114.5	8.5
	SD	26.85	9.14	28.28	20.12	28.22	16.54
	(SE)	( 13.42)	( 4.57)	( 14.14)	( 10.06)	( 9.98)	( 5.85)
	Min,	65,	-7,	74,	-13,	65,	-13,
	Max	127	14	133	30	133	30
Week 48	n	4	4	4	4	8	8
	Mean	103.3	11.3	110.8	11.3	107.0	11.3
	Median	100.5	7.0	115.5	11.5	115.5	7.5
	SD	32.87	11.79	21.14	15.17	25.90	12.58
	(SE)	( 16.43)	( 5.89)	( 10.57)	( 7.59)	( 9.16)	( 4.45)
	Min,	71,	3,	81,	-6,	71,	-6,
	Max	141	28	131	28	141	28

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	100.5	8.5	110.5	11.0	105.5	9.8
	Median	101.0	7.5	123.0	16.5	120.5	10.5
	SD	35.43	13.82	27.09	20.15	29.68	16.05
	(SE)	( 17.71)	( 6.91)	( 13.54)	( 10.07)	( 10.49)	( 5.67)
	Min,	61,	-7,	70,	-17,	61,	-17,
	Max	139	26	126	28	139	28
Week 56	n	4	4	3	3	7	7
	Mean	113.8	21.8	100.3	0.0	108.0	12.4
	Median	110.5	15.0	112.0	1.0	112.0	5.0
	SD	46.03	25.86	28.36	18.52	37.13	24.17
	(SE)	( 23.02)	( 12.93)	( 16.37)	( 10.69)	( 14.04)	( 9.13)
	Min,	68,	0,	68,	-19,	68,	-19,
	Max	166	57	121	18	166	57
Week 60	n	4	4	4	4	8	8
	Mean	115.0	23.0	106.5	7.0	110.8	15.0
	Median	116.0	20.5	109.5	3.5	109.5	6.5
	SD	47.21	25.42	16.54	14.31	33.06	20.92
	(SE)	( 23.60)	( 12.71)	( 8.27)	( 7.15)	( 11.69)	( 7.40)
	Min,	68,	0,	84,	-5,	68,	-5,
	Max	160	51	123	26	160	51

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	122.0	30.0	98.5	-1.0	110.3	14.5
	Median	125.5	30.0	105.5	0.0	105.5	9.0
	SD	59.66	37.59	23.39	19.30	43.79	32.25
	(SE)	( 29.83)	( 18.80)	( 11.69)	( 9.65)	( 15.48)	( 11.40)
	Min,	60,	-8,	66,	-21,	60,	-21,
	Max	177	68	117	17	177	68
Week 68	n	4	4	4	4	8	8
	Mean	115.8	23.8	101.0	1.5	108.4	12.6
	Median	117.0	21.5	104.5	-2.5	104.5	1.5
	SD	53.02	31.11	18.38	15.84	37.58	25.76
	(SE)	( 26.51)	( 15.55)	( 9.19)	( 7.92)	( 13.29)	( 9.11)
	Min,	65,	-3,	76,	-11,	65,	-11,
	Max	164	55	119	22	164	55
Week 72	n	3	3	4	4	7	7
	Mean	126.7	30.0	103.5	4.0	113.4	15.1
	Median	158.0	45.0	107.0	0.0	108.0	5.0
	SD	67.68	43.49	18.43	15.19	43.01	30.64
	(SE)	( 39.07)	( 25.11)	( 9.22)	( 7.59)	( 16.26)	( 11.58)
	Min,	49,	-19,	78,	-9,	49,	-19,
	Max	173	64	122	25	173	64

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	70.0	-3.0			70.0	-3.0
	Median	70.0	-3.0			70.0	-3.0
	SD	11.31	4.24			11.31	4.24
	(SE)	( 8.00)	( 3.00)			( 8.00)	( 3.00)
	Min,	62,	-6,			62,	-6,
	Max	78	0			78	0
Week 76	n	4	4	4	4	8	8
	Mean	104.5	12.5	99.0	-0.5	101.8	6.0
	Median	104.5	9.0	107.5	3.5	107.5	3.5
	SD	36.83	15.52	21.02	13.03	27.92	14.98
	(SE)	( 18.41)	( 7.76)	( 10.51)	( 6.51)	( 9.87)	( 5.29)
	Min,	68,	0,	68,	-19,	68,	-19,
	Max	141	32	113	10	141	32
Week 80	n	4	4	4	4	8	8
	Mean	110.0	18.0	101.5	2.0	105.8	10.0
	Median	108.5	18.0	106.5	2.0	106.5	13.0
	SD	38.36	18.07	19.23	15.60	28.45	17.82
	(SE)	( 19.18)	( 9.04)	( 9.61)	( 7.80)	( 10.06)	( 6.30)
	Min,	75,	-3,	75,	-12,	75,	-12,
	Max	148	39	118	16	148	39

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	114.0	22.0	108.0	8.5	111.0	15.3
	Median	105.5	10.5	105.5	1.5	105.5	9.0
	SD	45.80	27.87	33.40	29.29	37.25	27.43
	(SE)	( 22.90)	( 13.93)	( 16.70)	( 14.64)	( 13.17)	( 9.70)
	Min,	73,	4,	70,	-17,	70,	-17,
	Max	172	63	151	48	172	63
Week 88	n	4	4	4	4	8	8
	Mean	119.3	27.3	101.0	1.5	110.1	14.4
	Median	119.5	24.0	103.0	2.0	103.0	3.5
	SD	55.47	33.69	13.37	10.25	38.61	26.85
	(SE)	( 27.73)	( 16.84)	( 6.68)	( 5.12)	( 13.65)	( 9.49)
	Min,	66,	-2,	83,	-10,	66,	-10,
	Max	172	63	115	12	172	63
Week 92	n	4	4	4	4	8	8
	Mean	117.3	25.3	108.0	8.5	112.6	16.9
	Median	122.5	27.0	116.0	12.0	116.0	12.5
	SD	55.94	33.71	24.78	18.70	40.36	26.78
	(SE)	( 27.97)	( 16.85)	( 12.39)	( 9.35)	( 14.27)	( 9.47)
	Min,	58,	-10,	72,	-15,	58,	-15,
	Max	166	57	128	25	166	57

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	116.0	24.0	100.5	1.0	108.3	12.5
	Median	116.0	22.5	103.5	-0.5	103.5	1.5
	SD	53.43	31.27	25.96	19.98	39.76	27.23
	(SE)	( 26.71)	( 15.64)	( 12.98)	( 9.99)	( 14.06)	( 9.63)
	Min,	65,	-3,	66,	-21,	65,	-21,
	Max	167	54	129	26	167	54
Week 100	n	4	4	4	4	8	8
	Mean	135.0	43.0	111.3	11.8	123.1	27.4
	Median	140.0	45.5	112.0	12.0	112.0	12.0
	SD	74.45	52.20	23.00	12.89	52.57	38.96
	(SE)	( 37.22)	( 26.10)	( 11.50)	( 6.45)	( 18.59)	( 13.77)
	Min,	60,	-8,	83,	-4,	60,	-8,
	Max	200	89	138	27	200	89
Week 104	n	4	4	4	4	8	8
	Mean	135.0	43.0	110.0	10.5	122.5	26.8
	Median	132.0	36.5	119.0	13.5	119.0	13.5
	SD	75.73	54.31	24.86	19.50	53.86	41.58
	(SE)	( 37.87)	( 27.16)	( 12.43)	( 9.75)	( 19.04)	( 14.70)
	Min,	62,	-6,	74,	-13,	62,	-13,
	Max	214	105	128	28	214	105

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	133.8	41.8	109.3	9.8	121.5	25.8
	Median	141.0	45.5	118.5	12.0	118.5	15.0
	SD	68.30	46.01	20.24	13.82	48.44	35.80
	(SE)	( 34.15)	( 23.00)	( 10.12)	( 6.91)	( 17.12)	( 12.66)
	Min,	61,	-7,	79,	-8,	61,	-8,
	Max	192	83	121	23	192	83
Week 112	n	4	4	4	4	8	8
	Mean	124.0	32.0	111.3	11.8	117.6	21.9
	Median	126.5	31.0	118.0	11.0	118.0	11.0
	SD	58.15	36.11	19.28	13.60	40.68	27.48
	(SE)	( 29.08)	( 18.06)	( 9.64)	( 6.80)	( 14.38)	( 9.72)
	Min,	66,	-2,	83,	-4,	66,	-4,
	Max	177	68	126	29	177	68
Week 116	n	4	4	4	4	8	8
	Mean	125.5	33.5	113.0	13.5	119.3	23.5
	Median	123.5	34.5	117.0	13.5	117.0	13.5
	SD	62.46	40.63	8.68	5.32	41.82	28.88
	(SE)	( 31.23)	( 20.32)	( 4.34)	( 2.66)	( 14.79)	( 10.21)
	Min,	71,	-6,	100,	7,	71,	-6,
	Max	184	71	118	20	184	71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	147.3	50.7	100.0	0.5	120.3	22.0
	Median	191.0	78.0	104.0	1.0	110.0	8.0
	SD	80.00	55.32	13.98	12.07	53.58	42.57
	(SE)	( 46.19)	( 31.94)	( 6.99)	( 6.03)	( 20.25)	( 16.09)
	Min,	55,	-13,	81,	-13,	55,	-13,
	Max	196	87	111	13	196	87
Week 124	n	3	3	4	4	7	7
	Mean	146.0	49.3	104.3	4.8	122.1	23.9
	Median	183.0	74.0	106.5	0.5	115.0	4.0
	SD	68.46	43.59	16.46	12.76	46.86	35.82
	(SE)	( 39.53)	( 25.17)	( 8.23)	( 6.38)	( 17.71)	( 13.54)
	Min,	67,	-1,	84,	-5,	67,	-5,
	Max	188	75	120	23	188	75
Week 128	n	4	4	4	4	8	8
	Mean	137.5	45.5	106.3	6.8	121.9	26.1
	Median	148.5	58.0	107.0	7.0	119.0	17.0
	SD	53.02	37.97	19.82	11.93	40.65	33.28
	(SE)	( 26.51)	( 18.98)	( 9.91)	( 5.96)	( 14.37)	( 11.77)
	Min,	68,	-10,	82,	-5,	68,	-10,
	Max	185	76	129	18	185	76

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	113.5	21.5	103.5	4.0	108.5	12.8
	Median	113.5	22.5	101.5	1.5	101.5	1.5
	SD	57.81	35.86	11.27	13.29	38.92	26.72
	(SE)	( 28.90)	( 17.93)	( 5.63)	( 6.65)	( 13.76)	( 9.45)
	Min,	61,	-12,	92,	-9,	61,	-12,
	Max	166	53	119	22	166	53
Week 136	n	4	4	4	4	8	8
	Mean	105.3	13.3	97.3	-2.3	101.3	5.5
	Median	105.5	10.0	95.0	2.5	95.0	5.5
	SD	39.44	17.97	22.91	18.89	30.17	18.97
	(SE)	( 19.72)	( 8.98)	( 11.46)	( 9.45)	( 10.66)	( 6.71)
	Min,	66,	-2,	76,	-27,	66,	-27,
	Max	144	35	123	13	144	35
Week 140	n	4	4	4	4	8	8
	Mean	86.8	-5.3	102.8	3.3	94.8	-1.0
	Median	89.0	-5.5	98.0	6.0	96.0	-2.5
	SD	22.91	3.50	22.29	17.52	22.61	12.55
	(SE)	( 11.46)	( 1.75)	( 11.15)	( 8.76)	( 7.99)	( 4.44)
	Min,	61,	-9,	83,	-20,	61,	-20,
	Max	108	-1	132	21	132	21

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	81.3	-10.8	97.5	-2.0	89.4	-6.4
	Median	79.5	-9.0	94.5	2.5	91.5	-3.0
	SD	26.21	9.71	14.89	11.52	21.56	10.91
	(SE)	( 13.10)	( 4.85)	( 7.44)	( 5.76)	( 7.62)	( 3.86)
	Min,	55,	-23,	84,	-19,	55,	-23,
	Max	111	-2	117	6	117	6
Week 148	n	4	4	4	4	8	8
	Mean	85.8	-6.3	109.0	9.5	97.4	1.6
	Median	82.5	-6.0	110.0	15.0	104.0	-1.0
	SD	26.32	7.14	14.14	14.55	23.18	13.54
	(SE)	( 13.16)	( 3.57)	( 7.07)	( 7.27)	( 8.19)	( 4.79)
	Min,	63,	-15,	91,	-12,	63,	-15,
	Max	115	2	125	20	125	20
Week 152	n	4	4	3	3	7	7
	Mean	106.3	14.3	94.0	-1.7	101.0	7.4
	Median	106.0	16.0	97.0	2.0	97.0	2.0
	SD	42.48	20.69	7.00	13.87	31.01	18.72
	(SE)	( 21.24)	( 10.35)	( 4.04)	( 8.01)	( 11.72)	( 7.08)
	Min,	68,	-7,	86,	-17,	68,	-17,
	Max	145	32	99	10	145	32

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	117.3	25.3	104.5	5.0	110.9	15.1
	Median	114.5	24.0	98.5	6.5	98.5	9.0
	SD	51.62	31.08	18.91	14.67	36.63	24.97
	(SE)	( 25.81)	( 15.54)	( 9.46)	( 7.34)	( 12.95)	( 8.83)
	Min,	70,	-8,	89,	-14,	70,	-14,
	Max	170	61	132	21	170	61
Week 160	n	4	4	4	4	8	8
	Mean	110.3	18.3	103.3	3.8	106.8	11.0
	Median	110.5	18.0	102.0	5.5	102.0	5.5
	SD	49.98	28.25	11.15	11.67	33.73	21.46
	(SE)	( 24.99)	( 14.13)	( 5.57)	( 5.84)	( 11.93)	( 7.59)
	Min,	65,	-9,	91,	-12,	65,	-12,
	Max	155	46	118	16	155	46
Week 164	n	4	4	4	4	8	8
	Mean	122.8	30.8	101.3	1.8	112.0	16.3
	Median	127.5	32.0	101.0	9.0	101.0	11.0
	SD	51.98	29.81	24.58	22.46	39.36	28.94
	(SE)	( 25.99)	( 14.91)	( 12.29)	( 11.23)	( 13.91)	( 10.23)
	Min,	67,	-1,	72,	-31,	67,	-31,
	Max	169	60	131	20	169	60

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	117.8	25.8	100.3	0.8	109.0	13.3
	Median	119.0	23.5	96.5	4.0	96.5	9.0
	SD	50.86	29.18	20.42	15.44	37.08	25.41
	(SE)	( 25.43)	( 14.59)	( 10.21)	( 7.72)	( 13.11)	( 8.98)
	Min,	65,	-3,	83,	-19,	65,	-19,
	Max	168	59	125	14	168	59
Week 172	n	4	4	4	4	8	8
	Mean	115.8	23.8	98.3	-1.3	107.0	11.3
	Median	117.0	23.5	92.0	0.0	92.0	9.0
	SD	39.56	17.23	16.92	12.04	29.68	19.18
	(SE)	( 19.78)	( 8.62)	( 8.46)	( 6.02)	( 10.49)	( 6.78)
	Min,	75,	7,	86,	-17,	75,	-17,
	Max	154	41	123	12	154	41
Week 176	n	4	4	4	4	8	8
	Mean	110.5	18.5	102.0	2.5	106.3	10.5
	Median	115.5	20.0	99.5	7.5	101.5	19.0
	SD	33.91	13.20	24.04	22.84	27.59	19.27
	(SE)	( 16.95)	( 6.60)	( 12.02)	( 11.42)	( 9.75)	( 6.81)
	Min,	69,	1,	76,	-27,	69,	-27,
	Max	142	33	133	22	142	33

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	112.3	20.3	84.3	-11.3	100.3	6.7
	Median	118.0	22.5	88.0	-9.0	89.0	6.0
	SD	44.55	22.62	10.97	18.61	35.43	25.62
	(SE)	( 22.28)	( 11.31)	( 6.33)	( 10.74)	( 13.39)	( 9.68)
	Min,	61,	-7,	72,	-31,	61,	-31,
	Max	152	43	93	6	152	43
Week 184	n	4	4	4	4	8	8
	Mean	130.0	38.0	105.0	5.5	117.5	21.8
	Median	135.5	40.0	102.0	3.0	103.0	8.5
	SD	63.77	41.55	28.69	28.10	47.69	37.15
	(SE)	( 31.88)	( 20.77)	( 14.35)	( 14.05)	( 16.86)	( 13.13)
	Min,	63,	-5,	77,	-26,	63,	-26,
	Max	186	77	139	42	186	77

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Amylase (U/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	38.3		42.0		40.1	
	Median	38.5		38.5		38.5	
	SD	2.50		12.30		8.46	
	(SE)	( 1.25)		( 6.15)		( 2.99)	
	Min, Max	35, 41		32, 59		32, 59	
Week 2	n	4	4	4	4	8	
	Mean	40.0	1.8	43.3	1.3	41.6	1.5
	Median	39.5	2.0	40.5	1.5	40.5	2.0
	SD	3.16	3.69	8.02	4.99	5.90	4.07
	(SE)	( 1.58)	( 1.84)	( 4.01)	( 2.50)	( 2.09)	( 1.44)
	Min, Max	37, 44	-3, 6	37, 55	-4, 6	37, 55	-4, 6
Week 4	n	4	4	4	4	8	
	Mean	30.8	-7.5	36.8	-5.3	33.8	-6.4
	Median	30.0	-7.0	31.0	-4.0	30.0	-5.5
	SD	1.50	2.65	12.20	3.95	8.66	3.34
	(SE)	( 0.75)	( 1.32)	( 6.10)	( 1.97)	( 3.06)	( 1.18)
	Min, Max	30, 33	-11, -5	30, 55	-11, -2	30, 55	-11, -2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	30.8	-7.5	35.5	-6.5	33.1	-7.0
	Median	30.0	-8.0	30.5	-5.5	30.0	-8.0
	SD	1.50	1.73	10.34	5.07	7.30	3.55
	(SE)	( 0.75)	( 0.87)	( 5.17)	( 2.53)	( 2.58)	( 1.25)
	Min,	30,	-9,	30,	-13,	30,	-13,
	Max	33	-5	51	-2	51	-2
Week 8	n	4	4	4	4	8	8
	Mean	31.0	-7.3	35.3	-6.8	33.1	-7.0
	Median	30.0	-7.0	31.0	-7.0	30.0	-7.0
	SD	2.00	3.30	9.22	4.43	6.58	3.63
	(SE)	( 1.00)	( 1.65)	( 4.61)	( 2.21)	( 2.33)	( 1.28)
	Min,	30,	-11,	30,	-11,	30,	-11,
	Max	34	-4	49	-2	49	-2
Week 10	n	4	4	4	4	8	8
	Mean	30.0	-8.3	34.8	-7.3	32.4	-7.8
	Median	30.0	-8.5	30.0	-7.0	30.0	-8.5
	SD	0.00	2.50	9.50	5.12	6.72	3.77
	(SE)	( 0.00)	( 1.25)	( 4.75)	( 2.56)	( 2.38)	( 1.33)
	Min,	30,	-11,	30,	-13,	30,	-13,
	Max	30	-5	49	-2	49	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	30.0	-8.3	34.3	-7.8	32.1	-8.0
	Median	30.0	-8.5	30.0	-8.0	30.0	-8.5
	SD	0.00	2.50	8.50	5.56	6.01	4.00
	(SE)	( 0.00)	( 1.25)	( 4.25)	( 2.78)	( 2.12)	( 1.41)
	Min,	30,	-11,	30,	-13,	30,	-13,
	Max	30	-5	47	-2	47	-2
Week 15	n	4	4	4	4	8	8
	Mean	30.0	-8.3	33.8	-8.3	31.9	-8.3
	Median	30.0	-8.5	30.0	-8.5	30.0	-8.5
	SD	0.00	2.50	7.50	6.13	5.30	4.33
	(SE)	( 0.00)	( 1.25)	( 3.75)	( 3.07)	( 1.88)	( 1.53)
	Min,	30,	-11,	30,	-14,	30,	-14,
	Max	30	-5	45	-2	45	-2
Week 18	n	4	4	4	4	8	8
	Mean	30.0	-8.3	34.8	-7.3	32.4	-7.8
	Median	30.0	-8.5	30.0	-7.0	30.0	-8.5
	SD	0.00	2.50	9.50	5.12	6.72	3.77
	(SE)	( 0.00)	( 1.25)	( 4.75)	( 2.56)	( 2.38)	( 1.33)
	Min,	30,	-11,	30,	-13,	30,	-13,
	Max	30	-5	49	-2	49	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	30.0	-8.3	34.0	-8.0	32.0	-8.1
	Median	30.0	-8.5	32.0	-6.5	30.0	-8.5
	SD	0.00	2.50	5.66	6.68	4.28	4.67
	(SE)	( 0.00)	( 1.25)	( 2.83)	( 3.34)	( 1.51)	( 1.65)
	Min,	30,	-11,	30,	-17,	30,	-17,
	Max	30	-5	42	-2	42	-2
Week 24	n	4	4	4	4	8	8
	Mean	32.8	-5.5	35.8	-6.3	34.3	-5.9
	Median	32.0	-5.0	30.0	-5.0	30.0	-5.0
	SD	3.40	4.12	11.50	4.79	8.01	4.16
	(SE)	( 1.70)	( 2.06)	( 5.75)	( 2.39)	( 2.83)	( 1.47)
	Min,	30,	-11,	30,	-13,	30,	-13,
	Max	37	-1	53	-2	53	-1
Week 25	n	4	4	4	4	8	8
	Mean	30.0	-8.3	36.5	-5.5	33.3	-6.9
	Median	30.0	-8.5	31.0	-4.5	30.0	-6.5
	SD	0.00	2.50	11.70	3.87	8.41	3.36
	(SE)	( 0.00)	( 1.25)	( 5.85)	( 1.94)	( 2.97)	( 1.19)
	Min,	30,	-11,	30,	-11,	30,	-11,
	Max	30	-5	54	-2	54	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 28	n	4	4	4	4	8	8
	Mean	39.3	1.0	42.5	0.5	40.9	0.8
	Median	39.0	1.5	38.5	1.0	38.5	1.0
	SD	10.69	8.76	15.84	10.91	12.63	9.16
	(SE)	( 5.34)	( 4.38)	( 7.92)	( 5.45)	( 4.47)	( 3.24)
	Min,	30,	-8,	30,	-13,	30,	-13,
	Max	49	9	63	13	63	13
Week 32	n	4	4	3	3	7	7
	Mean	34.8	-3.5	43.7	-1.7	38.6	-2.7
	Median	35.5	-4.0	40.0	-1.0	36.0	-3.0
	SD	6.60	5.00	12.90	1.15	10.00	3.73
	(SE)	( 3.30)	( 2.50)	( 7.45)	( 0.67)	( 3.78)	( 1.41)
	Min,	26,	-9,	33,	-3,	26,	-9,
	Max	42	3	58	-1	58	3
Week 36	n	4	4	4	4	8	8
	Mean	34.0	-4.3	40.8	-1.3	37.4	-2.8
	Median	34.5	-3.5	38.5	-2.0	35.0	-3.0
	SD	1.41	1.89	11.90	2.22	8.63	2.49
	(SE)	( 0.71)	( 0.95)	( 5.95)	( 1.11)	( 3.05)	( 0.88)
	Min,	32,	-7,	29,	-3,	29,	-7,
	Max	35	-3	57	2	57	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	34.5	-3.8	41.0	-1.0	37.8	-2.4
	Median	35.5	-4.0	39.0	-2.5	35.5	-3.5
	SD	7.05	5.56	15.58	5.23	11.72	5.21
	(SE)	( 3.52)	( 2.78)	( 7.79)	( 2.61)	( 4.14)	( 1.84)
	Min,	25,	-10,	27,	-5,	25,	-10,
	Max	42	3	59	6	59	6
Week 44	n	4	4	4	4	8	8
	Mean	35.0	-3.3	37.3	-4.8	36.1	-4.0
	Median	37.0	-2.5	36.0	-4.5	36.5	-4.0
	SD	6.98	5.38	7.93	5.06	7.02	4.90
	(SE)	( 3.49)	( 2.69)	( 3.97)	( 2.53)	( 2.48)	( 1.73)
	Min,	25,	-10,	29,	-11,	25,	-11,
	Max	41	2	48	1	48	2
Week 48	n	4	4	4	4	8	8
	Mean	34.0	-4.3	39.5	-2.5	36.8	-3.4
	Median	35.0	-4.0	38.5	-2.0	35.0	-3.5
	SD	2.83	2.22	12.45	3.00	8.86	2.62
	(SE)	( 1.41)	( 1.11)	( 6.22)	( 1.50)	( 3.13)	( 0.92)
	Min,	30,	-7,	26,	-6,	26,	-7,
	Max	36	-2	55	0	55	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	36.0	-2.3	43.3	1.3	39.6	-0.5
	Median	35.5	-4.0	39.5	1.0	35.5	-1.5
	SD	6.16	5.19	16.21	4.03	12.00	4.69
	(SE)	( 3.08)	( 2.59)	( 8.11)	( 2.02)	( 4.24)	( 1.66)
	Min,	29,	-6,	29,	-3,	29,	-6,
	Max	44	5	65	6	65	6
Week 56	n	4	4	3	3	7	7
	Mean	34.0	-4.3	40.3	-1.3	36.7	-3.0
	Median	35.0	-4.5	30.0	-4.0	34.0	-4.0
	SD	4.32	2.50	19.66	4.62	12.23	3.56
	(SE)	( 2.16)	( 1.25)	( 11.35)	( 2.67)	( 4.62)	( 1.35)
	Min,	28,	-7,	28,	-4,	28,	-7,
	Max	38	-1	63	4	63	4
Week 60	n	4	4	4	4	8	8
	Mean	31.8	-6.5	38.8	-3.3	35.3	-4.9
	Median	32.0	-6.5	35.5	-3.0	32.0	-5.5
	SD	0.50	2.89	15.33	3.30	10.71	3.36
	(SE)	( 0.25)	( 1.44)	( 7.66)	( 1.65)	( 3.79)	( 1.19)
	Min,	31,	-10,	25,	-7,	25,	-10,
	Max	32	-3	59	0	59	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	34.8	-3.5	39.8	-2.3	37.3	-2.9
	Median	33.0	-4.0	40.0	-4.0	33.0	-4.0
	SD	4.19	4.20	12.82	5.19	9.22	4.42
	(SE)	( 2.10)	( 2.10)	( 6.41)	( 2.59)	( 3.26)	( 1.56)
	Min,	32,	-8,	26,	-6,	26,	-8,
	Max	41	2	53	5	53	5
Week 68	n	4	4	4	4	8	8
	Mean	32.5	-5.8	40.3	-1.8	36.4	-3.8
	Median	32.5	-6.5	34.5	-4.0	32.5	-4.5
	SD	3.70	2.63	17.27	5.19	12.28	4.37
	(SE)	( 1.85)	( 1.31)	( 8.63)	( 2.59)	( 4.34)	( 1.54)
	Min,	28,	-8,	27,	-5,	27,	-8,
	Max	37	-2	65	6	65	6
Week 72	n	3	3	4	4	7	7
	Mean	36.7	-1.7	38.5	-3.5	37.7	-2.7
	Median	39.0	-2.0	39.0	-6.0	39.0	-5.0
	SD	6.81	4.51	13.40	6.45	10.31	5.35
	(SE)	( 3.93)	( 2.60)	( 6.70)	( 3.23)	( 3.90)	( 2.02)
	Min,	29,	-6,	25,	-8,	25,	-8,
	Max	42	3	51	6	51	6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	31.5	-5.0			31.5	-5.0
	Median	31.5	-5.0			31.5	-5.0
	SD	2.12	0.00			2.12	0.00
	(SE)	( 1.50)	( 0.00)			( 1.50)	( 0.00)
	Min,	30,	-5,			30,	-5,
	Max	33	-5			33	-5
Week 76	n	4	4	4	4	8	8
	Mean	36.3	-2.0	41.5	-0.5	38.9	-1.3
	Median	34.5	-4.5	36.5	-2.0	34.5	-3.0
	SD	6.85	6.06	17.33	5.20	12.52	5.28
	(SE)	( 3.42)	( 3.03)	( 8.67)	( 2.60)	( 4.43)	( 1.87)
	Min,	30,	-6,	27,	-5,	27,	-6,
	Max	46	7	66	7	66	7
Week 80	n	4	4	4	4	8	8
	Mean	35.5	-2.8	41.5	-0.5	38.5	-1.6
	Median	35.5	-2.5	43.0	-1.0	36.5	-2.5
	SD	3.70	3.86	11.82	5.92	8.72	4.78
	(SE)	( 1.85)	( 1.93)	( 5.91)	( 2.96)	( 3.08)	( 1.69)
	Min,	31,	-7,	27,	-6,	27,	-7,
	Max	40	1	53	6	53	6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	35.3	-3.0	39.8	-2.3	37.5	-2.6
	Median	34.5	-3.5	37.5	-3.5	36.0	-3.5
	SD	3.59	3.16	11.00	2.87	7.95	2.83
	(SE)	( 1.80)	( 1.58)	( 5.50)	( 1.44)	( 2.81)	( 1.00)
	Min,	32,	-6,	29,	-4,	29,	-6,
	Max	40	1	55	2	55	2
Week 88	n	4	4	4	4	8	8
	Mean	34.3	-4.0	42.0	0.0	38.1	-2.0
	Median	34.0	-3.5	39.0	0.5	35.5	-1.0
	SD	4.03	3.92	13.14	1.41	9.91	3.46
	(SE)	( 2.02)	( 1.96)	( 6.57)	( 0.71)	( 3.50)	( 1.22)
	Min,	30,	-9,	30,	-2,	30,	-9,
	Max	39	0	60	1	60	1
Week 92	n	4	4	4	4	8	8
	Mean	33.5	-4.8	41.8	-0.3	37.6	-2.5
	Median	34.0	-3.5	35.5	-2.0	34.0	-3.5
	SD	1.91	3.59	19.86	7.63	13.78	6.02
	(SE)	( 0.96)	( 1.80)	( 9.93)	( 3.82)	( 4.87)	( 2.13)
	Min,	31,	-10,	27,	-7,	27,	-10,
	Max	35	-2	69	10	69	10

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	31.8	-6.5	39.5	-2.5	35.6	-4.5
	Median	30.5	-7.5	40.5	-2.0	34.0	-6.0
	SD	3.77	3.32	10.91	5.26	8.62	4.60
	(SE)	( 1.89)	( 1.66)	( 5.45)	( 2.63)	( 3.05)	( 1.63)
	Min,	29,	-9,	26,	-8,	26,	-9,
	Max	37	-2	51	2	51	2
Week 100	n	4	4	4	4	8	8
	Mean	34.3	-4.0	43.5	1.5	38.9	-1.3
	Median	34.5	-4.0	43.0	-1.0	35.0	-2.0
	SD	4.57	2.31	13.40	5.69	10.51	4.98
	(SE)	( 2.29)	( 1.15)	( 6.70)	( 2.84)	( 3.72)	( 1.76)
	Min,	29,	-6,	31,	-2,	29,	-6,
	Max	39	-2	57	10	57	10
Week 104	n	4	4	4	4	8	8
	Mean	35.5	-2.8	37.8	-4.3	36.6	-3.5
	Median	37.0	-2.5	37.5	-5.0	37.0	-3.0
	SD	4.73	2.50	11.35	5.62	8.14	4.11
	(SE)	( 2.36)	( 1.25)	( 5.68)	( 2.81)	( 2.88)	( 1.45)
	Min,	29,	-6,	27,	-10,	27,	-10,
	Max	39	0	49	3	49	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	32.8	-5.5	39.8	-2.3	36.3	-3.9
	Median	32.5	-5.5	36.0	-2.0	32.5	-2.5
	SD	3.50	3.11	12.53	0.50	9.30	2.70
	(SE)	( 1.75)	( 1.55)	( 6.26)	( 0.25)	( 3.29)	( 0.95)
	Min,	29,	-9,	30,	-3,	29,	-9,
	Max	37	-2	57	-2	57	-2
Week 112	n	4	4	4	4	8	8
	Mean	34.5	-3.8	36.8	-5.3	35.6	-4.5
	Median	35.0	-3.5	36.0	-6.5	35.5	-5.0
	SD	5.97	3.50	11.18	3.77	8.38	3.46
	(SE)	( 2.99)	( 1.75)	( 5.59)	( 1.89)	( 2.96)	( 1.22)
	Min,	27,	-8,	24,	-8,	24,	-8,
	Max	41	0	51	0	51	0
Week 116	n	4	4	4	4	8	8
	Mean	37.0	-1.3	44.5	2.5	40.8	0.6
	Median	37.0	-1.5	41.5	3.0	37.0	-0.5
	SD	3.37	0.96	15.63	3.70	11.21	3.20
	(SE)	( 1.68)	( 0.48)	( 7.82)	( 1.85)	( 3.96)	( 1.13)
	Min,	33,	-2,	30,	-2,	30,	-2,
	Max	41	0	65	6	65	6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	34.7	-3.7	39.3	-2.8	37.3	-3.1
	Median	36.0	-5.0	36.5	-3.5	36.0	-4.0
	SD	4.16	2.31	13.00	1.89	9.81	1.95
	(SE)	( 2.40)	( 1.33)	( 6.50)	( 0.95)	( 3.71)	( 0.74)
	Min,	30,	-5,	28,	-4,	28,	-5,
	Max	38	-1	56	0	56	0
Week 124	n	3	3	4	4	7	7
	Mean	39.0	0.7	37.5	-4.5	38.1	-2.3
	Median	43.0	2.0	38.0	-3.0	43.0	-3.0
	SD	9.64	7.09	8.70	6.76	8.34	6.87
	(SE)	( 5.57)	( 4.10)	( 4.35)	( 3.38)	( 3.15)	( 2.60)
	Min,	28,	-7,	29,	-14,	28,	-14,
	Max	46	7	45	2	46	7
Week 128	n	4	4	4	4	8	8
	Mean	35.5	-2.8	37.0	-5.0	36.3	-3.9
	Median	34.5	-2.5	35.0	-4.5	34.5	-3.5
	SD	2.38	2.75	12.36	3.16	8.28	3.00
	(SE)	( 1.19)	( 1.38)	( 6.18)	( 1.58)	( 2.93)	( 1.06)
	Min,	34,	-6,	25,	-9,	25,	-9,
	Max	39	0	53	-2	53	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 132	n	4	4	4	4	8	8
	Mean	34.0	-4.3	41.8	-0.3	37.9	-2.3
	Median	34.0	-4.5	40.0	-2.0	37.0	-3.5
	SD	4.08	2.50	12.26	6.50	9.42	5.04
	(SE)	( 2.04)	( 1.25)	( 6.13)	( 3.25)	( 3.33)	( 1.78)
	Min,	30,	-7,	29,	-6,	29,	-7,
	Max	38	-1	58	9	58	9
Week 136	n	4	4	4	4	8	8
	Mean	35.0	-3.3	42.8	0.8	38.9	-1.3
	Median	36.5	-2.5	40.0	0.5	36.5	-2.0
	SD	4.08	1.89	13.89	3.30	10.34	3.28
	(SE)	( 2.04)	( 0.95)	( 6.94)	( 1.65)	( 3.66)	( 1.16)
	Min,	29,	-6,	31,	-3,	29,	-6,
	Max	38	-2	60	5	60	5
Week 140	n	4	4	4	4	8	8
	Mean	33.3	-5.0	36.5	-5.5	34.9	-5.3
	Median	33.0	-6.5	37.0	-3.5	33.0	-5.0
	SD	4.57	3.37	8.19	6.56	6.38	4.83
	(SE)	( 2.29)	( 1.68)	( 4.09)	( 3.28)	( 2.26)	( 1.71)
	Min,	28,	-7,	28,	-15,	28,	-15,
	Max	39	0	44	0	44	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	36.5	-1.8	41.3	-0.8	38.9	-1.3
	Median	37.5	-0.5	41.0	1.5	39.5	1.5
	SD	9.04	7.76	8.06	5.56	8.32	6.27
	(SE)	( 4.52)	( 3.88)	( 4.03)	( 2.78)	( 2.94)	( 2.22)
	Min,	26,	-12,	33,	-9,	26,	-12,
	Max	45	6	50	3	50	6
Week 148	n	4	4	4	4	8	8
	Mean	35.3	-3.0	39.0	-3.0	37.1	-3.0
	Median	33.0	-5.5	35.0	-2.5	34.0	-4.0
	SD	9.78	7.53	12.36	2.94	10.51	5.29
	(SE)	( 4.89)	( 3.76)	( 6.18)	( 1.47)	( 3.72)	( 1.87)
	Min,	26,	-9,	29,	-7,	26,	-9,
	Max	49	8	57	0	57	8
Week 152	n	4	4	3	3	7	7
	Mean	31.3	-7.0	41.3	-4.0	35.6	-5.7
	Median	32.0	-7.5	40.0	-4.0	33.0	-5.0
	SD	3.86	3.16	12.06	1.00	9.22	2.81
	(SE)	( 1.93)	( 1.58)	( 6.96)	( 0.58)	( 3.48)	( 1.06)
	Min,	26,	-10,	30,	-5,	26,	-10,
	Max	35	-3	54	-3	54	-3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	31.3	-7.0	40.5	-1.5	35.9	-4.3
	Median	31.0	-7.5	35.5	-2.0	31.5	-4.5
	SD	1.26	1.41	14.20	2.52	10.56	3.49
	(SE)	( 0.63)	( 0.71)	( 7.10)	( 1.26)	( 3.73)	( 1.24)
	Min,	30,	-8,	30,	-4,	30,	-8,
	Max	33	-5	61	2	61	2
Week 160	n	4	4	4	4	8	8
	Mean	33.3	-5.0	40.8	-1.3	37.0	-3.1
	Median	34.5	-5.0	36.5	-1.5	34.5	-3.0
	SD	2.87	1.15	12.26	0.96	9.17	2.23
	(SE)	( 1.44)	( 0.58)	( 6.13)	( 0.48)	( 3.24)	( 0.79)
	Min,	29,	-6,	32,	-2,	29,	-6,
	Max	35	-4	58	0	58	0
Week 164	n	4	4	4	4	8	8
	Mean	34.5	-3.8	38.0	-4.0	36.3	-3.9
	Median	35.0	-3.0	36.5	-2.5	35.0	-2.5
	SD	2.65	2.36	8.45	4.08	6.09	3.09
	(SE)	( 1.32)	( 1.18)	( 4.22)	( 2.04)	( 2.15)	( 1.09)
	Min,	31,	-7,	30,	-10,	30,	-10,
	Max	37	-2	49	-1	49	-1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	35.8	-2.5	39.5	-2.5	37.6	-2.5
	Median	35.5	-4.0	38.0	-1.0	36.0	-3.0
	SD	5.06	3.70	7.94	4.51	6.48	3.82
	(SE)	( 2.53)	( 1.85)	( 3.97)	( 2.25)	( 2.29)	( 1.35)
	Min,	30,	-5,	32,	-9,	30,	-9,
	Max	42	3	50	1	50	3
Week 172	n	4	4	4	4	8	8
	Mean	34.0	-4.3	38.3	-3.8	36.1	-4.0
	Median	34.5	-5.0	38.0	-3.5	37.5	-4.5
	SD	4.24	2.36	6.95	6.65	5.79	4.63
	(SE)	( 2.12)	( 1.18)	( 3.47)	( 3.33)	( 2.05)	( 1.64)
	Min,	29,	-6,	30,	-12,	29,	-12,
	Max	38	-1	47	4	47	4
Week 176	n	4	4	4	4	8	8
	Mean	36.0	-2.3	39.8	-2.3	37.9	-2.3
	Median	37.0	-2.5	36.0	-2.5	37.0	-2.5
	SD	7.44	5.85	8.22	4.99	7.53	5.04
	(SE)	( 3.72)	( 2.93)	( 4.11)	( 2.50)	( 2.66)	( 1.78)
	Min,	26,	-9,	35,	-7,	26,	-9,
	Max	44	5	52	3	52	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	37.5	-0.8	44.0	-1.3	40.3	-1.0
	Median	37.5	-1.5	42.0	-1.0	39.0	-1.0
	SD	4.65	4.35	17.09	4.51	10.97	4.04
	(SE)	( 2.33)	( 2.17)	( 9.87)	( 2.60)	( 4.14)	( 1.53)
	Min,	32,	-5,	28,	-6,	28,	-6,
	Max	43	5	62	3	62	5
Week 184	n	4	4	4	4	8	8
	Mean	36.3	-2.0	45.0	3.0	40.6	0.5
	Median	37.5	-2.0	44.5	3.5	39.5	0.0
	SD	4.50	2.58	12.41	4.97	9.83	4.54
	(SE)	( 2.25)	( 1.29)	( 6.20)	( 2.48)	( 3.47)	( 1.60)
	Min,	30,	-5,	31,	-3,	30,	-5,
	Max	40	1	60	8	60	8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Alanine Aminotransferase (U/L)							
Baseline <sup>1</sup>	n	4	4	4	4	8	8
	Mean	337.8		433.3		385.5	
	Median	337.5		454.0		365.5	
	SD	35.03		210.50		148.73	
	(SE)	( 17.51)		( 105.25)		( 52.59)	
	Min,	298,		157,		157,	
	Max	378		668		668	
Week 2	n	4	4	4	4	8	8
	Mean	387.3	49.5	430.5	-2.8	408.9	23.4
	Median	366.0	19.5	403.0	-19.0	370.0	-5.5
	SD	100.66	88.44	250.88	68.98	178.47	78.56
	(SE)	( 50.33)	( 44.22)	( 125.44)	( 34.49)	( 63.10)	( 27.77)
	Min,	289,	-16,	155,	-66,	155,	-66,
	Max	528	175	761	93	761	175
Week 4	n	4	4	4	4	8	8
	Mean	365.0	27.3	512.3	79.0	438.6	53.1
	Median	349.0	15.0	585.0	63.0	409.0	40.0
	SD	71.11	62.25	216.47	89.23	168.66	76.41
	(SE)	( 35.55)	( 31.12)	( 108.24)	( 44.62)	( 59.63)	( 27.01)
	Min,	297,	-33,	206,	-11,	206,	-33,
	Max	465	112	673	201	673	201

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	336.5	-1.3	434.8	1.5	385.6	0.1
	Median	325.0	-8.5	495.5	58.0	371.5	31.5
	SD	50.15	43.71	154.95	122.09	118.85	84.91
	(SE)	( 25.07)	( 21.86)	( 77.48)	( 61.05)	( 42.02)	( 30.02)
	Min,	290,	-41,	205,	-181,	205,	-181,
	Max	406	53	543	71	543	71
Week 8	n	4	4	4	4	8	8
	Mean	419.5	81.8	528.0	94.8	473.8	88.3
	Median	413.0	63.0	547.0	96.5	422.0	64.0
	SD	75.85	59.02	270.78	96.63	193.01	74.45
	(SE)	( 37.92)	( 29.51)	( 135.39)	( 48.31)	( 68.24)	( 26.32)
	Min,	334,	36,	203,	-14,	203,	-14,
	Max	518	165	815	200	815	200
Week 10	n	4	4	4	4	8	8
	Mean	359.5	21.8	439.5	6.3	399.5	14.0
	Median	340.0	30.0	497.5	12.5	404.5	30.0
	SD	69.56	75.39	165.91	90.58	125.30	77.59
	(SE)	( 34.78)	( 37.69)	( 82.95)	( 45.29)	( 44.30)	( 27.43)
	Min,	300,	-78,	201,	-106,	201,	-106,
	Max	458	105	562	106	562	106

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	416.8	79.0	540.3	107.0	478.5	93.0
	Median	377.5	27.5	589.5	111.0	467.0	68.5
	SD	127.77	113.09	253.52	55.50	197.23	83.82
	(SE)	( 63.88)	( 56.54)	( 126.76)	( 27.75)	( 69.73)	( 29.63)
	Min,	311,	13,	193,	36,	193,	13,
	Max	601	248	789	170	789	248
Week 15	n	4	4	4	4	8	8
	Mean	381.5	43.8	396.8	-36.5	389.1	3.6
	Median	393.0	83.0	395.0	-21.5	393.0	-2.5
	SD	82.90	101.23	194.76	50.16	138.81	85.50
	(SE)	( 41.45)	( 50.62)	( 97.38)	( 25.08)	( 49.08)	( 30.23)
	Min,	272,	-106,	162,	-108,	162,	-108,
	Max	468	115	635	5	635	115
Week 18	n	4	4	4	4	8	8
	Mean	341.0	3.3	397.0	-36.3	369.0	-16.5
	Median	319.5	9.5	405.0	-23.5	349.5	-3.5
	SD	73.38	79.83	195.17	43.79	139.75	63.24
	(SE)	( 36.69)	( 39.92)	( 97.59)	( 21.90)	( 49.41)	( 22.36)
	Min,	278,	-100,	152,	-96,	152,	-100,
	Max	447	94	626	-2	626	94

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	373.3	35.5	381.3	-52.0	377.3	-8.3
	Median	328.0	-20.0	413.5	-40.5	378.5	-40.5
	SD	160.12	149.17	179.46	37.82	157.51	111.07
	(SE)	( 80.06)	( 74.58)	( 89.73)	( 18.91)	( 55.69)	( 39.27)
	Min,	234,	-68,	134,	-104,	134,	-104,
	Max	603	250	564	-23	603	250
Week 24	n	4	4	4	4	8	8
	Mean	397.0	59.3	422.5	-10.8	409.8	24.3
	Median	351.0	29.5	470.0	-8.0	393.0	7.5
	SD	130.29	124.53	183.50	63.28	147.96	98.81
	(SE)	( 65.15)	( 62.27)	( 91.75)	( 31.64)	( 52.31)	( 34.93)
	Min,	300,	-55,	170,	-88,	170,	-88,
	Max	586	233	580	61	586	233
Week 25	n	4	4	4	4	8	8
	Mean	293.3	-44.5	389.3	-44.0	341.3	-44.3
	Median	304.0	-46.0	410.0	-44.0	326.0	-44.0
	SD	125.76	110.70	188.77	96.28	157.11	96.05
	(SE)	( 62.88)	( 55.35)	( 94.39)	( 48.14)	( 55.55)	( 33.96)
	Min,	132,	-166,	158,	-153,	132,	-166,
	Max	433	80	579	65	579	80

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	372.0	34.3	392.3	-41.0	382.1	-3.4
	Median	342.0	-8.0	426.5	-27.5	385.5	-21.5
	SD	111.95	97.98	181.64	36.12	140.10	79.32
	(SE)	( 55.98)	( 48.99)	( 90.82)	( 18.06)	( 49.53)	( 28.04)
	Min,	272,	-26,	141,	-93,	141,	-93,
	Max	532	179	575	-16	575	179
Week 32	n	4	4	3	3	7	7
	Mean	284.8	-53.0	294.0	-61.0	288.7	-56.4
	Median	231.0	-95.0	328.0	-43.0	241.0	-89.0
	SD	122.88	113.84	154.83	41.07	124.76	84.03
	(SE)	( 61.44)	( 56.92)	( 89.39)	( 23.71)	( 47.15)	( 31.76)
	Min,	209,	-137,	125,	-108,	125,	-137,
	Max	468	115	429	-32	468	115
Week 36	n	4	4	4	4	8	8
	Mean	261.3	-76.5	317.5	-115.8	289.4	-96.1
	Median	221.5	-114.5	344.0	-121.5	248.0	-114.5
	SD	109.95	98.93	161.19	102.10	131.23	95.41
	(SE)	( 54.98)	( 49.46)	( 80.60)	( 51.05)	( 46.40)	( 33.73)
	Min,	179,	-147,	114,	-207,	114,	-207,
	Max	423	70	468	-13	468	70

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	279.8	-58.0	330.5	-102.8	305.1	-80.4
	Median	243.5	-66.5	351.0	-103.0	298.0	-88.5
	SD	123.14	123.28	163.53	55.59	136.73	91.71
	(SE)	( 61.57)	( 61.64)	( 81.77)	( 27.80)	( 48.34)	( 32.42)
	Min,	182,	-196,	117,	-165,	117,	-196,
	Max	450	97	503	-40	503	97
Week 44	n	4	4	4	4	8	8
	Mean	301.8	-36.0	357.5	-75.8	329.6	-55.9
	Median	252.5	-76.5	435.0	-58.0	339.0	-67.0
	SD	126.96	118.12	179.36	88.06	146.91	98.76
	(SE)	( 63.48)	( 59.06)	( 89.68)	( 44.03)	( 51.94)	( 34.92)
	Min,	212,	-128,	90,	-198,	90,	-198,
	Max	490	137	470	11	490	137
Week 48	n	4	4	4	4	8	8
	Mean	277.8	-60.0	287.0	-146.3	282.4	-103.1
	Median	195.0	-139.5	294.0	-160.0	236.0	-144.5
	SD	191.22	180.61	131.41	81.67	151.97	137.71
	(SE)	( 95.61)	( 90.31)	( 65.71)	( 40.84)	( 53.73)	( 48.69)
	Min,	158,	-171,	122,	-230,	122,	-230,
	Max	563	210	438	-35	563	210

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: I.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	226.3	-111.5	346.0	-87.3	286.1	-99.4
	Median	212.0	-98.0	392.0	-80.5	273.0	-98.0
	SD	74.40	83.99	175.54	70.05	140.27	72.76
	(SE)	( 37.20)	( 42.00)	( 87.77)	( 35.03)	( 49.59)	( 25.73)
	Min,	152,	-226,	106,	-174,	106,	-226,
	Max	329	-24	494	-14	494	-14
Week 56	n	4	4	3	3	7	7
	Mean	273.5	-64.3	344.3	-88.0	303.9	-74.4
	Median	185.0	-144.0	403.0	-59.0	197.0	-139.0
	SD	194.97	185.04	222.87	164.43	192.34	162.15
	(SE)	( 97.48)	( 92.52)	( 128.67)	( 94.93)	( 72.70)	( 61.29)
	Min,	159,	-181,	98,	-265,	98,	-265,
	Max	565	212	532	60	565	212
Week 60	n	4	4	4	4	8	8
	Mean	305.3	-32.5	360.8	-72.5	333.0	-52.5
	Median	296.5	-13.5	411.0	-54.0	333.5	-23.5
	SD	124.00	135.29	167.45	71.78	139.60	102.52
	(SE)	( 62.00)	( 67.65)	( 83.73)	( 35.89)	( 49.36)	( 36.25)
	Min,	163,	-215,	125,	-172,	125,	-215,
	Max	465	112	496	-10	496	112

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	289.0	-48.8	415.0	-18.3	352.0	-33.5
	Median	187.5	-122.5	450.5	-21.5	294.0	-48.5
	SD	205.34	198.24	238.02	39.04	216.53	133.27
	(SE)	( 102.67)	( 99.12)	( 119.01)	( 19.52)	( 76.56)	( 47.12)
	Min,	184,	-194,	97,	-60,	97,	-194,
	Max	597	244	662	30	662	244
Week 68	n	4	4	4	4	8	8
	Mean	267.0	-70.8	356.5	-76.8	311.8	-73.8
	Median	233.0	-86.5	395.0	-59.0	297.5	-69.5
	SD	81.16	77.71	154.35	67.63	123.78	67.52
	(SE)	( 40.58)	( 38.86)	( 77.18)	( 33.82)	( 43.76)	( 23.87)
	Min,	214,	-145,	140,	-172,	140,	-172,
	Max	388	35	496	-17	496	35
Week 72	n	3	3	4	4	7	7
	Mean	221.0	-111.7	379.0	-54.3	311.3	-78.9
	Median	223.0	-95.0	433.5	-63.0	237.0	-85.0
	SD	17.09	37.86	200.23	62.81	165.16	58.24
	(SE)	( 9.87)	( 21.86)	( 100.12)	( 31.40)	( 62.42)	( 22.01)
	Min,	203,	-155,	102,	-121,	102,	-155,
	Max	237	-85	547	30	547	30

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	280.0	-85.5			280.0	-85.5
	Median	280.0	-85.5			280.0	-85.5
	SD	151.32	169.00			151.32	169.00
	(SE)	( 107.00)	( 119.50)			( 107.00)	( 119.50)
	Min, Max	173, 387	-205, 34			173, 387	-205, 34
Week 76	n	4	4	4	4	8	8
	Mean	235.8	-102.0	363.5	-69.8	299.6	-85.9
	Median	220.0	-123.5	382.0	-67.5	285.0	-95.5
	SD	72.26	57.81	205.08	39.75	157.88	49.06
	(SE)	( 36.13)	( 28.91)	( 102.54)	( 19.88)	( 55.82)	( 17.34)
	Min, Max	167, 336	-144, -17	97, 593	-120, -24	97, 593	-144, -17
Week 80	n	4	4	4	4	8	8
	Mean	252.0	-85.8	323.5	-109.8	287.8	-97.8
	Median	204.5	-119.5	363.5	-82.5	262.0	-119.0
	SD	112.66	104.69	130.81	107.88	119.31	99.25
	(SE)	( 56.33)	( 52.34)	( 65.41)	( 53.94)	( 42.18)	( 35.09)
	Min, Max	179, 420	-171, 67	141, 426	-258, -16	141, 426	-258, 67

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	257.3	-80.5	317.8	-115.5	287.5	-98.0
	Median	203.5	-122.0	362.0	-72.5	284.0	-116.5
	SD	123.15	114.31	129.42	130.67	121.34	115.18
	(SE)	( 61.58)	( 57.15)	( 64.71)	( 65.34)	( 42.90)	( 40.72)
	Min,	181,	-166,	128,	-300,	128,	-300,
	Max	441	88	419	-17	441	88
Week 88	n	4	4	4	4	8	8
	Mean	218.8	-119.0	323.0	-110.3	270.9	-114.6
	Median	185.5	-151.0	396.5	-65.0	278.5	-92.0
	SD	100.79	93.58	153.43	110.68	132.47	95.00
	(SE)	( 50.39)	( 46.79)	( 76.71)	( 55.34)	( 46.83)	( 33.59)
	Min,	138,	-187,	93,	-275,	93,	-275,
	Max	366	13	406	-36	406	13
Week 92	n	4	4	4	4	8	8
	Mean	201.5	-136.3	299.8	-133.5	250.6	-134.9
	Median	165.5	-172.5	352.5	-101.5	273.0	-150.5
	SD	131.98	116.39	142.18	91.52	137.43	96.94
	(SE)	( 65.99)	( 58.19)	( 71.09)	( 45.76)	( 48.59)	( 34.27)
	Min,	89,	-233,	90,	-264,	89,	-264,
	Max	386	33	404	-67	404	33

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	274.0	-63.8	335.8	-97.5	304.9	-80.6
	Median	193.5	-144.5	403.0	-58.5	317.0	-97.5
	SD	208.52	193.30	162.73	125.58	176.28	151.98
	(SE)	( 104.26)	( 96.65)	( 81.36)	( 62.79)	( 62.32)	( 53.73)
	Min,	132,	-190,	94,	-280,	94,	-280,
	Max	577	224	443	7	577	224
Week 100	n	4	4	4	4	8	8
	Mean	230.0	-107.8	245.8	-187.5	237.9	-147.6
	Median	157.5	-180.5	252.5	-191.0	174.0	-180.5
	SD	175.73	164.07	137.10	126.96	146.15	142.35
	(SE)	( 87.86)	( 82.04)	( 68.55)	( 63.48)	( 51.67)	( 50.33)
	Min,	115,	-207,	96,	-307,	96,	-307,
	Max	490	137	382	-61	490	137
Week 104	n	4	4	4	4	8	8
	Mean	216.8	-121.0	256.0	-177.3	236.4	-149.1
	Median	157.5	-188.0	268.0	-118.5	218.0	-180.0
	SD	158.47	143.54	122.82	176.65	132.92	152.01
	(SE)	( 79.23)	( 71.77)	( 61.41)	( 88.32)	( 46.99)	( 53.74)
	Min,	105,	-202,	97,	-427,	97,	-427,
	Max	447	94	391	-45	447	94

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	192.5	-145.3	275.5	-157.8	234.0	-151.5
	Median	133.5	-204.5	307.5	-128.5	225.0	-188.5
	SD	148.09	135.65	136.30	137.86	139.03	126.79
	(SE)	( 74.05)	( 67.83)	( 68.15)	( 68.93)	( 49.16)	( 44.83)
	Min,	93,	-229,	84,	-341,	84,	-341,
	Max	410	57	403	-33	410	57
Week 112	n	4	4	4	4	8	8
	Mean	196.8	-141.0	270.3	-163.0	233.5	-152.0
	Median	172.0	-166.0	309.0	-145.0	229.5	-166.0
	SD	96.91	81.44	126.80	105.38	111.62	87.98
	(SE)	( 48.45)	( 40.72)	( 63.40)	( 52.69)	( 39.46)	( 31.10)
	Min,	113,	-209,	97,	-302,	97,	-302,
	Max	330	-23	366	-60	366	-23
Week 116	n	4	4	4	4	8	8
	Mean	238.3	-99.5	290.8	-142.5	264.5	-121.0
	Median	157.0	-182.0	290.0	-126.0	236.0	-182.0
	SD	190.96	177.91	158.25	179.44	164.77	167.01
	(SE)	( 95.48)	( 88.95)	( 79.12)	( 89.72)	( 58.25)	( 59.05)
	Min,	119,	-201,	98,	-367,	98,	-367,
	Max	520	167	485	49	520	167

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	156.3	-176.3	232.5	-200.8	199.9	-190.3
	Median	140.0	-182.0	262.5	-178.5	226.0	-182.0
	SD	63.11	22.05	72.47	159.12	74.91	113.98
	(SE)	( 36.43)	( 12.73)	( 36.24)	( 79.56)	( 28.31)	( 43.08)
	Min,	103,	-195,	125,	-414,	103,	-414,
	Max	226	-152	280	-32	280	-32
Week 124	n	3	3	4	4	7	7
	Mean	146.0	-186.7	273.0	-160.3	218.6	-171.6
	Median	125.0	-188.0	292.5	-161.5	190.0	-188.0
	SD	38.12	13.05	151.46	66.66	128.69	49.78
	(SE)	( 22.01)	( 7.54)	( 75.73)	( 33.33)	( 48.64)	( 18.81)
	Min,	123,	-199,	71,	-232,	71,	-232,
	Max	190	-173	436	-86	436	-86
Week 128	n	4	4	4	4	8	8
	Mean	187.8	-150.0	276.8	-156.5	232.3	-153.3
	Median	165.5	-172.5	236.0	-134.5	207.5	-172.5
	SD	82.43	69.72	201.30	221.33	150.14	151.95
	(SE)	( 41.21)	( 34.86)	( 100.65)	( 110.67)	( 53.08)	( 53.72)
	Min,	117,	-205,	78,	-442,	78,	-442,
	Max	303	-50	557	85	557	85

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	185.0	-152.8	281.3	-152.0	233.1	-152.4
	Median	140.0	-202.5	291.0	-163.0	238.5	-186.5
	SD	134.64	117.43	129.90	81.55	132.85	93.60
	(SE)	( 67.32)	( 58.72)	( 64.95)	( 40.77)	( 46.97)	( 33.09)
	Min,	85,	-228,	113,	-238,	85,	-238,
	Max	375	22	430	-44	430	22
Week 136	n	4	4	4	4	8	8
	Mean	171.8	-166.0	270.3	-163.0	221.0	-164.5
	Median	138.5	-199.5	321.0	-133.0	230.0	-161.5
	SD	109.36	96.75	131.74	98.67	123.84	90.48
	(SE)	( 54.68)	( 48.38)	( 65.87)	( 49.34)	( 43.78)	( 31.99)
	Min,	82,	-240,	77,	-306,	77,	-306,
	Max	328	-25	362	-80	362	-25
Week 140	n	4	4	4	4	8	8
	Mean	161.8	-176.0	275.0	-158.3	218.4	-167.1
	Median	150.5	-190.5	311.5	-98.0	232.5	-150.5
	SD	84.34	59.01	130.00	156.37	118.14	109.82
	(SE)	( 42.17)	( 29.50)	( 65.00)	( 78.18)	( 41.77)	( 38.83)
	Min,	88,	-228,	91,	-387,	88,	-387,
	Max	258	-95	386	-50	386	-50

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	153.5	-184.3	213.0	-220.3	183.3	-202.3
	Median	149.5	-188.5	235.5	-180.5	210.0	-180.5
	SD	83.12	58.13	87.08	164.92	84.99	116.08
	(SE)	( 41.56)	( 29.07)	( 43.54)	( 82.46)	( 30.05)	( 41.04)
	Min,	73,	-249,	91,	-454,	73,	-454,
	Max	242	-111	290	-66	290	-66
Week 148	n	4	4	4	4	8	8
	Mean	181.0	-156.8	227.5	-205.8	204.3	-181.3
	Median	170.0	-168.0	259.0	-148.5	233.0	-158.0
	SD	97.67	70.87	109.62	163.07	99.28	119.31
	(SE)	( 48.83)	( 35.44)	( 54.81)	( 81.53)	( 35.10)	( 42.18)
	Min,	.97,	-225,	74,	-443,	74,	-443,
	Max	287	-66	318	-83	318	-66
Week 152	n	4	4	3	3	7	7
	Mean	170.3	-167.5	205.0	-150.0	185.1	-160.0
	Median	157.0	-181.0	223.0	-157.0	174.0	-158.0
	SD	66.57	56.20	120.02	66.78	85.80	56.15
	(SE)	( 33.28)	( 28.10)	( 69.29)	( 38.55)	( 32.43)	( 21.22)
	Min,	106,	-216,	77,	-213,	77,	-216,
	Max	261	-92	315	-80	315	-80

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: F:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	150.3	-187.5	204.5	-228.8	177.4	-208.1
	Median	125.5	-193.5	228.0	-186.5	174.0	-192.0
	SD	58.96	55.08	98.86	154.37	80.74	109.54
	(SE)	( 29.48)	( 27.54)	( 49.43)	( 77.18)	( 28.55)	( 38.73)
	Min,	112,	-248,	65,	-450,	65,	-450,
	Max	238	-115	297	-92	297	-92
Week 160	n	4	4	4	4	8	8
	Mean	178.5	-159.3	198.8	-234.5	188.6	-196.9
	Median	152.0	-198.0	226.5	-216.0	200.5	-205.5
	SD	101.32	83.12	81.56	145.37	85.83	116.77
	(SE)	( 50.66)	( 41.56)	( 40.78)	( 72.68)	( 30.35)	( 41.28)
	Min,	92,	-206,	80,	-429,	80,	-429,
	Max	318	-35	262	-77	318	-35
Week 164	n	4	4	4	4	8	8
	Mean	184.8	-153.0	215.3	-218.0	200.0	-185.5
	Median	153.0	-195.5	215.0	-137.0	164.5	-190.5
	SD	104.30	88.03	131.83	209.44	111.25	152.74
	(SE)	( 52.15)	( 44.02)	( 65.92)	( 104.72)	( 39.33)	( 54.00)
	Min,	101,	-200,	70,	-523,	70,	-523,
	Max	332	-21	361	-75	361	-21

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	192.8	-145.0	187.8	-245.5	190.3	-195.3
	Median	141.0	-197.5	185.0	-193.0	171.5	-197.5
	SD	131.76	117.71	105.99	179.48	110.73	150.43
	(SE)	( 65.88)	( 58.86)	( 53.00)	( 89.74)	( 39.15)	( 53.19)
	Min,	105,	-216,	62,	-501,	62,	-501,
	Max	384	31	319	-95	384	31
Week 172	n	4	4	4	4	8	8
	Mean	154.0	-183.8	187.0	-246.3	170.5	-215.0
	Median	128.0	-213.5	197.0	-207.0	171.5	-213.5
	SD	89.21	71.64	84.70	173.34	82.44	127.25
	(SE)	( 44.60)	( 35.82)	( 42.35)	( 86.67)	( 29.15)	( 44.99)
	Min,	84,	-231,	76,	-490,	76,	-490,
	Max	276	-77	278	-81	278	-77
Week 176	n	4	4	4	4	8	8
	Mean	188.3	-149.5	154.3	-279.0	171.3	-214.3
	Median	145.0	-198.5	160.0	-246.0	160.0	-220.5
	SD	136.62	118.45	69.14	186.83	101.87	160.51
	(SE)	( 68.31)	( 59.22)	( 34.57)	( 93.41)	( 36.02)	( 56.75)
	Min,	84,	-227,	69,	-536,	69,	-536,
	Max	379	26	228	-88	379	26

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	4	4	3	3	7	7
	Mean	162.5	-175.3	173.3	-181.7	167.1	-178.0
	Median	128.0	-208.0	227.0	-209.0	152.0	-209.0
	SD	90.79	78.39	95.56	77.69	84.85	71.39
	(SE)	( 45.40)	( 39.19)	( 55.17)	( 44.86)	( 32.07)	( 26.98)
	Min,	100,	-226,	63,	-242,	63,	-242,
	Max	294	-59	230	-94	294	-59
Week 184	n	4	4	4	4	8	8
	Mean	149.8	-188.0	143.3	-290.0	146.5	-239.0
	Median	123.5	-214.5	133.5	-247.5	133.5	-214.5
	SD	97.45	77.96	79.65	206.29	82.47	154.32
	(SE)	( 48.72)	( 38.98)	( 39.83)	( 103.15)	( 29.16)	( 54.56)
	Min,	73,	-249,	64,	-572,	64,	-572,
	Max	279	-74	242	-93	279	-74

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Aspartate Aminotransferase (U/L)							
Baseline <sup>1</sup>	n	4	4	4	4	8	8
	Mean	195.5		234.3		214.9	
	Median	204.5		237.0		216.0	
	SD	28.80		86.34		63.08	
	(SE)	( 14.40)		( 43.17)		( 22.30)	
	Min,	155,		126,		126,	
	Max	218		337		337	
Week 2	n	4	4	4	4	8	8
	Mean	194.0	-1.5	201.8	-32.5	197.9	-17.0
	Median	193.5	-1.5	186.5	-30.5	188.0	-30.5
	SD	57.10	63.52	97.78	25.41	74.24	47.76
	(SE)	( 28.55)	( 31.76)	( 48.89)	( 12.70)	( 26.25)	( 16.88)
	Min,	129,	-66,	101,	-65,	101,	-66,
	Max	260	63	333	-4	333	63
Week 4	n	4	4	4	4	8	8
	Mean	215.3	19.8	295.8	61.5	255.5	40.6
	Median	201.5	17.0	310.5	65.0	245.5	45.0
	SD	51.09	42.86	68.43	33.31	70.55	41.96
	(SE)	( 25.55)	( 21.43)	( 34.21)	( 16.66)	( 24.94)	( 14.84)
	Min,	170,	-25,	205,	20,	170,	-25,
	Max	288	70	357	96	357	96

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	179.8	-15.8	246.5	12.3	213.1	-1.8
	Median	170.0	-16.5	266.5	31.5	207.0	5.5
	SD	35.45	25.76	72.49	65.46	63.75	48.42
	(SE)	( 17.73)	( 12.88)	( 36.25)	( 32.73)	( 22.54)	( 17.12)
	Min,	152,	-43,	143,	-81,	143,	-81,
	Max	227	13	310	67	310	67
Week 8	n	4	4	4	4	8	8
	Mean	289.3	93.8	369.0	134.8	329.1	114.3
	Median	281.5	84.5	282.0	64.5	282.0	76.5
	SD	50.27	29.75	238.79	167.16	165.34	113.29
	(SE)	( 25.13)	( 14.87)	( 119.40)	( 83.58)	( 58.46)	( 40.05)
	Min,	239,	69,	191,	26,	191,	26,
	Max	355	137	721	384	721	384
Week 10	n	4	4	4	4	8	8
	Mean	207.8	12.3	227.5	-6.8	217.6	2.8
	Median	197.5	-18.5	216.0	-30.5	197.5	-18.5
	SD	42.51	67.30	100.10	95.43	71.97	77.12
	(SE)	( 21.25)	( 33.65)	( 50.05)	( 47.71)	( 25.45)	( 27.26)
	Min,	168,	-27,	121,	-92,	121,	-92,
	Max	268	113	357	126	357	126

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	278.8	83.3	346.5	112.3	312.6	97.8
	Median	258.5	52.0	367.5	130.5	305.5	81.0
	SD	65.70	92.77	155.10	72.71	116.07	78.70
	(SE)	( 32.85)	( 46.38)	( 77.55)	( 36.35)	( 41.04)	( 27.83)
	Min,	224,	10,	139,	13,	139,	10,
	Max	374	219	512	175	512	219
Week 15	n	4	4	4	4	8	8
	Mean	231.3	35.8	230.8	-3.5	231.0	16.1
	Median	229.5	45.0	222.0	-11.5	222.0	11.5
	SD	103.55	87.00	61.91	35.12	78.98	64.91
	(SE)	( 51.77)	( 43.50)	( 30.95)	( 17.56)	( 27.92)	( 22.95)
	Min,	119,	-76,	169,	-34,	119,	-76,
	Max	347	129	310	43	347	129
Week 18	n	4	4	4	4	8	8
	Mean	187.3	-8.3	231.5	-2.8	209.4	-5.5
	Median	192.0	-16.0	223.5	8.0	192.0	-13.5
	SD	24.92	35.98	124.33	67.94	86.32	50.42
	(SE)	( 12.46)	( 17.99)	( 62.17)	( 33.97)	( 30.52)	( 17.83)
	Min,	153,	-42,	105,	-90,	105,	-90,
	Max	212	41	374	63	374	63

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	174.0	-21.5	183.3	-51.0	178.6	-36.3
	Median	180.0	-18.5	179.0	-44.0	180.0	-25.0
	SD	33.80	49.90	79.04	45.45	56.50	46.92
	(SE)	( 16.90)	( 24.95)	( 39.52)	( 22.73)	( 19.97)	( 16.59)
	Min,	129,	-85,	102,	-109,	102,	-109,
	Max	207	36	273	-7	273	36
Week 24	n	4	4	4	4	8	8
	Mean	271.8	76.3	326.8	92.5	299.3	84.4
	Median	250.5	34.5	345.5	61.5	283.5	59.0
	SD	100.53	122.65	123.34	71.90	108.24	93.48
	(SE)	( 50.26)	( 61.32)	( 61.67)	( 35.95)	( 38.27)	( 33.05)
	Min,	179,	-16,	174,	48,	174,	-16,
	Max	407	252	442	199	442	252
Week 25	n	4	4	4	4	8	8
	Mean	158.8	-36.8	278.3	44.0	218.5	3.6
	Median	156.5	-59.5	236.5	-20.0	172.0	-38.0
	SD	48.22	68.72	179.71	166.30	137.54	125.46
	(SE)	( 24.11)	( 34.36)	( 89.85)	( 83.15)	( 48.63)	( 44.36)
	Min,	105,	-90,	119,	-74,	105,	-90,
	Max	217	62	521	290	521	290

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	203.0	7.5	231.0	-3.3	217.0	2.1
	Median	213.5	14.5	259.0	-4.0	224.5	-1.5
	SD	34.57	54.08	80.78	53.18	59.44	49.98
	(SE)	( 17.29)	( 27.04)	( 40.39)	( 26.59)	( 21.02)	( 17.67)
	Min,	153,	-61,	113,	-67,	113,	-67,
	Max	232	62	293	62	293	62
Week 32	n	4	4	3	3	7	7
	Mean	213.5	18.0	199.7	-0.3	207.6	10.1
	Median	211.0	6.5	206.0	-8.0	206.0	-8.0
	SD	73.65	100.49	78.69	29.26	69.51	73.69
	(SE)	( 36.83)	( 50.24)	( 45.43)	( 16.90)	( 26.27)	( 27.85)
	Min,	141,	-77,	118,	-25,	118,	-77,
	Max	291	136	275	32	291	136
Week 36	n	4	4	4	4	8	8
	Mean	144.3	-51.3	212.3	-22.0	178.3	-36.6
	Median	132.0	-74.5	224.5	-19.0	161.0	-32.5
	SD	29.40	57.11	76.45	16.71	64.78	41.98
	(SE)	( 14.70)	( 28.56)	( 38.22)	( 8.36)	( 22.90)	( 14.84)
	Min,	125,	-89,	108,	-45,	108,	-89,
	Max	188	33	292	-5	292	33

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	183.5	-12.0	265.0	30.8	224.3	9.4
	Median	156.5	-50.0	288.0	31.0	195.5	-29.0
	SD	79.17	104.70	157.71	83.31	123.47	90.53
	(SE)	( 39.59)	( 52.35)	( 78.85)	( 41.66)	( 43.65)	( 32.01)
	Min,	124,	-90,	67,	-59,	67,	-90,
	Max	297	142	417	120	417	142
Week 44	n	4	4	4	4	8	8
	Mean	184.0	-11.5	175.5	-58.8	179.8	-35.1
	Median	159.0	-47.5	191.5	-45.5	180.5	-45.5
	SD	66.07	92.06	61.40	31.70	59.22	68.56
	(SE)	( 33.03)	( 46.03)	( 30.70)	( 15.85)	( 20.94)	( 24.24)
	Min,	138,	-76,	88,	-106,	88,	-106,
	Max	280	125	231	-38	280	125
Week 48	n	4	4	4	4	8	8
	Mean	155.3	-40.3	191.5	-42.8	173.4	-41.5
	Median	102.0	-104.5	209.0	-28.0	156.5	-63.5
	SD	118.12	145.71	59.11	58.83	88.61	102.88
	(SE)	( 59.06)	( 72.86)	( 29.55)	( 29.41)	( 31.33)	( 36.37)
	Min,	85,	-129,	106,	-126,	85,	-129,
	Max	332	177	242	11	332	177

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	151.3	-44.3	215.5	-18.8	183.4	-31.5
	Median	163.5	-36.0	237.0	-12.5	180.0	-20.5
	SD	46.39	49.45	76.55	53.11	67.92	49.42
	(SE)	( 23.20)	( 24.72)	( 38.27)	( 26.55)	( 24.01)	( 17.47)
	Min,	85,	-110,	106,	-89,	85,	-110,
	Max	193	5	282	39	282	39
Week 56	n	4	4	3	3	7	7
	Mean	141.3	-54.3	233.7	-1.7	180.9	-31.7
	Median	131.5	-75.0	235.0	-47.0	149.0	-47.0
	SD	45.44	73.86	154.00	129.11	106.67	95.26
	(SE)	( 22.72)	( 36.93)	( 88.91)	( 74.54)	( 40.32)	( 36.00)
	Min,	100,	-114,	79,	-102,	79,	-114,
	Max	202	47	387	144	387	144
Week 60	n	4	4	4	4	8	8
	Mean	233.8	38.3	250.3	16.0	242.0	27.1
	Median	265.0	63.5	273.0	-1.0	265.0	33.5
	SD	80.11	81.63	85.56	48.69	77.24	63.35
	(SE)	( 40.05)	( 40.82)	( 42.78)	( 24.34)	( 27.31)	( 22.40)
	Min,	115,	-80,	138,	-20,	115,	-80,
	Max	290	106	317	86	317	106

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	171.5	-24.0	311.5	77.3	241.5	26.6
	Median	116.0	-88.5	272.5	35.5	192.5	-7.0
	SD	116.40	143.86	219.84	137.99	179.22	141.27
	(SE)	( 58.20)	( 71.93)	( 109.92)	( 68.99)	( 63.36)	( 49.95)
	Min,	108,	-110,	87,	-39,	87,	-110,
	Max	346	191	614	277	614	277
Week 68	n	4	4	4	4	8	8
	Mean	153.5	-42.0	237.3	3.0	195.4	-19.5
	Median	158.5	-50.0	221.5	-6.5	175.5	-17.0
	SD	29.78	42.41	111.78	33.32	87.97	42.72
	(SE)	( 14.89)	( 21.21)	( 55.89)	( 16.66)	( 31.10)	( 15.10)
	Min,	114,	-81,	118,	-26,	114,	-81,
	Max	183	13	388	51	388	51
Week 72	n	3	3	4	4	7	7
	Mean	175.0	-34.0	279.0	44.8	234.4	11.0
	Median	173.0	-41.0	254.0	17.0	186.0	-9.0
	SD	10.15	22.34	169.43	86.82	132.21	75.54
	(SE)	( 5.86)	( 12.90)	( 84.72)	( 43.41)	( 49.97)	( 28.55)
	Min,	166,	-52,	100,	-26,	100,	-52,
	Max	186	-9	508	171	508	171

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	122.0	-53.0			122.0	-53.0
	Median	122.0	-53.0			122.0	-53.0
	SD	65.05	93.34			65.05	93.34
	(SE)	( 46.00)	( 66.00)			( 46.00)	( 66.00)
	Min,	76,	-119,			76,	-119,
	Max	168	13			168	13
Week 76	n	4	4	4	4	8	8
	Mean	128.0	-67.5	244.8	10.5	186.4	-28.5
	Median	125.5	-66.0	245.0	10.5	140.5	-42.5
	SD	20.22	38.31	140.09	67.03	111.71	65.52
	(SE)	( 10.11)	( 19.16)	( 70.04)	( 33.52)	( 39.50)	( 23.17)
	Min,	106,	-108,	81,	-50,	81,	-108,
	Max	155	-30	408	71	408	71
Week 80	n	4	4	4	4	8	8
	Mean	138.5	-57.0	214.8	-19.5	176.6	-38.3
	Median	139.5	-67.0	249.5	-4.5	156.5	-39.5
	SD	26.71	53.35	77.36	50.45	67.32	52.08
	(SE)	( 13.36)	( 26.67)	( 38.68)	( 25.23)	( 23.80)	( 18.41)
	Min,	105,	-109,	99,	-88,	99,	-109,
	Max	170	15	261	19	261	19

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	142.5	-53.0	245.0	10.8	193.8	-21.1
	Median	138.5	-68.0	263.0	5.0	171.0	-4.5
	SD	36.95	64.86	92.55	22.23	85.19	56.35
	(SE)	( 18.48)	( 32.43)	( 46.27)	( 11.12)	( 30.12)	( 19.92)
	Min,	104,	-110,	117,	-9,	104,	-110,
	Max	189	34	337	42	337	42
Week 88	n	4	4	4	4	8	8
	Mean	121.8	-73.8	224.3	-10.0	173.0	-41.9
	Median	131.5	-73.0	265.5	-7.5	158.5	-56.5
	SD	52.70	78.25	109.18	80.34	96.44	80.94
	(SE)	( 26.35)	( 39.12)	( 54.59)	( 40.17)	( 34.10)	( 28.62)
	Min,	50,	-168,	65,	-95,	50,	-168,
	Max	174	19	301	70	301	70
Week 92	n	4	4	4	4	8	8
	Mean	115.3	-80.3	184.3	-50.0	149.8	-65.1
	Median	96.5	-108.0	201.5	-64.5	139.0	-71.5
	SD	59.71	88.42	95.75	35.81	82.57	64.51
	(SE)	( 29.86)	( 44.21)	( 47.87)	( 17.90)	( 29.19)	( 22.81)
	Min,	67,	-151,	57,	-74,	57,	-151,
	Max	201	46	277	3	277	46

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	186.0	-9.5	301.5	67.3	243.8	28.9
	Median	131.5	-75.0	310.0	73.0	207.0	-10.0
	SD	129.25	157.36	176.73	95.61	156.07	127.33
	(SE)	( 64.62)	( 78.68)	( 88.37)	( 47.81)	( 55.18)	( 45.02)
	Min,	103,	-111,	81,	-45,	81,	-111,
	Max	378	223	505	168	505	223
Week 100	n	4	4	4	4	8	8
	Mean	139.0	-56.5	166.8	-67.5	152.9	-62.0
	Median	110.5	-94.0	171.5	-69.5	114.5	-80.0
	SD	86.84	115.42	88.93	61.34	82.72	85.77
	(SE)	( 43.42)	( 57.71)	( 44.47)	( 30.67)	( 29.24)	( 30.32)
	Min,	70,	-148,	76,	-138,	70,	-148,
	Max	265	110	248	7	265	110
Week 104	n	4	4	4	4	8	8
	Mean	141.8	-53.8	174.0	-60.3	157.9	-57.0
	Median	118.5	-88.0	149.5	-71.5	144.0	-75.0
	SD	85.32	113.86	97.14	109.80	86.38	103.61
	(SE)	( 42.66)	( 56.93)	( 48.57)	( 54.90)	( 30.54)	( 36.63)
	Min,	70,	-144,	85,	-179,	70,	-179,
	Max	260	105	312	81	312	105

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	98.8	-96.8	210.0	-24.3	154.4	-60.5
	Median	75.5	-129.0	223.0	-34.0	127.0	-90.5
	SD	51.01	79.12	112.91	99.07	100.57	91.60
	(SE)	( 25.50)	( 39.56)	( 56.45)	( 49.54)	( 35.56)	( 32.39)
	Min,	69,	-149,	61,	-131,	61,	-149,
	Max	175	20	333	102	333	102
Week 112	n	4	4	4	4	8	8
	Mean	127.0	-68.5	210.0	-24.3	168.5	-46.4
	Median	129.0	-75.5	176.0	-37.0	144.5	-56.5
	SD	22.11	46.84	134.19	62.59	99.47	56.38
	(SE)	( 11.05)	( 23.42)	( 67.09)	( 31.30)	( 35.17)	( 19.93)
	Min,	100,	-118,	88,	-86,	88,	-118,
	Max	150	-5	400	63	400	63
Week 116	n	4	4	4	4	8	8
	Mean	155.5	-40.0	228.8	-5.5	192.1	-22.8
	Median	113.0	-91.5	196.5	-54.0	151.0	-68.0
	SD	114.09	142.78	139.67	135.14	124.39	130.02
	(SE)	( 57.05)	( 71.39)	( 69.83)	( 67.57)	( 43.98)	( 45.97)
	Min,	75,	-143,	100,	-105,	75,	-143,
	Max	321	166	422	191	422	191

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	98.3	-110.7	153.8	-80.5	130.0	-93.4
	Median	82.0	-136.0	152.0	-85.0	140.0	-103.0
	SD	44.79	56.44	26.08	63.98	43.43	58.04
	(SE)	( 25.86)	( 32.58)	( 13.04)	( 31.99)	( 16.42)	( 21.94)
	Min,	64,	-150,	126,	-152,	64,	-152,
	Max	149	-46	185	0	185	0
Week 124	n	3	3	4	4	7	7
	Mean	99.7	-109.3	190.0	-44.3	151.3	-72.1
	Median	93.0	-121.0	184.5	-36.0	116.0	-79.0
	SD	14.22	26.50	126.08	60.48	101.72	57.21
	(SE)	( 8.21)	( 15.30)	( 63.04)	( 30.24)	( 38.45)	( 21.62)
	Min,	90,	-128,	52,	-115,	52,	-128,
	Max	116	-79	339	10	339	10
Week 128	n	4	4	4	4	8	8
	Mean	104.3	-91.3	236.8	2.5	170.5	-44.4
	Median	91.0	-114.5	155.0	-50.0	102.0	-85.0
	SD	35.01	63.69	241.56	243.70	174.78	172.34
	(SE)	( 17.50)	( 31.85)	( 120.78)	( 121.85)	( 61.79)	( 60.93)
	Min,	80,	-136,	51,	-233,	51,	-233,
	Max	155	0	586	343	586	343

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	123.0	-72.5	198.3	-36.0	160.6	-54.3
	Median	96.5	-108.0	156.0	-33.5	133.5	-58.5
	SD	85.78	114.53	116.24	59.23	102.77	86.64
	(SE)	( 42.89)	( 57.26)	( 58.12)	( 29.62)	( 36.34)	( 30.63)
	Min,	58,	-160,	113,	-108,	58,	-160,
	Max	241	86	368	31	368	86
Week 136	n	4	4	4	4	8	8
	Mean	98.5	-97.0	217.3	-17.0	157.9	-57.0
	Median	94.0	-110.5	231.5	-51.5	134.0	-60.0
	SD	43.40	71.41	111.92	79.68	101.02	82.07
	(SE)	( 21.70)	( 35.70)	( 55.96)	( 39.84)	( 35.71)	( 29.01)
	Min,	56,	-162,	73,	-67,	56,	-162,
	Max	150	-5	333	102	333	102
Week 140	n	4	4	4	4	8	8
	Mean	97.5	-98.0	221.8	-12.5	159.6	-55.3
	Median	94.5	-98.5	226.5	-50.0	118.5	-60.5
	SD	27.33	48.42	123.55	99.92	106.17	85.86
	(SE)	( 13.67)	( 24.21)	( 61.77)	( 49.96)	( 37.54)	( 30.36)
	Min,	69,	-145,	68,	-85,	68,	-145,
	Max	132	-50	366	135	366	135

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	108.0	-87.5	168.5	-65.8	138.3	-76.6
	Median	102.0	-87.0	178.0	-40.0	148.5	-40.0
	SD	49.11	70.52	42.00	68.56	53.25	65.43
	(SE)	( 24.55)	( 35.26)	( 21.00)	( 34.28)	( 18.83)	( 23.13)
	Min,	62,	-152,	110,	-167,	62,	-167,
	Max	166	-24	208	-16	208	-16
Week 148	n	4	4	4	4	8	8
	Mean	123.0	-72.5	172.5	-61.8	147.8	-67.1
	Median	111.5	-75.0	191.0	-66.5	151.5	-66.5
	SD	57.50	73.45	79.96	59.87	69.69	62.30
	(SE)	( 28.75)	( 36.73)	( 39.98)	( 29.93)	( 24.64)	( 22.03)
	Min,	68,	-146,	61,	-130,	61,	-146,
	Max	201	6	247	16	247	16
Week 152	n	4	4	3	3	7	7
	Mean	101.5	-94.0	122.0	-78.0	110.3	-87.1
	Median	108.0	-96.5	140.0	-81.0	122.0	-81.0
	SD	27.34	53.07	40.15	26.63	32.11	41.45
	(SE)	( 13.67)	( 26.54)	( 23.18)	( 15.37)	( 12.14)	( 15.67)
	Min,	66,	-152,	76,	-103,	66,	-152,
	Max	124	-31	150	-50	150	-31

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	91.8	-103.8	150.0	-84.3	120.9	-94.0
	Median	96.0	-107.5	160.0	-86.0	99.0	-96.0
	SD	12.82	35.77	75.51	24.92	59.02	30.38
	(SE)	( 6.41)	( 17.89)	( 37.76)	( 12.46)	( 20.87)	( 10.74)
	Min,	73,	-141,	53,	-110,	53,	-141,
	Max	102	-59	227	-55	227	-55
Week 160	n	4	4	4	4	8	8
	Mean	118.5	-77.0	144.0	-90.3	131.3	-83.6
	Median	116.5	-90.0	148.5	-88.5	142.0	-88.5
	SD	45.02	72.09	70.53	16.86	56.45	48.98
	(SE)	( 22.51)	( 36.04)	( 35.26)	( 8.43)	( 19.96)	( 17.32)
	Min,	74,	-140,	54,	-112,	54,	-140,
	Max	167	12	225	-72	225	12
Week 164	n	4	4	4	4	8	8
	Mean	123.8	-71.8	152.3	-82.0	138.0	-76.9
	Median	103.0	-103.5	152.0	-66.5	123.0	-71.5
	SD	67.01	95.58	81.03	95.21	70.50	88.49
	(SE)	( 33.50)	( 47.79)	( 40.52)	( 47.60)	( 24.93)	( 31.28)
	Min,	70,	-144,	57,	-212,	57,	-212,
	Max	219	64	248	17	248	64

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	108.0	-87.5	124.8	-109.5	116.4	-98.5
	Median	96.0	-108.5	138.0	-87.5	129.0	-87.5
	SD	47.70	76.22	57.99	61.54	49.97	65.20
	(SE)	( 23.85)	( 38.11)	( 29.00)	( 30.77)	( 17.67)	( 23.05)
	Min,	70,	-148,	43,	-200,	43,	-200,
	Max	170	15	180	-63	180	15
Week 172	n	4	4	4	4	8	8
	Mean	91.8	-103.8	146.5	-87.8	119.1	-95.8
	Median	85.0	-121.5	132.0	-66.5	115.5	-96.5
	SD	30.25	58.74	59.56	86.81	52.62	69.15
	(SE)	( 15.12)	( 29.37)	( 29.78)	( 43.41)	( 18.60)	( 24.45)
	Min,	66,	-148,	91,	-206,	66,	-206,
	Max	131	-24	231	-12	231	-12
Week 176	n	4	4	4	4	8	8
	Mean	116.0	-79.5	113.5	-120.8	114.8	-100.1
	Median	98.5	-108.0	123.5	-97.0	116.5	-97.0
	SD	61.13	89.79	35.09	74.36	46.16	79.44
	(SE)	( 30.56)	( 44.90)	( 17.54)	( 37.18)	( 16.32)	( 28.09)
	Min,	68,	-146,	66,	-229,	66,	-229,
	Max	199	44	141	-60	199	44

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	104.5	-91.0	144.7	-55.3	121.7	-75.7
	Median	86.0	-120.5	158.0	-78.0	89.0	-85.0
	SD	39.79	67.25	90.74	45.46	63.22	57.56
	(SE)	( 19.89)	( 33.62)	( 52.39)	( 26.24)	( 23.90)	( 21.76)
	Min,	82,	-132,	48,	-85,	48,	-132,
	Max	164	9	228	-3	228	9
Week 184	n	4	4	4	4	8	8
	Mean	106.0	-89.5	107.0	-127.3	106.5	-108.4
	Median	102.5	-88.0	101.5	-97.5	101.5	-97.5
	SD	54.63	77.29	49.48	88.27	48.26	79.42
	(SE)	( 27.32)	( 38.65)	( 24.74)	( 44.14)	( 17.06)	( 28.08)
	Min,	53,	-165,	55,	-253,	53,	-253,
	Max	166	-17	170	-61	170	-17

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Gamma Glutamyl Transferase (U/L)							
Baseline <sup>1</sup>	n	4	4	4	4	8	8
	Mean	13.8		10.3		12.0	
	Median	14.0		11.5		12.5	
	SD	1.50		3.59		3.16	
	(SE)	( 0.75)		( 1.80)		( 1.12)	
	Min,	12,		5,		5,	
	Max	15		13		15	
Week 2	n	4	4	4	4	8	8
	Mean	16.3	2.5	10.0	-0.3	13.1	1.1
	Median	16.0	2.5	11.5	-0.5	12.5	0.5
	SD	2.87	2.38	3.37	0.96	4.42	2.23
	(SE)	( 1.44)	( 1.19)	( 1.68)	( 0.48)	( 1.56)	( 0.79)
	Min,	13,	0,	5,	-1,	5,	-1,
	Max	20	5	12	1	20	5
Week 4	n	4	4	4	4	8	8
	Mean	15.0	1.3	10.0	-0.3	12.5	0.5
	Median	15.0	2.0	11.0	0.0	13.0	0.0
	SD	1.63	2.22	3.46	0.50	3.66	1.69
	(SE)	( 0.82)	( 1.11)	( 1.73)	( 0.25)	( 1.30)	( 0.60)
	Min,	13,	-2,	5,	-1,	5,	-2,
	Max	17	3	13	0	17	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	14.3	0.5	9.8	-0.5	12.0	0.0
	Median	14.0	0.5	11.0	-0.5	12.5	0.0
	SD	1.50	2.08	3.20	0.58	3.34	1.51
	(SE)	( 0.75)	( 1.04)	( 1.60)	( 0.29)	( 1.18)	( 0.53)
	Min,	13,	-2,	5,	-1,	5,	-2,
	Max	16	3	12	0	16	3
Week 8	n	4	4	4	4	8	8
	Mean	15.0	1.3	9.3	-1.0	12.1	0.1
	Median	15.0	1.0	10.5	-1.0	12.0	-0.5
	SD	1.83	2.06	2.87	0.82	3.80	1.89
	(SE)	( 0.91)	( 1.03)	( 1.44)	( 0.41)	( 1.34)	( 0.67)
	Min,	13,	-1,	5,	-2,	5,	-2,
	Max	17	4	11	0	17	4
Week 10	n	4	4	4	4	8	8
	Mean	14.0	0.3	8.3	-2.0	11.1	-0.9
	Median	14.0	0.5	8.0	-0.5	11.5	-0.5
	SD	2.45	3.50	3.77	3.37	4.26	3.40
	(SE)	( 1.22)	( 1.75)	( 1.89)	( 1.68)	( 1.51)	( 1.20)
	Min,	11,	-4,	5,	-7,	5,	-7,
	Max	17	4	12	0	17	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	14.3	0.5	9.8	-0.5	12.0	0.0
	Median	13.5	1.0	11.0	-0.5	12.5	0.0
	SD	1.89	1.91	3.20	0.58	3.42	1.41
	(SE)	( 0.95)	( 0.96)	( 1.60)	( 0.29)	( 1.21)	( 0.50)
	Min,	13,	-2,	5,	-1,	5,	-2,
	Max	17	2	12	0	17	2
Week 15	n	4	4	4	4	8	8
	Mean	12.5	-1.3	9.0	-1.3	10.8	-1.3
	Median	12.5	-1.0	8.0	0.0	11.0	0.0
	SD	2.38	2.22	4.90	3.95	4.03	2.96
	(SE)	( 1.19)	( 1.11)	( 2.45)	( 1.97)	( 1.42)	( 1.42)
	Min,	10,	-4,	5,	-7,	5,	-7,
	Max	15	1	15	2	15	2
Week 18	n	4	4	4	4	8	8
	Mean	13.3	-0.5	10.0	-0.3	11.6	-0.4
	Median	13.5	0.0	11.0	0.0	12.0	0.0
	SD	1.71	2.65	3.46	0.50	3.07	1.77
	(SE)	( 0.85)	( 1.32)	( 1.73)	( 0.25)	( 1.08)	( 0.63)
	Min,	11,	-4,	5,	-1,	5,	-4,
	Max	15	2	13	0	15	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	13.3	-0.5	10.0	-0.3	11.6	-0.4
	Median	13.0	-0.5	11.0	0.0	12.5	0.0
	SD	1.26	2.38	3.46	0.50	2.97	1.60
	(SE)	( 0.63)	( 1.19)	( 1.73)	( 0.25)	( 1.05)	( 0.56)
	Min,	12,	-3,	5,	-1,	5,	-3,
	Max	15	2	13	0	15	2
Week 24	n	4	4	4	4	8	8
	Mean	15.3	1.5	9.8	-0.5	12.5	0.5
	Median	15.5	1.0	11.0	-0.5	12.0	0.0
	SD	2.75	2.65	3.30	0.58	4.07	2.07
	(SE)	( 1.38)	( 1.32)	( 1.65)	( 0.29)	( 1.44)	( 0.73)
	Min,	12,	-1,	5,	-1,	5,	-1,
	Max	18	5	12	0	18	5
Week 25	n	4	4	4	4	8	8
	Mean	15.3	1.5	10.5	0.3	12.9	0.9
	Median	14.5	2.0	11.5	-0.5	13.0	1.0
	SD	3.40	3.32	3.87	1.89	4.22	2.59
	(SE)	( 1.70)	( 1.66)	( 1.94)	( 0.95)	( 1.49)	( 0.91)
	Min,	12,	-3,	5,	-1,	5,	-3,
	Max	20	5	14	3	20	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 28	n	4	4	4	4	8	8
	Mean	14.8	1.0	8.5	-1.8	11.6	-0.4
	Median	14.0	1.0	8.0	-0.5	13.0	0.0
	SD	2.22	1.63	4.12	2.87	4.53	2.62
	(SE)	( 1.11)	( 0.82)	( 2.06)	( 1.44)	( 1.60)	( 0.92)
	Min,	13,	-1,	5,	-6,	5,	-6,
	Max	18	3	13	0	18	3
Week 32	n	4	4	3	3	7	7
	Mean	13.0	-0.8	9.0	-1.0	11.3	-0.9
	Median	13.0	-1.0	10.0	-2.0	12.0	-2.0
	SD	0.82	1.50	2.65	1.73	2.69	1.46
	(SE)	( 0.41)	( 0.75)	( 1.53)	( 1.00)	( 1.02)	( 0.55)
	Min,	12,	-2,	6,	-2,	6,	-2,
	Max	14	1	11	1	14	1
Week 36	n	4	4	4	4	8	8
	Mean	13.0	-0.8	8.0	-2.3	10.5	-1.5
	Median	12.5	-1.5	8.0	-2.5	10.5	-1.5
	SD	2.16	2.63	1.83	2.75	3.25	2.62
	(SE)	( 1.08)	( 1.31)	( 0.91)	( 1.38)	( 1.15)	( 0.93)
	Min,	11,	-3,	6,	-5,	6,	-5,
	Max	16	3	10	1	16	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	12.8	-1.0	8.0	-2.3	10.4	-1.6
	Median	12.0	-1.5	8.0	-1.5	11.0	-1.5
	SD	2.36	2.94	2.94	2.63	3.54	2.67
	(SE)	( 1.18)	( 1.47)	( 1.47)	( 1.31)	( 1.25)	( 0.94)
	Min,	11,	-4,	5,	-6,	5,	-6,
	Max	16	3	11	0	16	3
Week 44	n	4	4	4	4	8	8
	Mean	12.5	-1.3	9.0	-1.3	10.8	-1.3
	Median	12.5	-1.0	9.0	-0.5	11.0	-1.0
	SD	1.73	2.06	3.37	1.89	3.11	1.83
	(SE)	( 0.87)	( 1.03)	( 1.68)	( 0.95)	( 1.10)	( 0.65)
	Min,	11,	-4,	5,	-4,	5,	-4,
	Max	14	1	13	0	14	1
Week 48	n	4	4	4	4	8	8
	Mean	12.8	-1.0	9.0	-1.3	10.9	-1.1
	Median	12.5	-1.0	9.5	-1.0	11.0	-1.0
	SD	2.06	2.45	2.94	1.26	3.09	1.81
	(SE)	( 1.03)	( 1.22)	( 1.47)	( 0.63)	( 1.09)	( 0.64)
	Min,	11,	-4,	5,	-3,	5,	-4,
	Max	15	2	12	0	15	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	11.8	-2.0	8.5	-1.8	10.1	-1.9
	Median	12.0	-2.5	8.5	-1.5	11.0	-2.0
	SD	1.26	1.41	2.89	1.71	2.70	1.46
	(SE)	( 0.63)	( 0.71)	( 1.44)	( 0.85)	( 0.95)	( 0.52)
	Min,	10,	-3,	5,	-4,	5,	-4,
	Max	13	0	12	0	13	0
Week 56	n	4	4	3	3	7	7
	Mean	12.5	-1.3	7.3	-2.0	10.3	-1.6
	Median	13.0	-1.5	7.0	-4.0	10.0	-2.0
	SD	1.73	1.71	0.58	3.46	3.04	2.37
	(SE)	( 0.87)	( 0.85)	( 0.33)	( 2.00)	( 1.15)	( 0.90)
	Min,	10,	-3,	7,	-4,	7,	-4,
	Max	14	1	8	2	14	2
Week 60	n	4	4	4	4	8	8
	Mean	14.3	0.5	7.8	-2.5	11.0	-1.0
	Median	14.0	1.0	8.0	-3.5	10.0	-2.0
	SD	3.30	3.70	1.26	2.38	4.17	3.30
	(SE)	( 1.65)	( 1.85)	( 0.63)	( 1.19)	( 1.48)	( 1.16)
	Min,	11,	-4,	6,	-4,	6,	-4,
	Max	18	4	9	1	18	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	14.3	0.5	8.5	-1.8	11.4	-0.6
	Median	14.0	0.5	8.0	-1.5	13.0	0.0
	SD	1.50	2.08	3.32	2.06	3.89	2.26
	(SE)	( 0.75)	( 1.04)	( 1.66)	( 1.03)	( 1.38)	( 0.80)
	Min,	13,	-2,	5,	-4,	5,	-4,
	Max	16	3	13	0	16	3
Week 68	n	4	4	4	4	8	8
	Mean	12.8	-1.0	8.3	-2.0	10.5	-1.5
	Median	13.0	0.0	8.0	-1.5	11.0	-0.5
	SD	2.06	2.71	2.99	2.16	3.38	2.33
	(SE)	( 1.03)	( 1.35)	( 1.49)	( 1.08)	( 1.20)	( 0.82)
	Min,	10,	-5,	5,	-5,	5,	-5,
	Max	15	1	12	0	15	1
Week 72	n	3	3	4	4	7	7
	Mean	14.7	1.3	9.3	-1.0	11.6	0.0
	Median	15.0	3.0	9.0	-1.0	11.0	0.0
	SD	3.51	2.89	2.87	1.83	4.08	2.45
	(SE)	( 2.03)	( 1.67)	( 1.44)	( 0.91)	( 1.54)	( 0.93)
	Min,	11,	-2,	6,	-3,	6,	-3,
	Max	18	3	13	1	18	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	11.0	-3.0			11.0	-3.0
	Median	11.0	-3.0			11.0	-3.0
	SD	0.00	1.41			0.00	1.41
	(SE)	( 0.00)	( 1.00)			( 0.00)	( 1.00)
	Min,	11,	-4,			11,	-4,
	Max	11	-2			11	-2
Week 76	n	4	4	4	4	8	8
	Mean	14.0	0.3	8.3	-2.0	11.1	-0.9
	Median	14.0	0.5	8.0	-3.0	10.5	-2.0
	SD	2.94	3.50	1.26	2.71	3.72	3.14
	(SE)	( 1.47)	( 1.75)	( 0.63)	( 1.35)	( 1.32)	( 1.11)
	Min,	11,	-4,	7,	-4,	7,	-4,
	Max	17	4	10	2	17	4
Week 80	n	4	4	4	4	8	8
	Mean	13.8	0.0	9.3	-1.0	11.5	-0.5
	Median	13.5	0.0	8.5	-1.5	11.5	-1.5
	SD	2.75	2.94	1.89	2.94	3.25	2.78
	(SE)	( 1.38)	( 1.47)	( 0.95)	( 1.47)	( 1.15)	( 0.98)
	Min,	11,	-3,	8,	-4,	8,	-4,
	Max	17	3	12	3	17	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	12.0	-1.8	9.0	-1.3	10.5	-1.5
	Median	12.0	-2.0	9.5	-1.5	11.0	-2.0
	SD	1.15	0.50	2.16	1.71	2.27	1.20
	(SE)	( 0.58)	( 0.25)	( 1.08)	( 0.85)	( 0.80)	( 0.42)
	Min,	11,	-2,	6,	-3,	6,	-3,
	Max	13	-1	11	1	13	1
Week 88	n	4	4	4	4	8	8
	Mean	17.0	3.3	11.0	0.8	14.0	2.0
	Median	13.5	1.0	11.0	-1.0	12.0	-1.0
	SD	8.83	8.34	1.15	4.19	6.65	6.26
	(SE)	( 4.42)	( 4.17)	( 0.58)	( 2.10)	( 2.35)	( 2.21)
	Min,	11,	-4,	10,	-2,	10,	-4,
	Max	30	15	12	7	30	15
Week 92	n	4	4	4	4	8	8
	Mean	13.0	-0.8	9.3	-1.0	11.1	-0.9
	Median	12.0	-1.0	9.5	-2.0	11.0	-2.0
	SD	2.71	2.22	1.71	2.00	2.90	1.96
	(SE)	( 1.35)	( 1.11)	( 0.85)	( 1.00)	( 1.03)	( 0.69)
	Min,	11,	-3,	7,	-2,	7,	-3,
	Max	17	2	11	2	17	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	17.0	3.3	8.8	-1.5	12.9	0.9
	Median	16.5	3.5	10.0	-1.5	11.5	-0.5
	SD	4.69	4.99	2.50	1.29	5.62	4.22
	(SE)	( 2.35)	( 2.50)	( 1.25)	( 0.65)	( 1.99)	( 1.49)
	Min,	13,	-2,	5,	-3,	5,	-3,
	Max	22	8	10	0	22	8
Week 100	n	4	4	4	4	8	8
	Mean	15.5	1.8	9.8	-0.5	12.6	0.6
	Median	16.0	2.5	10.0	-1.0	11.5	1.0
	SD	2.65	1.89	1.26	2.65	3.62	2.45
	(SE)	( 1.32)	( 0.95)	( 0.63)	( 1.32)	( 1.28)	( 0.86)
	Min,	12,	-1,	8,	-3,	8,	-3,
	Max	18	3	11	3	18	3
Week 104	n	4	4	4	4	8	8
	Mean	13.0	-0.8	8.8	-1.5	10.9	-1.1
	Median	12.5	0.0	8.5	-2.5	10.5	-1.5
	SD	2.16	2.36	0.96	3.11	2.75	2.59
	(SE)	( 1.08)	( 1.18)	( 0.48)	( 1.55)	( 0.97)	( 0.91)
	Min,	11,	-4,	8,	-4,	8,	-4,
	Max	16	1	10	3	16	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	13.8	0.0	8.3	-2.0	11.0	-1.0
	Median	14.5	0.5	8.5	-2.0	11.0	-1.5
	SD	1.89	3.16	2.50	1.63	3.59	2.56
	(SE)	( 0.95)	( 1.58)	( 1.25)	( 0.82)	( 1.27)	( 0.91)
	Min,	11,	-4,	5,	-4,	5,	-4,
	Max	15	3	11	0	15	3
Week 112	n	4	4	4	4	8	8
	Mean	11.8	-2.0	9.3	-1.0	10.5	-1.5
	Median	11.5	-2.5	9.0	-2.0	10.5	-2.0
	SD	1.71	2.16	1.26	2.71	1.93	2.33
	(SE)	( 0.85)	( 1.08)	( 0.63)	( 1.35)	( 0.68)	( 0.82)
	Min,	10,	-4,	8,	-3,	8,	-4,
	Max	14	1	11	3	14	3
Week 116	n	4	4	4	4	8	8
	Mean	13.0	-0.8	9.0	-1.3	11.0	-1.0
	Median	13.0	-0.5	9.0	-1.5	10.5	-1.5
	SD	2.45	3.50	1.83	2.50	2.93	2.83
	(SE)	( 1.22)	( 1.75)	( 0.91)	( 1.25)	( 1.04)	( 1.00)
	Min,	10,	-5,	7,	-4,	7,	-5,
	Max	16	3	11	2	16	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	16.0	2.7	9.0	-1.3	12.0	0.4
	Median	14.0	2.0	9.0	-1.5	11.0	0.0
	SD	4.36	3.06	1.83	2.50	4.69	3.26
	(SE)	( 2.52)	( 1.76)	( 0.91)	( 1.25)	( 1.77)	( 1.23)
	Min,	13,	0,	7,	-4,	7,	-4,
	Max	21	6	11	2	21	6
Week 124	n	3	3	4	4	7	7
	Mean	15.7	2.3	11.8	1.5	13.4	1.9
	Median	16.0	2.0	12.0	0.0	14.0	1.0
	SD	1.53	1.53	2.22	5.20	2.76	3.80
	(SE)	( 0.88)	( 0.88)	( 1.11)	( 2.60)	( 1.04)	( 1.44)
	Min,	14,	1,	9,	-3,	9,	-3,
	Max	17	4	14	9	17	9
Week 128	n	4	4	4	4	8	8
	Mean	15.0	1.3	11.3	1.0	13.1	1.1
	Median	15.5	1.5	11.0	0.5	12.5	1.0
	SD	2.94	4.11	1.50	2.94	2.95	3.31
	(SE)	( 1.47)	( 2.06)	( 0.75)	( 1.47)	( 1.04)	( 1.17)
	Min,	11,	-4,	10,	-2,	10,	-4,
	Max	18	6	13	5	18	6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 132	n	4	4	4	4	8	8
	Mean	12.5	-1.3	10.8	0.5	11.6	-0.4
	Median	12.0	-1.5	11.0	0.0	11.5	0.0
	SD	1.73	2.75	2.06	1.73	2.00	2.33
	(SE)	( 0.87)	( 1.38)	( 1.03)	( 0.87)	( 0.71)	( 0.82)
	Min,	11,	-4,	8,	-1,	8,	-4,
	Max	15	2	13	3	15	3
Week 136	n	4	4	4	4	8	8
	Mean	13.3	-0.5	9.0	-1.3	11.1	-0.9
	Median	13.0	-1.0	8.5	-1.5	11.0	-1.5
	SD	2.87	4.20	2.16	3.30	3.27	3.52
	(SE)	( 1.44)	( 2.10)	( 1.08)	( 1.65)	( 1.16)	( 1.16)
	Min,	10,	-5,	7,	-5,	7,	-5,
	Max	17	5	12	3	17	5
Week 140	n	4	4	4	4	8	8
	Mean	12.8	-1.0	8.0	-2.3	10.4	-1.6
	Median	13.5	-0.5	7.5	-3.0	9.5	-2.0
	SD	2.87	3.74	1.41	2.99	3.29	3.20
	(SE)	( 1.44)	( 1.87)	( 0.71)	( 1.49)	( 1.16)	( 1.13)
	Min,	9,	-6,	7,	-5,	7,	-6,
	Max	15	3	10	2	15	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	13.5	-0.3	8.8	-1.5	11.1	-0.9
	Median	14.5	0.5	8.0	-1.5	11.5	-0.5
	SD	2.38	3.59	2.99	2.38	3.56	2.90
	(SE)	( 1.19)	( 1.80)	( 1.49)	( 1.19)	( 1.26)	( 1.03)
	Min,	10,	-5,	6,	-4,	6,	-5,
	Max	15	3	13	1	15	3
Week 148	n	4	4	4	4	8	8
	Mean	13.8	0.0	9.8	-0.5	11.8	-0.3
	Median	14.0	0.0	8.5	-0.5	12.0	0.0
	SD	2.87	4.16	2.87	3.11	3.41	3.41
	(SE)	( 1.44)	( 2.08)	( 1.44)	( 1.55)	( 1.21)	( 1.21)
	Min,	10,	-5,	8,	-4,	8,	-5,
	Max	17	5	14	3	17	5
Week 152	n	4	4	3	3	7	7
	Mean	12.5	-1.3	9.7	-0.3	11.3	-0.9
	Median	12.5	-1.5	9.0	-2.0	12.0	-2.0
	SD	0.58	2.06	1.15	3.79	1.70	2.67
	(SE)	( 0.29)	( 1.03)	( 0.67)	( 2.19)	( 0.64)	( 1.01)
	Min,	12,	-3,	9,	-3,	9,	-3,
	Max	13	1	11	4	13	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	12.5	-1.3	9.5	-0.8	11.0	-1.0
	Median	12.5	-0.5	9.5	-1.0	11.0	-1.0
	SD	2.08	2.63	2.08	2.06	2.51	2.20
	(SE)	( 1.04)	( 1.31)	( 1.04)	( 1.03)	( 0.89)	( 0.78)
	Min,	10,	-5,	7,	-3,	7,	-5,
	Max	15	1	12	2	15	2
Week 160	n	4	4	4	4	8	8
	Mean	13.3	-0.5	9.0	-1.3	11.1	-0.9
	Median	14.0	1.5	9.0	-2.0	10.0	-0.5
	SD	3.77	4.36	1.63	2.22	3.52	3.23
	(SE)	( 1.89)	( 2.18)	( 0.82)	( 1.11)	( 1.25)	( 1.14)
	Min,	8,	-7,	7,	-3,	7,	-7,
	Max	17	2	11	2	17	2
Week 164	n	4	4	4	4	8	8
	Mean	13.0	-0.8	11.3	1.0	12.1	0.1
	Median	13.5	-0.5	9.5	1.5	12.0	0.0
	SD	1.41	2.75	3.86	3.56	2.85	3.09
	(SE)	( 0.71)	( 1.38)	( 1.93)	( 1.78)	( 1.01)	( 1.09)
	Min,	11,	-4,	9,	-3,	9,	-4,
	Max	14	2	17	4	17	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	14.0	0.3	9.5	-0.8	11.8	-0.3
	Median	14.0	0.5	9.5	-2.0	11.5	-1.0
	SD	0.82	1.71	0.58	3.20	2.49	2.43
	(SE)	( 0.41)	( 0.85)	( 0.29)	( 1.60)	( 0.88)	( 0.86)
	Min,	13,	-2,	9,	-3,	9,	-3,
	Max	15	2	10	4	15	4
Week 172	n	4	4	4	4	8	8
	Mean	12.5	-1.3	10.3	0.0	11.4	-0.6
	Median	12.5	-1.0	10.0	0.0	11.5	0.0
	SD	1.29	2.22	2.22	3.27	2.07	2.67
	(SE)	( 0.65)	( 1.11)	( 1.11)	( 1.63)	( 0.73)	( 0.94)
	Min,	11,	-4,	8,	-4,	8,	-4,
	Max	14	1	13	4	14	4
Week 176	n	4	4	4	4	8	8
	Mean	12.3	-1.5	10.3	0.0	11.3	-0.8
	Median	12.5	-1.5	10.5	-0.5	11.5	-1.0
	SD	0.96	2.08	1.71	3.74	1.67	2.92
	(SE)	( 0.48)	( 1.04)	( 0.85)	( 1.87)	( 0.59)	( 1.03)
	Min,	11,	-4,	8,	-4,	8,	-4,
	Max	13	1	12	5	13	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	13.5	-0.3	9.7	-0.3	11.9	-0.3
	Median	13.5	0.0	9.0	-1.0	12.0	0.0
	SD	1.29	1.26	2.08	3.06	2.54	1.98
	(SE)	( 0.65)	( 0.63)	( 1.20)	( 1.76)	( 0.96)	( 0.75)
	Min,	12,	-2,	8,	-3,	8,	-3,
	Max	15	1	12	3	15	3
Week 184	n	4	4	4	4	8	8
	Mean	13.0	-0.8	10.3	0.0	11.6	-0.4
	Median	13.0	-1.0	10.0	-0.5	11.0	-1.0
	SD	2.58	1.26	2.06	3.74	2.62	2.62
	(SE)	( 1.29)	( 0.63)	( 1.03)	( 1.87)	( 0.92)	( 0.92)
	Min,	10,	-2,	8,	-4,	8,	-4,
	Max	16	1	13	5	16	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Lactate Dehydrogenase (U/L)						
Baseline <sup>1</sup>	n	4	4	4	4	8
	Mean	1836.8		2786.8		2311.8
	Median	1962.0		1958.0		1962.0
	SD	271.70		1815.57		1304.68
	(SE)	( 135.85)		( 907.78)		( 461.27)
	Min,	1431,		1729,		1431,
	Max	1992		5502		5502
Week 2	n	4	4	4	4	8
	Mean	1843.8	7.0	2644.5	-142.3	2244.1
	Median	1999.5	15.5	1760.0	-138.0	1852.0
	SD	496.06	280.39	2024.04	252.47	1429.83
	(SE)	( 248.03)	( 140.20)	( 1012.02)	( 126.23)	( 505.52)
	Min,	1160,	-271,	1394,	-455,	1160,
	Max	2216	268	5664	162	5664
Week 4	n	4	4	4	4	8
	Mean	2037.8	201.0	3194.5	407.8	2616.1
	Median	2082.0	118.0	2429.5	367.5	2249.5
	SD	478.65	271.06	1759.19	174.16	1344.18
	(SE)	( 239.32)	( 135.53)	( 879.59)	( 87.08)	( 475.24)
	Min,	1412,	-19,	2097,	248,	1412,
	Max	2575	587	5822	648	5822

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	3	3	7	7
	Mean	1697.3	-139.5	2888.0	-251.3	2207.6	-187.4
	Median	1742.0	-165.5	2485.0	221.0	2009.0	-135.0
	SD	298.44	113.47	1077.58	993.61	914.72	582.32
	(SE)	( 149.22)	( 56.73)	( 622.14)	( 573.66)	( 345.73)	( 220.10)
	Min,	1296,	-244,	2070,	-1393,	1296,	-1393,
	Max	2009	17	4109	418	4109	418
Week 8	n	4	4	2	2	6	6
	Mean	2251.3	414.5	2367.0	409.0	2289.8	412.7
	Median	2305.0	390.5	2367.0	409.0	2341.0	409.0
	SD	364.84	164.84	161.22	7.07	297.72	127.75
	(SE)	( 182.42)	( 82.42)	( 114.00)	( 5.00)	( 121.54)	( 52.15)
	Min,	1775,	245,	2253,	404,	1775,	245,
	Max	2620	632	2481	414	2620	632
Week 10	n	4	4	4	4	8	8
	Mean	1721.8	-115.0	2364.3	-422.5	2043.0	-268.8
	Median	1783.0	-207.0	1785.5	-203.5	1783.0	-207.0
	SD	408.18	223.28	1242.12	588.61	922.27	443.69
	(SE)	( 204.09)	( 111.64)	( 621.06)	( 294.30)	( 326.07)	( 156.87)
	Min,	1169,	-262,	1662,	-1278,	1169,	-1278,
	Max	2152	216	4224	-5	4224	216

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	2089.5	252.8	3151.5	364.8	2620.5	308.8
	Median	2135.5	145.5	2318.5	360.5	2218.0	259.0
	SD	597.80	409.38	2133.60	364.88	1557.68	363.96
	(SE)	( 298.90)	( 204.69)	( 1066.80)	( 182.44)	( 550.72)	( 128.68)
	Min,	1316,	-115,	1653,	-76,	1316,	-115,
	Max	2771	835	6316	814	6316	835
Week 15	n	4	4	4	4	8	8
	Mean	1828.0	-8.8	2531.5	-255.3	2179.8	-132.0
	Median	1947.0	-17.0	1923.5	-312.5	1923.5	-209.5
	SD	699.18	471.64	1635.30	342.07	1223.52	403.54
	(SE)	( 349.59)	( 235.82)	( 817.65)	( 171.04)	( 432.58)	( 142.67)
	Min,	934,	-497,	1331,	-554,	934,	-554,
	Max	2484	496	4948	158	4948	496
Week 18	n	4	4	4	4	8	8
	Mean	1590.8	-246.0	2399.8	-387.0	1995.3	-316.5
	Median	1733.0	-229.0	1711.5	-441.0	1733.0	-275.5
	SD	360.13	96.69	1576.53	376.77	1143.58	265.56
	(SE)	( 180.07)	( 48.34)	( 788.26)	( 188.38)	( 404.32)	( 93.89)
	Min,	1056,	-375,	1437,	-763,	1056,	-763,
	Max	1841	-151	4739	97	4739	97

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2	2	4	4	6	6
	Mean	1503.0	-180.5	2122.5	-664.3	1916.0	-503.0
	Median	1503.0	-180.5	1441.0	-517.0	1441.0	-362.0
	SD	575.58	218.50	1387.19	445.28	1150.30	436.94
	(SE)	( 407.00)	( 154.50)	( 693.60)	( 222.64)	( 469.61)	( 178.38)
	Min,	1096,	-335,	1405,	-1299,	1096,	-1299,
	Max	1910	-26	4203	-324	4203	-26
Week 24	n	4	4	4	4	8	8
	Mean	1949.0	112.3	2817.0	30.3	2383.0	71.3
	Median	2026.5	36.5	2271.5	95.0	2051.0	95.0
	SD	503.68	315.98	1410.62	498.46	1084.80	388.84
	(SE)	( 251.84)	( 157.99)	( 705.31)	( 249.23)	( 383.53)	( 137.47)
	Min,	1288,	-143,	1860,	-637,	1288,	-637,
	Max	2455	519	4865	568	4865	568
Week 25	n	4	4	3	3	7	7
	Mean	1402.5	-434.3	1783.7	-98.0	1565.9	-290.1
	Median	1440.5	-507.5	1498.0	-231.0	1498.0	-470.0
	SD	398.21	236.59	593.52	658.65	488.08	452.66
	(SE)	( 199.10)	( 118.29)	( 342.67)	( 380.27)	( 184.48)	( 171.09)
	Min,	886,	-629,	1387,	-680,	886,	-680,
	Max	1843	-93	2466	617	2466	617

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	1771.8	-65.0	2403.3	-383.5	2087.5	-224.3
	Median	1756.0	-98.0	2049.5	-169.5	1848.0	-98.0
	SD	118.56	221.74	1226.97	674.67	874.73	495.11
	(SE)	( 59.28)	( 110.87)	( 613.48)	( 337.33)	( 309.27)	( 175.05)
	Min,	1653,	-286,	1349,	-1337,	1349,	-1337,
	Max	1922	222	4165	142	4165	222
Week 32	n	4	4	3	3	7	7
	Mean	678.0	-1158.8	663.7	-1218.0	671.9	-1184.1
	Median	660.0	-1220.0	607.0	-1225.0	640.0	-1225.0
	SD	95.19	270.69	157.82	92.70	113.54	201.26
	(SE)	( 47.60)	( 135.34)	( 91.12)	( 53.52)	( 42.92)	( 76.07)
	Min,	584,	-1404,	542,	-1307,	542,	-1404,
	Max	808	-791	842	-1122	842	-791
Week 36	n	4	4	4	4	8	8
	Mean	528.3	-1308.5	917.3	-1869.5	722.8	-1589.0
	Median	483.5	-1355.5	630.0	-1329.5	586.5	-1329.5
	SD	135.96	242.39	605.84	1210.12	456.58	861.80
	(SE)	( 67.98)	( 121.20)	( 302.92)	( 605.06)	( 161.42)	( 304.69)
	Min,	419,	-1511,	585,	-3678,	419,	-3678,
	Max	727	-1012	1824	-1141	1824	-1012

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	633.3	-1203.5	983.5	-1803.3	808.4	-1503.4
	Median	605.0	-1177.0	731.5	-1247.5	612.5	-1246.0
	SD	205.02	216.66	663.21	1172.14	491.50	843.63
	(SE)	( 102.51)	( 108.33)	( 331.61)	( 586.07)	( 173.77)	( 298.27)
	Min,	422,	-1451,	527,	-3558,	422,	-3558,
	Max	901	-1009	1944	-1160	1944	-1009
Week 44	n	4	4	4	4	8	8
	Mean	661.3	-1175.5	885.5	-1901.3	773.4	-1538.4
	Median	618.0	-1165.0	609.0	-1359.0	609.0	-1295.0
	SD	228.44	229.59	564.40	1253.81	416.24	920.23
	(SE)	( 114.22)	( 114.80)	( 282.20)	( 626.91)	( 147.16)	( 325.35)
	Min,	434,	-1411,	592,	-3770,	434,	-3770,
	Max	975	-961	1732	-1117	1732	-961
Week 48	n	4	4	4	4	8	8
	Mean	554.0	-1282.8	921.8	-1865.0	737.9	-1573.9
	Median	442.0	-1284.5	656.0	-1302.0	629.0	-1302.0
	SD	250.71	306.46	566.02	1250.84	450.42	898.70
	(SE)	( 125.35)	( 153.23)	( 283.01)	( 625.42)	( 159.25)	( 317.74)
	Min,	403,	-1555,	605,	-3732,	403,	-3732,
	Max	929	-1007	1770	-1124	1770	-1007

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	556.5	-1280.3	961.0	-1825.8	758.8	-1553.0
	Median	598.0	-1332.5	703.0	-1275.0	610.5	-1289.5
	SD	116.98	164.50	619.13	1202.23	465.72	846.20
	(SE)	( 58.49)	( 82.25)	( 309.56)	( 601.12)	( 164.66)	( 299.18)
	Min,	386,	-1411,	562,	-3626,	386,	-3626,
	Max	644	-1045	1876	-1127	1876	-1045
Week 56	n	4	4	3	3	7	7
	Mean	553.0	-1283.8	1083.0	-2016.3	780.1	-1597.7
	Median	493.5	-1322.5	964.0	-1220.0	517.0	-1220.0
	SD	175.58	317.05	641.83	1481.77	482.69	967.20
	(SE)	( 87.79)	( 158.53)	( 370.56)	( 855.50)	( 182.44)	( 365.57)
	Min,	416,	-1576,	509,	-3726,	416,	-3726,
	Max	809	-914	1776	-1103	1776	-914
Week 60	n	4	4	4	4	8	8
	Mean	739.0	-1097.8	1018.5	-1768.3	878.8	-1433.0
	Median	826.0	-1102.0	763.5	-1215.0	806.5	-1156.0
	SD	221.66	77.00	639.24	1179.42	467.44	852.73
	(SE)	( 110.83)	( 38.50)	( 319.62)	( 589.71)	( 165.27)	( 301.49)
	Min,	410,	-1166,	579,	-3534,	410,	-3534,
	Max	894	-1021	1968	-1109	1968	-1021

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	593.5	-1243.3	986.3	-1800.5	789.9	-1521.9
	Median	502.5	-1252.0	739.0	-1253.5	587.5	-1253.5
	SD	255.31	283.49	691.22	1134.71	526.09	821.57
	(SE)	( 127.65)	( 141.75)	( 345.61)	( 567.36)	( 186.00)	( 290.47)
	Min,	400,	-1502,	467,	-3502,	400,	-3502,
	Max	969	-967	2000	-1193	2000	-967
Week 68	n	4	4	4	4	8	8
	Mean	585.8	-1251.0	986.8	-1800.0	786.3	-1525.5
	Median	619.5	-1307.5	696.5	-1267.5	626.5	-1302.5
	SD	114.87	163.42	640.82	1176.09	477.06	830.88
	(SE)	( 57.43)	( 81.71)	( 320.41)	( 588.05)	( 168.67)	( 293.76)
	Min,	420,	-1378,	612,	-3560,	420,	-3560,
	Max	684	-1011	1942	-1105	1942	-1011
Week 72	n	3	3	4	4	7	7
	Mean	670.3	-1133.3	1016.5	-1770.3	868.1	-1497.3
	Median	614.0	-1374.0	796.5	-1257.5	785.0	-1259.0
	SD	99.31	422.05	673.23	1158.10	513.95	919.72
	(SE)	( 57.34)	( 243.67)	( 336.62)	( 579.05)	( 194.26)	( 347.62)
	Min,	612,	-1380,	473,	-3502,	473,	-3502,
	Max	785	-646	2000	-1064	2000	-646

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	528.5	-1155.0			528.5	-1155.0
	Median	528.5	-1155.0			528.5	-1155.0
	SD	258.09	98.99			258.09	98.99
	(SE)	( 182.50)	( 70.00)			( 182.50)	( 70.00)
	Min,	346,	-1225,			346,	-1225,
	Max	711	-1085			711	-1085
Week 76	n	4	4	4	4	8	8
	Mean	509.5	-1327.3	962.3	-1824.5	735.9	-1575.9
	Median	515.0	-1397.0	689.5	-1338.5	565.0	-1397.0
	SD	67.16	226.24	700.31	1124.98	520.27	796.85
	(SE)	( 33.58)	( 113.12)	( 350.15)	( 562.49)	( 183.94)	( 281.73)
	Min,	432,	-1516,	470,	-3502,	432,	-3502,
	Max	576	-999	2000	-1119	2000	-999
Week 80	n	4	4	4	4	8	8
	Mean	571.0	-1265.8	968.0	-1818.8	769.5	-1542.3
	Median	549.5	-1338.5	744.0	-1214.0	651.0	-1250.0
	SD	82.90	271.74	531.26	1286.33	411.01	910.03
	(SE)	( 41.45)	( 135.87)	( 265.63)	( 643.17)	( 145.32)	( 321.74)
	Min,	496,	-1496,	628,	-3746,	496,	-3746,
	Max	689	-890	1756	-1101	1756	-890

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	574.8	-1262.0	936.8	-1850.0	755.8	-1556.0
	Median	549.5	-1337.5	701.5	-1256.5	629.0	-1268.0
	SD	85.17	274.97	526.34	1290.42	399.10	919.15
	(SE)	( 42.59)	( 137.49)	( 263.17)	( 645.21)	( 141.10)	( 324.97)
	Min,	502,	-1490,	624,	-3782,	502,	-3782,
	Max	698	-883	1720	-1105	1720	-883
Week 88	n	4	4	4	4	8	8
	Mean	485.0	-1351.8	965.3	-1821.5	725.1	-1586.6
	Median	487.5	-1384.5	747.5	-1331.0	579.5	-1331.0
	SD	141.52	307.40	659.55	1176.27	510.79	834.58
	(SE)	( 70.76)	( 153.70)	( 329.77)	( 588.14)	( 180.59)	( 295.07)
	Min,	310,	-1678,	438,	-3574,	310,	-3574,
	Max	655.	-960	1928	-1050	1928	-960
Week 92	n	4	4	4	4	8	8
	Mean	491.3	-1345.5	936.0	-1850.8	713.6	-1598.1
	Median	439.0	-1374.0	664.0	-1350.5	554.5	-1350.5
	SD	190.80	330.18	695.63	1126.89	528.68	814.80
	(SE)	( 95.40)	( 165.09)	( 347.82)	( 563.44)	( 186.92)	( 288.07)
	Min,	323,	-1665,	448,	-3534,	323,	-3534,
	Max	764	-969	1968	-1168	1968	-969

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	630.8	-1206.0	976.8	-1810.0	803.8	-1508.0
	Median	509.0	-1207.0	774.0	-1278.0	654.5	-1278.0
	SD	275.47	365.52	637.80	1194.03	490.98	878.93
	(SE)	( 137.73)	( 182.76)	( 318.90)	( 597.02)	( 173.59)	( 310.75)
	Min,	465,	-1527,	453,	-3596,	453,	-3596,
	Max	1040	-883	1906	-1088	1906	-883
Week 100	n	4	4	4	4	8	8
	Mean	526.8	-1310.0	850.5	-1936.3	688.6	-1623.1
	Median	459.5	-1313.5	579.5	-1442.0	478.0	-1382.5
	SD	199.62	300.31	645.00	1191.56	474.68	871.32
	(SE)	( 99.81)	( 150.15)	( 322.50)	( 595.78)	( 167.82)	( 308.06)
	Min,	370,	-1618,	439,	-3698,	370,	-3698,
	Max	818	-995	1804	-1163	1804	-995
Week 104	n	4	4	4	4	8	8
	Mean	533.3	-1303.5	837.3	-1949.5	685.3	-1626.5
	Median	422.0	-1305.5	751.0	-1348.5	549.5	-1348.5
	SD	260.12	353.25	383.06	1481.87	343.93	1055.38
	(SE)	( 130.06)	( 176.63)	( 191.53)	( 740.94)	( 121.60)	( 373.13)
	Min,	369,	-1623,	495,	-4150,	369,	-4150,
	Max	920	-980	1352	-951	1352	-951

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	451.8	-1385.0	887.8	-1899.0	669.8	-1642.0
	Median	360.5	-1411.5	732.0	-1373.5	524.5	-1373.5
	SD	191.66	286.08	560.13	1287.09	452.24	905.83
	(SE)	( 95.83)	( 143.04)	( 280.07)	( 643.55)	( 159.89)	( 320.26)
	Min,	347,	-1633,	399,	-3814,	347,	-3814,
	Max	739	-1084	1688	-1035	1688	-1035
Week 112	n	4	4	4	4	8	8
	Mean	493.8	-1343.0	887.8	-1899.0	690.8	-1621.0
	Median	484.0	-1391.5	631.5	-1345.5	572.5	-1391.5
	SD	93.65	228.65	617.67	1200.93	460.02	853.72
	(SE)	( 46.82)	( 114.32)	( 308.83)	( 600.47)	( 162.64)	( 301.83)
	Min,	408,	-1566,	480,	-3694,	408,	-3694,
	Max	599	-1023	1808	-1211	1808	-1023
Week 116	n	4	4	4	4	8	8
	Mean	547.8	-1289.0	882.3	-1904.5	715.0	-1596.8
	Median	424.0	-1287.5	811.5	-1391.5	509.0	-1391.5
	SD	287.03	369.11	466.05	1456.95	400.45	1037.48
	(SE)	( 143.52)	( 184.56)	( 233.02)	( 728.47)	( 141.58)	( 366.80)
	Min,	368,	-1620,	448,	-4044,	368,	-4044,
	Max	975	-961	1458	-791	1458	-791

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	382.7	-1421.0	725.3	-2061.5	578.4	-1787.0
	Median	365.0	-1623.0	556.5	-1402.5	532.0	-1535.0
	SD	32.35	355.08	354.50	1463.62	310.99	1109.20
	(SE)	( 18.68)	( 205.01)	( 177.25)	( 731.81)	( 117.54)	( 419.24)
	Min,	363,	-1629,	532,	-4246,	363,	-4246,
	Max	420	-1011	1256	-1195	1256	-1011
Week 124	n	3	3	4	4	7	7
	Mean	386.0	-1417.7	876.8	-1910.0	666.4	-1699.0
	Median	393.0	-1599.0	581.0	-1487.5	414.0	-1591.0
	SD	32.08	347.51	761.89	1075.63	599.49	829.45
	(SE)	( 18.52)	( 200.63)	( 380.95)	( 537.81)	( 226.59)	( 313.50)
	Min,	351,	-1637,	345,	-3502,	345,	-3502,
	Max	414	-1017	2000	-1163	2000	-1017
Week 128	n	4	4	4	4	8	8
	Mean	424.3	-1412.5	737.0	-2049.8	580.6	-1731.1
	Median	376.0	-1477.5	788.0	-1304.5	484.5	-1345.5
	SD	113.81	271.56	303.80	1647.46	270.28	1144.91
	(SE)	( 56.90)	( 135.78)	( 151.90)	( 823.73)	( 95.56)	( 404.79)
	Min,	351,	-1637,	380,	-4515,	351,	-4515,
	Max	594	-1058	992	-1075	992	-1058

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	490.8	-1346.0	859.5	-1927.3	675.1	-1636.6
	Median	461.5	-1437.5	518.5	-1451.0	518.5	-1451.0
	SD	202.58	402.65	704.56	1113.40	518.83	835.04
	(SE)	( 101.29)	( 201.32)	( 352.28)	( 556.70)	( 183.43)	( 295.23)
	Min,	315,	-1673,	485,	-3586,	315,	-3586,
	Max	725	-836	1916	-1221	1916	-836
Week 136	n	4	4	4	4	8	8
	Mean	408.3	-1428.5	869.3	-1917.5	638.8	-1673.0
	Median	390.5	-1497.5	715.0	-1368.5	489.5	-1397.5
	SD	115.86	306.83	530.97	1310.36	432.78	918.99
	(SE)	( 57.93)	( 153.41)	( 265.49)	( 655.18)	( 153.01)	( 324.91)
	Min,	288,	-1700,	415,	-3870,	288,	-3870,
	Max	564	-1019	1632	-1063	1632	-1019
Week 140	n	4	4	4	4	8	8
	Mean	461.0	-1375.8	877.8	-1909.0	669.4	-1642.4
	Median	452.0	-1510.0	760.0	-1352.0	562.5	-1420.5
	SD	120.02	373.72	467.94	1390.91	386.83	985.00
	(SE)	( 60.01)	( 186.86)	( 233.97)	( 695.46)	( 136.77)	( 348.25)
	Min,	348,	-1644,	463,	-3974,	348,	-3974,
	Max	592	-839	1528	-958	1528	-839

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	410.3	-1426.5	755.0	-2031.8	582.6	-1729.1
	Median	401.0	-1538.0	624.5	-1339.0	491.0	-1442.5
	SD	67.74	304.56	355.62	1463.45	300.21	1030.67
	(SE)	( 33.87)	( 152.28)	( 177.81)	( 731.72)	( 106.14)	( 364.40)
	Min,	348,	-1640,	491,	-4222,	348,	-4222,
	Max	491	-990	1280	-1227	1280	-990
Week 148	n	4	4	4	4	8	8
	Mean	490.5	-1346.3	787.5	-1999.3	639.0	-1672.8
	Median	480.0	-1448.0	697.0	-1375.0	593.0	-1375.0
	SD	123.15	346.23	392.59	1452.13	312.66	1037.75
	(SE)	( 61.58)	( 173.11)	( 196.29)	( 726.07)	( 110.54)	( 366.90)
	Min,	374,	-1618,	420,	-4166,	374,	-4166,
	Max	628	-871	1336	-1081	1336	-871
Week 152	n	4	4	3	3	7	7
	Mean	452.3	-1384.5	500.0	-1381.7	472.7	-1383.3
	Median	463.5	-1451.5	505.0	-1344.0	486.0	-1397.0
	SD	83.12	281.90	73.63	100.92	76.90	207.68
	(SE)	( 41.56)	( 140.95)	( 42.51)	( 58.26)	( 29.06)	( 78.50)
	Min,	343,	-1645,	424,	-1496,	343,	-1645,
	Max	539	-990	571	-1305	571	-990

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	421.8	-1415.0	717.3	-2069.5	569.5	-1742.3
	Median	412.0	-1517.5	582.0	-1389.0	457.5	-1428.0
	SD	50.21	282.92	434.96	1392.62	327.28	993.91
	(SE)	( 25.10)	( 141.46)	( 217.48)	( 696.31)	( 115.71)	( 351.40)
	Min,	373,	-1619,	361,	-4158,	361,	-4158,
	Max	490	-1006	1344	-1342	1344	-1006
Week 160	n	4	4	4	4	8	8
	Mean	470.3	-1366.5	749.8	-2037.0	610.0	-1701.8
	Median	428.0	-1434.5	585.0	-1381.0	517.5	-1382.5
	SD	125.95	297.78	425.03	1393.54	326.40	999.36
	(SE)	( 62.97)	( 148.89)	( 212.51)	( 696.77)	( 115.40)	( 353.33)
	Min,	372,	-1616,	449,	-4122,	372,	-4122,
	Max	653	-981	1380	-1264	1380	-981
Week 164	n	4	4	4	4	8	8
	Mean	498.3	-1338.5	638.3	-2148.5	568.3	-1743.5
	Median	438.0	-1397.5	634.5	-1394.5	544.5	-1394.5
	SD	146.81	299.47	214.05	1635.81	185.67	1171.62
	(SE)	( 73.40)	( 149.74)	( 107.03)	( 817.91)	( 65.64)	( 414.23)
	Min,	402,	-1590,	380,	-4598,	380,	-4598,
	Max	715	-969	904	-1207	904	-969

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	445.0	-1391.8	651.5	-2135.3	548.3	-1763.5
	Median	410.0	-1474.0	579.0	-1419.0	481.5	-1419.0
	SD	93.91	281.75	326.08	1506.92	248.06	1079.43
	(SE)	( 46.95)	( 140.87)	( 163.04)	( 753.46)	( 87.70)	( 381.64)
	Min,	377,	-1611,	340,	-4394,	340,	-4394,
	Max	583	-1008	1108	-1309	1108	-1008
Week 172	n	4	4	4	4	8	8
	Mean	437.8	-1399.0	641.8	-2145.0	539.8	-1772.0
	Median	442.5	-1466.5	572.5	-1385.5	495.5	-1447.5
	SD	67.58	253.15	235.63	1586.45	194.02	1124.77
	(SE)	( 33.79)	( 126.57)	( 117.82)	( 793.23)	( 68.60)	( 397.67)
	Min,	367,	-1625,	442,	-4522,	367,	-4522,
	Max	499	-1038	980	-1287	980	-1038
Week 176	n	4	4	4	4	8	8
	Mean	442.8	-1394.0	556.8	-2230.0	499.8	-1812.0
	Median	388.5	-1452.0	523.5	-1447.0	461.0	-1447.0
	SD	141.05	294.50	172.58	1653.85	158.13	1187.05
	(SE)	( 70.52)	( 147.25)	( 86.29)	( 826.93)	( 55.91)	( 419.69)
	Min,	343,	-1645,	384,	-4706,	343,	-4706,
	Max	651	-1027	796	-1320	796	-1027

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	424.0	-1412.8	507.7	-1374.0	459.9	-1396.1
	Median	396.5	-1468.5	534.0	-1405.0	423.0	-1405.0
	SD	102.59	237.26	172.02	176.55	130.87	197.40
	(SE)	( 51.29)	( 118.63)	( 99.31)	( 101.93)	( 49.46)	( 74.61)
	Min,	335,	-1618,	324,	-1533,	324,	-1618,
	Max	568	-1096	665	-1184	665	-1096
Week 184	n	4	4	4	4	8	8
	Mean	413.0	-1423.8	517.0	-2269.8	465.0	-1846.8
	Median	428.5	-1529.0	529.5	-1477.0	491.0	-1504.0
	SD	124.60	360.23	119.88	1735.22	126.11	1245.20
	(SE)	( 62.30)	( 180.11)	( 59.94)	( 867.61)	( 44.59)	( 440.24)
	Min,	271,	-1717,	371,	-4864,	271,	-4864,
	Max	524	-920	638	-1261	638	-920

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
C Reactive Protein (mg/L)							
Baseline <sup>1</sup>	n	4	4	4	8		
	Mean	5.00		5.00	5.00		
	Median	5.00		5.00	5.00		
	SD	0.000		0.000	0.000		
	(SE)	( 0.000)		( 0.000)	( 0.000)		
	Min,	5.0,		5.0,	5.0,		
	Max	5.0		5.0	5.0		
Week 2	n	4	4	4	8	8	
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0
Week 4	n	4	4	4	8	8	
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0
Week 8	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0
Week 10	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0
Week 15	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0
Week 18	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0
Week 24	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0
Week 25	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	5.0,	0.0,	5.0,	0.0,	5.0,	0.0,
	Max	5.0	0.0	5.0	0.0	5.0	0.0
Week 32	n	4	4	4	4	8	8
	Mean	0.70	-4.30	0.93	-4.08	0.81	-4.19
	Median	0.70	-4.30	0.95	-4.05	0.70	-4.30
	SD	0.000	0.000	0.171	0.171	0.164	0.164
	(SE)	( 0.000)	( 0.000)	( 0.085)	( 0.085)	( 0.058)	( 0.058)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.7	-4.3	1.1	-3.9	1.1	-3.9
Week 36	n	4	4	4	4	8	8
	Mean	0.70	-4.30	0.90	-4.10	0.80	-4.20
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000	0.400	0.400	0.283	0.283
	(SE)	( 0.000)	( 0.000)	( 0.200)	( 0.200)	( 0.100)	( 0.100)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.7	-4.3	1.5	-3.5	1.5	-3.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	0.72	-4.28	1.68	-3.33	1.20	-3.80
	Median	0.70	-4.30	0.85	-4.15	0.70	-4.30
	SD	0.050	0.050	1.756	1.756	1.257	1.257
	(SE)	( 0.025)	( 0.025)	( 0.878)	( 0.878)	( 0.444)	( 0.444)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.8	-4.2	4.3	-0.7	4.3	-0.7
Week 44	n	4	4	4	4	8	8
	Mean	1.28	-3.73	0.70	-4.30	0.99	-4.01
	Median	1.40	-3.60	0.70	-4.30	0.70	-4.30
	SD	0.395	0.395	0.000	0.000	0.402	0.402
	(SE)	( 0.197)	( 0.197)	( 0.000)	( 0.000)	( 0.142)	( 0.142)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.6	-3.4	0.7	-4.3	1.6	-3.4
Week 48	n	4	4	4	4	8	8
	Mean	0.70	-4.30	1.03	-3.98	0.86	-4.14
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000	0.650	0.650	0.460	0.460
	(SE)	( 0.000)	( 0.000)	( 0.325)	( 0.325)	( 0.163)	( 0.163)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.7	-4.3	2.0	-3.0	2.0	-3.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	1.08	-3.93	0.70	-4.30	0.89	-4.11
	Median	0.85	-4.15	0.70	-4.30	0.70	-4.30
	SD	0.568	0.568	0.000	0.000	0.422	0.422
	(SE)	( 0.284)	( 0.284)	( 0.000)	( 0.000)	( 0.149)	( 0.149)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.9	-3.1	0.7	-4.3	1.9	-3.1
Week 56	n	4	4	3	3	7	7
	Mean	0.70	-4.30	0.77	-4.23	0.73	-4.27
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000	0.115	0.115	0.076	0.076
	(SE)	( 0.000)	( 0.000)	( 0.067)	( 0.067)	( 0.029)	( 0.029)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.7	-4.3	0.9	-4.1	0.9	-4.1
Week 60	n	4	4	4	4	8	8
	Mean	2.03	-2.97	0.70	-4.30	1.36	-3.64
	Median	2.00	-3.00	0.70	-4.30	0.70	-4.30
	SD	1.531	1.531	0.000	0.000	1.227	1.227
	(SE)	( 0.765)	( 0.765)	( 0.000)	( 0.000)	( 0.434)	( 0.434)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	3.4	-1.6	0.7	-4.3	3.4	-1.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	0.80	-4.20	0.83	-4.18	0.81	-4.19
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.200	0.200	0.250	0.250	0.210	0.210
	(SE)	( 0.100)	( 0.100)	( 0.125)	( 0.125)	( 0.074)	( 0.074)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.1	-3.9	1.2	-3.8	1.2	-3.8
Week 68	n	4	4	4	4	8	8
	Mean	1.15	-3.85	0.70	-4.30	0.93	-4.08
	Median	1.00	-4.00	0.70	-4.30	0.70	-4.30
	SD	0.574	0.574	0.000	0.000	0.446	0.446
	(SE)	( 0.287)	( 0.287)	( 0.000)	( 0.000)	( 0.158)	( 0.158)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.9	-3.1	0.7	-4.3	1.9	-3.1
Week 72	n	3	3	4	4	7	7
	Mean	1.00	-4.00	1.03	-3.98	1.01	-3.99
	Median	0.90	-4.10	1.00	-4.00	1.00	-4.00
	SD	0.361	0.361	0.287	0.287	0.291	0.291
	(SE)	( 0.208)	( 0.208)	( 0.144)	( 0.144)	( 0.110)	( 0.110)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.4	-3.6	1.4	-3.6	1.4	-3.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	0.70	-4.30			0.70	-4.30
	Median	0.70	-4.30			0.70	-4.30
	SD	0.000	0.000			0.000	0.000
	(SE)	( 0.000)	( 0.000)			( 0.000)	( 0.000)
	Min,	0.7,	-4.3,			0.7,	-4.3,
	Max	0.7	-4.3			0.7	-4.3
Week 76	n	4	4	4	4	8	8
	Mean	1.05	-3.95	0.83	-4.18	0.94	-4.06
	Median	0.90	-4.10	0.75	-4.25	0.75	-4.25
	SD	0.473	0.473	0.189	0.189	0.354	0.354
	(SE)	( 0.236)	( 0.236)	( 0.095)	( 0.095)	( 0.125)	( 0.125)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.7	-3.3	1.1	-3.9	1.7	-3.3
Week 80	n	4	4	4	4	8	8
	Mean	1.13	-3.88	0.78	-4.23	0.95	-4.05
	Median	1.10	-3.90	0.70	-4.30	0.70	-4.30
	SD	0.492	0.492	0.150	0.150	0.385	0.385
	(SE)	( 0.246)	( 0.246)	( 0.075)	( 0.075)	( 0.136)	( 0.136)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.6	-3.4	1.0	-4.0	1.6	-3.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	0.78	-4.23	2.33	-2.68	1.55	-3.45
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.150	0.150	3.250	3.250	2.285	2.285
	(SE)	( 0.075)	( 0.075)	( 1.625)	( 1.625)	( 0.808)	( 0.808)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.0	-4.0	7.2	2.2	7.2	2.2
Week 88	n	4	4	4	4	8	8
	Mean	1.80	-3.20	0.70	-4.30	1.25	-3.75
	Median	0.80	-4.20	0.70	-4.30	0.70	-4.30
	SD	2.069	2.069	0.000	0.000	1.476	1.476
	(SE)	( 1.034)	( 1.034)	( 0.000)	( 0.000)	( 0.522)	( 0.522)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	4.9	-0.1	0.7	-4.3	4.9	-0.1
Week 92	n	4	4	4	4	8	8
	Mean	0.80	-4.20	0.83	-4.18	0.81	-4.19
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.200	0.200	0.250	0.250	0.210	0.210
	(SE)	( 0.100)	( 0.100)	( 0.125)	( 0.125)	( 0.074)	( 0.074)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.1	-3.9	1.2	-3.8	1.2	-3.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	2.93	-2.08	0.75	-4.25	1.84	-3.16
	Median	2.00	-3.00	0.70	-4.30	0.75	-4.25
	SD	2.952	2.952	0.100	0.100	2.256	2.256
	(SE)	( 1.476)	( 1.476)	( 0.050)	( 0.050)	( 0.798)	( 0.798)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	7.0	2.0	0.9	-4.1	7.0	2.0
Week 100	n	4	4	4	4	8	8
	Mean	1.50	-3.50	0.85	-4.15	1.17	-3.83
	Median	1.25	-3.75	0.70	-4.30	0.70	-4.30
	SD	1.010	1.010	0.300	0.300	0.772	0.772
	(SE)	( 0.505)	( 0.505)	( 0.150)	( 0.150)	( 0.273)	( 0.273)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.8	-2.2	1.3	-3.7	2.8	-2.2
Week 104	n	4	4	4	4	8	8
	Mean	1.42	-3.58	5.28	0.28	3.35	-1.65
	Median	1.20	-3.80	0.70	-4.30	0.70	-4.30
	SD	0.914	0.914	9.150	9.150	6.362	6.362
	(SE)	( 0.457)	( 0.457)	( 4.575)	( 4.575)	( 2.249)	( 2.249)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.6	-2.4	19.0	14.0	19.0	14.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	4	4	4	4	8	8
	Mean	1.78	-3.23	1.13	-3.88	1.45	-3.55
	Median	1.75	-3.25	1.10	-3.90	1.10	-3.90
	SD	1.242	1.242	0.492	0.492	0.941	0.941
	(SE)	( 0.621)	( 0.621)	( 0.246)	( 0.246)	( 0.333)	( 0.333)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.9	-2.1	1.6	-3.4	2.9	-2.1
Week 112	n	4	4	4	4	8	8
	Mean	2.18	-2.83	0.95	-4.05	1.56	-3.44
	Median	1.10	-3.90	0.90	-4.10	0.90	-4.10
	SD	2.446	2.446	0.300	0.300	1.741	1.741
	(SE)	( 1.223)	( 1.223)	( 0.150)	( 0.150)	( 0.616)	( 0.616)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	5.8	0.8	1.3	-3.7	5.8	0.8
Week 116	n	4	4	4	4	8	8
	Mean	0.93	-4.08	0.72	-4.28	0.83	-4.18
	Median	0.90	-4.10	0.70	-4.30	0.70	-4.30
	SD	0.263	0.263	0.050	0.050	0.205	0.205
	(SE)	( 0.131)	( 0.131)	( 0.025)	( 0.025)	( 0.073)	( 0.073)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.2	-3.8	0.8	-4.2	1.2	-3.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 120	n	4	4	4	4	8	8
	Mean	1.47	-3.53	1.13	-3.88	1.30	-3.70
	Median	0.95	-4.05	0.70	-4.30	0.70	-4.30
	SD	1.239	1.239	0.850	0.850	1.001	1.001
	(SE)	( 0.620)	( 0.620)	( 0.425)	( 0.425)	( 0.354)	( 0.354)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	3.3	-1.7	2.4	-2.6	3.3	-1.7
Week 124	n	4	4	4	4	8	8
	Mean	1.50	-3.50	4.43	-0.57	2.96	-2.04
	Median	1.35	-3.65	1.65	-3.35	1.65	-3.35
	SD	0.956	0.956	5.995	5.995	4.270	4.270
	(SE)	( 0.478)	( 0.478)	( 2.997)	( 2.997)	( 1.510)	( 1.510)
	Min,	0.7,	-4.3,	1.0,	-4.0,	0.7,	-4.3,
	Max	2.6	-2.4	13.4	8.4	13.4	8.4
Week 128	n	4	4	4	4	8	8
	Mean	1.63	-3.38	1.18	-3.83	1.40	-3.60
	Median	1.25	-3.75	1.10	-3.90	1.10	-3.90
	SD	1.231	1.231	0.457	0.457	0.893	0.893
	(SE)	( 0.616)	( 0.616)	( 0.229)	( 0.229)	( 0.316)	( 0.316)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	3.3	-1.7	1.8	-3.2	3.3	-1.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	1.90	-3.10	0.75	-4.25	1.33	-3.68
	Median	1.00	-4.00	0.70	-4.30	0.70	-4.30
	SD	2.020	2.020	0.100	0.100	1.460	1.460
	(SE)	( 1.010)	( 1.010)	( 0.050)	( 0.050)	( 0.516)	( 0.516)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	4.9	-0.1	0.9	-4.1	4.9	-0.1
Week 136	n	4	4	4	4	8	8
	Mean	1.98	-3.03	0.83	-4.18	1.40	-3.60
	Median	1.20	-3.80	0.75	-4.25	0.95	-4.05
	SD	1.900	1.900	0.189	0.189	1.393	1.393
	(SE)	( 0.950)	( 0.950)	( 0.095)	( 0.095)	( 0.492)	( 0.492)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	4.8	-0.2	1.1	-3.9	4.8	-0.2
Week 140	n	4	4	4	4	8	8
	Mean	1.55	-3.45	0.83	-4.18	1.19	-3.81
	Median	1.40	-3.60	0.70	-4.30	0.70	-4.30
	SD	1.012	1.012	0.250	0.250	0.785	0.785
	(SE)	( 0.506)	( 0.506)	( 0.125)	( 0.125)	( 0.277)	( 0.277)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.7	-2.3	1.2	-3.8	2.7	-2.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	0.78	-4.23	0.75	-4.25	0.76	-4.24
	Median	0.75	-4.25	0.70	-4.30	0.70	-4.30
	SD	0.096	0.096	0.100	0.100	0.092	0.092
	(SE)	( 0.048)	( 0.048)	( 0.050)	( 0.050)	( 0.032)	( 0.032)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.9	-4.1	0.9	-4.1	0.9	-4.1
Week 148	n	4	4	4	4	8	8
	Mean	2.55	-2.45	0.75	-4.25	1.65	-3.35
	Median	2.00	-3.00	0.70	-4.30	0.75	-4.25
	SD	2.281	2.281	0.100	0.100	1.778	1.778
	(SE)	( 1.141)	( 1.141)	( 0.050)	( 0.050)	( 0.628)	( 0.628)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	5.5	0.5	0.9	-4.1	5.5	0.5
Week 152	n	4	4	4	4	8	8
	Mean	1.90	-3.10	1.35	-3.65	1.63	-3.38
	Median	2.00	-3.00	1.25	-3.75	1.85	-3.15
	SD	0.909	0.909	0.768	0.768	0.833	0.833
	(SE)	( 0.455)	( 0.455)	( 0.384)	( 0.384)	( 0.294)	( 0.294)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.9	-2.1	2.2	-2.8	2.9	-2.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 156	n	4	4	4	4	8	8
	Mean	1.75	-3.25	1.30	-3.70	1.53	-3.48
	Median	1.65	-3.35	1.25	-3.75	1.25	-3.75
	SD	1.223	1.223	0.698	0.698	0.953	0.953
	(SE)	( 0.612)	( 0.612)	( 0.349)	( 0.349)	( 0.337)	( 0.337)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	3.0	-2.0	2.0	-3.0	3.0	-2.0
Week 160	n	4	4	4	4	8	8
	Mean	1.78	-3.23	0.85	-4.15	1.31	-3.69
	Median	1.55	-3.45	0.80	-4.20	0.80	-4.20
	SD	1.295	1.295	0.191	0.191	0.989	0.989
	(SE)	( 0.647)	( 0.647)	( 0.096)	( 0.096)	( 0.350)	( 0.350)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	3.3	-1.7	1.1	-3.9	3.3	-1.7
Week 164	n	4	4	4	4	8	8
	Mean	1.45	-3.55	0.88	-4.13	1.16	-3.84
	Median	1.40	-3.60	0.90	-4.10	0.90	-4.10
	SD	0.819	0.819	0.126	0.126	0.623	0.623
	(SE)	( 0.409)	( 0.409)	( 0.063)	( 0.063)	( 0.220)	( 0.220)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.3	-2.7	1.0	-4.0	2.3	-2.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	1.18	-3.83	1.90	-3.10	1.54	-3.46
	Median	1.15	-3.85	0.70	-4.30	0.80	-4.20
	SD	0.457	0.457	2.400	2.400	1.646	1.646
	(SE)	( 0.229)	( 0.229)	( 1.200)	( 1.200)	( 0.582)	( 0.582)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.7	-3.3	5.5	0.5	5.5	0.5
Week 172	n	4	4	4	4	8	8
	Mean	1.53	-3.48	0.70	-4.30	1.11	-3.89
	Median	1.65	-3.35	0.70	-4.30	0.70	-4.30
	SD	0.655	0.655	0.000	0.000	0.615	0.615
	(SE)	( 0.328)	( 0.328)	( 0.000)	( 0.000)	( 0.217)	( 0.217)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.1	-2.9	0.7	-4.3	2.1	-2.9
Week 176	n	4	4	4	4	8	8
	Mean	0.95	-4.05	2.30	-2.70	1.63	-3.38
	Median	0.90	-4.10	0.75	-4.25	0.75	-4.25
	SD	0.300	0.300	3.134	3.134	2.184	2.184
	(SE)	( 0.150)	( 0.150)	( 1.567)	( 1.567)	( 0.772)	( 0.772)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.3	-3.7	7.0	2.0	7.0	2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	4	4	8	8
	Mean	1.43	-3.58	0.72	-4.28	1.08	-3.93
	Median	1.25	-3.75	0.70	-4.30	0.70	-4.30
	SD	0.885	0.885	0.050	0.050	0.690	0.690
	(SE)	( 0.442)	( 0.442)	( 0.025)	( 0.025)	( 0.244)	( 0.244)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.5	-2.5	0.8	-4.2	2.5	-2.5
Week 184	n	4	4	4	4	8	8
	Mean	2.13	-2.88	0.95	-4.05	1.54	-3.46
	Median	2.10	-2.90	0.85	-4.15	1.05	-3.95
	SD	1.438	1.438	0.332	0.332	1.153	1.153
	(SE)	( 0.719)	( 0.719)	( 0.166)	( 0.166)	( 0.407)	( 0.407)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	3.6	-1.4	1.4	-3.6	3.6	-1.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Creatine Kinase (U/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	7856.5		9358.8		8607.6	
	Median	7954.0		9386.5		8187.5	
	SD	1497.99		3577.95		2663.26	
	(SE)	( 749.00)		( 1788.98)		( 941.60)	
	Min,	6099,		5307,		5307,	
	Max	9419		13355		13355	
Week 2	n	4	4	4	4	8	
	Mean	7940.3	83.8	8032.5	-1326.3	7986.4	-621.3
	Median	8066.0	148.0	8057.0	-1533.5	8066.0	-1533.5
	SD	3212.64	3374.61	4051.80	1498.66	3385.51	2532.03
	(SE)	( 1606.32)	( 1687.30)	( 2025.90)	( 749.33)	( 1196.96)	( 895.21)
	Min,	4068,	-3117,	4272,	-2861,	4068,	-3117,
	Max	11561	3156	11744	623	11744	3156
Week 4	n	4	4	4	4	8	
	Mean	10291.8	2435.3	12663.5	3304.8	11477.6	2870.0
	Median	9255.0	1496.0	11251.0	3037.0	9424.5	2471.5
	SD	3568.56	3141.48	4536.86	1808.21	3985.75	2418.02
	(SE)	( 1784.28)	( 1570.74)	( 2268.43)	( 904.10)	( 1409.18)	( 854.90)
	Min,	7221,	36,	9268,	1616,	7221,	36,
	Max	15436	6713	18884	5529	18884	6713

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	7562.3	-294.3	10957.3	1598.5	9259.8	652.1
	Median	7768.0	-177.0	10972.5	1611.0	8127.0	569.0
	SD	737.01	811.09	3997.78	1001.94	3221.10	1317.48
	(SE)	( 368.51)	( 405.55)	( 1998.89)	( 500.97)	( 1138.83)	( 465.80)
	Min,	6577,	-1301,	6113,	660,	6113,	-1301,
	Max	8136	478	15771	2512	15771	2512
Week 8	n	4	4	4	4	8	8
	Mean	13409.3	5552.8	16716.3	7357.5	15062.8	6455.1
	Median	13540.0	5434.5	14928.0	4424.5	14172.0	5434.5
	SD	1307.15	856.46	9425.45	7740.63	6475.40	5188.82
	(SE)	( 653.58)	( 428.23)	( 4712.72)	( 3870.31)	( 2289.40)	( 1834.52)
	Min,	11932,	4747,	7283,	1976,	7283,	1976,
	Max	14625	6595	29726	18605	29726	18605
Week 10	n	4	4	4	4	8	8
	Mean	8861.3	1004.8	9153.0	-205.8	9007.1	399.5
	Median	7991.5	-498.0	10224.5	-394.0	9505.5	-498.0
	SD	2719.85	3769.98	2550.30	2627.96	2445.84	3077.27
	(SE)	( 1359.92)	( 1884.99)	( 1275.15)	( 1313.98)	( 864.74)	( 1087.98)
	Min,	6757,	-1591,	5351,	-3195,	5351,	-3195,
	Max	12705	6606	10812	3160	12705	6606

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	11223.0	3366.5	12230.3	2871.5	11726.6	3119.0
	Median	11398.5	2327.5	13637.0	2685.5	12393.0	2640.5
	SD	2933.04	3631.23	3975.68	1697.60	3278.83	2637.45
	(SE)	( 1466.52)	( 1815.61)	( 1987.84)	( 848.80)	( 1159.24)	( 932.48)
	Min,	7560,	375,	6511,	1204,	6511,	375,
	Max	14535	8436	15136	4911	15136	8436
Week 15	n	4	4	4	4	8	8
	Mean	10807.0	2950.5	10065.3	706.5	10436.1	1828.5
	Median	10953.0	3194.0	10822.0	-82.5	10822.0	467.5
	SD	6313.51	5129.30	3152.74	3019.93	4636.82	4077.12
	(SE)	( 3156.76)	( 2564.65)	( 1576.37)	( 1509.97)	( 1639.36)	( 1441.48)
	Min,	4124,	-3061,	5633,	-2019,	4124,	-3061,
	Max	17198	8475	12984	5010	17198	8475
Week 18	n	4	4	4	4	8	8
	Mean	8235.5	379.0	8459.8	-899.0	8347.6	-260.0
	Median	8076.0	317.0	8761.0	-55.5	8424.0	108.0
	SD	2196.93	1649.84	3154.64	3171.11	2519.50	2437.80
	(SE)	( 1098.46)	( 824.92)	( 1577.32)	( 1585.55)	( 890.78)	( 861.89)
	Min,	5822,	-1363,	4391,	-5337,	4391,	-5337,
	Max	10968	2245	11926	1852	11926	2245

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	6910.5	-946.0	7708.3	-1650.5	7309.4	-1298.3
	Median	7119.5	-1261.0	7364.5	-854.5	7364.5	-1261.0
	SD	918.46	1828.00	3447.39	3095.83	2374.18	2383.57
	(SE)	( 459.23)	( 914.00)	( 1723.69)	( 1547.92)	( 839.40)	( 842.72)
	Min,	5748,	-2818,	3858,	-6018,	3858,	-6018,
	Max	7655	1556	12246	1125	12246	1556
Week 24	n	4	4	4	4	8	8
	Mean	9914.8	2058.3	13156.3	3797.5	11535.5	2927.9
	Median	9817.0	746.0	12113.0	3809.0	10380.0	3122.0
	SD	3561.30	4347.62	4731.70	1628.86	4246.51	3178.38
	(SE)	( 1780.65)	( 2173.81)	( 2365.85)	( 814.43)	( 1501.37)	( 1123.73)
	Min,	5917,	-1268,	9269,	1797,	5917,	-1268,
	Max	14108	8009	19130	5775	19130	8009
Week 25	n	4	4	4	4	8	8
	Mean	5801.8	-2054.8	9065.5	-293.3	7433.6	-1174.0
	Median	6123.0	-2948.0	8766.0	-1126.0	7122.5	-1904.5
	SD	2086.77	2736.14	4041.69	5018.70	3451.17	3858.70
	(SE)	( 1043.38)	( 1368.07)	( 2020.85)	( 2509.35)	( 1220.17)	( 1364.26)
	Min,	2978,	-4207,	4515,	-5484,	2978,	-5484,
	Max	7983	1884	14215	6563	14215	6563

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	8124.8	268.3	9508.8	150.0	8816.8	209.1
	Median	8244.0	290.0	9549.5	137.0	9289.0	137.0
	SD	1471.24	2940.09	3532.72	1688.24	2612.20	2220.39
	(SE)	( 735.62)	( 1470.05)	( 1766.36)	( 844.12)	( 923.55)	( 785.03)
	Min,	6586,	-2833,	5153,	-1884,	5153,	-2833,
	Max	9425	3326	13783	2210	13783	3326
Week 32	n	4	4	3	3	7	7
	Mean	10720.0	2863.5	10032.0	1260.7	10425.1	2176.6
	Median	10948.0	3130.0	7288.0	1581.0	9328.0	1581.0
	SD	2827.76	4123.85	5103.08	1490.54	3579.64	3158.75
	(SE)	( 1413.88)	( 2061.93)	( 2946.26)	( 860.57)	( 1352.98)	( 1193.89)
	Min,	7448,	-1275,	6888,	-364,	6888,	-1275,
	Max	13536	6469	15920	2565	15920	6469
Week 36	n	4	4	4	4	8	8
	Mean	6680.5	-1176.0	9966.5	607.8	8323.5	-284.1
	Median	5518.0	-2730.5	10555.5	594.5	6882.0	-78.0
	SD	2822.25	4133.92	4372.10	1023.35	3832.88	2946.50
	(SE)	( 1411.12)	( 2066.96)	( 2186.05)	( 511.67)	( 1355.13)	( 1041.75)
	Min,	4805,	-4025,	4681,	-626,	4681,	-4025,
	Max	10881	4782	14074	1868	14074	4782

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	8827.3	970.8	10904.3	1545.5	9865.8	1258.1
	Median	7223.0	-731.0	10648.5	1262.0	7223.0	-731.0
	SD	4396.64	5670.75	7720.49	4165.49	5921.35	4616.53
	(SE)	( 2198.32)	( 2835.37)	( 3860.24)	( 2082.75)	( 2093.51)	( 1632.19)
	Min,	5580,	-3839,	2759,	-2548,	2759,	-3839,
	Max	15283	9184	19561	6206	19561	9184
Week 44	n	4	4	4	4	8	8
	Mean	7556.3	-300.3	6533.3	-2825.5	7044.8	-1562.9
	Median	6897.5	-1320.0	6959.5	-2696.0	6928.5	-1658.0
	SD	2224.43	3378.75	2291.26	1498.79	2160.92	2770.79
	(SE)	( 1112.22)	( 1689.38)	( 1145.63)	( 749.40)	( 764.00)	( 979.62)
	Min,	5735,	-3157,	3441,	-4582,	3441,	-4582,
	Max	10695	4596	8773	-1328	10695	4596
Week 48	n	4	4	4	4	8	8
	Mean	5184.8	-2671.8	7796.5	-1562.3	6490.6	-2117.0
	Median	3797.5	-4342.5	7781.0	-1519.0	5440.5	-3233.0
	SD	3149.65	4374.67	2822.48	2928.96	3100.75	3497.18
	(SE)	( 1574.83)	( 2187.34)	( 1411.24)	( 1464.48)	( 1096.28)	( 1236.44)
	Min,	3255,	-5792,	4805,	-5045,	3255,	-5792,
	Max	9889	3790	10819	1834	10819	3790

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	6541.0	-1315.5	9214.8	-144.0	7877.9	-729.8
	Median	7083.5	-654.5	8385.5	-341.5	7517.5	-413.5
	SD	2614.68	1987.24	4292.38	1349.36	3587.30	1692.61
	(SE)	( 1307.34)	( 993.62)	( 2146.19)	( 674.68)	( 1268.30)	( 598.43)
	Min,	2976,	-4209,	5053,	-1573,	2976,	-4209,
	Max	9021	256	15035	1680	15035	1680
Week 56	n	4	4	3	3	7	7
	Mean	5750.5	-2106.0	9951.0	23.3	7550.7	-1193.4
	Median	5828.0	-2126.0	8587.0	-1680.0	6603.0	-1680.0
	SD	1531.81	3023.02	7104.89	3714.47	4800.09	3234.79
	(SE)	( 765.90)	( 1511.51)	( 4102.01)	( 2144.55)	( 1814.26)	( 1222.64)
	Min,	3968,	-5451,	3627,	-2534,	3627,	-5451,
	Max	7378	1279	17639	4284	17639	4284
Week 60	n	4	4	4	4	8	8
	Mean	10795.8	2939.3	8935.8	-423.0	9865.8	1258.1
	Median	12167.5	4408.5	9377.5	-247.0	9873.5	1658.0
	SD	4724.79	3918.49	1536.59	2458.44	3401.12	3521.46
	(SE)	( 2362.39)	( 1959.24)	( 768.29)	( 1229.22)	( 1202.48)	( 1245.02)
	Min,	4340,	-2845,	6727,	-3094,	4340,	-3094,
	Max	14508	5785	10261	1896	14508	5785

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	6897.5	-959.0	10470.3	1111.5	8683.9	76.3
	Median	5254.5	-3094.0	10354.0	-78.0	7424.5	-1627.5
	SD	3748.01	4919.36	5683.09	3742.93	4848.63	4195.29
	(SE)	( 1874.00)	( 2459.68)	( 2841.55)	( 1871.47)	( 1714.25)	( 1483.26)
	Min,	4619,	-4011,	3751,	-1699,	3751,	-4011,
	Max	12462	6363	17422	6301	17422	6363
Week 68	n	4	4	4	4	8	8
	Mean	6541.0	-1315.5	8517.3	-841.5	7529.1	-1078.5
	Median	6448.0	-1352.0	8540.5	-822.0	6556.5	-822.0
	SD	2003.92	1632.33	3458.91	1634.53	2822.12	1533.34
	(SE)	( 1001.96)	( 816.17)	( 1729.45)	( 817.27)	( 997.77)	( 542.12)
	Min,	4185,	-3000,	4743,	-2846,	4185,	-3000,
	Max	9083	442	12245	1124	12245	1124
Week 72	n	3	3	4	4	7	7
	Mean	7760.3	-682.0	10361.8	1003.0	9246.9	280.9
	Median	8494.0	-229.0	10679.5	743.5	9579.0	-229.0
	SD	2275.99	1138.24	4880.86	3368.54	3946.09	2629.94
	(SE)	( 1314.04)	( 657.17)	( 2440.43)	( 1684.27)	( 1491.48)	( 994.02)
	Min,	5208,	-1977,	4092,	-2350,	4092,	-2350,
	Max	9579	160	15996	4875	15996	4875

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	2	2	0	0	2	2
	Mean	4882.5	-1759.5			4882.5	-1759.5
	Median	4882.5	-1759.5			4882.5	-1759.5
	SD	3046.92	3814.84			3046.92	3814.84
	(SE)	( 2154.50)	( 2697.50)			( 2154.50)	( 2697.50)
	Min,	2728,	-4457,			2728,	-4457,
	Max	7037	938			7037	938
Week 76	n	4	4	4	4	8	8
	Mean	5084.0	-2772.5	8470.8	-888.0	6777.4	-1830.3
	Median	5099.5	-2281.0	9548.0	-820.5	5673.0	-1875.0
	SD	795.20	1787.99	3587.03	3308.66	3010.40	2660.16
	(SE)	( 397.60)	( 893.99)	( 1793.51)	( 1654.33)	( 1064.34)	( 940.51)
	Min,	4123,	-5296,	3410,	-4861,	3410,	-5296,
	Max	6014	-1232	11377	2950	11377	2950
Week 80	n	4	4	4	4	8	8
	Mean	5851.3	-2005.3	8773.0	-585.8	7312.1	-1295.5
	Median	5673.0	-2281.0	9594.5	-1379.5	6711.5	-1900.0
	SD	1346.84	2793.18	2784.37	2598.14	2557.15	2610.05
	(SE)	( 673.42)	( 1396.59)	( 1392.18)	( 1299.07)	( 904.09)	( 922.79)
	Min,	4402,	-5017,	4929,	-2596,	4402,	-5017,
	Max	7657	1558	10974	3012	10974	3012

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	6006.3	-1850.3	9881.3	522.5	7943.8	-663.9
	Median	5797.0	-2157.0	10090.5	449.0	6897.5	207.0
	SD	1400.47	2828.27	3549.68	428.77	3245.13	2261.76
	(SE)	( 700.24)	( 1414.14)	( 1774.84)	( 214.39)	( 1147.33)	( 799.65)
	Min,	4526,	-4893,	5890,	99,	4526,	-4893,
	Max	7905	1806	13454	1093	13454	1806
Week 88	n	4	4	4	4	8	8
	Mean	5074.8	-2781.8	8525.0	-833.8	6799.9	-1807.8
	Median	5688.5	-2613.5	9796.0	-2077.0	6618.5	-2154.0
	SD	2337.17	3335.16	4085.42	3121.89	3591.01	3166.74
	(SE)	( 1168.58)	( 1667.58)	( 2042.71)	( 1560.94)	( 1269.61)	( 1119.61)
	Min,	1761,	-6962,	2883,	-2968,	1761,	-6962,
	Max	7161	1062	11625	3787	11625	3787
Week 92	n	4	4	4	4	8	8
	Mean	4743.0	-3113.5	8036.8	-1322.0	6389.9	-2217.8
	Median	4216.0	-4086.0	8680.0	-820.5	6231.0	-2913.5
	SD	2317.89	3556.05	3906.28	2851.17	3455.69	3133.76
	(SE)	( 1158.95)	( 1778.03)	( 1953.14)	( 1425.59)	( 1221.77)	( 1107.95)
	Min,	2542,	-6181,	2697,	-4737,	2542,	-6181,
	Max	7998	1899	12090	1090	12090	1899

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	7370.3	-486.3	12020.3	2661.5	9695.3	1087.6
	Median	5936.5	-2327.5	10850.0	852.0	8463.0	-1224.5
	SD	4027.01	5168.71	7180.65	5625.48	5935.13	5276.65
	(SE)	( 2013.50)	( 2584.36)	( 3590.32)	( 2812.74)	( 2098.39)	( 1865.58)
	Min,	4402,	-4397,	4588,	-1730,	4402,	-4397,
	Max	13206	7107	21793	10672	21793	10672
Week 100	n	4	4	4	4	8	8
	Mean	5308.8	-2547.8	6393.8	-2965.0	5851.3	-2756.4
	Median	4696.5	-3605.5	6851.0	-2277.5	5223.5	-2565.5
	SD	2291.54	3618.56	2269.77	3458.34	2189.70	3284.39
	(SE)	( 1145.77)	( 1809.28)	( 1134.88)	( 1729.17)	( 774.17)	( 1161.21)
	Min,	3255,	-5468,	3534,	-7744,	3255,	-7744,
	Max	8587	2488	8339	439	8587	2488
Week 104	n	4	4	4	4	8	8
	Mean	6409.3	-1447.3	7548.5	-1810.3	6978.9	-1628.8
	Median	4960.0	-2994.0	7316.0	-2587.5	6122.5	-2994.0
	SD	3991.93	5364.58	2797.85	4054.60	3248.88	4406.48
	(SE)	( 1995.97)	( 2682.29)	( 1398.93)	( 2027.30)	( 1148.65)	( 1557.92)
	Min,	3441,	-5978,	4402,	-5574,	3441,	-5978,
	Max	12276	6177	11160	3508	12276	6177

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	3898.3	-3958.3	7936.0	-1422.8	5917.1	-2690.5
	Median	2790.0	-5164.0	8726.5	-2805.5	5022.0	-3511.5
	SD	2452.38	3748.06	3973.89	3625.70	3742.13	3673.04
	(SE)	( 1226.19)	( 1874.03)	( 1986.94)	( 1812.85)	( 1323.04)	( 1298.62)
	Min,	2449,	-6970,	2697,	-4022,	2449,	-6970,
	Max	7564	1465	11594	3942	11594	3942
Week 112	n	4	4	4	4	8	8
	Mean	6021.8	-1834.8	8215.0	-1143.8	7118.4	-1489.3
	Median	5673.0	-1931.5	6665.0	-1163.0	6587.5	-1380.0
	SD	1780.70	2024.18	5229.42	4732.34	3801.77	3389.73
	(SE)	( 890.35)	( 1012.09)	( 2614.71)	( 2366.17)	( 1344.13)	( 1198.45)
	Min,	4526,	-4104,	3751,	-6907,	3751,	-6907,
	Max	8215	628	15779	4658	15779	4658
Week 116	n	4	4	4	4	8	8
	Mean	5319.0	-2537.5	8757.5	-601.3	7038.3	-1569.4
	Median	4061.0	-5010.0	7703.5	-2355.0	6014.0	-4256.0
	SD	5580.59	6474.07	4592.36	5740.22	5075.78	5758.09
	(SE)	( 2790.29)	( 3237.04)	( 2296.18)	( 2870.11)	( 1794.56)	( 2035.79)
	Min,	10,	-7175,	4402,	-5264,	10,	-7175,
	Max	13144	7045	15221	7569	15221	7569

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	3	3	4	4	7	7
	Mean	4185.0	-4257.3	6362.8	-2996.0	5429.4	-3536.6
	Median	4216.0	-4507.0	6293.0	-2256.5	5704.0	-3526.0
	SD	1534.73	2660.30	999.84	3796.80	1624.81	3165.67
	(SE)	( 886.08)	( 1535.93)	( 499.92)	( 1898.40)	( 614.12)	( 1196.51)
	Min,	2635,	-6784,	5270,	-8085,	2635,	-8085,
	Max	5704	-1481	7595	614	7595	614
Week 124	n	3	3	4	4	7	7
	Mean	5290.7	-3151.7	6710.0	-2648.8	6101.7	-2864.3
	Median	4185.0	-4538.0	6833.0	-1627.0	5363.0	-3634.0
	SD	2105.80	3224.36	4190.35	4065.41	3291.39	3435.34
	(SE)	( 1215.78)	( 1861.59)	( 2095.18)	( 2032.71)	( 1244.03)	( 1298.44)
	Min,	3968,	-5451,	1673,	-7992,	1673,	-7992,
	Max	7719	534	11501	651	11501	651
Week 128	n	4	4	4	4	8	8
	Mean	4231.5	-3625.0	7590.5	-1768.3	5911.0	-2696.6
	Median	3968.0	-4032.5	5471.5	-1776.5	3968.0	-3217.0
	SD	979.16	2450.70	7258.59	5263.59	5120.04	3928.45
	(SE)	( 489.58)	( 1225.35)	( 3629.30)	( 2631.80)	( 1810.21)	( 1388.92)
	Min,	3441,	-5885,	1656,	-7928,	1656,	-7928,
	Max	5549	-550	17763	4408	17763	4408

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	4479.5	-3377.0	6959.5	-2399.3	5719.5	-2888.1
	Median	3255.0	-4761.0	5828.0	-1442.0	5037.5	-3109.5
	SD	3088.15	4477.22	3115.92	3508.12	3163.13	3760.11
	(SE)	( 1544.07)	( 2238.61)	( 1557.96)	( 1754.06)	( 1118.33)	( 1329.40)
	Min,	2418,	-6877,	4650,	-7124,	2418,	-7124,
	Max	8990	2891	11532	411	11532	2891
Week 136	n	4	4	4	4	8	8
	Mean	3724.3	-4132.3	8230.5	-1128.3	5977.4	-2630.3
	Median	3906.0	-4101.5	9393.0	-1828.0	4913.5	-2402.0
	SD	1494.06	2794.50	4046.46	3796.87	3711.58	3479.01
	(SE)	( 747.03)	( 1397.25)	( 2023.23)	( 1898.44)	( 1312.24)	( 1230.02)
	Min,	1877,	-6846,	2480,	-4861,	1877,	-6846,
	Max	5208	-1480	11656	4004	11656	4004
Week 140	n	4	4	4	4	8	8
	Mean	3898.3	-3958.3	8703.3	-655.5	6300.8	-2306.9
	Median	3813.0	-4141.0	10075.0	-913.5	4231.5	-2758.5
	SD	447.36	1854.58	3771.94	3467.21	3574.89	3121.34
	(SE)	( 223.68)	( 927.29)	( 1885.97)	( 1733.61)	( 1263.92)	( 1103.56)
	Min,	3472,	-5947,	3317,	-4489,	3317,	-5947,
	Max	4495	-1604	11346	3694	11346	3694

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	4588.0	-3268.5	7509.8	-1849.0	6048.9	-2558.8
	Median	4743.0	-2839.0	7688.0	-1828.0	6386.0	-2162.5
	SD	2170.89	3581.48	1518.13	2570.01	2333.78	2983.90
	(SE)	( 1085.44)	( 1790.74)	( 759.06)	( 1285.00)	( 825.12)	( 1054.97)
	Min,	2108,	-7311,	5549,	-4241,	2108,	-7311,
	Max	6758	-85	9114	501	9114	501
Week 148	n	4	4	4	4	8	8
	Mean	4719.5	-3137.0	6913.0	-2445.8	5816.3	-2791.4
	Median	4122.5	-3288.5	8199.5	-2928.5	6168.5	-2928.5
	SD	2216.54	3294.30	2990.28	2186.14	2704.16	2614.53
	(SE)	( 1108.27)	( 1647.15)	( 1495.14)	( 1093.07)	( 956.06)	( 1054.97)
	Min,	2759,	-6660,	2449,	-4551,	2449,	-6660,
	Max	7874	689	8804	625	8804	689
Week 152	n	4	4	3	3	7	7
	Mean	4068.8	-3787.8	4495.0	-4276.3	4251.4	-3997.1
	Median	4231.5	-4070.5	4402.0	-3250.0	4402.0	-3250.0
	SD	843.05	2059.80	1598.53	2585.11	1122.07	2101.71
	(SE)	( 421.53)	( 1029.90)	( 922.91)	( 1492.51)	( 424.10)	( 794.37)
	Min,	2914,	-5809,	2945,	-7217,	2914,	-7217,
	Max	4898	-1201	6138	-2362	6138	-1201

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	3712.3	-4144.3	7089.3	-2269.5	5400.8	-3206.9
	Median	3472.0	-4001.5	7037.0	-3011.5	4014.5	-3466.5
	SD	886.03	1553.66	4315.93	1927.72	3402.63	1905.60
	(SE)	( 443.02)	( 776.83)	( 2157.96)	( 963.86)	( 1203.01)	( 673.73)
	Min, Max	2945, 4960	-6164, -2410	2596, 11687	-3621, 566	2596, 11687	-6164, 566
Week 160	n	4	4	4	4	8	8
	Mean	4735.3	-3121.3	5587.8	-3771.0	5161.5	-3446.1
	Median	4510.5	-3443.5	6153.5	-3362.5	5409.5	-3362.5
	SD	2129.07	3617.26	2537.51	1287.88	2215.83	2537.54
	(SE)	( 1064.54)	( 1808.63)	( 1268.75)	( 643.94)	( 783.41)	( 897.16)
	Min, Max	2790, 7130	-6629, 1031	2294, 7750	-5605, -2754	2294, 7750	-6629, 1031
Week 164	n	4	4	4	4	8	8
	Mean	5022.0	-2834.5	5564.5	-3794.3	5293.3	-3314.4
	Median	3813.0	-4141.0	5394.0	-3596.0	4402.0	-3977.0
	SD	2891.04	4223.90	2467.24	2002.45	2504.99	3102.90
	(SE)	( 1445.52)	( 2111.95)	( 1233.62)	( 1001.23)	( 885.65)	( 1097.04)
	Min, Max	3131, 9331	-6288, 3232	2759, 8711	-6192, -1793	2759, 9331	-6288, 3232

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	4177.3	-3679.3	4721.5	-4637.3	4449.4	-4158.3
	Median	4045.5	-4032.5	4572.5	-4460.5	4402.0	-4460.5
	SD	1149.75	2622.25	2767.88	1160.44	1983.56	1945.84
	(SE)	( 574.88)	( 1311.12)	( 1383.94)	( 580.22)	( 701.30)	( 687.96)
	Min,	3100,	-6071,	1526,	-6037,	1526,	-6071,
	Max	5518	-581	8215	-3591	8215	-581
Week 172	n	4	4	4	4	8	8
	Mean	3720.0	-4136.5	5952.0	-3406.8	4836.0	-3771.6
	Median	3735.5	-4249.5	5053.0	-2691.5	4603.5	-2861.0
	SD	1129.98	2571.72	2858.51	2914.32	2339.33	2574.22
	(SE)	( 564.99)	( 1285.86)	( 1429.25)	( 1457.16)	( 827.08)	( 910.12)
	Min,	2666,	-6598,	3627,	-7494,	2666,	-7494,
	Max	4743	-1449	10075	-750	10075	-750
Week 176	n	4	4	4	4	8	8
	Mean	2882.5	-4974.0	3568.5	-5790.3	3225.5	-5382.1
	Median	1999.0	-5955.0	3844.0	-5140.5	3642.5	-5140.5
	SD	3530.45	5002.48	2598.38	4035.96	2893.05	4230.40
	(SE)	( 1765.22)	( 2501.24)	( 1299.19)	( 2017.98)	( 1022.85)	( 1495.67)
	Min,	92,	-9327,	169,	-10952,	92,	-10952,
	Max	7440	1341	6417	-1928	7440	1341

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	4	4	3	3	7	7
	Mean	2349.5	-5507.0	2571.7	-6199.7	2444.7	-5803.9
	Median	1345.0	-6609.0	1570.0	-7397.0	1570.0	-7397.0
	SD	3055.80	4501.28	2948.02	2133.00	2753.18	3432.84
	(SE)	( 1527.90)	( 2250.64)	( 1702.04)	( 1231.49)	( 1040.60)	( 1297.49)
	Min,	105,	-9314,	255,	-7465,	105,	-9314,
	Max	6603	504	5890	-3737	6603	504
Week 184	n	4	4	4	4	8	8
	Mean	4059.0	-3797.5	4340.0	-5018.8	4199.5	-4408.1
	Median	3704.5	-4054.5	4464.0	-5223.5	3766.5	-4557.5
	SD	2357.52	3449.14	1727.31	3212.63	1919.16	3154.03
	(SE)	( 1178.76)	( 1724.57)	( 863.65)	( 1606.32)	( 678.53)	( 1115.12)
	Min,	1635,	-7088,	2511,	-7897,	1635,	-7897,
	Max	7192	7	5921	-1731	7192	7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Cystatin C (mg/L)						
Baseline <sup>1</sup>	n	4	4	4	8	8
	Mean	0.65	0.68	0.66	0.65	0.70
	Median	0.65	0.70	0.70	0.60	0.60
	SD	0.058	0.126	0.092	0.131	0.099
	(SE)	( 0.029)	( 0.063)	( 0.032)	( 0.046)	( 0.035)
	Min,	0.6,	0.5,	0.5,	0.5,	-0.1,
	Max	0.7	0.8	0.8	0.9	0.1
Week 12	n	4	4	4	8	8
	Mean	0.58	-0.08	0.73	0.65	-0.01
	Median	0.60	-0.10	0.70	0.60	-0.05
	SD	0.050	0.050	0.150	0.131	0.099
	(SE)	( 0.025)	( 0.025)	( 0.075)	( 0.046)	( 0.035)
	Min,	0.5,	-0.1,	0.6,	0.5,	-0.1,
	Max	0.6	0.0	0.9	0.9	0.1
Week 24	n	4	4	4	8	8
	Mean	0.63	-0.03	0.73	0.68	0.01
	Median	0.60	0.00	0.70	0.65	0.00
	SD	0.050	0.050	0.126	0.104	0.099
	(SE)	( 0.025)	( 0.025)	( 0.063)	( 0.037)	( 0.035)
	Min,	0.6,	-0.1,	0.6,	0.6,	-0.1,
	Max	0.7	0.0	0.9	0.9	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 32	n	4	4	4	4	8	8
	Mean	0.62	-0.03	0.70	0.02	0.66	-0.00
	Median	0.63	-0.04	0.72	0.03	0.68	-0.02
	SD	0.074	0.088	0.093	0.058	0.087	0.074
	(SE)	( 0.037)	( 0.044)	( 0.046)	( 0.029)	( 0.031)	( 0.026)
	Min,	0.5,	-0.1,	0.6,	-0.0,	0.5,	-0.1,
	Max	0.7	0.1	0.8	0.1	0.8	0.1
Week 36	n	4	4	4	4	8	8
	Mean	0.70	0.05	0.69	0.01	0.69	0.03
	Median	0.70	0.04	0.69	0.03	0.69	0.04
	SD	0.111	0.117	0.122	0.154	0.108	0.128
	(SE)	( 0.056)	( 0.059)	( 0.061)	( 0.077)	( 0.038)	( 0.038)
	Min,	0.6,	-0.1,	0.5,	-0.2,	0.5,	-0.2,
	Max	0.8	0.2	0.8	0.2	0.8	0.2
Week 40	n	4	4	4	4	8	8
	Mean	0.74	0.09	0.69	0.02	0.72	0.06
	Median	0.71	0.06	0.67	0.01	0.68	0.04
	SD	0.128	0.087	0.091	0.068	0.106	0.082
	(SE)	( 0.064)	( 0.043)	( 0.046)	( 0.034)	( 0.038)	( 0.029)
	Min,	0.6,	0.0,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.9	0.2	0.8	0.1	0.9	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 44	n	4	4	4	4	8	8
	Mean	0.68	0.03	0.72	0.05	0.70	0.04
	Median	0.70	0.02	0.76	0.06	0.74	0.06
	SD	0.082	0.071	0.075	0.063	0.076	0.063
	(SE)	( 0.041)	( 0.035)	( 0.038)	( 0.032)	( 0.027)	( 0.022)
	Min,	0.6,	-0.0,	0.6,	-0.0,	0.6,	-0.0,
	Max	0.8	0.1	0.8	0.1	0.8	0.1
Week 48	n	4	4	4	4	8	8
	Mean	0.71	0.06	0.69	0.02	0.70	0.04
	Median	0.74	0.04	0.65	0.01	0.70	0.04
	SD	0.084	0.082	0.113	0.095	0.093	0.086
	(SE)	( 0.042)	( 0.041)	( 0.056)	( 0.048)	( 0.033)	( 0.030)
	Min,	0.6,	-0.0,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.8	0.2	0.9	0.1	0.9	0.2
Week 52	n	4	4	4	4	8	8
	Mean	0.73	0.08	0.78	0.11	0.76	0.09
	Median	0.73	0.08	0.76	0.06	0.76	0.07
	SD	0.073	0.077	0.068	0.117	0.071	0.093
	(SE)	( 0.037)	( 0.039)	( 0.034)	( 0.059)	( 0.025)	( 0.033)
	Min,	0.7,	-0.0,	0.7,	0.0,	0.7,	-0.0,
	Max	0.8	0.2	0.9	0.3	0.9	0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 56	n	4	4	3	3	7	7
	Mean	0.66	0.01	0.75	0.08	0.70	0.04
	Median	0.64	0.03	0.72	0.09	0.65	0.05
	SD	0.064	0.061	0.132	0.056	0.101	0.066
	(SE)	( 0.032)	( 0.031)	( 0.076)	( 0.032)	( 0.038)	( 0.025)
	Min,	0.6,	-0.1,	0.6,	0.0,	0.6,	-0.1,
	Max	0.8	0.1	0.9	0.1	0.9	0.1
Week 60	n	4	4	4	4	8	8
	Mean	0.71	0.06	0.67	-0.01	0.69	0.03
	Median	0.73	0.03	0.66	0.01	0.71	0.01
	SD	0.096	0.099	0.107	0.077	0.096	0.088
	(SE)	( 0.048)	( 0.050)	( 0.054)	( 0.039)	( 0.034)	( 0.031)
	Min,	0.6,	-0.0,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.8	0.2	0.8	0.1	0.8	0.2
Week 64	n	4	4	4	4	8	8
	Mean	0.59	-0.06	0.69	0.01	0.64	-0.03
	Median	0.60	-0.08	0.65	-0.00	0.62	-0.06
	SD	0.040	0.051	0.105	0.096	0.090	0.081
	(SE)	( 0.020)	( 0.026)	( 0.053)	( 0.048)	( 0.032)	( 0.029)
	Min,	0.5,	-0.1,	0.6,	-0.1,	0.5,	-0.1,
	Max	0.6	0.0	0.8	0.1	0.8	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 68	n	4	4	4	4	8	8
	Mean	0.58	-0.07	0.67	-0.00	0.63	-0.04
	Median	0.59	-0.08	0.69	-0.01	0.63	-0.07
	SD	0.060	0.075	0.094	0.127	0.088	0.102
	(SE)	( 0.030)	( 0.037)	( 0.047)	( 0.063)	( 0.031)	( 0.036)
	Min,	0.5,	-0.2,	0.6,	-0.2,	0.5,	-0.2,
	Max	0.6	0.0	0.8	0.1	0.8	0.1
Week 72	n	4	4	3	3	7	7
	Mean	0.63	-0.03	0.70	0.03	0.66	0.00
	Median	0.63	-0.03	0.70	0.02	0.64	0.00
	SD	0.031	0.031	0.180	0.042	0.114	0.045
	(SE)	( 0.016)	( 0.016)	( 0.104)	( 0.024)	( 0.043)	( 0.017)
	Min,	0.6,	-0.1,	0.5,	0.0,	0.5,	-0.1,
	Max	0.7	0.0	0.9	0.1	0.9	0.1
Week 73	n	2	2	0	0	2	2
	Mean	0.65	0.00			0.65	0.00
	Median	0.65	0.00			0.65	0.00
	SD	0.028	0.042			0.028	0.042
	(SE)	( 0.020)	( 0.030)			( 0.020)	( 0.030)
	Min,	0.6,	-0.0,			0.6,	-0.0,
	Max	0.7	0.0			0.7	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 76	n	4	4	4	4	8	8
	Mean	0.64	-0.02	0.71	0.03	0.67	0.01
	Median	0.61	-0.04	0.70	0.05	0.65	0.02
	SD	0.066	0.105	0.119	0.048	0.097	0.079
	(SE)	( 0.033)	( 0.053)	( 0.060)	( 0.024)	( 0.034)	( 0.028)
	Min,	0.6,	-0.1,	0.6,	-0.0,	0.6,	-0.1,
	Max	0.7	0.1	0.9	0.1	0.9	0.1
Week 80	n	4	4	4	4	8	8
	Mean	0.62	-0.03	0.68	0.00	0.65	-0.01
	Median	0.63	-0.04	0.67	-0.03	0.65	-0.03
	SD	0.050	0.022	0.068	0.103	0.063	0.071
	(SE)	( 0.025)	( 0.011)	( 0.034)	( 0.052)	( 0.022)	( 0.025)
	Min,	0.6,	-0.1,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.7	0.0	0.8	0.2	0.8	0.2
Week 84	n	4	4	4	4	8	8
	Mean	0.72	0.07	0.76	0.08	0.74	0.07
	Median	0.73	0.04	0.77	0.10	0.75	0.08
	SD	0.111	0.117	0.112	0.062	0.106	0.087
	(SE)	( 0.055)	( 0.058)	( 0.056)	( 0.031)	( 0.037)	( 0.031)
	Min,	0.6,	-0.0,	0.6,	0.0,	0.6,	-0.0,
	Max	0.8	0.2	0.9	0.1	0.9	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 88	n	4	4	3	3	7	7
	Mean	0.66	0.01	0.71	0.05	0.68	0.03
	Median	0.68	-0.01	0.72	0.02	0.70	0.00
	SD	0.055	0.068	0.050	0.103	0.056	0.079
	(SE)	( 0.028)	( 0.034)	( 0.029)	( 0.059)	( 0.021)	( 0.030)
	Min,	0.6,	-0.1,	0.7,	-0.0,	0.6,	-0.1,
	Max	0.7	0.1	0.8	0.2	0.8	0.2
Week 92	n	4	4	4	4	8	8
	Mean	0.66	0.01	0.70	0.03	0.68	0.02
	Median	0.67	-0.02	0.69	0.04	0.68	0.02
	SD	0.090	0.101	0.100	0.075	0.092	0.083
	(SE)	( 0.045)	( 0.050)	( 0.050)	( 0.038)	( 0.032)	( 0.029)
	Min,	0.6,	-0.1,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.7	0.1	0.8	0.1	0.8	0.1
Week 96	n	4	4	4	4	8	8
	Mean	0.68	0.03	0.67	-0.01	0.68	0.01
	Median	0.69	0.03	0.69	0.01	0.69	0.02
	SD	0.079	0.065	0.102	0.066	0.085	0.063
	(SE)	( 0.039)	( 0.032)	( 0.051)	( 0.033)	( 0.030)	( 0.022)
	Min,	0.6,	-0.0,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.8	0.1	0.8	0.1	0.8	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 100	n	4	4	4	4	8	8
	Mean	0.70	0.05	0.72	0.05	0.71	0.05
	Median	0.72	0.04	0.72	0.05	0.72	0.04
	SD	0.048	0.048	0.100	0.049	0.074	0.045
	(SE)	( 0.024)	( 0.024)	( 0.050)	( 0.025)	( 0.026)	( 0.016)
	Min,	0.6,	0.0,	0.6,	-0.0,	0.6,	-0.0,
	Max	0.7	0.1	0.9	0.1	0.9	0.1
Week 104	n	4	4	4	4	8	8
	Mean	0.70	0.05	0.59	-0.09	0.65	-0.02
	Median	0.69	0.07	0.57	-0.09	0.67	0.02
	SD	0.050	0.064	0.064	0.121	0.080	0.116
	(SE)	( 0.025)	( 0.032)	( 0.032)	( 0.060)	( 0.028)	( 0.041)
	Min,	0.7,	-0.0,	0.5,	-0.2,	0.5,	-0.2,
	Max	0.8	0.1	0.7	0.1	0.8	0.1
Week 108	n	4	4	4	4	8	8
	Mean	0.60	-0.05	0.65	-0.02	0.63	-0.04
	Median	0.62	-0.08	0.65	-0.01	0.62	-0.05
	SD	0.053	0.062	0.113	0.062	0.087	0.059
	(SE)	( 0.027)	( 0.031)	( 0.057)	( 0.031)	( 0.031)	( 0.021)
	Min,	0.5,	-0.1,	0.5,	-0.1,	0.5,	-0.1,
	Max	0.6	0.0	0.8	0.0	0.8	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 112	n	4	4	4	4	8	8
	Mean	0.60	-0.06	0.62	-0.06	0.61	-0.06
	Median	0.62	-0.09	0.59	-0.05	0.61	-0.06
	SD	0.101	0.104	0.105	0.082	0.096	0.087
	(SE)	( 0.050)	( 0.052)	( 0.052)	( 0.041)	( 0.034)	( 0.031)
	Min,	0.5,	-0.1,	0.5,	-0.2,	0.5,	-0.2,
	Max	0.7	0.1	0.8	0.0	0.8	0.1
Week 116	n	4	4	4	4	8	8
	Mean	0.63	-0.02	0.65	-0.03	0.64	-0.03
	Median	0.65	-0.05	0.62	-0.05	0.62	-0.05
	SD	0.098	0.100	0.085	0.077	0.086	0.083
	(SE)	( 0.049)	( 0.050)	( 0.043)	( 0.039)	( 0.030)	( 0.029)
	Min,	0.5,	-0.1,	0.6,	-0.1,	0.5,	-0.1,
	Max	0.7	0.1	0.8	0.1	0.8	0.1
Week 120	n	4	4	4	4	8	8
	Mean	0.61	-0.05	0.62	-0.06	0.61	-0.05
	Median	0.63	-0.07	0.57	-0.08	0.58	-0.07
	SD	0.071	0.076	0.108	0.095	0.085	0.080
	(SE)	( 0.036)	( 0.038)	( 0.054)	( 0.048)	( 0.030)	( 0.028)
	Min,	0.5,	-0.1,	0.6,	-0.1,	0.5,	-0.1,
	Max	0.7	0.1	0.8	0.1	0.8	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 124	n	4	4	4	4	8	8
	Mean	0.61	-0.04	0.68	0.00	0.65	-0.02
	Median	0.62	-0.04	0.68	0.01	0.63	-0.01
	SD	0.017	0.044	0.102	0.114	0.076	0.083
	(SE)	( 0.009)	( 0.022)	( 0.051)	( 0.057)	( 0.027)	( 0.029)
	Min,	0.6,	-0.1,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.6	0.0	0.8	0.1	0.8	0.1
Week 128	n	4	4	4	4	8	8
	Mean	0.56	-0.09	0.64	-0.04	0.60	-0.06
	Median	0.60	-0.11	0.61	-0.03	0.60	-0.07
	SD	0.081	0.073	0.116	0.073	0.102	0.074
	(SE)	( 0.041)	( 0.036)	( 0.058)	( 0.037)	( 0.036)	( 0.026)
	Min,	0.4,	-0.2,	0.5,	-0.1,	0.4,	-0.2,
	Max	0.6	0.0	0.8	0.0	0.8	0.0
Week 132	n	4	4	4	4	8	8
	Mean	0.58	-0.07	0.64	-0.04	0.61	-0.06
	Median	0.59	-0.07	0.63	-0.04	0.63	-0.07
	SD	0.093	0.112	0.064	0.104	0.079	0.102
	(SE)	( 0.046)	( 0.056)	( 0.032)	( 0.052)	( 0.028)	( 0.036)
	Min,	0.5,	-0.2,	0.6,	-0.2,	0.5,	-0.2,
	Max	0.7	0.1	0.7	0.1	0.7	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 136	n	4	4	4	4	8	8
	Mean	0.60	-0.06	0.65	-0.02	0.62	-0.04
	Median	0.60	-0.05	0.64	-0.05	0.61	-0.05
	SD	0.019	0.066	0.064	0.084	0.053	0.072
	(SE)	( 0.010)	( 0.033)	( 0.032)	( 0.042)	( 0.019)	( 0.026)
	Min,	0.6,	-0.1,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.6	0.0	0.7	0.1	0.7	0.1
Week 140	n	4	4	4	4	8	8
	Mean	0.57	-0.08	0.58	-0.10	0.57	-0.09
	Median	0.60	-0.11	0.57	-0.14	0.58	-0.11
	SD	0.054	0.054	0.024	0.110	0.038	0.081
	(SE)	( 0.027)	( 0.027)	( 0.012)	( 0.055)	( 0.014)	( 0.029)
	Min,	0.5,	-0.1,	0.6,	-0.2,	0.5,	-0.2,
	Max	0.6	0.0	0.6	0.1	0.6	0.1
Week 144	n	4	4	4	4	8	8
	Mean	0.54	-0.11	0.55	-0.12	0.55	-0.12
	Median	0.58	-0.13	0.55	-0.16	0.57	-0.14
	SD	0.080	0.072	0.029	0.106	0.056	0.084
	(SE)	( 0.040)	( 0.036)	( 0.014)	( 0.053)	( 0.020)	( 0.030)
	Min,	0.4,	-0.2,	0.5,	-0.2,	0.4,	-0.2,
	Max	0.6	-0.0	0.6	0.0	0.6	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 148	n	4	4	4	4	8	8
	Mean	0.62	-0.03	0.63	-0.04	0.63	-0.04
	Median	0.62	-0.07	0.64	-0.07	0.64	-0.07
	SD	0.080	0.102	0.066	0.139	0.068	0.113
	(SE)	( 0.040)	( 0.051)	( 0.033)	( 0.069)	( 0.024)	( 0.040)
	Min,	0.5,	-0.1,	0.6,	-0.2,	0.5,	-0.2,
	Max	0.7	0.1	0.7	0.1	0.7	0.1
Week 152	n	4	4	4	4	8	8
	Mean	0.58	-0.07	0.67	-0.01	0.62	-0.04
	Median	0.57	-0.05	0.67	-0.04	0.62	-0.05
	SD	0.053	0.043	0.059	0.108	0.068	0.082
	(SE)	( 0.027)	( 0.021)	( 0.030)	( 0.054)	( 0.024)	( 0.029)
	Min,	0.5,	-0.1,	0.6,	-0.1,	0.5,	-0.1,
	Max	0.7	-0.0	0.7	0.1	0.7	0.1
Week 156	n	4	4	4	4	8	8
	Mean	0.56	-0.09	0.63	-0.04	0.60	-0.07
	Median	0.56	-0.09	0.64	-0.07	0.59	-0.09
	SD	0.037	0.058	0.053	0.081	0.057	0.070
	(SE)	( 0.018)	( 0.029)	( 0.027)	( 0.040)	( 0.020)	( 0.025)
	Min,	0.5,	-0.2,	0.6,	-0.1,	0.5,	-0.2,
	Max	0.6	-0.0	0.7	0.1	0.7	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 160	n	4	4	4	4	8	8
	Mean	0.56	-0.09	0.58	-0.10	0.57	-0.10
	Median	0.56	-0.10	0.58	-0.15	0.57	-0.13
	SD	0.015	0.057	0.041	0.114	0.031	0.083
	(SE)	( 0.007)	( 0.028)	( 0.021)	( 0.057)	( 0.011)	( 0.030)
	Min,	0.5,	-0.2,	0.5,	-0.2,	0.5,	-0.2,
	Max	0.6	-0.0	0.6	0.1	0.6	0.1
Week 164	n	4	4	4	4	8	8
	Mean	0.60	-0.05	0.67	-0.01	0.64	-0.03
	Median	0.60	-0.06	0.65	-0.01	0.61	-0.02
	SD	0.029	0.072	0.098	0.086	0.076	0.077
	(SE)	( 0.014)	( 0.036)	( 0.049)	( 0.043)	( 0.027)	( 0.027)
	Min,	0.6,	-0.1,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.6	0.0	0.8	0.1	0.8	0.1
Week 168	n	4	4	4	4	8	8
	Mean	0.57	-0.08	0.67	-0.01	0.62	-0.04
	Median	0.59	-0.09	0.67	-0.03	0.60	-0.07
	SD	0.038	0.033	0.068	0.073	0.071	0.064
	(SE)	( 0.019)	( 0.017)	( 0.034)	( 0.037)	( 0.025)	( 0.023)
	Min,	0.5,	-0.1,	0.6,	-0.1,	0.5,	-0.1,
	Max	0.6	-0.0	0.7	0.1	0.7	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 172	n	4	4	4	4	8	8
	Mean	0.60	-0.05	0.58	-0.10	0.59	-0.07
	Median	0.61	-0.06	0.58	-0.09	0.59	-0.07
	SD	0.107	0.120	0.118	0.091	0.105	0.102
	(SE)	( 0.054)	( 0.060)	( 0.059)	( 0.046)	( 0.037)	( 0.036)
	Min,	0.5,	-0.2,	0.5,	-0.2,	0.5,	-0.2,
	Max	0.7	0.1	0.7	0.0	0.7	0.1
Week 176	n	4	4	4	4	8	8
	Mean	0.60	-0.06	0.64	-0.04	0.62	-0.05
	Median	0.58	-0.08	0.64	-0.05	0.58	-0.07
	SD	0.044	0.085	0.073	0.085	0.060	0.080
	(SE)	( 0.022)	( 0.043)	( 0.036)	( 0.043)	( 0.021)	( 0.028)
	Min,	0.6,	-0.1,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.7	0.1	0.7	0.1	0.7	0.1
Week 180	n	4	4	4	4	8	8
	Mean	0.51	-0.14	0.56	-0.12	0.53	-0.13
	Median	0.51	-0.14	0.57	-0.12	0.53	-0.12
	SD	0.034	0.080	0.100	0.038	0.074	0.059
	(SE)	( 0.017)	( 0.040)	( 0.050)	( 0.019)	( 0.026)	( 0.021)
	Min,	0.5,	-0.2,	0.4,	-0.2,	0.4,	-0.2,
	Max	0.6	-0.1	0.7	-0.1	0.7	-0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.1  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 184	n	4	4	4	4	8	8
	Mean	0.60	-0.05	0.60	-0.08	0.60	-0.06
	Median	0.61	-0.06	0.60	-0.09	0.61	-0.06
	SD	0.042	0.067	0.115	0.089	0.080	0.074
	(SE)	( 0.021)	( 0.033)	( 0.058)	( 0.044)	( 0.028)	( 0.026)
	Min,	0.6,	-0.1,	0.5,	-0.2,	0.5,	-0.2,
	Max	0.6	0.0	0.7	0.0	0.7	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Sodium (mmol/L)						
Week 1	n	2	2		4	
	Mean	141.0	141.0		141.0	
	Median	141.0	141.0		141.0	
	SD	1.41	0.00		0.82	
	{SE}	( 1.00)	( 0.00)		( 0.41)	
	Min,	140,	141,		140,	
	Max	142	141		142	
Week 2	n	2	2		4	
	Mean	139.5	142.0		140.8	
	Median	139.5	142.0		141.0	
	SD	2.12	1.41		2.06	
	{SE}	( 1.50)	( 1.00)		( 1.03)	
	Min,	138,	141,		138,	
	Max	141	143		143	
Week 4	n	2	2		4	
	Mean	140.5	140.0		140.3	
	Median	140.5	140.0		140.5	
	SD	0.71	1.41		0.96	
	{SE}	( 0.50)	( 1.00)		( 0.48)	
	Min,	140,	139,		139,	
	Max	141	141		141	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	140.5		140.5		140.5	
	Median	140.5		140.5		140.5	
	SD	2.12		2.12		1.73	
	(SE)	( 1.50)		( 1.50)		( 0.87)	
	Min,	139,		139,		139,	
	Max	142		142		142	
Week 8	n	2		2		4	
	Mean	140.0		139.5		139.8	
	Median	140.0		139.5		140.0	
	SD	0.00		0.71		0.50	
	(SE)	( 0.00)		( 0.50)		( 0.25)	
	Min,	140,		139,		139,	
	Max	140		140		140	
Week 10	n	2		2		4	
	Mean	138.5		138.5		138.5	
	Median	138.5		138.5		138.5	
	SD	0.71		0.71		0.58	
	(SE)	( 0.50)		( 0.50)		( 0.29)	
	Min,	138,		138,		138,	
	Max	139		139		139	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	138.5		140.0		139.3	
	Median	138.5		140.0		140.0	
	SD	3.54		1.41		2.36	
	(SE)	( 2.50)		( 1.00)		( 1.18)	
	Min,	136,		139,		136,	
	Max	141		141		141	
Week 15	n	2		2		4	
	Mean	139.5		139.5		139.5	
	Median	139.5		139.5		139.5	
	SD	0.71		0.71		0.58	
	(SE)	( 0.50)		( 0.50)		( 0.29)	
	Min,	139,		139,		139,	
	Max	140		140		140	
Week 18	n	2		2		4	
	Mean	139.0		138.5		138.8	
	Median	139.0		138.5		138.5	
	SD	1.41		0.71		0.96	
	(SE)	( 1.00)		( 0.50)		( 0.48)	
	Min,	138,		138,		138,	
	Max	140		139		140	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	140.0		141.5		140.8	
	Median	140.0		141.5		140.0	
	SD	0.00		2.12		1.50	
	(SE)	( 0.00)		( 1.50)		( 0.75)	
	Min,	140,		140,		140,	
	Max	140		143		143	
Week 24	n	2		2		4	
	Mean	141.0		141.0		141.0	
	Median	141.0		141.0		141.0	
	SD	0.00		1.41		0.82	
	(SE)	( 0.00)		( 1.00)		( 0.41)	
	Min,	141,		140,		140,	
	Max	141		142		142	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	141.5		143.0		142.3	
	Median	141.5		143.0		142.5	
	SD	2.12		1.41		1.71	
	(SE)	( 1.50)		( 1.00)		( 0.85)	
	Min,	140,		142,		140,	
	Max	143		144		144	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	136.0	-5.5	140.5	-2.5	138.3	-4.0
	Median	136.0	-5.5	140.5	-2.5	138.0	-5.0
	SD	1.41	0.71	2.12	3.54	2.99	2.71
	(SE)	( 1.00)	( 0.50)	( 1.50)	( 2.50)	( 1.49)	( 1.35)
	Min,	135,	-6,	139,	-5,	135,	-6,
	Max	137	-5	142	0	142	0
Week 32	n	2	2	2	2	4	4
	Mean	138.5	-3.0	138.5	-4.5	138.5	-3.8
	Median	138.5	-3.0	138.5	-4.5	138.5	-3.5
	SD	0.71	1.41	0.71	2.12	0.58	1.71
	(SE)	( 0.50)	( 1.00)	( 0.50)	( 1.50)	( 0.29)	( 0.85)
	Min,	138,	-4,	138,	-6,	138,	-6,
	Max	139	-2	139	-3	139	-2
Week 36	n	2	2	1	1	3	3
	Mean	140.5	-1.0	140.0	-2.0	140.3	-1.3
	Median	140.5	-1.0	140.0	-2.0	140.0	-1.0
	SD	2.12	0.00			1.53	0.58
	(SE)	( 1.50)	( 0.00)			( 0.88)	( 0.33)
	Min,	139,	-1,	140,	-2,	139,	-2,
	Max	142	-1	140	-2	142	-1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	138.0	-3.5	139.0	-4.0	138.5	-3.8
	Median	138.0	-3.5	139.0	-4.0	139.0	-3.5
	SD	2.83	0.71	1.41	2.83	1.91	1.71
	(SE)	( 2.00)	( 0.50)	( 1.00)	( 2.00)	( 0.96)	( 0.85)
	Min, Max	136, 140	-4, -3	138, 140	-6, -2	136, 140	-6, -2
Week 44	n	2	2	2	2	4	4
	Mean	139.0	-2.5	141.5	-1.5	140.3	-2.0
	Median	139.0	-2.5	141.5	-1.5	140.5	-2.5
	SD	1.41	0.71	0.71	2.12	1.71	1.41
	(SE)	( 1.00)	( 0.50)	( 0.50)	( 1.50)	( 0.85)	( 0.71)
	Min, Max	138, 140	-3, -2	141, 142	-3, 0	138, 142	-3, 0
Week 48	n	2	2	2	2	4	4
	Mean	139.5	-2.0	141.0	-2.0	140.3	-2.0
	Median	139.5	-2.0	141.0	-2.0	140.0	-2.0
	SD	0.71	2.83	1.41	0.00	1.26	1.63
	(SE)	( 0.50)	( 2.00)	( 1.00)	( 0.00)	( 0.63)	( 0.82)
	Min, Max	139, 140	-4, 0	140, 142	-2, -2	139, 142	-4, 0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	140.0	-1.5	139.0	-4.0	139.5	-2.8
	Median	140.0	-1.5	139.0	-4.0	140.0	-3.0
	SD	0.00	2.12	2.83	1.41	1.73	2.06
	(SE)	( 0.00)	( 1.50)	( 2.00)	( 1.00)	( 0.87)	( 1.03)
	Min,	140,	-3,	137,	-5,	137,	-5,
	Max	140	0	141	-3	141	0
Week 56	n	2	2	2	2	4	4
	Mean	139.5	-2.0	140.0	-3.0	139.8	-2.5
	Median	139.5	-2.0	140.0	-3.0	139.5	-2.0
	SD	0.71	1.41	1.41	2.83	0.96	1.91
	(SE)	( 0.50)	( 1.00)	( 1.00)	( 2.00)	( 0.48)	( 0.96)
	Min,	139,	-3,	139,	-5,	139,	-5,
	Max	140	-1	141	-1	141	-1
Week 60	n	2	2	2	2	4	4
	Mean	138.5	-3.0	138.0	-5.0	138.3	-4.0
	Median	138.5	-3.0	138.0	-5.0	138.0	-4.0
	SD	0.71	1.41	0.00	1.41	0.50	1.63
	(SE)	( 0.50)	( 1.00)	( 0.00)	( 1.00)	( 0.25)	( 0.82)
	Min,	138,	-4,	138,	-6,	138,	-6,
	Max	139	-2	138	-4	139	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	139.0	-2.5	137.5	-5.5	138.3	-4.0
	Median	139.0	-2.5	137.5	-5.5	138.5	-4.0
	SD	1.41	3.54	2.12	3.54	1.71	3.37
	(SE)	( 1.00)	( 2.50)	( 1.50)	( 2.50)	( 0.85)	( 1.68)
	Min,	138,	-5,	136,	-8,	136,	-8,
	Max	140	0	139	-3	140	0
Week 68	n	2	2	2	2	4	4
	Mean	137.5	-4.0	138.5	-4.5	138.0	-4.3
	Median	137.5	-4.0	138.5	-4.5	137.5	-4.0
	SD	0.71	1.41	2.12	3.54	1.41	2.22
	(SE)	( 0.50)	( 1.00)	( 1.50)	( 2.50)	( 0.71)	( 1.11)
	Min,	137,	-5,	137,	-7,	137,	-7,
	Max	138	-3	140	-2	140	-2
Week 72	n	2	2	0	0	2	2
	Mean	139.0	-2.5			139.0	-2.5
	Median	139.0	-2.5			139.0	-2.5
	SD	0.00	2.12			0.00	2.12
	(SE)	( 0.00)	( 1.50)			( 0.00)	( 1.50)
	Min,	139,	-4,			139,	-4,
	Max	139	-1			139	-1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			137.0	-7.0	137.0	-7.0
	Median			137.0	-7.0	137.0	-7.0
	SD						
	(SE)						
	Min, Max			137, 137	-7, -7	137, 137	-7, -7
Week 76	n	2	2	2	2	4	4
	Mean	139.5	-2.0	137.0	-6.0	138.3	-4.0
	Median	139.5	-2.0	137.0	-6.0	137.5	-3.5
	SD	2.12	0.00	0.00	1.41	1.89	2.45
	(SE)	( 1.50)	( 0.00)	( 0.00)	( 1.00)	( 0.95)	( 1.22)
	Min, Max	138, 141	-2, -2	137, 137	-7, -5	137, 141	-7, -2
Week 80	n	2	2	2	2	4	4
	Mean	140.0	-1.5	138.0	-5.0	139.0	-3.3
	Median	140.0	-1.5	138.0	-5.0	139.0	-2.5
	SD	1.41	0.71	1.41	2.83	1.63	2.63
	(SE)	( 1.00)	( 0.50)	( 1.00)	( 2.00)	( 0.82)	( 1.31)
	Min, Max	139, 141	-2, -1	137, 139	-7, -3	137, 141	-7, -1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	140.0	-1.5	138.0	-5.0	139.0	-3.3
	Median	140.0	-1.5	138.0	-5.0	138.5	-4.0
	SD	1.41	3.54	0.00	1.41	1.41	2.99
	(SE)	( 1.00)	( 2.50)	( 0.00)	( 1.00)	( 0.71)	( 1.49)
	Min,	139,	-4,	138,	-6,	138,	-6,
	Max	141	1	138	-4	141	1
Week 88	n	2	2	2	2	4	4
	Mean	139.0	-2.5	139.5	-3.5	139.3	-3.0
	Median	139.0	-2.5	139.5	-3.5	139.0	-3.5
	SD	0.00	2.12	2.12	0.71	1.26	1.41
	(SE)	( 0.00)	( 1.50)	( 1.50)	( 0.50)	( 0.63)	( 0.71)
	Min,	139,	-4,	138,	-4,	138,	-4,
	Max	139	-1	141	-3	141	-1
Week 92	n	2	2	2	2	4	4
	Mean	138.5	-3.0	137.0	-6.0	137.8	-4.5
	Median	138.5	-3.0	137.0	-6.0	138.0	-4.0
	SD	0.71	1.41	1.41	2.83	1.26	2.52
	(SE)	( 0.50)	( 1.00)	( 1.00)	( 2.00)	( 0.63)	( 1.26)
	Min,	138,	-4,	136,	-8,	136,	-8,
	Max	139	-2	138	-4	139	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	138.5	-3.0	139.0	-4.0	138.8	-3.5
	Median	138.5	-3.0	139.0	-4.0	139.0	-3.0
	SD	3.54	1.41	1.41	2.83	2.22	1.91
	(SE)	( 2.50)	( 1.00)	( 1.00)	( 2.00)	( 1.11)	( 0.96)
	Min,	136,	-4,	138,	-6,	136,	-6,
	Max	141	-2	140	-2	141	-2
Week 100	n	2	2	2	2	4	4
	Mean	139.5	-2.0	137.0	-6.0	138.3	-4.0
	Median	139.5	-2.0	137.0	-6.0	137.5	-3.5
	SD	3.54	1.41	1.41	2.83	2.63	2.94
	(SE)	( 2.50)	( 1.00)	( 1.00)	( 2.00)	( 1.31)	( 1.47)
	Min,	137,	-3,	136,	-8,	136,	-8,
	Max	142	-1	138	-4	142	-1
Week 104	n	2	2	2	2	4	4
	Mean	141.5	0.0	137.5	-5.5	139.5	-2.8
	Median	141.5	0.0	137.5	-5.5	138.5	-3.0
	SD	3.54	1.41	0.71	0.71	3.11	3.30
	(SE)	( 2.50)	( 1.00)	( 0.50)	( 0.50)	( 1.55)	( 1.65)
	Min,	139,	-1,	137,	-6,	137,	-6,
	Max	144	1	138	-5	144	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	138.5	-3.0	137.5	-5.5	138.0	-4.3
	Median	138.5	-3.0	137.5	-5.5	138.5	-3.0
	SD	0.71	1.41	4.95	6.36	2.94	4.03
	(SE)	( 0.50)	( 1.00)	( 3.50)	( 4.50)	( 1.47)	( 2.02)
	Min,	138,	-4,	134,	-10,	134,	-10,
	Max	139	-2	141	-1	141	-1
Week 112	n	2	2	2	2	4	4
	Mean	137.0	-4.5	138.0	-5.0	137.5	-4.8
	Median	137.0	-4.5	138.0	-5.0	138.0	-4.5
	SD	1.41	0.71	0.00	1.41	1.00	0.96
	(SE)	( 1.00)	( 0.50)	( 0.00)	( 1.00)	( 0.50)	( 0.48)
	Min,	136,	-5,	138,	-6,	136,	-6,
	Max	138	-4	138	-4	138	-4
Week 116	n	2	2	2	2	4	4
	Mean	140.0	-1.5	140.5	-2.5	140.3	-2.0
	Median	140.0	-1.5	140.5	-2.5	140.0	-2.5
	SD	0.00	2.12	2.12	0.71	1.26	1.41
	(SE)	( 0.00)	( 1.50)	( 1.50)	( 0.50)	( 0.63)	( 0.71)
	Min,	140,	-3,	139,	-3,	139,	-3,
	Max	140	0	142	-2	142	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	137.5	-4.0	136.0	-7.0	136.8	-5.5
	Median	137.5	-4.0	136.0	-7.0	137.5	-4.0
	SD	2.12	0.00	7.07	5.66	4.35	3.70
	(SE)	( 1.50)	( 0.00)	( 5.00)	( 4.00)	( 2.17)	( 1.85)
	Min,	136,	-4,	131,	-11,	131,	-11,
	Max	139	-4	141	-3	141	-3
Week 124	n	2	2	2	2	4	4
	Mean	137.5	-4.0	139.0	-4.0	138.3	-4.0
	Median	137.5	-4.0	139.0	-4.0	138.0	-4.0
	SD	0.71	2.83	1.41	0.00	1.26	1.63
	(SE)	( 0.50)	( 2.00)	( 1.00)	( 0.00)	( 0.63)	( 0.82)
	Min,	137,	-6,	138,	-4,	137,	-6,
	Max	138	-2	140	-4	140	-2
Week 128	n	2	2	2	2	4	4
	Mean	138.5	-3.0	138.0	-5.0	138.3	-4.0
	Median	138.5	-3.0	138.0	-5.0	138.5	-3.5
	SD	0.71	1.41	1.41	2.83	0.96	2.16
	(SE)	( 0.50)	( 1.00)	( 1.00)	( 2.00)	( 0.48)	( 1.08)
	Min,	138,	-4,	137,	-7,	137,	-7,
	Max	139	-2	139	-3	139	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	139.5	-2.0	138.5	-4.5	139.0	-3.3
	Median	139.5	-2.0	138.5	-4.5	138.5	-3.0
	SD	2.12	0.00	0.71	0.71	1.41	1.50
	(SE)	( 1.50)	( 0.00)	( 0.50)	( 0.50)	( 0.71)	( 0.75)
	Min,	138,	-2,	138,	-5,	138,	-5,
	Max	141	-2	139	-4	141	-2
Week 136	n	2	2	2	2	4	4
	Mean	138.0	-3.5	138.5	-4.5	138.3	-4.0
	Median	138.0	-3.5	138.5	-4.5	138.0	-3.5
	SD	1.41	0.71	2.12	3.54	1.50	2.16
	(SE)	( 1.00)	( 0.50)	( 1.50)	( 2.50)	( 0.75)	( 1.08)
	Min,	137,	-4,	137,	-7,	137,	-7,
	Max	139	-3	140	-2	140	-2
Week 140	n	2	2	2	2	4	4
	Mean	139.0	-2.5	138.5	-4.5	138.8	-3.5
	Median	139.0	-2.5	138.5	-4.5	138.5	-3.0
	SD	1.41	0.71	0.71	2.12	0.96	1.73
	(SE)	( 1.00)	( 0.50)	( 0.50)	( 1.50)	( 0.48)	( 0.87)
	Min,	138,	-3,	138,	-6,	138,	-6,
	Max	140	-2	139	-3	140	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	138.5	-3.0	137.0	-6.0	137.8	-4.5
	Median	138.5	-3.0	137.0	-6.0	138.0	-3.0
	SD	2.12	0.00	2.83	4.24	2.22	3.00
	(SE)	( 1.50)	( 0.00)	( 2.00)	( 3.00)	( 1.11)	( 1.50)
	Min,	137,	-3,	135,	-9,	135,	-9,
	Max	140	-3	139	-3	140	-3
Week 148	n	2	2	2	2	4	4
	Mean	138.0	-3.5	139.0	-4.0	138.5	-3.8
	Median	138.0	-3.5	139.0	-4.0	139.0	-4.0
	SD	2.83	0.71	1.41	0.00	1.91	0.50
	(SE)	( 2.00)	( 0.50)	( 1.00)	( 0.00)	( 0.96)	( 0.25)
	Min,	136,	-4,	138,	-4,	136,	-4,
	Max	140	-3	140	-4	140	-3
Week 152	n	2	2	2	2	4	4
	Mean	138.0	-3.5	135.5	-7.5	136.8	-5.5
	Median	138.0	-3.5	135.5	-7.5	137.5	-4.0
	SD	1.41	0.71	3.54	4.95	2.63	3.70
	(SE)	( 1.00)	( 0.50)	( 2.50)	( 3.50)	( 1.31)	( 1.85)
	Min,	137,	-4,	133,	-11,	133,	-11,
	Max	139	-3	138	-4	139	-3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	137.5	-4.0	136.0	-7.0	136.8	-5.5
	Median	137.5	-4.0	136.0	-7.0	137.0	-5.0
	SD	0.71	1.41	1.41	2.83	1.26	2.52
	(SE)	( 0.50)	( 1.00)	( 1.00)	( 2.00)	( 0.63)	( 1.26)
	Min,	137,	-5,	135,	-9,	135,	-9,
	Max	138	-3	137	-5	138	-3
Week 160	n	2	2	2	2	4	4
	Mean	136.5	-5.0	137.0	-6.0	136.8	-5.5
	Median	136.5	-5.0	137.0	-6.0	137.0	-5.5
	SD	0.71	1.41	0.00	1.41	0.50	1.29
	(SE)	( 0.50)	( 1.00)	( 0.00)	( 1.00)	( 0.25)	( 0.65)
	Min,	136,	-6,	137,	-7,	136,	-7,
	Max	137	-4	137	-5	137	-4
Week 164	n	2	2	2	2	4	4
	Mean	139.0	-2.5	137.0	-6.0	138.0	-4.3
	Median	139.0	-2.5	137.0	-6.0	137.5	-4.0
	SD	1.41	0.71	0.00	1.41	1.41	2.22
	(SE)	( 1.00)	( 0.50)	( 0.00)	( 1.00)	( 0.71)	( 1.11)
	Min,	138,	-3,	137,	-7,	137,	-7,
	Max	140	-2	137	-5	140	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	138.5	-3.0	136.5	-6.5	137.5	-4.8
	Median	138.5	-3.0	136.5	-6.5	137.5	-5.0
	SD	0.71	1.41	0.71	0.71	1.29	2.22
	(SE)	( 0.50)	( 1.00)	( 0.50)	( 0.50)	( 0.65)	( 1.11)
	Min,	138,	-4,	136,	-7,	136,	-7,
	Max	139	-2	137	-6	139	-2
Week 172	n	2	2	2	2	4	4
	Mean	140.5	-1.0	138.0	-5.0	139.3	-3.0
	Median	140.5	-1.0	138.0	-5.0	138.5	-3.5
	SD	3.54	1.41	1.41	0.00	2.63	2.45
	(SE)	( 2.50)	( 1.00)	( 1.00)	( 0.00)	( 1.31)	( 1.22)
	Min,	138,	-2,	137,	-5,	137,	-5,
	Max	143	0	139	-5	143	0
Week 176	n	2	2	2	2	4	4
	Mean	139.0	-2.5	139.0	-4.0	139.0	-3.3
	Median	139.0	-2.5	139.0	-4.0	139.0	-3.0
	SD	1.41	0.71	0.00	1.41	0.82	1.26
	(SE)	( 1.00)	( 0.50)	( 0.00)	( 1.00)	( 0.41)	( 0.63)
	Min,	138,	-3,	139,	-5,	138,	-5,
	Max	140	-2	139	-3	140	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	139.5	-2.0	139.0	-4.0	139.3	-3.0
	Median	139.5	-2.0	139.0	-4.0	139.5	-3.0
	SD	0.71	2.83	1.41	2.83	0.96	2.58
	(SE)	( 0.50)	( 2.00)	( 1.00)	( 2.00)	( 0.48)	( 1.29)
	Min,	139,	-4,	138,	-6,	138,	-6,
	Max	140	0	140	-2	140	0
Week 184	n	2	2	2	2	4	4
	Mean	137.5	-4.0	140.5	-2.5	139.0	-3.3
	Median	137.5	-4.0	140.5	-2.5	139.5	-4.0
	SD	2.12	0.00	0.71	2.12	2.16	1.50
	(SE)	( 1.50)	( 0.00)	( 0.50)	( 1.50)	( 1.08)	( 0.75)
	Min,	136,	-4,	140,	-4,	136,	-4,
	Max	139	-4	141	-1	141	-1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Potassium (mmol/L)						
Week 1	n	2	2		4	
	Mean	4.10	4.05		4.08	
	Median	4.10	4.05		4.10	
	SD	0.000	0.071		0.050	
	(SE)	( 0.000)	( 0.050)		( 0.025)	
	Min, Max	4.1, 4.1	4.0, 4.1		4.0, 4.1	
Week 2	n	2	2		4	
	Mean	4.60	3.65		4.13	
	Median	4.60	3.65		3.90	
	SD	0.707	0.071		0.685	
	(SE)	( 0.500)	( 0.050)		( 0.342)	
	Min, Max	4.1, 5.1	3.6, 3.7		3.6, 5.1	
Week 4	n	2	2		4	
	Mean	3.85	3.55		3.70	
	Median	3.85	3.55		3.80	
	SD	0.212	0.495		0.356	
	(SE)	( 0.150)	( 0.350)		( 0.178)	
	Min, Max	3.7, 4.0	3.2, 3.9		3.2, 4.0	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	3.90		4.00		3.95	
	Median	3.90		4.00		3.90	
	SD	0.000		0.283		0.173	
	(SE)	( 0.000)		( 0.200)		( 0.087)	
	Min,	3.9,		3.8,		3.8,	
	Max	3.9		4.2		4.2	
Week 8	n	2		2		4	
	Mean	3.70		4.20		3.95	
	Median	3.70		4.20		4.00	
	SD	0.283		0.141		0.342	
	(SE)	( 0.200)		( 0.100)		( 0.171)	
	Min,	3.5,		4.1,		3.5,	
	Max	3.9		4.3		4.3	
Week 10	n	2		2		4	
	Mean	3.65		3.65		3.65	
	Median	3.65		3.65		3.65	
	SD	0.212		0.354		0.238	
	(SE)	( 0.150)		( 0.250)		( 0.119)	
	Min,	3.5,		3.4,		3.4,	
	Max	3.8		3.9		3.9	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	3.85		4.10		3.98	
	Median	3.85		4.10		4.10	
	SD	0.636		0.141		0.403	
	(SE)	( 0.450)		( 0.100)		( 0.202)	
	Min,	3.4,		4.0,		3.4,	
	Max	4.3		4.2		4.3	
Week 15	n	2		2		4	
	Mean	3.50		4.00		3.75	
	Median	3.50		4.00		3.75	
	SD	0.566		0.566		0.545	
	(SE)	( 0.400)		( 0.400)		( 0.272)	
	Min,	3.1,		3.6,		3.1,	
	Max	3.9		4.4		4.4	
Week 18	n	2		2		4	
	Mean	3.90		4.20		4.05	
	Median	3.90		4.20		4.15	
	SD	0.424		0.141		0.311	
	(SE)	( 0.300)		( 0.100)		( 0.155)	
	Min,	3.6,		4.1,		3.6,	
	Max	4.2		4.3		4.3	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2	2		4	
	Mean	3.75	3.70		3.73	
	Median	3.75	3.70		3.70	
	SD	0.071	0.000		0.050	
	(SE)	( 0.050)	( 0.000)		( 0.025)	
	Min, Max	3.7, 3.8	3.7, 3.7		3.7, 3.8	
Week 24	n	2	2		4	
	Mean	3.55	3.85		3.70	
	Median	3.55	3.85		3.85	
	SD	0.778	0.212		0.497	
	(SE)	( 0.550)	( 0.150)		( 0.248)	
	Min, Max	3.0, 4.1	3.7, 4.0		3.0, 4.1	
Baseline <sup>1</sup>	n	2	2		4	
	Mean	4.20	3.60		3.90	
	Median	4.20	3.60		3.75	
	SD	0.424	0.000		0.424	
	(SE)	( 0.300)	( 0.000)		( 0.212)	
	Min, Max	3.9, 4.5	3.6, 3.6		3.6, 4.5	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	3.75	-0.45	3.80	0.20	3.78	-0.13
	Median	3.75	-0.45	3.80	0.20	3.80	-0.10
	SD	0.212	0.212	0.141	0.141	0.150	0.403
	(SE)	( 0.150)	( 0.150)	( 0.100)	( 0.100)	( 0.075)	( 0.202)
	Min,	3.6,	-0.6,	3.7,	0.1,	3.6,	-0.6,
	Max	3.9	-0.3	3.9	0.3	3.9	0.3
Week 32	n	2	2	2	2	4	4
	Mean	3.70	-0.50	4.05	0.45	3.88	-0.03
	Median	3.70	-0.50	4.05	0.45	3.90	0.05
	SD	0.141	0.283	0.071	0.071	0.222	0.574
	(SE)	( 0.100)	( 0.200)	( 0.050)	( 0.050)	( 0.111)	( 0.287)
	Min,	3.6,	-0.7,	4.0,	0.4,	3.6,	-0.7,
	Max	3.8	-0.3	4.1	0.5	4.1	0.5
Week 36	n	2	2	1	1	3	3
	Mean	4.00	-0.20	4.10	0.50	4.03	0.03
	Median	4.00	-0.20	4.10	0.50	4.10	0.00
	SD	0.141	0.283			0.115	0.451
	(SE)	( 0.100)	( 0.200)			( 0.067)	( 0.260)
	Min,	3.9,	-0.4,	4.1,	0.5,	3.9,	-0.4,
	Max	4.1	0.0	4.1	0.5	4.1	0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	4.20	0.00	4.15	0.55	4.18	0.28
	Median	4.20	0.00	4.15	0.55	4.20	0.20
	SD	0.283	0.141	0.354	0.354	0.263	0.386
	(SE)	( 0.200)	( 0.100)	( 0.250)	( 0.250)	( 0.131)	( 0.193)
	Min,	4.0,	-0.1,	3.9,	0.3,	3.9,	-0.1,
	Max	4.4	0.1	4.4	0.8	4.4	0.8
Week 44	n	2	2	2	2	4	4
	Mean	3.90	-0.30	4.00	0.40	3.95	0.05
	Median	3.90	-0.30	4.00	0.40	3.90	0.15
	SD	0.141	0.566	0.283	0.283	0.191	0.545
	(SE)	( 0.100)	( 0.400)	( 0.200)	( 0.200)	( 0.096)	( 0.272)
	Min,	3.8,	-0.7,	3.8,	0.2,	3.8,	-0.7,
	Max	4.0	0.1	4.2	0.6	4.2	0.6
Week 48	n	2	2	2	2	4	4
	Mean	4.05	-0.15	4.00	0.40	4.03	0.13
	Median	4.05	-0.15	4.00	0.40	4.00	0.30
	SD	0.071	0.495	0.000	0.000	0.050	0.427
	(SE)	( 0.050)	( 0.350)	( 0.000)	( 0.000)	( 0.025)	( 0.214)
	Min,	4.0,	-0.5,	4.0,	0.4,	4.0,	-0.5,
	Max	4.1	0.2	4.0	0.4	4.1	0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	4.05	-0.15	4.35	0.75	4.20	0.30
	Median	4.05	-0.15	4.35	0.75	4.20	0.20
	SD	0.354	0.071	0.354	0.354	0.337	0.560
	(SE)	( 0.250)	( 0.050)	( 0.250)	( 0.250)	( 0.168)	( 0.280)
	Min,	3.8,	-0.2,	4.1,	0.5,	3.8,	-0.2,
	Max	4.3	-0.1	4.6	1.0	4.6	1.0
Week 56	n	2	2	2	2	4	4
	Mean	3.85	-0.35	4.15	0.55	4.00	0.10
	Median	3.85	-0.35	4.15	0.55	3.90	0.10
	SD	0.071	0.354	0.354	0.354	0.271	0.594
	(SE)	( 0.050)	( 0.250)	( 0.250)	( 0.250)	( 0.135)	( 0.297)
	Min,	3.8,	-0.6,	3.9,	0.3,	3.8,	-0.6,
	Max	3.9	-0.1	4.4	0.8	4.4	0.8
Week 60	n	2	2	2	2	4	4
	Mean	4.15	-0.05	3.80	0.20	3.98	0.08
	Median	4.15	-0.05	3.80	0.20	4.00	0.15
	SD	0.071	0.354	0.141	0.141	0.222	0.263
	(SE)	( 0.050)	( 0.250)	( 0.100)	( 0.100)	( 0.111)	( 0.131)
	Min,	4.1,	-0.3,	3.7,	0.1,	3.7,	-0.3,
	Max	4.2	0.2	3.9	0.3	4.2	0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	3.50	-0.70	4.10	0.50	3.80	-0.10
	Median	3.50	-0.70	4.10	0.50	3.75	-0.10
	SD	0.141	0.283	0.283	0.283	0.392	0.730
	(SE)	( 0.100)	( 0.200)	( 0.200)	( 0.200)	( 0.196)	( 0.365)
	Min,	3.4,	-0.9,	3.9,	0.3,	3.4,	-0.9,
	Max	3.6	-0.5	4.3	0.7	4.3	0.7
Week 68	n	2	2	2	2	4	4
	Mean	3.95	-0.25	3.70	0.10	3.83	-0.08
	Median	3.95	-0.25	3.70	0.10	3.70	0.10
	SD	0.495	0.919	0.141	0.141	0.330	0.574
	(SE)	( 0.350)	( 0.650)	( 0.100)	( 0.100)	( 0.165)	( 0.287)
	Min,	3.6,	-0.9,	3.6,	0.0,	3.6,	-0.9,
	Max	4.3	0.4	3.8	0.2	4.3	0.4
Week 72	n	2	2	0	0	2	2
	Mean	4.00	-0.20			4.00	-0.20
	Median	4.00	-0.20			4.00	-0.20
	SD	0.283	0.707			0.283	0.707
	(SE)	( 0.200)	( 0.500)			( 0.200)	( 0.500)
	Min,	3.8,	-0.7,			3.8,	-0.7,
	Max	4.2	0.3			4.2	0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			4.30	0.70	4.30	0.70
	Median			4.30	0.70	4.30	0.70
	SD (SE)						
	Min,			4.3,	0.7,	4.3,	0.7,
	Max			4.3	0.7	4.3	0.7
Week 76	n	2	2	2	2	4	4
	Mean	4.15	-0.05	4.00	0.40	4.08	0.18
	Median	4.15	-0.05	4.00	0.40	4.15	0.20
	SD (SE)	0.071 ( 0.050)	0.354 ( 0.250)	0.283 ( 0.200)	0.283 ( 0.200)	0.189 ( 0.095)	0.369 ( 0.184)
	Min,	4.1,	-0.3,	3.8,	0.2,	3.8,	-0.3,
	Max	4.2	0.2	4.2	0.6	4.2	0.6
Week 80	n	2	2	2	2	4	4
	Mean	3.95	-0.25	4.05	0.45	4.00	0.10
	Median	3.95	-0.25	4.05	0.45	3.95	0.20
	SD (SE)	0.071 ( 0.050)	0.495 ( 0.350)	0.212 ( 0.150)	0.212 ( 0.150)	0.141 ( 0.071)	0.510 ( 0.255)
	Min,	3.9,	-0.6,	3.9,	0.3,	3.9,	-0.6,
	Max	4.0	0.1	4.2	0.6	4.2	0.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	3.95	-0.25	4.10	0.50	4.03	0.13
	Median	3.95	-0.25	4.10	0.50	4.05	0.25
	SD	0.071	0.354	0.000	0.000	0.096	0.479
	(SE)	( 0.050)	( 0.250)	( 0.000)	( 0.000)	( 0.048)	( 0.239)
	Min,	3.9,	-0.5,	4.1,	0.5,	3.9,	-0.5,
	Max	4.0	0.0	4.1	0.5	4.1	0.5
Week 88	n	2	2	2	2	4	4
	Mean	4.15	-0.05	4.20	0.60	4.18	0.28
	Median	4.15	-0.05	4.20	0.60	4.20	0.45
	SD	0.071	0.495	0.000	0.000	0.050	0.472
	(SE)	( 0.050)	( 0.350)	( 0.000)	( 0.000)	( 0.025)	( 0.236)
	Min,	4.1,	-0.4,	4.2,	0.6,	4.1,	-0.4,
	Max	4.2	0.3	4.2	0.6	4.2	0.6
Week 92	n	2	2	2	2	4	4
	Mean	4.20	0.00	4.05	0.45	4.13	0.23
	Median	4.20	0.00	4.05	0.45	4.10	0.40
	SD	0.283	0.707	0.212	0.212	0.222	0.499
	(SE)	( 0.200)	( 0.500)	( 0.150)	( 0.150)	( 0.111)	( 0.250)
	Min,	4.0,	-0.5,	3.9,	0.3,	3.9,	-0.5,
	Max	4.4	0.5	4.2	0.6	4.4	0.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	3.95	-0.25	4.10	0.50	4.03	0.13
	Median	3.95	-0.25	4.10	0.50	3.95	0.15
	SD	0.071	0.495	0.424	0.424	0.263	0.574
	(SE)	( 0.050)	( 0.350)	( 0.300)	( 0.300)	( 0.131)	( 0.287)
	Min,	3.9,	-0.6,	3.8,	0.2,	3.8,	-0.6,
	Max	4.0	0.1	4.4	0.8	4.4	0.8
Week 100	n	2	2	2	2	4	4
	Mean	4.00	-0.20	4.00	0.40	4.00	0.10
	Median	4.00	-0.20	4.00	0.40	4.00	0.35
	SD	0.424	0.849	0.141	0.141	0.258	0.606
	(SE)	( 0.300)	( 0.600)	( 0.100)	( 0.100)	( 0.129)	( 0.303)
	Min,	3.7,	-0.8,	3.9,	0.3,	3.7,	-0.8,
	Max	4.3	0.4	4.1	0.5	4.3	0.5
Week 104	n	2	2	2	2	4	4
	Mean	4.30	0.10	4.15	0.55	4.23	0.33
	Median	4.30	0.10	4.15	0.55	4.25	0.35
	SD	0.141	0.283	0.212	0.212	0.171	0.330
	(SE)	( 0.100)	( 0.200)	( 0.150)	( 0.150)	( 0.085)	( 0.165)
	Min,	4.2,	-0.1,	4.0,	0.4,	4.0,	-0.1,
	Max	4.4	0.3	4.3	0.7	4.4	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	3.90	-0.30	3.95	0.35	3.93	0.03
	Median	3.90	-0.30	3.95	0.35	3.95	0.10
	SD	0.141	0.283	0.071	0.071	0.096	0.411
	(SE)	( 0.100)	( 0.200)	( 0.050)	( 0.050)	( 0.048)	( 0.206)
	Min,	3.8,	-0.5,	3.9,	0.3,	3.8,	-0.5,
	Max	4.0	-0.1	4.0	0.4	4.0	0.4
Week 112	n	2	2	2	2	4	4
	Mean	4.20	0.00	3.75	0.15	3.98	0.08
	Median	4.20	0.00	3.75	0.15	3.95	0.15
	SD	0.141	0.283	0.071	0.071	0.275	0.189
	(SE)	( 0.100)	( 0.200)	( 0.050)	( 0.050)	( 0.138)	( 0.095)
	Min,	4.1,	-0.2,	3.7,	0.1,	3.7,	-0.2,
	Max	4.3	0.2	3.8	0.2	4.3	0.2
Week 116	n	2	2	2	2	4	4
	Mean	3.95	-0.25	4.20	0.60	4.08	0.18
	Median	3.95	-0.25	4.20	0.60	4.10	0.20
	SD	0.212	0.212	0.141	0.141	0.206	0.512
	(SE)	( 0.150)	( 0.150)	( 0.100)	( 0.100)	( 0.103)	( 0.256)
	Min,	3.8,	-0.4,	4.1,	0.5,	3.8,	-0.4,
	Max	4.1	-0.1	4.3	0.7	4.3	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	4.55	0.35	3.80	0.20	4.18	0.28
	Median	4.55	0.35	3.80	0.20	4.15	0.20
	SD	0.212	0.636	0.141	0.141	0.457	0.386
	(SE)	( 0.150)	( 0.450)	( 0.100)	( 0.100)	( 0.229)	( 0.193)
	Min,	4.4,	-0.1,	3.7,	0.1,	3.7,	-0.1,
	Max	4.7	0.8	3.9	0.3	4.7	0.8
Week 124	n	2	2	2	2	4	4
	Mean	4.10	-0.10	3.90	0.30	4.00	0.10
	Median	4.10	-0.10	3.90	0.30	4.05	0.20
	SD	0.000	0.424	0.141	0.141	0.141	0.346
	(SE)	( 0.000)	( 0.300)	( 0.100)	( 0.100)	( 0.071)	( 0.173)
	Min,	4.1,	-0.4,	3.8,	0.2,	3.8,	-0.4,
	Max	4.1	0.2	4.0	0.4	4.1	0.4
Week 128	n	2	2	2	2	4	4
	Mean	4.30	0.10	4.00	0.40	4.15	0.25
	Median	4.30	0.10	4.00	0.40	4.20	0.35
	SD	0.000	0.424	0.141	0.141	0.191	0.311
	(SE)	( 0.000)	( 0.300)	( 0.100)	( 0.100)	( 0.096)	( 0.155)
	Min,	4.3,	-0.2,	3.9,	0.3,	3.9,	-0.2,
	Max	4.3	0.4	4.1	0.5	4.3	0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	4.25	0.05	3.60	0.00	3.93	0.03
	Median	4.25	0.05	3.60	0.00	3.95	0.00
	SD	0.071	0.495	0.141	0.141	0.386	0.299
	(SE)	( 0.050)	( 0.350)	( 0.100)	( 0.100)	( 0.193)	( 0.149)
	Min,	4.2,	-0.3,	3.5,	-0.1,	3.5,	-0.3,
	Max	4.3	0.4	3.7	0.1	4.3	0.4
Week 136	n	2	2	2	2	4	4
	Mean	3.95	-0.25	4.15	0.55	4.05	0.15
	Median	3.95	-0.25	4.15	0.55	4.10	0.10
	SD	0.354	0.071	0.212	0.212	0.265	0.480
	(SE)	( 0.250)	( 0.050)	( 0.150)	( 0.150)	( 0.132)	( 0.240)
	Min,	3.7,	-0.3,	4.0,	0.4,	3.7,	-0.3,
	Max	4.2	-0.2	4.3	0.7	4.3	0.7
Week 140	n	2	2	2	2	4	4
	Mean	4.05	-0.15	4.20	0.60	4.13	0.23
	Median	4.05	-0.15	4.20	0.60	4.10	0.30
	SD	0.071	0.354	0.141	0.141	0.126	0.486
	(SE)	( 0.050)	( 0.250)	( 0.100)	( 0.100)	( 0.063)	( 0.243)
	Min,	4.0,	-0.4,	4.1,	0.5,	4.0,	-0.4,
	Max	4.1	0.1	4.3	0.7	4.3	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	3.90	-0.30	4.00	0.40	3.95	0.05
	Median	3.90	-0.30	4.00	0.40	3.90	0.00
	SD	0.141	0.283	0.424	0.424	0.265	0.500
	(SE)	( 0.100)	( 0.200)	( 0.300)	( 0.300)	( 0.132)	( 0.250)
	Min,	3.8,	-0.5,	3.7,	0.1,	3.7,	-0.5,
	Max	4.0	-0.1	4.3	0.7	4.3	0.7
Week 148	n	2	2	2	2	4	4
	Mean	4.25	0.05	4.00	0.40	4.13	0.23
	Median	4.25	0.05	4.00	0.40	4.00	0.40
	SD	0.495	0.919	0.141	0.141	0.330	0.574
	(SE)	( 0.350)	( 0.650)	( 0.100)	( 0.100)	( 0.165)	( 0.287)
	Min,	3.9,	-0.6,	3.9,	0.3,	3.9,	-0.6,
	Max	4.6	0.7	4.1	0.5	4.6	0.7
Week 152	n	2	2	2	2	4	4
	Mean	4.15	-0.05	4.10	0.50	4.13	0.23
	Median	4.15	-0.05	4.10	0.50	4.10	0.45
	SD	0.212	0.636	0.000	0.000	0.126	0.486
	(SE)	( 0.150)	( 0.450)	( 0.000)	( 0.000)	( 0.063)	( 0.243)
	Min,	4.0,	-0.5,	4.1,	0.5,	4.0,	-0.5,
	Max	4.3	0.4	4.1	0.5	4.3	0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	4.05	-0.15	4.25	0.65	4.15	0.25
	Median	4.05	-0.15	4.25	0.65	4.15	0.25
	SD	0.212	0.212	0.212	0.212	0.208	0.493
	(SE)	( 0.150)	( 0.150)	( 0.150)	( 0.150)	( 0.104)	( 0.247)
	Min,	3.9,	-0.3,	4.1,	0.5,	3.9,	-0.3,
	Max	4.2	0.0	4.4	0.8	4.4	0.8
Week 160	n	2	2	2	2	4	4
	Mean	3.90	-0.30	4.10	0.50	4.00	0.10
	Median	3.90	-0.30	4.10	0.50	4.00	0.25
	SD	0.141	0.566	0.141	0.141	0.163	0.572
	(SE)	( 0.100)	( 0.400)	( 0.100)	( 0.100)	( 0.082)	( 0.286)
	Min,	3.8,	-0.7,	4.0,	0.4,	3.8,	-0.7,
	Max	4.0	0.1	4.2	0.6	4.2	0.6
Week 164	n	2	2	2	2	4	4
	Mean	3.95	-0.25	4.10	0.50	4.03	0.13
	Median	3.95	-0.25	4.10	0.50	4.05	0.15
	SD	0.212	0.212	0.141	0.141	0.171	0.457
	(SE)	( 0.150)	( 0.150)	( 0.100)	( 0.100)	( 0.085)	( 0.229)
	Min,	3.8,	-0.4,	4.0,	0.4,	3.8,	-0.4,
	Max	4.1	-0.1	4.2	0.6	4.2	0.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	4.00	-0.20	4.10	0.50	4.05	0.15
	Median	4.00	-0.20	4.10	0.50	4.10	0.25
	SD	0.141	0.283	0.000	0.000	0.100	0.436
	(SE)	( 0.100)	( 0.200)	( 0.000)	( 0.000)	( 0.050)	( 0.218)
	Min,	3.9,	-0.4,	4.1,	0.5,	3.9,	-0.4,
	Max	4.1	0.0	4.1	0.5	4.1	0.5
Week 172	n	2	2	2	2	4	4
	Mean	3.85	-0.35	4.00	0.40	3.93	0.03
	Median	3.85	-0.35	4.00	0.40	4.00	0.00
	SD	0.354	0.071	0.141	0.141	0.236	0.443
	(SE)	( 0.250)	( 0.050)	( 0.100)	( 0.100)	( 0.118)	( 0.221)
	Min,	3.6,	-0.4,	3.9,	0.3,	3.6,	-0.4,
	Max	4.1	-0.3	4.1	0.5	4.1	0.5
Week 176	n	2	2	2	2	4	4
	Mean	4.15	-0.05	4.25	0.65	4.20	0.30
	Median	4.15	-0.05	4.25	0.65	4.25	0.35
	SD	0.212	0.212	0.071	0.071	0.141	0.424
	(SE)	( 0.150)	( 0.150)	( 0.050)	( 0.050)	( 0.071)	( 0.212)
	Min,	4.0,	-0.2,	4.2,	0.6,	4.0,	-0.2,
	Max	4.3	0.1	4.3	0.7	4.3	0.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	2	2	2	2	4	4
	Mean	4.05	-0.15	4.05	0.45	4.05	0.15
	Median	4.05	-0.15	4.05	0.45	4.05	0.25
	SD	0.071	0.495	0.212	0.212	0.129	0.465
	(SE)	( 0.050)	( 0.350)	( 0.150)	( 0.150)	( 0.065)	( 0.233)
	Min,	4.0,	-0.5,	3.9,	0.3,	3.9,	-0.5,
	Max	4.1	0.2	4.2	0.6	4.2	0.6
Week 184	n	2	2	2	2	4	4
	Mean	4.25	0.05	3.75	0.15	4.00	0.10
	Median	4.25	0.05	3.75	0.15	4.00	0.15
	SD	0.212	0.636	0.212	0.212	0.337	0.392
	(SE)	( 0.150)	( 0.450)	( 0.150)	( 0.150)	( 0.168)	( 0.196)
	Min,	4.1,	-0.4,	3.6,	0.0,	3.6,	-0.4,
	Max	4.4	0.5	3.9	0.3	4.4	0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Chloride (mmol/L)						
Week 1	n	2	2		4	
	Mean	102.5		103.5		103.0
	Median	102.5		103.5		103.5
	SD	3.54		2.12		2.45
	(SE)	( 2.50)		( 1.50)		( 1.22)
	Min,	100,		102,		100,
	Max	105		105		105
Week 2	n	2	2		4	
	Mean	103.0		106.0		104.5
	Median	103.0		106.0		104.0
	SD	1.41		2.83		2.52
	(SE)	( 1.00)		( 2.00)		( 1.26)
	Min,	102,		104,		102,
	Max	104		108		108
Week 4	n	2	2		4	
	Mean	103.5		104.5		104.0
	Median	103.5		104.5		104.0
	SD	2.12		2.12		1.83
	(SE)	( 1.50)		( 1.50)		( 0.91)
	Min,	102,		103,		102,
	Max	105		106		106

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	102.5		103.0		102.8	
	Median	102.5		103.0		103.0	
	SD	3.54		0.00		2.06	
	(SE)	( 2.50)		( 0.00)		( 1.03)	
	Min,	100,		103,		100,	
	Max	105		103		105	
Week 8	n	2		2		4	
	Mean	104.0		103.0		103.5	
	Median	104.0		103.0		103.0	
	SD	1.41		0.00		1.00	
	(SE)	( 1.00)		( 0.00)		( 0.50)	
	Min,	103,		103,		103,	
	Max	105		103		105	
Week 10	n	2		2		4	
	Mean	103.0		103.5		103.3	
	Median	103.0		103.5		103.5	
	SD	1.41		0.71		0.96	
	(SE)	( 1.00)		( 0.50)		( 0.48)	
	Min,	102,		103,		102,	
	Max	104		104		104	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	102.5		103.5		103.0	
	Median	102.5		103.5		103.5	
	SD	3.54		2.12		2.45	
	(SE)	( 2.50)		( 1.50)		( 1.22)	
	Min,	100,		102,		100,	
	Max	105		105		105	
Week 15	n	2		2		4	
	Mean	104.0		105.5		104.8	
	Median	104.0		105.5		105.0	
	SD	1.41		0.71		1.26	
	(SE)	( 1.00)		( 0.50)		( 0.63)	
	Min,	103,		105,		103,	
	Max	105		106		106	
Week 18	n	2		2		4	
	Mean	103.0		103.0		103.0	
	Median	103.0		103.0		103.0	
	SD	2.83		1.41		1.83	
	(SE)	( 2.00)		( 1.00)		( 0.91)	
	Min,	101,		102,		101,	
	Max	105		104		105	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	104.5		105.5		105.0	
	Median	104.5		105.5		105.5	
	SD	3.54		0.71		2.16	
	(SE)	( 2.50)		( 0.50)		( 1.08)	
	Min,	102,		105,		102,	
	Max	107		106		107	
Week 24	n	2		2		4	
	Mean	103.0		105.5		104.3	
	Median	103.0		105.5		105.0	
	SD	2.83		0.71		2.22	
	(SE)	( 2.00)		( 0.50)		( 1.11)	
	Min,	101,		105,		101,	
	Max	105		106		106	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	104.5		105.0		104.8	
	Median	104.5		105.0		105.0	
	SD	3.54		0.00		2.06	
	(SE)	( 2.50)		( 0.00)		( 1.03)	
	Min,	102,		105,		102,	
	Max	107		105		107	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	105.5	1.0	106.0	1.0	105.8	1.0
	Median	105.5	1.0	106.0	1.0	106.0	1.0
	SD	2.12	1.41	1.41	1.41	1.50	1.15
	(SE)	( 1.50)	( 1.00)	( 1.00)	( 1.00)	( 0.75)	( 0.58)
	Min,	104,	0,	105,	0,	104,	0,
	Max	107	2	107	2	107	2
Week 32	n	2	2	2	2	4	4
	Mean	102.5	-2.0	103.0	-2.0	102.8	-2.0
	Median	102.5	-2.0	103.0	-2.0	102.5	-2.0
	SD	0.71	2.83	1.41	1.41	0.96	1.83
	(SE)	( 0.50)	( 2.00)	( 1.00)	( 1.00)	( 0.48)	( 0.91)
	Min,	102,	-4,	102,	-3,	102,	-4,
	Max	103	0	104	-1	104	0
Week 36	n	2	2	1	1	3	3
	Mean	103.5	-1.0	101.0	-4.0	102.7	-2.0
	Median	103.5	-1.0	101.0	-4.0	102.0	-2.0
	SD	2.12	1.41			2.08	2.00
	(SE)	( 1.50)	( 1.00)			( 1.20)	( 1.15)
	Min,	102,	-2,	101,	-4,	101,	-4,
	Max	105	0	101	-4	105	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	102.0	-2.5	101.5	-3.5	101.8	-3.0
	Median	102.0	-2.5	101.5	-3.5	101.5	-2.5
	SD	2.83	0.71	2.12	2.12	2.06	1.41
	(SE)	( 2.00)	( 0.50)	( 1.50)	( 1.50)	( 1.03)	( 0.71)
	Min,	100,	-3,	100,	-5,	100,	-5,
	Max	104	-2	103	-2	104	-2
Week 44	n	2	2	2	2	4	4
	Mean	103.5	-1.0	104.0	-1.0	103.8	-1.0
	Median	103.5	-1.0	104.0	-1.0	103.5	-1.0
	SD	0.71	4.24	1.41	1.41	0.96	2.58
	(SE)	( 0.50)	( 3.00)	( 1.00)	( 1.00)	( 0.48)	( 1.29)
	Min,	103,	-4,	103,	-2,	103,	-4,
	Max	104	2	105	0	105	2
Week 48	n	2	2	2	2	4	4
	Mean	102.5	-2.0	103.0	-2.0	102.8	-2.0
	Median	102.5	-2.0	103.0	-2.0	102.5	-2.0
	SD	0.71	4.24	2.83	2.83	1.71	2.94
	(SE)	( 0.50)	( 3.00)	( 2.00)	( 2.00)	( 0.85)	( 1.47)
	Min,	102,	-5,	101,	-4,	101,	-5,
	Max	103	1	105	0	105	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	102.5	-2.0	102.5	-2.5	102.5	-2.3
	Median	102.5	-2.0	102.5	-2.5	102.5	-2.0
	SD	0.71	2.83	3.54	3.54	2.08	2.63
	(SE)	( 0.50)	( 2.00)	( 2.50)	( 2.50)	( 1.04)	( 1.31)
	Min,	102,	-4,	100,	-5,	100,	-5,
	Max	103	0	105	0	105	0
Week 56	n	2	2	2	2	4	4
	Mean	102.0	-2.5	102.5	-2.5	102.3	-2.5
	Median	102.0	-2.5	102.5	-2.5	102.5	-2.5
	SD	1.41	4.95	0.71	0.71	0.96	2.89
	(SE)	( 1.00)	( 3.50)	( 0.50)	( 0.50)	( 0.48)	( 1.44)
	Min,	101,	-6,	102,	-3,	101,	-6,
	Max	103	1	103	-2	103	1
Week 60	n	2	2	2	2	4	4
	Mean	102.5	-2.0	101.0	-4.0	101.8	-3.0
	Median	102.5	-2.0	101.0	-4.0	101.0	-4.0
	SD	3.54	7.07	0.00	0.00	2.22	4.24
	(SE)	( 2.50)	( 5.00)	( 0.00)	( 0.00)	( 1.11)	( 2.12)
	Min,	100,	-7,	101,	-4,	100,	-7,
	Max	105	3	101	-4	105	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 64	n	2	2	2	2	4	4
	Mean	102.0	-2.5	100.5	-4.5	101.3	-3.5
	Median	102.0	-2.5	100.5	-4.5	101.0	-4.5
	SD	1.41	4.95	0.71	0.71	1.26	3.11
	(SE)	( 1.00)	( 3.50)	( 0.50)	( 0.50)	( 0.63)	( 1.55)
	Min,	101,	-6,	100,	-5,	100,	-6,
	Max	103	1	101	-4	103	1
Week 68	n	2	2	2	2	4	4
	Mean	101.0	-3.5	103.5	-1.5	102.3	-2.5
	Median	101.0	-3.5	103.5	-1.5	102.0	-1.5
	SD	2.83	6.36	3.54	3.54	2.99	4.36
	(SE)	( 2.00)	( 4.50)	( 2.50)	( 2.50)	( 1.49)	( 2.18)
	Min,	99,	-8,	101,	-4,	99,	-8,
	Max	103	1	106	1	106	1
Week 72	n	2	2	0	0	2	2
	Mean	102.0	-2.5			102.0	-2.5
	Median	102.0	-2.5			102.0	-2.5
	SD	2.83	6.36			2.83	6.36
	(SE)	( 2.00)	( 4.50)			( 2.00)	( 4.50)
	Min,	100,	-7,			100,	-7,
	Max	104	2			104	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			99.0	-6.0	99.0	-6.0
	Median			99.0	-6.0	99.0	-6.0
	SD						
	(SE)						
	Min, Max			99, 99	-6, -6	99, 99	-6, -6
Week 76	n	2	2	2	2	4	4
	Mean	102.0	-2.5	99.0	-6.0	100.5	-4.3
	Median	102.0	-2.5	99.0	-6.0	100.5	-4.5
	SD	1.41	2.12	1.41	1.41	2.08	2.50
	(SE)	( 1.00)	( 1.50)	( 1.00)	( 1.00)	( 1.04)	( 1.25)
	Min, Max	101, 103	-4, -1	98, 100	-7, -5	98, 103	-7, -1
Week 80	n	2	2	2	2	4	4
	Mean	102.0	-2.5	102.5	-2.5	102.3	-2.5
	Median	102.0	-2.5	102.5	-2.5	102.0	-2.5
	SD	0.00	3.54	0.71	0.71	0.50	2.08
	(SE)	( 0.00)	( 2.50)	( 0.50)	( 0.50)	( 0.25)	( 1.04)
	Min, Max	102, 102	-5, 0	102, 103	-3, -2	102, 103	-5, 0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	102.0	-2.5	102.0	-3.0	102.0	-2.8
	Median	102.0	-2.5	102.0	-3.0	102.0	-3.0
	SD	2.83	6.36	1.41	1.41	1.83	3.77
	(SE)	( 2.00)	( 4.50)	( 1.00)	( 1.00)	( 0.91)	( 1.89)
	Min,	100,	-7,	101,	-4,	100,	-7,
	Max	104	2	103	-2	104	2
Week 88	n	2	2	2	2	4	4
	Mean	101.5	-3.0	102.0	-3.0	101.8	-3.0
	Median	101.5	-3.0	102.0	-3.0	101.5	-3.0
	SD	0.71	4.24	1.41	1.41	0.96	2.58
	(SE)	( 0.50)	( 3.00)	( 1.00)	( 1.00)	( 0.48)	( 1.29)
	Min,	101,	-6,	101,	-4,	101,	-6,
	Max	102	0	103	-2	103	0
Week 92	n	2	2	2	2	4	4
	Mean	102.5	-2.0	101.5	-3.5	102.0	-2.8
	Median	102.5	-2.0	101.5	-3.5	101.5	-3.5
	SD	2.12	5.66	0.71	0.71	1.41	3.40
	(SE)	( 1.50)	( 4.00)	( 0.50)	( 0.50)	( 0.71)	( 1.70)
	Min,	101,	-6,	101,	-4,	101,	-6,
	Max	104	2	102	-3	104	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	104.0	-0.5	102.0	-3.0	103.0	-1.8
	Median	104.0	-0.5	102.0	-3.0	103.5	-2.5
	SD	0.00	3.54	1.41	1.41	1.41	2.63
	(SE)	( 0.00)	( 2.50)	( 1.00)	( 1.00)	( 0.71)	( 1.31)
	Min,	104,	-3,	101,	-4,	101,	-4,
	Max	104	2	103	-2	104	2
Week 100	n	2	2	2	2	4	4
	Mean	102.5	-2.0	102.5	-2.5	102.5	-2.3
	Median	102.5	-2.0	102.5	-2.5	102.5	-2.5
	SD	2.12	1.41	0.71	0.71	1.29	0.96
	(SE)	( 1.50)	( 1.00)	( 0.50)	( 0.50)	( 0.65)	( 0.48)
	Min,	101,	-3,	102,	-3,	101,	-3,
	Max	104	-1	103	-2	104	-1
Week 104	n	2	2	2	2	4	4
	Mean	105.0	0.5	102.0	-3.0	103.5	-1.3
	Median	105.0	0.5	102.0	-3.0	103.5	-2.5
	SD	0.00	3.54	0.00	0.00	1.73	2.87
	(SE)	( 0.00)	( 2.50)	( 0.00)	( 0.00)	( 0.87)	( 1.44)
	Min,	105,	-2,	102,	-3,	102,	-3,
	Max	105	3	102	-3	105	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	101.5	-3.0	102.0	-3.0	101.8	-3.0
	Median	101.5	-3.0	102.0	-3.0	101.5	-3.0
	SD	2.12	5.66	2.83	2.83	2.06	3.65
	(SE)	( 1.50)	( 4.00)	( 2.00)	( 2.00)	( 1.03)	( 1.83)
	Min,	100,	-7,	100,	-5,	100,	-7,
	Max	103	1	104	-1	104	1
Week 112	n	2	2	2	2	4	4
	Mean	101.0	-3.5	102.0	-3.0	101.5	-3.3
	Median	101.0	-3.5	102.0	-3.0	101.0	-3.0
	SD	0.00	3.54	1.41	1.41	1.00	2.22
	(SE)	( 0.00)	( 2.50)	( 1.00)	( 1.00)	( 0.50)	( 1.11)
	Min,	101,	-6,	101,	-4,	101,	-6,
	Max	101	-1	103	-2	103	-1
Week 116	n	2	2	2	2	4	4
	Mean	102.0	-2.5	103.0	-2.0	102.5	-2.3
	Median	102.0	-2.5	103.0	-2.0	103.0	-2.0
	SD	2.83	6.36	0.00	0.00	1.73	3.69
	(SE)	( 2.00)	( 4.50)	( 0.00)	( 0.00)	( 0.87)	( 1.84)
	Min,	100,	-7,	103,	-2,	100,	-7,
	Max	104	2	103	-2	104	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	101.5	-3.0	101.5	-3.5	101.5	-3.3
	Median	101.5	-3.0	101.5	-3.5	101.5	-3.0
	SD	0.71	2.83	4.95	4.95	2.89	3.30
	(SE)	( 0.50)	( 2.00)	( 3.50)	( 3.50)	( 1.44)	( 1.65)
	Min,	101,	-5,	98,	-7,	98,	-7,
	Max	102	-1	105	0	105	0
Week 124	n	2	2	2	2	4	4
	Mean	100.5	-4.0	102.0	-3.0	101.3	-3.5
	Median	100.5	-4.0	102.0	-3.0	101.0	-3.0
	SD	0.71	2.83	1.41	1.41	1.26	1.91
	(SE)	( 0.50)	( 2.00)	( 1.00)	( 1.00)	( 0.63)	( 0.96)
	Min,	100,	-6,	101,	-4,	100,	-6,
	Max	101	-2	103	-2	103	-2
Week 128	n	2	2	2	2	4	4
	Mean	101.0	-3.5	100.5	-4.5	100.8	-4.0
	Median	101.0	-3.5	100.5	-4.5	100.5	-4.5
	SD	1.41	2.12	0.71	0.71	0.96	1.41
	(SE)	( 1.00)	( 1.50)	( 0.50)	( 0.50)	( 0.48)	( 0.71)
	Min,	100,	-5,	100,	-5,	100,	-5,
	Max	102	-2	101	-4	102	-2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	103.0	-1.5	102.0	-3.0	102.5	-2.3
	Median	103.0	-1.5	102.0	-3.0	102.5	-2.5
	SD	1.41	2.12	1.41	1.41	1.29	1.71
	(SE)	( 1.00)	( 1.50)	( 1.00)	( 1.00)	( 0.65)	( 0.85)
	Min,	102,	-3,	101,	-4,	101,	-4,
	Max	104	0	103	-2	104	0
Week 136	n	2	2	2	2	4	4
	Mean	101.5	-3.0	102.5	-2.5	102.0	-2.8
	Median	101.5	-3.0	102.5	-2.5	102.0	-2.5
	SD	0.71	4.24	0.71	0.71	0.82	2.50
	(SE)	( 0.50)	( 3.00)	( 0.50)	( 0.50)	( 0.41)	( 1.25)
	Min,	101,	-6,	102,	-3,	101,	-6,
	Max	102	0	103	-2	103	0
Week 140	n	2	2	2	2	4	4
	Mean	102.0	-2.5	101.5	-3.5	101.8	-3.0
	Median	102.0	-2.5	101.5	-3.5	102.0	-3.5
	SD	0.00	3.54	0.71	0.71	0.50	2.16
	(SE)	( 0.00)	( 2.50)	( 0.50)	( 0.50)	( 0.25)	( 1.08)
	Min,	102,	-5,	101,	-4,	101,	-5,
	Max	102	0	102	-3	102	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	104.0	-0.5	101.0	-4.0	102.5	-2.3
	Median	104.0	-0.5	101.0	-4.0	102.5	-2.5
	SD	1.41	2.12	1.41	1.41	2.08	2.50
	(SE)	( 1.00)	( 1.50)	( 1.00)	( 1.00)	( 1.04)	( 1.25)
	Min,	103,	-2,	100,	-5,	100,	-5,
	Max	105	1	102	-3	105	1
Week 148	n	2	2	2	2	4	4
	Mean	103.0	-1.5	102.5	-2.5	102.8	-2.0
	Median	103.0	-1.5	102.5	-2.5	102.5	-2.0
	SD	2.83	0.71	0.71	0.71	1.71	0.82
	(SE)	( 2.00)	( 0.50)	( 0.50)	( 0.50)	( 0.85)	( 0.41)
	Min,	101,	-2,	102,	-3,	101,	-3,
	Max	105	-1	103	-2	105	-1
Week 152	n	2	2	2	2	4	4
	Mean	102.0	-2.5	99.5	-5.5	100.8	-4.0
	Median	102.0	-2.5	99.5	-5.5	101.0	-4.0
	SD	1.41	2.12	2.12	2.12	2.06	2.45
	(SE)	( 1.00)	( 1.50)	( 1.50)	( 1.50)	( 1.03)	( 1.22)
	Min,	101,	-4,	98,	-7,	98,	-7,
	Max	103	-1	101	-4	103	-1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 156	n	2	2	2	2	4	4
	Mean	101.5	-3.0	101.5	-3.5	101.5	-3.3
	Median	101.5	-3.0	101.5	-3.5	101.5	-3.5
	SD	0.71	4.24	2.12	2.12	1.29	2.75
	(SE)	( 0.50)	( 3.00)	( 1.50)	( 1.50)	( 0.65)	( 1.38)
	Min,	101,	-6,	100,	-5,	100,	-6,
	Max	102	0	103	-2	103	0
Week 160	n	2	2	2	2	4	4
	Mean	101.5	-3.0	100.0	-5.0	100.8	-4.0
	Median	101.5	-3.0	100.0	-5.0	100.5	-5.0
	SD	0.71	4.24	0.00	0.00	0.96	2.71
	(SE)	( 0.50)	( 3.00)	( 0.00)	( 0.00)	( 0.48)	( 1.35)
	Min,	101,	-6,	100,	-5,	100,	-6,
	Max	102	0	100	-5	102	0
Week 164	n	2	2	2	2	4	4
	Mean	102.5	-2.0	101.0	-4.0	101.8	-3.0
	Median	102.5	-2.0	101.0	-4.0	102.0	-4.0
	SD	0.71	4.24	1.41	1.41	1.26	2.83
	(SE)	( 0.50)	( 3.00)	( 1.00)	( 1.00)	( 0.63)	( 1.41)
	Min,	102,	-5,	100,	-5,	100,	-5,
	Max	103	1	102	-3	103	1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 168	n	2	2	2	2	4	4
	Mean	101.5	-3.0	101.5	-3.5	101.5	-3.3
	Median	101.5	-3.0	101.5	-3.5	101.5	-3.5
	SD	0.71	4.24	0.71	0.71	0.58	2.50
	(SE)	( 0.50)	( 3.00)	( 0.50)	( 0.50)	( 0.29)	( 1.25)
	Min,	101,	-6,	101,	-4,	101,	-6,
	Max	102	0	102	-3	102	0
Week 172	n	2	2	2	2	4	4
	Mean	103.5	-1.0	101.0	-4.0	102.3	-2.5
	Median	103.5	-1.0	101.0	-4.0	101.5	-3.0
	SD	2.12	1.41	0.00	0.00	1.89	1.91
	(SE)	( 1.50)	( 1.00)	( 0.00)	( 0.00)	( 0.95)	( 0.95)
	Min,	102,	-2,	101,	-4,	101,	-4,
	Max	105	0	101	-4	105	0
Week 176	n	2	2	2	2	4	4
	Mean	103.5	-1.0	102.5	-2.5	103.0	-1.8
	Median	103.5	-1.0	102.5	-2.5	103.5	-2.5
	SD	0.71	4.24	2.12	2.12	1.41	2.87
	(SE)	( 0.50)	( 3.00)	( 1.50)	( 1.50)	( 0.71)	( 1.44)
	Min,	103,	-4,	101,	-4,	101,	-4,
	Max	104	2	104	-1	104	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	102.0	-2.5	100.0	-5.0	101.0	-3.8
	Median	102.0	-2.5	100.0	-5.0	101.5	-4.5
	SD	0.00	3.54	1.41	1.41	1.41	2.63
	(SE)	( 0.00)	( 2.50)	( 1.00)	( 1.00)	( 0.71)	( 1.31)
	Min,	102,	-5,	99,	-6,	99,	-6,
	Max	102	0	101	-4	102	0
Week 184	n	2	2	2	2	4	4
	Mean	101.0	-3.5	103.5	-1.5	102.3	-2.5
	Median	101.0	-3.5	103.5	-1.5	101.5	-2.0
	SD	0.00	3.54	2.12	2.12	1.89	2.65
	(SE)	( 0.00)	( 2.50)	( 1.50)	( 1.50)	( 0.95)	( 1.32)
	Min,	101,	-6,	102,	-3,	101,	-6,
	Max	101	-1	105	0	105	0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Calcium (mmol/L)						
Week 1	n	2	2		4	
	Mean	2.3500	2.3875		2.3688	
	Median	2.3500	2.3875		2.3750	
	SD	0.03536	0.01768		0.03146	
	(SE)	( 0.02500)	( 0.01250)		( 0.01573)	
	Min,	2.325,	2.375,		2.325,	
	Max	2.375	2.400		2.400	
Week 2	n	2	2		4	
	Mean	2.3500	2.3500		2.3500	
	Median	2.3500	2.3500		2.3500	
	SD	0.00000	0.03536		0.02041	
	(SE)	( 0.00000)	( 0.02500)		( 0.01021)	
	Min,	2.350,	2.325,		2.325,	
	Max	2.350	2.375		2.375	
Week 4	n	2	2		4	
	Mean	2.3375	2.3625		2.3500	
	Median	2.3375	2.3625		2.3500	
	SD	0.05303	0.05303		0.04564	
	(SE)	( 0.03750)	( 0.03750)		( 0.02282)	
	Min,	2.300,	2.325,		2.300,	
	Max	2.375	2.400		2.400	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	2.2875		2.4250		2.3563	
	Median	2.2875		2.4250		2.3500	
	SD	0.01768		0.03536		0.08260	
	(SE)	( 0.01250)		( 0.02500)		( 0.04130)	
	Min,	2.275,		2.400,		2.275,	
	Max	2.300		2.450		2.450	
Week 8	n	2		2		4	
	Mean	2.2500		2.3875		2.3187	
	Median	2.2500		2.3875		2.3125	
	SD	0.03536		0.05303		0.08750	
	(SE)	( 0.02500)		( 0.03750)		( 0.04375)	
	Min,	2.225,		2.350,		2.225,	
	Max	2.275		2.425		2.425	
Week 10	n	2		2		4	
	Mean	2.2625		2.2375		2.2500	
	Median	2.2625		2.2375		2.2625	
	SD	0.01768		0.08839		0.05401	
	(SE)	( 0.01250)		( 0.06250)		( 0.02700)	
	Min,	2.250,		2.175,		2.175,	
	Max	2.275		2.300		2.300	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	2.3125		2.4125		2.3625	
	Median	2.3125		2.4125		2.3750	
	SD	0.05303		0.01768		0.06614	
	(SE)	( 0.03750)		( 0.01250)		( 0.03307)	
	Min,	2.275,		2.400,		2.275,	
	Max	2.350		2.425		2.425	
Week 15	n	2		2		4	
	Mean	2.2750		2.3375		2.3063	
	Median	2.2750		2.3375		2.2875	
	SD	0.03536		0.08839		0.06575	
	(SE)	( 0.02500)		( 0.06250)		( 0.03287)	
	Min,	2.250,		2.275,		2.250,	
	Max	2.300		2.400		2.400	
Week 18	n	2		2		4	
	Mean	2.2625		2.3000		2.2813	
	Median	2.2625		2.3000		2.2750	
	SD	0.05303		0.07071		0.05543	
	(SE)	( 0.03750)		( 0.05000)		( 0.02772)	
	Min,	2.225,		2.250,		2.225,	
	Max	2.300		2.350		2.350	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	2.2625		2.3625		2.3125	
	Median	2.2625		2.3625		2.3375	
	SD	0.08839		0.01768		0.07773	
	(SE)	( 0.06250)		( 0.01250)		( 0.03886)	
	Min,	2.200,		2.350,		2.200,	
	Max	2.325		2.375		2.375	
Week 24	n	2		2		4	
	Mean	2.3250		2.3375		2.3313	
	Median	2.3250		2.3375		2.3375	
	SD	0.03536		0.01768		0.02394	
	(SE)	( 0.02500)		( 0.01250)		( 0.01197)	
	Min,	2.300,		2.325,		2.300,	
	Max	2.350		2.350		2.350	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	2.3250		2.3625		2.3438	
	Median	2.3250		2.3625		2.3625	
	SD	0.14142		0.05303		0.08985	
	(SE)	( 0.10000)		( 0.03750)		( 0.04492)	
	Min,	2.225,		2.325,		2.225,	
	Max	2.425		2.400		2.425	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	2.2250	-0.1000	2.3250	-0.0375	2.2750	-0.0688
	Median	2.2250	-0.1000	2.3250	-0.0375	2.2750	-0.0375
	SD	0.03536	0.10607	0.03536	0.01768	0.06455	0.07181
	(SE)	( 0.02500)	( 0.07500)	( 0.02500)	( 0.01250)	( 0.03227)	( 0.03590)
	Min,	2.200,	-0.175,	2.300,	-0.050,	2.200,	-0.175,
	Max	2.250	-0.025	2.350	-0.025	2.350	-0.025
	Week 32	n	2	2	2	2	4
Mean		2.2750	-0.0500	2.4375	0.0750	2.3563	0.0125
Median		2.2750	-0.0500	2.4375	0.0750	2.3625	0.0500
SD		0.07071	0.21213	0.05303	0.10607	0.10680	0.15478
(SE)		( 0.05000)	( 0.15000)	( 0.03750)	( 0.07500)	( 0.05340)	( 0.07739)
Min,		2.225,	-0.200,	2.400,	0.000,	2.225,	-0.200,
Max		2.325	0.100	2.475	0.150	2.475	0.150
Week 36		n	2	2	1	1	3
	Mean	2.2875	-0.0375	2.4500	0.1250	2.3417	0.0167
	Median	2.2875	-0.0375	2.4500	0.1250	2.3000	0.0750
	SD	0.01768	0.15910			0.09465	0.14649
	(SE)	( 0.01250)	( 0.11250)			( 0.05465)	( 0.08457)
	Min,	2.275,	-0.150,	2.450,	0.125,	2.275,	-0.150,
	Max	2.300	0.075	2.450	0.125	2.450	0.125

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	2.3250	0.0000	2.3250	-0.0375	2.3250	-0.0188
	Median	2.3250	0.0000	2.3250	-0.0375	2.3250	-0.0375
	SD	0.03536	0.10607	0.07071	0.01768	0.04564	0.06575
	(SE)	( 0.02500)	( 0.07500)	( 0.05000)	( 0.01250)	( 0.02282)	( 0.03287)
	Min,	2.300,	-0.075,	2.275,	-0.050,	2.275,	-0.075,
	Max	2.350	0.075	2.375	-0.025	2.375	0.075
Week 44	n	2	2	2	2	4	4
	Mean	2.3250	0.0000	2.3375	-0.0250	2.3313	-0.0125
	Median	2.3250	0.0000	2.3375	-0.0250	2.3250	-0.0250
	SD	0.00000	0.14142	0.01768	0.07071	0.01250	0.09242
	(SE)	( 0.00000)	( 0.10000)	( 0.01250)	( 0.05000)	( 0.00625)	( 0.04621)
	Min,	2.325,	-0.100,	2.325,	-0.075,	2.325,	-0.100,
	Max	2.325	0.100	2.350	0.025	2.350	0.100
Week 48	n	2	2	2	2	4	4
	Mean	2.4000	0.0750	2.4250	0.0625	2.4125	0.0688
	Median	2.4000	0.0750	2.4250	0.0625	2.4125	0.0625
	SD	0.00000	0.14142	0.00000	0.05303	0.01443	0.08750
	(SE)	( 0.00000)	( 0.10000)	( 0.00000)	( 0.03750)	( 0.00722)	( 0.04375)
	Min,	2.400,	-0.025,	2.425,	0.025,	2.400,	-0.025,
	Max	2.400	0.175	2.425	0.100	2.425	0.175

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	2.3000	-0.0250	2.4375	0.0750	2.3688	0.0250
	Median	2.3000	-0.0250	2.4375	0.0750	2.3625	0.0250
	SD	0.03536	0.10607	0.05303	0.10607	0.08750	0.10408
	(SE)	( 0.02500)	( 0.07500)	( 0.03750)	( 0.07500)	( 0.04375)	( 0.05204)
	Min,	2.275,	-0.100,	2.400,	0.000,	2.275,	-0.100,
	Max	2.325	0.050	2.475	0.150	2.475	0.150
Week 56	n	2	2	2	2	4	4
	Mean	2.4125	0.0875	2.4750	0.1125	2.4438	0.1000
	Median	2.4125	0.0875	2.4750	0.1125	2.4750	0.1000
	SD	0.08839	0.05303	0.00000	0.05303	0.06250	0.04564
	(SE)	( 0.06250)	( 0.03750)	( 0.00000)	( 0.03750)	( 0.03125)	( 0.02282)
	Min,	2.350,	0.050,	2.475,	0.075,	2.350,	0.050,
	Max	2.475	0.125	2.475	0.150	2.475	0.150
Week 60	n	2	2	2	2	4	4
	Mean	2.3250	0.0000	2.4125	0.0500	2.3688	0.0250
	Median	2.3250	0.0000	2.4125	0.0500	2.3500	0.0125
	SD	0.03536	0.10607	0.08839	0.14142	0.07465	0.10607
	(SE)	( 0.02500)	( 0.07500)	( 0.06250)	( 0.10000)	( 0.03733)	( 0.05303)
	Min,	2.300,	-0.075,	2.350,	-0.050,	2.300,	-0.075,
	Max	2.350	0.075	2.475	0.150	2.475	0.150

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	2.3375	0.0125	2.4375	0.0750	2.3875	0.0438
	Median	2.3375	0.0125	2.4375	0.0750	2.3500	0.0375
	SD	0.01768	0.15910	0.12374	0.17678	0.09242	0.14197
	(SE)	( 0.01250)	( 0.11250)	( 0.08750)	( 0.12500)	( 0.04621)	( 0.07099)
	Min,	2.325,	-0.100,	2.350,	-0.050,	2.325,	-0.100,
	Max	2.350	0.125	2.525	0.200	2.525	0.200
Week 68	n	2	2	2	2	4	4
	Mean	2.3250	0.0000	2.1875	-0.1750	2.2563	-0.0875
	Median	2.3250	0.0000	2.1875	-0.1750	2.3000	-0.1125
	SD	0.00000	0.14142	0.12374	0.07071	0.10680	0.13617
	(SE)	( 0.00000)	( 0.10000)	( 0.08750)	( 0.05000)	( 0.05340)	( 0.06808)
	Min,	2.325,	-0.100,	2.100,	-0.225,	2.100,	-0.225,
	Max	2.325	0.100	2.275	-0.125	2.325	0.100
Week 72	n	2	2	0	0	2	2
	Mean	2.3250	0.0000			2.3250	0.0000
	Median	2.3250	0.0000			2.3250	0.0000
	SD	0.00000	0.14142			0.00000	0.14142
	(SE)	( 0.00000)	( 0.10000)			( 0.00000)	( 0.10000)
	Min,	2.325,	-0.100,			2.325,	-0.100,
	Max	2.325	0.100			2.325	0.100

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			2.3750	-0.0250	2.3750	-0.0250
	Median			2.3750	-0.0250	2.3750	-0.0250
	SD						
	(SE)						
	Min, Max			2.375, 2.375	-0.025, -0.025	2.375, 2.375	-0.025, -0.025
Week 76	n	2	2	2	2	4	4
	Mean	2.3875	0.0625	2.4500	0.0875	2.4188	0.0750
	Median	2.3875	0.0625	2.4500	0.0875	2.4250	0.0875
	SD	0.01768	0.15910	0.00000	0.05303	0.03750	0.09789
	(SE)	( 0.01250)	( 0.11250)	( 0.00000)	( 0.03750)	( 0.01875)	( 0.04895)
	Min, Max	2.375, 2.400	-0.050, 0.175	2.450, 2.450	0.050, 0.125	2.375, 2.450	-0.050, 0.175
Week 80	n	2	2	2	2	4	4
	Mean	2.4125	0.0875	2.3875	0.0250	2.4000	0.0563
	Median	2.4125	0.0875	2.3875	0.0250	2.4000	0.0250
	SD	0.05303	0.19445	0.05303	0.10607	0.04564	0.13288
	(SE)	( 0.03750)	( 0.13750)	( 0.03750)	( 0.07500)	( 0.02282)	( 0.06644)
	Min, Max	2.375, 2.450	-0.050, 0.225	2.350, 2.425	-0.050, 0.100	2.350, 2.450	-0.050, 0.225

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	2.3625	0.0375	2.4375	0.0750	2.4000	0.0563
	Median	2.3625	0.0375	2.4375	0.0750	2.4125	0.0750
	SD	0.08839	0.22981	0.05303	0.10607	0.07360	0.14773
	(SE)	( 0.06250)	( 0.16250)	( 0.03750)	( 0.07500)	( 0.03680)	( 0.07386)
	Min,	2.300,	-0.125,	2.400,	0.000,	2.300,	-0.125,
	Max	2.425	0.200	2.475	0.150	2.475	0.200
Week 88	n	2	2	2	2	4	4
	Mean	2.3125	-0.0125	2.3625	0.0000	2.3375	-0.0063
	Median	2.3125	-0.0125	2.3625	0.0000	2.3250	0.0000
	SD	0.01768	0.12374	0.05303	0.10607	0.04330	0.09437
	(SE)	( 0.01250)	( 0.08750)	( 0.03750)	( 0.07500)	( 0.02165)	( 0.04719)
	Min,	2.300,	-0.100,	2.325,	-0.075,	2.300,	-0.100,
	Max	2.325	0.075	2.400	0.075	2.400	0.075
Week 92	n	2	2	2	2	4	4
	Mean	2.3125	-0.0125	2.3750	0.0125	2.3438	0.0000
	Median	2.3125	-0.0125	2.3750	0.0125	2.3125	0.0000
	SD	0.01768	0.15910	0.10607	0.15910	0.07181	0.13070
	(SE)	( 0.01250)	( 0.11250)	( 0.07500)	( 0.11250)	( 0.03590)	( 0.06535)
	Min,	2.300,	-0.125,	2.300,	-0.100,	2.300,	-0.125,
	Max	2.325	0.100	2.450	0.125	2.450	0.125

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	2.2750	-0.0500	2.4250	0.0625	2.3500	0.0063
	Median	2.2750	-0.0500	2.4250	0.0625	2.3375	0.0500
	SD	0.00000	0.14142	0.03536	0.01768	0.08898	0.10483
	(SE)	( 0.00000)	( 0.10000)	( 0.02500)	( 0.01250)	( 0.04449)	( 0.05242)
	Min,	2.275,	-0.150,	2.400,	0.050,	2.275,	-0.150,
	Max	2.275	0.050	2.450	0.075	2.450	0.075
Week 100	n	2	2	2	2	4	4
	Mean	2.3500	0.0250	2.3750	0.0125	2.3625	0.0188
	Median	2.3500	0.0250	2.3750	0.0125	2.3500	0.0250
	SD	0.00000	0.14142	0.10607	0.15910	0.06292	0.12311
	(SE)	( 0.00000)	( 0.10000)	( 0.07500)	( 0.11250)	( 0.03146)	( 0.06156)
	Min,	2.350,	-0.075,	2.300,	-0.100,	2.300,	-0.100,
	Max	2.350	0.125	2.450	0.125	2.450	0.125
Week 104	n	2	2	2	2	4	4
	Mean	2.3625	0.0375	2.3750	0.0125	2.3688	0.0250
	Median	2.3625	0.0375	2.3750	0.0125	2.3625	0.0125
	SD	0.01768	0.12374	0.07071	0.01768	0.04270	0.07360
	(SE)	( 0.01250)	( 0.08750)	( 0.05000)	( 0.01250)	( 0.02135)	( 0.03680)
	Min,	2.350,	-0.050,	2.325,	0.000,	2.325,	-0.050,
	Max	2.375	0.125	2.425	0.025	2.425	0.125

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	2.4125	0.0875	2.4625	0.1000	2.4375	0.0938
	Median	2.4125	0.0875	2.4625	0.1000	2.4250	0.1000
	SD	0.01768	0.15910	0.05303	0.10607	0.04330	0.11063
	(SE)	( 0.01250)	( 0.11250)	( 0.03750)	( 0.07500)	( 0.02165)	( 0.05532)
	Min,	2.400,	-0.025,	2.425,	0.025,	2.400,	-0.025,
	Max	2.425	0.200	2.500	0.175	2.500	0.200
Week 112	n	2	2	2	2	4	4
	Mean	2.3875	0.0625	2.4375	0.0750	2.4125	0.0688
	Median	2.3875	0.0625	2.4375	0.0750	2.4250	0.0750
	SD	0.05303	0.19445	0.01768	0.07071	0.04330	0.11968
	(SE)	( 0.03750)	( 0.13750)	( 0.01250)	( 0.05000)	( 0.02165)	( 0.05984)
	Min,	2.350,	-0.075,	2.425,	0.025,	2.350,	-0.075,
	Max	2.425	0.200	2.450	0.125	2.450	0.200
Week 116	n	2	2	2	2	4	4
	Mean	2.3375	0.0125	2.3750	0.0125	2.3563	0.0125
	Median	2.3375	0.0125	2.3750	0.0125	2.3625	0.0125
	SD	0.05303	0.08839	0.03536	0.08839	0.04270	0.07217
	(SE)	( 0.03750)	( 0.06250)	( 0.02500)	( 0.06250)	( 0.02135)	( 0.03608)
	Min,	2.300,	-0.050,	2.350,	-0.050,	2.300,	-0.050,
	Max	2.375	0.075	2.400	0.075	2.400	0.075

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	2.3750	0.0500	2.3625	0.0000	2.3688	0.0250
	Median	2.3750	0.0500	2.3625	0.0000	2.3750	0.0000
	SD	0.00000	0.14142	0.01768	0.03536	0.01250	0.08898
	(SE)	( 0.00000)	( 0.10000)	( 0.01250)	( 0.02500)	( 0.00625)	( 0.04449)
	Min,	2.375,	-0.050,	2.350,	-0.025,	2.350,	-0.050,
	Max	2.375	0.150	2.375	0.025	2.375	0.150
Week 124	n	2	2	2	2	4	4
	Mean	2.3750	0.0500	2.3875	0.0250	2.3813	0.0375
	Median	2.3750	0.0500	2.3875	0.0250	2.3875	0.0250
	SD	0.03536	0.10607	0.01768	0.07071	0.02394	0.07500
	(SE)	( 0.02500)	( 0.07500)	( 0.01250)	( 0.05000)	( 0.01197)	( 0.03750)
	Min,	2.350,	-0.025,	2.375,	-0.025,	2.350,	-0.025,
	Max	2.400	0.125	2.400	0.075	2.400	0.125
Week 128	n	2	2	2	2	4	4
	Mean	2.3500	0.0250	2.4500	0.0875	2.4000	0.0563
	Median	2.3500	0.0250	2.4500	0.0875	2.4250	0.0875
	SD	0.14142	0.28284	0.07071	0.12374	0.10801	0.18186
	(SE)	( 0.10000)	( 0.20000)	( 0.05000)	( 0.08750)	( 0.05401)	( 0.09093)
	Min,	2.250,	-0.175,	2.400,	0.000,	2.250,	-0.175,
	Max	2.450	0.225	2.500	0.175	2.500	0.225

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	2.4250	0.1000	2.0875	-0.2750	2.2562	-0.0875
	Median	2.4250	0.1000	2.0875	-0.2750	2.3125	-0.1000
	SD	0.03536	0.17678	0.19445	0.14142	0.22581	0.25290
	(SE)	( 0.02500)	( 0.12500)	( 0.13750)	( 0.10000)	( 0.11290)	( 0.12645)
	Min,	2.400,	-0.025,	1.950,	-0.375,	1.950,	-0.375,
	Max	2.450	0.225	2.225	-0.175	2.450	0.225
Week 136	n	2	2	2	2	4	4
	Mean	2.3500	0.0250	2.3750	0.0125	2.3625	0.0188
	Median	2.3500	0.0250	2.3750	0.0125	2.3500	0.0125
	SD	0.03536	0.17678	0.10607	0.15910	0.06614	0.13750
	(SE)	( 0.02500)	( 0.12500)	( 0.07500)	( 0.11250)	( 0.03307)	( 0.06875)
	Min,	2.325,	-0.100,	2.300,	-0.100,	2.300,	-0.100,
	Max	2.375	0.150	2.450	0.125	2.450	0.150
Week 140	n	2	2	2	2	4	4
	Mean	2.3125	-0.0125	2.3375	-0.0250	2.3250	-0.0187
	Median	2.3125	-0.0125	2.3375	-0.0250	2.3125	-0.0125
	SD	0.01768	0.12374	0.26517	0.31820	0.15411	0.19725
	(SE)	( 0.01250)	( 0.08750)	( 0.18750)	( 0.22500)	( 0.07706)	( 0.09862)
	Min,	2.300,	-0.100,	2.150,	-0.250,	2.150,	-0.250,
	Max	2.325	0.075	2.525	0.200	2.525	0.200

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	2.2625	-0.0625	2.3750	0.0125	2.3188	-0.0250
	Median	2.2625	-0.0625	2.3750	0.0125	2.3000	-0.0125
	SD	0.01768	0.15910	0.07071	0.12374	0.07739	0.12416
	(SE)	( 0.01250)	( 0.11250)	( 0.05000)	( 0.08750)	( 0.03870)	( 0.06208)
	Min,	2.250,	-0.175,	2.325,	-0.075,	2.250,	-0.175,
	Max	2.275	0.050	2.425	0.100	2.425	0.100
Week 148	n	2	2	2	2	4	4
	Mean	2.3375	0.0125	2.3875	0.0250	2.3625	0.0188
	Median	2.3375	0.0125	2.3875	0.0250	2.3625	0.0250
	SD	0.05303	0.19445	0.05303	0.10607	0.05204	0.12809
	(SE)	( 0.03750)	( 0.13750)	( 0.03750)	( 0.07500)	( 0.02602)	( 0.06404)
	Min,	2.300,	-0.125,	2.350,	-0.050,	2.300,	-0.125,
	Max	2.375	0.150	2.425	0.100	2.425	0.150
Week 152	n	2	2	2	2	4	4
	Mean	2.3500	0.0250	2.4000	0.0375	2.3750	0.0313
	Median	2.3500	0.0250	2.4000	0.0375	2.3625	0.0375
	SD	0.00000	0.14142	0.03536	0.08839	0.03536	0.09656
	(SE)	( 0.00000)	( 0.10000)	( 0.02500)	( 0.06250)	( 0.01768)	( 0.04828)
	Min,	2.350,	-0.075,	2.375,	-0.025,	2.350,	-0.075,
	Max	2.350	0.125	2.425	0.100	2.425	0.125

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	2.3125	-0.0125	2.4250	0.0625	2.3688	0.0250
	Median	2.3125	-0.0125	2.4250	0.0625	2.4125	0.0625
	SD	0.12374	0.26517	0.00000	0.05303	0.09656	0.16202
	(SE)	( 0.08750)	( 0.18750)	( 0.00000)	( 0.03750)	( 0.04828)	( 0.08101)
	Min,	2.225,	-0.200,	2.425,	0.025,	2.225,	-0.200,
	Max	2.400	0.175	2.425	0.100	2.425	0.175
Week 160	n	2	2	2	2	4	4
	Mean	2.3250	0.0000	2.4125	0.0500	2.3688	0.0250
	Median	2.3250	0.0000	2.4125	0.0500	2.3500	0.0125
	SD	0.03536	0.10607	0.08839	0.14142	0.07465	0.10607
	(SE)	( 0.02500)	( 0.07500)	( 0.06250)	( 0.10000)	( 0.03733)	( 0.05303)
	Min,	2.300,	-0.075,	2.350,	-0.050,	2.300,	-0.075,
	Max	2.350	0.075	2.475	0.150	2.475	0.150
Week 164	n	2	2	2	2	4	4
	Mean	2.3500	0.0250	2.3750	0.0125	2.3625	0.0188
	Median	2.3500	0.0250	2.3750	0.0125	2.3500	0.0250
	SD	0.00000	0.14142	0.10607	0.15910	0.06292	0.12311
	(SE)	( 0.00000)	( 0.10000)	( 0.07500)	( 0.11250)	( 0.03146)	( 0.06156)
	Min,	2.350,	-0.075,	2.300,	-0.100,	2.300,	-0.100,
	Max	2.350	0.125	2.450	0.125	2.450	0.125

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	2.3750	0.0500	2.4500	0.0875	2.4125	0.0688
	Median	2.3750	0.0500	2.4500	0.0875	2.4000	0.0875
	SD	0.00000	0.14142	0.03536	0.01768	0.04787	0.08509
	(SE)	( 0.00000)	( 0.10000)	( 0.02500)	( 0.01250)	( 0.02394)	( 0.04254)
	Min,	2.375,	-0.050,	2.425,	0.075,	2.375,	-0.050,
	Max	2.375	0.150	2.475	0.100	2.475	0.150
Week 172	n	2	2	2	2	4	4
	Mean	2.4000	0.0750	2.3875	0.0250	2.3938	0.0500
	Median	2.4000	0.0750	2.3875	0.0250	2.3875	0.0625
	SD	0.07071	0.07071	0.05303	0.10607	0.05154	0.07906
	(SE)	( 0.05000)	( 0.05000)	( 0.03750)	( 0.07500)	( 0.02577)	( 0.03953)
	Min,	2.350,	0.025,	2.350,	-0.050,	2.350,	-0.050,
	Max	2.450	0.125	2.425	0.100	2.450	0.125
Week 176	n	2	2	2	2	4	4
	Mean	2.3750	0.0500	2.4250	0.0625	2.4000	0.0563
	Median	2.3750	0.0500	2.4250	0.0625	2.4000	0.0500
	SD	0.07071	0.07071	0.07071	0.12374	0.06455	0.08260
	(SE)	( 0.05000)	( 0.05000)	( 0.05000)	( 0.08750)	( 0.03227)	( 0.04130)
	Min,	2.325,	0.000,	2.375,	-0.025,	2.325,	-0.025,
	Max	2.425	0.100	2.475	0.150	2.475	0.150

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	2.4125	0.0875	2.3875	0.0250	2.4000	0.0563
	Median	2.4125	0.0875	2.3875	0.0250	2.4125	0.0500
	SD	0.01768	0.12374	0.05303	0.10607	0.03536	0.10078
	(SE)	( 0.01250)	( 0.08750)	( 0.03750)	( 0.07500)	( 0.01768)	( 0.05039)
	Min,	2.400,	0.000,	2.350,	-0.050,	2.350,	-0.050,
	Max	2.425	0.175	2.425	0.100	2.425	0.175
Week 184	n	2	2	2	2	4	4
	Mean	2.3125	-0.0125	2.3125	-0.0500	2.3125	-0.0313
	Median	2.3125	-0.0125	2.3125	-0.0500	2.3125	-0.0500
	SD	0.01768	0.15910	0.05303	0.00000	0.03227	0.09437
	(SE)	( 0.01250)	( 0.11250)	( 0.03750)	( 0.00000)	( 0.01614)	( 0.04719)
	Min,	2.300,	-0.125,	2.275,	-0.050,	2.275,	-0.125,
	Max	2.325	0.100	2.350	-0.050	2.350	0.100

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Glucose (mmol/L)						
Week 1	n	2	2		4	
	Mean	5.16150	5.02275		5.09213	
	Median	5.16150	5.02275		5.02275	
	SD	1.334310	0.117733		0.777495	
	(SE)	( 0.943500)	( 0.083250)		( 0.388748)	
	Min,	4.2180,	4.9395,		4.2180,	
	Max	6.1050	5.1060		6.1050	
Week 2	n	2	2		4	
	Mean	4.93950	5.05050		4.99500	
	Median	4.93950	5.05050		5.05050	
	SD	1.020355	0.784889		0.745988	
	(SE)	( 0.721500)	( 0.555000)		( 0.372994)	
	Min,	4.2180,	4.4955,		4.2180,	
	Max	5.6610	5.6055		5.6610	
Week 4	n	2	2		4	
	Mean	5.18925	5.52225		5.35575	
	Median	5.18925	5.52225		5.52225	
	SD	1.373555	0.824133		0.944588	
	(SE)	( 0.971250)	( 0.582750)		( 0.472294)	
	Min,	4.2180,	4.9395,		4.2180,	
	Max	6.1605	6.1050		6.1605	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	4.85625		4.46775		4.66200	
	Median	4.85625		4.46775		4.49550	
	SD	0.824133		0.353200		0.564174	
	(SE)	( 0.582750)		( 0.249750)		( 0.282087)	
	Min,	4.2735,		4.2180,		4.2180,	
	Max	5.4390		4.7175		5.4390	
Week 8	n	2		2		4	
	Mean	4.96725		5.79975		5.38350	
	Median	4.96725		5.79975		5.55000	
	SD	1.138088		0.667155		0.900629	
	(SE)	( 0.804750)		( 0.471750)		( 0.450314)	
	Min,	4.1625,		5.3280,		4.1625,	
	Max	5.7720		6.2715		6.2715	
Week 10	n	2		1		3	
	Mean	4.99500		5.99400		5.32800	
	Median	4.99500		5.99400		5.99400	
	SD	1.412799				1.153546	
	(SE)	( 0.999000)				( 0.666000)	
	Min,	3.9960,		5.9940,		3.9960,	
	Max	5.9940		5.9940		5.9940	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2	2		4	
	Mean	4.66200	5.57775		5.11988	
	Median	4.66200	5.57775		5.18925	
	SD	0.549422	0.353200		0.649413	
	(SE)	( 0.388500)	( 0.249750)		( 0.324707)	
	Min,	4.2735,	5.3280,		4.2735,	
	Max	5.0505	5.8275		5.8275	
Week 15	n	2	2		4	
	Mean	4.66200	4.05150		4.35675	
	Median	4.66200	4.05150		4.66200	
	SD	0.000000	1.491288		0.930350	
	(SE)	( 0.000000)	( 1.054500)		( 0.465175)	
	Min,	4.6620,	2.9970,		2.9970,	
	Max	4.6620	5.1060		5.1060	
Week 18	n	2	2		4	
	Mean	4.07925	4.80075		4.44000	
	Median	4.07925	4.80075		4.49550	
	SD	0.274711	0.117733		0.450884	
	(SE)	( 0.194250)	( 0.083250)		( 0.225442)	
	Min,	3.8850,	4.7175,		3.8850,	
	Max	4.2735	4.8840		4.8840	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2	2		4	
	Mean	4.71750	3.96825		4.34288	
	Median	4.71750	3.96825		4.21800	
	SD	0.470933	0.117733		0.515433	
	(SE)	( 0.333000)	( 0.083250)		( 0.257717)	
	Min,	4.3845,	3.8850,		3.8850,	
	Max	5.0505	4.0515		5.0505	
Week 24	n	2	2		4	
	Mean	4.07925	6.63225		5.35575	
	Median	4.07925	6.63225		5.30025	
	SD	0.667155	0.824133		1.596047	
	(SE)	( 0.471750)	( 0.582750)		( 0.798024)	
	Min,	3.6075,	6.0495,		3.6075,	
	Max	4.5510	7.2150		7.2150	
Baseline <sup>1</sup>	n	2	2		4	
	Mean	4.27350	3.94050		4.10700	
	Median	4.27350	3.94050		4.05150	
	SD	0.392444	0.235467		0.326775	
	(SE)	( 0.277500)	( 0.166500)		( 0.163388)	
	Min,	3.9960,	3.7740,		3.7740,	
	Max	4.5510	4.1070		4.5510	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	4.93950	0.66600	5.24475	1.30425	5.09213	0.98513
	Median	4.93950	0.66600	5.24475	1.30425	4.96725	0.80475
	SD	0.784889	0.392444	1.138088	0.902622	0.817409	0.677274
	(SE)	( 0.555000)	( 0.277500)	( 0.804750)	( 0.638250)	( 0.408705)	( 0.338637)
	Min,	4.3845,	0.3885,	4.4400,	0.6660,	4.3845,	0.3885,
	Max	5.4945	0.9435	6.0495	1.9425	6.0495	1.9425
Week 32	n	2	2	2	2	4	4
	Mean	4.66200	0.38850	5.63325	1.69275	5.14763	1.04063
	Median	4.66200	0.38850	5.63325	1.69275	5.07825	1.19325
	SD	1.098844	1.491288	1.295066	1.059600	1.129599	1.297146
	(SE)	( 0.777000)	( 1.054500)	( 0.915750)	( 0.749250)	( 0.564799)	( 0.648573)
	Min,	3.8850,	-0.6660,	4.7175,	0.9435,	3.8850,	-0.6660,
	Max	5.4390	1.4430	6.5490	2.4420	6.5490	2.4420
Week 36	n	2	2	1	1	3	3
	Mean	4.71750	0.44400	5.88300	2.10900	5.10600	0.99900
	Median	4.71750	0.44400	5.88300	2.10900	4.88400	0.88800
	SD	0.235467	0.627911			0.693195	1.058873
	(SE)	( 0.166500)	( 0.444000)			( 0.400216)	( 0.611340)
	Min,	4.5510,	0.0000,	5.8830,	2.1090,	4.5510,	0.0000,
	Max	4.8840	0.8880	5.8830	2.1090	5.8830	2.1090

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	4.80075	0.52725	4.21800	0.27750	4.50938	0.40238
	Median	4.80075	0.52725	4.21800	0.27750	4.63425	0.30525
	SD	0.510178	0.902622	0.863377	0.627911	0.669651	0.650992
	(SE)	( 0.360750)	( 0.638250)	( 0.610500)	( 0.444000)	( 0.334826)	( 0.325496)
	Min,	4.4400,	-0.1110,	3.6075,	-0.1665,	3.6075,	-0.1665,
	Max	5.1615	1.1655	4.8285	0.7215	5.1615	1.1655
Week 44	n	2	2	2	2	4	4
	Mean	5.21700	0.94350	4.85625	0.91575	5.03663	0.92963
	Median	5.21700	0.94350	4.85625	0.91575	4.85625	0.91575
	SD	1.020355	1.412799	0.196222	0.431689	0.635024	0.853059
	(SE)	( 0.721500)	( 0.999000)	( 0.138750)	( 0.305250)	( 0.317512)	( 0.426529)
	Min,	4.4955,	-0.0555,	4.7175,	0.6105,	4.4955,	-0.0555,
	Max	5.9385	1.9425	4.9950	1.2210	5.9385	1.9425
Week 48	n	2	2	2	2	4	4
	Mean	4.21800	-0.05550	5.27250	1.33200	4.74525	0.63825
	Median	4.21800	-0.05550	5.27250	1.33200	4.35675	0.30525
	SD	0.156978	0.549422	1.255822	1.491288	0.951087	1.218053
	(SE)	( 0.111000)	( 0.388500)	( 0.888000)	( 1.054500)	( 0.475544)	( 0.609027)
	Min,	4.1070,	-0.4440,	4.3845,	0.2775,	4.1070,	-0.4440,
	Max	4.3290	0.3330	6.1605	2.3865	6.1605	2.3865

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	4.57875	0.30525	6.27150	2.33100	5.42513	1.31813
	Median	4.57875	0.30525	6.27150	2.33100	4.74525	0.86025
	SD	0.353200	0.745644	2.276177	2.040710	1.650367	1.715046
	(SE)	( 0.249750)	( 0.527250)	( 1.609500)	( 1.443000)	( 0.825183)	( 0.857523)
	Min,	4.3290,	-0.2220,	4.6620,	0.8880,	4.3290,	-0.2220,
	Max	4.8285	0.8325	7.8810	3.7740	7.8810	3.7740
Week 56	n	2	2	2	2	4	4
	Mean	5.07825	0.80475	5.30025	1.35975	5.18925	1.08225
	Median	5.07825	0.80475	5.30025	1.35975	5.30025	1.27650
	SD	1.295066	1.687510	0.902622	1.138088	0.920363	1.218053
	(SE)	( 0.915750)	( 1.193250)	( 0.638250)	( 0.804750)	( 0.460182)	( 0.609027)
	Min,	4.1625,	-0.3885,	4.6620,	0.5550,	4.1625,	-0.3885,
	Max	5.9940	1.9980	5.9385	2.1645	5.9940	2.1645
Week 60	n	2	2	2	2	4	4
	Mean	5.30025	1.02675	4.46775	0.52725	4.88400	0.77700
	Median	5.30025	1.02675	4.46775	0.52725	4.99500	0.66600
	SD	0.039244	0.431689	0.353200	0.117733	0.522605	0.387176
	(SE)	( 0.027750)	( 0.305250)	( 0.249750)	( 0.083250)	( 0.261302)	( 0.193588)
	Min,	5.2725,	0.7215,	4.2180,	0.4440,	4.2180,	0.4440,
	Max	5.3280	1.3320	4.7175	0.6105	5.3280	1.3320

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	4.88400	0.61050	5.05050	1.11000	4.96725	0.86025
	Median	4.88400	0.61050	5.05050	1.11000	5.05050	1.11000
	SD	1.648266	2.040710	0.392444	0.156978	0.982940	1.216366
	(SE)	( 1.165500)	( 1.443000)	( 0.277500)	( 0.111000)	( 0.491470)	( 0.608183)
	Min,	3.7185,	-0.8325,	4.7730,	0.9990,	3.7185,	-0.8325,
	Max	6.0495	2.0535	5.3280	1.2210	6.0495	2.0535
Week 68	n	2	2	2	2	4	4
	Mean	5.79975	1.52625	4.82850	0.88800	5.31413	1.20713
	Median	5.79975	1.52625	4.82850	0.88800	5.05050	0.88800
	SD	1.530533	1.922977	0.784889	0.549422	1.140454	1.212032
	(SE)	( 1.082250)	( 1.359750)	( 0.555000)	( 0.388500)	( 0.570227)	( 0.606016)
	Min,	4.7175,	0.1665,	4.2735,	0.4995,	4.2735,	0.1665,
	Max	6.8820	2.8860	5.3835	1.2765	6.8820	2.8860
Week 72	n	2	2	0	0	2	2
	Mean	5.21700	0.94350			5.21700	0.94350
	Median	5.21700	0.94350			5.21700	0.94350
	SD	0.784889	1.177333			0.784889	1.177333
	(SE)	( 0.555000)	( 0.832500)			( 0.555000)	( 0.832500)
	Min,	4.6620,	0.1110,			4.6620,	0.1110,
	Max	5.7720	1.7760			5.7720	1.7760

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			6.21600	2.10900	6.21600	2.10900
	Median			6.21600	2.10900	6.21600	2.10900
	SD						
	(SE)						
	Min,			6.2160,	2.1090,	6.2160,	2.1090,
	Max			6.2160	2.1090	6.2160	2.1090
Week 76	n	2	2	2	2	4	4
	Mean	5.52225	1.24875	6.10500	2.16450	5.81363	1.70663
	Median	5.52225	1.24875	6.10500	2.16450	6.02175	1.97025
	SD	0.981111	1.373555	0.392444	0.627911	0.696704	1.019726
	(SE)	( 0.693750)	( 0.971250)	( 0.277500)	( 0.444000)	( 0.348352)	( 0.509863)
	Min,	4.8285,	0.2775,	5.8275,	1.7205,	4.8285,	0.2775,
	Max	6.2160	2.2200	6.3825	2.6085	6.3825	2.6085
Week 80	n	2	2	2	2	4	4
	Mean	5.13375	0.86025	5.99400	2.05350	5.56388	1.45688
	Median	5.13375	0.86025	5.99400	2.05350	5.91075	2.02575
	SD	1.452044	1.844488	0.470933	0.235467	1.011639	1.275595
	(SE)	( 1.026750)	( 1.304250)	( 0.333000)	( 0.166500)	( 0.505819)	( 0.637797)
	Min,	4.1070,	-0.4440,	5.6610,	1.8870,	4.1070,	-0.4440,
	Max	6.1605	2.1645	6.3270	2.2200	6.3270	2.2200

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	6.32700	2.05350	5.13375	1.19325	5.73038	1.62338
	Median	6.32700	2.05350	5.13375	1.19325	5.13375	1.19325
	SD	3.531998	3.924443	0.117733	0.353200	2.153503	2.328521
	(SE)	( 2.497500)	( 2.775000)	( 0.083250)	( 0.249750)	( 1.076751)	( 1.164261)
	Min,	3.8295,	-0.7215,	5.0505,	0.9435,	3.8295,	-0.7215,
	Max	8.8245	4.8285	5.2170	1.4430	8.8245	4.8285
Week 88	n	2	2	2	2	4	4
	Mean	5.82750	1.55400	5.24475	1.30425	5.53613	1.42913
	Median	5.82750	1.55400	5.24475	1.30425	5.71650	1.55400
	SD	0.156978	0.235467	0.667155	0.902622	0.519402	0.557538
	(SE)	( 0.111000)	( 0.166500)	( 0.471750)	( 0.638250)	( 0.259701)	( 0.278769)
	Min,	5.7165,	1.3875,	4.7730,	0.6660,	4.7730,	0.6660,
	Max	5.9385	1.7205	5.7165	1.9425	5.9385	1.9425
Week 92	n	2	2	2	2	4	4
	Mean	5.55000	1.27650	5.05050	1.11000	5.30025	1.19325
	Median	5.55000	1.27650	5.05050	1.11000	5.05050	1.11000
	SD	1.569777	1.962221	0.470933	0.706400	0.989188	1.207896
	(SE)	( 1.110000)	( 1.387500)	( 0.333000)	( 0.499500)	( 0.494594)	( 0.603948)
	Min,	4.4400,	-0.1110,	4.7175,	0.6105,	4.4400,	-0.1110,
	Max	6.6600	2.6640	5.3835	1.6095	6.6600	2.6640

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	4.60650	0.33300	6.24375	2.30325	5.42513	1.31813
	Median	4.60650	0.33300	6.24375	2.30325	4.99500	1.05450
	SD	0.078489	0.313955	1.295066	1.059600	1.206088	1.304250
	(SE)	( 0.055500)	( 0.222000)	( 0.915750)	( 0.749250)	( 0.603044)	( 0.652125)
	Min,	4.5510,	0.1110,	5.3280,	1.5540,	4.5510,	0.1110,
	Max	4.6620	0.5550	7.1595	3.0525	7.1595	3.0525
Week 100	n	2	2	2	2	4	4
	Mean	4.57875	0.30525	5.85525	1.91475	5.21700	1.11000
	Median	4.57875	0.30525	5.85525	1.91475	4.82850	0.94350
	SD	0.274711	0.667155	1.373555	1.138088	1.094162	1.201503
	(SE)	( 0.194250)	( 0.471750)	( 0.971250)	( 0.804750)	( 0.547081)	( 0.600752)
	Min,	4.3845,	-0.1665,	4.8840,	1.1100,	4.3845,	-0.1665,
	Max	4.7730	0.7770	6.8265	2.7195	6.8265	2.7195
Week 104	n	2	2	2	2	4	4
	Mean	5.30025	1.02675	5.43900	1.49850	5.36963	1.26263
	Median	5.30025	1.02675	5.43900	1.49850	5.43900	1.33200
	SD	0.588666	0.196222	0.235467	0.000000	0.374711	0.294987
	(SE)	( 0.416250)	( 0.138750)	( 0.166500)	( 0.000000)	( 0.187355)	( 0.147493)
	Min,	4.8840,	0.8880,	5.2725,	1.4985,	4.8840,	0.8880,
	Max	5.7165	1.1655	5.6055	1.4985	5.7165	1.4985

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	4.80075	0.52725	5.16150	1.22100	4.98113	0.87413
	Median	4.80075	0.52725	5.16150	1.22100	5.13375	1.08225
	SD	0.588666	0.981111	0.156978	0.392444	0.408783	0.729813
	(SE)	( 0.416250)	( 0.693750)	( 0.111000)	( 0.277500)	( 0.204392)	( 0.364906)
	Min,	4.3845,	-0.1665,	5.0505,	0.9435,	4.3845,	-0.1665,
	Max	5.2170	1.2210	5.2725	1.4985	5.2725	1.4985
Week 112	n	2	2	2	2	4	4
	Mean	5.21700	0.94350	5.91075	1.97025	5.56388	1.45688
	Median	5.21700	0.94350	5.91075	1.97025	5.88300	1.97025
	SD	1.569777	1.962221	0.667155	0.431689	1.063106	1.302675
	(SE)	( 1.110000)	( 1.387500)	( 0.471750)	( 0.305250)	( 0.531553)	( 0.651337)
	Min,	4.1070,	-0.4440,	5.4390,	1.6650,	4.1070,	-0.4440,
	Max	6.3270	2.3310	6.3825	2.2755	6.3825	2.3310
Week 116	n	2	2	2	2	4	4
	Mean	5.02275	0.74925	5.68875	1.74825	5.35575	1.24875
	Median	5.02275	0.74925	5.68875	1.74825	5.10600	1.05450
	SD	0.353200	0.745644	1.059600	1.295066	0.750790	1.037815
	(SE)	( 0.249750)	( 0.527250)	( 0.749250)	( 0.915750)	( 0.375395)	( 0.518908)
	Min,	4.7730,	0.2220,	4.9395,	0.8325,	4.7730,	0.2220,
	Max	5.2725	1.2765	6.4380	2.6640	6.4380	2.6640

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	5.79975	1.52625	5.71650	1.77600	5.75813	1.65113
	Median	5.79975	1.52625	5.71650	1.77600	5.71650	1.77600
	SD	0.824133	1.216577	0.392444	0.627911	0.529194	0.803473
	(SE)	( 0.582750)	( 0.860250)	( 0.277500)	( 0.444000)	( 0.264597)	( 0.401737)
	Min,	5.2170,	0.6660,	5.4390,	1.3320,	5.2170,	0.6660,
	Max	6.3825	2.3865	5.9940	2.2200	6.3825	2.3865
Week 124	n	2	2	2	2	4	4
	Mean	5.24475	0.97125	6.79875	2.85825	6.02175	1.91475
	Median	5.24475	0.97125	6.79875	2.85825	5.99400	2.10900
	SD	0.745644	1.138088	0.824133	0.588666	1.103041	1.316883
	(SE)	( 0.527250)	( 0.804750)	( 0.582750)	( 0.416250)	( 0.551520)	( 0.658441)
	Min,	4.7175,	0.1665,	6.2160,	2.4420,	4.7175,	0.1665,
	Max	5.7720	1.7760	7.3815	3.2745	7.3815	3.2745
Week 128	n	2	2	2	2	4	4
	Mean	4.80075	0.52725	5.74425	1.80375	5.27250	1.16550
	Median	4.80075	0.52725	5.74425	1.80375	5.05050	1.16550
	SD	0.431689	0.824133	1.059600	0.824133	0.856212	0.997972
	(SE)	( 0.305250)	( 0.582750)	( 0.749250)	( 0.582750)	( 0.428106)	( 0.498986)
	Min,	4.4955,	-0.0555,	4.9950,	1.2210,	4.4955,	-0.0555,
	Max	5.1060	1.1100	6.4935	2.3865	6.4935	2.3865

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	4.74525	0.47175	6.90975	2.96925	5.82750	1.72050
	Median	4.74525	0.47175	6.90975	2.96925	5.24475	1.35975
	SD	0.824133	1.216577	2.472399	2.236932	1.955932	2.059242
	(SE)	( 0.582750)	( 0.860250)	( 1.748250)	( 1.581750)	( 0.977966)	( 1.029621)
	Min,	4.1625,	-0.3885,	5.1615,	1.3875,	4.1625,	-0.3885,
	Max	5.3280	1.3320	8.6580	4.5510	8.6580	4.5510
Week 136	n	2	2	2	2	4	4
	Mean	5.38350	1.11000	5.82750	1.88700	5.60550	1.49850
	Median	5.38350	1.11000	5.82750	1.88700	5.38350	1.30425
	SD	0.078489	0.313955	1.098844	0.863377	0.685749	0.694674
	(SE)	( 0.055500)	( 0.222000)	( 0.777000)	( 0.610500)	( 0.342874)	( 0.347337)
	Min,	5.3280,	0.8880,	5.0505,	1.2765,	5.0505,	0.8880,
	Max	5.4390	1.3320	6.6045	2.4975	6.6045	2.4975
Week 140	n	2	2	2	2	4	4
	Mean	6.02175	1.74825	4.96725	1.02675	5.49450	1.38750
	Median	6.02175	1.74825	4.96725	1.02675	5.13375	1.24875
	SD	1.452044	1.059600	0.431689	0.667155	1.065639	0.834348
	(SE)	( 1.026750)	( 0.749250)	( 0.305250)	( 0.471750)	( 0.532819)	( 0.417174)
	Min,	4.9950,	0.9990,	4.6620,	0.5550,	4.6620,	0.5550,
	Max	7.0485	2.4975	5.2725	1.4985	7.0485	2.4975

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	5.38350	1.11000	5.07825	1.13775	5.23088	1.12388
	Median	5.38350	1.11000	5.07825	1.13775	5.07825	1.13775
	SD	1.098844	1.491288	0.510178	0.745644	0.721322	0.962756
	(SE)	( 0.777000)	( 1.054500)	( 0.360750)	( 0.527250)	( 0.360661)	( 0.481378)
	Min,	4.6065,	0.0555,	4.7175,	0.6105,	4.6065,	0.0555,
	Max	6.1605	2.1645	5.4390	1.6650	6.1605	2.1645
Week 148	n	2	2	2	2	4	4
	Mean	4.41225	0.13875	5.35575	1.41525	4.88400	0.77700
	Median	4.41225	0.13875	5.35575	1.41525	4.99500	0.97125
	SD	0.353200	0.745644	0.039244	0.196222	0.582089	0.860996
	(SE)	( 0.249750)	( 0.527250)	( 0.027750)	( 0.138750)	( 0.291044)	( 0.430498)
	Min,	4.1625,	-0.3885,	5.3280,	1.2765,	4.1625,	-0.3885,
	Max	4.6620	0.6660	5.3835	1.5540	5.3835	1.5540
Week 152	n	2	2	2	2	4	4
	Mean	5.38350	1.11000	5.16150	1.22100	5.27250	1.16550
	Median	5.38350	1.11000	5.16150	1.22100	5.16150	1.22100
	SD	1.020355	0.627911	0.235467	0.470933	0.618022	0.457665
	(SE)	( 0.721500)	( 0.444000)	( 0.166500)	( 0.333000)	( 0.309011)	( 0.228832)
	Min,	4.6620,	0.6660,	4.9950,	0.8880,	4.6620,	0.6660,
	Max	6.1050	1.5540	5.3280	1.5540	6.1050	1.5540

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	5.32800	1.05450	5.68875	1.74825	5.50838	1.40138
	Median	5.32800	1.05450	5.68875	1.74825	5.66100	1.74825
	SD	1.098844	1.491288	0.667155	0.431689	0.770864	0.981765
	(SE)	( 0.777000)	( 1.054500)	( 0.471750)	( 0.305250)	( 0.385432)	( 0.490882)
	Min,	4.5510,	0.0000,	5.2170,	1.4430,	4.5510,	0.0000,
	Max	6.1050	2.1090	6.1605	2.0535	6.1605	2.1090
Week 160	n	2	2	2	2	4	4
	Mean	5.05050	0.77700	4.99500	1.05450	5.02275	0.91575
	Median	5.05050	0.77700	4.99500	1.05450	4.99500	1.05450
	SD	0.549422	0.941866	0.078489	0.156978	0.322028	0.574096
	(SE)	( 0.388500)	( 0.666000)	( 0.055500)	( 0.111000)	( 0.161014)	( 0.287048)
	Min,	4.6620,	0.1110,	4.9395,	0.9435,	4.6620,	0.1110,
	Max	5.4390	1.4430	5.0505	1.1655	5.4390	1.4430
Week 164	n	2	2	2	2	4	4
	Mean	5.05050	0.77700	4.99500	1.05450	5.02275	0.91575
	Median	5.05050	0.77700	4.99500	1.05450	5.05050	0.86025
	SD	0.392444	0.784889	0.706400	0.941866	0.467651	0.725757
	(SE)	( 0.277500)	( 0.555000)	( 0.499500)	( 0.666000)	( 0.233826)	( 0.362878)
	Min,	4.7730,	0.2220,	4.4955,	0.3885,	4.4955,	0.2220,
	Max	5.3280	1.3320	5.4945	1.7205	5.4945	1.7205

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	5.10600	0.83250	4.80075	0.86025	4.95338	0.84638
	Median	5.10600	0.83250	4.80075	0.86025	5.10600	0.83250
	SD	0.313955	0.706400	0.902622	1.138088	0.579215	0.773523
	(SE)	( 0.222000)	( 0.499500)	( 0.638250)	( 0.804750)	( 0.289608)	( 0.386762)
	Min,	4.8840,	0.3330,	4.1625,	0.0555,	4.1625,	0.0555,
	Max	5.3280	1.3320	5.4390	1.6650	5.4390	1.6650
Week 172	n	2	2	2	2	4	4
	Mean	5.55000	1.27650	5.27250	1.33200	5.41125	1.30425
	Median	5.55000	1.27650	5.27250	1.33200	5.27250	1.33200
	SD	0.549422	0.941866	0.078489	0.313955	0.358251	0.574096
	(SE)	( 0.388500)	( 0.666000)	( 0.055500)	( 0.222000)	( 0.179125)	( 0.287048)
	Min,	5.1615,	0.6105,	5.2170,	1.1100,	5.1615,	0.6105,
	Max	5.9385	1.9425	5.3280	1.5540	5.9385	1.9425
Week 176	n	2	2	2	2	4	4
	Mean	5.46675	1.19325	5.77200	1.83150	5.61938	1.51238
	Median	5.46675	1.19325	5.77200	1.83150	5.77200	1.83150
	SD	1.295066	1.687510	0.784889	0.549422	0.891894	1.088871
	(SE)	( 0.915750)	( 1.193250)	( 0.555000)	( 0.388500)	( 0.445947)	( 0.544435)
	Min,	4.5510,	0.0000,	5.2170,	1.4430,	4.5510,	0.0000,
	Max	6.3825	2.3865	6.3270	2.2200	6.3825	2.3865

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	5.74425	1.47075	5.96625	2.02575	5.85525	1.74825
	Median	5.74425	1.47075	5.96625	2.02575	5.96625	2.02575
	SD	2.158443	2.550888	0.981111	1.216577	1.374862	1.662840
	(SE)	( 1.526250)	( 1.803750)	( 0.693750)	( 0.860250)	( 0.687431)	( 0.831420)
	Min,	4.2180,	-0.3330,	5.2725,	1.1655,	4.2180,	-0.3330,
	Max	7.2705	3.2745	6.6600	2.8860	7.2705	3.2745
Week 184	n	2	2	2	2	4	4
	Mean	4.85625	0.58275	5.79975	1.85925	5.32800	1.22100
	Median	4.85625	0.58275	5.79975	1.85925	5.43900	1.55400
	SD	0.667155	1.059600	0.353200	0.117733	0.697624	0.960220
	(SE)	( 0.471750)	( 0.749250)	( 0.249750)	( 0.083250)	( 0.348812)	( 0.480110)
	Min,	4.3845,	-0.1665,	5.5500,	1.7760,	4.3845,	-0.1665,
	Max	5.3280	1.3320	6.0495	1.9425	6.0495	1.9425

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Creatinine (umol/L)						
Week 1	n	2	2		4	
	Mean	30.4980	25.1940		27.8460	
	Median	30.4980	25.1940		27.4040	
	SD	3.12541	1.87525		3.71561	
	(SE)	( 2.21000)	( 1.32600)		( 1.85780)	
	Min,	28.288,	23.868,		23.868,	
	Max	32.708	26.520		32.708	
Week 2	n	2	2		4	
	Mean	28.7300	25.1940		26.9620	
	Median	28.7300	25.1940		25.6360	
	SD	4.37558	0.62508		3.26801	
	(SE)	( 3.09400)	( 0.44200)		( 1.63401)	
	Min,	25.636,	24.752,		24.752,	
	Max	31.824	25.636		31.824	
Week 4	n	2	2		4	
	Mean	30.0560	25.1940		27.6250	
	Median	30.0560	25.1940		26.9620	
	SD	2.50033	0.62508		3.17708	
	(SE)	( 1.76800)	( 0.44200)		( 1.58854)	
	Min,	28.288,	24.752,		24.752,	
	Max	31.824	25.636		31.824	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2	2		4	
	Mean	29.1720	22.5420		25.8570	
	Median	29.1720	22.5420		26.9620	
	SD	0.00000	3.12541		4.23183	
	(SE)	( 0.00000)	( 2.21000)		( 2.11591)	
	Min,	29.172,	20.332,		20.332,	
	Max	29.172	24.752		29.172	
Week 8	n	2	2		4	
	Mean	31.3820	23.4260		27.4040	
	Median	31.3820	23.4260		28.2880	
	SD	0.62508	3.12541		4.94829	
	(SE)	( 0.44200)	( 2.21000)		( 2.47415)	
	Min,	30.940,	21.216,		21.216,	
	Max	31.824	25.636		31.824	
Week 10	n	2	2		4	
	Mean	28.2880	23.8680		26.0780	
	Median	28.2880	23.8680		25.1940	
	SD	2.50033	0.00000		2.93190	
	(SE)	( 1.76800)	( 0.00000)		( 1.46595)	
	Min,	26.520,	23.868,		23.868,	
	Max	30.056	23.868		30.056	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2	2		4	
	Mean	29.1720	23.4260		26.2990	
	Median	29.1720	23.4260		26.9620	
	SD	1.25016	3.12541		3.84481	
	(SE)	( 0.88400)	( 2.21000)		( 1.92240)	
	Min,	28.288,	21.216,		21.216,	
	Max	30.056	25.636		30.056	
Week 15	n	2	2		4	
	Mean	26.0780	21.6580		23.8680	
	Median	26.0780	21.6580		23.8680	
	SD	0.62508	0.62508		2.60243	
	(SE)	( 0.44200)	( 0.44200)		( 1.30121)	
	Min,	25.636,	21.216,		21.216,	
	Max	26.520	22.100		26.520	
Week 18	n	2	2		4	
	Mean	26.0780	21.6580		23.8680	
	Median	26.0780	21.6580		23.8680	
	SD	0.62508	0.62508		2.60243	
	(SE)	( 0.44200)	( 0.44200)		( 1.30121)	
	Min,	25.636,	21.216,		21.216,	
	Max	26.520	22.100		26.520	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2	2		4	
	Mean	29.1720	23.4260		26.2990	
	Median	29.1720	23.4260		26.0780	
	SD	1.25016	0.62508		3.41419	
	(SE)	( 0.88400)	( 0.44200)		( 1.70710)	
	Min,	28.288,	22.984,		22.984,	
	Max	30.056	23.868		30.056	
Week 24	n	2	2		4	
	Mean	29.6140	21.6580		25.6360	
	Median	29.6140	21.6580		26.5200	
	SD	0.62508	3.12541		4.94829	
	(SE)	( 0.44200)	( 2.21000)		( 2.47415)	
	Min,	29.172,	19.448,		19.448,	
	Max	30.056	23.868		30.056	
Baseline <sup>1</sup>	n	2	2		4	
	Mean	25.6360	22.9840		24.3100	
	Median	25.6360	22.9840		23.4260	
	SD	2.50033	0.00000		2.10434	
	(SE)	( 1.76800)	( 0.00000)		( 1.05217)	
	Min,	23.868,	22.984,		22.984,	
	Max	27.404	22.984		27.404	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	30.9400	5.3040	24.3100	1.3260	27.6250	3.3150
	Median	30.9400	5.3040	24.3100	1.3260	28.2880	3.9780
	SD	1.25016	1.25016	3.12541	3.12541	4.29294	3.00863
	(SE)	( 0.88400)	( 0.88400)	( 2.21000)	( 2.21000)	( 2.14647)	( 1.50432)
	Min,	30.056,	4.420,	22.100,	-0.884,	22.100,	-0.884,
	Max	31.824	6.188	26.520	3.536	31.824	6.188
Week 32	n	2	2	2	2	4	4
	Mean	21.2160	-4.4200	14.1440	-8.8400	17.6800	-6.6300
	Median	21.2160	-4.4200	14.1440	-8.8400	16.7960	-6.6300
	SD	3.75049	1.25016	1.25016	1.25016	4.67769	2.74847
	(SE)	( 2.65200)	( 0.88400)	( 0.88400)	( 0.88400)	( 2.33884)	( 1.37423)
	Min,	18.564,	-5.304,	13.260,	-9.724,	13.260,	-9.724,
	Max	23.868	-3.536	15.028	-7.956	23.868	-3.536
Week 36	n	2	2	1	1	3	3
	Mean	20.7740	-4.8620	11.4920	-11.4920	17.6800	-7.0720
	Median	20.7740	-4.8620	11.4920	-11.4920	19.4480	-5.3040
	SD	1.87525	0.62508			5.52058	3.85327
	(SE)	( 1.32600)	( 0.44200)			( 3.18731)	( 2.22468)
	Min,	19.448,	-5.304,	11.492,	-11.492,	11.492,	-11.492,
	Max	22.100	-4.420	11.492	-11.492	22.100	-4.420

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	20.7740	-4.8620	16.7960	-6.1880	18.7850	-5.5250
	Median	20.7740	-4.8620	16.7960	-6.1880	18.5640	-6.1880
	SD	0.62508	1.87525	0.00000	0.00000	2.32488	1.32600
	(SE)	( 0.44200)	( 1.32600)	( 0.00000)	( 0.00000)	( 1.16244)	( 0.66300)
	Min,	20.332,	-6.188,	16.796,	-6.188,	16.796,	-6.188,
	Max	21.216	-3.536	16.796	-6.188	21.216	-3.536
Week 44	n	2	2	2	2	4	4
	Mean	22.5420	-3.0940	20.3320	-2.6520	21.4370	-2.8730
	Median	22.5420	-3.0940	20.3320	-2.6520	20.7740	-2.6520
	SD	1.87525	4.37558	0.00000	0.00000	1.67338	2.53910
	(SE)	( 1.32600)	( 3.09400)	( 0.00000)	( 0.00000)	( 0.83669)	( 1.26955)
	Min,	21.216,	-6.188,	20.332,	-2.652,	20.332,	-6.188,
	Max	23.868	0.000	20.332	-2.652	23.868	0.000
Week 48	n	2	2	2	2	4	4
	Mean	24.3100	-1.3260	15.9120	-7.0720	20.1110	-4.1990
	Median	24.3100	-1.3260	15.9120	-7.0720	19.8900	-3.9780
	SD	1.87525	0.62508	1.25016	1.25016	5.02015	3.41419
	(SE)	( 1.32600)	( 0.44200)	( 0.88400)	( 0.88400)	( 2.51008)	( 1.70710)
	Min,	22.984,	-1.768,	15.028,	-7.956,	15.028,	-7.956,
	Max	25.636	-0.884	16.796	-6.188	25.636	-0.884

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	21.2160	-4.4200	16.7960	-6.1880	19.0060	-5.3040
	Median	21.2160	-4.4200	16.7960	-6.1880	19.0060	-6.1880
	SD	1.25016	3.75049	1.25016	1.25016	2.74847	2.50033
	(SE)	( 0.88400)	( 2.65200)	( 0.88400)	( 0.88400)	( 1.37423)	( 1.25016)
	Min,	20.332,	-7.072,	15.912,	-7.072,	15.912,	-7.072,
	Max	22.100	-1.768	17.680	-5.304	22.100	-1.768
Week 56	n	2	2	2	2	4	4
	Mean	20.3320	-5.3040	14.1440	-8.8400	17.2380	-7.0720
	Median	20.3320	-5.3040	14.1440	-8.8400	16.7960	-8.3980
	SD	3.75049	6.25082	2.50033	2.50033	4.42000	4.39043
	(SE)	( 2.65200)	( 4.42000)	( 1.76800)	( 1.76800)	( 2.21000)	( 2.19522)
	Min,	17.680,	-9.724,	12.376,	-10.608,	12.376,	-10.608,
	Max	22.984	-0.884	15.912	-7.072	22.984	-0.884
Week 60	n	2	2	2	2	4	4
	Mean	22.5420	-3.0940	18.1220	-4.8620	20.3320	-3.9780
	Median	22.5420	-3.0940	18.1220	-4.8620	21.2160	-3.9780
	SD	3.12541	5.62574	5.62574	5.62574	4.50753	4.70545
	(SE)	( 2.21000)	( 3.97800)	( 3.97800)	( 3.97800)	( 2.25377)	( 2.35272)
	Min,	20.332,	-7.072,	14.144,	-8.840,	14.144,	-8.840,
	Max	24.752	0.884	22.100	-0.884	24.752	0.884

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	21.6580	-3.9780	14.5860	-8.3980	18.1220	-6.1880
	Median	21.6580	-3.9780	14.5860	-8.3980	18.1220	-6.6300
	SD	0.62508	1.87525	0.62508	0.62508	4.11480	2.79545
	(SE)	( 0.44200)	( 1.32600)	( 0.44200)	( 0.44200)	( 2.05740)	( 1.39773)
	Min,	21.216,	-5.304,	14.144,	-8.840,	14.144,	-8.840,
	Max	22.100	-2.652	15.028	-7.956	22.100	-2.652
Week 68	n	2	2	2	2	4	4
	Mean	22.1000	-3.5360	15.4700	-7.5140	18.7850	-5.5250
	Median	22.1000	-3.5360	15.4700	-7.5140	19.4480	-5.7460
	SD	0.00000	2.50033	1.87525	1.87525	3.97800	2.92077
	(SE)	( 0.00000)	( 1.76800)	( 1.32600)	( 1.32600)	( 1.98900)	( 1.46038)
	Min,	22.100,	-5.304,	14.144,	-8.840,	14.144,	-8.840,
	Max	22.100	-1.768	16.796	-6.188	22.100	-1.768
Week 72	n	2	2	0	0	2	2
	Mean	20.7740	-4.8620			20.7740	-4.8620
	Median	20.7740	-4.8620			20.7740	-4.8620
	SD	1.87525	0.62508			1.87525	0.62508
	(SE)	( 1.32600)	( 0.44200)			( 1.32600)	( 0.44200)
	Min,	19.448,	-5.304,			19.448,	-5.304,
	Max	22.100	-4.420			22.100	-4.420

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			15.9120	-7.0720	15.9120	-7.0720
	Median			15.9120	-7.0720	15.9120	-7.0720
	SD						
	(SE)						
	Min, Max			15.912, 15.912	-7.072, -7.072	15.912, 15.912	-7.072, -7.072
Week 76	n	2	2	2	2	4	4
	Mean	21.2160	-4.4200	15.9120	-7.0720	18.5640	-5.7460
	Median	21.2160	-4.4200	15.9120	-7.0720	19.4480	-4.8620
	SD	1.25016	1.25016	3.75049	3.75049	3.81932	2.74847
	(SE)	( 0.88400)	( 0.88400)	( 2.65200)	( 2.65200)	( 1.90966)	( 1.37423)
	Min, Max	20.332, 22.100	-5.304, -3.536	13.260, 18.564	-9.724, -4.420	13.260, 22.100	-9.724, -3.536
Week 80	n	2	2	2	2	4	4
	Mean	22.9840	-2.6520	12.3760	-10.6080	17.6800	-6.6300
	Median	22.9840	-2.6520	12.3760	-10.6080	17.6800	-6.6300
	SD	1.25016	1.25016	1.25016	1.25016	6.20901	4.70545
	(SE)	( 0.88400)	( 0.88400)	( 0.88400)	( 0.88400)	( 3.10451)	( 2.35272)
	Min, Max	22.100, 23.868	-3.536, -1.768	11.492, 13.260	-11.492, -9.724	11.492, 23.868	-11.492, -1.768

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	22.5420	-3.0940	14.5860	-8.3980	18.5640	-5.7460
	Median	22.5420	-3.0940	14.5860	-8.3980	19.8900	-4.8620
	SD	0.62508	1.87525	4.37558	4.37558	5.25466	4.11480
	(SE)	( 0.44200)	( 1.32600)	( 3.09400)	( 3.09400)	( 2.62733)	( 2.05740)
	Min,	22.100,	-4.420,	11.492,	-11.492,	11.492,	-11.492,
	Max	22.984	-1.768	17.680	-5.304	22.984	-1.768
Week 88	n	2	2	2	2	4	4
	Mean	22.5420	-3.0940	13.2600	-9.7240	17.9010	-6.4090
	Median	22.5420	-3.0940	13.2600	-9.7240	18.1220	-5.7460
	SD	1.87525	0.62508	2.50033	2.50033	5.65461	4.10688
	(SE)	( 1.32600)	( 0.44200)	( 1.76800)	( 1.76800)	( 2.82730)	( 2.05344)
	Min,	21.216,	-3.536,	11.492,	-11.492,	11.492,	-11.492,
	Max	23.868	-2.652	15.028	-7.956	23.868	-2.652
Week 92	n	2	2	2	2	4	4
	Mean	19.8900	-5.7460	14.1440	-8.8400	17.0170	-7.2930
	Median	19.8900	-5.7460	14.1440	-8.8400	17.2380	-7.9560
	SD	1.87525	4.37558	2.50033	2.50033	3.77645	3.41419
	(SE)	( 1.32600)	( 3.09400)	( 1.76800)	( 1.76800)	( 1.88822)	( 1.70710)
	Min,	18.564,	-8.840,	12.376,	-10.608,	12.376,	-10.608,
	Max	21.216	-2.652	15.912	-7.072	21.216	-2.652

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	21.6580	-3.9780	15.4700	-7.5140	18.5640	-5.7460
	Median	21.6580	-3.9780	15.4700	-7.5140	19.4480	-5.3040
	SD	0.62508	1.87525	3.12541	3.12541	4.01872	2.93190
	(SE)	( 0.44200)	( 1.32600)	( 2.21000)	( 2.21000)	( 2.00936)	( 1.46595)
	Min,	21.216,	-5.304,	13.260,	-9.724,	13.260,	-9.724,
	Max	22.100	-2.652	17.680	-5.304	22.100	-2.652
Week 100	n	2	2	2	2	4	4
	Mean	22.1000	-3.5360	12.8180	-10.1660	17.4590	-6.8510
	Median	22.1000	-3.5360	12.8180	-10.1660	19.0060	-6.1880
	SD	0.00000	2.50033	4.37558	4.37558	5.92456	4.80813
	(SE)	( 0.00000)	( 1.76800)	( 3.09400)	( 3.09400)	( 2.96228)	( 2.40406)
	Min,	22.100,	-5.304,	9.724,	-13.260,	9.724,	-13.260,
	Max	22.100	-1.768	15.912	-7.072	22.100	-1.768
Week 104	n	2	2	2	2	4	4
	Mean	22.9840	-2.6520	18.1220	-4.8620	20.5530	-3.7570
	Median	22.9840	-2.6520	18.1220	-4.8620	22.1000	-2.6520
	SD	1.25016	1.25016	5.62574	5.62574	4.35320	3.56352
	(SE)	( 0.88400)	( 0.88400)	( 3.97800)	( 3.97800)	( 2.17660)	( 1.78176)
	Min,	22.100,	-3.536,	14.144,	-8.840,	14.144,	-8.840,
	Max	23.868	-1.768	22.100	-0.884	23.868	-0.884

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	22.9840	-2.6520	15.0280	-7.9560	19.0060	-5.3040
	Median	22.9840	-2.6520	15.0280	-7.9560	19.4480	-4.8620
	SD	1.25016	1.25016	2.50033	2.50033	4.86869	3.46155
	(SE)	( 0.88400)	( 0.88400)	( 1.76800)	( 1.76800)	( 2.43435)	( 1.73077)
	Min,	22.100,	-3.536,	13.260,	-9.724,	13.260,	-9.724,
	Max	23.868	-1.768	16.796	-6.188	23.868	-1.768
Week 112	n	2	2	2	2	4	4
	Mean	21.6580	-3.9780	13.2600	-9.7240	17.4590	-6.8510
	Median	21.6580	-3.9780	13.2600	-9.7240	17.6800	-7.0720
	SD	0.62508	1.87525	1.25016	1.25016	4.91528	3.56352
	(SE)	( 0.44200)	( 1.32600)	( 0.88400)	( 0.88400)	( 2.45764)	( 1.78176)
	Min,	21.216,	-5.304,	12.376,	-10.608,	12.376,	-10.608,
	Max	22.100	-2.652	14.144	-8.840	22.100	-2.652
Week 116	n	2	2	2	2	4	4
	Mean	22.1000	-3.5360	21.6580	-1.3260	21.8790	-2.4310
	Median	22.1000	-3.5360	21.6580	-1.3260	22.1000	-3.5360
	SD	3.75049	1.25016	8.12607	8.12607	5.17348	4.91528
	(SE)	( 2.65200)	( 0.88400)	( 5.74600)	( 5.74600)	( 2.58674)	( 2.45764)
	Min,	19.448,	-4.420,	15.912,	-7.072,	15.912,	-7.072,
	Max	24.752	-2.652	27.404	4.420	27.404	4.420

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	21.2160	-4.4200	13.7020	-9.2820	17.4590	-6.8510
	Median	21.2160	-4.4200	13.7020	-9.2820	16.7960	-8.3980
	SD	5.00066	7.50099	3.12541	3.12541	5.51468	5.46724
	(SE)	( 3.53600)	( 5.30400)	( 2.21000)	( 2.21000)	( 2.75734)	( 2.73362)
	Min,	17.680,	-9.724,	11.492,	-11.492,	11.492,	-11.492,
	Max	24.752	0.884	15.912	-7.072	24.752	0.884
Week 124	n	2	2	2	2	4	4
	Mean	22.5420	-3.0940	11.9340	-11.0500	17.2380	-7.0720
	Median	22.5420	-3.0940	11.9340	-11.0500	15.9120	-9.2820
	SD	4.37558	6.87591	0.62508	0.62508	6.63491	6.08185
	(SE)	( 3.09400)	( 4.86200)	( 0.44200)	( 0.44200)	( 3.31745)	( 3.04093)
	Min,	19.448,	-7.956,	11.492,	-11.492,	11.492,	-11.492,
	Max	25.636	1.768	12.376	-10.608	25.636	1.768
Week 128	n	2	2	2	2	4	4
	Mean	21.6580	-3.9780	13.2600	-9.7240	17.4590	-6.8510
	Median	21.6580	-3.9780	13.2600	-9.7240	17.2380	-6.1880
	SD	3.12541	0.62508	2.50033	2.50033	5.37110	3.63588
	(SE)	( 2.21000)	( 0.44200)	( 1.76800)	( 1.76800)	( 2.68555)	( 1.81794)
	Min,	19.448,	-4.420,	11.492,	-11.492,	11.492,	-11.492,
	Max	23.868	-3.536	15.028	-7.956	23.868	-3.536

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	23.4260	-2.2100	15.4700	-7.5140	19.4480	-4.8620
	Median	23.4260	-2.2100	15.4700	-7.5140	19.4480	-5.7460
	SD	4.37558	6.87591	4.37558	4.37558	5.81920	5.61415
	(SE)	( 3.09400)	( 4.86200)	( 3.09400)	( 3.09400)	( 2.90960)	( 2.80708)
	Min,	20.332,	-7.072,	12.376,	-10.608,	12.376,	-10.608,
	Max	26.520	2.652	18.564	-4.420	26.520	2.652
Week 136	n	2	2	2	2	4	4
	Mean	26.0780	0.4420	13.2600	-9.7240	19.6690	-4.6410
	Median	26.0780	0.4420	13.2600	-9.7240	19.0060	-6.1880
	SD	6.87591	9.37624	5.00066	5.00066	8.88042	8.49054
	(SE)	( 4.86200)	( 6.63000)	( 3.53600)	( 3.53600)	( 4.44021)	( 4.24527)
	Min,	21.216,	-6.188,	9.724,	-13.260,	9.724,	-13.260,
	Max	30.940	7.072	16.796	-6.188	30.940	7.072
Week 140	n	2	2	2	2	4	4
	Mean	23.8680	-1.7680	11.4920	-11.4920	17.6800	-6.6300
	Median	23.8680	-1.7680	11.4920	-11.4920	15.9120	-9.2820
	SD	5.00066	7.50099	0.00000	0.00000	7.70653	7.09039
	(SE)	( 3.53600)	( 5.30400)	( 0.00000)	( 0.00000)	( 3.85327)	( 3.54520)
	Min,	20.332,	-7.072,	11.492,	-11.492,	11.492,	-11.492,
	Max	27.404	3.536	11.492	-11.492	27.404	3.536

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	22.1000	-3.5360	11.9340	-11.0500	17.0170	-7.2930
	Median	22.1000	-3.5360	11.9340	-11.0500	15.4700	-7.9560
	SD	5.00066	2.50033	0.62508	0.62508	6.55095	4.58630
	(SE)	( 3.53600)	( 1.76800)	( 0.44200)	( 0.44200)	( 3.27548)	( 2.29315)
	Min,	18.564,	-5.304,	11.492,	-11.492,	11.492,	-11.492,
	Max	25.636	-1.768	12.376	-10.608	25.636	-1.768
Week 148	n	2	2	2	2	4	4
	Mean	23.8680	-1.7680	14.1440	-8.8400	19.0060	-5.3040
	Median	23.8680	-1.7680	14.1440	-8.8400	19.0060	-5.3040
	SD	1.25016	1.25016	1.25016	1.25016	5.70620	4.20868
	(SE)	( 0.88400)	( 0.88400)	( 0.88400)	( 0.88400)	( 2.85310)	( 2.10434)
	Min,	22.984,	-2.652,	13.260,	-9.724,	13.260,	-9.724,
	Max	24.752	-0.884	15.028	-7.956	24.752	-0.884
Week 152	n	2	2	2	2	4	4
	Mean	20.3320	-5.3040	13.7020	-9.2820	17.0170	-7.2930
	Median	20.3320	-5.3040	13.7020	-9.2820	17.2380	-7.9560
	SD	0.00000	2.50033	0.62508	0.62508	3.84481	2.73660
	(SE)	( 0.00000)	( 1.76800)	( 0.44200)	( 0.44200)	( 1.92240)	( 1.36830)
	Min,	20.332,	-7.072,	13.260,	-9.724,	13.260,	-9.724,
	Max	20.332	-3.536	14.144	-8.840	20.332	-3.536

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	26.9620	1.3260	15.9120	-7.0720	21.4370	-2.8730
	Median	26.9620	1.3260	15.9120	-7.0720	21.6580	-3.5360
	SD	3.12541	5.62574	3.75049	3.75049	6.97464	6.22472
	(SE)	( 2.21000)	( 3.97800)	( 2.65200)	( 2.65200)	( 3.48732)	( 3.11236)
	Min,	24.752,	-2.652,	13.260,	-9.724,	13.260,	-9.724,
	Max	29.172	5.304	18.564	-4.420	29.172	5.304
Week 160	n	2	2	2	2	4	4
	Mean	20.3320	-5.3040	12.8180	-10.1660	16.5750	-7.7350
	Median	20.3320	-5.3040	12.8180	-10.1660	17.2380	-7.9560
	SD	0.00000	2.50033	1.87525	1.87525	4.47127	3.33703
	(SE)	( 0.00000)	( 1.76800)	( 1.32600)	( 1.32600)	( 2.23563)	( 1.66851)
	Min,	20.332,	-7.072,	11.492,	-11.492,	11.492,	-11.492,
	Max	20.332	-3.536	14.144	-8.840	20.332	-3.536
Week 164	n	2	2	2	2	4	4
	Mean	19.8900	-5.7460	12.3760	-10.6080	16.1330	-8.1770
	Median	19.8900	-5.7460	12.3760	-10.6080	15.4700	-7.9560
	SD	4.37558	1.87525	2.50033	2.50033	5.22358	3.33703
	(SE)	( 3.09400)	( 1.32600)	( 1.76800)	( 1.76800)	( 2.61179)	( 1.66851)
	Min,	16.796,	-7.072,	10.608,	-12.376,	10.608,	-12.376,
	Max	22.984	-4.420	14.144	-8.840	22.984	-4.420

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	19.8900	-5.7460	10.6080	-12.3760	15.2490	-9.0610
	Median	19.8900	-5.7460	10.6080	-12.3760	14.5860	-8.8400
	SD	3.12541	0.62508	1.25016	1.25016	5.70049	3.91197
	(SE)	( 2.21000)	( 0.44200)	( 0.88400)	( 0.88400)	( 2.85024)	( 1.95599)
	Min,	17.680,	-6.188,	9.724,	-13.260,	9.724,	-13.260,
	Max	22.100	-5.304	11.492	-11.492	22.100	-5.304
Week 172	n	2	2	2	2	4	4
	Mean	19.0060	-6.6300	14.1440	-8.8400	16.5750	-7.7350
	Median	19.0060	-6.6300	14.1440	-8.8400	16.7960	-7.0720
	SD	1.87525	0.62508	2.50033	2.50033	3.33703	1.96014
	(SE)	( 1.32600)	( 0.44200)	( 1.76800)	( 1.76800)	( 1.66851)	( 0.98007)
	Min,	17.680,	-7.072,	12.376,	-10.608,	12.376,	-10.608,
	Max	20.332	-6.188	15.912	-7.072	20.332	-6.188
Week 176	n	2	2	2	2	4	4
	Mean	20.3320	-5.3040	15.0280	-7.9560	17.6800	-6.6300
	Median	20.3320	-5.3040	15.0280	-7.9560	18.5640	-5.3040
	SD	2.50033	0.00000	5.00066	5.00066	4.44937	3.26801
	(SE)	( 1.76800)	( 0.00000)	( 3.53600)	( 3.53600)	( 2.22468)	( 1.63401)
	Min,	18.564,	-5.304,	11.492,	-11.492,	11.492,	-11.492,
	Max	22.100	-5.304	18.564	-4.420	22.100	-4.420

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	22.9840	-2.6520	16.7960	-6.1880	19.8900	-4.4200
	Median	22.9840	-2.6520	16.7960	-6.1880	20.3320	-3.0940
	SD	6.25082	3.75049	7.50099	7.50099	6.67405	5.25466
	(SE)	( 4.42000)	( 2.65200)	( 5.30400)	( 5.30400)	( 3.33703)	( 2.62733)
	Min,	18.564,	-5.304,	11.492,	-11.492,	11.492,	-11.492,
	Max	27.404	0.000	22.100	-0.884	27.404	0.000
Week 184	n	2	2	2	2	4	4
	Mean	22.5420	-3.0940	15.4700	-7.5140	19.0060	-5.3040
	Median	22.5420	-3.0940	15.4700	-7.5140	19.8900	-5.3040
	SD	3.12541	5.62574	5.62574	5.62574	5.52058	5.25466
	(SE)	( 2.21000)	( 3.97800)	( 3.97800)	( 3.97800)	( 2.76029)	( 2.62733)
	Min,	20.332,	-7.072,	11.492,	-11.492,	11.492,	-11.492,
	Max	24.752	0.884	19.448	-3.536	24.752	0.884

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Blood Urea Nitrogen (mmol/L)						
Week 1	n	2	2		4	
	Mean	3.0345	2.8560		2.9453	
	Median	3.0345	2.8560		2.8560	
	SD	2.77681	0.50487		1.63273	
	(SE)	( 1.96350)	( 0.35700)		( 0.81637)	
	Min, Max	1.071, 4.998	2.499, 3.213		1.071, 4.998	
Week 2	n	2	2		4	
	Mean	3.7485	3.7485		3.7485	
	Median	3.7485	3.7485		3.7485	
	SD	1.26219	0.75731		0.84983	
	(SE)	( 0.89250)	( 0.53550)		( 0.42491)	
	Min, Max	2.856, 4.641	3.213, 4.284		2.856, 4.641	
Week 4	n	2	2		4	
	Mean	3.0345	3.5700		3.3023	
	Median	3.0345	3.5700		3.5700	
	SD	1.26219	0.50487		0.84356	
	(SE)	( 0.89250)	( 0.35700)		( 0.42178)	
	Min, Max	2.142, 3.927	3.213, 3.927		2.142, 3.927	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	3.9270		3.3915		3.6593	
	Median	3.9270		3.3915		3.3915	
	SD	2.01950		1.26219		1.40928	
	(SE)	( 1.42800)		( 0.89250)		( 0.70464)	
	Min,	2.499,		2.499,		2.499,	
	Max	5.355		4.284		5.355	
Week 8	n	2		2		4	
	Mean	4.6410		4.1055		4.3733	
	Median	4.6410		4.1055		4.1055	
	SD	2.52437		0.75731		1.55271	
	(SE)	( 1.78500)		( 0.53550)		( 0.77636)	
	Min,	2.856,		3.570,		2.856,	
	Max	6.426		4.641		6.426	
Week 10	n	2		2		4	
	Mean	3.5700		3.9270		3.7485	
	Median	3.5700		3.9270		3.9270	
	SD	1.51462		0.50487		0.94453	
	(SE)	( 1.07100)		( 0.35700)		( 0.47227)	
	Min,	2.499,		3.570,		2.499,	
	Max	4.641		4.284		4.641	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2	2		4	
	Mean	3.0345	3.9270		3.4808	
	Median	3.0345	3.9270		3.7485	
	SD	1.76706	1.00975		1.28305	
	(SE)	( 1.24950)	( 0.71400)		( 0.64152)	
	Min,	1.785,	3.213,		1.785,	
	Max	4.284	4.641		4.641	
Week 15	n	2	2		4	
	Mean	2.6775	4.4625		3.5700	
	Median	2.6775	4.4625		3.9270	
	SD	1.76706	0.75731		1.51462	
	(SE)	( 1.24950)	( 0.53550)		( 0.75731)	
	Min,	1.428,	3.927,		1.428,	
	Max	3.927	4.998		4.998	
Week 18	n	2	2		4	
	Mean	3.7485	3.0345		3.3915	
	Median	3.7485	3.0345		3.0345	
	SD	2.77681	1.26219		1.80864	
	(SE)	( 1.96350)	( 0.89250)		( 0.90432)	
	Min,	1.785,	2.142,		1.785,	
	Max	5.712	3.927		5.712	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	2.8560		4.2840		3.5700	
	Median	2.8560		4.2840		3.7485	
	SD	1.51462		1.00975		1.33577	
	(SE)	( 1.07100)		( 0.71400)		( 0.66789)	
	Min,	1.785,		3.570,		1.785,	
	Max	3.927		4.998		4.998	
Week 24	n	2		2		4	
	Mean	3.7485		3.5700		3.6593	
	Median	3.7485		3.5700		3.5700	
	SD	2.27193		0.50487		1.34765	
	(SE)	( 1.60650)		( 0.35700)		( 0.67382)	
	Min,	2.142,		3.213,		2.142,	
	Max	5.355		3.927		5.355	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	3.3915		3.9270		3.6593	
	Median	3.3915		3.9270		3.9270	
	SD	1.76706		1.00975		1.21502	
	(SE)	( 1.24950)		( 0.71400)		( 0.60751)	
	Min,	2.142,		3.213,		2.142,	
	Max	4.641		4.641		4.641	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	3.5700	0.1785	3.3915	-0.5355	3.4808	-0.1785
	Median	3.5700	0.1785	3.3915	-0.5355	3.3915	0.1785
	SD	1.51462	0.25244	0.25244	1.26219	0.89250	0.84983
	(SE)	( 1.07100)	( 0.17850)	( 0.17850)	( 0.89250)	( 0.44625)	( 0.42491)
	Min,	2.499,	0.000,	3.213,	-1.428,	2.499,	-1.428,
	Max	4.641	0.357	3.570	0.357	4.641	0.357
Week 32	n	2	2	2	2	4	4
	Mean	3.5700	0.1785	3.5700	-0.3570	3.5700	-0.0893
	Median	3.5700	0.1785	3.5700	-0.3570	3.5700	0.0000
	SD	1.51462	0.25244	0.50487	0.50487	0.92177	0.44922
	(SE)	( 1.07100)	( 0.17850)	( 0.35700)	( 0.35700)	( 0.46089)	( 0.22461)
	Min,	2.499,	0.000,	3.213,	-0.714,	2.499,	-0.714,
	Max	4.641	0.357	3.927	0.000	4.641	0.357
Week 36	n	2	2	1	1	3	3
	Mean	3.3915	0.0000	3.9270	0.7140	3.5700	0.2380
	Median	3.3915	0.0000	3.9270	0.7140	3.9270	0.0000
	SD	1.76706	0.00000			1.28718	0.41223
	(SE)	( 1.24950)	( 0.00000)			( 0.74315)	( 0.23800)
	Min,	2.142,	0.000,	3.927,	0.714,	2.142,	0.000,
	Max	4.641	0.000	3.927	0.714	4.641	0.714

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	3.9270	0.5355	4.1055	0.1785	4.0163	0.3570
	Median	3.9270	0.5355	4.1055	0.1785	4.1055	0.5355
	SD	2.01950	0.25244	0.25244	0.75731	1.17954	0.50487
	(SE)	( 1.42800)	( 0.17850)	( 0.17850)	( 0.53550)	( 0.58977)	( 0.25244)
	Min,	2.499,	0.357,	3.927,	-0.357,	2.499,	-0.357,
	Max	5.355	0.714	4.284	0.714	5.355	0.714
Week 44	n	2	2	2	2	4	4
	Mean	4.1055	0.7140	4.2840	0.3570	4.1948	0.5355
	Median	4.1055	0.7140	4.2840	0.3570	4.2840	0.3570
	SD	2.77681	1.00975	1.00975	0.00000	1.70901	0.61834
	(SE)	( 1.96350)	( 0.71400)	( 0.71400)	( 0.00000)	( 0.85450)	( 0.30917)
	Min,	2.142,	0.000,	3.570,	0.357,	2.142,	0.000,
	Max	6.069	1.428	4.998	0.357	6.069	1.428
Week 48	n	2	2	2	2	4	4
	Mean	4.1055	0.7140	3.2130	-0.7140	3.6593	0.0000
	Median	4.1055	0.7140	3.2130	-0.7140	3.2130	0.0000
	SD	2.27193	0.50487	0.50487	0.50487	1.43911	0.92177
	(SE)	( 1.60650)	( 0.35700)	( 0.35700)	( 0.35700)	( 0.71956)	( 0.46089)
	Min,	2.499,	0.357,	2.856,	-1.071,	2.499,	-1.071,
	Max	5.712	1.071	3.570	-0.357	5.712	1.071

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	3.0345	-0.3570	3.2130	-0.7140	3.1238	-0.5355
	Median	3.0345	-0.3570	3.2130	-0.7140	3.2130	-0.5355
	SD	1.76706	0.00000	1.00975	0.00000	1.17954	0.20611
	(SE)	( 1.24950)	( 0.00000)	( 0.71400)	( 0.00000)	( 0.58977)	( 0.10306)
	Min,	1.785,	-0.357,	2.499,	-0.714,	1.785,	-0.714,
	Max	4.284	-0.357	3.927	-0.714	4.284	-0.357
Week 56	n	2	2	2	2	4	4
	Mean	3.3915	0.0000	3.0345	-0.8925	3.2130	-0.4463
	Median	3.3915	0.0000	3.0345	-0.8925	3.0345	-0.5355
	SD	2.27193	0.50487	1.26219	0.25244	1.51462	0.60969
	(SE)	( 1.60650)	( 0.35700)	( 0.89250)	( 0.17850)	( 0.75731)	( 0.30485)
	Min,	1.785,	-0.357,	2.142,	-1.071,	1.785,	-1.071,
	Max	4.998	0.357	3.927	-0.714	4.998	0.357
Week 60	n	2	2	2	2	4	4
	Mean	4.1055	0.7140	3.3915	-0.5355	3.7485	0.0893
	Median	4.1055	0.7140	3.3915	-0.5355	3.3915	-0.1785
	SD	2.77681	1.00975	1.26219	0.25244	1.80864	0.93889
	(SE)	( 1.96350)	( 0.71400)	( 0.89250)	( 0.17850)	( 0.90432)	( 0.46945)
	Min,	2.142,	0.000,	2.499,	-0.714,	2.142,	-0.714,
	Max	6.069	1.428	4.284	-0.357	6.069	1.428

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	4.1055	0.7140	3.3915	-0.5355	3.7485	0.0893
	Median	4.1055	0.7140	3.3915	-0.5355	3.3915	-0.5355
	SD	3.78656	2.01950	1.26219	0.25244	2.34101	1.37881
	(SE)	( 2.67750)	( 1.42800)	( 0.89250)	( 0.17850)	( 1.17050)	( 0.68940)
	Min,	1.428,	-0.714,	2.499,	-0.714,	1.428,	-0.714,
	Max	6.783	2.142	4.284	-0.357	6.783	2.142
Week 68	n	2	2	2	2	4	4
	Mean	4.4625	1.0710	3.7485	-0.1785	4.1055	0.4463
	Median	4.4625	1.0710	3.7485	-0.1785	3.9270	0.5355
	SD	3.28168	1.51462	2.77681	1.76706	2.51594	1.52510
	(SE)	( 2.32050)	( 1.07100)	( 1.96350)	( 1.24950)	( 1.25797)	( 0.76255)
	Min,	2.142,	0.000,	1.785,	-1.428,	1.785,	-1.428,
	Max	6.783	2.142	5.712	1.071	6.783	2.142
Week 72	n	2	2	0	0	2	2
	Mean	3.9270	0.5355			3.9270	0.5355
	Median	3.9270	0.5355			3.9270	0.5355
	SD	1.51462	0.25244			1.51462	0.25244
	(SE)	( 1.07100)	( 0.17850)			( 1.07100)	( 0.17850)
	Min,	2.856,	0.357,			2.856,	0.357,
	Max	4.998	0.714			4.998	0.714

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			4.6410	0.0000	4.6410	0.0000
	Median			4.6410	0.0000	4.6410	0.0000
	SD (SE)						
	Min,			4.641,	0.000,	4.641,	0.000,
	Max			4.641	0.000	4.641	0.000
Week 76	n	2	2	2	2	4	4
	Mean	4.2840	0.8925	3.2130	-0.7140	3.7485	0.0893
	Median	4.2840	0.8925	3.2130	-0.7140	3.3915	0.1785
	SD (SE)	1.00975 ( 0.71400)	0.75731 ( 0.53550)	0.00000 ( 0.00000)	1.00975 ( 0.71400)	0.84983 ( 0.42491)	1.17954 ( 0.58977)
	Min,	3.570,	0.357,	3.213,	-1.428,	3.213,	-1.428,
	Max	4.998	1.428	3.213	0.000	4.998	1.428
Week 80	n	2	2	2	2	4	4
	Mean	3.9270	0.5355	2.6775	-1.2495	3.3023	-0.3570
	Median	3.9270	0.5355	2.6775	-1.2495	3.0345	-0.3570
	SD (SE)	2.01950 ( 1.42800)	0.25244 ( 0.17850)	1.26219 ( 0.89250)	0.25244 ( 0.17850)	1.55271 ( 0.77636)	1.05098 ( 0.52549)
	Min,	2.499,	0.357,	1.785,	-1.428,	1.785,	-1.428,
	Max	5.355	0.714	3.570	-1.071	5.355	0.714

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	3.7485	0.3570	3.3915	-0.5355	3.5700	-0.0893
	Median	3.7485	0.3570	3.3915	-0.5355	3.5700	0.1785
	SD	1.76706	0.00000	1.76706	0.75731	1.45745	0.67579
	(SE)	( 1.24950)	( 0.00000)	( 1.24950)	( 0.53550)	( 0.72872)	( 0.33790)
	Min,	2.499,	0.357,	2.142,	-1.071,	2.142,	-1.071,
	Max	4.998	0.357	4.641	0.000	4.998	0.357
Week 88	n	2	2	2	2	4	4
	Mean	4.4625	1.0710	3.2130	-0.7140	3.8378	0.1785
	Median	4.4625	1.0710	3.2130	-0.7140	3.3915	0.0000
	SD	2.77681	1.00975	1.51462	0.50487	1.96350	1.21939
	(SE)	( 1.96350)	( 0.71400)	( 1.07100)	( 0.35700)	( 0.98175)	( 0.60969)
	Min,	2.499,	0.357,	2.142,	-1.071,	2.142,	-1.071,
	Max	6.426	1.785	4.284	-0.357	6.426	1.785
Week 92	n	2	2	2	2	4	4
	Mean	3.3915	0.0000	3.0345	-0.8925	3.2130	-0.4463
	Median	3.3915	0.0000	3.0345	-0.8925	3.0345	-0.5355
	SD	2.27193	0.50487	1.26219	0.25244	1.51462	0.60969
	(SE)	( 1.60650)	( 0.35700)	( 0.89250)	( 0.17850)	( 0.75731)	( 0.30485)
	Min,	1.785,	-0.357,	2.142,	-1.071,	1.785,	-1.071,
	Max	4.998	0.357	3.927	-0.714	4.998	0.357

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	3.5700	0.1785	2.8560	-1.0710	3.2130	-0.4463
	Median	3.5700	0.1785	2.8560	-1.0710	3.2130	-0.7140
	SD	1.00975	0.75731	1.00975	0.00000	0.92177	0.84356
	(SE)	( 0.71400)	( 0.53550)	( 0.71400)	( 0.00000)	( 0.46089)	( 0.42178)
	Min,	2.856,	-0.357,	2.142,	-1.071,	2.142,	-1.071,
	Max	4.284	0.714	3.570	-1.071	4.284	0.714
Week 100	n	2	2	2	2	4	4
	Mean	2.8560	-0.5355	2.8560	-1.0710	2.8560	-0.8033
	Median	2.8560	-0.5355	2.8560	-1.0710	2.8560	-0.8925
	SD	1.00975	0.75731	0.50487	0.50487	0.65179	0.60969
	(SE)	( 0.71400)	( 0.53550)	( 0.35700)	( 0.35700)	( 0.32589)	( 0.30485)
	Min,	2.142,	-1.071,	2.499,	-1.428,	2.142,	-1.428,
	Max	3.570	0.000	3.213	-0.714	3.570	0.000
Week 104	n	2	2	2	2	4	4
	Mean	3.2130	-0.1785	3.7485	-0.1785	3.4808	-0.1785
	Median	3.2130	-0.1785	3.7485	-0.1785	3.7485	-0.1785
	SD	1.51462	0.25244	0.25244	1.26219	0.93889	0.74315
	(SE)	( 1.07100)	( 0.17850)	( 0.17850)	( 0.89250)	( 0.46945)	( 0.37158)
	Min,	2.142,	-0.357,	3.570,	-1.071,	2.142,	-1.071,
	Max	4.284	0.000	3.927	0.714	4.284	0.714

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	3.7485	0.3570	3.7485	-0.1785	3.7485	0.0893
	Median	3.7485	0.3570	3.7485	-0.1785	3.7485	0.1785
	SD	1.76706	0.00000	1.26219	0.25244	1.25374	0.34180
	(SE)	( 1.24950)	( 0.00000)	( 0.89250)	( 0.17850)	( 0.62687)	( 0.17090)
	Min,	2.499,	0.357,	2.856,	-0.357,	2.499,	-0.357,
	Max	4.998	0.357	4.641	0.000	4.998	0.357
Week 112	n	2	2	2	2	4	4
	Mean	3.5700	0.1785	3.0345	-0.8925	3.3023	-0.3570
	Median	3.5700	0.1785	3.0345	-0.8925	3.0345	0.1785
	SD	1.51462	0.25244	0.75731	1.76706	1.02540	1.20184
	(SE)	( 1.07100)	( 0.17850)	( 0.53550)	( 1.24950)	( 0.51270)	( 0.60092)
	Min,	2.499,	0.000,	2.499,	-2.142,	2.499,	-2.142,
	Max	4.641	0.357	3.570	0.357	4.641	0.357
Week 116	n	2	2	2	2	4	4
	Mean	3.9270	0.5355	4.4625	0.5355	4.1948	0.5355
	Median	3.9270	0.5355	4.4625	0.5355	4.4625	0.5355
	SD	2.01950	0.25244	0.25244	0.75731	1.21502	0.46089
	(SE)	( 1.42800)	( 0.17850)	( 0.17850)	( 0.53550)	( 0.60751)	( 0.23044)
	Min,	2.499,	0.357,	4.284,	0.000,	2.499,	0.000,
	Max	5.355	0.714	4.641	1.071	5.355	1.071

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	3.2130	-0.1785	3.2130	-0.7140	3.2130	-0.4462
	Median	3.2130	-0.1785	3.2130	-0.7140	3.2130	-0.1785
	SD	1.00975	0.75731	0.50487	1.51462	0.65179	1.02540
	(SE)	( 0.71400)	( 0.53550)	( 0.35700)	( 1.07100)	( 0.32589)	( 0.51270)
	Min,	2.499,	-0.714,	2.856,	-1.785,	2.499,	-1.785,
	Max	3.927	0.357	3.570	0.357	3.927	0.357
Week 124	n	2	2	2	2	4	4
	Mean	4.1055	0.7140	2.4990	-1.4280	3.3023	-0.3570
	Median	4.1055	0.7140	2.4990	-1.4280	2.8560	0.1785
	SD	1.76706	0.00000	0.50487	1.51462	1.40928	1.51462
	(SE)	( 1.24950)	( 0.00000)	( 0.35700)	( 1.07100)	( 0.70464)	( 0.75731)
	Min,	2.856,	0.714,	2.142,	-2.499,	2.142,	-2.499,
	Max	5.355	0.714	2.856	-0.357	5.355	0.714
Week 128	n	2	2	2	2	4	4
	Mean	3.0345	-0.3570	2.8560	-1.0710	2.9453	-0.7140
	Median	3.0345	-0.3570	2.8560	-1.0710	2.8560	-0.8925
	SD	2.27193	0.50487	1.00975	0.00000	1.43911	0.50487
	(SE)	( 1.60650)	( 0.35700)	( 0.71400)	( 0.00000)	( 0.71956)	( 0.25244)
	Min,	1.428,	-0.714,	2.142,	-1.071,	1.428,	-1.071,
	Max	4.641	0.000	3.570	-1.071	4.641	0.000

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	3.3915	0.0000	2.8560	-1.0710	3.1238	-0.5355
	Median	3.3915	0.0000	2.8560	-1.0710	2.8560	-0.7140
	SD	2.27193	0.50487	1.00975	0.00000	1.46834	0.68360
	(SE)	( 1.60650)	( 0.35700)	( 0.71400)	( 0.00000)	( 0.73417)	( 0.34180)
	Min,	1.785,	-0.357,	2.142,	-1.071,	1.785,	-1.071,
	Max	4.998	0.357	3.570	-1.071	4.998	0.357
Week 136	n	2	2	2	2	4	4
	Mean	4.1055	0.7140	2.8560	-1.0710	3.4808	-0.1785
	Median	4.1055	0.7140	2.8560	-1.0710	2.8560	-0.5355
	SD	3.28168	1.51462	0.50487	0.50487	2.04822	1.38266
	(SE)	( 2.32050)	( 1.07100)	( 0.35700)	( 0.35700)	( 1.02411)	( 0.69133)
	Min,	1.785,	-0.357,	2.499,	-1.428,	1.785,	-1.428,
	Max	6.426	1.785	3.213	-0.714	6.426	1.785
Week 140	n	2	2	2	2	4	4
	Mean	3.9270	0.5355	2.8560	-1.0710	3.3915	-0.2678
	Median	3.9270	0.5355	2.8560	-1.0710	2.8560	-0.1785
	SD	2.52437	0.75731	0.00000	1.00975	1.58319	1.17954
	(SE)	( 1.78500)	( 0.53550)	( 0.00000)	( 0.71400)	( 0.79160)	( 0.58977)
	Min,	2.142,	0.000,	2.856,	-1.785,	2.142,	-1.785,
	Max	5.712	1.071	2.856	-0.357	5.712	1.071

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	3.7485	0.3570	2.6775	-1.2495	3.2130	-0.4463
	Median	3.7485	0.3570	2.6775	-1.2495	2.8560	0.1785
	SD	2.27193	0.50487	1.26219	2.27193	1.62294	1.63273
	(SE)	( 1.60650)	( 0.35700)	( 0.89250)	( 1.60650)	( 0.81147)	( 0.81637)
	Min,	2.142,	0.000,	1.785,	-2.856,	1.785,	-2.856,
	Max	5.355	0.714	3.570	0.357	5.355	0.714
Week 148	n	2	2	2	2	4	4
	Mean	3.0345	-0.3570	2.8560	-1.0710	2.9453	-0.7140
	Median	3.0345	-0.3570	2.8560	-1.0710	2.8560	-0.5355
	SD	1.26219	0.50487	0.00000	1.00975	0.73597	0.77121
	(SE)	( 0.89250)	( 0.35700)	( 0.00000)	( 0.71400)	( 0.36799)	( 0.38560)
	Min,	2.142,	-0.714,	2.856,	-1.785,	2.142,	-1.785,
	Max	3.927	0.000	2.856	-0.357	3.927	0.000
Week 152	n	2	2	2	2	4	4
	Mean	3.7485	0.3570	3.9270	0.0000	3.8378	0.1785
	Median	3.7485	0.3570	3.9270	0.0000	3.9270	0.3570
	SD	1.26219	0.50487	0.50487	1.51462	0.79160	0.94453
	(SE)	( 0.89250)	( 0.35700)	( 0.35700)	( 1.07100)	( 0.39580)	( 0.47227)
	Min,	2.856,	0.000,	3.570,	-1.071,	2.856,	-1.071,
	Max	4.641	0.714	4.284	1.071	4.641	1.071

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	4.2840	0.8925	3.3915	-0.5355	3.8378	0.1785
	Median	4.2840	0.8925	3.3915	-0.5355	3.3915	0.3570
	SD	2.01950	0.25244	0.25244	0.75731	1.28305	0.94453
	(SE)	( 1.42800)	( 0.17850)	( 0.17850)	( 0.53550)	( 0.64152)	( 0.47227)
	Min,	2.856,	0.714,	3.213,	-1.071,	2.856,	-1.071,
	Max	5.712	1.071	3.570	0.000	5.712	1.071
Week 160	n	2	2	2	2	4	4
	Mean	3.9270	0.5355	3.3915	-0.5355	3.6593	0.0000
	Median	3.9270	0.5355	3.3915	-0.5355	3.3915	0.1785
	SD	2.01950	0.25244	0.25244	0.75731	1.21502	0.77121
	(SE)	( 1.42800)	( 0.17850)	( 0.17850)	( 0.53550)	( 0.60751)	( 0.38560)
	Min,	2.499,	0.357,	3.213,	-1.071,	2.499,	-1.071,
	Max	5.355	0.714	3.570	0.000	5.355	0.714
Week 164	n	2	2	2	2	4	4
	Mean	4.1055	0.7140	3.2130	-0.7140	3.6593	0.0000
	Median	4.1055	0.7140	3.2130	-0.7140	3.2130	0.1785
	SD	1.76706	0.00000	0.50487	0.50487	1.17954	0.87447
	(SE)	( 1.24950)	( 0.00000)	( 0.35700)	( 0.35700)	( 0.58977)	( 0.43723)
	Min,	2.856,	0.714,	2.856,	-1.071,	2.856,	-1.071,
	Max	5.355	0.714	3.570	-0.357	5.355	0.714

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	4.1055	0.7140	3.2130	-0.7140	3.6593	0.0000
	Median	4.1055	0.7140	3.2130	-0.7140	3.5700	0.1785
	SD	1.76706	0.00000	1.51462	0.50487	1.43911	0.87447
	(SE)	( 1.24950)	( 0.00000)	( 1.07100)	( 0.35700)	( 0.71956)	( 0.43723)
	Min, Max	2.856, 5.355	0.714, 0.714	2.142, 4.284	-1.071, -0.357	2.142, 5.355	-1.071, 0.714
Week 172	n	2	2	2	2	4	4
	Mean	3.9270	0.5355	2.8560	-1.0710	3.3915	-0.2678
	Median	3.9270	0.5355	2.8560	-1.0710	2.8560	-0.1785
	SD	2.01950	0.25244	0.50487	0.50487	1.35158	0.98310
	(SE)	( 1.42800)	( 0.17850)	( 0.35700)	( 0.35700)	( 0.67579)	( 0.49155)
	Min, Max	2.499, 5.355	0.357, 0.714	2.499, 3.213	-1.428, -0.714	2.499, 5.355	-1.428, 0.714
Week 176	n	2	2	2	2	4	4
	Mean	3.9270	0.5355	4.1055	0.1785	4.0163	0.3570
	Median	3.9270	0.5355	4.1055	0.1785	4.1055	0.1785
	SD	1.00975	0.75731	0.75731	0.25244	0.73597	0.50487
	(SE)	( 0.71400)	( 0.53550)	( 0.53550)	( 0.17850)	( 0.36799)	( 0.25244)
	Min, Max	3.213, 4.641	0.000, 1.071	3.570, 4.641	0.000, 0.357	3.213, 4.641	0.000, 1.071

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	2	2	2	2	4	4
	Mean	4.4625	1.0710	3.0345	-0.8925	3.7485	0.0893
	Median	4.4625	1.0710	3.0345	-0.8925	3.7485	-0.1785
	SD	0.75731	1.00975	0.75731	0.25244	1.03057	1.28305
	(SE)	( 0.53550)	( 0.71400)	( 0.53550)	( 0.17850)	( 0.51529)	( 0.64152)
	Min,	3.927,	0.357,	2.499,	-1.071,	2.499,	-1.071,
	Max	4.998	1.785	3.570	-0.714	4.998	1.785
Week 184	n	2	2	2	2	4	4
	Mean	4.2840	0.8925	3.2130	-0.7140	3.7485	0.0893
	Median	4.2840	0.8925	3.2130	-0.7140	3.7485	0.1785
	SD	1.51462	0.25244	1.51462	0.50487	1.38266	0.98310
	(SE)	( 1.07100)	( 0.17850)	( 1.07100)	( 0.35700)	( 0.69133)	( 0.49155)
	Min,	3.213,	0.714,	2.142,	-1.071,	2.142,	-1.071,
	Max	5.355	1.071	4.284	-0.357	5.355	1.071

'Baseline is the last non-missing assessment prior to dosing with Eteplirsen.'

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Protein (g/dL)						
Week 1	n	2	2		4	
	Mean	7.10	6.90		7.00	
	Median	7.10	6.90		7.00	
	SD	0.283	0.283		0.258	
	(SE)	( 0.200)	( 0.200)		( 0.129)	
	Min, Max	6.9, 7.3	6.7, 7.1		6.7, 7.3	
Week 2	n	2	2		4	
	Mean	7.40	6.90		7.15	
	Median	7.40	6.90		7.05	
	SD	0.566	0.283		0.465	
	(SE)	( 0.400)	( 0.200)		( 0.233)	
	Min, Max	7.0, 7.8	6.7, 7.1		6.7, 7.8	
Week 4	n	2	2		4	
	Mean	6.95	6.90		6.93	
	Median	6.95	6.90		6.95	
	SD	0.354	0.566		0.386	
	(SE)	( 0.250)	( 0.400)		( 0.193)	
	Min, Max	6.7, 7.2	6.5, 7.3		6.5, 7.3	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2	2		4	
	Mean	6.35	6.95		6.65	
	Median	6.35	6.95		6.70	
	SD	0.212	0.071		0.370	
	(SE)	( 0.150)	( 0.050)		( 0.185)	
	Min,	6.2,	6.9,		6.2,	
	Max	6.5	7.0		7.0	
Week 8	n	2	2		4	
	Mean	6.45	6.60		6.53	
	Median	6.45	6.60		6.55	
	SD	0.354	0.283		0.275	
	(SE)	( 0.250)	( 0.200)		( 0.138)	
	Min,	6.2,	6.4,		6.2,	
	Max	6.7	6.8		6.8	
Week 10	n	2	2		4	
	Mean	6.35	6.10		6.23	
	Median	6.35	6.10		6.25	
	SD	0.071	0.141		0.171	
	(SE)	( 0.050)	( 0.100)		( 0.085)	
	Min,	6.3,	6.0,		6.0,	
	Max	6.4	6.2		6.4	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2	2		4	
	Mean	6.60	6.85		6.73	
	Median	6.60	6.85		6.80	
	SD	0.283	0.071		0.222	
	(SE)	( 0.200)	( 0.050)		( 0.111)	
	Min,	6.4,	6.8,		6.4,	
	Max	6.8	6.9		6.9	
Week 15	n	2	2		4	
	Mean	6.30	6.40		6.35	
	Median	6.30	6.40		6.30	
	SD	0.141	0.566		0.342	
	(SE)	( 0.100)	( 0.400)		( 0.171)	
	Min,	6.2,	6.0,		6.0,	
	Max	6.4	6.8		6.8	
Week 18	n	2	2		4	
	Mean	6.50	6.60		6.55	
	Median	6.50	6.60		6.50	
	SD	0.283	0.424		0.300	
	(SE)	( 0.200)	( 0.300)		( 0.150)	
	Min,	6.3,	6.3,		6.3,	
	Max	6.7	6.9		6.9	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	6.25		6.60		6.43	
	Median	6.25		6.60		6.55	
	SD	0.495		0.141		0.359	
	(SE)	( 0.350)		( 0.100)		( 0.180)	
	Min,	5.9,		6.5,		5.9,	
	Max	6.6		6.7		6.7	
Week 24	n	2		2		4	
	Mean	6.50		6.40		6.45	
	Median	6.50		6.40		6.50	
	SD	0.141		0.283		0.191	
	(SE)	( 0.100)		( 0.200)		( 0.096)	
	Min,	6.4,		6.2,		6.2,	
	Max	6.6		6.6		6.6	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	6.70		6.65		6.68	
	Median	6.70		6.65		6.65	
	SD	0.283		0.071		0.171	
	(SE)	( 0.200)		( 0.050)		( 0.085)	
	Min,	6.5,		6.6,		6.5,	
	Max	6.9		6.7		6.9	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 28	n	2	2	2	2	4	4
	Mean	6.35	-0.35	6.70	0.05	6.53	-0.15
	Median	6.35	-0.35	6.70	0.05	6.45	-0.20
	SD	0.071	0.212	0.283	0.354	0.263	0.332
	(SE)	( 0.050)	( 0.150)	( 0.200)	( 0.250)	( 0.131)	( 0.166)
	Min,	6.3,	-0.5,	6.5,	-0.2,	6.3,	-0.5,
	Max	6.4	-0.2	6.9	0.3	6.9	0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Albumin (g/dL)						
Week 1	n	2	2		4	
	Mean	4.50	4.20		4.35	
	Median	4.50	4.20		4.30	
	SD	0.283	0.141		0.252	
	(SE)	( 0.200)	( 0.100)		( 0.126)	
	Min, Max	4.3, 4.7	4.1, 4.3		4.1, 4.7	
Week 2	n	2	2		4	
	Mean	4.60	4.10		4.35	
	Median	4.60	4.10		4.35	
	SD	0.141	0.141		0.311	
	(SE)	( 0.100)	( 0.100)		( 0.155)	
	Min, Max	4.5, 4.7	4.0, 4.2		4.0, 4.7	
Week 4	n	2	2		4	
	Mean	4.10	4.00		4.05	
	Median	4.10	4.00		4.10	
	SD	0.141	0.424		0.265	
	(SE)	( 0.100)	( 0.300)		( 0.132)	
	Min, Max	4.0, 4.2	3.7, 4.3		3.7, 4.3	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2	2		4	
	Mean	3.85	4.15		4.00	
	Median	3.85	4.15		4.00	
	SD	0.071	0.071		0.183	
	(SE)	( 0.050)	( 0.050)		( 0.091)	
	Min,	3.8,	4.1,		3.8,	
	Max	3.9	4.2		4.2	
Week 8	n	2	2		4	
	Mean	4.00	4.00		4.00	
	Median	4.00	4.00		4.00	
	SD	0.283	0.141		0.183	
	(SE)	( 0.200)	( 0.100)		( 0.091)	
	Min,	3.8,	3.9,		3.8,	
	Max	4.2	4.1		4.2	
Week 10	n	2	2		4	
	Mean	3.90	3.55		3.73	
	Median	3.90	3.55		3.80	
	SD	0.000	0.212		0.236	
	(SE)	( 0.000)	( 0.150)		( 0.118)	
	Min,	3.9,	3.4,		3.4,	
	Max	3.9	3.7		3.9	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	4.15		4.20		4.18	
	Median	4.15		4.20		4.20	
	SD	0.354		0.141		0.222	
	(SE)	( 0.250)		( 0.100)		( 0.111)	
	Min, Max	3.9, 4.4		4.1, 4.3		3.9, 4.4	
Week 15	n	2		2		4	
	Mean	3.85		3.75		3.80	
	Median	3.85		3.75		3.85	
	SD	0.071		0.495		0.294	
	(SE)	( 0.050)		( 0.350)		( 0.147)	
	Min, Max	3.8, 3.9		3.4, 4.1		3.4, 4.1	
Week 18	n	2		2		4	
	Mean	3.95		3.85		3.90	
	Median	3.95		3.85		3.85	
	SD	0.354		0.212		0.245	
	(SE)	( 0.250)		( 0.150)		( 0.122)	
	Min, Max	3.7, 4.2		3.7, 4.0		3.7, 4.2	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	3.85		3.85		3.85	
	Median	3.85		3.85		3.85	
	SD	0.212		0.071		0.129	
	(SE)	( 0.150)		( 0.050)		( 0.065)	
	Min, Max	3.7, 4.0		3.8, 3.9		3.7, 4.0	
Week 24	n	2		2		4	
	Mean	4.20		3.90		4.05	
	Median	4.20		3.90		3.95	
	SD	0.283		0.000		0.238	
	(SE)	( 0.200)		( 0.000)		( 0.119)	
	Min, Max	4.0, 4.4		3.9, 3.9		3.9, 4.4	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	4.25		4.05		4.15	
	Median	4.25		4.05		4.05	
	SD	0.495		0.071		0.311	
	(SE)	( 0.350)		( 0.050)		( 0.155)	
	Min, Max	3.9, 4.6		4.0, 4.1		3.9, 4.6	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	3.75	-0.50	3.80	-0.25	3.78	-0.38
	Median	3.75	-0.50	3.80	-0.25	3.80	-0.25
	SD	0.071	0.424	0.000	0.071	0.050	0.287
	(SE)	( 0.050)	( 0.300)	( 0.000)	( 0.050)	( 0.025)	( 0.144)
	Min, Max	3.7, 3.8	-0.8, -0.2	3.8, 3.8	-0.3, -0.2	3.7, 3.8	-0.8, -0.2
Week 32	n	2	2	2	2	4	4
	Mean	4.00	-0.25	4.15	0.10	4.08	-0.08
	Median	4.00	-0.25	4.15	0.10	4.15	0.00
	SD	0.283	0.212	0.071	0.000	0.189	0.236
	(SE)	( 0.200)	( 0.150)	( 0.050)	( 0.000)	( 0.095)	( 0.118)
	Min, Max	3.8, 4.2	-0.4, -0.1	4.1, 4.2	0.1, 0.1	3.8, 4.2	-0.4, 0.1
Week 36	n	2	2	2	2	4	4
	Mean	4.20	-0.05	4.30	0.25	4.25	0.10
	Median	4.20	-0.05	4.30	0.25	4.20	0.20
	SD	0.000	0.495	0.141	0.212	0.100	0.356
	(SE)	( 0.000)	( 0.350)	( 0.100)	( 0.150)	( 0.050)	( 0.178)
	Min, Max	4.2, 4.2	-0.4, 0.3	4.2, 4.4	0.1, 0.4	4.2, 4.4	-0.4, 0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	4.40	0.15	3.90	-0.15	4.15	0.00
	Median	4.40	0.15	3.90	-0.15	4.15	0.00
	SD	0.283	0.212	0.283	0.212	0.370	0.245
	(SE)	( 0.200)	( 0.150)	( 0.200)	( 0.150)	( 0.185)	( 0.122)
	Min,	4.2,	0.0,	3.7,	-0.3,	3.7,	-0.3,
	Max	4.6	0.3	4.1	0.0	4.6	0.3
Week 44	n	2	2	2	2	4	4
	Mean	4.20	-0.05	4.10	0.05	4.15	0.00
	Median	4.20	-0.05	4.10	0.05	4.10	0.05
	SD	0.141	0.354	0.000	0.071	0.100	0.216
	(SE)	( 0.100)	( 0.250)	( 0.000)	( 0.050)	( 0.050)	( 0.108)
	Min,	4.1,	-0.3,	4.1,	0.0,	4.1,	-0.3,
	Max	4.3	0.2	4.1	0.1	4.3	0.2
Week 48	n	2	2	2	2	4	4
	Mean	4.50	0.25	4.10	0.05	4.30	0.15
	Median	4.50	0.25	4.10	0.05	4.20	0.15
	SD	0.424	0.071	0.141	0.071	0.346	0.129
	(SE)	( 0.300)	( 0.050)	( 0.100)	( 0.050)	( 0.173)	( 0.065)
	Min,	4.2,	0.2,	4.0,	0.0,	4.0,	0.0,
	Max	4.8	0.3	4.2	0.1	4.8	0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	4.15	-0.10	4.30	0.25	4.23	0.08
	Median	4.15	-0.10	4.30	0.25	4.25	0.10
	SD	0.212	0.283	0.141	0.212	0.171	0.287
	(SE)	( 0.150)	( 0.200)	( 0.100)	( 0.150)	( 0.085)	( 0.144)
	Min, Max	4.0, 4.3	-0.3, 0.1	4.2, 4.4	0.1, 0.4	4.0, 4.4	-0.3, 0.4
Week 56	n	2	2	2	2	4	4
	Mean	4.30	0.05	4.25	0.20	4.28	0.13
	Median	4.30	0.05	4.25	0.20	4.25	0.05
	SD	0.566	0.071	0.354	0.283	0.386	0.189
	(SE)	( 0.400)	( 0.050)	( 0.250)	( 0.200)	( 0.193)	( 0.095)
	Min, Max	3.9, 4.7	0.0, 0.1	4.0, 4.5	0.0, 0.4	3.9, 4.7	0.0, 0.4
Week 60	n	2	2	2	2	4	4
	Mean	4.45	0.20	4.25	0.20	4.35	0.20
	Median	4.45	0.20	4.25	0.20	4.30	0.20
	SD	0.354	0.141	0.212	0.141	0.265	0.115
	(SE)	( 0.250)	( 0.100)	( 0.150)	( 0.100)	( 0.132)	( 0.058)
	Min, Max	4.2, 4.7	0.1, 0.3	4.1, 4.4	0.1, 0.3	4.1, 4.7	0.1, 0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	4.35	0.10	4.40	0.35	4.38	0.23
	Median	4.35	0.10	4.40	0.35	4.40	0.20
	SD	0.495	0.000	0.000	0.071	0.287	0.150
	(SE)	( 0.350)	( 0.000)	( 0.000)	( 0.050)	( 0.144)	( 0.075)
	Min, Max	4.0, 4.7	0.1, 0.1	4.4, 4.4	0.3, 0.4	4.0, 4.7	0.1, 0.4
Week 68	n	2	2	2	2	4	4
	Mean	4.45	0.20	3.65	-0.40	4.05	-0.10
	Median	4.45	0.20	3.65	-0.40	4.10	0.00
	SD	0.354	0.141	0.495	0.424	0.580	0.432
	(SE)	( 0.250)	( 0.100)	( 0.350)	( 0.300)	( 0.290)	( 0.216)
	Min, Max	4.2, 4.7	0.1, 0.3	3.3, 4.0	-0.7, -0.1	3.3, 4.7	-0.7, 0.3
Week 72	n	2	2	0	0	2	2
	Mean	4.20	-0.05			4.20	-0.05
	Median	4.20	-0.05			4.20	-0.05
	SD	0.283	0.212			0.283	0.212
	(SE)	( 0.200)	( 0.150)			( 0.200)	( 0.150)
	Min, Max	4.0, 4.4	-0.2, 0.1			4.0, 4.4	-0.2, 0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			4.40	0.30	4.40	0.30
	Median			4.40	0.30	4.40	0.30
	SD						
	(SE)						
	Min, Max			4.4, 4.4	0.3, 0.3	4.4, 4.4	0.3, 0.3
Week 76	n	2	2	2	2	4	4
	Mean	4.30	0.05	4.35	0.30	4.33	0.18
	Median	4.30	0.05	4.35	0.30	4.35	0.15
	SD	0.424	0.071	0.071	0.141	0.250	0.171
	(SE)	( 0.300)	( 0.050)	( 0.050)	( 0.100)	( 0.125)	( 0.085)
	Min, Max	4.0, 4.6	0.0, 0.1	4.3, 4.4	0.2, 0.4	4.0, 4.6	0.0, 0.4
Week 80	n	2	2	2	2	4	4
	Mean	4.45	0.20	4.30	0.25	4.38	0.23
	Median	4.45	0.20	4.30	0.25	4.35	0.25
	SD	0.212	0.283	0.141	0.071	0.171	0.171
	(SE)	( 0.150)	( 0.200)	( 0.100)	( 0.050)	( 0.085)	( 0.085)
	Min, Max	4.3, 4.6	0.0, 0.4	4.2, 4.4	0.2, 0.3	4.2, 4.6	0.0, 0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	4.35	0.10	4.55	0.50	4.45	0.30
	Median	4.35	0.10	4.55	0.50	4.40	0.30
	SD	0.212	0.283	0.354	0.283	0.265	0.327
	(SE)	( 0.150)	( 0.200)	( 0.250)	( 0.200)	( 0.132)	( 0.163)
	Min,	4.2,	-0.1,	4.3,	0.3,	4.2,	-0.1,
	Max	4.5	0.3	4.8	0.7	4.8	0.7
Week 88	n	2	2	2	2	4	4
	Mean	4.40	0.15	4.35	0.30	4.38	0.23
	Median	4.40	0.15	4.35	0.30	4.35	0.30
	SD	0.283	0.212	0.071	0.000	0.171	0.150
	(SE)	( 0.200)	( 0.150)	( 0.050)	( 0.000)	( 0.085)	( 0.075)
	Min,	4.2,	0.0,	4.3,	0.3,	4.2,	0.0,
	Max	4.6	0.3	4.4	0.3	4.6	0.3
Week 92	n	2	2	2	2	4	4
	Mean	4.45	0.20	4.10	0.05	4.28	0.13
	Median	4.45	0.20	4.10	0.05	4.10	0.15
	SD	0.495	0.000	0.000	0.071	0.350	0.096
	(SE)	( 0.350)	( 0.000)	( 0.000)	( 0.050)	( 0.175)	( 0.048)
	Min,	4.1,	0.2,	4.1,	0.0,	4.1,	0.0,
	Max	4.8	0.2	4.1	0.1	4.8	0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	4.25	0.00	4.35	0.30	4.30	0.15
	Median	4.25	0.00	4.35	0.30	4.35	0.20
	SD	0.212	0.283	0.071	0.141	0.141	0.252
	(SE)	( 0.150)	( 0.200)	( 0.050)	( 0.100)	( 0.071)	( 0.126)
	Min, Max	4.1, 4.4	-0.2, 0.2	4.3, 4.4	0.2, 0.4	4.1, 4.4	-0.2, 0.4
Week 100	n	2	2	2	2	4	4
	Mean	4.30	0.05	4.20	0.15	4.25	0.10
	Median	4.30	0.05	4.20	0.15	4.25	0.15
	SD	0.141	0.354	0.141	0.071	0.129	0.216
	(SE)	( 0.100)	( 0.250)	( 0.100)	( 0.050)	( 0.065)	( 0.108)
	Min, Max	4.2, 4.4	-0.2, 0.3	4.1, 4.3	0.1, 0.2	4.1, 4.4	-0.2, 0.3
Week 104	n	2	2	2	2	4	4
	Mean	4.40	0.15	4.30	0.25	4.35	0.20
	Median	4.40	0.15	4.30	0.25	4.40	0.20
	SD	0.141	0.354	0.424	0.354	0.265	0.294
	(SE)	( 0.100)	( 0.250)	( 0.300)	( 0.250)	( 0.132)	( 0.147)
	Min, Max	4.3, 4.5	-0.1, 0.4	4.0, 4.6	0.0, 0.5	4.0, 4.6	-0.1, 0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	4.40	0.15	4.30	0.25	4.35	0.20
	Median	4.40	0.15	4.30	0.25	4.30	0.15
	SD	0.424	0.071	0.141	0.212	0.265	0.141
	(SE)	( 0.300)	( 0.050)	( 0.100)	( 0.150)	( 0.132)	( 0.071)
	Min, Max	4.1, 4.7	0.1, 0.2	4.2, 4.4	0.1, 0.4	4.1, 4.7	0.1, 0.4
Week 112	n	2	2	2	2	4	4
	Mean	4.35	0.10	4.40	0.35	4.38	0.23
	Median	4.35	0.10	4.40	0.35	4.40	0.25
	SD	0.354	0.141	0.000	0.071	0.206	0.171
	(SE)	( 0.250)	( 0.100)	( 0.000)	( 0.050)	( 0.103)	( 0.085)
	Min, Max	4.1, 4.6	0.0, 0.2	4.4, 4.4	0.3, 0.4	4.1, 4.6	0.0, 0.4
Week 116	n	2	2	2	2	4	4
	Mean	4.30	0.05	4.20	0.15	4.25	0.10
	Median	4.30	0.05	4.20	0.15	4.20	0.10
	SD	0.566	0.071	0.141	0.071	0.342	0.082
	(SE)	( 0.400)	( 0.050)	( 0.100)	( 0.050)	( 0.171)	( 0.041)
	Min, Max	3.9, 4.7	0.0, 0.1	4.1, 4.3	0.1, 0.2	3.9, 4.7	0.0, 0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	4.40	0.15	4.05	0.00	4.23	0.08
	Median	4.40	0.15	4.05	0.00	4.10	0.05
	SD	0.424	0.071	0.071	0.000	0.320	0.096
	(SE)	( 0.300)	( 0.050)	( 0.050)	( 0.000)	( 0.160)	( 0.048)
	Min, Max	4.1, 4.7	0.1, 0.2	4.0, 4.1	0.0, 0.0	4.0, 4.7	0.0, 0.2
Week 124	n	2	2	2	2	4	4
	Mean	4.35	0.10	4.15	0.10	4.25	0.10
	Median	4.35	0.10	4.15	0.10	4.15	0.10
	SD	0.354	0.141	0.071	0.000	0.238	0.082
	(SE)	( 0.250)	( 0.100)	( 0.050)	( 0.000)	( 0.119)	( 0.041)
	Min, Max	4.1, 4.6	0.0, 0.2	4.1, 4.2	0.1, 0.1	4.1, 4.6	0.0, 0.2
Week 128	n	2	2	2	2	4	4
	Mean	4.05	-0.20	4.15	0.10	4.10	-0.05
	Median	4.05	-0.20	4.15	0.10	4.10	0.10
	SD	0.071	0.566	0.071	0.000	0.082	0.370
	(SE)	( 0.050)	( 0.400)	( 0.050)	( 0.000)	( 0.041)	( 0.185)
	Min, Max	4.0, 4.1	-0.6, 0.2	4.1, 4.2	0.1, 0.1	4.0, 4.2	-0.6, 0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	4.45	0.20	4.05	0.00	4.25	0.10
	Median	4.45	0.20	4.05	0.00	4.15	0.10
	SD	0.354	0.141	0.071	0.141	0.311	0.163
	(SE)	( 0.250)	( 0.100)	( 0.050)	( 0.100)	( 0.155)	( 0.082)
	Min, Max	4.2, 4.7	0.1, 0.3	4.0, 4.1	-0.1, 0.1	4.0, 4.7	-0.1, 0.3
Week 136	n	2	2	2	2	4	4
	Mean	4.35	0.10	4.20	0.15	4.28	0.13
	Median	4.35	0.10	4.20	0.15	4.20	0.15
	SD	0.354	0.141	0.000	0.071	0.222	0.096
	(SE)	( 0.250)	( 0.100)	( 0.000)	( 0.050)	( 0.111)	( 0.048)
	Min, Max	4.1, 4.6	0.0, 0.2	4.2, 4.2	0.1, 0.2	4.1, 4.6	0.0, 0.2
Week 140	n	2	2	2	2	4	4
	Mean	4.25	0.00	4.20	0.15	4.23	0.08
	Median	4.25	0.00	4.20	0.15	4.20	0.00
	SD	0.354	0.141	0.283	0.354	0.263	0.236
	(SE)	( 0.250)	( 0.100)	( 0.200)	( 0.250)	( 0.131)	( 0.118)
	Min, Max	4.0, 4.5	-0.1, 0.1	4.0, 4.4	-0.1, 0.4	4.0, 4.5	-0.1, 0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	4.25	0.00	4.25	0.20	4.25	0.10
	Median	4.25	0.00	4.25	0.20	4.25	0.20
	SD	0.071	0.566	0.071	0.141	0.058	0.356
	(SE)	( 0.050)	( 0.400)	( 0.050)	( 0.100)	( 0.029)	( 0.178)
	Min, Max	4.2, 4.3	-0.4, 0.4	4.2, 4.3	0.1, 0.3	4.2, 4.3	-0.4, 0.4
Week 148	n	2	2	2	2	4	4
	Mean	4.35	0.10	4.20	0.15	4.28	0.13
	Median	4.35	0.10	4.20	0.15	4.25	0.15
	SD	0.071	0.566	0.000	0.071	0.096	0.330
	(SE)	( 0.050)	( 0.400)	( 0.000)	( 0.050)	( 0.048)	( 0.165)
	Min, Max	4.3, 4.4	-0.3, 0.5	4.2, 4.2	0.1, 0.2	4.2, 4.4	-0.3, 0.5
Week 152	n	2	2	2	2	4	4
	Mean	4.30	0.05	4.15	0.10	4.23	0.08
	Median	4.30	0.05	4.15	0.10	4.25	0.10
	SD	0.000	0.495	0.071	0.000	0.096	0.287
	(SE)	( 0.000)	( 0.350)	( 0.050)	( 0.000)	( 0.048)	( 0.144)
	Min, Max	4.3, 4.3	-0.3, 0.4	4.1, 4.2	0.1, 0.1	4.1, 4.3	-0.3, 0.4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	4.25	0.00	4.30	0.25	4.28	0.13
	Median	4.25	0.00	4.30	0.25	4.30	0.15
	SD	0.212	0.283	0.141	0.212	0.150	0.250
	(SE)	( 0.150)	( 0.200)	( 0.100)	( 0.150)	( 0.075)	( 0.125)
	Min, Max	4.1, 4.4	-0.2, 0.2	4.2, 4.4	0.1, 0.4	4.1, 4.4	-0.2, 0.4
Week 160	n	2	2	2	2	4	4
	Mean	4.20	-0.05	4.10	0.05	4.15	0.00
	Median	4.20	-0.05	4.10	0.05	4.10	0.00
	SD	0.424	0.071	0.000	0.071	0.252	0.082
	(SE)	( 0.300)	( 0.050)	( 0.000)	( 0.050)	( 0.126)	( 0.041)
	Min, Max	3.9, 4.5	-0.1, 0.0	4.1, 4.1	0.0, 0.1	3.9, 4.5	-0.1, 0.1
Week 164	n	2	2	2	2	4	4
	Mean	4.15	-0.10	4.15	0.10	4.15	0.00
	Median	4.15	-0.10	4.15	0.10	4.15	-0.05
	SD	0.354	0.141	0.212	0.283	0.238	0.216
	(SE)	( 0.250)	( 0.100)	( 0.150)	( 0.200)	( 0.119)	( 0.108)
	Min, Max	3.9, 4.4	-0.2, 0.0	4.0, 4.3	-0.1, 0.3	3.9, 4.4	-0.2, 0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	4.40	0.15	4.30	0.25	4.35	0.20
	Median	4.40	0.15	4.30	0.25	4.30	0.25
	SD	0.283	0.212	0.000	0.071	0.173	0.141
	(SE)	( 0.200)	( 0.150)	( 0.000)	( 0.050)	( 0.087)	( 0.071)
	Min,	4.2,	0.0,	4.3,	0.2,	4.2,	0.0,
	Max	4.6	0.3	4.3	0.3	4.6	0.3
Week 172	n	2	2	2	2	4	4
	Mean	4.25	0.00	4.05	0.00	4.15	0.00
	Median	4.25	0.00	4.05	0.00	4.05	0.00
	SD	0.495	0.000	0.071	0.141	0.311	0.082
	(SE)	( 0.350)	( 0.000)	( 0.050)	( 0.100)	( 0.155)	( 0.041)
	Min,	3.9,	0.0,	4.0,	-0.1,	3.9,	-0.1,
	Max	4.6	0.0	4.1	0.1	4.6	0.1
Week 176	n	2	2	2	2	4	4
	Mean	4.15	-0.10	4.00	-0.05	4.08	-0.08
	Median	4.15	-0.10	4.00	-0.05	4.00	-0.10
	SD	0.636	0.141	0.283	0.212	0.411	0.150
	(SE)	( 0.450)	( 0.100)	( 0.200)	( 0.150)	( 0.206)	( 0.075)
	Min,	3.7,	-0.2,	3.8,	-0.2,	3.7,	-0.2,
	Max	4.6	0.0	4.2	0.1	4.6	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	2	2	2	2	4	4
	Mean	4.25	0.00	4.05	0.00	4.15	0.00
	Median	4.25	0.00	4.05	0.00	4.10	0.00
	SD	0.354	0.141	0.212	0.141	0.265	0.115
	(SE)	( 0.250)	( 0.100)	( 0.150)	( 0.100)	( 0.132)	( 0.058)
	Min,	4.0,	-0.1,	3.9,	-0.1,	3.9,	-0.1,
	Max	4.5	0.1	4.2	0.1	4.5	0.1
Week 184	n	2	2	2	2	4	4
	Mean	4.30	0.05	3.95	-0.10	4.13	-0.03
	Median	4.30	0.05	3.95	-0.10	4.05	0.00
	SD	0.424	0.071	0.212	0.141	0.340	0.126
	(SE)	( 0.300)	( 0.050)	( 0.150)	( 0.100)	( 0.170)	( 0.063)
	Min,	4.0,	0.0,	3.8,	-0.2,	3.8,	-0.2,
	Max	4.6	0.1	4.1	0.0	4.6	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Uric Acid (mmol/L)						
Week 1	n	2	2		4	
	Mean	0.18585	0.22125		0.20355	
	Median	0.18585	0.22125		0.22125	
	SD	0.129330	0.004172		0.077453	
	(SE)	( 0.091450)	( 0.002950)		( 0.038726)	
	Min, Max	0.0944, 0.2773	0.2183, 0.2242		0.0944, 0.2773	
Week 2	n	2	2		4	
	Mean	0.20060	0.27435		0.23748	
	Median	0.20060	0.27435		0.25665	
	SD	0.075095	0.020860		0.061950	
	(SE)	( 0.053100)	( 0.014750)		( 0.030975)	
	Min, Max	0.1475, 0.2537	0.2596, 0.2891		0.1475, 0.2891	
Week 4	n	2	2		4	
	Mean	0.20650	0.24485		0.22568	
	Median	0.20650	0.24485		0.24190	
	SD	0.091782	0.045891		0.063248	
	(SE)	( 0.064900)	( 0.032450)		( 0.031624)	
	Min, Max	0.1416, 0.2714	0.2124, 0.2773		0.1416, 0.2773	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2	2		4	
	Mean	0.20355	0.22420		0.21388	
	Median	0.20355	0.22420		0.22420	
	SD	0.104298	0.025032		0.063064	
	(SE)	( 0.073750)	( 0.017700)		( 0.031532)	
	Min,	0.1298,	0.2065,		0.1298,	
	Max	0.2773	0.2419		0.2773	
Week 8	n	2	2		4	
	Mean	0.21830	0.23895		0.22863	
	Median	0.21830	0.23895		0.23895	
	SD	0.050063	0.004172		0.031359	
	(SE)	( 0.035400)	( 0.002950)		( 0.015679)	
	Min,	0.1829,	0.2360,		0.1829,	
	Max	0.2537	0.2419		0.2537	
Week 10	n	2	2		4	
	Mean	0.19765	0.22420		0.21093	
	Median	0.19765	0.22420		0.20945	
	SD	0.054235	0.058407		0.048503	
	(SE)	( 0.038350)	( 0.041300)		( 0.024252)	
	Min,	0.1593,	0.1829,		0.1593,	
	Max	0.2360	0.2655		0.2655	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4
	Mean	0.21535		0.19175		0.20355
	Median	0.21535		0.19175		0.19175
	SD	0.120986		0.062579		0.079814
	(SE)	( 0.085550)		( 0.044250)		( 0.039907)
	Min,	0.1298,		0.1475,		0.1298,
	Max	0.3009		0.2360		0.3009
Week 15	n	2		2		4
	Mean	0.20945		0.18290		0.19618
	Median	0.20945		0.18290		0.18290
	SD	0.112642		0.066751		0.077134
	(SE)	( 0.079650)		( 0.047200)		( 0.038567)
	Min,	0.1298,		0.1357,		0.1298,
	Max	0.2891		0.2301		0.2891
Week 18	n	2		2		4
	Mean	0.21240		0.18290		0.19765
	Median	0.21240		0.18290		0.18290
	SD	0.075095		0.008344		0.046830
	(SE)	( 0.053100)		( 0.005900)		( 0.023415)
	Min,	0.1593,		0.1770,		0.1593,
	Max	0.2655		0.1888		0.2655

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4
	Mean	0.21830		0.19175		0.20503
	Median	0.21830		0.19175		0.19470
	SD	0.066751		0.037547		0.046799
	(SE)	( 0.047200)		( 0.026550)		( 0.023399)
	Min,	0.1711,		0.1652,		0.1652,
	Max	0.2655		0.2183		0.2655
Week 24	n	2		2		4
	Mean	0.24780		0.19175		0.21978
	Median	0.24780		0.19175		0.19175
	SD	0.100126		0.004172		0.066293
	(SE)	( 0.070800)		( 0.002950)		( 0.033147)
	Min,	0.1770,		0.1888,		0.1770,
	Max	0.3186		0.1947		0.3186
Baseline <sup>1</sup>	n	2		2		4
	Mean	0.13865		0.19765		0.16815
	Median	0.13865		0.19765		0.18585
	SD	0.079267		0.029204		0.059490
	(SE)	( 0.056050)		( 0.020650)		( 0.029745)
	Min,	0.0826,		0.1770,		0.0826,
	Max	0.1947		0.2183		0.2183

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	0.23010	0.09145	0.21830	0.02065	0.22420	0.05605
	Median	0.23010	0.09145	0.21830	0.02065	0.21830	0.05605
	SD	0.083439	0.004172	0.025032	0.004172	0.050754	0.041018
	(SE)	( 0.059000)	( 0.002950)	( 0.017700)	( 0.002950)	( 0.025377)	( 0.020509)
	Min,	0.1711,	0.0885,	0.2006,	0.0177,	0.1711,	0.0177,
	Max	0.2891	0.0944	0.2360	0.0236	0.2891	0.0944
Week 32	n	2	2	2	2	4	4
	Mean	0.24485	0.10620	0.21240	0.01475	0.22863	0.06048
	Median	0.24485	0.10620	0.21240	0.01475	0.22125	0.06490
	SD	0.070923	0.008344	0.050063	0.020860	0.053508	0.054369
	(SE)	( 0.050150)	( 0.005900)	( 0.035400)	( 0.014750)	( 0.026754)	( 0.027184)
	Min,	0.1947,	0.1003,	0.1770,	0.0000,	0.1770,	0.0000,
	Max	0.2950	0.1121	0.2478	0.0295	0.2950	0.1121
Week 36	n	2	2	1	1	3	3
	Mean	0.22715	0.08850	0.24780	0.02950	0.23403	0.06883
	Median	0.22715	0.08850	0.24780	0.02950	0.24780	0.07080
	SD	0.054235	0.025032			0.040160	0.038388
	(SE)	( 0.038350)	( 0.017700)			( 0.023187)	( 0.022163)
	Min,	0.1888,	0.0708,	0.2478,	0.0295,	0.1888,	0.0295,
	Max	0.2655	0.1062	0.2478	0.0295	0.2655	0.1062

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	0.23600	0.09735	0.20650	0.00885	0.22125	0.05310
	Median	0.23600	0.09735	0.20650	0.00885	0.22125	0.07080
	SD	0.083439	0.004172	0.083439	0.054235	0.070224	0.059975
	(SE)	( 0.059000)	( 0.002950)	( 0.059000)	( 0.038350)	( 0.035112)	( 0.029988)
	Min,	0.1770,	0.0944,	0.1475,	-0.0295,	0.1475,	-0.0295,
	Max	0.2950	0.1003	0.2655	0.0472	0.2950	0.1003
Week 44	n	2	2	2	2	4	4
	Mean	0.27435	0.13570	0.21240	0.01475	0.24338	0.07523
	Median	0.27435	0.13570	0.21240	0.01475	0.22125	0.07080
	SD	0.104298	0.025032	0.041719	0.012516	0.074064	0.071675
	(SE)	( 0.073750)	( 0.017700)	( 0.029500)	( 0.008850)	( 0.037032)	( 0.035838)
	Min,	0.2006,	0.1180,	0.1829,	0.0059,	0.1829,	0.0059,
	Max	0.3481	0.1534	0.2419	0.0236	0.3481	0.1534
Week 48	n	2	2	2	2	4	4
	Mean	0.23305	0.09440	0.24485	0.04720	0.23895	0.07080
	Median	0.23305	0.09440	0.24485	0.04720	0.24485	0.06785
	SD	0.095954	0.016688	0.037547	0.008344	0.059878	0.029303
	(SE)	( 0.067850)	( 0.011800)	( 0.026550)	( 0.005900)	( 0.029939)	( 0.014651)
	Min,	0.1652,	0.0826,	0.2183,	0.0413,	0.1652,	0.0413,
	Max	0.3009	0.1062	0.2714	0.0531	0.3009	0.1062

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 52	n	2	2	2	2	4	4
	Mean	0.21830	0.07965	0.21535	0.01770	0.21683	0.04868
	Median	0.21830	0.07965	0.21535	0.01770	0.21535	0.05015
	SD	0.116814	0.037547	0.070923	0.041719	0.078918	0.048264
	(SE)	( 0.082600)	( 0.026550)	( 0.050150)	( 0.029500)	( 0.039459)	( 0.024132)
	Min,	0.1357,	0.0531,	0.1652,	-0.0118,	0.1357,	-0.0118,
	Max	0.3009	0.1062	0.2655	0.0472	0.3009	0.1062
Week 56	n	2	2	2	2	4	4
	Mean	0.19175	0.05310	0.20650	0.00885	0.19913	0.03098
	Median	0.19175	0.05310	0.20650	0.00885	0.20650	0.03540
	SD	0.087611	0.008344	0.050063	0.020860	0.058877	0.028652
	(SE)	( 0.061950)	( 0.005900)	( 0.035400)	( 0.014750)	( 0.029438)	( 0.014326)
	Min,	0.1298,	0.0472,	0.1711,	-0.0059,	0.1298,	-0.0059,
	Max	0.2537	0.0590	0.2419	0.0236	0.2537	0.0590
Week 60	n	2	2	2	2	4	4
	Mean	0.23895	0.10030	0.27140	0.07375	0.25518	0.08703
	Median	0.23895	0.10030	0.27140	0.07375	0.25665	0.07375
	SD	0.020860	0.100126	0.016688	0.012516	0.024267	0.060241
	(SE)	( 0.014750)	( 0.070800)	( 0.011800)	( 0.008850)	( 0.012133)	( 0.030120)
	Min,	0.2242,	0.0295,	0.2596,	0.0649,	0.2242,	0.0295,
	Max	0.2537	0.1711	0.2832	0.0826	0.2832	0.1711

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	0.22420	0.08555	0.22420	0.02655	0.22420	0.05605
	Median	0.22420	0.08555	0.22420	0.02655	0.22420	0.05605
	SD	0.025032	0.054235	0.083439	0.054235	0.050294	0.055869
	(SE)	( 0.017700)	( 0.038350)	( 0.059000)	( 0.038350)	( 0.025147)	( 0.027934)
	Min,	0.2065,	0.0472,	0.1652,	-0.0118,	0.1652,	-0.0118,
	Max	0.2419	0.1239	0.2832	0.0649	0.2832	0.1239
Week 68	n	2	2	2	2	4	4
	Mean	0.22715	0.08850	0.22420	0.02655	0.22568	0.05753
	Median	0.22715	0.08850	0.22420	0.02655	0.22715	0.04425
	SD	0.029204	0.050063	0.041719	0.012516	0.029451	0.046550
	(SE)	( 0.020650)	( 0.035400)	( 0.029500)	( 0.008850)	( 0.014725)	( 0.023275)
	Min,	0.2065,	0.0531,	0.1947,	0.0177,	0.1947,	0.0177,
	Max	0.2478	0.1239	0.2537	0.0354	0.2537	0.1239
Week 72	n	2	2	0	0	2	2
	Mean	0.17995	0.04130			0.17995	0.04130
	Median	0.17995	0.04130			0.17995	0.04130
	SD	0.037547	0.041719			0.037547	0.041719
	(SE)	( 0.026550)	( 0.029500)			( 0.026550)	( 0.029500)
	Min,	0.1534,	0.0118,			0.1534,	0.0118,
	Max	0.2065	0.0708			0.2065	0.0708

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			0.17700	0.00000	0.17700	0.00000
	Median			0.17700	0.00000	0.17700	0.00000
	SD						
	(SE)						
	Min, Max			0.1770, 0.1770	0.0000, 0.0000	0.1770, 0.1770	0.0000, 0.0000
Week 76	n	2	2	2	2	4	4
	Mean	0.20355	0.06490	0.19765	0.00000	0.20060	0.03245
	Median	0.20355	0.06490	0.19765	0.00000	0.19765	0.03245
	SD	0.054235	0.025032	0.004172	0.025032	0.031589	0.042682
	(SE)	( 0.038350)	( 0.017700)	( 0.002950)	( 0.017700)	( 0.015795)	( 0.021341)
	Min, Max	0.1652, 0.2419	0.0472, 0.0826	0.1947, 0.2006	-0.0177, 0.0177	0.1652, 0.2419	-0.0177, 0.0826
Week 80	n	2	2	2	2	4	4
	Mean	0.19470	0.05605	0.22715	0.02950	0.21093	0.04278
	Median	0.19470	0.05605	0.22715	0.02950	0.21830	0.03835
	SD	0.058407	0.020860	0.037547	0.008344	0.044250	0.020080
	(SE)	( 0.041300)	( 0.014750)	( 0.026550)	( 0.005900)	( 0.022125)	( 0.010040)
	Min, Max	0.1534, 0.2360	0.0413, 0.0708	0.2006, 0.2537	0.0236, 0.0354	0.1534, 0.2537	0.0236, 0.0708

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	0.23600	0.09735	0.21535	0.01770	0.22568	0.05753
	Median	0.23600	0.09735	0.21535	0.01770	0.23600	0.05015
	SD	0.025032	0.054235	0.062579	0.033375	0.040699	0.058877
	(SE)	( 0.017700)	( 0.038350)	( 0.044250)	( 0.023600)	( 0.020349)	( 0.029438)
	Min,	0.2183,	0.0590,	0.1711,	-0.0059,	0.1711,	-0.0059,
	Max	0.2537	0.1357	0.2596	0.0413	0.2596	0.1357
Week 88	n	2	2	2	2	4	4
	Mean	0.18585	0.04720	0.22125	0.02360	0.20355	0.03540
	Median	0.18585	0.04720	0.22125	0.02360	0.19765	0.03540
	SD	0.045891	0.033375	0.062579	0.033375	0.049245	0.030467
	(SE)	( 0.032450)	( 0.023600)	( 0.044250)	( 0.023600)	( 0.024623)	( 0.015234)
	Min,	0.1534,	0.0236,	0.1770,	0.0000,	0.1534,	0.0000,
	Max	0.2183	0.0708	0.2655	0.0472	0.2655	0.0708
Week 92	n	2	2	2	2	4	4
	Mean	0.19765	0.05900	0.25665	0.05900	0.22715	0.05900
	Median	0.19765	0.05900	0.25665	0.05900	0.20945	0.05900
	SD	0.062579	0.016688	0.112642	0.083439	0.081824	0.049127
	(SE)	( 0.044250)	( 0.011800)	( 0.079650)	( 0.059000)	( 0.040912)	( 0.024564)
	Min,	0.1534,	0.0472,	0.1770,	0.0000,	0.1534,	0.0000,
	Max	0.2419	0.0708	0.3363	0.1180	0.3363	0.1180

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	0.23895	0.10030	0.27140	0.07375	0.25518	0.08703
	Median	0.23895	0.10030	0.27140	0.07375	0.27140	0.09145
	SD	0.062579	0.016688	0.000000	0.029204	0.040699	0.024740
	(SE)	( 0.044250)	( 0.011800)	( 0.000000)	( 0.020650)	( 0.020349)	( 0.012370)
	Min, Max	0.1947, 0.2832	0.0885, 0.1121	0.2714, 0.2714	0.0531, 0.0944	0.1947, 0.2832	0.0531, 0.1121
Week 100	n	2	2	2	2	4	4
	Mean	0.23010	0.09145	0.24485	0.04720	0.23748	0.06933
	Median	0.23010	0.09145	0.24485	0.04720	0.24485	0.06195
	SD	0.108470	0.029204	0.037547	0.008344	0.066816	0.030987
	(SE)	( 0.076700)	( 0.020650)	( 0.026550)	( 0.005900)	( 0.033408)	( 0.015493)
	Min, Max	0.1534, 0.3068	0.0708, 0.1121	0.2183, 0.2714	0.0413, 0.0531	0.1534, 0.3068	0.0413, 0.1121
Week 104	n	2	2	2	2	4	4
	Mean	0.24190	0.10325	0.25075	0.05310	0.24633	0.07818
	Median	0.24190	0.10325	0.25075	0.05310	0.25075	0.08260
	SD	0.083439	0.004172	0.045891	0.016688	0.055216	0.030610
	(SE)	( 0.059000)	( 0.002950)	( 0.032450)	( 0.011800)	( 0.027608)	( 0.015305)
	Min, Max	0.1829, 0.3009	0.1003, 0.1062	0.2183, 0.2832	0.0413, 0.0649	0.1829, 0.3009	0.0413, 0.1062

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	0.22125	0.08260	0.22715	0.02950	0.22420	0.05605
	Median	0.22125	0.08260	0.22715	0.02950	0.22125	0.05605
	SD	0.045891	0.033375	0.062579	0.033375	0.044933	0.041018
	(SE)	( 0.032450)	( 0.023600)	( 0.044250)	( 0.023600)	( 0.022467)	( 0.020509)
	Min,	0.1888,	0.0590,	0.1829,	0.0059,	0.1829,	0.0059,
	Max	0.2537	0.1062	0.2714	0.0531	0.2714	0.1062
Week 112	n	2	2	2	2	4	4
	Mean	0.17700	0.03835	0.18880	-0.00885	0.18290	0.01475
	Median	0.17700	0.03835	0.18880	-0.00885	0.18585	0.01475
	SD	0.058407	0.020860	0.050063	0.020860	0.044933	0.032136
	(SE)	( 0.041300)	( 0.014750)	( 0.035400)	( 0.014750)	( 0.022467)	( 0.016068)
	Min,	0.1357,	0.0236,	0.1534,	-0.0236,	0.1357,	-0.0236,
	Max	0.2183	0.0531	0.2242	0.0059	0.2242	0.0531
Week 116	n	2	2	2	2	4	4
	Mean	0.17995	0.04130	0.24485	0.04720	0.21240	0.04425
	Median	0.17995	0.04130	0.24485	0.04720	0.22420	0.04720
	SD	0.045891	0.033375	0.012516	0.016688	0.046457	0.021811
	(SE)	( 0.032450)	( 0.023600)	( 0.008850)	( 0.011800)	( 0.023228)	( 0.010906)
	Min,	0.1475,	0.0177,	0.2360,	0.0354,	0.1475,	0.0177,
	Max	0.2124	0.0649	0.2537	0.0590	0.2537	0.0649

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 120	n	2	2	2	2	4	4
	Mean	0.18585	0.04720	0.22420	0.02655	0.20503	0.03688
	Median	0.18585	0.04720	0.22420	0.02655	0.20355	0.04720
	SD	0.070923	0.008344	0.075095	0.045891	0.063613	0.029451
	(SE)	( 0.050150)	( 0.005900)	( 0.053100)	( 0.032450)	( 0.031807)	( 0.014725)
	Min,	0.1357,	0.0413,	0.1711,	-0.0059,	0.1357,	-0.0059,
	Max	0.2360	0.0531	0.2773	0.0590	0.2773	0.0590
Week 124	n	2	2	2	2	4	4
	Mean	0.17995	0.04130	0.25075	0.05310	0.21535	0.04720
	Median	0.17995	0.04130	0.25075	0.05310	0.23010	0.04720
	SD	0.045891	0.033375	0.004172	0.033375	0.048772	0.028090
	(SE)	( 0.032450)	( 0.023600)	( 0.002950)	( 0.023600)	( 0.024386)	( 0.014045)
	Min,	0.1475,	0.0177,	0.2478,	0.0295,	0.1475,	0.0177,
	Max	0.2124	0.0649	0.2537	0.0767	0.2537	0.0767
Week 128	n	2	2	2	2	4	4
	Mean	0.28320	0.14455	0.21535	0.01770	0.24928	0.08113
	Median	0.28320	0.14455	0.21535	0.01770	0.21830	0.06785
	SD	0.150189	0.070923	0.062579	0.033375	0.101779	0.086091
	(SE)	( 0.106200)	( 0.050150)	( 0.044250)	( 0.023600)	( 0.050889)	( 0.043045)
	Min,	0.1770,	0.0944,	0.1711,	-0.0059,	0.1711,	-0.0059,
	Max	0.3894	0.1947	0.2596	0.0413	0.3894	0.1947

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	0.18585	0.04720	0.22715	0.02950	0.20650	0.03835
	Median	0.18585	0.04720	0.22715	0.02950	0.21535	0.04720
	SD	0.079267	0.000000	0.054235	0.025032	0.060361	0.017700
	(SE)	( 0.056050)	( 0.000000)	( 0.038350)	( 0.017700)	( 0.030180)	( 0.008850)
	Min, Max	0.1298, 0.2419	0.0472, 0.0472	0.1888, 0.2655	0.0118, 0.0472	0.1298, 0.2655	0.0118, 0.0472
Week 136	n	2	2	2	2	4	4
	Mean	0.17700	0.03835	0.24485	0.04720	0.21093	0.04278
	Median	0.17700	0.03835	0.24485	0.04720	0.22125	0.04425
	SD	0.066751	0.012516	0.037547	0.008344	0.059074	0.010076
	(SE)	( 0.047200)	( 0.008850)	( 0.026550)	( 0.005900)	( 0.029537)	( 0.005038)
	Min, Max	0.1298, 0.2242	0.0295, 0.0472	0.2183, 0.2714	0.0413, 0.0531	0.1298, 0.2714	0.0295, 0.0531
Week 140	n	2	2	2	2	4	4
	Mean	0.22420	0.08555	0.24780	0.05015	0.23600	0.06785
	Median	0.22420	0.08555	0.24780	0.05015	0.24485	0.06785
	SD	0.066751	0.012516	0.041719	0.012516	0.047445	0.022851
	(SE)	( 0.047200)	( 0.008850)	( 0.029500)	( 0.008850)	( 0.023723)	( 0.011425)
	Min, Max	0.1770, 0.2714	0.0767, 0.0944	0.2183, 0.2773	0.0413, 0.0590	0.1770, 0.2773	0.0413, 0.0944

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	0.18585	0.04720	0.23010	0.03245	0.20798	0.03983
	Median	0.18585	0.04720	0.23010	0.03245	0.22715	0.04130
	SD	0.062579	0.016688	0.008344	0.020860	0.044511	0.017618
	(SE)	( 0.044250)	( 0.011800)	( 0.005900)	( 0.014750)	( 0.022256)	( 0.008809)
	Min,	0.1416,	0.0354,	0.2242,	0.0177,	0.1416,	0.0177,
	Max	0.2301	0.0590	0.2360	0.0472	0.2360	0.0590
Week 148	n	2	2	2	2	4	4
	Mean	0.21535	0.07670	0.26550	0.06785	0.24043	0.07228
	Median	0.21535	0.07670	0.26550	0.06785	0.26550	0.07375
	SD	0.095954	0.016688	0.008344	0.020860	0.062695	0.016247
	(SE)	( 0.067850)	( 0.011800)	( 0.005900)	( 0.014750)	( 0.031347)	( 0.008124)
	Min,	0.1475,	0.0649,	0.2596,	0.0531,	0.1475,	0.0531,
	Max	0.2832	0.0885	0.2714	0.0826	0.2832	0.0885
Week 152	n	2	2	2	2	4	4
	Mean	0.23305	0.09440	0.26255	0.06490	0.24780	0.07965
	Median	0.23305	0.09440	0.26255	0.06490	0.26255	0.07670
	SD	0.112642	0.033375	0.004172	0.025032	0.067270	0.029500
	(SE)	( 0.079650)	( 0.023600)	( 0.002950)	( 0.017700)	( 0.033635)	( 0.014750)
	Min,	0.1534,	0.0708,	0.2596,	0.0472,	0.1534,	0.0472,
	Max	0.3127	0.1180	0.2655	0.0826	0.3127	0.1180

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		Change from Baseline
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 156	n	2	2	2	2	4	4
	Mean	0.19765	0.05900	0.23305	0.03540	0.21535	0.04720
	Median	0.19765	0.05900	0.23305	0.03540	0.23305	0.04425
	SD	0.087611	0.008344	0.029204	0.000000	0.057101	0.014452
	(SE)	( 0.061950)	( 0.005900)	( 0.020650)	( 0.000000)	( 0.028551)	( 0.007226)
	Min,	0.1357,	0.0531,	0.2124,	0.0354,	0.1357,	0.0354,
	Max	0.2596	0.0649	0.2537	0.0354	0.2596	0.0649
Week 160	n	2	2	2	2	4	4
	Mean	0.19470	0.05605	0.25960	0.06195	0.22715	0.05900
	Median	0.19470	0.05605	0.25960	0.06195	0.23600	0.05900
	SD	0.066751	0.012516	0.041719	0.012516	0.058902	0.010772
	(SE)	( 0.047200)	( 0.008850)	( 0.029500)	( 0.008850)	( 0.029451)	( 0.005386)
	Min,	0.1475,	0.0472,	0.2301,	0.0531,	0.1475,	0.0472,
	Max	0.2419	0.0649	0.2891	0.0708	0.2891	0.0708
Week 164	n	2	2	2	2	4	4
	Mean	0.18585	0.04720	0.21240	0.01475	0.19913	0.03098
	Median	0.18585	0.04720	0.21240	0.01475	0.20945	0.03835
	SD	0.079267	0.000000	0.050063	0.020860	0.056257	0.022272
	(SE)	( 0.056050)	( 0.000000)	( 0.035400)	( 0.014750)	( 0.028128)	( 0.011136)
	Min,	0.1298,	0.0472,	0.1770,	0.0000,	0.1298,	0.0000,
	Max	0.2419	0.0472	0.2478	0.0295	0.2478	0.0472

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	0.17405	0.03540	0.19470	-0.00295	0.18438	0.01623
	Median	0.17405	0.03540	0.19470	-0.00295	0.17700	0.02950
	SD	0.062579	0.016688	0.083439	0.054235	0.061386	0.039542
	(SE)	( 0.044250)	( 0.011800)	( 0.059000)	( 0.038350)	( 0.030693)	( 0.019771)
	Min,	0.1298,	0.0236,	0.1357,	-0.0413,	0.1298,	-0.0413,
	Max	0.2183	0.0472	0.2537	0.0354	0.2537	0.0472
Week 172	n	2	2	2	2	4	4
	Mean	0.17995	0.04130	0.18290	-0.01475	0.18143	0.01328
	Median	0.17995	0.04130	0.18290	-0.01475	0.17995	0.00295
	SD	0.037547	0.041719	0.041719	0.012516	0.032450	0.040983
	(SE)	( 0.026550)	( 0.029500)	( 0.029500)	( 0.008850)	( 0.016225)	( 0.020491)
	Min,	0.1534,	0.0118,	0.1534,	-0.0236,	0.1534,	-0.0236,
	Max	0.2065	0.0708	0.2124	-0.0059	0.2124	0.0708
Week 176	n	2	2	2	2	4	4
	Mean	0.21535	0.07670	0.26255	0.06490	0.23895	0.07080
	Median	0.21535	0.07670	0.26255	0.06490	0.26255	0.06785
	SD	0.095954	0.016688	0.020860	0.008344	0.062903	0.012745
	(SE)	( 0.067850)	( 0.011800)	( 0.014750)	( 0.005900)	( 0.031451)	( 0.006373)
	Min,	0.1475,	0.0649,	0.2478,	0.0590,	0.1475,	0.0590,
	Max	0.2832	0.0885	0.2773	0.0708	0.2832	0.0885

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	0.20355	0.06490	0.24190	0.04425	0.22273	0.05458
	Median	0.20355	0.06490	0.24190	0.04425	0.22125	0.05605
	SD	0.054235	0.025032	0.058407	0.029204	0.051067	0.025205
	(SE)	( 0.038350)	( 0.017700)	( 0.041300)	( 0.020650)	( 0.025534)	( 0.012602)
	Min,	0.1652,	0.0472,	0.2006,	0.0236,	0.1652,	0.0236,
	Max	0.2419	0.0826	0.2832	0.0649	0.2832	0.0826
Week 184	n	2	2	2	2	4	4
	Mean	0.19175	0.05310	0.25075	0.05310	0.22125	0.05310
	Median	0.19175	0.05310	0.25075	0.05310	0.21240	0.05310
	SD	0.029204	0.050063	0.054235	0.025032	0.049245	0.032316
	(SE)	( 0.020650)	( 0.035400)	( 0.038350)	( 0.017700)	( 0.024623)	( 0.016158)
	Min,	0.1711,	0.0177,	0.2124,	0.0354,	0.1711,	0.0177,
	Max	0.2124	0.0885	0.2891	0.0708	0.2891	0.0885

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Bilirubin (umol/L)						
Week 1	n	2	2		4	
	Mean	5.130	3.420		4.275	
	Median	5.130	3.420		5.130	
	SD	0.0000	4.8366		2.9618	
	(SE)	( 0.0000)	( 3.4200)		( 1.4809)	
	Min, Max	5.13, 5.13	0.00, 6.84		0.00, 6.84	
Week 2	n	2	2		4	
	Mean	11.115	3.420		7.268	
	Median	11.115	3.420		4.275	
	SD	10.8824	2.4183		7.8206	
	(SE)	( 7.6950)	( 1.7100)		( 3.9103)	
	Min, Max	3.42, 18.81	1.71, 5.13		1.71, 18.81	
Week 4	n	2	2		4	
	Mean	7.695	4.275		5.985	
	Median	7.695	4.275		5.130	
	SD	3.6275	1.2092		2.9618	
	(SE)	( 2.5650)	( 0.8550)		( 1.4809)	
	Min, Max	5.13, 10.26	3.42, 5.13		3.42, 10.26	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	4.275		5.130		4.703	
	Median	4.275		5.130		4.275	
	SD	1.2092		2.4183		1.6372	
	(SE)	( 0.8550)		( 1.7100)		( 0.8186)	
	Min, Max	3.42, 5.13		3.42, 6.84		3.42, 6.84	
Week 8	n	2		2		4	
	Mean	5.985		5.130		5.558	
	Median	5.985		5.130		5.130	
	SD	1.2092		0.0000		0.8550	
	(SE)	( 0.8550)		( 0.0000)		( 0.4275)	
	Min, Max	5.13, 6.84		5.13, 5.13		5.13, 6.84	
Week 10	n	2		2		4	
	Mean	9.405		5.130		7.268	
	Median	9.405		5.130		7.695	
	SD	1.2092		2.4183		2.9204	
	(SE)	( 0.8550)		( 1.7100)		( 1.4602)	
	Min, Max	8.55, 10.26		3.42, 6.84		3.42, 10.26	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2	2		4	
	Mean	6.840	5.130		5.985	
	Median	6.840	5.130		5.985	
	SD	2.4183	2.4183		2.2076	
	(SE)	( 1.7100)	( 1.7100)		( 1.1038)	
	Min,	5.13,	3.42,		3.42,	
	Max	8.55	6.84		8.55	
Week 15	n	2	2		4	
	Mean	5.985	2.565		4.275	
	Median	5.985	2.565		4.275	
	SD	1.2092	1.2092		2.2076	
	(SE)	( 0.8550)	( 0.8550)		( 1.1038)	
	Min,	5.13,	1.71,		1.71,	
	Max	6.84	3.42		6.84	
Week 18	n	2	2		4	
	Mean	7.695	4.275		5.985	
	Median	7.695	4.275		5.985	
	SD	1.2092	1.2092		2.2076	
	(SE)	( 0.8550)	( 0.8550)		( 1.1038)	
	Min,	6.84,	3.42,		3.42,	
	Max	8.55	5.13		8.55	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg			50 mg/kg		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4
	Mean	6.840		5.985		6.413
	Median	6.840		5.985		5.985
	SD	2.4183		1.2092		1.6372
	(SE)	( 1.7100)		( 0.8550)		( 0.8186)
	Min,	5.13,		5.13,		5.13,
	Max	8.55		6.84		8.55
Week 24	n	2		2		4
	Mean	6.840		5.130		5.985
	Median	6.840		5.130		5.985
	SD	2.4183		2.4183		2.2076
	(SE)	( 1.7100)		( 1.7100)		( 1.1038)
	Min,	5.13,		3.42,		3.42,
	Max	8.55		6.84		8.55
Baseline <sup>1</sup>	n	2		2		4
	Mean	5.130		4.275		4.703
	Median	5.130		4.275		4.275
	SD	2.4183		1.2092		1.6372
	(SE)	( 1.7100)		( 0.8550)		( 0.8186)
	Min,	3.42,		3.42,		3.42,
	Max	6.84		5.13		6.84

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	5.985	0.855	3.420	-0.855	4.703	0.000
	Median	5.985	0.855	3.420	-0.855	5.130	0.855
	SD	3.6275	1.2092	4.8366	3.6275	3.7917	2.4183
	(SE)	( 2.5650)	( 0.8550)	( 3.4200)	( 2.5650)	( 1.8958)	( 1.2092)
	Min, Max	3.42, 8.55	0.00, 1.71	0.00, 6.84	-3.42, 1.71	0.00, 8.55	-3.42, 1.71
Week 32	n	2	2	2	2	4	4
	Mean	4.275	-0.855	3.420	-0.855	3.848	-0.855
	Median	4.275	-0.855	3.420	-0.855	3.420	-0.855
	SD	3.6275	1.2092	2.4183	1.2092	2.5650	0.9873
	(SE)	( 2.5650)	( 0.8550)	( 1.7100)	( 0.8550)	( 1.2825)	( 0.4936)
	Min, Max	1.71, 6.84	-1.71, 0.00	1.71, 5.13	-1.71, 0.00	1.71, 6.84	-1.71, 0.00
Week 36	n	2	2	1	1	3	3
	Mean	3.420	-1.710	3.420	-1.710	3.420	-1.710
	Median	3.420	-1.710	3.420	-1.710	3.420	-1.710
	SD	2.4183	0.0000			1.7100	0.0000
	(SE)	( 1.7100)	( 0.0000)			( 0.9873)	( 0.0000)
	Min, Max	1.71, 5.13	-1.71, -1.71	3.42, 3.42	-1.71, -1.71	1.71, 5.13	-1.71, -1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	4.275	-0.855	2.565	-1.710	3.420	-1.283
	Median	4.275	-0.855	2.565	-1.710	3.420	-1.710
	SD	1.2092	1.2092	1.2092	0.0000	1.3962	0.8550
	(SE)	( 0.8550)	( 0.8550)	( 0.8550)	( 0.0000)	( 0.6981)	( 0.4275)
	Min,	3.42,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	5.13	0.00	3.42	-1.71	5.13	0.00
Week 44	n	2	2	2	2	4	4
	Mean	4.275	-0.855	2.565	-1.710	3.420	-1.283
	Median	4.275	-0.855	2.565	-1.710	3.420	-1.710
	SD	1.2092	1.2092	1.2092	0.0000	1.3962	0.8550
	(SE)	( 0.8550)	( 0.8550)	( 0.8550)	( 0.0000)	( 0.6981)	( 0.4275)
	Min,	3.42,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	5.13	0.00	3.42	-1.71	5.13	0.00
Week 48	n	2	2	2	2	4	4
	Mean	5.985	0.855	3.420	-0.855	4.703	0.000
	Median	5.985	0.855	3.420	-0.855	5.130	-0.855
	SD	1.2092	3.6275	2.4183	1.2092	2.1517	2.4183
	(SE)	( 0.8550)	( 2.5650)	( 1.7100)	( 0.8550)	( 1.0759)	( 1.2092)
	Min,	5.13,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	6.84	3.42	5.13	0.00	6.84	3.42

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	2.565	-2.565	3.420	-0.855	2.993	-1.710
	Median	2.565	-2.565	3.420	-0.855	2.565	-1.710
	SD	1.2092	1.2092	2.4183	1.2092	1.6372	1.3962
	(SE)	( 0.8550)	( 0.8550)	( 1.7100)	( 0.8550)	( 0.8186)	( 0.6981)
	Min,	1.71,	-3.42,	1.71,	-1.71,	1.71,	-3.42,
	Max	3.42	-1.71	5.13	0.00	5.13	0.00
Week 56	n	2	2	2	2	4	4
	Mean	4.275	-0.855	3.420	-0.855	3.848	-0.855
	Median	4.275	-0.855	3.420	-0.855	3.420	-0.855
	SD	1.2092	3.6275	0.0000	1.2092	0.8550	2.2076
	(SE)	( 0.8550)	( 2.5650)	( 0.0000)	( 0.8550)	( 0.4275)	( 1.1038)
	Min,	3.42,	-3.42,	3.42,	-1.71,	3.42,	-3.42,
	Max	5.13	1.71	3.42	0.00	5.13	1.71
Week 60	n	2	2	2	2	4	4
	Mean	4.275	-0.855	4.275	0.000	4.275	-0.428
	Median	4.275	-0.855	4.275	0.000	4.275	-0.855
	SD	1.2092	1.2092	3.6275	2.4183	2.2076	1.6372
	(SE)	( 0.8550)	( 0.8550)	( 2.5650)	( 1.7100)	( 1.1038)	( 0.8186)
	Min,	3.42,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	5.13	0.00	6.84	1.71	6.84	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	4.275	-0.855	4.275	0.000	4.275	-0.428
	Median	4.275	-0.855	4.275	0.000	4.275	-0.855
	SD	1.2092	1.2092	3.6275	2.4183	2.2076	1.6372
	(SE)	( 0.8550)	( 0.8550)	( 2.5650)	( 1.7100)	( 1.1038)	( 0.8186)
	Min, Max	3.42, 5.13	-1.71, 0.00	1.71, 6.84	-1.71, 1.71	1.71, 6.84	-1.71, 1.71
Week 68	n	2	2	2	2	4	4
	Mean	6.840	1.710	2.565	-1.710	4.703	0.000
	Median	6.840	1.710	2.565	-1.710	4.275	0.000
	SD	2.4183	0.0000	1.2092	0.0000	2.9204	1.9745
	(SE)	( 1.7100)	( 0.0000)	( 0.8550)	( 0.0000)	( 1.4602)	( 0.9873)
	Min, Max	5.13, 8.55	1.71, 1.71	1.71, 3.42	-1.71, -1.71	1.71, 8.55	-1.71, 1.71
Week 72	n	2	2	0	0	2	2
	Mean	3.420	-1.710			3.420	-1.710
	Median	3.420	-1.710			3.420	-1.710
	SD	0.0000	2.4183			0.0000	2.4183
	(SE)	( 0.0000)	( 1.7100)			( 0.0000)	( 1.7100)
	Min, Max	3.42, 3.42	-3.42, 0.00			3.42, 3.42	-3.42, 0.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			1.710	-1.710	1.710	-1.710
	Median			1.710	-1.710	1.710	-1.710
	SD						
	(SE)						
	Min, Max			1.71, 1.71	-1.71, -1.71	1.71, 1.71	-1.71, -1.71
Week 76	n	2	2	2	2	4	4
	Mean	5.130	0.000	2.565	-1.710	3.848	-0.855
	Median	5.130	0.000	2.565	-1.710	4.275	-1.710
	SD	0.0000	2.4183	1.2092	0.0000	1.6372	1.7100
	(SE)	( 0.0000)	( 1.7100)	( 0.8550)	( 0.0000)	( 0.8186)	( 0.8550)
	Min, Max	5.13, 5.13	-1.71, 1.71	1.71, 3.42	-1.71, -1.71	1.71, 5.13	-1.71, 1.71
Week 80	n	2	2	2	2	4	4
	Mean	5.130	0.000	2.565	-1.710	3.848	-0.855
	Median	5.130	0.000	2.565	-1.710	3.420	-0.855
	SD	2.4183	0.0000	1.2092	0.0000	2.1517	0.9873
	(SE)	( 1.7100)	( 0.0000)	( 0.8550)	( 0.0000)	( 1.0759)	( 0.4936)
	Min, Max	3.42, 6.84	0.00, 0.00	1.71, 3.42	-1.71, -1.71	1.71, 6.84	-1.71, 0.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	3.420	-1.710	2.565	-1.710	2.993	-1.710
	Median	3.420	-1.710	2.565	-1.710	2.565	-1.710
	SD	2.4183	0.0000	1.2092	0.0000	1.6372	0.0000
	(SE)	( 1.7100)	( 0.0000)	( 0.8550)	( 0.0000)	( 0.8186)	( 0.0000)
	Min, Max	1.71, 5.13	-1.71, -1.71	1.71, 3.42	-1.71, -1.71	1.71, 5.13	-1.71, -1.71
Week 88	n	2	2	2	2	4	4
	Mean	4.275	-0.855	4.275	0.000	4.275	-0.428
	Median	4.275	-0.855	4.275	0.000	4.275	0.000
	SD	1.2092	1.2092	1.2092	0.0000	0.9873	0.8550
	(SE)	( 0.8550)	( 0.8550)	( 0.8550)	( 0.0000)	( 0.4936)	( 0.4275)
	Min, Max	3.42, 5.13	-1.71, 0.00	3.42, 5.13	0.00, 0.00	3.42, 5.13	-1.71, 0.00
Week 92	n	2	2	2	2	4	4
	Mean	4.275	-0.855	4.275	0.000	4.275	-0.428
	Median	4.275	-0.855	4.275	0.000	4.275	-0.855
	SD	1.2092	1.2092	3.6275	2.4183	2.2076	1.6372
	(SE)	( 0.8550)	( 0.8550)	( 2.5650)	( 1.7100)	( 1.1038)	( 0.8186)
	Min, Max	3.42, 5.13	-1.71, 0.00	1.71, 6.84	-1.71, 1.71	1.71, 6.84	-1.71, 1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	4.275	-0.855	3.420	-0.855	3.848	-0.855
	Median	4.275	-0.855	3.420	-0.855	4.275	-0.855
	SD	1.2092	3.6275	2.4183	1.2092	1.6372	2.2076
	(SE)	( 0.8550)	( 2.5650)	( 1.7100)	( 0.8550)	( 0.8186)	( 1.1038)
	Min,	3.42,	-3.42,	1.71,	-1.71,	1.71,	-3.42,
	Max	5.13	1.71	5.13	0.00	5.13	1.71
Week 100	n	2	2	2	2	4	4
	Mean	3.420	-1.710	4.275	0.000	3.848	-0.855
	Median	3.420	-1.710	4.275	0.000	3.420	-0.855
	SD	0.0000	2.4183	3.6275	2.4183	2.1517	2.2076
	(SE)	( 0.0000)	( 1.7100)	( 2.5650)	( 1.7100)	( 1.0759)	( 1.1038)
	Min,	3.42,	-3.42,	1.71,	-1.71,	1.71,	-3.42,
	Max	3.42	0.00	6.84	1.71	6.84	1.71
Week 104	n	2	2	2	2	4	4
	Mean	5.130	0.000	5.985	1.710	5.558	0.855
	Median	5.130	0.000	5.985	1.710	5.130	0.855
	SD	0.0000	2.4183	3.6275	2.4183	2.1517	2.2076
	(SE)	( 0.0000)	( 1.7100)	( 2.5650)	( 1.7100)	( 1.0759)	( 1.1038)
	Min,	5.13,	-1.71,	3.42,	0.00,	3.42,	-1.71,
	Max	5.13	1.71	8.55	3.42	8.55	3.42

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen							
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks			
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline		
Week 108	n	2	2	2	2	4	4	
	Mean	4.275	-0.855	5.985	1.710	5.130	0.428	
	Median	4.275	-0.855	5.985	1.710	4.275	0.000	
	SD	1.2092	1.2092	3.6275	2.4183	2.4183	2.1517	
	(SE)	( 0.8550)	( 0.8550)	( 2.5650)	( 1.7100)	( 1.2092)	( 1.0759)	
	Min,	3.42,	-1.71,	3.42,	0.00,	3.42,	-1.71,	
	Max	5.13	0.00	8.55	3.42	8.55	3.42	
Week 112	n	2	2	2	2	4	4	
	Mean	2.565	-2.565	3.420	-0.855	2.993	-1.710	
	Median	2.565	-2.565	3.420	-0.855	2.565	-1.710	
	SD	1.2092	1.2092	2.4183	1.2092	1.6372	1.3962	
	(SE)	( 0.8550)	( 0.8550)	( 1.7100)	( 0.8550)	( 0.8186)	( 0.6981)	
	Min,	1.71,	-3.42,	1.71,	-1.71,	1.71,	-3.42,	
	Max	3.42	-1.71	5.13	0.00	5.13	0.00	
Week 116	n	2	2	2	2	4	4	
	Mean	3.420	-1.710	2.565	-1.710	2.993	-1.710	
	Median	3.420	-1.710	2.565	-1.710	3.420	-1.710	
	SD	0.0000	2.4183	1.2092	0.0000	0.8550	1.3962	
	(SE)	( 0.0000)	( 1.7100)	( 0.8550)	( 0.0000)	( 0.4275)	( 0.6981)	
	Min,	3.42,	-3.42,	1.71,	-1.71,	1.71,	-3.42,	
	Max	3.42	0.00	3.42	-1.71	3.42	0.00	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	2.565	-2.565	3.420	-0.855	2.993	-1.710
	Median	2.565	-2.565	3.420	-0.855	2.565	-1.710
	SD	1.2092	1.2092	2.4183	1.2092	1.6372	1.3962
	(SE)	( 0.8550)	( 0.8550)	( 1.7100)	( 0.8550)	( 0.8186)	( 0.6981)
	Min, Max	1.71, 3.42	-3.42, -1.71	1.71, 5.13	-1.71, 0.00	1.71, 5.13	-3.42, 0.00
Week 124	n	2	2	2	2	4	4
	Mean	3.420	-1.710	4.275	0.000	3.848	-0.855
	Median	3.420	-1.710	4.275	0.000	3.420	-0.855
	SD	0.0000	2.4183	3.6275	2.4183	2.1517	2.2076
	(SE)	( 0.0000)	( 1.7100)	( 2.5650)	( 1.7100)	( 1.0759)	( 1.1038)
	Min, Max	3.42, 3.42	-3.42, 0.00	1.71, 6.84	-1.71, 1.71	1.71, 6.84	-3.42, 1.71
Week 128	n	2	2	2	2	4	4
	Mean	5.130	0.000	3.420	-0.855	4.275	-0.428
	Median	5.130	0.000	3.420	-0.855	4.275	0.000
	SD	2.4183	0.0000	2.4183	1.2092	2.2076	0.8550
	(SE)	( 1.7100)	( 0.0000)	( 1.7100)	( 0.8550)	( 1.1038)	( 0.4275)
	Min, Max	3.42, 6.84	0.00, 0.00	1.71, 5.13	-1.71, 0.00	1.71, 6.84	-1.71, 0.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	5.130	0.000	4.275	0.000	4.703	0.000
	Median	5.130	0.000	4.275	0.000	5.130	0.000
	SD	2.4183	0.0000	3.6275	2.4183	2.5650	1.3962
	(SE)	( 1.7100)	( 0.0000)	( 2.5650)	( 1.7100)	( 1.2825)	( 0.6981)
	Min,	3.42,	0.00,	1.71,	-1.71,	1.71,	-1.71,
	Max	6.84	0.00	6.84	1.71	6.84	1.71
Week 136	n	2	2	2	2	4	4
	Mean	4.275	-0.855	3.420	-0.855	3.848	-0.855
	Median	4.275	-0.855	3.420	-0.855	4.275	-0.855
	SD	1.2092	1.2092	2.4183	1.2092	1.6372	0.9873
	(SE)	( 0.8550)	( 0.8550)	( 1.7100)	( 0.8550)	( 0.8186)	( 0.4936)
	Min,	3.42,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	5.13	0.00	5.13	0.00	5.13	0.00
Week 140	n	2	2	2	2	4	4
	Mean	1.710	-3.420	4.275	0.000	2.993	-1.710
	Median	1.710	-3.420	4.275	0.000	2.565	-0.855
	SD	0.0000	2.4183	1.2092	0.0000	1.6372	2.4183
	(SE)	( 0.0000)	( 1.7100)	( 0.8550)	( 0.0000)	( 0.8186)	( 1.2092)
	Min,	1.71,	-5.13,	3.42,	0.00,	1.71,	-5.13,
	Max	1.71	-1.71	5.13	0.00	5.13	0.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	3.420	-1.710	3.420	-0.855	3.420	-1.283
	Median	3.420	-1.710	3.420	-0.855	3.420	-1.710
	SD	2.4183	0.0000	2.4183	1.2092	1.9745	0.8550
	(SE)	( 1.7100)	( 0.0000)	( 1.7100)	( 0.8550)	( 0.9873)	( 0.4275)
	Min,	1.71,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	5.13	-1.71	5.13	0.00	5.13	0.00
Week 148	n	2	2	2	2	4	4
	Mean	3.420	-1.710	5.985	1.710	4.703	0.000
	Median	3.420	-1.710	5.985	1.710	3.420	0.000
	SD	0.0000	2.4183	3.6275	2.4183	2.5650	2.7924
	(SE)	( 0.0000)	( 1.7100)	( 2.5650)	( 1.7100)	( 1.2825)	( 1.3962)
	Min,	3.42,	-3.42,	3.42,	0.00,	3.42,	-3.42,
	Max	3.42	0.00	8.55	3.42	8.55	3.42
Week 152	n	2	2	2	2	4	4
	Mean	4.275	-0.855	5.985	1.710	5.130	0.428
	Median	4.275	-0.855	5.985	1.710	4.275	0.855
	SD	1.2092	3.6275	3.6275	2.4183	2.4183	2.9204
	(SE)	( 0.8550)	( 2.5650)	( 2.5650)	( 1.7100)	( 1.2092)	( 1.4602)
	Min,	3.42,	-3.42,	3.42,	0.00,	3.42,	-3.42,
	Max	5.13	1.71	8.55	3.42	8.55	3.42

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	4.275	-0.855	4.275	0.000	4.275	-0.428
	Median	4.275	-0.855	4.275	0.000	4.275	0.000
	SD	3.6275	1.2092	1.2092	0.0000	2.2076	0.8550
	(SE)	( 2.5650)	( 0.8550)	( 0.8550)	( 0.0000)	( 1.1038)	( 0.4275)
	Min,	1.71,	-1.71,	3.42,	0.00,	1.71,	-1.71,
	Max	6.84	0.00	5.13	0.00	6.84	0.00
Week 160	n	2	2	2	2	4	4
	Mean	5.130	0.000	5.985	1.710	5.557	0.855
	Median	5.130	0.000	5.985	1.710	5.130	0.000
	SD	0.0000	2.4183	6.0458	4.8366	3.5253	3.2744
	(SE)	( 0.0000)	( 1.7100)	( 4.2750)	( 3.4200)	( 1.7626)	( 1.6372)
	Min,	5.13,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	5.13	1.71	10.26	5.13	10.26	5.13
Week 164	n	2	2	2	2	4	4
	Mean	4.275	-0.855	5.130	0.855	4.703	0.000
	Median	4.275	-0.855	5.130	0.855	4.275	0.000
	SD	1.2092	1.2092	2.4183	1.2092	1.6372	1.3962
	(SE)	( 0.8550)	( 0.8550)	( 1.7100)	( 0.8550)	( 0.8186)	( 0.6981)
	Min,	3.42,	-1.71,	3.42,	0.00,	3.42,	-1.71,
	Max	5.13	0.00	6.84	1.71	6.84	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	3.420	-1.710	5.130	0.855	4.275	-0.428
	Median	3.420	-1.710	5.130	0.855	3.420	0.000
	SD	0.0000	2.4183	2.4183	1.2092	1.7100	2.1517
	(SE)	( 0.0000)	( 1.7100)	( 1.7100)	( 0.8550)	( 0.8550)	( 1.0759)
	Min,	3.42,	-3.42,	3.42,	0.00,	3.42,	-3.42,
	Max	3.42	0.00	6.84	1.71	6.84	1.71
Week 172	n	2	2	2	2	4	4
	Mean	3.420	-1.710	3.420	-0.855	3.420	-1.283
	Median	3.420	-1.710	3.420	-0.855	3.420	-0.855
	SD	0.0000	2.4183	2.4183	1.2092	1.3962	1.6372
	(SE)	( 0.0000)	( 1.7100)	( 1.7100)	( 0.8550)	( 0.6981)	( 0.8186)
	Min,	3.42,	-3.42,	1.71,	-1.71,	1.71,	-3.42,
	Max	3.42	0.00	5.13	0.00	5.13	0.00
Week 176	n	2	2	2	2	4	4
	Mean	4.275	-0.855	4.275	0.000	4.275	-0.428
	Median	4.275	-0.855	4.275	0.000	4.275	0.000
	SD	1.2092	3.6275	1.2092	0.0000	0.9873	2.1517
	(SE)	( 0.8550)	( 2.5650)	( 0.8550)	( 0.0000)	( 0.4936)	( 1.0759)
	Min,	3.42,	-3.42,	3.42,	0.00,	3.42,	-3.42,
	Max	5.13	1.71	5.13	0.00	5.13	1.71

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	2	2	2	2	4	4
	Mean	5.130	0.000	4.275	0.000	4.703	0.000
	Median	5.130	0.000	4.275	0.000	5.130	0.000
	SD	0.0000	2.4183	3.6275	2.4183	2.1517	1.9745
	(SE)	( 0.0000)	( 1.7100)	( 2.5650)	( 1.7100)	( 1.0759)	( 0.9873)
	Min,	5.13,	-1.71,	1.71,	-1.71,	1.71,	-1.71,
	Max	5.13	1.71	6.84	1.71	6.84	1.71
Week 184	n	2	2	2	2	4	4
	Mean	5.130	0.000	2.565	-1.710	3.848	-0.855
	Median	5.130	0.000	2.565	-1.710	3.420	-0.855
	SD	2.4183	0.0000	1.2092	0.0000	2.1517	0.9873
	(SE)	( 1.7100)	( 0.0000)	( 0.8550)	( 0.0000)	( 1.0759)	( 0.4936)
	Min,	3.42,	0.00,	1.71,	-1.71,	1.71,	-1.71,
	Max	6.84	0.00	3.42	-1.71	6.84	0.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Alkaline Phosphatase (U/L)						
Week 1	n	2	2		4	
	Mean	59.0	40.0		49.5	
	Median	59.0	40.0		54.0	
	SD	9.90	22.63		17.99	
	(SE)	( 7.00)	( 16.00)		( 9.00)	
	Min, Max	52, 66	24, 56		24, 66	
Week 2	n	2	2		4	
	Mean	51.5	47.0		49.3	
	Median	51.5	47.0		51.5	
	SD	16.26	24.04		16.96	
	(SE)	( 11.50)	( 17.00)		( 8.48)	
	Min, Max	40, 63	30, 64		30, 64	
Week 4	n	2	2		4	
	Mean	57.5	46.0		51.8	
	Median	57.5	46.0		51.5	
	SD	16.26	15.56		14.59	
	(SE)	( 11.50)	( 11.00)		( 7.30)	
	Min, Max	46, 69	35, 57		35, 69	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4
	Mean	57.0		44.0		50.5
	Median	57.0		44.0		53.0
	SD	12.73		19.80		15.52
	(SE)	( 9.00)		( 14.00)		( 7.76)
	Min, Max	48, 66		30, 58		30, 66
Week 8	n	2		2		4
	Mean	53.0		46.0		49.5
	Median	53.0		46.0		53.0
	SD	14.14		26.87		17.99
	(SE)	( 10.00)		( 19.00)		( 9.00)
	Min, Max	43, 63		27, 65		27, 65
Week 10	n	2		2		4
	Mean	50.0		45.5		47.8
	Median	50.0		45.5		48.5
	SD	15.56		17.68		13.84
	(SE)	( 11.00)		( 12.50)		( 6.92)
	Min, Max	39, 61		33, 58		33, 61

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	63.5		47.5		55.5	
	Median	63.5		47.5		58.5	
	SD	16.26		24.75		19.43	
	(SE)	( 11.50)		( 17.50)		( 9.72)	
	Min,	52,		30,		30,	
	Max	75		65		75	
Week 15	n	2		2		4	
	Mean	52.0		45.5		48.8	
	Median	52.0		45.5		52.0	
	SD	12.73		26.16		17.21	
	(SE)	( 9.00)		( 18.50)		( 8.61)	
	Min,	43,		27,		27,	
	Max	61		64		64	
Week 18	n	2		2		4	
	Mean	59.5		49.0		54.3	
	Median	59.5		49.0		59.5	
	SD	0.71		21.21		13.67	
	(SE)	( 0.50)		( 15.00)		( 6.84)	
	Min,	59,		34,		34,	
	Max	60		64		64	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	52.0		49.0		50.5	
	Median	52.0		49.0		52.0	
	SD	4.24		24.04		14.20	
	(SE)	( 3.00)		( 17.00)		( 7.10)	
	Min, Max	49, 55		32, 66		32, 66	
Week 24	n	2		2		4	
	Mean	57.0		46.5		51.8	
	Median	57.0		46.5		54.5	
	SD	12.73		20.51		15.20	
	(SE)	( 9.00)		( 14.50)		( 7.60)	
	Min, Max	48, 66		32, 61		32, 66	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	59.5		52.5		56.0	
	Median	59.5		52.5		59.5	
	SD	10.61		30.41		19.03	
	(SE)	( 7.50)		( 21.50)		( 9.51)	
	Min, Max	52, 67		31, 74		31, 74	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	50.5	-9.0	48.0	-4.5	49.3	-6.8
	Median	50.5	-9.0	48.0	-4.5	50.5	-9.0
	SD	12.02	1.41	18.38	12.02	12.76	7.46
	(SE)	( 8.50)	( 1.00)	( 13.00)	( 8.50)	( 6.38)	( 3.73)
	Min, Max	42, 59	-10, -8	35, 61	-13, 4	35, 61	-13, 4
Week 32	n	2	2	2	2	4	4
	Mean	62.5	3.0	43.0	-9.5	52.8	-3.3
	Median	62.5	3.0	43.0	-9.5	52.0	-7.5
	SD	27.58	16.97	25.46	4.95	24.42	12.50
	(SE)	( 19.50)	( 12.00)	( 18.00)	( 3.50)	( 12.21)	( 6.25)
	Min, Max	43, 82	-9, 15	25, 61	-13, -6	25, 82	-13, 15
Week 36	n	2	2	1	1	3	3
	Mean	56.0	-3.5	62.0	-12.0	58.0	-6.3
	Median	56.0	-3.5	62.0	-12.0	62.0	-8.0
	SD	16.97	6.36			12.49	6.66
	(SE)	( 12.00)	( 4.50)			( 7.21)	( 3.84)
	Min, Max	44, 68	-8, 1	62, 62	-12, -12	44, 68	-12, 1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	54.5	-5.0	38.0	-14.5	46.3	-9.8
	Median	54.5	-5.0	38.0	-14.5	48.5	-7.0
	SD	13.44	2.83	19.80	10.61	16.78	8.38
	(SE)	( 9.50)	( 2.00)	( 14.00)	( 7.50)	( 8.39)	( 4.19)
	Min, Max	45, 64	-7, -3	24, 52	-22, -7	24, 64	-22, -3
Week 44	n	2	2	2	2	4	4
	Mean	55.0	-4.5	40.5	-12.0	47.8	-8.3
	Median	55.0	-4.5	40.5	-12.0	49.5	-5.5
	SD	14.14	3.54	19.09	11.31	16.07	8.10
	(SE)	( 10.00)	( 2.50)	( 13.50)	( 8.00)	( 8.04)	( 4.05)
	Min, Max	45, 65	-7, -2	27, 54	-20, -4	27, 65	-20, -2
Week 48	n	2	2	2	2	4	4
	Mean	56.0	-3.5	38.5	-14.0	47.3	-8.8
	Median	56.0	-3.5	38.5	-14.0	48.0	-5.0
	SD	14.14	3.54	16.26	14.14	16.03	10.37
	(SE)	( 10.00)	( 2.50)	( 11.50)	( 10.00)	( 8.01)	( 5.19)
	Min, Max	46, 66	-6, -1	27, 50	-24, -4	27, 66	-24, -1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	55.0	-4.5	41.5	-11.0	48.3	-7.8
	Median	55.0	-4.5	41.5	-11.0	52.5	-7.5
	SD	14.14	3.54	26.16	4.24	18.86	4.92
	(SE)	( 10.00)	( 2.50)	( 18.50)	( 3.00)	( 9.43)	( 2.46)
	Min, Max	45, 65	-7, -2	23, 60	-14, -8	23, 65	-14, -2
Week 56	n	2	2	2	2	4	4
	Mean	58.5	-1.0	39.5	-13.0	49.0	-7.0
	Median	58.5	-1.0	39.5	-13.0	52.0	-5.0
	SD	13.44	2.83	21.92	8.49	18.46	8.64
	(SE)	( 9.50)	( 2.00)	( 15.50)	( 6.00)	( 9.23)	( 4.32)
	Min, Max	49, 68	-3, 1	24, 55	-19, -7	24, 68	-19, 1
Week 60	n	2	2	2	2	4	4
	Mean	58.0	-1.5	46.5	-6.0	52.3	-3.8
	Median	58.0	-1.5	46.5	-6.0	56.0	-3.0
	SD	14.14	3.54	24.75	5.66	17.75	4.65
	(SE)	( 10.00)	( 2.50)	( 17.50)	( 4.00)	( 8.87)	( 2.32)
	Min, Max	48, 68	-4, 1	29, 64	-10, -2	29, 68	-10, 1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	63.5	4.0	60.5	8.0	62.0	6.0
	Median	63.5	4.0	60.5	8.0	63.5	4.0
	SD	14.85	4.24	54.45	24.04	32.63	14.28
	(SE)	( 10.50)	( 3.00)	( 38.50)	( 17.00)	( 16.31)	( 7.14)
	Min, Max	53, 74	1, 7	22, 99	-9, 25	22, 99	-9, 25
Week 68	n	2	2	2	2	4	4
	Mean	64.0	4.5	51.0	-1.5	57.5	1.5
	Median	64.0	4.5	51.0	-1.5	64.0	1.0
	SD	16.97	6.36	35.36	4.95	23.85	5.80
	(SE)	( 12.00)	( 4.50)	( 25.00)	( 3.50)	( 11.93)	( 2.90)
	Min, Max	52, 76	0, 9	26, 76	-5, 2	26, 76	-5, 9
Week 72	n	2	2	0	0	2	2
	Mean	65.0	5.5			65.0	5.5
	Median	65.0	5.5			65.0	5.5
	SD	21.21	10.61			21.21	10.61
	(SE)	( 15.00)	( 7.50)			( 15.00)	( 7.50)
	Min, Max	50, 80	-2, 13			50, 80	-2, 13

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			21.0	-10.0	21.0	-10.0
	Median			21.0	-10.0	21.0	-10.0
	SD						
	(SE)						
	Min, Max			21, 21	-10, -10	21, 21	-10, -10
Week 76	n	2	2	2	2	4	4
	Mean	67.5	8.0	61.5	9.0	64.5	8.5
	Median	67.5	8.0	61.5	9.0	67.5	8.0
	SD	3.54	7.07	60.10	29.70	34.93	17.64
	(SE)	( 2.50)	( 5.00)	( 42.50)	( 21.00)	( 17.47)	( 8.82)
	Min, Max	65, 70	3, 13	19, 104	-12, 30	19, 104	-12, 30
Week 80	n	2	2	2	2	4	4
	Mean	69.0	9.5	52.0	-0.5	60.5	4.5
	Median	69.0	9.5	52.0	-0.5	69.0	4.5
	SD	1.41	12.02	42.43	12.02	26.40	11.39
	(SE)	( 1.00)	( 8.50)	( 30.00)	( 8.50)	( 13.20)	( 5.69)
	Min, Max	68, 70	1, 18	22, 82	-9, 8	22, 82	-9, 18

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 84	n	2	2	2	2	4	4
	Mean	66.5	7.0	43.0	-9.5	54.8	-1.3
	Median	66.5	7.0	43.0	-9.5	63.5	-1.5
	SD	7.78	2.83	32.53	2.12	23.60	9.74
	(SE)	( 5.50)	( 2.00)	( 23.00)	( 1.50)	( 11.80)	( 4.87)
	Min, Max	61, 72	5, 9	20, 66	-11, -8	20, 72	-11, 9
Week 88	n	2	2	2	2	4	4
	Mean	67.5	8.0	38.5	-14.0	53.0	-3.0
	Median	67.5	8.0	38.5	-14.0	60.5	-3.5
	SD	7.78	2.83	28.99	1.41	24.10	12.83
	(SE)	( 5.50)	( 2.00)	( 20.50)	( 1.00)	( 12.05)	( 6.42)
	Min, Max	62, 73	6, 10	18, 59	-15, -13	18, 73	-15, 10
Week 92	n	2	2	2	2	4	4
	Mean	67.5	8.0	40.0	-12.5	53.8	-2.3
	Median	67.5	8.0	40.0	-12.5	59.0	-0.5
	SD	10.61	0.00	25.46	4.95	22.49	12.18
	(SE)	( 7.50)	( 0.00)	( 18.00)	( 3.50)	( 11.24)	( 6.09)
	Min, Max	60, 75	8, 8	22, 58	-16, -9	22, 75	-16, 8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	72.0	12.5	36.0	-16.5	54.0	-2.0
	Median	72.0	12.5	36.0	-16.5	56.5	-3.0
	SD	18.38	7.78	25.46	4.95	27.58	17.57
	(SE)	( 13.00)	( 5.50)	( 18.00)	( 3.50)	( 13.79)	( 8.78)
	Min, Max	59, 85	7, 18	18, 54	-20, -13	18, 85	-20, 18
Week 100	n	2	2	2	2	4	4
	Mean	64.0	4.5	36.0	-16.5	50.0	-6.0
	Median	64.0	4.5	36.0	-16.5	53.5	-5.0
	SD	14.14	3.54	24.04	6.36	22.82	12.83
	(SE)	( 10.00)	( 2.50)	( 17.00)	( 4.50)	( 11.41)	( 6.42)
	Min, Max	54, 74	2, 7	19, 53	-21, -12	19, 74	-21, 7
Week 104	n	2	2	2	2	4	4
	Mean	57.0	-2.5	36.0	-16.5	46.5	-9.5
	Median	57.0	-2.5	36.0	-16.5	48.5	-7.0
	SD	14.14	3.54	19.80	10.61	18.56	10.34
	(SE)	( 10.00)	( 2.50)	( 14.00)	( 7.50)	( 9.28)	( 5.17)
	Min, Max	47, 67	-5, 0	22, 50	-24, -9	22, 67	-24, 0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	63.0	3.5	36.5	-16.0	49.8	-6.3
	Median	63.0	3.5	36.5	-16.0	51.5	-7.5
	SD	19.80	9.19	24.75	5.66	23.85	12.87
	(SE)	( 14.00)	( 6.50)	( 17.50)	( 4.00)	( 11.93)	( 6.43)
	Min, Max	49, 77	-3, 10	19, 54	-20, -12	19, 77	-20, 10
Week 112	n	2	2	2	2	4	4
	Mean	63.0	3.5	37.5	-15.0	50.3	-5.8
	Median	63.0	3.5	37.5	-15.0	53.5	-3.5
	SD	12.73	2.12	21.92	8.49	20.76	11.81
	(SE)	( 9.00)	( 1.50)	( 15.50)	( 6.00)	( 10.38)	( 5.91)
	Min, Max	54, 72	2, 5	22, 53	-21, -9	22, 72	-21, 5
Week 116	n	2	2	2	2	4	4
	Mean	56.5	-3.0	39.5	-13.0	48.0	-8.0
	Median	56.5	-3.0	39.5	-13.0	52.0	-9.0
	SD	16.26	5.66	27.58	2.83	20.93	6.83
	(SE)	( 11.50)	( 4.00)	( 19.50)	( 2.00)	( 10.46)	( 3.42)
	Min, Max	45, 68	-7, 1	20, 59	-15, -11	20, 68	-15, 1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	53.5	-6.0	35.0	-17.5	44.3	-11.8
	Median	53.5	-6.0	35.0	-17.5	48.5	-11.0
	SD	13.44	2.83	25.46	4.95	19.75	7.41
	(SE)	( 9.50)	( 2.00)	( 18.00)	( 3.50)	( 9.88)	( 3.71)
	Min, Max	44, 63	-8, -4	17, 53	-21, -14	17, 63	-21, -4
Week 124	n	2	2	2	2	4	4
	Mean	51.5	-8.0	33.0	-19.5	42.3	-13.8
	Median	51.5	-8.0	33.0	-19.5	48.5	-13.0
	SD	4.95	5.66	22.63	7.78	17.11	8.66
	(SE)	( 3.50)	( 4.00)	( 16.00)	( 5.50)	( 8.56)	( 4.33)
	Min, Max	48, 55	-12, -4	17, 49	-25, -14	17, 55	-25, -4
Week 128	n	2	2	2	2	4	4
	Mean	56.5	-3.0	33.5	-19.0	45.0	-11.0
	Median	56.5	-3.0	33.5	-19.0	51.0	-10.0
	SD	6.36	4.24	23.33	7.07	19.27	10.39
	(SE)	( 4.50)	( 3.00)	( 16.50)	( 5.00)	( 9.64)	( 5.20)
	Min, Max	52, 61	-6, 0	17, 50	-24, -14	17, 61	-24, 0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	52.5	-7.0	34.0	-18.5	43.3	-12.8
	Median	52.5	-7.0	34.0	-18.5	48.5	-11.0
	SD	9.19	1.41	24.04	6.36	18.30	7.63
	(SE)	( 6.50)	( 1.00)	( 17.00)	( 4.50)	( 9.15)	( 3.82)
	Min, Max	46, 59	-8, -6	17, 51	-23, -14	17, 59	-23, -6
Week 136	n	2	2	2	2	4	4
	Mean	53.0	-6.5	33.5	-19.0	43.3	-12.8
	Median	53.0	-6.5	33.5	-19.0	47.5	-10.5
	SD	11.31	0.71	23.33	7.07	18.73	8.30
	(SE)	( 8.00)	( 0.50)	( 16.50)	( 5.00)	( 9.37)	( 4.15)
	Min, Max	45, 61	-7, -6	17, 50	-24, -14	17, 61	-24, -6
Week 140	n	2	2	2	2	4	4
	Mean	52.0	-7.5	32.0	-20.5	42.0	-14.0
	Median	52.0	-7.5	32.0	-20.5	47.0	-12.0
	SD	8.49	2.12	22.63	7.78	18.11	8.83
	(SE)	( 6.00)	( 1.50)	( 16.00)	( 5.50)	( 9.06)	( 4.42)
	Min, Max	46, 58	-9, -6	16, 48	-26, -15	16, 58	-26, -6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	47.0	-12.5	31.5	-21.0	39.3	-16.8
	Median	47.0	-12.5	31.5	-21.0	42.0	-15.0
	SD	14.14	3.54	21.92	8.49	17.52	7.23
	(SE)	( 10.00)	( 2.50)	( 15.50)	( 6.00)	( 8.76)	( 3.61)
	Min, Max	37, 57	-15, -10	16, 47	-27, -15	16, 57	-27, -10
Week 148	n	2	2	2	2	4	4
	Mean	50.5	-9.0	33.0	-19.5	41.8	-14.3
	Median	50.5	-9.0	33.0	-19.5	44.5	-10.0
	SD	10.61	0.00	18.38	12.02	15.88	9.22
	(SE)	( 7.50)	( 0.00)	( 13.00)	( 8.50)	( 7.94)	( 4.61)
	Min, Max	43, 58	-9, -9	20, 46	-28, -11	20, 58	-28, -9
Week 152	n	2	2	2	2	4	4
	Mean	48.0	-11.5	30.5	-22.0	39.3	-16.8
	Median	48.0	-11.5	30.5	-22.0	43.0	-13.5
	SD	9.90	0.71	20.51	9.90	16.58	8.34
	(SE)	( 7.00)	( 0.50)	( 14.50)	( 7.00)	( 8.29)	( 4.17)
	Min, Max	41, 55	-12, -11	16, 45	-29, -15	16, 55	-29, -11

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	52.0	-7.5	32.5	-20.0	42.3	-13.8
	Median	52.0	-7.5	32.5	-20.0	42.0	-12.0
	SD	18.38	7.78	17.68	12.73	18.54	11.24
	(SE)	( 13.00)	( 5.50)	( 12.50)	( 9.00)	( 9.27)	( 5.62)
	Min, Max	39, 65	-13, -2	20, 45	-29, -11	20, 65	-29, -2
Week 160	n	2	2	2	2	4	4
	Mean	50.0	-9.5	32.5	-20.0	41.3	-14.8
	Median	50.0	-9.5	32.5	-20.0	43.0	-12.0
	SD	14.14	3.54	19.09	11.31	17.04	9.14
	(SE)	( 10.00)	( 2.50)	( 13.50)	( 8.00)	( 8.52)	( 4.57)
	Min, Max	40, 60	-12, -7	19, 46	-28, -12	19, 60	-28, -7
Week 164	n	2	2	2	2	4	4
	Mean	48.5	-11.0	31.0	-21.5	39.8	-16.3
	Median	48.5	-11.0	31.0	-21.5	41.5	-15.0
	SD	16.26	5.66	21.21	9.19	18.45	8.69
	(SE)	( 11.50)	( 4.00)	( 15.00)	( 6.50)	( 9.22)	( 4.35)
	Min, Max	37, 60	-15, -7	16, 46	-28, -15	16, 60	-28, -7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	48.5	-11.0	32.5	-20.0	40.5	-15.5
	Median	48.5	-11.0	32.5	-20.0	43.0	-13.0
	SD	13.44	2.83	20.51	9.90	16.90	7.90
	(SE)	( 9.50)	( 2.00)	( 14.50)	( 7.00)	( 8.45)	( 3.95)
	Min, Max	39, 58	-13, -9	18, 47	-27, -13	18, 58	-27, -9
Week 172	n	2	2	2	2	4	4
	Mean	70.0	10.5	31.5	-21.0	50.8	-5.3
	Median	70.0	10.5	31.5	-21.0	52.0	-11.5
	SD	16.97	27.58	20.51	9.90	27.02	24.84
	(SE)	( 12.00)	( 19.50)	( 14.50)	( 7.00)	( 13.51)	( 12.42)
	Min, Max	58, 82	-9, 30	17, 46	-28, -14	17, 82	-28, 30
Week 176	n	2	2	2	2	4	4
	Mean	57.5	-2.0	31.0	-21.5	44.3	-11.8
	Median	57.5	-2.0	31.0	-21.5	50.5	-11.0
	SD	3.54	7.07	21.21	9.19	19.70	13.10
	(SE)	( 2.50)	( 5.00)	( 15.00)	( 6.50)	( 9.85)	( 6.55)
	Min, Max	55, 60	-7, 3	16, 46	-28, -15	16, 60	-28, 3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	62.5	3.0	32.5	-20.0	47.5	-8.5
	Median	62.5	3.0	32.5	-20.0	54.5	-9.0
	SD	0.71	11.31	20.51	9.90	20.98	15.86
	(SE)	( 0.50)	( 8.00)	( 14.50)	( 7.00)	( 10.49)	( 7.93)
	Min, Max	62, 63	-5, 11	18, 47	-27, -13	18, 63	-27, 11
Week 184	n	2	2	2	2	4	4
	Mean	61.5	2.0	29.5	-23.0	45.5	-10.5
	Median	61.5	2.0	29.5	-23.0	51.0	-10.5
	SD	2.12	12.73	17.68	12.73	21.14	17.79
	(SE)	( 1.50)	( 9.00)	( 12.50)	( 9.00)	( 10.57)	( 8.89)
	Min, Max	60, 63	-7, 11	17, 42	-32, -14	17, 63	-32, 11

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Amylase (U/L)						
Week 1	n	2	2		4	
	Mean	35.0	43.5		39.3	
	Median	35.0	43.5		40.5	
	SD	7.07	3.54		6.70	
	(SE)	( 5.00)	( 2.50)		( 3.35)	
	Min, Max	30, 40	41, 46		30, 46	
Week 2	n	2	2		4	
	Mean	40.5	47.0		43.8	
	Median	40.5	47.0		41.5	
	SD	3.54	9.90		7.14	
	(SE)	( 2.50)	( 7.00)		( 3.57)	
	Min, Max	38, 43	40, 54		38, 54	
Week 4	n	2	2		4	
	Mean	30.0	36.0		33.0	
	Median	30.0	36.0		30.0	
	SD	0.00	8.49		6.00	
	(SE)	( 0.00)	( 6.00)		( 3.00)	
	Min, Max	30, 30	30, 42		30, 42	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	30.0		34.5		32.3	
	Median	30.0		34.5		30.0	
	SD	0.00		6.36		4.50	
	(SE)	( 0.00)		( 4.50)		( 2.25)	
	Min,	30,		30,		30,	
	Max	30		39		39	
Week 8	n	2		2		4	
	Mean	30.0		36.5		33.3	
	Median	30.0		36.5		30.0	
	SD	0.00		9.19		6.50	
	(SE)	( 0.00)		( 6.50)		( 3.25)	
	Min,	30,		30,		30,	
	Max	30		43		43	
Week 10	n	2		2		4	
	Mean	30.0		30.0		30.0	
	Median	30.0		30.0		30.0	
	SD	0.00		0.00		0.00	
	(SE)	( 0.00)		( 0.00)		( 0.00)	
	Min,	30,		30,		30,	
	Max	30		30		30	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	30.0		35.0		32.5	
	Median	30.0		35.0		32.0	
	SD	0.00		1.41		3.00	
	(SE)	( 0.00)		( 1.00)		( 1.50)	
	Min,	30,		34,		30,	
	Max	30		36		36	
Week 15	n	2		2		4	
	Mean	30.0		34.0		32.0	
	Median	30.0		34.0		30.0	
	SD	0.00		5.66		4.00	
	(SE)	( 0.00)		( 4.00)		( 2.00)	
	Min,	30,		30,		30,	
	Max	30		38		38	
Week 18	n	2		2		4	
	Mean	30.0		37.0		33.5	
	Median	30.0		37.0		30.0	
	SD	0.00		9.90		7.00	
	(SE)	( 0.00)		( 7.00)		( 3.50)	
	Min,	30,		30,		30,	
	Max	30		44		44	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	30.0		32.0		31.0	
	Median	30.0		32.0		30.0	
	SD	0.00		2.83		2.00	
	(SE)	( 0.00)		( 2.00)		( 1.00)	
	Min, Max	30, 30		30, 34		30, 34	
Week 24	n	2		2		4	
	Mean	30.0		35.0		32.5	
	Median	30.0		35.0		30.0	
	SD	0.00		7.07		5.00	
	(SE)	( 0.00)		( 5.00)		( 2.50)	
	Min, Max	30, 30		30, 40		30, 40	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	30.5		34.5		32.5	
	Median	30.5		34.5		30.5	
	SD	0.71		6.36		4.36	
	(SE)	( 0.50)		( 4.50)		( 2.18)	
	Min, Max	30, 31		30, 39		30, 39	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	35.0	4.5	44.5	10.0	39.8	7.3
	Median	35.0	4.5	44.5	10.0	37.0	4.5
	SD	7.07	6.36	14.85	21.21	10.97	13.18
	(SE)	( 5.00)	( 4.50)	( 10.50)	( 15.00)	( 5.48)	( 6.59)
	Min, Max	30, 40	0, 9	34, 55	-5, 25	30, 55	-5, 25
Week 32	n	2	2	2	2	4	4
	Mean	28.0	-2.5	42.5	8.0	35.3	2.8
	Median	28.0	-2.5	42.5	8.0	37.0	3.5
	SD	7.07	6.36	2.12	4.24	9.39	7.50
	(SE)	( 5.00)	( 4.50)	( 1.50)	( 3.00)	( 4.70)	( 3.75)
	Min, Max	23, 33	-7, 2	41, 44	5, 11	23, 44	-7, 11
Week 36	n	2	2	1	1	3	3
	Mean	28.0	-2.5	45.0	6.0	33.7	0.3
	Median	28.0	-2.5	45.0	6.0	30.0	-1.0
	SD	2.83	2.12			10.02	5.13
	(SE)	( 2.00)	( 1.50)			( 5.78)	( 2.96)
	Min, Max	26, 30	-4, -1	45, 45	6, 6	26, 45	-4, 6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	29.0	-1.5	39.0	4.5	34.0	1.5
	Median	29.0	-1.5	39.0	4.5	36.0	2.0
	SD	7.07	6.36	1.41	4.95	7.12	5.80
	(SE)	( 5.00)	( 4.50)	( 1.00)	( 3.50)	( 3.56)	( 2.90)
	Min,	24,	-6,	38,	1,	24,	-6,
	Max	34	3	40	8	40	8
Week 44	n	2	2	2	2	4	4
	Mean	25.5	-5.0	40.0	5.5	32.8	0.3
	Median	25.5	-5.0	40.0	5.5	32.5	0.5
	SD	3.54	2.83	4.24	2.12	8.96	6.40
	(SE)	( 2.50)	( 2.00)	( 3.00)	( 1.50)	( 4.48)	( 3.20)
	Min,	23,	-7,	37,	4,	23,	-7,
	Max	28	-3	43	7	43	7
Week 48	n	2	2	2	2	4	4
	Mean	29.0	-1.5	39.5	5.0	34.3	1.8
	Median	29.0	-1.5	39.5	5.0	37.0	2.5
	SD	8.49	7.78	0.71	5.66	7.80	6.70
	(SE)	( 6.00)	( 5.50)	( 0.50)	( 4.00)	( 3.90)	( 3.35)
	Min,	23,	-7,	39,	1,	23,	-7,
	Max	35	4	40	9	40	9

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	27.0	-3.5	40.5	6.0	33.8	1.3
	Median	27.0	-3.5	40.5	6.0	36.5	2.0
	SD	8.49	7.78	0.71	5.66	9.22	7.80
	(SE)	( 6.00)	( 5.50)	( 0.50)	( 4.00)	( 4.61)	( 3.90)
	Min,	21,	-9,	40,	2,	21,	-9,
	Max	33	2	41	10	41	10
Week 56	n	2	2	2	2	4	4
	Mean	29.5	-1.0	44.0	9.5	36.8	4.3
	Median	29.5	-1.0	44.0	9.5	39.0	6.0
	SD	9.19	8.49	2.83	3.54	10.05	8.06
	(SE)	( 6.50)	( 6.00)	( 2.00)	( 2.50)	( 5.02)	( 4.03)
	Min,	23,	-7,	42,	7,	23,	-7,
	Max	36	5	46	12	46	12
Week 60	n	2	2	2	2	4	4
	Mean	32.5	2.0	41.5	7.0	37.0	4.5
	Median	32.5	2.0	41.5	7.0	38.5	6.0
	SD	7.78	7.07	3.54	2.83	7.16	5.26
	(SE)	( 5.50)	( 5.00)	( 2.50)	( 2.00)	( 3.58)	( 2.63)
	Min,	27,	-3,	39,	5,	27,	-3,
	Max	38	7	44	9	44	9

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	30.0	-0.5	45.5	11.0	37.8	5.3
	Median	30.0	-0.5	45.5	11.0	39.5	9.0
	SD	12.73	12.02	7.78	1.41	12.42	9.64
	(SE)	( 9.00)	( 8.50)	( 5.50)	( 1.00)	( 6.21)	( 4.82)
	Min, Max	21, 39	-9, 8	40, 51	10, 12	21, 51	-9, 12
Week 68	n	2	2	2	2	4	4
	Mean	29.0	-1.5	47.5	13.0	38.3	5.8
	Median	29.0	-1.5	47.5	13.0	35.0	4.5
	SD	5.66	4.95	14.85	8.49	14.08	10.11
	(SE)	( 4.00)	( 3.50)	( 10.50)	( 6.00)	( 7.04)	( 5.06)
	Min, Max	25, 33	-5, 2	37, 58	7, 19	25, 58	-5, 19
Week 72	n	2	2	0	0	2	2
	Mean	26.5	-4.0			26.5	-4.0
	Median	26.5	-4.0			26.5	-4.0
	SD	4.95	4.24			4.95	4.24
	(SE)	( 3.50)	( 3.00)			( 3.50)	( 3.00)
	Min, Max	23, 30	-7, -1			23, 30	-7, -1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			37.0	7.0	37.0	7.0
	Median			37.0	7.0	37.0	7.0
	SD (SE)						
	Min,			37,	7,	37,	7,
	Max			37	7	37	7
Week 76	n	2	2	2	2	4	4
	Mean	29.5	-1.0	50.0	15.5	39.8	7.3
	Median	29.5	-1.0	50.0	15.5	38.0	7.5
	SD (SE)	7.78 ( 5.50)	7.07 ( 5.00)	12.73 ( 9.00)	6.36 ( 4.50)	14.64 ( 7.32)	11.00 ( 5.50)
	Min,	24,	-6,	41,	11,	24,	-6,
	Max	35	4	59	20	59	20
Week 80	n	2	2	2	2	4	4
	Mean	30.5	0.0	51.0	16.5	40.8	8.3
	Median	30.5	0.0	51.0	16.5	39.0	8.5
	SD (SE)	9.19 ( 6.50)	8.49 ( 6.00)	14.14 ( 10.00)	7.78 ( 5.50)	15.33 ( 7.66)	11.62 ( 5.81)
	Min,	24,	-6,	41,	11,	24,	-6,
	Max	37	6	61	22	61	22

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 84	n	2	2	2	2	4	4
	Mean	33.0	2.5	45.5	11.0	39.3	6.8
	Median	33.0	2.5	45.5	11.0	43.0	9.5
	SD	12.73	12.02	2.12	4.24	10.37	8.85
	(SE)	( 9.00)	( 8.50)	( 1.50)	( 3.00)	( 5.19)	( 4.42)
	Min,	24,	-6,	44,	8,	24,	-6,
	Max	42	11	47	14	47	14
Week 88	n	2	2	2	2	4	4
	Mean	29.5	-1.0	48.0	13.5	38.8	6.3
	Median	29.5	-1.0	48.0	13.5	42.0	8.0
	SD	10.61	9.90	1.41	4.95	12.34	10.53
	(SE)	( 7.50)	( 7.00)	( 1.00)	( 3.50)	( 6.17)	( 5.27)
	Min,	22,	-8,	47,	10,	22,	-8,
	Max	37	6	49	17	49	17
Week 92	n	2	2	2	2	4	4
	Mean	32.5	2.0	36.0	1.5	34.3	1.8
	Median	32.5	2.0	36.0	1.5	35.0	2.0
	SD	4.95	4.24	2.83	9.19	3.86	5.85
	(SE)	( 3.50)	( 3.00)	( 2.00)	( 6.50)	( 1.93)	( 2.93)
	Min,	29,	-1,	34,	-5,	29,	-5,
	Max	36	5	38	8	38	8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	26.5	-4.0	44.0	9.5	35.3	2.8
	Median	26.5	-4.0	44.0	9.5	36.5	2.5
	SD	4.95	4.24	1.41	4.95	10.53	8.66
	(SE)	( 3.50)	( 3.00)	( 1.00)	( 3.50)	( 5.27)	( 4.33)
	Min, Max	23, 30	-7, -1	43, 45	6, 13	23, 45	-7, 13
Week 100	n	2	2	2	2	4	4
	Mean	33.0	2.5	39.5	5.0	36.3	3.8
	Median	33.0	2.5	39.5	5.0	39.0	5.0
	SD	9.90	9.19	2.12	4.24	6.95	6.02
	(SE)	( 7.00)	( 6.50)	( 1.50)	( 3.00)	( 3.47)	( 3.01)
	Min, Max	26, 40	-4, 9	38, 41	2, 8	26, 41	-4, 9
Week 104	n	2	2	2	2	4	4
	Mean	31.0	0.5	45.5	11.0	38.3	5.8
	Median	31.0	0.5	45.5	11.0	41.0	9.5
	SD	12.73	12.02	4.95	1.41	11.50	9.25
	(SE)	( 9.00)	( 8.50)	( 3.50)	( 1.00)	( 5.75)	( 4.63)
	Min, Max	22, 40	-8, 9	42, 49	10, 12	22, 49	-8, 12

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	2	2	2	2	4	4
	Mean	29.0	-1.5	40.0	5.5	34.5	2.0
	Median	29.0	-1.5	40.0	5.5	35.0	4.5
	SD	8.49	7.78	7.07	0.71	9.00	6.06
	(SE)	( 6.00)	( 5.50)	( 5.00)	( 0.50)	( 4.50)	( 3.03)
	Min, Max	23, 35	-7, 4	35, 45	5, 6	23, 45	-7, 6
Week 112	n	2	2	2	2	4	4
	Mean	31.0	0.5	42.5	8.0	36.8	4.3
	Median	31.0	0.5	42.5	8.0	38.5	5.0
	SD	7.07	6.36	2.12	4.24	7.89	6.18
	(SE)	( 5.00)	( 4.50)	( 1.50)	( 3.00)	( 3.94)	( 3.09)
	Min, Max	26, 36	-4, 5	41, 44	5, 11	26, 44	-4, 11
Week 116	n	2	2	2	2	4	4
	Mean	30.5	0.0	44.5	10.0	37.5	5.0
	Median	30.5	0.0	44.5	10.0	38.5	8.0
	SD	12.02	11.31	9.19	2.83	11.90	8.87
	(SE)	( 8.50)	( 8.00)	( 6.50)	( 2.00)	( 5.95)	( 4.43)
	Min, Max	22, 39	-8, 8	38, 51	8, 12	22, 51	-8, 12

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	30.0	-0.5	44.0	9.5	37.0	4.5
	Median	30.0	-0.5	44.0	9.5	38.0	7.5
	SD	11.31	10.61	8.49	2.12	11.49	8.50
	(SE)	( 8.00)	( 7.50)	( 6.00)	( 1.50)	( 5.74)	( 4.25)
	Min, Max	22, 38	-8, 7	38, 50	8, 11	22, 50	-8, 11
Week 124	n	2	2	2	2	4	4
	Mean	32.0	1.5	43.5	9.0	37.8	5.3
	Median	32.0	1.5	43.5	9.0	36.0	5.5
	SD	9.90	9.19	14.85	8.49	12.26	8.42
	(SE)	( 7.00)	( 6.50)	( 10.50)	( 6.00)	( 6.13)	( 4.21)
	Min, Max	25, 39	-5, 8	33, 54	3, 15	25, 54	-5, 15
Week 128	n	2	2	2	2	4	4
	Mean	26.5	-4.0	47.0	12.5	36.8	4.3
	Median	26.5	-4.0	47.0	12.5	38.0	6.0
	SD	7.78	7.07	4.24	2.12	12.89	10.44
	(SE)	( 5.50)	( 5.00)	( 3.00)	( 1.50)	( 6.45)	( 5.22)
	Min, Max	21, 32	-9, 1	44, 50	11, 14	21, 50	-9, 14

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	31.0	0.5	37.5	3.0	34.3	1.8
	Median	31.0	0.5	37.5	3.0	35.5	3.0
	SD	11.31	10.61	7.78	1.41	8.77	6.34
	(SE)	( 8.00)	( 7.50)	( 5.50)	( 1.00)	( 4.39)	( 3.17)
	Min,	23,	-7,	32,	2,	23,	-7,
	Max	39	8	43	4	43	8
Week 136	n	2	2	2	2	4	4
	Mean	29.0	-1.5	38.5	4.0	33.8	1.3
	Median	29.0	-1.5	38.5	4.0	36.5	4.0
	SD	12.73	12.02	4.95	1.41	9.60	7.68
	(SE)	( 9.00)	( 8.50)	( 3.50)	( 1.00)	( 4.80)	( 3.84)
	Min,	20,	-10,	35,	3,	20,	-10,
	Max	38	7	42	5	42	7
Week 140	n	2	2	2	2	4	4
	Mean	27.5	-3.0	47.5	13.0	37.5	5.0
	Median	27.5	-3.0	47.5	13.0	41.5	7.0
	SD	12.02	11.31	0.71	5.66	13.48	11.78
	(SE)	( 8.50)	( 8.00)	( 0.50)	( 4.00)	( 6.74)	( 5.89)
	Min,	19,	-11,	47,	9,	19,	-11,
	Max	36	5	48	17	48	17

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	31.5	1.0	41.0	6.5	36.3	3.8
	Median	31.5	1.0	41.0	6.5	36.0	5.5
	SD	9.19	8.49	9.90	3.54	9.54	6.18
	(SE)	( 6.50)	( 6.00)	( 7.00)	( 2.50)	( 4.77)	( 3.09)
	Min, Max	25, 38	-5, 7	34, 48	4, 9	25, 48	-5, 9
Week 148	n	2	2	2	2	4	4
	Mean	30.5	0.0	43.5	9.0	37.0	4.5
	Median	30.5	0.0	43.5	9.0	35.5	5.0
	SD	4.95	4.24	9.19	2.83	9.63	5.97
	(SE)	( 3.50)	( 3.00)	( 6.50)	( 2.00)	( 4.81)	( 2.99)
	Min, Max	27, 34	-3, 3	37, 50	7, 11	27, 50	-3, 11
Week 152	n	2	2	2	2	4	4
	Mean	28.0	-2.5	47.0	12.5	37.5	5.0
	Median	28.0	-2.5	47.0	12.5	36.5	6.0
	SD	4.24	3.54	7.07	0.71	11.96	8.91
	(SE)	( 3.00)	( 2.50)	( 5.00)	( 0.50)	( 5.98)	( 4.45)
	Min, Max	25, 31	-5, 0	42, 52	12, 13	25, 52	-5, 13

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	33.5	3.0	44.0	9.5	38.8	6.3
	Median	33.5	3.0	44.0	9.5	39.5	8.5
	SD	7.78	7.07	5.66	0.71	8.22	5.56
	(SE)	( 5.50)	( 5.00)	( 4.00)	( 0.50)	( 4.11)	( 2.78)
	Min, Max	28, 39	-2, 8	40, 48	9, 10	28, 48	-2, 10
Week 160	n	2	2	2	2	4	4
	Mean	29.0	-1.5	43.5	9.0	36.3	3.8
	Median	29.0	-1.5	43.5	9.0	37.5	7.0
	SD	11.31	10.61	7.78	1.41	11.53	8.66
	(SE)	( 8.00)	( 7.50)	( 5.50)	( 1.00)	( 5.76)	( 4.33)
	Min, Max	21, 37	-9, 6	38, 49	8, 10	21, 49	-9, 10
Week 164	n	2	2	2	2	4	4
	Mean	30.0	-0.5	41.5	7.0	35.8	3.3
	Median	30.0	-0.5	41.5	7.0	36.0	5.5
	SD	9.90	9.19	9.19	2.83	10.24	7.04
	(SE)	( 7.00)	( 6.50)	( 6.50)	( 2.00)	( 5.12)	( 3.52)
	Min, Max	23, 37	-7, 6	35, 48	5, 9	23, 48	-7, 9

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	29.0	-1.5	44.5	10.0	36.8	4.3
	Median	29.0	-1.5	44.5	10.0	40.5	5.5
	SD	12.73	12.02	2.12	8.49	11.64	10.78
	(SE)	( 9.00)	( 8.50)	( 1.50)	( 6.00)	( 5.82)	( 5.39)
	Min,	20,	-10,	43,	4,	20,	-10,
	Max	38	7	46	16	46	16
Week 172	n	2	2	2	2	4	4
	Mean	31.0	0.5	48.5	14.0	39.8	7.3
	Median	31.0	0.5	48.5	14.0	43.0	8.5
	SD	9.90	9.19	0.71	5.66	11.62	9.98
	(SE)	( 7.00)	( 6.50)	( 0.50)	( 4.00)	( 5.81)	( 4.99)
	Min,	24,	-6,	48,	10,	24,	-6,
	Max	38	7	49	18	49	18
Week 176	n	2	2	2	2	4	4
	Mean	34.5	4.0	41.0	6.5	37.8	5.3
	Median	34.5	4.0	41.0	6.5	37.0	6.5
	SD	9.19	8.49	11.31	4.95	9.22	5.85
	(SE)	( 6.50)	( 6.00)	( 8.00)	( 3.50)	( 4.61)	( 2.93)
	Min,	28,	-2,	33,	3,	28,	-2,
	Max	41	10	49	10	49	10

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	30.5	0.0	43.0	8.5	36.8	4.3
	Median	30.5	0.0	43.0	8.5	37.0	6.5
	SD	7.78	7.07	7.07	0.71	9.43	6.40
	(SE)	( 5.50)	( 5.00)	( 5.00)	( 0.50)	( 4.71)	( 3.20)
	Min, Max	25, 36	-5, 5	38, 48	8, 9	25, 48	-5, 9
Week 184	n	2	2	2	2	4	4
	Mean	34.0	3.5	45.0	10.5	39.5	7.0
	Median	34.0	3.5	45.0	10.5	39.5	9.0
	SD	9.90	9.19	9.90	3.54	10.28	6.98
	(SE)	( 7.00)	( 6.50)	( 7.00)	( 2.50)	( 5.14)	( 3.49)
	Min, Max	27, 41	-3, 10	38, 52	8, 13	27, 52	-3, 13

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Alanine Aminotransferase (U/L)						
Week 1	n	2	2		4	
	Mean	411.0	550.5		480.8	
	Median	411.0	550.5		411.0	
	SD	36.77	386.79		238.34	
	(SE)	( 26.00)	( 273.50)		( 119.17)	
	Min,	385,	277,		277,	
	Max	437	824		824	
Week 2	n	2	2		4	
	Mean	420.0	315.0		367.5	
	Median	420.0	315.0		401.5	
	SD	69.30	165.46		120.01	
	(SE)	( 49.00)	( 117.00)		( 60.00)	
	Min,	371,	198,		198,	
	Max	469	432		469	
Week 4	n	2	2		4	
	Mean	435.0	419.0		427.0	
	Median	435.0	419.0		435.0	
	SD	29.70	206.48		120.79	
	(SE)	( 21.00)	( 146.00)		( 60.39)	
	Min,	414,	273,		273,	
	Max	456	565		565	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	396.5		415.0		405.8	
	Median	396.5		415.0		396.5	
	SD	82.73		261.63		158.78	
	(SE)	( 58.50)		( 185.00)		( 79.39)	
	Min, Max	338, 455		230, 600		230, 600	
Week 8	n	2		2		4	
	Mean	537.5		544.5		541.0	
	Median	537.5		544.5		537.5	
	SD	48.79		273.65		160.53	
	(SE)	( 34.50)		( 193.50)		( 80.27)	
	Min, Max	503, 572		351, 738		351, 738	
Week 10	n	2		2		4	
	Mean	462.0		398.0		430.0	
	Median	462.0		398.0		444.5	
	SD	5.66		46.67		45.85	
	(SE)	( 4.00)		( 33.00)		( 22.92)	
	Min, Max	458, 466		365, 431		365, 466	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	496.0		621.0		558.5	
	Median	496.0		621.0		496.0	
	SD	8.49		394.57		239.01	
	(SE)	( 6.00)		( 279.00)		( 119.51)	
	Min, Max	490, 502		342, 900		342, 900	
Week 15	n	2		2		4	
	Mean	424.0		419.5		421.8	
	Median	424.0		419.5		424.0	
	SD	21.21		219.91		127.58	
	(SE)	( 15.00)		( 155.50)		( 63.79)	
	Min, Max	409, 439		264, 575		264, 575	
Week 18	n	2		2		4	
	Mean	374.5		486.5		430.5	
	Median	374.5		486.5		385.5	
	SD	47.38		174.66		122.87	
	(SE)	( 33.50)		( 123.50)		( 61.44)	
	Min, Max	341, 408		363, 610		341, 610	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	391.5		461.0		426.3	
	Median	391.5		461.0		391.5	
	SD	16.26		257.39		154.21	
	(SE)	( 11.50)		( 182.00)		( 77.11)	
	Min, Max	380, 403		279, 643		279, 643	
Week 24	n	2		2		4	
	Mean	466.5		482.0		474.3	
	Median	466.5		482.0		466.5	
	SD	38.89		234.76		137.68	
	(SE)	( 27.50)		( 166.00)		( 68.84)	
	Min, Max	439, 494		316, 648		316, 648	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	352.5		412.0		382.3	
	Median	352.5		412.0		352.5	
	SD	60.10		183.85		116.84	
	(SE)	( 42.50)		( 130.00)		( 58.42)	
	Min, Max	310, 395		282, 542		282, 542	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	369.5	17.0	424.5	12.5	397.0	14.8
	Median	369.5	17.0	424.5	12.5	369.5	17.0
	SD	72.83	12.73	272.24	88.39	165.77	51.62
	(SE)	( 51.50)	( 9.00)	( 192.50)	( 62.50)	( 82.89)	( 25.81)
	Min,	318,	8,	232,	-50,	232,	-50,
	Max	421	26	617	75	617	75
Week 32	n	2	2	2	2	4	4
	Mean	383.0	30.5	368.0	-44.0	375.5	-6.8
	Median	383.0	30.5	368.0	-44.0	383.0	-8.0
	SD	86.27	26.16	206.48	22.63	129.48	47.42
	(SE)	( 61.00)	( 18.50)	( 146.00)	( 16.00)	( 64.74)	( 23.71)
	Min,	322,	12,	222,	-60,	222,	-60,
	Max	444	49	514	-28	514	49
Week 36	n	2	2	1	1	3	3
	Mean	321.5	-31.0	531.0	-11.0	391.3	-24.3
	Median	321.5	-31.0	531.0	-11.0	361.0	-28.0
	SD	55.86	4.24			127.24	11.93
	(SE)	( 39.50)	( 3.00)			( 73.46)	( 6.89)
	Min,	282,	-34,	531,	-11,	282,	-34,
	Max	361	-28	531	-11	531	-11

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	335.5	-17.0	377.0	-35.0	356.3	-26.0
	Median	335.5	-17.0	377.0	-35.0	377.0	-17.0
	SD	135.06	74.95	74.95	108.89	92.34	77.03
	(SE)	( 95.50)	( 53.00)	( 53.00)	( 77.00)	( 46.17)	( 38.51)
	Min, Max	240, 431	-70, 36	324, 430	-112, 42	240, 431	-112, 42
Week 44	n	2	2	2	2	4	4
	Mean	385.0	32.5	327.5	-84.5	356.3	-26.0
	Median	385.0	32.5	327.5	-84.5	385.0	-15.5
	SD	7.07	53.03	101.12	82.73	67.28	88.22
	(SE)	( 5.00)	( 37.50)	( 71.50)	( 58.50)	( 33.64)	( 44.11)
	Min, Max	380, 390	-5, 70	256, 399	-143, -26	256, 399	-143, 70
Week 48	n	2	2	2	2	4	4
	Mean	338.5	-14.0	368.5	-43.5	353.5	-28.8
	Median	338.5	-14.0	368.5	-43.5	338.5	-19.0
	SD	60.10	0.00	211.42	27.58	128.08	23.31
	(SE)	( 42.50)	( 0.00)	( 149.50)	( 19.50)	( 64.04)	( 11.66)
	Min, Max	296, 381	-14, -14	219, 518	-63, -24	219, 518	-63, -14

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	340.5	-12.0	307.0	-105.0	323.8	-58.5
	Median	340.5	-12.0	307.0	-105.0	338.5	-29.5
	SD	50.20	9.90	91.92	91.92	63.49	75.71
	(SE)	( 35.50)	( 7.00)	( 65.00)	( 65.00)	( 31.74)	( 37.86)
	Min, Max	305, 376	-19, -5	242, 372	-170, -40	242, 376	-170, -5
Week 56	n	2	2	2	2	4	4
	Mean	308.0	-44.5	331.0	-81.0	319.5	-62.8
	Median	308.0	-44.5	331.0	-81.0	308.0	-59.0
	SD	2.83	57.28	115.97	67.88	68.28	55.44
	(SE)	( 2.00)	( 40.50)	( 82.00)	( 48.00)	( 34.14)	( 27.72)
	Min, Max	306, 310	-85, -4	249, 413	-129, -33	249, 413	-129, -4
Week 60	n	2	2	2	2	4	4
	Mean	360.5	8.0	354.5	-57.5	357.5	-24.8
	Median	360.5	8.0	354.5	-57.5	360.5	-27.0
	SD	3.54	63.64	126.57	57.28	73.19	62.24
	(SE)	( 2.50)	( 45.00)	( 89.50)	( 40.50)	( 36.59)	( 31.12)
	Min, Max	358, 363	-37, 53	265, 444	-98, -17	265, 444	-98, 53

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	333.5	-19.0	307.5	-104.5	320.5	-61.8
	Median	333.5	-19.0	307.5	-104.5	333.5	-54.0
	SD	48.79	11.31	150.61	33.23	92.63	53.36
	(SE)	( 34.50)	( 8.00)	( 106.50)	( 23.50)	( 46.32)	( 26.68)
	Min, Max	299, 368	-27, -11	201, 414	-128, -81	201, 414	-128, -11
Week 68	n	2	2	2	2	4	4
	Mean	376.0	23.5	206.0	-206.0	291.0	-91.3
	Median	376.0	23.5	206.0	-206.0	267.0	-29.0
	SD	72.12	12.02	4.24	188.09	106.65	171.46
	(SE)	( 51.00)	( 8.50)	( 3.00)	( 133.00)	( 53.32)	( 85.73)
	Min, Max	325, 427	15, 32	203, 209	-339, -73	203, 427	-339, 32
Week 72	n	2	2	0	0	2	2
	Mean	304.5	-48.0			304.5	-48.0
	Median	304.5	-48.0			304.5	-48.0
	SD	4.95	55.15			4.95	55.15
	(SE)	( 3.50)	( 39.00)			( 3.50)	( 39.00)
	Min, Max	301, 308	-87, -9			301, 308	-87, -9

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			203.0	-79.0	203.0	-79.0
	Median			203.0	-79.0	203.0	-79.0
	SD						
	(SE)						
	Min, Max			203, 203	-79, -79	203, 203	-79, -79
Week 76	n	2	2	2	2	4	4
	Mean	388.0	35.5	272.5	-139.5	330.3	-52.0
	Median	388.0	35.5	272.5	-139.5	277.5	-54.0
	SD	199.40	139.30	50.20	133.64	136.17	150.43
	(SE)	( 141.00)	( 98.50)	( 35.50)	( 94.50)	( 68.08)	( 75.22)
	Min, Max	247, 529	-63, 134	237, 308	-234, -45	237, 529	-234, 134
Week 80	n	2	2	2	2	4	4
	Mean	370.5	18.0	308.0	-104.0	339.3	-43.0
	Median	370.5	18.0	308.0	-104.0	370.5	-50.5
	SD	99.70	39.60	202.23	18.38	135.09	74.81
	(SE)	( 70.50)	( 28.00)	( 143.00)	( 13.00)	( 67.54)	( 37.41)
	Min, Max	300, 441	-10, 46	165, 451	-117, -91	165, 451	-117, 46

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	245.5	-107.0	309.0	-103.0	277.3	-105.0
	Median	245.5	-107.0	309.0	-103.0	245.5	-107.0
	SD	51.62	8.49	169.71	14.14	108.78	9.80
	(SE)	( 36.50)	( 6.00)	( 120.00)	( 10.00)	( 54.39)	( 4.90)
	Min, Max	209, 282	-113, -101	189, 429	-113, -93	189, 429	-113, -93
Week 88	n	2	2	2	2	4	4
	Mean	368.5	16.0	248.0	-164.0	308.3	-74.0
	Median	368.5	16.0	248.0	-164.0	348.5	-70.5
	SD	19.09	41.01	132.94	50.91	104.17	110.57
	(SE)	( 13.50)	( 29.00)	( 94.00)	( 36.00)	( 52.09)	( 55.28)
	Min, Max	355, 382	-13, 45	154, 342	-200, -128	154, 382	-200, 45
Week 92	n	2	2	2	2	4	4
	Mean	336.0	-16.5	313.5	-98.5	324.8	-57.5
	Median	336.0	-16.5	313.5	-98.5	336.0	-96.5
	SD	60.81	120.92	194.45	10.61	118.35	84.57
	(SE)	( 43.00)	( 85.50)	( 137.50)	( 7.50)	( 59.17)	( 42.29)
	Min, Max	293, 379	-102, 69	176, 451	-106, -91	176, 451	-106, 69

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 96	n	2	2	2	2	4	4
	Mean	206.5	-146.0	243.5	-168.5	225.0	-157.3
	Median	206.5	-146.0	243.5	-168.5	208.5	-146.0
	SD	72.83	12.73	119.50	64.35	83.57	40.04
	(SE)	( 51.50)	( 9.00)	( 84.50)	( 45.50)	( 41.79)	( 20.02)
	Min,	155,	-155,	159,	-214,	155,	-214,
	Max	258	-137	328	-123	328	-123
Week 100	n	2	2	2	2	4	4
	Mean	253.5	-99.0	279.0	-133.0	266.3	-116.0
	Median	253.5	-99.0	279.0	-133.0	253.5	-118.0
	SD	17.68	42.43	147.08	36.77	86.78	37.89
	(SE)	( 12.50)	( 30.00)	( 104.00)	( 26.00)	( 43.39)	( 18.95)
	Min,	241,	-129,	175,	-159,	175,	-159,
	Max	266	-69	383	-107	383	-69
Week 104	n	2	2	2	2	4	4
	Mean	248.0	-104.5	300.0	-112.0	274.0	-108.3
	Median	248.0	-104.5	300.0	-112.0	267.0	-106.5
	SD	49.50	109.60	69.30	114.55	57.61	91.63
	(SE)	( 35.00)	( 77.50)	( 49.00)	( 81.00)	( 28.80)	( 45.82)
	Min,	213,	-182,	251,	-193,	213,	-193,
	Max	283	-27	349	-31	349	-27

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	267.0	-85.5	266.0	-146.0	266.5	-115.8
	Median	267.0	-85.5	266.0	-146.0	267.0	-117.5
	SD	11.31	48.79	140.01	43.84	81.10	51.52
	(SE)	( 8.00)	( 34.50)	( 99.00)	( 31.00)	( 40.55)	( 25.76)
	Min, Max	259, 275	-120, -51	167, 365	-177, -115	167, 365	-177, -51
Week 112	n	2	2	2	2	4	4
	Mean	284.5	-68.0	282.5	-129.5	283.5	-98.8
	Median	284.5	-68.0	282.5	-129.5	284.5	-96.5
	SD	79.90	19.80	157.68	26.16	102.07	40.24
	(SE)	( 56.50)	( 14.00)	( 111.50)	( 18.50)	( 51.03)	( 20.12)
	Min, Max	228, 341	-82, -54	171, 394	-148, -111	171, 394	-148, -54
Week 116	n	2	2	2	2	4	4
	Mean	263.0	-89.5	211.0	-201.0	237.0	-145.3
	Median	263.0	-89.5	211.0	-201.0	263.0	-139.5
	SD	2.83	62.93	104.65	79.20	67.49	86.92
	(SE)	( 2.00)	( 44.50)	( 74.00)	( 56.00)	( 33.74)	( 43.46)
	Min, Max	261, 265	-134, -45	137, 285	-257, -145	137, 285	-257, -45

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	330.0	-22.5	247.5	-164.5	288.8	-93.5
	Median	330.0	-22.5	247.5	-164.5	327.5	-88.5
	SD	4.24	55.86	113.84	70.00	81.21	96.93
	(SE)	( 3.00)	( 39.50)	( 80.50)	( 49.50)	( 40.60)	( 48.46)
	Min,	327,	-62,	167,	-214,	167,	-214,
	Max	333	17	328	-115	333	17
Week 124	n	2	2	2	2	4	4
	Mean	272.0	-80.5	244.5	-167.5	258.3	-124.0
	Median	272.0	-80.5	244.5	-167.5	272.0	-107.0
	SD	16.97	43.13	92.63	91.22	56.64	76.92
	(SE)	( 12.00)	( 30.50)	( 65.50)	( 64.50)	( 28.32)	( 38.46)
	Min,	260,	-111,	179,	-232,	179,	-232,
	Max	284	-50	310	-103	310	-50
Week 128	n	2	2	2	2	4	4
	Mean	182.0	-170.5	237.0	-175.0	209.5	-172.8
	Median	182.0	-170.5	237.0	-175.0	182.0	-170.5
	SD	26.87	33.23	111.72	72.12	73.55	45.92
	(SE)	( 19.00)	( 23.50)	( 79.00)	( 51.00)	( 36.78)	( 22.96)
	Min,	163,	-194,	158,	-226,	158,	-226,
	Max	201	-147	316	-124	316	-124

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	233.0	-119.5	250.5	-161.5	241.8	-140.5
	Median	233.0	-119.5	250.5	-161.5	233.0	-144.5
	SD	21.21	38.89	156.27	27.58	91.61	36.68
	(SE)	( 15.00)	( 27.50)	( 110.50)	( 19.50)	( 45.80)	( 18.34)
	Min,	218,	-147,	140,	-181,	140,	-181,
	Max	248	-92	361	-142	361	-92
Week 136	n	2	2	2	2	4	4
	Mean	272.5	-80.0	265.0	-147.0	268.8	-113.5
	Median	272.5	-80.0	265.0	-147.0	272.5	-136.0
	SD	44.55	104.65	142.84	41.01	86.49	75.55
	(SE)	( 31.50)	( 74.00)	( 101.00)	( 29.00)	( 43.25)	( 37.77)
	Min,	241,	-154,	164,	-176,	164,	-176,
	Max	304	-6	366	-118	366	-6
Week 140	n	2	2	2	2	4	4
	Mean	248.5	-104.0	205.5	-206.5	227.0	-155.3
	Median	248.5	-104.0	205.5	-206.5	215.5	-126.0
	SD	96.87	36.77	64.35	119.50	71.59	93.34
	(SE)	( 68.50)	( 26.00)	( 45.50)	( 84.50)	( 35.79)	( 46.67)
	Min,	180,	-130,	160,	-291,	160,	-291,
	Max	317	-78	251	-122	317	-78

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	216.5	-136.0	235.5	-176.5	226.0	-156.3
	Median	216.5	-136.0	235.5	-176.5	224.5	-136.0
	SD	38.89	21.21	43.13	140.71	35.28	85.42
	(SE)	( 27.50)	( 15.00)	( 30.50)	( 99.50)	( 17.64)	( 42.71)
	Min, Max	189, 244	-151, -121	205, 266	-276, -77	189, 266	-276, -77
Week 148	n	2	2	2	2	4	4
	Mean	214.5	-138.0	204.0	-208.0	209.3	-173.0
	Median	214.5	-138.0	204.0	-208.0	214.5	-144.0
	SD	50.20	9.90	91.92	91.92	60.77	66.95
	(SE)	( 35.50)	( 7.00)	( 65.00)	( 65.00)	( 30.39)	( 33.48)
	Min, Max	179, 250	-145, -131	139, 269	-273, -143	139, 269	-273, -131
Week 152	n	2	2	2	2	4	4
	Mean	279.0	-73.5	225.5	-186.5	252.3	-130.0
	Median	279.0	-73.5	225.5	-186.5	226.5	-102.0
	SD	118.79	58.69	45.96	137.89	79.76	108.36
	(SE)	( 84.00)	( 41.50)	( 32.50)	( 97.50)	( 39.88)	( 54.18)
	Min, Max	195, 363	-115, -32	193, 258	-284, -89	193, 363	-284, -32

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 156	n	2	2	2	2	4	4
	Mean	225.5	-127.0	242.0	-170.0	233.8	-148.5
	Median	225.5	-127.0	242.0	-170.0	225.5	-132.0
	SD	21.92	38.18	98.99	84.85	59.31	59.18
	(SE)	( 15.50)	( 27.00)	( 70.00)	( 60.00)	( 29.65)	( 29.59)
	Min,	210,	-154,	172,	-230,	172,	-230,
	Max	241	-100	312	-110	312	-100
Week 160	n	2	2	2	2	4	4
	Mean	270.0	-82.5	185.5	-226.5	227.8	-154.5
	Median	270.0	-82.5	185.5	-226.5	207.5	-130.0
	SD	115.97	55.86	58.69	125.16	89.50	114.78
	(SE)	( 82.00)	( 39.50)	( 41.50)	( 88.50)	( 44.75)	( 57.39)
	Min,	188,	-122,	144,	-315,	144,	-315,
	Max	352	-43	227	-138	352	-43
Week 164	n	2	2	2	2	4	4
	Mean	268.5	-84.0	208.0	-204.0	238.3	-144.0
	Median	268.5	-84.0	208.0	-204.0	209.5	-96.5
	SD	95.46	35.36	14.14	169.71	65.76	121.72
	(SE)	( 67.50)	( 25.00)	( 10.00)	( 120.00)	( 32.88)	( 60.86)
	Min,	201,	-109,	198,	-324,	198,	-324,
	Max	336	-59	218	-84	336	-59

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	272.0	-80.5	196.0	-216.0	234.0	-148.3
	Median	272.0	-80.5	196.0	-216.0	255.0	-125.5
	SD	31.11	28.99	90.51	93.34	70.56	96.46
	(SE)	( 22.00)	( 20.50)	( 64.00)	( 66.00)	( 35.28)	( 48.23)
	Min, Max	250, 294	-101, -60	132, 260	-282, -150	132, 294	-282, -60
Week 172	n	2	2	2	2	4	4
	Mean	251.0	-101.5	202.0	-210.0	226.5	-155.8
	Median	251.0	-101.5	202.0	-210.0	213.5	-127.5
	SD	100.41	40.31	63.64	120.21	74.24	96.34
	(SE)	( 71.00)	( 28.50)	( 45.00)	( 85.00)	( 37.12)	( 48.17)
	Min, Max	180, 322	-130, -73	157, 247	-295, -125	157, 322	-295, -73
Week 176	n	2	2	2	2	4	4
	Mean	257.5	-95.0	200.5	-211.5	229.0	-153.3
	Median	257.5	-95.0	200.5	-211.5	242.5	-154.0
	SD	103.94	43.84	142.13	41.72	106.86	75.80
	(SE)	( 73.50)	( 31.00)	( 100.50)	( 29.50)	( 53.43)	( 37.90)
	Min, Max	184, 331	-126, -64	100, 301	-241, -182	100, 331	-241, -64

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	266.0	-86.5	145.5	-266.5	205.8	-176.5
	Median	266.0	-86.5	145.5	-266.5	186.0	-157.5
	SD	123.04	62.93	67.18	116.67	106.73	129.06
	(SE)	( 87.00)	( 44.50)	( 47.50)	( 82.50)	( 53.36)	( 64.53)
	Min, Max	179, 353	-131, -42	98, 193	-349, -184	98, 353	-349, -42
Week 184	n	2	2	2	2	4	4
	Mean	212.0	-140.5	123.5	-288.5	167.8	-214.5
	Median	212.0	-140.5	123.5	-288.5	149.0	-189.5
	SD	113.14	53.03	60.10	123.74	89.90	115.51
	(SE)	( 80.00)	( 37.50)	( 42.50)	( 87.50)	( 44.95)	( 57.76)
	Min, Max	132, 292	-178, -103	81, 166	-376, -201	81, 292	-376, -103

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Aspartate Aminotransferase (U/L)						
Week 1	n	2	2		4	
	Mean	247.0	323.5		285.3	
	Median	247.0	323.5		276.0	
	SD	114.55	140.71		113.69	
	(SE)	( 81.00)	( 99.50)		( 56.84)	
	Min, Max	166, 328	224, 423		166, 423	
Week 2	n	2	2		4	
	Mean	236.5	141.0		188.8	
	Median	236.5	141.0		196.5	
	SD	3.54	25.46		57.10	
	(SE)	( 2.50)	( 18.00)		( 28.55)	
	Min, Max	234, 239	123, 159		123, 239	
Week 4	n	2	2		4	
	Mean	264.5	317.5		291.0	
	Median	264.5	317.5		264.5	
	SD	36.06	152.03		95.26	
	(SE)	( 25.50)	( 107.50)		( 47.63)	
	Min, Max	239, 290	210, 425		210, 425	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	202.0		192.5		197.3	
	Median	202.0		192.5		202.0	
	SD	18.38		91.22		54.00	
	(SE)	( 13.00)		( 64.50)		( 27.00)	
	Min, Max	189, 215		128, 257		128, 257	
Week 8	n	2		2		4	
	Mean	435.0		415.5		425.3	
	Median	435.0		415.5		420.0	
	SD	275.77		260.92		219.48	
	(SE)	( 195.00)		( 184.50)		( 109.74)	
	Min, Max	240, 630		231, 600		231, 630	
Week 10	n	2		2		4	
	Mean	270.5		165.5		218.0	
	Median	270.5		165.5		193.0	
	SD	75.66		4.95		74.78	
	(SE)	( 53.50)		( 3.50)		( 37.39)	
	Min, Max	217, 324		162, 169		162, 324	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4
	Mean	367.5		403.5		385.5
	Median	367.5		403.5		367.5
	SD	70.00		269.41		162.05
	(SE)	( 49.50)		( 190.50)		( 81.02)
	Min,	318,		213,		213,
	Max	417		594		594
Week 15	n	2		2		4
	Mean	206.5		185.0		195.8
	Median	206.5		185.0		201.0
	SD	82.73		97.58		74.90
	(SE)	( 58.50)		( 69.00)		( 37.45)
	Min,	148,		116,		116,
	Max	265		254		265
Week 18	n	2		2		4
	Mean	162.5		326.5		244.5
	Median	162.5		326.5		203.5
	SD	23.33		139.30		124.96
	(SE)	( 16.50)		( 98.50)		( 62.48)
	Min,	146,		228,		146,
	Max	179		425		425

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	195.5		243.0		219.3	
	Median	195.5		243.0		220.0	
	SD	89.80		87.68		77.48	
	(SE)	( 63.50)		( 62.00)		( 38.74)	
	Min, Max	132, 259		181, 305		132, 305	
Week 24	n	2		2		4	
	Mean	342.0		335.5		338.8	
	Median	342.0		335.5		335.5	
	SD	140.01		53.03		86.52	
	(SE)	( 99.00)		( 37.50)		( 43.26)	
	Min, Max	243, 441		298, 373		243, 441	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	185.0		215.0		200.0	
	Median	185.0		215.0		185.0	
	SD	31.11		89.10		57.17	
	(SE)	( 22.00)		( 63.00)		( 28.59)	
	Min, Max	163, 207		152, 278		152, 278	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	151.5	-33.5	208.0	-7.0	179.8	-20.3
	Median	151.5	-33.5	208.0	-7.0	151.5	-23.5
	SD	7.78	23.33	121.62	32.53	77.56	27.72
	(SE)	( 5.50)	( 16.50)	( 86.00)	( 23.00)	( 38.78)	( 13.86)
	Min,	146,	-50,	122,	-30,	122,	-50,
	Max	157	-17	294	16	294	16
Week 32	n	2	2	2	2	4	4
	Mean	259.5	74.5	204.0	-11.0	231.8	31.8
	Median	259.5	74.5	204.0	-11.0	235.0	9.5
	SD	55.86	86.97	65.05	24.04	58.97	71.77
	(SE)	( 39.50)	( 61.50)	( 46.00)	( 17.00)	( 29.49)	( 35.88)
	Min,	220,	13,	158,	-28,	158,	-28,
	Max	299	136	250	6	299	136
Week 36	n	2	2	1	1	3	3
	Mean	212.5	27.5	311.0	33.0	245.3	29.3
	Median	212.5	27.5	311.0	33.0	259.0	33.0
	SD	65.76	96.87			73.46	68.57
	(SE)	( 46.50)	( 68.50)			( 42.41)	( 39.59)
	Min,	166,	-41,	311,	33,	166,	-41,
	Max	259	96	311	33	311	96

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	194.0	9.0	319.0	104.0	256.5	56.5
	Median	194.0	9.0	319.0	104.0	268.5	26.0
	SD	63.64	32.53	29.70	118.79	82.78	89.81
	(SE)	( 45.00)	( 23.00)	( 21.00)	( 84.00)	( 41.39)	( 44.90)
	Min,	149,	-14,	298,	20,	149,	-14,
	Max	239	32	340	188	340	188
Week 44	n	2	2	2	2	4	4
	Mean	338.5	153.5	177.0	-38.0	257.8	57.8
	Median	338.5	153.5	177.0	-38.0	240.0	60.5
	SD	137.89	169.00	87.68	176.78	132.64	179.33
	(SE)	( 97.50)	( 119.50)	( 62.00)	( 125.00)	( 66.32)	( 89.67)
	Min,	241,	34,	115,	-163,	115,	-163,
	Max	436	273	239	87	436	273
Week 48	n	2	2	2	2	4	4
	Mean	235.0	50.0	212.0	-3.0	223.5	23.5
	Median	235.0	50.0	212.0	-3.0	235.0	-3.0
	SD	66.47	97.58	104.65	15.56	72.80	64.74
	(SE)	( 47.00)	( 69.00)	( 74.00)	( 11.00)	( 36.40)	( 32.37)
	Min,	188,	-19,	138,	-14,	138,	-19,
	Max	282	119	286	8	286	119

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	213.0	28.0	159.5	-55.5	186.3	-13.8
	Median	213.0	28.0	159.5	-55.5	168.5	-28.5
	SD	74.95	106.07	24.75	64.35	55.05	86.34
	(SE)	( 53.00)	( 75.00)	( 17.50)	( 45.50)	( 27.53)	( 43.17)
	Min, Max	160, 266	-47, 103	142, 177	-101, -10	142, 266	-101, 103
Week 56	n	2	2	2	2	4	4
	Mean	200.5	15.5	212.5	-2.5	206.5	6.5
	Median	200.5	15.5	212.5	-2.5	204.5	15.5
	SD	19.09	12.02	24.75	113.84	19.33	66.91
	(SE)	( 13.50)	( 8.50)	( 17.50)	( 80.50)	( 9.67)	( 33.45)
	Min, Max	187, 214	7, 24	195, 230	-83, 78	187, 230	-83, 78
Week 60	n	2	2	2	2	4	4
	Mean	258.0	73.0	202.0	-13.0	230.0	30.0
	Median	258.0	73.0	202.0	-13.0	243.5	29.0
	SD	42.43	11.31	80.61	8.49	61.74	50.32
	(SE)	( 30.00)	( 8.00)	( 57.00)	( 6.00)	( 30.87)	( 25.16)
	Min, Max	228, 288	65, 81	145, 259	-19, -7	145, 288	-19, 81

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	226.0	41.0	171.0	-44.0	198.5	-1.5
	Median	226.0	41.0	171.0	-44.0	193.5	-44.0
	SD	98.99	130.11	84.85	4.24	81.70	89.76
	(SE)	( 70.00)	( 92.00)	( 60.00)	( 3.00)	( 40.85)	( 44.88)
	Min, Max	156, 296	-51, 133	111, 231	-47, -41	111, 296	-51, 133
Week 68	n	2	2	2	2	4	4
	Mean	281.0	96.0	139.0	-76.0	210.0	10.0
	Median	281.0	96.0	139.0	-76.0	202.0	44.5
	SD	48.08	16.97	25.46	114.55	87.80	119.71
	(SE)	( 34.00)	( 12.00)	( 18.00)	( 81.00)	( 43.90)	( 59.86)
	Min, Max	247, 315	84, 108	121, 157	-157, 5	121, 315	-157, 108
Week 72	n	2	2	0	0	2	2
	Mean	174.5	-10.5			174.5	-10.5
	Median	174.5	-10.5			174.5	-10.5
	SD	3.54	34.65			3.54	34.65
	(SE)	( 2.50)	( 24.50)			( 2.50)	( 24.50)
	Min, Max	172, 177	-35, 14			172, 177	-35, 14

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			192.0	40.0	192.0	40.0
	Median			192.0	40.0	192.0	40.0
	SD						
	(SE)						
	Min, Max			192, 192	40, 40	192, 192	40, 40
Week 76	n	2	2	2	2	4	4
	Mean	299.5	114.5	179.5	-35.5	239.5	39.5
	Median	299.5	114.5	179.5	-35.5	212.5	55.0
	SD	142.13	111.02	65.76	154.86	113.91	140.01
	(SE)	( 100.50)	( 78.50)	( 46.50)	( 109.50)	( 56.95)	( 70.00)
	Min, Max	199, 400	36, 193	133, 226	-145, 74	133, 400	-145, 193
Week 80	n	2	2	2	2	4	4
	Mean	218.5	33.5	190.0	-25.0	204.3	4.3
	Median	218.5	33.5	190.0	-25.0	218.5	9.0
	SD	65.76	34.65	137.18	48.08	89.36	48.08
	(SE)	( 46.50)	( 24.50)	( 97.00)	( 34.00)	( 44.68)	( 24.04)
	Min, Max	172, 265	9, 58	93, 287	-59, 9	93, 287	-59, 58

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	192.5	7.5	177.5	-37.5	185.0	-15.0
	Median	192.5	7.5	177.5	-37.5	180.5	-17.5
	SD	70.00	38.89	57.28	31.82	52.93	38.94
	(SE)	( 49.50)	( 27.50)	( 40.50)	( 22.50)	( 26.47)	( 19.47)
	Min,	143,	-20,	137,	-60,	137,	-60,
	Max	242	35	218	-15	242	35
Week 88	n	2	2	2	2	4	4
	Mean	310.0	125.0	120.0	-95.0	215.0	15.0
	Median	310.0	125.0	120.0	-95.0	198.5	-7.0
	SD	83.44	114.55	36.77	52.33	121.67	146.36
	(SE)	( 59.00)	( 81.00)	( 26.00)	( 37.00)	( 60.84)	( 73.18)
	Min,	251,	44,	94,	-132,	94,	-132,
	Max	369	206	146	-58	369	206
Week 92	n	2	2	2	2	4	4
	Mean	236.0	51.0	149.0	-66.0	192.5	-7.5
	Median	236.0	51.0	149.0	-66.0	180.0	-43.5
	SD	97.58	128.69	62.23	26.87	83.59	101.61
	(SE)	( 69.00)	( 91.00)	( 44.00)	( 19.00)	( 41.80)	( 50.80)
	Min,	167,	-40,	105,	-85,	105,	-85,
	Max	305	142	193	-47	305	142

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 96	n	2	2	2	2	4	4
	Mean	150.5	-34.5	112.5	-102.5	131.5	-68.5
	Median	150.5	-34.5	112.5	-102.5	127.0	-75.0
	SD	75.66	44.55	62.93	26.16	60.91	49.31
	(SE)	( 53.50)	( 31.50)	( 44.50)	( 18.50)	( 30.45)	( 24.65)
	Min,	97,	-66,	68,	-121,	68,	-121,
	Max	204	-3	157	-84	204	-3
Week 100	n	2	2	2	2	4	4
	Mean	139.0	-46.0	131.0	-84.0	135.0	-65.0
	Median	139.0	-46.0	131.0	-84.0	139.0	-63.0
	SD	12.73	18.38	65.05	24.04	38.55	28.05
	(SE)	( 9.00)	( 13.00)	( 46.00)	( 17.00)	( 19.27)	( 14.02)
	Min,	130,	-59,	85,	-101,	85,	-101,
	Max	148	-33	177	-67	177	-33
Week 104	n	2	2	2	2	4	4
	Mean	143.5	-41.5	158.0	-57.0	150.8	-49.3
	Median	143.5	-41.5	158.0	-57.0	158.0	-41.5
	SD	40.31	71.42	11.31	100.41	25.58	71.70
	(SE)	( 28.50)	( 50.50)	( 8.00)	( 71.00)	( 12.79)	( 35.85)
	Min,	115,	-92,	150,	-128,	115,	-128,
	Max	172	9	166	14	172	14

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	2	2	2	2	4	4
	Mean	183.5	-1.5	170.0	-45.0	176.8	-23.3
	Median	183.5	-1.5	170.0	-45.0	183.5	-16.5
	SD	3.54	34.65	35.36	53.74	21.95	44.65
	(SE)	( 2.50)	( 24.50)	( 25.00)	( 38.00)	( 10.97)	( 22.32)
	Min, Max	181, 186	-26, 23	145, 195	-83, -7	145, 195	-83, 23
Week 112	n	2	2	2	2	4	4
	Mean	186.5	1.5	184.5	-30.5	185.5	-14.5
	Median	186.5	1.5	184.5	-30.5	186.5	-18.0
	SD	16.26	14.85	94.05	4.95	55.12	20.57
	(SE)	( 11.50)	( 10.50)	( 66.50)	( 3.50)	( 27.56)	( 10.28)
	Min, Max	175, 198	-9, 12	118, 251	-34, -27	118, 251	-34, 12
Week 116	n	2	2	2	2	4	4
	Mean	160.5	-24.5	102.0	-113.0	131.3	-68.8
	Median	160.5	-24.5	102.0	-113.0	123.0	-80.5
	SD	57.28	88.39	33.94	55.15	51.17	78.92
	(SE)	( 40.50)	( 62.50)	( 24.00)	( 39.00)	( 25.58)	( 39.46)
	Min, Max	120, 201	-87, 38	78, 126	-152, -74	78, 201	-152, 38

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	263.5	78.5	160.0	-55.0	211.8	11.8
	Median	263.5	78.5	160.0	-55.0	212.5	3.0
	SD	71.42	40.31	73.54	15.56	84.10	81.01
	(SE)	( 50.50)	( 28.50)	( 52.00)	( 11.00)	( 42.05)	( 40.51)
	Min,	213,	50,	108,	-66,	108,	-66,
	Max	314	107	212	-44	314	107
Week 124	n	2	2	2	2	4	4
	Mean	198.0	13.0	140.5	-74.5	169.3	-30.8
	Median	198.0	13.0	140.5	-74.5	181.0	-22.0
	SD	15.56	15.56	48.79	40.31	44.46	56.34
	(SE)	( 11.00)	( 11.00)	( 34.50)	( 28.50)	( 22.23)	( 28.17)
	Min,	187,	2,	106,	-103,	106,	-103,
	Max	209	24	175	-46	209	24
Week 128	n	2	2	2	2	4	4
	Mean	103.5	-81.5	141.5	-73.5	122.5	-77.5
	Median	103.5	-81.5	141.5	-73.5	115.5	-81.5
	SD	41.72	10.61	61.52	27.58	48.20	17.67
	(SE)	( 29.50)	( 7.50)	( 43.50)	( 19.50)	( 24.10)	( 8.84)
	Min,	74,	-89,	98,	-93,	74,	-93,
	Max	133	-74	185	-54	185	-54

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	152.5	-32.5	120.5	-94.5	136.5	-63.5
	Median	152.5	-32.5	120.5	-94.5	152.5	-62.5
	SD	4.95	36.06	50.20	38.89	34.49	47.11
	(SE)	( 3.50)	( 25.50)	( 35.50)	( 27.50)	( 17.25)	( 23.55)
	Min, Max	149, 156	-58, -7	85, 156	-122, -67	85, 156	-122, -7
Week 136	n	2	2	2	2	4	4
	Mean	215.0	30.0	201.5	-13.5	208.3	8.3
	Median	215.0	30.0	201.5	-13.5	215.0	-13.5
	SD	96.17	127.28	147.79	58.69	102.10	84.73
	(SE)	( 68.00)	( 90.00)	( 104.50)	( 41.50)	( 51.05)	( 42.36)
	Min, Max	147, 283	-60, 120	97, 306	-55, 28	97, 306	-60, 120
Week 140	n	2	2	2	2	4	4
	Mean	196.0	11.0	139.0	-76.0	167.5	-32.5
	Median	196.0	11.0	139.0	-76.0	166.5	-15.0
	SD	36.77	5.66	33.94	55.15	43.79	59.56
	(SE)	( 26.00)	( 4.00)	( 24.00)	( 39.00)	( 21.90)	( 29.78)
	Min, Max	170, 222	7, 15	115, 163	-115, -37	115, 222	-115, 15

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	160.5	-24.5	154.5	-60.5	157.5	-42.5
	Median	160.5	-24.5	154.5	-60.5	160.5	-24.5
	SD	0.71	30.41	19.09	108.19	11.56	68.13
	(SE)	( 0.50)	( 21.50)	( 13.50)	( 76.50)	( 5.78)	( 34.06)
	Min, Max	160, 161	-46, -3	141, 168	-137, 16	141, 168	-137, 16
Week 148	n	2	2	2	2	4	4
	Mean	146.5	-38.5	119.5	-95.5	133.0	-67.0
	Median	146.5	-38.5	119.5	-95.5	130.0	-53.0
	SD	44.55	13.44	36.06	53.03	36.58	45.61
	(SE)	( 31.50)	( 9.50)	( 25.50)	( 37.50)	( 18.29)	( 22.81)
	Min, Max	115, 178	-48, -29	94, 145	-133, -58	94, 178	-133, -29
Week 152	n	2	2	2	2	4	4
	Mean	209.0	24.0	141.0	-74.0	175.0	-25.0
	Median	209.0	24.0	141.0	-74.0	141.0	-21.5
	SD	118.79	87.68	8.49	97.58	79.18	94.54
	(SE)	( 84.00)	( 62.00)	( 6.00)	( 69.00)	( 39.59)	( 47.27)
	Min, Max	125, 293	-38, 86	135, 147	-143, -5	125, 293	-143, 86

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	132.5	-52.5	106.0	-109.0	119.3	-80.8
	Median	132.5	-52.5	106.0	-109.0	122.0	-64.5
	SD	33.23	2.12	41.01	48.08	34.10	42.85
	(SE)	( 23.50)	( 1.50)	( 29.00)	( 34.00)	( 17.05)	( 21.43)
	Min, Max	109, 156	-54, -51	77, 135	-143, -75	77, 156	-143, -51
Week 160	n	2	2	2	2	4	4
	Mean	148.5	-36.5	133.5	-81.5	141.0	-59.0
	Median	148.5	-36.5	133.5	-81.5	133.5	-43.0
	SD	68.59	37.48	6.36	82.73	40.70	58.52
	(SE)	( 48.50)	( 26.50)	( 4.50)	( 58.50)	( 20.35)	( 29.26)
	Min, Max	100, 197	-63, -10	129, 138	-140, -23	100, 197	-140, -10
Week 164	n	2	2	2	2	4	4
	Mean	162.5	-22.5	119.5	-95.5	141.0	-59.0
	Median	162.5	-22.5	119.5	-95.5	126.5	-31.0
	SD	57.28	26.16	16.26	105.36	42.40	75.53
	(SE)	( 40.50)	( 18.50)	( 11.50)	( 74.50)	( 21.20)	( 37.76)
	Min, Max	122, 203	-41, -4	108, 131	-170, -21	108, 203	-170, -4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	175.5	-9.5	122.5	-92.5	149.0	-51.0
	Median	175.5	-9.5	122.5	-92.5	172.0	-53.5
	SD	6.36	24.75	71.42	17.68	51.48	51.04
	(SE)	( 4.50)	( 17.50)	( 50.50)	( 12.50)	( 25.74)	( 25.52)
	Min, Max	171, 180	-27, 8	72, 173	-105, -80	72, 180	-105, 8
Week 172	n	2	2	2	2	4	4
	Mean	183.5	-1.5	111.5	-103.5	147.5	-52.5
	Median	183.5	-1.5	111.5	-103.5	131.0	-43.0
	SD	70.00	38.89	23.33	65.76	59.52	73.58
	(SE)	( 49.50)	( 27.50)	( 16.50)	( 46.50)	( 29.76)	( 36.79)
	Min, Max	134, 233	-29, 26	95, 128	-150, -57	95, 233	-150, 26
Week 176	n	2	2	2	2	4	4
	Mean	139.0	-46.0	129.0	-86.0	134.0	-66.0
	Median	139.0	-46.0	129.0	-86.0	139.0	-71.0
	SD	50.91	19.80	94.75	5.66	62.37	25.97
	(SE)	( 36.00)	( 14.00)	( 67.00)	( 4.00)	( 31.18)	( 12.99)
	Min, Max	103, 175	-60, -32	62, 196	-90, -82	62, 196	-90, -32

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	2	2	2	2	4	4
	Mean	247.5	62.5	94.5	-120.5	171.0	-29.0
	Median	247.5	62.5	94.5	-120.5	144.5	-32.5
	SD	102.53	71.42	27.58	61.52	107.52	118.85
	(SE)	( 72.50)	( 50.50)	( 19.50)	( 43.50)	( 53.76)	( 59.42)
	Min,	175,	12,	75,	-164,	75,	-164,
	Max	320	113	114	-77	320	113
Week 184	n	2	2	2	2	4	4
	Mean	122.0	-63.0	67.0	-148.0	94.5	-105.5
	Median	122.0	-63.0	67.0	-148.0	74.5	-97.0
	SD	76.37	45.25	19.80	69.30	55.52	68.50
	(SE)	( 54.00)	( 32.00)	( 14.00)	( 49.00)	( 27.76)	( 34.25)
	Min,	68,	-95,	53,	-197,	53,	-197,
	Max	176	-31	81	-99	176	-31

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Gamma Glutamyl Transferase (U/L)						
Week 1	n	2	2		4	
	Mean	15.0	8.5		11.8	
	Median	15.0	8.5		11.0	
	SD	7.07	4.95		6.24	
	(SE)	( 5.00)	( 3.50)		( 3.12)	
	Min, Max	10, 20	5, 12		5, 20	
Week 2	n	2	2		4	
	Mean	15.5	10.0		12.8	
	Median	15.5	10.0		13.5	
	SD	4.95	7.07		5.91	
	(SE)	( 3.50)	( 5.00)		( 2.95)	
	Min, Max	12, 19	5, 15		5, 19	
Week 4	n	2	2		4	
	Mean	15.0	10.5		12.8	
	Median	15.0	10.5		14.0	
	SD	4.24	7.78		5.74	
	(SE)	( 3.00)	( 5.50)		( 2.87)	
	Min, Max	12, 18	5, 16		5, 18	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	14.5		8.5		11.5	
	Median	14.5		8.5		12.0	
	SD	3.54		4.95		4.93	
	(SE)	( 2.50)		( 3.50)		( 2.47)	
	Min,	12,		5,		5,	
	Max	17		12		17	
Week 8	n	2		2		4	
	Mean	14.5		9.0		11.8	
	Median	14.5		9.0		12.5	
	SD	3.54		5.66		4.99	
	(SE)	( 2.50)		( 4.00)		( 2.50)	
	Min,	12,		5,		5,	
	Max	17		13		17	
Week 10	n	2		2		4	
	Mean	14.0		8.5		11.3	
	Median	14.0		8.5		11.0	
	SD	5.66		4.95		5.38	
	(SE)	( 4.00)		( 3.50)		( 2.69)	
	Min,	10,		5,		5,	
	Max	18		12		18	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	11.5		9.5		10.5	
	Median	11.5		9.5		9.5	
	SD	9.19		6.36		6.56	
	(SE)	( 6.50)		( 4.50)		( 3.28)	
	Min,	5,		5,		5,	
	Max	18		14		18	
Week 15	n	2		2		4	
	Mean	11.0		9.5		10.3	
	Median	11.0		9.5		9.5	
	SD	8.49		6.36		6.18	
	(SE)	( 6.00)		( 4.50)		( 3.09)	
	Min,	5,		5,		5,	
	Max	17		14		17	
Week 18	n	2		2		4	
	Mean	15.0		9.5		12.3	
	Median	15.0		9.5		13.5	
	SD	2.83		6.36		5.12	
	(SE)	( 2.00)		( 4.50)		( 2.56)	
	Min,	13,		5,		5,	
	Max	17		14		17	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	13.5		11.0		12.3	
	Median	13.5		11.0		13.5	
	SD	3.54		8.49		5.50	
	(SE)	( 2.50)		( 6.00)		( 2.75)	
	Min,	11,		5,		5,	
	Max	16		17		17	
Week 24	n	2		2		4	
	Mean	11.0		9.5		10.3	
	Median	11.0		9.5		9.5	
	SD	8.49		6.36		6.18	
	(SE)	( 6.00)		( 4.50)		( 3.09)	
	Min,	5,		5,		5,	
	Max	17		14		17	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	12.0		9.5		10.8	
	Median	12.0		9.5		9.5	
	SD	9.90		6.36		6.95	
	(SE)	( 7.00)		( 4.50)		( 3.47)	
	Min,	5,		5,		5,	
	Max	19		14		19	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	13.0	1.0	9.5	0.0	11.3	0.5
	Median	13.0	1.0	9.5	0.0	12.0	0.0
	SD	4.24	5.66	6.36	0.00	4.86	3.32
	(SE)	( 3.00)	( 4.00)	( 4.50)	( 0.00)	( 2.43)	( 1.66)
	Min,	10,	-3,	5,	0,	5,	-3,
	Max	16	5	14	0	16	5
Week 32	n	2	2	2	2	4	4
	Mean	11.5	-0.5	10.0	0.5	10.8	0.0
	Median	11.5	-0.5	10.0	0.5	10.5	0.5
	SD	6.36	3.54	5.66	0.71	4.99	2.16
	(SE)	( 4.50)	( 2.50)	( 4.00)	( 0.50)	( 2.50)	( 1.08)
	Min,	7,	-3,	6,	0,	6,	-3,
	Max	16	2	14	1	16	2
Week 36	n	2	2	1	1	3	3
	Mean	11.5	-0.5	6.0	1.0	9.7	0.0
	Median	11.5	-0.5	6.0	1.0	7.0	1.0
	SD	6.36	3.54			5.51	2.65
	(SE)	( 4.50)	( 2.50)			( 3.18)	( 1.53)
	Min,	7,	-3,	6,	1,	6,	-3,
	Max	16	2	6	1	16	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	13.0	1.0	8.0	-1.5	10.5	-0.3
	Median	13.0	1.0	8.0	-1.5	9.5	-0.5
	SD	7.07	2.83	4.24	2.12	5.57	2.50
	(SE)	( 5.00)	( 2.00)	( 3.00)	( 1.50)	( 2.78)	( 1.25)
	Min,	8,	-1,	5,	-3,	5,	-3,
	Max	18	3	11	0	18	3
Week 44	n	2	2	2	2	4	4
	Mean	12.5	0.5	9.5	0.0	11.0	0.3
	Median	12.5	0.5	9.5	0.0	10.0	0.0
	SD	7.78	2.12	4.95	1.41	5.60	1.50
	(SE)	( 5.50)	( 1.50)	( 3.50)	( 1.00)	( 2.80)	( 0.75)
	Min,	7,	-1,	6,	-1,	6,	-1,
	Max	18	2	13	1	18	2
Week 48	n	2	2	2	2	4	4
	Mean	15.5	3.5	9.5	0.0	12.5	1.8
	Median	15.5	3.5	9.5	0.0	11.0	2.0
	SD	9.19	0.71	4.95	1.41	6.95	2.22
	(SE)	( 6.50)	( 0.50)	( 3.50)	( 1.00)	( 3.48)	( 1.11)
	Min,	9,	3,	6,	-1,	6,	-1,
	Max	22	4	13	1	22	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	13.0	1.0	8.5	-1.0	10.8	0.0
	Median	13.0	1.0	8.5	-1.0	10.0	-0.5
	SD	7.07	2.83	4.95	1.41	5.62	2.16
	(SE)	( 5.00)	( 2.00)	( 3.50)	( 1.00)	( 2.81)	( 1.08)
	Min, Max	8, 18	-1, 3	5, 12	-2, 0	5, 18	-2, 3
Week 56	n	2	2	2	2	4	4
	Mean	12.5	0.5	8.5	-1.0	10.5	-0.3
	Median	12.5	0.5	8.5	-1.0	9.5	-0.5
	SD	7.78	2.12	4.95	1.41	5.80	1.71
	(SE)	( 5.50)	( 1.50)	( 3.50)	( 1.00)	( 2.90)	( 0.85)
	Min, Max	7, 18	-1, 2	5, 12	-2, 0	5, 18	-2, 2
Week 60	n	2	2	2	2	4	4
	Mean	11.0	-1.0	9.0	-0.5	10.0	-0.8
	Median	11.0	-1.0	9.0	-0.5	9.5	-0.5
	SD	7.07	2.83	5.66	0.71	5.35	1.71
	(SE)	( 5.00)	( 2.00)	( 4.00)	( 0.50)	( 2.68)	( 0.85)
	Min, Max	6, 16	-3, 1	5, 13	-1, 0	5, 16	-3, 1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	13.0	1.0	8.5	-1.0	10.8	0.0
	Median	13.0	1.0	8.5	-1.0	9.5	0.0
	SD	7.07	2.83	3.54	2.83	5.25	2.58
	(SE)	( 5.00)	( 2.00)	( 2.50)	( 2.00)	( 2.63)	( 1.29)
	Min,	8,	-1,	6,	-3,	6,	-3,
	Max	18	3	11	1	18	3
Week 68	n	2	2	2	2	4	4
	Mean	13.0	1.0	7.0	-2.5	10.0	-0.8
	Median	13.0	1.0	7.0	-2.5	9.0	-1.0
	SD	7.07	2.83	4.24	2.12	5.89	2.87
	(SE)	( 5.00)	( 2.00)	( 3.00)	( 1.50)	( 2.94)	( 1.44)
	Min,	8,	-1,	4,	-4,	4,	-4,
	Max	18	3	10	-1	18	3
Week 72	n	2	2	0	0	2	2
	Mean	14.0	2.0			14.0	2.0
	Median	14.0	2.0			14.0	2.0
	SD	8.49	1.41			8.49	1.41
	(SE)	( 6.00)	( 1.00)			( 6.00)	( 1.00)
	Min,	8,	1,			8,	1,
	Max	20	3			20	3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			13.0	-1.0	13.0	-1.0
	Median			13.0	-1.0	13.0	-1.0
	SD						
	(SE)						
	Min, Max			13, 13	-1, -1	13, 13	-1, -1
Week 76	n	2	2	2	2	4	4
	Mean	12.0	0.0	9.5	0.0	10.8	0.0
	Median	12.0	0.0	9.5	0.0	10.0	0.0
	SD	8.49	1.41	6.36	0.00	6.29	0.82
	(SE)	( 6.00)	( 1.00)	( 4.50)	( 0.00)	( 3.15)	( 0.41)
	Min, Max	6, 18	-1, 1	5, 14	0, 0	5, 18	-1, 1
Week 80	n	2	2	2	2	4	4
	Mean	13.0	1.0	9.5	0.0	11.3	0.5
	Median	13.0	1.0	9.5	0.0	10.5	0.0
	SD	5.66	4.24	3.54	2.83	4.35	3.00
	(SE)	( 4.00)	( 3.00)	( 2.50)	( 2.00)	( 2.17)	( 1.50)
	Min, Max	9, 17	-2, 4	7, 12	-2, 2	7, 17	-2, 4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	12.0	0.0	8.5	-1.0	10.3	-0.5
	Median	12.0	0.0	8.5	-1.0	9.5	-1.0
	SD	5.66	4.24	3.54	2.83	4.35	3.00
	(SE)	( 4.00)	( 3.00)	( 2.50)	( 2.00)	( 2.17)	( 1.50)
	Min, Max	8, 16	-3, 3	6, 11	-3, 1	6, 16	-3, 3
Week 88	n	2	2	2	2	4	4
	Mean	15.0	3.0	11.0	1.5	13.0	2.3
	Median	15.0	3.0	11.0	1.5	12.0	2.0
	SD	7.07	2.83	4.24	2.12	5.29	2.22
	(SE)	( 5.00)	( 2.00)	( 3.00)	( 1.50)	( 2.65)	( 1.11)
	Min, Max	10, 20	1, 5	8, 14	0, 3	8, 20	0, 5
Week 92	n	2	2	2	2	4	4
	Mean	13.0	1.0	10.0	0.5	11.5	0.8
	Median	13.0	1.0	10.0	0.5	10.0	1.0
	SD	9.90	0.00	5.66	0.71	6.81	0.50
	(SE)	( 7.00)	( 0.00)	( 4.00)	( 0.50)	( 3.40)	( 0.25)
	Min, Max	6, 20	1, 1	6, 14	0, 1	6, 20	0, 1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	13.0	1.0	10.0	0.5	11.5	0.8
	Median	13.0	1.0	10.0	0.5	10.0	1.0
	SD	7.07	2.83	2.83	3.54	4.73	2.63
	(SE)	( 5.00)	( 2.00)	( 2.00)	( 2.50)	( 2.36)	( 1.31)
	Min, Max	8, 18	-1, 3	8, 12	-2, 3	8, 18	-2, 3
Week 100	n	2	2	2	2	4	4
	Mean	14.0	2.0	10.0	0.5	12.0	1.3
	Median	14.0	2.0	10.0	0.5	12.0	0.5
	SD	4.24	5.66	4.24	2.12	4.16	3.59
	(SE)	( 3.00)	( 4.00)	( 3.00)	( 1.50)	( 2.08)	( 1.80)
	Min, Max	11, 17	-2, 6	7, 13	-1, 2	7, 17	-2, 6
Week 104	n	2	2	2	2	4	4
	Mean	13.0	1.0	8.5	-1.0	10.8	0.0
	Median	13.0	1.0	8.5	-1.0	9.0	0.5
	SD	9.90	0.00	4.95	1.41	6.90	1.41
	(SE)	( 7.00)	( 0.00)	( 3.50)	( 1.00)	( 3.45)	( 0.71)
	Min, Max	6, 20	1, 1	5, 12	-2, 0	5, 20	-2, 1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	2	2	2	4	4	
	Mean	15.5	3.5	10.0	0.5	12.8	2.0
	Median	15.5	3.5	10.0	0.5	11.5	2.0
	SD	9.19	0.71	5.66	0.71	6.99	1.83
	(SE)	( 6.50)	( 0.50)	( 4.00)	( 0.50)	( 3.50)	( 0.91)
	Min,	9,	3,	6,	0,	6,	0,
	Max	22	4	14	1	22	4
Week 112	n	2	2	2	4	4	
	Mean	12.0	0.0	10.5	1.0	11.3	0.5
	Median	12.0	0.0	10.5	1.0	10.5	1.0
	SD	7.07	2.83	4.95	1.41	5.06	1.91
	(SE)	( 5.00)	( 2.00)	( 3.50)	( 1.00)	( 2.53)	( 0.96)
	Min,	7,	-2,	7,	0,	7,	-2,
	Max	17	2	14	2	17	2
Week 116	n	2	2	2	4	4	
	Mean	13.5	1.5	10.0	0.5	11.8	1.0
	Median	13.5	1.5	10.0	0.5	10.0	1.5
	SD	9.19	0.71	4.24	2.12	6.18	1.41
	(SE)	( 6.50)	( 0.50)	( 3.00)	( 1.50)	( 3.09)	( 0.71)
	Min,	7,	1,	7,	-1,	7,	-1,
	Max	20	2	13	2	20	2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	11.5	-0.5	8.0	-1.5	9.8	-1.0
	Median	11.5	-0.5	8.0	-1.5	8.5	-1.0
	SD	6.36	3.54	2.83	3.54	4.50	2.94
	(SE)	( 4.50)	( 2.50)	( 2.00)	( 2.50)	( 2.25)	( 1.47)
	Min, Max	7, 16	-3, 2	6, 10	-4, 1	6, 16	-4, 2
Week 124	n	2	2	2	2	4	4
	Mean	13.0	1.0	9.0	-0.5	11.0	0.3
	Median	13.0	1.0	9.0	-0.5	10.5	-0.5
	SD	5.66	4.24	4.24	2.12	4.69	2.87
	(SE)	( 4.00)	( 3.00)	( 3.00)	( 1.50)	( 2.35)	( 1.44)
	Min, Max	9, 17	-2, 4	6, 12	-2, 1	6, 17	-2, 4
Week 128	n	2	2	2	2	4	4
	Mean	12.5	0.5	10.0	0.5	11.3	0.5
	Median	12.5	0.5	10.0	0.5	11.0	0.5
	SD	6.36	3.54	5.66	0.71	5.12	2.08
	(SE)	( 4.50)	( 2.50)	( 4.00)	( 0.50)	( 2.56)	( 1.04)
	Min, Max	8, 17	-2, 3	6, 14	0, 1	6, 17	-2, 3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		Change from Baseline
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 132	n	2	2	2	2	4	4
	Mean	14.0	2.0	7.5	-2.0	10.8	0.0
	Median	14.0	2.0	7.5	-2.0	10.5	-1.0
	SD	5.66	4.24	4.95	1.41	5.74	3.46
	(SE)	( 4.00)	( 3.00)	( 3.50)	( 1.00)	( 2.87)	( 1.73)
	Min,	10,	-1,	4,	-3,	4,	-3,
	Max	18	5	11	-1	18	5
Week 136	n	2	2	2	2	4	4
	Mean	12.0	0.0	9.0	-0.5	10.5	-0.3
	Median	12.0	0.0	9.0	-0.5	10.0	-0.5
	SD	5.66	4.24	4.24	2.12	4.43	2.75
	(SE)	( 4.00)	( 3.00)	( 3.00)	( 1.50)	( 2.22)	( 1.38)
	Min,	8,	-3,	6,	-2,	6,	-3,
	Max	16	3	12	1	16	3
Week 140	n	2	2	2	2	4	4
	Mean	12.5	0.5	9.5	0.0	11.0	0.3
	Median	12.5	0.5	9.5	0.0	10.0	0.0
	SD	4.95	4.95	2.12	4.24	3.56	3.77
	(SE)	( 3.50)	( 3.50)	( 1.50)	( 3.00)	( 1.78)	( 1.89)
	Min,	9,	-3,	8,	-3,	8,	-3,
	Max	16	4	11	3	16	4

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	12.0	0.0	9.5	0.0	10.8	0.0
	Median	12.0	0.0	9.5	0.0	11.0	0.0
	SD	4.24	5.66	4.95	1.41	4.03	3.37
	(SE)	( 3.00)	( 4.00)	( 3.50)	( 1.00)	( 2.02)	( 1.68)
	Min,	9,	-4,	6,	-1,	6,	-4,
	Max	15	4	13	1	15	4
Week 148	n	2	2	2	2	4	4
	Mean	12.5	0.5	9.5	0.0	11.0	0.3
	Median	12.5	0.5	9.5	0.0	11.5	0.0
	SD	3.54	6.36	4.95	1.41	3.92	3.77
	(SE)	( 2.50)	( 4.50)	( 3.50)	( 1.00)	( 1.96)	( 1.89)
	Min,	10,	-4,	6,	-1,	6,	-4,
	Max	15	5	13	1	15	5
Week 152	n	2	2	2	2	4	4
	Mean	12.0	0.0	10.0	0.5	11.0	0.3
	Median	12.0	0.0	10.0	0.5	12.0	0.5
	SD	2.83	7.07	7.07	0.71	4.55	4.11
	(SE)	( 2.00)	( 5.00)	( 5.00)	( 0.50)	( 2.27)	( 2.06)
	Min,	10,	-5,	5,	0,	5,	-5,
	Max	14	5	15	1	15	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	12.5	0.5	10.0	0.5	11.3	0.5
	Median	12.5	0.5	10.0	0.5	11.5	0.5
	SD	4.95	4.95	5.66	0.71	4.57	2.89
	(SE)	( 3.50)	( 3.50)	( 4.00)	( 0.50)	( 2.29)	( 1.44)
	Min, Max	9, 16	-3, 4	6, 14	0, 1	6, 16	-3, 4
Week 160	n	2	2	2	2	4	4
	Mean	13.0	1.0	9.0	-0.5	11.0	0.3
	Median	13.0	1.0	9.0	-0.5	10.5	-0.5
	SD	7.07	2.83	5.66	0.71	5.72	1.89
	(SE)	( 5.00)	( 2.00)	( 4.00)	( 0.50)	( 2.86)	( 0.95)
	Min, Max	8, 18	-1, 3	5, 13	-1, 0	5, 18	-1, 3
Week 164	n	2	2	2	2	4	4
	Mean	14.0	2.0	11.0	1.5	12.5	1.8
	Median	14.0	2.0	11.0	1.5	12.5	1.5
	SD	5.66	4.24	5.66	0.71	4.93	2.50
	(SE)	( 4.00)	( 3.00)	( 4.00)	( 0.50)	( 2.47)	( 1.25)
	Min, Max	10, 18	-1, 5	7, 15	1, 2	7, 18	-1, 5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	14.0	2.0	11.0	1.5	12.5	1.8
	Median	14.0	2.0	11.0	1.5	13.0	1.5
	SD	5.66	4.24	7.07	0.71	5.51	2.50
	(SE)	( 4.00)	( 3.00)	( 5.00)	( 0.50)	( 2.75)	( 1.25)
	Min,	10,	-1,	6,	1,	6,	-1,
	Max	18	5	16	2	18	5
Week 172	n	2	2	2	2	4	4
	Mean	14.0	2.0	10.5	1.0	12.3	1.5
	Median	14.0	2.0	10.5	1.0	13.0	1.0
	SD	4.24	5.66	6.36	0.00	4.86	3.32
	(SE)	( 3.00)	( 4.00)	( 4.50)	( 0.00)	( 2.43)	( 1.66)
	Min,	11,	-2,	6,	1,	6,	-2,
	Max	17	6	15	1	17	6
Week 176	n	2	2	2	2	4	4
	Mean	15.0	3.0	11.5	2.0	13.3	2.5
	Median	15.0	3.0	11.5	2.0	13.0	2.0
	SD	7.07	2.83	6.36	0.00	5.85	1.73
	(SE)	( 5.00)	( 2.00)	( 4.50)	( 0.00)	( 2.93)	( 0.87)
	Min,	10,	1,	7,	2,	7,	1,
	Max	20	5	16	2	20	5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	14.0	2.0	13.0	3.5	13.5	2.8
	Median	14.0	2.0	13.0	3.5	14.0	3.5
	SD	2.83	7.07	7.07	0.71	4.43	4.19
	(SE)	( 2.00)	( 5.00)	( 5.00)	( 0.50)	( 2.22)	( 2.10)
	Min, Max	12, 16	-3, 7	8, 18	3, 4	8, 18	-3, 7
Week 184	n	2	2	2	2	4	4
	Mean	15.5	3.5	13.0	3.5	14.3	3.5
	Median	15.5	3.5	13.0	3.5	15.5	3.5
	SD	3.54	6.36	9.90	3.54	6.24	4.20
	(SE)	( 2.50)	( 4.50)	( 7.00)	( 2.50)	( 3.12)	( 2.10)
	Min, Max	13, 18	-1, 8	6, 20	1, 6	6, 20	-1, 8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Lactate Dehydrogenase (U/L)						
Week 1	n	2	2		4	
	Mean	2168.5	2251.5		2210.0	
	Median	2168.5	2251.5		2168.5	
	SD	150.61	1225.42		714.43	
	(SE)	( 106.50)	( 866.50)		( 357.21)	
	Min,	2062,	1385,		1385,	
	Max	2275	3118		3118	
Week 2	n	1	2		3	
	Mean	2601.0	1403.5		1802.7	
	Median	2601.0	1403.5		1846.0	
	SD		625.79		820.86	
	(SE)		( 442.50)		( 473.92)	
	Min,	2601,	961,		961,	
	Max	2601	1846		2601	
Week 4	n	2	2		4	
	Mean	2207.5	2748.0		2477.8	
	Median	2207.5	2748.0		2207.5	
	SD	573.46	1910.60		1193.23	
	(SE)	( 405.50)	( 1351.00)		( 596.62)	
	Min,	1802,	1397,		1397,	
	Max	2613	4099		4099	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		1		3	
	Mean	1860.5		1035.0		1585.3	
	Median	1860.5		1035.0		1555.0	
	SD	432.04				566.11	
	(SE)	( 305.50)				( 326.84)	
	Min, Max	1555, 2166		1035, 1035		1035, 2166	
Week 8	n	2		2		4	
	Mean	3462.5		3317.0		3389.8	
	Median	3462.5		3317.0		3462.5	
	SD	1448.86		2527.20		1683.95	
	(SE)	( 1024.50)		( 1787.00)		( 841.98)	
	Min, Max	2438, 4487		1530, 5104		1530, 5104	
Week 10	n	2		2		4	
	Mean	2321.5		1650.5		1986.0	
	Median	2321.5		1650.5		2101.0	
	SD	320.32		645.59		568.52	
	(SE)	( 226.50)		( 456.50)		( 284.26)	
	Min, Max	2095, 2548		1194, 2107		1194, 2548	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	2562.5		2447.5		2505.0	
	Median	2562.5		2447.5		2562.5	
	SD	102.53		1553.51		901.32	
	(SE)	( 72.50)		( 1098.50)		( 450.66)	
	Min, Max	2490, 2635		1349, 3546		1349, 3546	
Week 15	n	2		2		4	
	Mean	1804.5		1760.5		1782.5	
	Median	1804.5		1760.5		1804.5	
	SD	111.02		1092.48		634.50	
	(SE)	( 78.50)		( 772.50)		( 317.25)	
	Min, Max	1726, 1883		988, 2533		988, 2533	
Week 18	n	2		2		4	
	Mean	1622.0		2633.0		2127.5	
	Median	1622.0		2633.0		1733.5	
	SD	630.74		1745.14		1220.04	
	(SE)	( 446.00)		( 1234.00)		( 610.02)	
	Min, Max	1176, 2068		1399, 3867		1176, 3867	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	1632.5		1922.0		1777.3	
	Median	1632.5		1922.0		1632.5	
	SD	85.56		1096.02		656.35	
	(SE)	( 60.50)		( 775.00)		( 328.17)	
	Min,	1572,		1147,		1147,	
	Max	1693		2697		2697	
Week 24	n	2		2		4	
	Mean	2416.0		2111.0		2263.5	
	Median	2416.0		2111.0		2416.0	
	SD	35.36		1013.99		611.68	
	(SE)	( 25.00)		( 717.00)		( 305.84)	
	Min,	2391,		1394,		1394,	
	Max	2441		2828		2828	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	1590.0		1716.0		1653.0	
	Median	1590.0		1716.0		1590.0	
	SD	530.33		1055.00		685.60	
	(SE)	( 375.00)		( 746.00)		( 342.80)	
	Min,	1215,		970,		970,	
	Max	1965		2462		2462	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	1512.5	-77.5	1769.5	53.5	1641.0	-12.0
	Median	1512.5	-77.5	1769.5	53.5	1512.5	-10.5
	SD	389.62	140.71	1191.47	136.47	738.80	136.12
	(SE)	( 275.50)	( 99.50)	( 842.50)	( 96.50)	( 369.40)	( 68.06)
	Min, Max	1237, 1788	-177, 22	927, 2612	-43, 150	927, 2612	-177, 150
Week 32	n	2	2	2	2	4	4
	Mean	841.5	-748.5	733.0	-983.0	787.3	-865.8
	Median	841.5	-748.5	733.0	-983.0	841.5	-799.0
	SD	84.15	446.18	420.02	634.98	255.13	468.07
	(SE)	( 59.50)	( 315.50)	( 297.00)	( 449.00)	( 127.56)	( 234.04)
	Min, Max	782, 901	-1064, -433	436, 1030	-1432, -534	436, 1030	-1432, -433
Week 36	n	2	2	1	1	3	3
	Mean	725.5	-864.5	1080.0	-1382.0	843.7	-1037.0
	Median	725.5	-864.5	1080.0	-1382.0	734.0	-1231.0
	SD	12.02	518.31			204.85	472.85
	(SE)	( 8.50)	( 366.50)			( 118.27)	( 273.00)
	Min, Max	717, 734	-1231, -498	1080, 1080	-1382, -1382	717, 1080	-1382, -498

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	709.5	-880.5	879.0	-837.0	794.3	-858.8
	Median	709.5	-880.5	879.0	-837.0	836.5	-880.5
	SD	238.29	292.04	118.79	936.21	182.23	566.76
	(SE)	( 168.50)	( 206.50)	( 84.00)	( 662.00)	( 91.12)	( 283.38)
	Min, Max	541, 878	-1087, -674	795, 963	-1499, -175	541, 963	-1499, -175
Week 44	n	2	2	2	2	4	4
	Mean	910.0	-680.0	665.0	-1051.0	787.5	-865.5
	Median	910.0	-680.0	665.0	-1051.0	750.0	-717.5
	SD	108.89	639.22	2.83	1057.83	154.80	745.04
	(SE)	( 77.00)	( 452.00)	( 2.00)	( 748.00)	( 77.40)	( 372.52)
	Min, Max	833, 987	-1132, -228	663, 667	-1799, -303	663, 987	-1799, -228
Week 48	n	2	2	2	2	4	4
	Mean	754.0	-836.0	790.5	-925.5	772.3	-880.8
	Median	754.0	-836.0	790.5	-925.5	754.0	-836.0
	SD	5.66	524.67	400.93	654.07	232.46	486.86
	(SE)	( 4.00)	( 371.00)	( 283.50)	( 462.50)	( 116.23)	( 243.43)
	Min, Max	750, 758	-1207, -465	507, 1074	-1388, -463	507, 1074	-1388, -463

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	632.5	-957.5	638.5	-1077.5	635.5	-1017.5
	Median	632.5	-957.5	638.5	-1077.5	632.5	-957.5
	SD	127.99	402.34	163.34	891.66	119.86	569.02
	(SE)	( 90.50)	( 284.50)	( 115.50)	( 630.50)	( 59.93)	( 284.51)
	Min, Max	542, 723	-1242, -673	523, 754	-1708, -447	523, 754	-1708, -447
Week 56	n	2	2	2	2	4	4
	Mean	654.0	-936.0	735.0	-981.0	694.5	-958.5
	Median	654.0	-936.0	735.0	-981.0	671.0	-936.0
	SD	115.97	414.36	182.43	872.57	133.28	558.30
	(SE)	( 82.00)	( 293.00)	( 129.00)	( 617.00)	( 66.64)	( 279.15)
	Min, Max	572, 736	-1229, -643	606, 864	-1598, -364	572, 864	-1598, -364
Week 60	n	2	2	2	2	4	4
	Mean	772.0	-818.0	721.5	-994.5	746.8	-906.3
	Median	772.0	-818.0	721.5	-994.5	772.0	-818.0
	SD	176.78	353.55	293.45	761.55	199.93	495.35
	(SE)	( 125.00)	( 250.00)	( 207.50)	( 538.50)	( 99.96)	( 247.68)
	Min, Max	647, 897	-1068, -568	514, 929	-1533, -456	514, 929	-1533, -456

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	667.0	-923.0	643.0	-1073.0	655.0	-998.0
	Median	667.0	-923.0	643.0	-1073.0	667.0	-923.0
	SD	70.71	459.62	328.10	726.91	194.27	504.03
	(SE)	( 50.00)	( 325.00)	( 232.00)	( 514.00)	( 97.14)	( 252.02)
	Min, Max	617, 717	-1248, -598	411, 875	-1587, -559	411, 875	-1587, -559
Week 68	n	2	2	2	2	4	4
	Mean	821.5	-768.5	507.5	-1208.5	664.5	-988.5
	Median	821.5	-768.5	507.5	-1208.5	610.5	-768.5
	SD	208.60	321.73	55.86	999.14	220.02	657.11
	(SE)	( 147.50)	( 227.50)	( 39.50)	( 706.50)	( 110.01)	( 328.56)
	Min, Max	674, 969	-996, -541	468, 547	-1915, -502	468, 969	-1915, -502
Week 72	n	2	2	0	0	2	2
	Mean	627.5	-962.5			627.5	-962.5
	Median	627.5	-962.5			627.5	-962.5
	SD	61.52	468.81			61.52	468.81
	(SE)	( 43.50)	( 331.50)			( 43.50)	( 331.50)
	Min, Max	584, 671	-1294, -631			584, 671	-1294, -631

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			505.0	-465.0	505.0	-465.0
	Median			505.0	-465.0	505.0	-465.0
	SD						
	(SE)						
	Min, Max			505, 505	-465, -465	505, 505	-465, -465
Week 76	n	2	2	2	2	4	4
	Mean	782.5	-807.5	616.0	-1100.0	699.3	-953.8
	Median	782.5	-807.5	616.0	-1100.0	616.0	-807.5
	SD	415.07	115.26	21.21	1033.79	258.49	623.85
	(SE)	( 293.50)	( 81.50)	( 15.00)	( 731.00)	( 129.25)	( 311.92)
	Min, Max	489, 1076	-889, -726	601, 631	-1831, -369	489, 1076	-1831, -369
Week 80	n	2	2	2	2	4	4
	Mean	704.0	-886.0	642.0	-1074.0	673.0	-980.0
	Median	704.0	-886.0	642.0	-1074.0	704.0	-886.0
	SD	260.22	270.11	364.87	690.14	261.20	441.43
	(SE)	( 184.00)	( 191.00)	( 258.00)	( 488.00)	( 130.60)	( 220.72)
	Min, Max	520, 888	-1077, -695	384, 900	-1562, -586	384, 900	-1562, -586

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	608.5	-981.5	641.5	-1074.5	625.0	-1028.0
	Median	608.5	-981.5	641.5	-1074.5	608.5	-981.5
	SD	140.71	389.62	260.92	794.08	172.21	513.49
	(SE)	( 99.50)	( 275.50)	( 184.50)	( 561.50)	( 86.11)	( 256.74)
	Min, Max	509, 708	-1257, -706	457, 826	-1636, -513	457, 826	-1636, -513
Week 88	n	2	2	2	2	4	4
	Mean	883.5	-706.5	530.5	-1185.5	707.0	-946.0
	Median	883.5	-706.5	530.5	-1185.5	761.0	-861.0
	SD	65.76	596.09	218.50	836.51	242.68	654.35
	(SE)	( 46.50)	( 421.50)	( 154.50)	( 591.50)	( 121.34)	( 327.17)
	Min, Max	837, 930	-1128, -285	376, 685	-1777, -594	376, 930	-1777, -285
Week 92	n	2	2	2	2	4	4
	Mean	768.5	-821.5	603.5	-1112.5	686.0	-967.0
	Median	768.5	-821.5	603.5	-1112.5	727.0	-920.0
	SD	137.89	668.22	253.85	801.15	192.07	625.31
	(SE)	( 97.50)	( 472.50)	( 179.50)	( 566.50)	( 96.04)	( 312.66)
	Min, Max	671, 866	-1294, -349	424, 783	-1679, -546	424, 866	-1679, -349

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	520.0	-1070.0	507.0	-1209.0	513.5	-1139.5
	Median	520.0	-1070.0	507.0	-1209.0	520.0	-1070.0
	SD	165.46	364.87	212.13	842.87	155.51	536.31
	(SE)	( 117.00)	( 258.00)	( 150.00)	( 596.00)	( 77.75)	( 268.15)
	Min, Max	403, 637	-1328, -812	357, 657	-1805, -613	357, 657	-1805, -613
Week 100	n	2	2	2	2	4	4
	Mean	573.5	-1016.5	558.5	-1157.5	566.0	-1087.0
	Median	573.5	-1016.5	558.5	-1157.5	573.5	-1016.5
	SD	70.00	460.33	251.02	803.98	150.71	541.04
	(SE)	( 49.50)	( 325.50)	( 177.50)	( 568.50)	( 75.35)	( 270.52)
	Min, Max	524, 623	-1342, -691	381, 736	-1726, -589	381, 736	-1726, -589
Week 104	n	2	2	2	2	4	4
	Mean	573.5	-1016.5	613.0	-1103.0	593.3	-1059.8
	Median	573.5	-1016.5	613.0	-1103.0	577.0	-1016.5
	SD	3.54	526.79	49.50	1005.51	36.62	657.28
	(SE)	( 2.50)	( 372.50)	( 35.00)	( 711.00)	( 18.31)	( 328.64)
	Min, Max	571, 576	-1389, -644	578, 648	-1814, -392	571, 648	-1814, -392

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201. & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	641.0	-949.0	579.0	-1137.0	610.0	-1043.0
	Median	641.0	-949.0	579.0	-1137.0	637.0	-949.0
	SD	115.97	414.36	192.33	862.67	134.52	563.10
	(SE)	( 82.00)	( 293.00)	( 136.00)	( 610.00)	( 67.26)	( 281.55)
	Min, Max	559, 723	-1242, -656	443, 715	-1747, -527	443, 723	-1747, -527
Week 112	n	2	2	2	2	4	4
	Mean	631.0	-959.0	641.5	-1074.5	636.3	-1016.8
	Median	631.0	-959.0	641.5	-1074.5	631.0	-959.0
	SD	151.32	379.01	309.01	746.00	198.74	487.68
	(SE)	( 107.00)	( 268.00)	( 218.50)	( 527.50)	( 99.37)	( 243.84)
	Min, Max	524, 738	-1227, -691	423, 860	-1602, -547	423, 860	-1602, -547
Week 116	n	2	2	2	2	4	4
	Mean	558.5	-1031.5	469.5	-1246.5	514.0	-1139.0
	Median	558.5	-1031.5	469.5	-1246.5	558.5	-1031.5
	SD	34.65	495.68	184.55	870.45	119.97	591.50
	(SE)	( 24.50)	( 350.50)	( 130.50)	( 615.50)	( 59.99)	( 295.75)
	Min, Max	534, 583	-1382, -681	339, 600	-1862, -631	339, 600	-1862, -631

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	736.5	-853.5	523.0	-1193.0	629.8	-1023.3
	Median	736.5	-853.5	523.0	-1193.0	644.0	-853.5
	SD	163.34	366.99	203.65	851.36	194.71	570.01
	(SE)	( 115.50)	( 259.50)	( 144.00)	( 602.00)	( 97.35)	( 285.01)
	Min, Max	621, 852	-1113, -594	379, 667	-1795, -591	379, 852	-1795, -591
Week 124	n	2	2	2	2	4	4
	Mean	615.5	-974.5	500.5	-1215.5	558.0	-1095.0
	Median	615.5	-974.5	500.5	-1215.5	570.5	-974.5
	SD	116.67	413.66	152.03	902.98	129.03	590.07
	(SE)	( 82.50)	( 292.50)	( 107.50)	( 638.50)	( 64.52)	( 295.04)
	Min, Max	533, 698	-1267, -682	393, 608	-1854, -577	393, 698	-1854, -577
Week 128	n	2	2	2	2	4	4
	Mean	433.0	-1157.0	538.0	-1178.0	485.5	-1167.5
	Median	433.0	-1157.0	538.0	-1178.0	445.5	-1157.0
	SD	130.11	400.22	243.24	811.76	170.41	522.68
	(SE)	( 92.00)	( 283.00)	( 172.00)	( 574.00)	( 85.21)	( 261.34)
	Min, Max	341, 525	-1440, -874	366, 710	-1752, -604	341, 710	-1752, -604

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	532.5	-1057.5	497.0	-1219.0	514.8	-1138.3
	Median	532.5	-1057.5	497.0	-1219.0	532.5	-1057.5
	SD	133.64	396.69	196.58	858.43	138.76	553.88
	(SE)	( 94.50)	( 280.50)	( 139.00)	( 607.00)	( 69.38)	( 276.94)
	Min, Max	438, 627	-1338, -777	358, 636	-1826, -612	358, 636	-1826, -612
Week 136	n	2	2	2	2	4	4
	Mean	616.5	-973.5	687.5	-1028.5	652.0	-1001.0
	Median	616.5	-973.5	687.5	-1028.5	616.5	-973.5
	SD	7.78	538.11	408.00	647.00	239.14	486.89
	(SE)	( 5.50)	( 380.50)	( 288.50)	( 457.50)	( 119.57)	( 243.45)
	Min, Max	611, 622	-1354, -593	399, 976	-1486, -571	399, 976	-1486, -571
Week 140	n	2	2	2	2	4	4
	Mean	626.0	-964.0	501.5	-1214.5	563.8	-1089.3
	Median	626.0	-964.0	501.5	-1214.5	553.5	-964.0
	SD	202.23	328.10	173.24	881.76	169.72	562.11
	(SE)	( 143.00)	( 232.00)	( 122.50)	( 623.50)	( 84.86)	( 281.05)
	Min, Max	483, 769	-1196, -732	379, 624	-1838, -591	379, 769	-1838, -591

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	514.5	-1075.5	579.0	-1137.0	546.8	-1106.3
	Median	514.5	-1075.5	579.0	-1137.0	552.0	-1075.5
	SD	130.81	399.52	115.97	939.04	107.58	590.25
	(SE)	( 92.50)	( 282.50)	( 82.00)	( 664.00)	( 53.79)	( 295.13)
	Min, Max	422, 607	-1358, -793	497, 661	-1801, -473	422, 661	-1801, -473
Week 148	n	2	2	2	2	4	4
	Mean	589.0	-1001.0	461.5	-1254.5	525.3	-1127.8
	Median	589.0	-1001.0	461.5	-1254.5	559.0	-1001.0
	SD	101.82	428.51	197.28	857.72	147.81	572.59
	(SE)	( 72.00)	( 303.00)	( 139.50)	( 606.50)	( 73.91)	( 286.29)
	Min, Max	517, 661	-1304, -698	322, 601	-1861, -648	322, 661	-1861, -648
Week 152	n	2	2	2	2	4	4
	Mean	654.0	-936.0	523.0	-1193.0	588.5	-1064.5
	Median	654.0	-936.0	523.0	-1193.0	545.0	-936.0
	SD	270.11	260.22	147.08	907.93	193.01	565.12
	(SE)	( 191.00)	( 184.00)	( 104.00)	( 642.00)	( 96.50)	( 282.56)
	Min, Max	463, 845	-1120, -752	419, 627	-1835, -551	419, 845	-1835, -551

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	538.5	-1051.5	489.5	-1226.5	514.0	-1139.0
	Median	538.5	-1051.5	489.5	-1226.5	529.5	-1051.5
	SD	177.48	352.85	221.32	833.68	166.22	532.34
	(SE)	( 125.50)	( 249.50)	( 156.50)	( 589.50)	( 83.11)	( 266.17)
	Min, Max	413, 664	-1301, -802	333, 646	-1816, -637	333, 664	-1816, -637
Week 160	n	2	2	2	2	4	4
	Mean	588.0	-1002.0	476.0	-1240.0	532.0	-1121.0
	Median	588.0	-1002.0	476.0	-1240.0	476.0	-1002.0
	SD	313.96	216.37	110.31	944.69	202.71	576.17
	(SE)	( 222.00)	( 153.00)	( 78.00)	( 668.00)	( 101.36)	( 288.08)
	Min, Max	366, 810	-1155, -849	398, 554	-1908, -572	366, 810	-1908, -572
Week 164	n	2	2	2	2	4	4
	Mean	583.5	-1006.5	455.5	-1260.5	519.5	-1133.5
	Median	583.5	-1006.5	455.5	-1260.5	464.0	-1006.5
	SD	251.02	279.31	94.05	960.96	171.50	596.09
	(SE)	( 177.50)	( 197.50)	( 66.50)	( 679.50)	( 85.75)	( 298.04)
	Min, Max	406, 761	-1204, -809	389, 522	-1940, -581	389, 761	-1940, -581

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	604.0	-986.0	497.5	-1218.5	550.8	-1102.3
	Median	604.0	-986.0	497.5	-1218.5	578.5	-986.0
	SD	173.95	356.38	252.44	802.57	187.37	524.46
	(SE)	( 123.00)	( 252.00)	( 178.50)	( 567.50)	( 93.69)	( 262.23)
	Min,	481,	-1238,	319,	-1786,	319,	-1786,
	Max	727	-734	676	-651	727	-651
Week 172	n	2	2	2	2	4	4
	Mean	603.5	-986.5	446.0	-1270.0	524.8	-1128.3
	Median	603.5	-986.5	446.0	-1270.0	476.5	-986.5
	SD	275.06	255.27	138.59	916.41	199.73	573.10
	(SE)	( 194.50)	( 180.50)	( 98.00)	( 648.00)	( 99.86)	( 286.55)
	Min,	409,	-1167,	348,	-1918,	348,	-1918,
	Max	798	-806	544	-622	798	-622
Week 176	n	2	2	2	2	4	4
	Mean	560.5	-1029.5	467.0	-1249.0	513.8	-1139.3
	Median	560.5	-1029.5	467.0	-1249.0	524.0	-1029.5
	SD	248.19	282.14	277.19	777.82	221.49	494.23
	(SE)	( 175.50)	( 199.50)	( 196.00)	( 550.00)	( 110.75)	( 247.11)
	Min,	385,	-1229,	271,	-1799,	271,	-1799,
	Max	736	-830	663	-699	736	-699

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	680.0	-910.0	369.5	-1346.5	524.8	-1128.3
	Median	680.0	-910.0	369.5	-1346.5	471.5	-910.0
	SD	267.29	263.04	116.67	938.33	245.94	616.49
	(SE)	( 189.00)	( 186.00)	( 82.50)	( 663.50)	( 122.97)	( 308.25)
	Min,	491,	-1096,	287,	-2010,	287,	-2010,
	Max	869	-724	452	-683	869	-683
Week 184	n	2	2	2	2	4	4
	Mean	542.0	-1048.0	329.5	-1386.5	435.8	-1217.3
	Median	542.0	-1048.0	329.5	-1386.5	378.0	-1048.0
	SD	263.04	267.29	99.70	955.30	203.54	605.15
	(SE)	( 186.00)	( 189.00)	( 70.50)	( 675.50)	( 101.77)	( 302.58)
	Min,	356,	-1237,	259,	-2062,	259,	-2062,
	Max	728	-859	400	-711	728	-711

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
C Reactive Protein (mg/L)						
Week 1	n	2	2		4	
	Mean	5.00	5.00		5.00	
	Median	5.00	5.00		5.00	
	SD	0.000	0.000		0.000	
	(SE)	( 0.000)	( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0	5.0, 5.0		5.0, 5.0	
Week 2	n	2	2		4	
	Mean	5.00	5.00		5.00	
	Median	5.00	5.00		5.00	
	SD	0.000	0.000		0.000	
	(SE)	( 0.000)	( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0	5.0, 5.0		5.0, 5.0	
Week 4	n	2	2		4	
	Mean	5.00	5.00		5.00	
	Median	5.00	5.00		5.00	
	SD	0.000	0.000		0.000	
	(SE)	( 0.000)	( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0	5.0, 5.0		5.0, 5.0	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2	2		4	
	Mean	5.00	5.00		5.00	
	Median	5.00	5.00		5.00	
	SD	0.000	0.000		0.000	
	(SE)	( 0.000)	( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0	5.0, 5.0		5.0, 5.0	
Week 8	n	2	2		4	
	Mean	5.00	5.00		5.00	
	Median	5.00	5.00		5.00	
	SD	0.000	0.000		0.000	
	(SE)	( 0.000)	( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0	5.0, 5.0		5.0, 5.0	
Week 10	n	2	2		4	
	Mean	5.00	5.00		5.00	
	Median	5.00	5.00		5.00	
	SD	0.000	0.000		0.000	
	(SE)	( 0.000)	( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0	5.0, 5.0		5.0, 5.0	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4
	Mean	5.00		5.00		5.00
	Median	5.00		5.00		5.00
	SD	0.000		0.000		0.000
	(SE)	( 0.000)		( 0.000)		( 0.000)
	Min,	5.0,		5.0,		5.0,
	Max	5.0		5.0		5.0
Week 15	n	2		2		4
	Mean	5.00		5.00		5.00
	Median	5.00		5.00		5.00
	SD	0.000		0.000		0.000
	(SE)	( 0.000)		( 0.000)		( 0.000)
	Min,	5.0,		5.0,		5.0,
	Max	5.0		5.0		5.0
Week 18	n	2		2		4
	Mean	31.50		5.00		18.25
	Median	31.50		5.00		5.00
	SD	37.477		0.000		26.500
	(SE)	( 26.500)		( 0.000)		( 13.250)
	Min,	5.0,		5.0,		5.0,
	Max	58.0		5.0		58.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	5.00		5.00		5.00	
	Median	5.00		5.00		5.00	
	SD	0.000		0.000		0.000	
	(SE)	( 0.000)		( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0		5.0, 5.0		5.0, 5.0	
Week 24	n	2		2		4	
	Mean	5.00		5.00		5.00	
	Median	5.00		5.00		5.00	
	SD	0.000		0.000		0.000	
	(SE)	( 0.000)		( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0		5.0, 5.0		5.0, 5.0	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	5.00		5.00		5.00	
	Median	5.00		5.00		5.00	
	SD	0.000		0.000		0.000	
	(SE)	( 0.000)		( 0.000)		( 0.000)	
	Min, Max	5.0, 5.0		5.0, 5.0		5.0, 5.0	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	5.00	0.00	5.00	0.00	5.00	0.00
	Median	5.00	0.00	5.00	0.00	5.00	0.00
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min, Max	5.0, 5.0	0.0, 0.0	5.0, 5.0	0.0, 0.0	5.0, 5.0	0.0, 0.0
Week 32	n	2	2	2	2	4	4
	Mean	0.70	-4.30	0.70	-4.30	0.70	-4.30
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min, Max	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3
Week 36	n	2	2	1	1	3	3
	Mean	0.70	-4.30	0.70	-4.30	0.70	-4.30
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000			0.000	0.000
	(SE)	( 0.000)	( 0.000)			( 0.000)	( 0.000)
	Min, Max	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 40	n	2	2	2	2	4	4
	Mean	0.75	-4.25	0.70	-4.30	0.72	-4.28
	Median	0.75	-4.25	0.70	-4.30	0.70	-4.30
	SD	0.071	0.071	0.000	0.000	0.050	0.050
	(SE)	( 0.050)	( 0.050)	( 0.000)	( 0.000)	( 0.025)	( 0.025)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.8	-4.2	0.7	-4.3	0.8	-4.2
Week 44	n	2	2	2	2	4	4
	Mean	1.95	-3.05	0.70	-4.30	1.33	-3.68
	Median	1.95	-3.05	0.70	-4.30	1.25	-3.75
	SD	0.212	0.212	0.000	0.000	0.732	0.732
	(SE)	( 0.150)	( 0.150)	( 0.000)	( 0.000)	( 0.366)	( 0.366)
	Min,	1.8,	-3.2,	0.7,	-4.3,	0.7,	-4.3,
	Max	2.1	-2.9	0.7	-4.3	2.1	-2.9
Week 48	n	2	2	2	2	4	4
	Mean	0.70	-4.30	0.70	-4.30	0.70	-4.30
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.7	-4.3	0.7	-4.3	0.7	-4.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	0.90	-4.10	0.80	-4.20	0.85	-4.15
	Median	0.90	-4.10	0.80	-4.20	0.80	-4.20
	SD	0.283	0.283	0.141	0.141	0.191	0.191
	(SE)	( 0.200)	( 0.200)	( 0.100)	( 0.100)	( 0.096)	( 0.096)
	Min, Max	0.7, 1.1	-4.3, -3.9	0.7, 0.9	-4.3, -4.1	0.7, 1.1	-4.3, -3.9
Week 56	n	2	2	2	2	4	4
	Mean	6.20	1.20	0.70	-4.30	3.45	-1.55
	Median	6.20	1.20	0.70	-4.30	0.70	-4.30
	SD	7.778	7.778	0.000	0.000	5.500	5.500
	(SE)	( 5.500)	( 5.500)	( 0.000)	( 0.000)	( 2.750)	( 2.750)
	Min, Max	0.7, 11.7	-4.3, 6.7	0.7, 0.7	-4.3, -4.3	0.7, 11.7	-4.3, 6.7
Week 60	n	2	2	2	2	4	4
	Mean	0.90	-4.10	0.70	-4.30	0.80	-4.20
	Median	0.90	-4.10	0.70	-4.30	0.75	-4.25
	SD	0.141	0.141	0.000	0.000	0.141	0.141
	(SE)	( 0.100)	( 0.100)	( 0.000)	( 0.000)	( 0.071)	( 0.071)
	Min, Max	0.8, 1.0	-4.2, -4.0	0.7, 0.7	-4.3, -4.3	0.7, 1.0	-4.3, -4.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	4.30	-0.70	0.70	-4.30	2.50	-2.50
	Median	4.30	-0.70	0.70	-4.30	1.00	-4.00
	SD	4.243	4.243	0.000	0.000	3.212	3.212
	(SE)	( 3.000)	( 3.000)	( 0.000)	( 0.000)	( 1.606)	( 1.606)
	Min,	1.3,	-3.7,	0.7,	-4.3,	0.7,	-4.3,
	Max	7.3	2.3	0.7	-4.3	7.3	2.3
Week 68	n	2	2	2	2	4	4
	Mean	0.80	-4.20	0.70	-4.30	0.75	-4.25
	Median	0.80	-4.20	0.70	-4.30	0.70	-4.30
	SD	0.141	0.141	0.000	0.000	0.100	0.100
	(SE)	( 0.100)	( 0.100)	( 0.000)	( 0.000)	( 0.050)	( 0.050)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.9	-4.1	0.7	-4.3	0.9	-4.1
Week 72	n	2	2	0	0	2	2
	Mean	1.75	-3.25			1.75	-3.25
	Median	1.75	-3.25			1.75	-3.25
	SD	1.485	1.485			1.485	1.485
	(SE)	( 1.050)	( 1.050)			( 1.050)	( 1.050)
	Min,	0.7,	-4.3,			0.7,	-4.3,
	Max	2.8	-2.2			2.8	-2.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			0.70	-4.30	0.70	-4.30
	Median			0.70	-4.30	0.70	-4.30
	SD (SE)						
	Min,			0.7,	-4.3,	0.7,	-4.3,
	Max			0.7	-4.3	0.7	-4.3
Week 76	n	2	2	2	2	4	4
	Mean	1.15	-3.85	0.70	-4.30	0.93	-4.08
	Median	1.15	-3.85	0.70	-4.30	0.80	-4.20
	SD (SE)	0.354 ( 0.250)	0.354 ( 0.250)	0.000 ( 0.000)	0.000 ( 0.000)	0.330 ( 0.165)	0.330 ( 0.165)
	Min,	0.9,	-4.1,	0.7,	-4.3,	0.7,	-4.3,
	Max	1.4	-3.6	0.7	-4.3	1.4	-3.6
Week 80	n	2	2	2	2	4	4
	Mean	0.70	-4.30	0.70	-4.30	0.70	-4.30
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD (SE)	0.000 ( 0.000)	0.000 ( 0.000)	0.000 ( 0.000)	0.000 ( 0.000)	0.000 ( 0.000)	0.000 ( 0.000)
	Min,	0.7,	-4.3,	0.7,	-4.3,	0.7,	-4.3,
	Max	0.7	-4.3	0.7	-4.3	0.7	-4.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: F:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	0.70	-4.30	0.70	-4.30	0.70	-4.30
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min, Max	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3
Week 88	n	2	2	2	2	4	4
	Mean	2.30	-2.70	0.70	-4.30	1.50	-3.50
	Median	2.30	-2.70	0.70	-4.30	0.70	-4.30
	SD	2.263	2.263	0.000	0.000	1.600	1.600
	(SE)	( 1.600)	( 1.600)	( 0.000)	( 0.000)	( 0.800)	( 0.800)
	Min, Max	0.7, 3.9	-4.3, -1.1	0.7, 0.7	-4.3, -4.3	0.7, 3.9	-4.3, -1.1
Week 92	n	2	2	2	2	4	4
	Mean	0.95	-4.05	2.05	-2.95	1.50	-3.50
	Median	0.95	-4.05	2.05	-2.95	1.00	-4.00
	SD	0.354	0.354	1.768	1.768	1.219	1.219
	(SE)	( 0.250)	( 0.250)	( 1.250)	( 1.250)	( 0.610)	( 0.610)
	Min, Max	0.7, 1.2	-4.3, -3.8	0.8, 3.3	-4.2, -1.7	0.7, 3.3	-4.3, -1.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	1.55	-3.45	0.85	-4.15	1.20	-3.80
	Median	1.55	-3.45	0.85	-4.15	0.85	-4.15
	SD	1.202	1.202	0.212	0.212	0.812	0.812
	(SE)	( 0.850)	( 0.850)	( 0.150)	( 0.150)	( 0.406)	( 0.406)
	Min, Max	0.7, 2.4	-4.3, -2.6	0.7, 1.0	-4.3, -4.0	0.7, 2.4	-4.3, -2.6
Week 100	n	2	2	2	2	4	4
	Mean	2.45	-2.55	0.70	-4.30	1.58	-3.43
	Median	2.45	-2.55	0.70	-4.30	0.85	-4.15
	SD	2.051	2.051	0.000	0.000	1.556	1.556
	(SE)	( 1.450)	( 1.450)	( 0.000)	( 0.000)	( 0.778)	( 0.778)
	Min, Max	1.0, 3.9	-4.0, -1.1	0.7, 0.7	-4.3, -4.3	0.7, 3.9	-4.3, -1.1
Week 104	n	2	2	2	2	4	4
	Mean	1.35	-3.65	0.85	-4.15	1.10	-3.90
	Median	1.35	-3.65	0.85	-4.15	0.85	-4.15
	SD	0.919	0.919	0.212	0.212	0.616	0.616
	(SE)	( 0.650)	( 0.650)	( 0.150)	( 0.150)	( 0.308)	( 0.308)
	Min, Max	0.7, 2.0	-4.3, -3.0	0.7, 1.0	-4.3, -4.0	0.7, 2.0	-4.3, -3.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	2	2	2	2	4	4
	Mean	1.35	-3.65	0.75	-4.25	1.05	-3.95
	Median	1.35	-3.65	0.75	-4.25	0.75	-4.25
	SD	0.919	0.919	0.071	0.071	0.635	0.635
	(SE)	( 0.650)	( 0.650)	( 0.050)	( 0.050)	( 0.318)	( 0.318)
	Min, Max	0.7, 2.0	-4.3, -3.0	0.7, 0.8	-4.3, -4.2	0.7, 2.0	-4.3, -3.0
Week 112	n	2	2	2	2	4	4
	Mean	1.05	-3.95	0.70	-4.30	0.88	-4.13
	Median	1.05	-3.95	0.70	-4.30	0.70	-4.30
	SD	0.495	0.495	0.000	0.000	0.350	0.350
	(SE)	( 0.350)	( 0.350)	( 0.000)	( 0.000)	( 0.175)	( 0.175)
	Min, Max	0.7, 1.4	-4.3, -3.6	0.7, 0.7	-4.3, -4.3	0.7, 1.4	-4.3, -3.6
Week 116	n	2	2	2	2	4	4
	Mean	1.15	-3.85	0.75	-4.25	0.95	-4.05
	Median	1.15	-3.85	0.75	-4.25	0.85	-4.15
	SD	0.354	0.354	0.071	0.071	0.311	0.311
	(SE)	( 0.250)	( 0.250)	( 0.050)	( 0.050)	( 0.155)	( 0.155)
	Min, Max	0.9, 1.4	-4.1, -3.6	0.7, 0.8	-4.3, -4.2	0.7, 1.4	-4.3, -3.6

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	1.10	-3.90	0.70	-4.30	0.90	-4.10
	Median	1.10	-3.90	0.70	-4.30	0.75	-4.25
	SD	0.424	0.424	0.000	0.000	0.337	0.337
	(SE)	( 0.300)	( 0.300)	( 0.000)	( 0.000)	( 0.168)	( 0.168)
	Min, Max	0.8, 1.4	-4.2, -3.6	0.7, 0.7	-4.3, -4.3	0.7, 1.4	-4.3, -3.6
Week 124	n	2	2	2	2	4	4
	Mean	0.70	-4.30	0.70	-4.30	0.70	-4.30
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min, Max	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3
Week 128	n	2	2	2	2	4	4
	Mean	29.80	24.80	0.70	-4.30	15.25	10.25
	Median	29.80	24.80	0.70	-4.30	11.80	6.80
	SD	9.758	9.758	0.000	0.000	17.720	17.720
	(SE)	( 6.900)	( 6.900)	( 0.000)	( 0.000)	( 8.860)	( 8.860)
	Min, Max	22.9, 36.7	17.9, 31.7	0.7, 0.7	-4.3, -4.3	0.7, 36.7	-4.3, 31.7

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	0.80	-4.20	0.70	-4.30	0.75	-4.25
	Median	0.80	-4.20	0.70	-4.30	0.70	-4.30
	SD	0.141	0.141	0.000	0.000	0.100	0.100
	(SE)	( 0.100)	( 0.100)	( 0.000)	( 0.000)	( 0.050)	( 0.050)
	Min, Max	0.7, 0.9	-4.3, -4.1	0.7, 0.7	-4.3, -4.3	0.7, 0.9	-4.3, -4.1
Week 136	n	2	2	2	2	4	4
	Mean	0.75	-4.25	0.70	-4.30	0.72	-4.28
	Median	0.75	-4.25	0.70	-4.30	0.70	-4.30
	SD	0.071	0.071	0.000	0.000	0.050	0.050
	(SE)	( 0.050)	( 0.050)	( 0.000)	( 0.000)	( 0.025)	( 0.025)
	Min, Max	0.7, 0.8	-4.3, -4.2	0.7, 0.7	-4.3, -4.3	0.7, 0.8	-4.3, -4.2
Week 140	n	2	2	2	2	4	4
	Mean	7.90	2.90	0.85	-4.15	4.38	-0.63
	Median	7.90	2.90	0.85	-4.15	1.00	-4.00
	SD	9.758	9.758	0.212	0.212	6.951	6.951
	(SE)	( 6.900)	( 6.900)	( 0.150)	( 0.150)	( 3.476)	( 3.476)
	Min, Max	1.0, 14.8	-4.0, 9.8	0.7, 1.0	-4.3, -4.0	0.7, 14.8	-4.3, 9.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	0.75	-4.25	0.95	-4.05	0.85	-4.15
	Median	0.75	-4.25	0.95	-4.05	0.75	-4.25
	SD	0.071	0.071	0.354	0.354	0.238	0.238
	(SE)	( 0.050)	( 0.050)	( 0.250)	( 0.250)	( 0.119)	( 0.119)
	Min, Max	0.7, 0.8	-4.3, -4.2	0.7, 1.2	-4.3, -3.8	0.7, 1.2	-4.3, -3.8
Week 148	n	2	2	2	2	4	4
	Mean	0.70	-4.30	0.75	-4.25	0.72	-4.28
	Median	0.70	-4.30	0.75	-4.25	0.70	-4.30
	SD	0.000	0.000	0.071	0.071	0.050	0.050
	(SE)	( 0.000)	( 0.000)	( 0.050)	( 0.050)	( 0.025)	( 0.025)
	Min, Max	0.7, 0.7	-4.3, -4.3	0.7, 0.8	-4.3, -4.2	0.7, 0.8	-4.3, -4.2
Week 152	n	2	2	2	2	4	4
	Mean	1.45	-3.55	1.10	-3.90	1.28	-3.73
	Median	1.45	-3.55	1.10	-3.90	1.10	-3.90
	SD	1.061	1.061	0.566	0.566	0.723	0.723
	(SE)	( 0.750)	( 0.750)	( 0.400)	( 0.400)	( 0.361)	( 0.361)
	Min, Max	0.7, 2.2	-4.3, -2.8	0.7, 1.5	-4.3, -3.5	0.7, 2.2	-4.3, -2.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	0.95	-4.05	0.70	-4.30	0.83	-4.18
	Median	0.95	-4.05	0.70	-4.30	0.70	-4.30
	SD	0.354	0.354	0.000	0.000	0.250	0.250
	(SE)	( 0.250)	( 0.250)	( 0.000)	( 0.000)	( 0.125)	( 0.125)
	Min, Max	0.7, 1.2	-4.3, -3.8	0.7, 0.7	-4.3, -4.3	0.7, 1.2	-4.3, -3.8
Week 160	n	2	2	2	2	4	4
	Mean	1.60	-3.40	0.95	-4.05	1.28	-3.73
	Median	1.60	-3.40	0.95	-4.05	0.95	-4.05
	SD	1.273	1.273	0.354	0.354	0.850	0.850
	(SE)	( 0.900)	( 0.900)	( 0.250)	( 0.250)	( 0.425)	( 0.425)
	Min, Max	0.7, 2.5	-4.3, -2.5	0.7, 1.2	-4.3, -3.8	0.7, 2.5	-4.3, -2.5
Week 164	n	2	2	2	2	4	4
	Mean	0.85	-4.15	0.95	-4.05	0.90	-4.10
	Median	0.85	-4.15	0.95	-4.05	0.85	-4.15
	SD	0.212	0.212	0.354	0.354	0.245	0.245
	(SE)	( 0.150)	( 0.150)	( 0.250)	( 0.250)	( 0.122)	( 0.122)
	Min, Max	0.7, 1.0	-4.3, -4.0	0.7, 1.2	-4.3, -3.8	0.7, 1.2	-4.3, -3.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	2.60	-2.40	0.70	-4.30	1.65	-3.35
	Median	2.60	-2.40	0.70	-4.30	0.75	-4.25
	SD	2.546	2.546	0.000	0.000	1.834	1.834
	(SE)	( 1.800)	( 1.800)	( 0.000)	( 0.000)	( 0.917)	( 0.917)
	Min, Max	0.8, 4.4	-4.2, -0.6	0.7, 0.7	-4.3, -4.3	0.7, 4.4	-4.3, -0.6
Week 172	n	2	2	2	2	4	4
	Mean	1.10	-3.90	0.70	-4.30	0.90	-4.10
	Median	1.10	-3.90	0.70	-4.30	0.70	-4.30
	SD	0.566	0.566	0.000	0.000	0.400	0.400
	(SE)	( 0.400)	( 0.400)	( 0.000)	( 0.000)	( 0.200)	( 0.200)
	Min, Max	0.7, 1.5	-4.3, -3.5	0.7, 0.7	-4.3, -4.3	0.7, 1.5	-4.3, -3.5
Week 176	n	2	2	2	2	4	4
	Mean	0.70	-4.30	0.70	-4.30	0.70	-4.30
	Median	0.70	-4.30	0.70	-4.30	0.70	-4.30
	SD	0.000	0.000	0.000	0.000	0.000	0.000
	(SE)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)	( 0.000)
	Min, Max	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3	0.7, 0.7	-4.3, -4.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	2	2	2	2	4	4
	Mean	0.80	-4.20	0.70	-4.30	0.75	-4.25
	Median	0.80	-4.20	0.70	-4.30	0.70	-4.30
	SD	0.141	0.141	0.000	0.000	0.100	0.100
	(SE)	( 0.100)	( 0.100)	( 0.000)	( 0.000)	( 0.050)	( 0.050)
	Min, Max	0.7, 0.9	-4.3, -4.1	0.7, 0.7	-4.3, -4.3	0.7, 0.9	-4.3, -4.1
Week 184	n	2	2	2	2	4	4
	Mean	0.90	-4.10	0.95	-4.05	0.93	-4.08
	Median	0.90	-4.10	0.95	-4.05	0.90	-4.10
	SD	0.141	0.141	0.354	0.354	0.222	0.222
	(SE)	( 0.100)	( 0.100)	( 0.250)	( 0.250)	( 0.111)	( 0.111)
	Min, Max	0.8, 1.0	-4.2, -4.0	0.7, 1.2	-4.3, -3.8	0.7, 1.2	-4.3, -3.8

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Creatine Kinase (U/L)						
Week 1	n	2	2		4	
	Mean	11218.0	12292.0		11755.0	
	Median	11218.0	12292.0		11408.0	
	SD	7030.06	8011.52		6184.92	
	(SE)	( 4971.00)	( 5665.00)		( 3092.46)	
	Min, Max	6247, 16189	6627, 17957		6247, 17957	
Week 2	n	2	2		4	
	Mean	8775.5	5416.5		7096.0	
	Median	8775.5	5416.5		8125.5	
	SD	30.41	2942.27		2578.16	
	(SE)	( 21.50)	( 2080.50)		( 1289.08)	
	Min, Max	8754, 8797	3336, 7497		3336, 8797	
Week 4	n	2	2		4	
	Mean	12893.5	19232.0		16062.8	
	Median	12893.5	19232.0		12893.5	
	SD	1542.20	13976.67		8905.10	
	(SE)	( 1090.50)	( 9883.00)		( 4452.55)	
	Min, Max	11803, 13984	9349, 29115		9349, 29115	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	8476.0		8157.5		8316.8	
	Median	8476.0		8157.5		8476.0	
	SD	1873.83		6227.49		3759.18	
	(SE)	( 1325.00)		( 4403.50)		( 1879.59)	
	Min,	7151,		3754,		3754,	
	Max	9801		12561		12561	
Week 8	n	2		2		4	
	Mean	12989.0		24489.0		18739.0	
	Median	12989.0		24489.0		12989.0	
	SD	3346.03		21288.16		14102.38	
	(SE)	( 2366.00)		(15053.00)		( 7051.19)	
	Min,	10623,		9436,		9436,	
	Max	15355		39542		39542	
Week 10	n	2		2		4	
	Mean	15078.0		7674.5		11376.3	
	Median	15078.0		7674.5		10112.5	
	SD	8246.28		4671.85		6943.56	
	(SE)	( 5831.00)		( 3303.50)		( 3471.78)	
	Min,	9247,		4371,		4371,	
	Max	20909		10978		20909	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	17461.0		14948.0		16204.5	
	Median	17461.0		14948.0		17461.0	
	SD	5260.87		11093.09		7235.30	
	(SE)	( 3720.00)		( 7844.00)		( 3617.65)	
	Min, Max	13741, 21181		7104, 22792		7104, 22792	
Week 15	n	2		2		4	
	Mean	8946.0		8695.0		8820.5	
	Median	8946.0		8695.0		8946.0	
	SD	2281.13		7700.39		4639.06	
	(SE)	( 1613.00)		( 5445.00)		( 2319.53)	
	Min, Max	7333, 10559		3250, 14140		3250, 14140	
Week 18	n	2		2		4	
	Mean	7070.5		15932.0		11501.3	
	Median	7070.5		15932.0		7314.5	
	SD	647.00		12488.92		8849.07	
	(SE)	( 457.50)		( 8831.00)		( 4424.53)	
	Min, Max	6613, 7528		7101, 24763		6613, 24763	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	7447.0		11018.0		9232.5	
	Median	7447.0		11018.0		8241.5	
	SD	3747.67		6550.64		4820.37	
	(SE)	( 2650.00)		( 4632.00)		( 2410.18)	
	Min, Max	4797, 10097		6386, 15650		4797, 15650	
Week 24	n	2		2		4	
	Mean	13752.0		13808.5		13780.3	
	Median	13752.0		13808.5		13752.0	
	SD	6066.98		6261.43		5033.78	
	(SE)	( 4290.00)		( 4427.50)		( 2516.89)	
	Min, Max	9462, 18042		9381, 18236		9381, 18236	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	7924.0		8727.0		8325.5	
	Median	7924.0		8727.0		7924.0	
	SD	1787.57		7116.32		4261.54	
	(SE)	( 1264.00)		( 5032.00)		( 2130.77)	
	Min, Max	6660, 9188		3695, 13759		3695, 13759	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	6627.0	-1297.0	8463.5	-263.5	7545.3	-780.3
	Median	6627.0	-1297.0	8463.5	-263.5	6627.0	-263.5
	SD	527.50	2315.07	6837.02	279.31	4098.61	1472.60
	(SE)	( 373.00)	( 1637.00)	( 4834.50)	( 197.50)	( 2049.30)	( 736.30)
	Min, Max	6254, 7000	-2934, 340	3629, 13298	-461, -66	3629, 13298	-2934, 340
Week 32	n	2	2	2	2	4	4
	Mean	13892.0	5968.0	11444.0	2717.0	12668.0	4342.5
	Median	13892.0	5968.0	11444.0	2717.0	13556.0	2717.0
	SD	4813.98	6601.55	7325.63	209.30	5254.58	4250.23
	(SE)	( 3404.00)	( 4668.00)	( 5180.00)	( 148.00)	( 2627.29)	( 2125.11)
	Min, Max	10488, 17296	1300, 10636	6264, 16624	2569, 2865	6264, 17296	1300, 10636
Week 36	n	2	2	1	1	3	3
	Mean	12415.5	4491.5	18941.0	5182.0	14590.7	4721.7
	Median	12415.5	4491.5	18941.0	5182.0	16926.0	5182.0
	SD	6378.81	8166.38			5876.96	5788.25
	(SE)	( 4510.50)	( 5774.50)			( 3393.06)	( 3341.84)
	Min, Max	7905, 16926	-1283, 10266	18941, 18941	5182, 5182	7905, 18941	-1283, 10266

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	9067.5	1143.5	14105.0	5378.0	11586.3	3260.8
	Median	9067.5	1143.5	14105.0	5378.0	11795.5	1167.5
	SD	1468.66	318.91	876.81	6239.51	3071.49	4357.53
	(SE)	( 1038.50)	( 225.50)	( 620.00)	( 4412.00)	( 1535.75)	( 2178.76)
	Min,	8029,	918,	13485,	966,	8029,	918,
	Max	10106	1369	14725	9790	14725	9790
Week 44	n	2	2	2	2	4	4
	Mean	17484.0	9560.0	9036.5	309.5	13260.3	4934.8
	Median	17484.0	9560.0	9036.5	309.5	10648.5	4207.0
	SD	11968.49	13756.06	4581.34	11697.67	8861.79	11713.76
	(SE)	( 8463.00)	( 9727.00)	( 3239.50)	( 8271.50)	( 4430.89)	( 5856.88)
	Min,	9021,	-167,	5797,	-7962,	5797,	-7962,
	Max	25947	19287	12276	8581	25947	19287
Week 48	n	2	2	2	2	4	4
	Mean	10571.0	2647.0	8432.0	-295.0	9501.5	1176.0
	Median	10571.0	2647.0	8432.0	-295.0	9393.0	-179.5
	SD	4734.79	6522.35	4427.90	2688.42	3941.23	4413.01
	(SE)	( 3348.00)	( 4612.00)	( 3131.00)	( 1901.00)	( 1970.61)	( 2206.51)
	Min,	7223,	-1965,	5301,	-2196,	5301,	-2196,
	Max	13919	7259	11563	1606	13919	7259

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	9067.5	1143.5	7548.5	-1178.5	8308.0	-17.5
	Median	9067.5	1143.5	7548.5	-1178.5	7982.5	471.5
	SD	2433.15	4220.72	1512.50	5603.82	1872.19	4266.50
	(SE)	( 1720.50)	( 2984.50)	( 1069.50)	( 3962.50)	( 936.09)	( 2133.25)
	Min,	7347,	-1841,	6479,	-5141,	6479,	-5141,
	Max	10788	4128	8618	2784	10788	4128
Week 56	n	2	2	2	2	4	4
	Mean	10679.5	2755.5	9098.5	371.5	9889.0	1563.5
	Median	10679.5	2755.5	9098.5	371.5	9501.5	2755.5
	SD	1249.46	3037.02	153.44	6962.88	1166.80	4596.69
	(SE)	( 883.50)	( 2147.50)	( 108.50)	( 4923.50)	( 583.40)	( 2298.34)
	Min,	9796,	608,	8990,	-4552,	8990,	-4552,
	Max	11563	4903	9207	5295	11563	5295
Week 60	n	2	2	2	2	4	4
	Mean	13934.5	6010.5	8649.0	-78.0	11291.8	2966.3
	Median	13934.5	6010.5	8649.0	-78.0	11997.0	3161.5
	SD	3178.44	1390.88	5173.19	1943.13	4647.61	3776.25
	(SE)	( 2247.50)	( 983.50)	( 3658.00)	( 1374.00)	( 2323.81)	( 1888.12)
	Min,	11687,	5027,	4991,	-1452,	4991,	-1452,
	Max	16182	6994	12307	1296	16182	6994

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	9672.0	1748.0	6913.0	-1814.0	8292.5	-33.0
	Median	9672.0	1748.0	6913.0	-1814.0	8494.0	-1543.5
	SD	4515.58	6303.15	5085.51	2030.81	4237.33	4341.34
	(SE)	( 3193.00)	( 4457.00)	( 3596.00)	( 1436.00)	( 2118.67)	( 2170.67)
	Min, Max	6479, 12865	-2709, 6205	3317, 10509	-3250, -378	3317, 12865	-3250, 6205
Week 68	n	2	2	2	2	4	4
	Mean	13500.5	5576.5	6711.5	-2015.5	10106.0	1780.5
	Median	13500.5	5576.5	6711.5	-2015.5	8850.5	3673.0
	SD	3616.85	1829.29	65.76	7182.08	4441.34	6125.55
	(SE)	( 2557.50)	( 1293.50)	( 46.50)	( 5078.50)	( 2220.67)	( 3062.77)
	Min, Max	10943, 16058	4283, 6870	6665, 6758	-7094, 3063	6665, 16058	-7094, 6870
Week 72	n	2	2	0	0	2	2
	Mean	8246.0	322.0			8246.0	322.0
	Median	8246.0	322.0			8246.0	322.0
	SD	219.20	2006.77			219.20	2006.77
	(SE)	( 155.00)	( 1419.00)			( 155.00)	( 1419.00)
	Min, Max	8091, 8401	-1097, 1741			8091, 8401	-1097, 1741

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			7347.0	3652.0	7347.0	3652.0
	Median			7347.0	3652.0	7347.0	3652.0
	SD						
	(SE)						
	Min, Max			7347, 7347	3652, 3652	7347, 7347	3652, 3652
Week 76	n	2	2	2	2	4	4
	Mean	14911.0	6987.0	8928.0	201.0	11919.5	3594.0
	Median	14911.0	6987.0	8928.0	201.0	10617.5	5440.0
	SD	7058.34	5270.77	3375.73	10492.05	5686.59	7829.73
	(SE)	( 4991.00)	( 3727.00)	( 2387.00)	( 7419.00)	( 2843.30)	( 3914.86)
	Min, Max	9920, 19902	3260, 10714	6541, 11315	-7218, 7620	6541, 19902	-7218, 10714
Week 80	n	2	2	2	2	4	4
	Mean	10896.5	2972.5	7998.0	-729.0	9447.3	1121.8
	Median	10896.5	2972.5	7998.0	-729.0	10896.5	1138.0
	SD	854.89	932.67	6137.69	978.64	3949.82	2275.13
	(SE)	( 604.50)	( 659.50)	( 4340.00)	( 692.00)	( 1974.91)	( 1137.57)
	Min, Max	10292, 11501	2313, 3632	3658, 12338	-1421, -37	3658, 12338	-1421, 3632

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	11904.0	3980.0	8075.5	-651.5	9989.8	1664.3
	Median	11904.0	3980.0	8075.5	-651.5	10989.5	2293.5
	SD	2148.19	360.62	4975.91	2140.41	3831.09	2953.09
	(SE)	( 1519.00)	( 255.00)	( 3518.50)	( 1513.50)	( 1915.55)	( 1476.54)
	Min, Max	10385, 13423	3725, 4235	4557, 11594	-2165, 862	4557, 13423	-2165, 4235
Week 88	n	2	2	2	2	4	4
	Mean	16926.0	9002.0	4991.0	-3736.0	10958.5	2633.0
	Median	16926.0	9002.0	4991.0	-3736.0	10493.5	2037.0
	SD	4164.86	5952.42	2849.64	4266.68	7481.33	8483.17
	(SE)	( 2945.00)	( 4209.00)	( 2015.00)	( 3017.00)	( 3740.66)	( 4241.59)
	Min, Max	13981, 19871	4793, 13211	2976, 7006	-6753, -719	2976, 19871	-6753, 13211
Week 92	n	2	2	2	2	4	4
	Mean	12198.5	4274.5	6510.0	-2217.0	9354.3	1028.8
	Median	12198.5	4274.5	6510.0	-2217.0	8494.0	-210.5
	SD	5633.52	7421.09	3200.37	3915.96	4977.88	6125.00
	(SE)	( 3983.50)	( 5247.50)	( 2263.00)	( 2769.00)	( 2488.94)	( 3062.50)
	Min, Max	8215, 16182	-973, 9522	4247, 8773	-4986, 552	4247, 16182	-4986, 9522

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	6246.5	-1677.5	4665.5	-4061.5	5456.0	-2869.5
	Median	6246.5	-1677.5	4665.5	-4061.5	5533.5	-2046.5
	SD	3178.44	1390.88	3397.65	3718.67	2837.02	2673.73
	(SE)	( 2247.50)	( 983.50)	( 2402.50)	( 2629.50)	( 1418.51)	( 1336.87)
	Min, Max	3999, 8494	-2661, -694	2263, 7068	-6691, -1432	2263, 8494	-6691, -694
Week 100	n	2	2	2	2	4	4
	Mean	6990.5	-933.5	5130.5	-3596.5	6060.5	-2265.0
	Median	6990.5	-933.5	5130.5	-3596.5	6603.0	-2086.0
	SD	1644.02	3431.59	3178.44	3937.88	2328.44	3384.98
	(SE)	( 1162.50)	( 2426.50)	( 2247.50)	( 2784.50)	( 1164.22)	( 1692.49)
	Min, Max	5828, 8153	-3360, 1493	2883, 7378	-6381, -812	2883, 8153	-6381, 1493
Week 104	n	2	2	2	2	4	4
	Mean	7006.0	-918.0	5921.0	-2806.0	6463.5	-1862.0
	Median	7006.0	-918.0	5921.0	-2806.0	5983.0	-1078.5
	SD	2235.87	4023.44	876.81	6239.51	1521.53	4422.82
	(SE)	( 1581.00)	( 2845.00)	( 620.00)	( 4412.00)	( 760.76)	( 2211.41)
	Min, Max	5425, 8587	-3763, 1927	5301, 6541	-7218, 1606	5301, 8587	-7218, 1927

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	11005.0	3081.0	6587.5	-2139.5	8796.3	470.8
	Median	11005.0	3081.0	6587.5	-2139.5	9021.0	1665.0
	SD	657.61	2445.18	1293.30	5823.02	2684.48	4730.75
	(SE)	( 465.00)	( 1729.00)	( 914.50)	( 4117.50)	( 1342.24)	( 2365.38)
	Min, Max	10540, 11470	1352, 4810	5673, 7502	-6257, 1978	5673, 11470	-6257, 4810
Week 112	n	2	2	2	2	4	4
	Mean	8943.5	1019.5	7409.0	-1318.0	8176.3	-149.3
	Median	8943.5	1019.5	7409.0	-1318.0	8943.5	874.5
	SD	1424.82	362.75	3857.97	3258.35	2534.35	2324.67
	(SE)	( 1007.50)	( 256.50)	( 2728.00)	( 2304.00)	( 1267.17)	( 1162.34)
	Min, Max	7936, 9951	763, 1276	4681, 10137	-3622, 986	4681, 10137	-3622, 1276
Week 116	n	2	2	2	2	4	4
	Mean	7130.0	-794.0	4386.5	-4340.5	5758.3	-2567.3
	Median	7130.0	-794.0	4386.5	-4340.5	5936.5	-2287.5
	SD	2016.67	3804.23	2520.84	4595.49	2445.97	4007.01
	(SE)	( 1426.00)	( 2690.00)	( 1782.50)	( 3249.50)	( 1222.99)	( 2003.50)
	Min, Max	5704, 8556	-3484, 1896	2604, 6169	-7590, -1091	2604, 8556	-7590, 1896

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	13810.5	5886.5	7037.0	-1690.0	10423.8	2098.3
	Median	13810.5	5886.5	7037.0	-1690.0	9532.5	1751.0
	SD	6203.45	4415.88	3682.61	3433.71	5713.28	5437.33
	(SE)	( 4386.50)	( 3122.50)	( 2604.00)	( 2428.00)	( 2856.64)	( 2718.67)
	Min, Max	9424, 18197	2764, 9009	4433, 9641	-4118, 738	4433, 18197	-4118, 9009
Week 124	n	2	2	2	2	4	4
	Mean	9375.0	1451.0	5967.5	-2759.5	7671.3	-654.3
	Median	9375.0	1451.0	5967.5	-2759.5	7840.5	1060.5
	SD	1516.04	271.53	1994.75	5121.57	2441.89	3831.13
	(SE)	( 1072.00)	( 192.00)	( 1410.50)	( 3621.50)	( 1220.94)	( 1915.56)
	Min, Max	8303, 10447	1259, 1643	4557, 7378	-6381, 862	4557, 10447	-6381, 1643
Week 128	n	2	2	2	2	4	4
	Mean	5022.0	-2902.0	6277.5	-2449.5	5649.8	-2675.8
	Median	5022.0	-2902.0	6277.5	-2449.5	5022.0	-2902.0
	SD	2016.67	229.10	3967.58	3148.75	2669.89	1841.36
	(SE)	( 1426.00)	( 162.00)	( 2805.50)	( 2226.50)	( 1334.94)	( 920.68)
	Min, Max	3596, 6448	-3064, -2740	3472, 9083	-4676, -223	3472, 9083	-4676, -223

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	6417.0	-1507.0	4665.5	-4061.5	5541.3	-2784.3
	Median	6417.0	-1507.0	4665.5	-4061.5	5859.0	-1507.0
	SD	1359.06	428.51	2257.79	4858.53	1826.88	3178.81
	(SE)	( 961.00)	( 303.00)	( 1596.50)	( 3435.50)	( 913.44)	( 1589.40)
	Min,	5456,	-1810,	3069,	-7497,	3069,	-7497,
	Max	7378	-1204	6262	-626	7378	-626
Week 136	n	2	2	2	2	4	4
	Mean	10385.0	2461.0	9687.5	960.5	10036.3	1710.8
	Median	10385.0	2461.0	9687.5	960.5	10385.0	960.5
	SD	5217.03	7004.60	9053.09	1936.77	6046.00	4284.35
	(SE)	( 3689.00)	( 4953.00)	( 6401.50)	( 1369.50)	( 3023.00)	( 2142.18)
	Min,	6696,	-2492,	3286,	-409,	3286,	-2492,
	Max	14074	7414	16089	2330	16089	7414
Week 140	n	2	2	2	2	4	4
	Mean	9610.0	1686.0	5936.5	-2790.5	7773.3	-552.3
	Median	9610.0	1686.0	5936.5	-2790.5	8153.0	952.0
	SD	1402.90	384.67	2477.00	4639.33	2683.17	3728.73
	(SE)	( 992.00)	( 272.00)	( 1751.50)	( 3280.50)	( 1341.59)	( 1864.37)
	Min,	8618,	1414,	4185,	-6071,	4185,	-6071,
	Max	10602	1958	7688	490	10602	1958

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	7114.5	-809.5	5843.5	-2883.5	6479.0	-1846.5
	Median	7114.5	-809.5	5843.5	-2883.5	6556.5	-809.5
	SD	21.92	1809.49	241.12	6875.20	747.01	4275.67
	(SE)	( 15.50)	( 1279.50)	( 170.50)	( 4861.50)	( 373.50)	( 2137.84)
	Min, Max	7099, 7130	-2089, 470	5673, 6014	-7745, 1978	5673, 7130	-7745, 1978
Week 148	n	2	2	2	2	4	4
	Mean	6107.0	-1817.0	4200.5	-4526.5	5153.8	-3171.8
	Median	6107.0	-1817.0	4200.5	-4526.5	5068.5	-1817.0
	SD	2586.60	799.03	2345.47	4770.85	2296.84	3201.09
	(SE)	( 1829.00)	( 565.00)	( 1658.50)	( 3373.50)	( 1148.42)	( 1600.54)
	Min, Max	4278, 7936	-2382, -1252	2542, 5859	-7900, -1153	2542, 7936	-7900, -1153
Week 152	n	2	2	2	2	4	4
	Mean	9625.5	1701.5	5285.5	-3441.5	7455.5	-870.0
	Median	9625.5	1701.5	5285.5	-3441.5	6246.5	30.5
	SD	4888.23	3100.66	1468.66	5647.66	3868.13	4759.57
	(SE)	( 3456.50)	( 2192.50)	( 1038.50)	( 3993.50)	( 1934.07)	( 2379.79)
	Min, Max	6169, 13082	-491, 3894	4247, 6324	-7435, 552	4247, 13082	-7435, 3894

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	6293.0	-1631.0	3797.5	-4929.5	5045.3	-3280.3
	Median	6293.0	-1631.0	3797.5	-4929.5	4898.0	-1631.0
	SD	1841.31	53.74	1424.82	5691.50	1970.45	3798.08
	(SE)	( 1302.00)	( 38.00)	( 1007.50)	( 4024.50)	( 985.23)	( 1899.04)
	Min,	4991,	-1669,	2790,	-8954,	2790,	-8954,
	Max	7595	-1593	4805	-905	7595	-905
Week 160	n	2	2	2	2	4	4
	Mean	6200.0	-1724.0	4510.5	-4216.5	5355.3	-2970.3
	Median	6200.0	-1724.0	4510.5	-4216.5	4603.5	-1724.0
	SD	2805.80	1018.23	679.53	6436.79	1931.21	4028.30
	(SE)	( 1984.00)	( 720.00)	( 480.50)	( 4551.50)	( 965.60)	( 2014.15)
	Min,	4216,	-2444,	4030,	-8768,	4030,	-8768,
	Max	8184	-1004	4991	335	8184	335
Week 164	n	2	2	2	2	4	4
	Mean	6987.0	-937.0	4076.5	-4650.5	5531.8	-2793.8
	Median	6987.0	-937.0	4076.5	-4650.5	5177.0	-937.0
	SD	1726.75	60.81	723.37	6392.95	1998.00	4268.63
	(SE)	( 1221.00)	( 43.00)	( 511.50)	( 4520.50)	( 999.00)	( 2134.32)
	Min,	5766,	-980,	3565,	-9171,	3565,	-9171,
	Max	8208	-894	4588	-130	8208	-130

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	7502.0	-422.0	5533.5	-3193.5	6517.8	-1807.8
	Median	7502.0	-422.0	5533.5	-3193.5	7502.0	-1590.0
	SD	306.88	2094.45	4405.98	2710.34	2791.76	2543.87
	(SE)	( 217.00)	( 1481.00)	( 3115.50)	( 1916.50)	( 1395.88)	( 1271.94)
	Min, Max	7285, 7719	-1903, 1059	2418, 8649	-5110, -1277	2418, 8649	-5110, 1059
Week 172	n	2	2	2	2	4	4
	Mean	8292.5	368.5	5409.5	-3317.5	6851.0	-1474.5
	Median	8292.5	368.5	5409.5	-3317.5	6990.5	270.0
	SD	1644.02	143.54	2038.59	5077.73	2248.73	3623.56
	(SE)	( 1162.50)	( 101.50)	( 1441.50)	( 3590.50)	( 1124.36)	( 1811.78)
	Min, Max	7130, 9455	267, 470	3968, 6851	-6908, 273	3968, 9455	-6908, 470
Week 176	n	2	2	2	2	4	4
	Mean	5688.5	-2235.5	4654.0	-4073.0	5171.3	-3154.3
	Median	5688.5	-2235.5	4654.0	-4073.0	5688.5	-3096.5
	SD	2257.79	470.23	6482.75	633.57	4008.07	1154.55
	(SE)	( 1596.50)	( 332.50)	( 4584.00)	( 448.00)	( 2004.04)	( 577.27)
	Min, Max	4092, 7285	-2568, -1903	70, 9238	-4521, -3625	70, 9238	-4521, -1903

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	396.0	-7528.0	1912.5	-6814.5	1154.3	-7171.3
	Median	396.0	-7528.0	1912.5	-6814.5	396.0	-7528.0
	SD	91.92	1695.64	2600.03	4516.29	1738.62	2815.50
	(SE)	( 65.00)	( 1199.00)	( 1838.50)	( 3193.50)	( 869.31)	( 1407.75)
	Min, Max	331, 461	-8727, -6329	74, 3751	-10008, -3621	74, 3751	-10008, -3621
Week 184	n	2	2	2	2	4	4
	Mean	4991.0	-2933.0	2015.0	-6712.0	3503.0	-4822.5
	Median	4991.0	-2933.0	2015.0	-6712.0	2402.5	-3240.0
	SD	3770.29	1982.73	657.61	6458.71	2799.06	4469.42
	(SE)	( 2666.00)	( 1402.00)	( 465.00)	( 4567.00)	( 1399.53)	( 2234.71)
	Min, Max	2325, 7657	-4335, -1531	1550, 2480	-11279, -2145	1550, 7657	-11279, -1531

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Cystatin C (mg/L)						
Week 1	n	2	2		4	
	Mean	0.65	0.60		0.63	
	Median	0.65	0.60		0.60	
	SD	0.071	0.000		0.050	
	(SE)	( 0.050)	( 0.000)		( 0.025)	
	Min,	0.6,	0.6,		0.6,	
	Max	0.7	0.6		0.7	
Week 12	n	2	2		4	
	Mean	0.70	0.65		0.68	
	Median	0.70	0.65		0.70	
	SD	0.000	0.071		0.050	
	(SE)	( 0.000)	( 0.050)		( 0.025)	
	Min,	0.7,	0.6,		0.6,	
	Max	0.7	0.7		0.7	
Baseline <sup>1</sup>	n	2	2		4	
	Mean	0.70	0.60		0.65	
	Median	0.70	0.60		0.65	
	SD	0.000	0.000		0.058	
	(SE)	( 0.000)	( 0.000)		( 0.029)	
	Min,	0.7,	0.6,		0.6,	
	Max	0.7	0.6		0.7	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 32	n	2	2	2	2	4	4
	Mean	0.75	0.05	0.59	-0.01	0.67	0.02
	Median	0.75	0.05	0.59	-0.01	0.67	0.02
	SD	0.007	0.007	0.014	0.014	0.090	0.033
	(SE)	( 0.005)	( 0.005)	( 0.010)	( 0.010)	( 0.045)	( 0.017)
	Min, Max	0.7, 0.8	0.0, 0.1	0.6, 0.6	-0.0, 0.0	0.6, 0.8	-0.0, 0.1
Week 36	n	2	2	2	2	4	4
	Mean	0.74	0.04	0.58	-0.02	0.66	0.01
	Median	0.74	0.04	0.58	-0.02	0.69	0.04
	SD	0.057	0.057	0.141	0.141	0.128	0.095
	(SE)	( 0.040)	( 0.040)	( 0.100)	( 0.100)	( 0.064)	( 0.047)
	Min, Max	0.7, 0.8	0.0, 0.1	0.5, 0.7	-0.1, 0.1	0.5, 0.8	-0.1, 0.1
Week 40	n	2	2	2	2	4	4
	Mean	0.80	0.10	0.77	0.17	0.78	0.13
	Median	0.80	0.10	0.77	0.17	0.80	0.10
	SD	0.042	0.042	0.134	0.134	0.084	0.090
	(SE)	( 0.030)	( 0.030)	( 0.095)	( 0.095)	( 0.042)	( 0.045)
	Min, Max	0.8, 0.8	0.1, 0.1	0.7, 0.9	0.1, 0.3	0.7, 0.9	0.1, 0.3

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 44	n	2	2	2	2	4	4
	Mean	0.89	0.19	0.72	0.12	0.80	0.15
	Median	0.89	0.19	0.72	0.12	0.78	0.13
	SD	0.177	0.177	0.106	0.106	0.154	0.126
	(SE)	( 0.125)	( 0.125)	( 0.075)	( 0.075)	( 0.077)	( 0.063)
	Min, Max	0.8, 1.0	0.1, 0.3	0.6, 0.8	0.0, 0.2	0.6, 1.0	0.0, 0.3
Week 48	n	2	2	2	2	4	4
	Mean	0.90	0.20	0.70	0.10	0.80	0.15
	Median	0.90	0.20	0.70	0.10	0.80	0.15
	SD	0.064	0.064	0.064	0.064	0.127	0.078
	(SE)	( 0.045)	( 0.045)	( 0.045)	( 0.045)	( 0.063)	( 0.039)
	Min, Max	0.9, 0.9	0.2, 0.2	0.7, 0.7	0.1, 0.1	0.7, 0.9	0.1, 0.2
Week 52	n	2	2	1	1	3	3
	Mean	0.76	0.06	0.60	0.00	0.70	0.04
	Median	0.76	0.06	0.60	0.00	0.67	0.00
	SD	0.120	0.120			0.123	0.091
	(SE)	( 0.085)	( 0.085)			( 0.071)	( 0.052)
	Min, Max	0.7, 0.8	-0.0, 0.1	0.6, 0.6	0.0, 0.0	0.6, 0.8	-0.0, 0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 56	n	2	2	2	2	4	4
	Mean	0.69	-0.01	0.62	0.02	0.66	0.01
	Median	0.69	-0.01	0.62	0.02	0.64	0.02
	SD	0.057	0.057	0.014	0.014	0.053	0.038
	(SE)	( 0.040)	( 0.040)	( 0.010)	( 0.010)	( 0.026)	( 0.019)
	Min, Max	0.7, 0.7	-0.1, 0.0	0.6, 0.6	0.0, 0.0	0.6, 0.7	-0.1, 0.0
Week 60	n	2	2	2	2	4	4
	Mean	0.72	0.02	0.67	0.07	0.69	0.04
	Median	0.72	0.02	0.67	0.07	0.71	0.03
	SD	0.042	0.042	0.078	0.078	0.060	0.057
	(SE)	( 0.030)	( 0.030)	( 0.055)	( 0.055)	( 0.030)	( 0.029)
	Min, Max	0.7, 0.8	-0.0, 0.1	0.6, 0.7	0.0, 0.1	0.6, 0.8	-0.0, 0.1
Week 64	n	2	2	2	2	4	4
	Mean	0.77	0.07	0.67	0.07	0.72	0.07
	Median	0.77	0.07	0.67	0.07	0.74	0.07
	SD	0.000	0.000	0.064	0.064	0.071	0.037
	(SE)	( 0.000)	( 0.000)	( 0.045)	( 0.045)	( 0.035)	( 0.018)
	Min, Max	0.8, 0.8	0.1, 0.1	0.6, 0.7	0.0, 0.1	0.6, 0.8	0.0, 0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 68	n	2	2	2	2	4	4
	Mean	0.73	0.03	0.66	0.06	0.69	0.04
	Median	0.73	0.03	0.66	0.06	0.71	0.03
	SD	0.049	0.049	0.085	0.085	0.068	0.060
	(SE)	( 0.035)	( 0.035)	( 0.060)	( 0.060)	( 0.034)	( 0.030)
	Min,	0.7,	-0.0,	0.6,	0.0,	0.6,	-0.0,
	Max	0.8	0.1	0.7	0.1	0.8	0.1
Week 72	n	2	2	0	0	2	2
	Mean	0.77	0.07			0.77	0.07
	Median	0.77	0.07			0.77	0.07
	SD	0.113	0.113			0.113	0.113
	(SE)	( 0.080)	( 0.080)			( 0.080)	( 0.080)
	Min,	0.7,	-0.0,			0.7,	-0.0,
	Max	0.9	0.2			0.9	0.2
Week 73	n	0	0	1	1	1	1
	Mean			0.62	0.02	0.62	0.02
	Median			0.62	0.02	0.62	0.02
	SD						
	(SE)						
	Min,			0.6,	0.0,	0.6,	0.0,
	Max			0.6	0.0	0.6	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 76	n	2	2	2	2	4	4
	Mean	0.74	0.04	0.64	0.04	0.69	0.04
	Median	0.74	0.04	0.64	0.04	0.70	0.04
	SD	0.000	0.000	0.028	0.028	0.060	0.016
	(SE)	( 0.000)	( 0.000)	( 0.020)	( 0.020)	( 0.030)	( 0.008)
	Min,	0.7,	0.0,	0.6,	0.0,	0.6,	0.0,
	Max	0.7	0.0	0.7	0.1	0.7	0.1
Week 80	n	2	2	2	2	4	4
	Mean	0.76	0.06	0.64	0.04	0.70	0.05
	Median	0.76	0.06	0.64	0.04	0.72	0.06
	SD	0.042	0.042	0.092	0.092	0.093	0.060
	(SE)	( 0.030)	( 0.030)	( 0.065)	( 0.065)	( 0.046)	( 0.030)
	Min,	0.7,	0.0,	0.6,	-0.0,	0.6,	-0.0,
	Max	0.8	0.1	0.7	0.1	0.8	0.1
Week 84	n	2	2	2	2	4	4
	Mean	0.75	0.05	0.67	0.07	0.71	0.06
	Median	0.75	0.05	0.67	0.07	0.71	0.06
	SD	0.049	0.049	0.057	0.057	0.061	0.046
	(SE)	( 0.035)	( 0.035)	( 0.040)	( 0.040)	( 0.031)	( 0.023)
	Min,	0.7,	0.0,	0.6,	0.0,	0.6,	0.0,
	Max	0.8	0.1	0.7	0.1	0.8	0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 88	n	2	2	2	2	4	4
	Mean	0.72	0.02	0.57	-0.04	0.64	-0.01
	Median	0.72	0.02	0.57	-0.04	0.63	-0.02
	SD	0.064	0.064	0.035	0.035	0.096	0.051
	(SE)	( 0.045)	( 0.045)	( 0.025)	( 0.025)	( 0.048)	( 0.025)
	Min, Max	0.7, 0.8	-0.0, 0.1	0.5, 0.6	-0.1, -0.0	0.5, 0.8	-0.1, 0.1
Week 92	n	2	2	2	2	4	4
	Mean	0.74	0.04	0.61	0.01	0.67	0.02
	Median	0.74	0.04	0.61	0.01	0.68	0.03
	SD	0.021	0.021	0.049	0.049	0.081	0.036
	(SE)	( 0.015)	( 0.015)	( 0.035)	( 0.035)	( 0.041)	( 0.018)
	Min, Max	0.7, 0.8	0.0, 0.1	0.6, 0.6	-0.0, 0.0	0.6, 0.8	-0.0, 0.1
Week 96	n	2	2	2	2	4	4
	Mean	0.80	0.10	0.61	0.01	0.70	0.05
	Median	0.80	0.10	0.61	0.01	0.69	0.04
	SD	0.042	0.042	0.007	0.007	0.115	0.060
	(SE)	( 0.030)	( 0.030)	( 0.005)	( 0.005)	( 0.058)	( 0.030)
	Min, Max	0.8, 0.8	0.1, 0.1	0.6, 0.6	0.0, 0.0	0.6, 0.8	0.0, 0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 100	n	2	2	2	2	4	4
	Mean	0.88	0.18	0.65	0.05	0.77	0.12
	Median	0.88	0.18	0.65	0.05	0.79	0.14
	SD	0.014	0.014	0.071	0.071	0.139	0.086
	(SE)	( 0.010)	( 0.010)	( 0.050)	( 0.050)	( 0.070)	( 0.043)
	Min, Max	0.9, 0.9	0.2, 0.2	0.6, 0.7	0.0, 0.1	0.6, 0.9	0.0, 0.2
Week 104	n	2	2	2	2	4	4
	Mean	0.75	0.05	0.68	0.08	0.71	0.06
	Median	0.75	0.05	0.68	0.08	0.74	0.05
	SD	0.035	0.035	0.106	0.106	0.076	0.067
	(SE)	( 0.025)	( 0.025)	( 0.075)	( 0.075)	( 0.038)	( 0.033)
	Min, Max	0.7, 0.8	0.0, 0.1	0.6, 0.8	0.0, 0.2	0.6, 0.8	0.0, 0.2
Week 108	n	2	2	2	2	4	4
	Mean	0.80	0.10	0.61	0.01	0.71	0.06
	Median	0.80	0.10	0.61	0.01	0.68	0.03
	SD	0.141	0.141	0.071	0.071	0.143	0.105
	(SE)	( 0.100)	( 0.100)	( 0.050)	( 0.050)	( 0.071)	( 0.053)
	Min, Max	0.7, 0.9	0.0, 0.2	0.6, 0.7	-0.0, 0.1	0.6, 0.9	-0.0, 0.2

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weers  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 112	n	2	2	2	2	4	4
	Mean	0.79	0.09	0.58	-0.03	0.68	0.03
	Median	0.79	0.09	0.58	-0.03	0.66	0.01
	SD	0.078	0.078	0.007	0.007	0.129	0.078
	(SE)	( 0.055)	( 0.055)	( 0.005)	( 0.005)	( 0.065)	( 0.039)
	Min, Max	0.7, 0.8	0.0, 0.1	0.6, 0.6	-0.0, -0.0	0.6, 0.8	-0.0, 0.1
Week 116	n	2	2	2	2	4	4
	Mean	0.73	0.03	0.52	-0.08	0.63	-0.03
	Median	0.73	0.03	0.52	-0.08	0.61	-0.05
	SD	0.113	0.113	0.057	0.057	0.142	0.097
	(SE)	( 0.080)	( 0.080)	( 0.040)	( 0.040)	( 0.071)	( 0.048)
	Min, Max	0.7, 0.8	-0.1, 0.1	0.5, 0.6	-0.1, -0.0	0.5, 0.8	-0.1, 0.1
Week 120	n	2	2	2	2	4	4
	Mean	0.58	-0.13	0.55	-0.05	0.56	-0.09
	Median	0.58	-0.13	0.55	-0.05	0.58	-0.10
	SD	0.078	0.078	0.113	0.113	0.081	0.090
	(SE)	( 0.055)	( 0.055)	( 0.080)	( 0.080)	( 0.040)	( 0.045)
	Min, Max	0.5, 0.6	-0.2, -0.1	0.5, 0.6	-0.1, 0.0	0.5, 0.6	-0.2, 0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 124	n	2	2	2	2	4	4
	Mean	0.69	-0.01	0.51	-0.09	0.60	-0.05
	Median	0.69	-0.01	0.51	-0.09	0.61	-0.04
	SD	0.028	0.028	0.057	0.057	0.110	0.059
	(SE)	( 0.020)	( 0.020)	( 0.040)	( 0.040)	( 0.055)	( 0.029)
	Min, Max	0.7, 0.7	-0.0, 0.0	0.5, 0.6	-0.1, -0.1	0.5, 0.7	-0.1, 0.0
Week 128	n	2	2	2	2	4	4
	Mean	0.50	-0.20	0.52	-0.08	0.51	-0.14
	Median	0.50	-0.20	0.52	-0.08	0.52	-0.13
	SD	0.042	0.042	0.000	0.000	0.027	0.073
	(SE)	( 0.030)	( 0.030)	( 0.000)	( 0.000)	( 0.014)	( 0.037)
	Min, Max	0.5, 0.5	-0.2, -0.2	0.5, 0.5	-0.1, -0.1	0.5, 0.5	-0.2, -0.1
Week 132	n	2	2	2	2	4	4
	Mean	0.60	-0.11	0.54	-0.06	0.57	-0.08
	Median	0.60	-0.11	0.54	-0.06	0.59	-0.11
	SD	0.035	0.035	0.099	0.099	0.068	0.066
	(SE)	( 0.025)	( 0.025)	( 0.070)	( 0.070)	( 0.034)	( 0.033)
	Min, Max	0.6, 0.6	-0.1, -0.1	0.5, 0.6	-0.1, 0.0	0.5, 0.6	-0.1, 0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 136	n	2	2	2	2	4	4
	Mean	0.65	-0.06	0.58	-0.03	0.61	-0.04
	Median	0.65	-0.06	0.58	-0.03	0.62	-0.05
	SD	0.049	0.049	0.064	0.064	0.062	0.050
	(SE)	( 0.035)	( 0.035)	( 0.045)	( 0.045)	( 0.031)	( 0.025)
	Min, Max	0.6, 0.7	-0.1, -0.0	0.5, 0.6	-0.1, 0.0	0.5, 0.7	-0.1, 0.0
Week 140	n	2	2	2	2	4	4
	Mean	0.66	-0.04	0.60	-0.01	0.63	-0.02
	Median	0.66	-0.04	0.60	-0.01	0.60	-0.01
	SD	0.099	0.099	0.021	0.021	0.069	0.062
	(SE)	( 0.070)	( 0.070)	( 0.015)	( 0.015)	( 0.035)	( 0.031)
	Min, Max	0.6, 0.7	-0.1, 0.0	0.6, 0.6	-0.0, 0.0	0.6, 0.7	-0.1, 0.0
Week 144	n	2	2	2	2	4	4
	Mean	0.70	-0.01	0.58	-0.02	0.64	-0.01
	Median	0.70	-0.01	0.58	-0.02	0.60	-0.02
	SD	0.163	0.163	0.057	0.057	0.120	0.100
	(SE)	( 0.115)	( 0.115)	( 0.040)	( 0.040)	( 0.060)	( 0.050)
	Min, Max	0.6, 0.8	-0.1, 0.1	0.5, 0.6	-0.1, 0.0	0.5, 0.8	-0.1, 0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 148	n	2	2	2	2	4	4
	Mean	0.74	0.04	0.57	-0.04	0.65	0.00
	Median	0.74	0.04	0.57	-0.04	0.63	-0.02
	SD	0.078	0.078	0.021	0.021	0.109	0.062
	(SE)	( 0.055)	( 0.055)	( 0.015)	( 0.015)	( 0.054)	( 0.031)
	Min,	0.7,	-0.0,	0.6,	-0.1,	0.6,	-0.1,
	Max	0.8	0.1	0.6	-0.0	0.8	0.1
Week 152	n	2	2	2	2	4	4
	Mean	0.70	0.00	0.63	0.03	0.66	0.01
	Median	0.70	0.00	0.63	0.03	0.63	0.03
	SD	0.127	0.127	0.007	0.007	0.085	0.075
	(SE)	( 0.090)	( 0.090)	( 0.005)	( 0.005)	( 0.043)	( 0.038)
	Min,	0.6,	-0.1,	0.6,	0.0,	0.6,	-0.1,
	Max	0.8	0.1	0.6	0.0	0.8	0.1
Week 156	n	2	2	2	2	4	4
	Mean	0.69	-0.02	0.55	-0.05	0.62	-0.03
	Median	0.69	-0.02	0.55	-0.05	0.63	-0.03
	SD	0.049	0.049	0.071	0.071	0.093	0.054
	(SE)	( 0.035)	( 0.035)	( 0.050)	( 0.050)	( 0.046)	( 0.027)
	Min,	0.7,	-0.1,	0.5,	-0.1,	0.5,	-0.1,
	Max	0.7	0.0	0.6	0.0	0.7	0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 160	n	2	2	2	2	4	4
	Mean	0.60	-0.10	0.59	-0.02	0.59	-0.06
	Median	0.60	-0.10	0.59	-0.02	0.60	-0.06
	SD	0.000	0.000	0.007	0.007	0.010	0.049
	(SE)	( 0.000)	( 0.000)	( 0.005)	( 0.005)	( 0.005)	( 0.025)
	Min,	0.6,	-0.1,	0.6,	-0.0,	0.6,	-0.1,
	Max	0.6	-0.1	0.6	-0.0	0.6	-0.0
Week 164	n	2	2	2	2	4	4
	Mean	0.69	-0.02	0.58	-0.02	0.63	-0.02
	Median	0.69	-0.02	0.58	-0.02	0.62	-0.02
	SD	0.064	0.064	0.014	0.014	0.071	0.038
	(SE)	( 0.045)	( 0.045)	( 0.010)	( 0.010)	( 0.036)	( 0.019)
	Min,	0.6,	-0.1,	0.6,	-0.0,	0.6,	-0.1,
	Max	0.7	0.0	0.6	-0.0	0.7	0.0
Week 168	n	2	2	2	2	4	4
	Mean	0.62	-0.08	0.55	-0.06	0.58	-0.07
	Median	0.62	-0.08	0.55	-0.06	0.58	-0.06
	SD	0.085	0.085	0.064	0.064	0.075	0.063
	(SE)	( 0.060)	( 0.060)	( 0.045)	( 0.045)	( 0.038)	( 0.031)
	Min,	0.6,	-0.1,	0.5,	-0.1,	0.5,	-0.1,
	Max	0.7	-0.0	0.6	-0.0	0.7	-0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 172	n	2	2	2	2	4	4
	Mean	0.64	-0.07	0.54	-0.07	0.59	-0.07
	Median	0.64	-0.07	0.54	-0.07	0.60	-0.07
	SD	0.021	0.021	0.064	0.064	0.070	0.039
	(SE)	( 0.015)	( 0.015)	( 0.045)	( 0.045)	( 0.035)	( 0.019)
	Min, Max	0.6, 0.7	-0.1, -0.1	0.5, 0.6	-0.1, -0.0	0.5, 0.7	-0.1, -0.0
Week 176	n	2	2	2	2	4	4
	Mean	0.62	-0.08	0.56	-0.05	0.59	-0.06
	Median	0.62	-0.08	0.56	-0.05	0.62	-0.08
	SD	0.042	0.042	0.120	0.120	0.083	0.076
	(SE)	( 0.030)	( 0.030)	( 0.085)	( 0.085)	( 0.041)	( 0.038)
	Min, Max	0.6, 0.7	-0.1, -0.1	0.5, 0.6	-0.1, 0.0	0.5, 0.7	-0.1, 0.0
Week 180	n	2	2	2	2	4	4
	Mean	0.57	-0.13	0.47	-0.13	0.52	-0.13
	Median	0.57	-0.13	0.47	-0.13	0.53	-0.13
	SD	0.028	0.028	0.042	0.042	0.065	0.029
	(SE)	( 0.020)	( 0.020)	( 0.030)	( 0.030)	( 0.032)	( 0.015)
	Min, Max	0.6, 0.6	-0.2, -0.1	0.4, 0.5	-0.2, -0.1	0.4, 0.6	-0.2, -0.1

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.1.1.2  
 Summary and Change from Baseline of Serum Chemistry Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 184	n	2	2	2	2	4	4
	Mean	0.65	-0.06	0.50	-0.11	0.57	-0.08
	Median	0.65	-0.06	0.50	-0.11	0.57	-0.09
	SD	0.035	0.035	0.021	0.021	0.090	0.037
	(SE)	( 0.025)	( 0.025)	( 0.015)	( 0.015)	( 0.045)	( 0.019)
	Min,	0.6,	-0.1,	0.5,	-0.1,	0.5,	-0.1,
	Max	0.7	-0.0	0.5	-0.1	0.7	-0.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.1

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Specific Gravity							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	1.0060		1.0113		1.0086	
	Median	1.0050		1.0110		1.0055	
	SD	0.00424		0.00950		0.00737	
	(SE)	( 0.00212)		( 0.00475)		( 0.00260)	
	Min, Max	1.002, 1.012		1.001, 1.022		1.001, 1.022	
Week 2	n	4	4	4	4	8	8
	Mean	1.0090	0.0030	1.0218	0.0105	1.0154	0.0068
	Median	1.0105	0.0030	1.0225	0.0115	1.0155	0.0055
	SD	0.00572	0.00337	0.00340	0.00866	0.00809	0.00729
	(SE)	( 0.00286)	( 0.00168)	( 0.00170)	( 0.00433)	( 0.00286)	( 0.00258)
	Min, Max	1.001, 1.014	-0.001, 0.007	1.017, 1.025	0.000, 0.019	1.001, 1.025	-0.001, 0.019
Week 4	n	4	4	4	4	8	8
	Mean	1.0103	0.0043	1.0065	-0.0048	1.0084	-0.0003
	Median	1.0105	0.0070	1.0045	-0.0045	1.0070	0.0055
	SD	0.00386	0.00695	0.00592	0.01382	0.00504	0.01121
	(SE)	( 0.00193)	( 0.00347)	( 0.00296)	( 0.00691)	( 0.00178)	( 0.00396)
	Min, Max	1.006, 1.014	-0.006, 0.009	1.002, 1.015	-0.019, 0.009	1.002, 1.015	-0.019, 0.009

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.15.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	1.0140	0.0080	1.0133	0.0020	1.0136	0.0050
	Median	1.0150	0.0085	1.0125	0.0010	1.0145	0.0080
	SD	0.00683	0.00374	0.01181	0.00938	0.00894	0.00735
	(SE)	( 0.00342)	( 0.00187)	( 0.00591)	( 0.00469)	( 0.00316)	( 0.00260)
	Min,	1.005,	0.003,	1.000,	-0.006,	1.000,	-0.006,
	Max	1.021	0.012	1.028	0.012	1.028	0.012
Week 8	n	4	4	4	4	8	8
	Mean	1.0090	0.0030	1.0170	0.0058	1.0130	0.0044
	Median	1.0105	0.0065	1.0190	0.0035	1.0115	0.0050
	SD	0.00408	0.00804	0.00548	0.00780	0.00619	0.00748
	(SE)	( 0.00204)	( 0.00402)	( 0.00274)	( 0.00390)	( 0.00219)	( 0.00265)
	Min,	1.003,	-0.009,	1.009,	-0.001,	1.003,	-0.009,
	Max	1.012	0.008	1.021	0.017	1.021	0.017
Week 10	n	4	4	4	4	8	8
	Mean	1.0110	0.0050	1.0193	0.0080	1.0151	0.0065
	Median	1.0100	0.0015	1.0185	0.0080	1.0120	0.0060
	SD	0.00744	0.00990	0.00974	0.00416	0.00916	0.00721
	(SE)	( 0.00372)	( 0.00495)	( 0.00487)	( 0.00208)	( 0.00324)	( 0.00255)
	Min,	1.003,	-0.002,	1.009,	0.003,	1.003,	-0.002,
	Max	1.021	0.019	1.031	0.013	1.031	0.019

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 12	n	4	4	4	4	8	8
	Mean	1.0130	0.0070	1.0088	-0.0025	1.0109	0.0023
	Median	1.0140	0.0070	1.0015	-0.0025	1.0095	0.0050
	SD	0.00510	0.00258	0.01484	0.00961	0.01052	0.00826
	(SE)	( 0.00255)	( 0.00129)	( 0.00742)	( 0.00480)	( 0.00372)	( 0.00292)
	Min,	1.006,	0.004,	1.001,	-0.014,	1.001,	-0.014,
	Max	1.018	0.010	1.031	0.009	1.031	0.010
Week 15	n	4	4	4	4	8	8
	Mean	1.0125	0.0065	1.0163	0.0050	1.0144	0.0058
	Median	1.0095	0.0060	1.0175	0.0025	1.0125	0.0050
	SD	0.00926	0.00597	0.01090	0.01023	0.00958	0.00780
	(SE)	( 0.00463)	( 0.00299)	( 0.00545)	( 0.00512)	( 0.00339)	( 0.00276)
	Min,	1.005,	0.000,	1.002,	-0.004,	1.002,	-0.004,
	Max	1.026	0.014	1.028	0.019	1.028	0.019
Week 18	n	4	4	4	4	8	8
	Mean	1.0125	0.0065	1.0140	0.0028	1.0133	0.0046
	Median	1.0130	0.0070	1.0155	0.0015	1.0140	0.0050
	SD	0.00772	0.00580	0.00845	0.01330	0.00754	0.00971
	(SE)	( 0.00386)	( 0.00290)	( 0.00422)	( 0.00665)	( 0.00266)	( 0.00343)
	Min,	1.004,	-0.001,	1.004,	-0.012,	1.004,	-0.012,
	Max	1.020	0.013	1.021	0.020	1.021	0.020

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	1.0150	0.0090	1.0153	0.0040	1.0151	0.0065
	Median	1.0180	0.0095	1.0165	0.0055	1.0180	0.0095
	SD	0.00829	0.00627	0.00585	0.01525	0.00664	0.01112
	(SE)	( 0.00414)	( 0.00314)	( 0.00293)	( 0.00763)	( 0.00235)	( 0.00393)
	Min,	1.003,	0.001,	1.008,	-0.014,	1.003,	-0.014,
	Max	1.021	0.016	1.020	0.019	1.021	0.019
Week 24	n	4	4	4	4	8	8
	Mean	1.0160	0.0100	1.0183	0.0070	1.0171	0.0085
	Median	1.0195	0.0110	1.0175	0.0050	1.0190	0.0065
	SD	0.00735	0.00600	0.00750	0.00548	0.00698	0.00555
	(SE)	( 0.00367)	( 0.00300)	( 0.00375)	( 0.00274)	( 0.00247)	( 0.00196)
	Min,	1.005,	0.003,	1.010,	0.003,	1.005,	0.003,
	Max	1.020	0.015	1.028	0.015	1.028	0.015
Week 25	n	4	4	4	4	8	8
	Mean	1.0128	0.0068	1.0183	0.0070	1.0155	0.0069
	Median	1.0130	0.0065	1.0185	0.0050	1.0160	0.0065
	SD	0.00556	0.00492	0.00275	0.01049	0.00501	0.00759
	(SE)	( 0.00278)	( 0.00246)	( 0.00138)	( 0.00524)	( 0.00177)	( 0.00268)
	Min,	1.006,	0.001,	1.015,	-0.002,	1.006,	-0.002,
	Max	1.019	0.013	1.021	0.020	1.021	0.020

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	1.0163	0.0103	1.0150	0.0038	1.0156	0.0070
	Median	1.0160	0.0105	1.0140	0.0020	1.0150	0.0090
	SD	0.00299	0.00171	0.00668	0.00723	0.00484	0.00598
	(SE)	( 0.00149)	( 0.00085)	( 0.00334)	( 0.00361)	( 0.00171)	( 0.00211)
	Min, Max	1.013, 1.020	0.008, 0.012	1.008, 1.024	-0.003, 0.014	1.008, 1.024	-0.003, 0.014
Week 32	n	4	4	4	4	8	8
	Mean	1.0213	0.0153	1.0200	0.0088	1.0206	0.0120
	Median	1.0250	0.0165	1.0175	0.0085	1.0225	0.0110
	SD	0.01109	0.00954	0.00707	0.00818	0.00863	0.00893
	(SE)	( 0.00554)	( 0.00477)	( 0.00354)	( 0.00409)	( 0.00305)	( 0.00316)
	Min, Max	1.005, 1.030	0.003, 0.025	1.015, 1.030	-0.001, 0.019	1.005, 1.030	-0.001, 0.025
Week 36	n	4	4	4	4	8	8
	Mean	1.0225	0.0165	1.0200	0.0088	1.0213	0.0126
	Median	1.0225	0.0190	1.0225	0.0135	1.0225	0.0185
	SD	0.00289	0.00574	0.01080	0.01415	0.00744	0.01082
	(SE)	( 0.00144)	( 0.00287)	( 0.00540)	( 0.00708)	( 0.00263)	( 0.00383)
	Min, Max	1.020, 1.025	0.008, 0.020	1.005, 1.030	-0.011, 0.019	1.005, 1.030	-0.011, 0.020

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 40	n	4	4	4	4	8	8
	Mean	1.0213	0.0153	1.0175	0.0063	1.0194	0.0108
	Median	1.0225	0.0140	1.0175	0.0035	1.0225	0.0115
	SD	0.00479	0.00556	0.01443	0.01704	0.01016	0.01268
	(SE)	( 0.00239)	( 0.00278)	( 0.00722)	( 0.00852)	( 0.00359)	( 0.00448)
	Min,	1.015,	0.010,	1.005,	-0.011,	1.005,	-0.011,
	Max	1.025	0.023	1.030	0.029	1.030	0.029
Week 44	n	4	4	4	4	8	8
	Mean	1.0200	0.0140	1.0163	0.0050	1.0181	0.0095
	Median	1.0225	0.0165	1.0125	0.0015	1.0175	0.0120
	SD	0.01080	0.00762	0.00946	0.01828	0.00961	0.01383
	(SE)	( 0.00540)	( 0.00381)	( 0.00473)	( 0.00914)	( 0.00340)	( 0.00489)
	Min,	1.005,	0.003,	1.010,	-0.012,	1.005,	-0.012,
	Max	1.030	0.020	1.030	0.029	1.030	0.029
Week 48	n	4	4	4	4	8	8
	Mean	1.0188	0.0128	1.0225	0.0113	1.0206	0.0120
	Median	1.0200	0.0140	1.0225	0.0115	1.0200	0.0135
	SD	0.00629	0.00556	0.00289	0.01081	0.00496	0.00800
	(SE)	( 0.00315)	( 0.00278)	( 0.00144)	( 0.00541)	( 0.00175)	( 0.00283)
	Min,	1.010,	0.005,	1.020,	-0.002,	1.010,	-0.002,
	Max	1.025	0.018	1.025	0.024	1.025	0.024

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	1.0125	0.0065	1.0200	0.0088	1.0163	0.0076
	Median	1.0100	0.0065	1.0200	0.0090	1.0175	0.0070
	SD	0.00957	0.00603	0.00816	0.01723	0.00916	0.01201
	(SE)	( 0.00479)	( 0.00301)	( 0.00408)	( 0.00862)	( 0.00324)	( 0.00425)
	Min,	1.005,	0.000,	1.010,	-0.012,	1.005,	-0.012,
	Max	1.025	0.013	1.030	0.029	1.030	0.029
Week 56	n	4	4	3	3	7	7
	Mean	1.0163	0.0103	1.0267	0.0190	1.0207	0.0140
	Median	1.0150	0.0100	1.0250	0.0190	1.0250	0.0150
	SD	0.01109	0.00737	0.00289	0.00500	0.00976	0.00757
	(SE)	( 0.00554)	( 0.00368)	( 0.00167)	( 0.00289)	( 0.00369)	( 0.00286)
	Min,	1.005,	0.003,	1.025,	0.014,	1.005,	0.003,
	Max	1.030	0.018	1.030	0.024	1.030	0.024
Week 60	n	4	4	4	4	8	8
	Mean	1.0225	0.0165	1.0225	0.0113	1.0225	0.0139
	Median	1.0250	0.0165	1.0225	0.0115	1.0225	0.0145
	SD	0.00957	0.00705	0.00645	0.01081	0.00756	0.00890
	(SE)	( 0.00479)	( 0.00352)	( 0.00323)	( 0.00541)	( 0.00267)	( 0.00315)
	Min,	1.010,	0.008,	1.015,	-0.002,	1.010,	-0.002,
	Max	1.030	0.025	1.030	0.024	1.030	0.025

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	1.0150	0.0090	1.0175	0.0063	1.0163	0.0076
	Median	1.0150	0.0080	1.0175	0.0090	1.0150	0.0080
	SD	0.00577	0.00424	0.01190	0.01752	0.00876	0.01189
	(SE)	( 0.00289)	( 0.00212)	( 0.00595)	( 0.00876)	( 0.00310)	( 0.00420)
	Min,	1.010,	0.005,	1.005,	-0.017,	1.005,	-0.017,
	Max	1.020	0.015	1.030	0.024	1.030	0.024
Week 68	n	4	4	4	4	8	8
	Mean	1.0150	0.0090	1.0213	0.0100	1.0181	0.0095
	Median	1.0150	0.0100	1.0225	0.0165	1.0200	0.0145
	SD	0.00577	0.00920	0.00854	0.01485	0.00753	0.01145
	(SE)	( 0.00289)	( 0.00460)	( 0.00427)	( 0.00743)	( 0.00266)	( 0.00405)
	Min,	1.010,	-0.002,	1.010,	-0.012,	1.010,	-0.012,
	Max	1.020	0.018	1.030	0.019	1.030	0.019
Week 72	n	4	4	4	4	8	8
	Mean	1.0200	0.0140	1.0200	0.0088	1.0200	0.0114
	Median	1.0200	0.0125	1.0175	0.0115	1.0200	0.0120
	SD	0.00408	0.00668	0.00707	0.01127	0.00535	0.00902
	(SE)	( 0.00204)	( 0.00334)	( 0.00354)	( 0.00563)	( 0.00189)	( 0.00319)
	Min,	1.015,	0.008,	1.015,	-0.007,	1.015,	-0.007,
	Max	1.025	0.023	1.030	0.019	1.030	0.023

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	0	0	0	0
	Mean						
	Median						
	SD						
	(SE)						
	Min,						
	Max						
Week 76	n	4	4	4	4	8	8
	Mean	1.0100	0.0040	1.0225	0.0113	1.0163	0.0076
	Median	1.0100	0.0030	1.0225	0.0115	1.0150	0.0060
	SD	0.00577	0.00424	0.00866	0.01484	0.00954	0.01082
	(SE)	( 0.00289)	( 0.00212)	( 0.00433)	( 0.00742)	( 0.00337)	( 0.00383)
	Min,	1.005,	0.000,	1.015,	-0.007,	1.005,	-0.007,
	Max	1.015	0.010	1.030	0.029	1.030	0.029
Week 80	n	4	4	4	4	8	8
	Mean	1.0113	0.0053	1.0163	0.0050	1.0138	0.0051
	Median	1.0125	0.0050	1.0175	-0.0010	1.0150	-0.0005
	SD	0.00479	0.00737	0.00854	0.01268	0.00694	0.00960
	(SE)	( 0.00239)	( 0.00368)	( 0.00427)	( 0.00634)	( 0.00245)	( 0.00339)
	Min,	1.005,	-0.002,	1.005,	-0.002,	1.005,	-0.002,
	Max	1.015	0.013	1.025	0.024	1.025	0.024

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 84	n	4	4	4	4	8	8
	Mean	1.0175	0.0115	1.0125	0.0012	1.0150	0.0064
	Median	1.0175	0.0115	1.0100	-0.0010	1.0150	0.0095
	SD	0.00645	0.00311	0.00957	0.01880	0.00802	0.01363
	(SE)	( 0.00323)	( 0.00155)	( 0.00479)	( 0.00940)	( 0.00283)	( 0.00482)
	Min,	1.010,	0.008,	1.005,	-0.017,	1.005,	-0.017,
	Max	1.025	0.015	1.025	0.024	1.025	0.024
Week 88	n	4	4	4	4	8	8
	Mean	1.0188	0.0128	1.0213	0.0100	1.0200	0.0114
	Median	1.0200	0.0130	1.0225	0.0115	1.0200	0.0115
	SD	0.00629	0.00737	0.00854	0.01695	0.00707	0.01219
	(SE)	( 0.00315)	( 0.00368)	( 0.00427)	( 0.00848)	( 0.00250)	( 0.00431)
	Min,	1.010,	0.005,	1.010,	-0.012,	1.010,	-0.012,
	Max	1.025	0.020	1.030	0.029	1.030	0.029
Week 92	n	4	4	4	4	8	8
	Mean	1.0175	0.0115	1.0163	0.0050	1.0169	0.0083
	Median	1.0175	0.0115	1.0175	0.0090	1.0175	0.0115
	SD	0.00289	0.00311	0.00854	0.01744	0.00594	0.01210
	(SE)	( 0.00144)	( 0.00155)	( 0.00427)	( 0.00872)	( 0.00210)	( 0.00428)
	Min,	1.015,	0.008,	1.005,	-0.017,	1.005,	-0.017,
	Max	1.020	0.015	1.025	0.019	1.025	0.019

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	1.0225	0.0165	1.0213	0.0100	1.0219	0.0133
	Median	1.0225	0.0175	1.0200	0.0090	1.0200	0.0145
	SD	0.00289	0.00656	0.00250	0.01143	0.00259	0.00930
	(SE)	( 0.00144)	( 0.00328)	( 0.00125)	( 0.00572)	( 0.00091)	( 0.00329)
	Min,	1.020,	0.008,	1.020,	-0.002,	1.020,	-0.002,
	Max	1.025	0.023	1.025	0.024	1.025	0.024
Week 100	n	4	4	4	4	8	8
	Mean	1.0225	0.0165	1.0163	0.0050	1.0194	0.0108
	Median	1.0225	0.0150	1.0150	0.0040	1.0200	0.0140
	SD	0.00289	0.00443	0.00629	0.01530	0.00563	0.01210
	(SE)	( 0.00144)	( 0.00222)	( 0.00315)	( 0.00765)	( 0.00199)	( 0.00428)
	Min,	1.020,	0.013,	1.010,	-0.012,	1.010,	-0.012,
	Max	1.025	0.023	1.025	0.024	1.025	0.024
Week 104	n	4	4	4	4	8	8
	Mean	1.0163	0.0103	1.0150	0.0038	1.0156	0.0070
	Median	1.0150	0.0115	1.0150	0.0065	1.0150	0.0115
	SD	0.00629	0.00377	0.00913	0.01817	0.00729	0.01264
	(SE)	( 0.00315)	( 0.00189)	( 0.00456)	( 0.00909)	( 0.00258)	( 0.00447)
	Min,	1.010,	0.005,	1.005,	-0.017,	1.005,	-0.017,
	Max	1.025	0.013	1.025	0.019	1.025	0.019

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	4	4	4	4	8	8
	Mean	1.0200	0.0140	1.0150	0.0038	1.0175	0.0089
	Median	1.0200	0.0140	1.0175	0.0065	1.0175	0.0095
	SD	0.00913	0.00589	0.00707	0.01517	0.00802	0.01198
	(SE)	( 0.00456)	( 0.00294)	( 0.00354)	( 0.00759)	( 0.00283)	( 0.00424)
	Min,	1.010,	0.008,	1.005,	-0.017,	1.005,	-0.017,
	Max	1.030	0.020	1.020	0.019	1.030	0.020
Week 112	n	4	4	4	4	8	8
	Mean	1.0163	0.0103	1.0150	0.0038	1.0156	0.0070
	Median	1.0175	0.0115	1.0125	0.0015	1.0175	0.0110
	SD	0.00479	0.00585	0.01225	0.02153	0.00863	0.01501
	(SE)	( 0.00239)	( 0.00293)	( 0.00612)	( 0.01077)	( 0.00305)	( 0.00531)
	Min,	1.010,	0.003,	1.005,	-0.017,	1.005,	-0.017,
	Max	1.020	0.015	1.030	0.029	1.030	0.029
Week 116	n	4	4	4	4	8	8
	Mean	1.0138	0.0078	1.0150	0.0038	1.0144	0.0058
	Median	1.0150	0.0090	1.0175	0.0090	1.0150	0.0090
	SD	0.00629	0.00330	0.00707	0.01461	0.00623	0.01004
	(SE)	( 0.00315)	( 0.00165)	( 0.00354)	( 0.00731)	( 0.00220)	( 0.00355)
	Min,	1.005,	0.003,	1.005,	-0.017,	1.005,	-0.017,
	Max	1.020	0.010	1.020	0.014	1.020	0.014

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	4	4	4	4	8	8
	Mean	1.0213	0.0153	1.0188	0.0075	1.0200	0.0114
	Median	1.0200	0.0150	1.0200	0.0115	1.0200	0.0145
	SD	0.00629	0.01021	0.00629	0.01363	0.00598	0.01189
	(SE)	( 0.00315)	( 0.00511)	( 0.00315)	( 0.00681)	( 0.00211)	( 0.00420)
	Min,	1.015,	0.003,	1.010,	-0.012,	1.010,	-0.012,
	Max	1.030	0.028	1.025	0.019	1.030	0.028
Week 124	n	4	4	4	4	8	8
	Mean	1.0213	0.0153	1.0213	0.0100	1.0213	0.0126
	Median	1.0200	0.0165	1.0225	0.0140	1.0200	0.0165
	SD	0.00629	0.00377	0.00479	0.01227	0.00518	0.00886
	(SE)	( 0.00315)	( 0.00189)	( 0.00239)	( 0.00614)	( 0.00183)	( 0.00313)
	Min,	1.015,	0.010,	1.015,	-0.007,	1.015,	-0.007,
	Max	1.030	0.018	1.025	0.019	1.030	0.019
Week 128	n	4	4	4	4	8	8
	Mean	1.0163	0.0103	1.0250	0.0138	1.0206	0.0120
	Median	1.0150	0.0115	1.0250	0.0140	1.0200	0.0115
	SD	0.00750	0.00954	0.00577	0.01506	0.00776	0.01182
	(SE)	( 0.00375)	( 0.00477)	( 0.00289)	( 0.00753)	( 0.00274)	( 0.00418)
	Min,	1.010,	-0.002,	1.020,	-0.002,	1.010,	-0.002,
	Max	1.025	0.020	1.030	0.029	1.030	0.029

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	1.0163	0.0103	1.0263	0.0150	1.0213	0.0126
	Median	1.0175	0.0115	1.0275	0.0140	1.0200	0.0140
	SD	0.00479	0.00585	0.00479	0.00663	0.00694	0.00632
	(SE)	( 0.00239)	( 0.00293)	( 0.00239)	( 0.00332)	( 0.00245)	( 0.00224)
	Min, Max	1.010, 1.020	0.003, 0.015	1.020, 1.030	0.008, 0.024	1.010, 1.030	0.003, 0.024
Week 136	n	4	4	4	4	8	8
	Mean	1.0175	0.0115	1.0263	0.0150	1.0219	0.0133
	Median	1.0200	0.0150	1.0275	0.0165	1.0225	0.0150
	SD	0.00866	0.01290	0.00479	0.01294	0.00799	0.01210
	(SE)	( 0.00433)	( 0.00645)	( 0.00239)	( 0.00647)	( 0.00282)	( 0.00428)
	Min, Max	1.005, 1.025	-0.007, 0.023	1.020, 1.030	-0.002, 0.029	1.005, 1.030	-0.007, 0.029
Week 140	n	4	4	4	4	8	8
	Mean	1.0150	0.0090	1.0213	0.0100	1.0181	0.0095
	Median	1.0150	0.0090	1.0200	0.0090	1.0175	0.0090
	SD	0.00408	0.00115	0.00629	0.01344	0.00594	0.00885
	(SE)	( 0.00204)	( 0.00058)	( 0.00315)	( 0.00672)	( 0.00210)	( 0.00313)
	Min, Max	1.010, 1.020	0.008, 0.010	1.015, 1.030	-0.002, 0.024	1.010, 1.030	-0.002, 0.024

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 144	n	4	4	4	4	8	8
	Mean	1.0113	0.0053	1.0200	0.0088	1.0156	0.0070
	Median	1.0100	0.0065	1.0200	0.0060	1.0125	0.0065
	SD	0.00250	0.00525	0.00816	0.01603	0.00729	0.01120
	(SE)	( 0.00125)	( 0.00263)	( 0.00408)	( 0.00801)	( 0.00258)	( 0.00396)
	Min,	1.010,	-0.002,	1.010,	-0.006,	1.010,	-0.006,
	Max	1.015	0.010	1.030	0.029	1.030	0.029
Week 148	n	4	4	4	4	8	8
	Mean	1.0200	0.0140	1.0263	0.0150	1.0231	0.0145
	Median	1.0225	0.0175	1.0275	0.0115	1.0250	0.0145
	SD	0.00707	0.01117	0.00479	0.00970	0.00651	0.00970
	(SE)	( 0.00354)	( 0.00558)	( 0.00239)	( 0.00485)	( 0.00230)	( 0.00343)
	Min,	1.010,	-0.002,	1.020,	0.008,	1.010,	-0.002,
	Max	1.025	0.023	1.030	0.029	1.030	0.029
Week 152	n	2	2	4	4	6	6
	Mean	1.0225	0.0155	1.0213	0.0100	1.0217	0.0118
	Median	1.0225	0.0155	1.0225	0.0090	1.0225	0.0110
	SD	0.00354	0.00354	0.00479	0.00663	0.00408	0.00608
	(SE)	( 0.00250)	( 0.00250)	( 0.00239)	( 0.00332)	( 0.00167)	( 0.00248)
	Min,	1.020,	0.013,	1.015,	0.003,	1.015,	0.003,
	Max	1.025	0.018	1.025	0.019	1.025	0.019

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 156	n	4	4	4	4	8	8
	Mean	1.0150	0.0090	1.0250	0.0138	1.0200	0.0114
	Median	1.0150	0.0115	1.0275	0.0165	1.0200	0.0130
	SD	0.00816	0.00616	0.00707	0.01517	0.00886	0.01102
	(SE)	( 0.00408)	( 0.00308)	( 0.00354)	( 0.00759)	( 0.00313)	( 0.00390)
	Min,	1.005,	0.000,	1.015,	-0.007,	1.005,	-0.007,
	Max	1.025	0.013	1.030	0.029	1.030	0.029
Week 160	n	4	4	4	4	8	8
	Mean	1.0175	0.0115	1.0263	0.0150	1.0219	0.0133
	Median	1.0175	0.0140	1.0250	0.0165	1.0250	0.0165
	SD	0.00866	0.01063	0.00250	0.00898	0.00753	0.00930
	(SE)	( 0.00433)	( 0.00532)	( 0.00125)	( 0.00449)	( 0.00266)	( 0.00329)
	Min,	1.010,	-0.002,	1.025,	0.003,	1.010,	-0.002,
	Max	1.025	0.020	1.030	0.024	1.030	0.024
Week 164	n	4	4	4	4	8	8
	Mean	1.0175	0.0115	1.0250	0.0138	1.0213	0.0126
	Median	1.0175	0.0125	1.0275	0.0115	1.0200	0.0120
	SD	0.00289	0.00656	0.00707	0.01112	0.00641	0.00853
	(SE)	( 0.00144)	( 0.00328)	( 0.00354)	( 0.00556)	( 0.00227)	( 0.00302)
	Min,	1.015,	0.003,	1.015,	0.003,	1.015,	0.003,
	Max	1.020	0.018	1.030	0.029	1.030	0.029

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	1.0200	0.0140	1.0250	0.0138	1.0225	0.0139
	Median	1.0200	0.0125	1.0250	0.0115	1.0225	0.0120
	SD	0.00408	0.00668	0.00408	0.00732	0.00463	0.00649
	(SE)	( 0.00204)	( 0.00334)	( 0.00204)	( 0.00366)	( 0.00164)	( 0.00229)
	Min,	1.015,	0.008,	1.020,	0.008,	1.015,	0.008,
	Max	1.025	0.023	1.030	0.024	1.030	0.024
Week 172	n	4	4	4	4	8	8
	Mean	1.0188	0.0128	1.0250	0.0138	1.0219	0.0133
	Median	1.0175	0.0140	1.0275	0.0115	1.0250	0.0115
	SD	0.01031	0.01215	0.00707	0.00732	0.00884	0.00930
	(SE)	( 0.00515)	( 0.00607)	( 0.00354)	( 0.00366)	( 0.00312)	( 0.00329)
	Min,	1.010,	-0.002,	1.015,	0.008,	1.010,	-0.002,
	Max	1.030	0.025	1.030	0.024	1.030	0.025
Week 176	n	4	4	4	4	8	8
	Mean	1.0188	0.0128	1.0263	0.0150	1.0225	0.0139
	Median	1.0200	0.0165	1.0275	0.0140	1.0225	0.0145
	SD	0.00629	0.01005	0.00479	0.01068	0.00655	0.00967
	(SE)	( 0.00315)	( 0.00502)	( 0.00239)	( 0.00534)	( 0.00231)	( 0.00342)
	Min,	1.010,	-0.002,	1.020,	0.003,	1.010,	-0.002,
	Max	1.025	0.020	1.030	0.029	1.030	0.029

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	4	4	4	4	8	8
	Mean	1.0125	0.0065	1.0238	0.0125	1.0181	0.0095
	Median	1.0125	0.0090	1.0250	0.0140	1.0175	0.0095
	SD	0.00289	0.00574	0.00250	0.01150	0.00651	0.00901
	(SE)	( 0.00144)	( 0.00287)	( 0.00125)	( 0.00575)	( 0.00230)	( 0.00318)
	Min,	1.010,	-0.002,	1.020,	-0.002,	1.010,	-0.002,
	Max	1.015	0.010	1.025	0.024	1.025	0.024
Week 184	n	4	4	4	4	8	8
	Mean	1.0200	0.0140	1.0263	0.0150	1.0231	0.0145
	Median	1.0225	0.0190	1.0275	0.0165	1.0250	0.0190
	SD	0.01080	0.01465	0.00479	0.01417	0.00843	0.01335
	(SE)	( 0.00540)	( 0.00733)	( 0.00239)	( 0.00708)	( 0.00298)	( 0.00472)
	Min,	1.005,	-0.007,	1.020,	-0.002,	1.005,	-0.007,
	Max	1.030	0.025	1.030	0.029	1.030	0.029

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
pH							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	6.25		6.25		6.25	
	Median	6.25		6.00		6.25	
	SD	0.645		0.957		0.756	
	(SE)	( 0.323)		( 0.479)		( 0.267)	
	Min, Max	5.5, 7.0		5.5, 7.5		5.5, 7.5	
Week 2	n	4	4	4	4	8	8
	Mean	5.88	-0.38	6.13	-0.13	6.00	-0.25
	Median	5.75	-0.50	6.00	0.00	6.00	-0.50
	SD	0.854	1.031	0.250	1.109	0.598	1.000
	(SE)	( 0.427)	( 0.515)	( 0.125)	( 0.554)	( 0.211)	( 0.354)
	Min, Max	5.0, 7.0	-1.5, 1.0	6.0, 6.5	-1.5, 1.0	5.0, 7.0	-1.5, 1.0
Week 4	n	4	4	4	4	8	8
	Mean	6.63	0.38	6.38	0.13	6.50	0.25
	Median	6.25	0.25	6.50	0.00	6.50	0.25
	SD	0.946	0.479	0.629	1.315	0.756	0.926
	(SE)	( 0.473)	( 0.239)	( 0.315)	( 0.657)	( 0.267)	( 0.327)
	Min, Max	6.0, 8.0	0.0, 1.0	5.5, 7.0	-1.0, 1.5	5.5, 8.0	-1.0, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	4	4	4	4	8	8
	Mean	5.88	-0.38	6.38	0.13	6.13	-0.13
	Median	5.50	-0.75	5.75	-0.25	5.50	-0.75
	SD	0.750	1.315	1.436	2.175	1.094	1.685
	(SE)	( 0.375)	( 0.657)	( 0.718)	( 1.087)	( 0.387)	( 0.596)
	Min, Max	5.5, 7.0	-1.5, 1.5	5.5, 8.5	-2.0, 3.0	5.5, 8.5	-2.0, 3.0
Week 8	n	4	4	4	4	8	8
	Mean	6.63	0.38	6.38	0.13	6.50	0.25
	Median	7.00	0.50	6.75	0.00	7.00	0.50
	SD	1.109	0.629	0.946	1.109	0.964	0.845
	(SE)	( 0.554)	( 0.315)	( 0.473)	( 0.554)	( 0.341)	( 0.299)
	Min, Max	5.0, 7.5	-0.5, 1.0	5.0, 7.0	-1.0, 1.5	5.0, 7.5	-1.0, 1.5
Week 10	n	4	4	4	4	8	8
	Mean	6.00	-0.25	6.25	0.00	6.13	-0.13
	Median	6.00	-0.25	6.25	0.25	6.25	0.00
	SD	0.913	1.041	0.289	1.080	0.641	0.991
	(SE)	( 0.456)	( 0.520)	( 0.144)	( 0.540)	( 0.227)	( 0.350)
	Min, Max	5.0, 7.0	-1.5, 1.0	6.0, 6.5	-1.5, 1.0	5.0, 7.0	-1.5, 1.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 12	n	4	4	4	4	8	8
	Mean	7.00	0.75	6.63	0.38	6.81	0.56
	Median	7.00	0.50	6.75	0.25	7.00	0.50
	SD	0.408	0.500	0.854	1.250	0.651	0.904
	(SE)	( 0.204)	( 0.250)	( 0.427)	( 0.625)	( 0.230)	( 0.320)
	Min,	6.5,	0.5,	5.5,	-1.0,	5.5,	-1.0,
	Max	7.5	1.5	7.5	2.0	7.5	2.0
Week 15	n	4	4	4	4	8	8
	Mean	6.13	-0.13	5.63	-0.63	5.88	-0.38
	Median	6.25	-0.25	5.50	-0.75	5.50	-0.50
	SD	1.031	0.854	0.629	1.250	0.835	1.026
	(SE)	( 0.515)	( 0.427)	( 0.315)	( 0.625)	( 0.295)	( 0.363)
	Min,	5.0,	-1.0,	5.0,	-2.0,	5.0,	-2.0,
	Max	7.0	1.0	6.5	1.0	7.0	1.0
Week 18	n	4	4	4	4	8	8
	Mean	5.88	-0.38	5.75	-0.50	5.81	-0.44
	Median	6.00	0.00	6.00	-0.50	6.00	0.00
	SD	0.750	1.109	0.500	1.155	0.594	1.050
	(SE)	( 0.375)	( 0.554)	( 0.250)	( 0.577)	( 0.210)	( 0.371)
	Min,	5.0,	-2.0,	5.0,	-1.5,	5.0,	-2.0,
	Max	6.5	0.5	6.0	0.5	6.5	0.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	5.38	-0.88	5.63	-0.63	5.50	-0.75
	Median	5.50	-0.75	5.75	-0.50	5.50	-0.50
	SD	0.250	0.854	0.479	1.031	0.378	0.886
	(SE)	( 0.125)	( 0.427)	( 0.239)	( 0.515)	( 0.134)	( 0.313)
	Min, Max	5.0, 5.5	-2.0, 0.0	5.0, 6.0	-2.0, 0.5	5.0, 6.0	-2.0, 0.5
Week 24	n	4	4	4	4	8	8
	Mean	5.88	-0.38	6.38	0.13	6.13	-0.13
	Median	5.50	-0.25	6.25	0.00	6.00	0.00
	SD	1.181	1.250	0.854	1.436	0.991	1.275
	(SE)	( 0.591)	( 0.625)	( 0.427)	( 0.718)	( 0.350)	( 0.451)
	Min, Max	5.0, 7.5	-2.0, 1.0	5.5, 7.5	-1.5, 2.0	5.0, 7.5	-2.0, 2.0
Week 25	n	4	4	4	4	8	8
	Mean	6.38	0.13	5.75	-0.50	6.06	-0.19
	Median	6.75	0.00	5.75	-0.50	6.00	0.00
	SD	0.946	0.629	0.289	0.913	0.729	0.799
	(SE)	( 0.473)	( 0.315)	( 0.144)	( 0.456)	( 0.258)	( 0.282)
	Min, Max	5.0, 7.0	-0.5, 1.0	5.5, 6.0	-1.5, 0.5	5.0, 7.0	-1.5, 1.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	5.50	-0.75	5.63	-0.63	5.56	-0.69
	Median	5.50	-0.75	5.50	-0.25	5.50	-0.50
	SD	0.000	0.645	0.250	0.946	0.177	0.753
	(SE)	( 0.000)	( 0.323)	( 0.125)	( 0.473)	( 0.063)	( 0.266)
	Min, Max	5.5, 5.5	-1.5, 0.0	5.5, 6.0	-2.0, 0.0	5.5, 6.0	-2.0, 0.0
Week 32	n	4	4	4	4	8	8
	Mean	6.38	0.13	6.63	0.38	6.50	0.25
	Median	6.25	0.00	6.50	0.25	6.50	0.00
	SD	0.479	1.031	0.629	1.377	0.535	1.134
	(SE)	( 0.239)	( 0.515)	( 0.315)	( 0.688)	( 0.189)	( 0.401)
	Min, Max	6.0, 7.0	-1.0, 1.5	6.0, 7.5	-1.0, 2.0	6.0, 7.5	-1.0, 2.0
Week 36	n	4	4	4	4	8	8
	Mean	6.50	0.25	6.63	0.38	6.56	0.31
	Median	6.50	0.50	6.50	0.25	6.50	0.50
	SD	0.408	0.500	0.629	1.250	0.496	0.884
	(SE)	( 0.204)	( 0.250)	( 0.315)	( 0.625)	( 0.175)	( 0.313)
	Min, Max	6.0, 7.0	-0.5, 0.5	6.0, 7.5	-1.0, 2.0	6.0, 7.5	-1.0, 2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	6.25	0.00	6.63	0.38	6.44	0.19
	Median	6.25	0.00	6.75	0.50	6.50	0.50
	SD	0.289	0.577	0.479	0.629	0.417	0.594
	(SE)	( 0.144)	( 0.289)	( 0.239)	( 0.315)	( 0.148)	( 0.210)
	Min, Max	6.0, 6.5	-0.5, 0.5	6.0, 7.0	-0.5, 1.0	6.0, 7.0	-0.5, 1.0
Week 44	n	4	4	4	4	8	8
	Mean	6.88	0.63	6.63	0.38	6.75	0.50
	Median	7.00	0.50	6.50	0.50	6.75	0.50
	SD	0.629	1.109	0.250	1.109	0.463	1.035
	(SE)	( 0.315)	( 0.554)	( 0.125)	( 0.554)	( 0.164)	( 0.366)
	Min, Max	6.0, 7.5	-0.5, 2.0	6.5, 7.0	-1.0, 1.5	6.0, 7.5	-1.0, 2.0
Week 48	n	4	4	4	4	8	8
	Mean	6.63	0.38	6.38	0.13	6.50	0.25
	Median	6.50	0.50	6.25	0.50	6.50	0.50
	SD	0.250	0.629	0.479	1.109	0.378	0.845
	(SE)	( 0.125)	( 0.315)	( 0.239)	( 0.554)	( 0.134)	( 0.299)
	Min, Max	6.5, 7.0	-0.5, 1.0	6.0, 7.0	-1.5, 1.0	6.0, 7.0	-1.5, 1.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	7.38	1.13	6.88	0.63	7.13	0.88
	Median	7.50	1.25	6.75	0.50	7.25	1.00
	SD	0.629	0.479	0.479	1.109	0.582	0.835
	(SE)	( 0.315)	( 0.239)	( 0.239)	( 0.554)	( 0.206)	( 0.295)
	Min, Max	6.5, 8.0	0.5, 1.5	6.5, 7.5	-0.5, 2.0	6.5, 8.0	-0.5, 2.0
Week 56	n	4	4	3	3	7	7
	Mean	6.63	0.38	6.33	-0.17	6.50	0.14
	Median	6.50	0.25	6.50	0.00	6.50	0.00
	SD	0.250	0.854	0.289	0.764	0.289	0.802
	(SE)	( 0.125)	( 0.427)	( 0.167)	( 0.441)	( 0.109)	( 0.303)
	Min, Max	6.5, 7.0	-0.5, 1.5	6.0, 6.5	-1.0, 0.5	6.0, 7.0	-1.0, 1.5
Week 60	n	4	4	4	4	8	8
	Mean	6.63	0.38	6.50	0.25	6.56	0.31
	Median	6.50	0.00	6.25	0.25	6.25	0.00
	SD	0.750	1.109	0.707	1.555	0.678	1.252
	(SE)	( 0.375)	( 0.554)	( 0.354)	( 0.777)	( 0.240)	( 0.443)
	Min, Max	6.0, 7.5	-0.5, 2.0	6.0, 7.5	-1.5, 2.0	6.0, 7.5	-1.5, 2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	4	4	4	8	8
	Mean	7.25	1.00	6.75	0.50	7.00	0.75
	Median	7.25	1.00	6.75	0.25	7.00	0.75
	SD	0.289	0.816	0.645	0.707	0.535	0.756
	(SE)	( 0.144)	( 0.408)	( 0.323)	( 0.354)	( 0.189)	( 0.267)
	Min, Max	7.0, 7.5	0.0, 2.0	6.0, 7.5	0.0, 1.5	6.0, 7.5	0.0, 2.0
Week 68	n	4	4	4	4	8	8
	Mean	7.25	1.00	6.38	0.13	6.81	0.56
	Median	7.25	1.25	6.50	0.25	6.75	0.75
	SD	0.289	0.707	0.250	0.854	0.530	0.863
	(SE)	( 0.144)	( 0.354)	( 0.125)	( 0.427)	( 0.188)	( 0.305)
	Min, Max	7.0, 7.5	0.0, 1.5	6.0, 6.5	-1.0, 1.0	6.0, 7.5	-1.0, 1.5
Week 72	n	4	4	4	4	8	8
	Mean	7.00	0.75	7.13	0.88	7.06	0.81
	Median	7.00	0.75	7.25	1.00	7.25	0.75
	SD	0.577	0.645	0.479	1.315	0.496	0.961
	(SE)	( 0.289)	( 0.323)	( 0.239)	( 0.657)	( 0.175)	( 0.340)
	Min, Max	6.5, 7.5	0.0, 1.5	6.5, 7.5	-0.5, 2.0	6.5, 7.5	-0.5, 2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	0	0	0	0
	Mean						
	Median						
	SD						
	(SE)						
	Min,						
	Max						
Week 76	n	4	4	4	4	8	8
	Mean	7.25	1.00	6.75	0.50	7.00	0.75
	Median	7.00	1.25	6.50	0.75	7.00	1.00
	SD	0.500	0.707	0.866	0.707	0.707	0.707
	(SE)	( 0.250)	( 0.354)	( 0.433)	( 0.354)	( 0.250)	( 0.250)
	Min,	7.0,	0.0,	6.0,	-0.5,	6.0,	-0.5,
	Max	8.0	1.5	8.0	1.0	8.0	1.5
Week 80	n	4	4	4	4	8	8
	Mean	7.00	0.75	6.50	0.25	6.75	0.50
	Median	7.00	0.50	6.50	0.50	6.75	0.50
	SD	0.408	0.866	0.408	0.866	0.463	0.845
	(SE)	( 0.204)	( 0.433)	( 0.204)	( 0.433)	( 0.164)	( 0.299)
	Min,	6.5,	0.0,	6.0,	-1.0,	6.0,	-1.0,
	Max	7.5	2.0	7.0	1.0	7.5	2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	4	4	4	8	8
	Mean	7.50	1.25	6.50	0.25	7.00	0.75
	Median	7.50	1.25	6.50	0.50	7.25	0.50
	SD	0.000	0.645	0.577	0.500	0.655	0.756
	(SE)	( 0.000)	( 0.323)	( 0.289)	( 0.250)	( 0.231)	( 0.267)
	Min, Max	7.5, 7.5	0.5, 2.0	6.0, 7.0	-0.5, 0.5	6.0, 7.5	-0.5, 2.0
Week 88	n	4	4	4	4	8	8
	Mean	7.00	0.75	6.25	0.00	6.63	0.38
	Median	7.25	1.25	6.00	0.00	6.50	0.75
	SD	0.707	1.190	0.500	1.291	0.694	1.217
	(SE)	( 0.354)	( 0.595)	( 0.250)	( 0.645)	( 0.245)	( 0.430)
	Min, Max	6.0, 7.5	-1.0, 1.5	6.0, 7.0	-1.5, 1.5	6.0, 7.5	-1.5, 1.5
Week 92	n	4	4	4	4	8	8
	Mean	7.38	1.13	6.50	0.25	6.94	0.69
	Median	7.50	1.00	6.50	0.00	7.00	0.75
	SD	0.250	0.629	0.577	0.957	0.623	0.884
	(SE)	( 0.125)	( 0.315)	( 0.289)	( 0.479)	( 0.220)	( 0.313)
	Min, Max	7.0, 7.5	0.5, 2.0	6.0, 7.0	-0.5, 1.5	6.0, 7.5	-0.5, 2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	6.63	0.38	6.38	0.13	6.50	0.25
	Median	6.75	0.25	6.00	0.25	6.25	0.25
	SD	0.854	0.479	0.750	0.479	0.756	0.463
	(SE)	( 0.427)	( 0.239)	( 0.375)	( 0.239)	( 0.267)	( 0.164)
	Min, Max	5.5, 7.5	0.0, 1.0	6.0, 7.5	-0.5, 0.5	5.5, 7.5	-0.5, 1.0
Week 100	n	4	4	4	4	8	8
	Mean	7.13	0.88	6.75	0.50	6.94	0.69
	Median	7.25	0.50	6.50	0.50	6.75	0.50
	SD	0.854	0.750	0.866	0.408	0.821	0.594
	(SE)	( 0.427)	( 0.375)	( 0.433)	( 0.204)	( 0.290)	( 0.210)
	Min, Max	6.0, 8.0	0.5, 2.0	6.0, 8.0	0.0, 1.0	6.0, 8.0	0.0, 2.0
Week 104	n	4	4	4	4	8	8
	Mean	6.38	0.13	6.50	0.25	6.44	0.19
	Median	6.25	0.25	6.50	0.50	6.50	0.25
	SD	0.479	0.479	0.000	0.957	0.320	0.704
	(SE)	( 0.239)	( 0.239)	( 0.000)	( 0.479)	( 0.113)	( 0.249)
	Min, Max	6.0, 7.0	-0.5, 0.5	6.5, 6.5	-1.0, 1.0	6.0, 7.0	-1.0, 1.0

\*Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		Change from Baseline
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	4	4	4	4	8	8
	Mean	7.38	1.13	6.63	0.38	7.00	0.75
	Median	7.50	1.00	6.75	0.25	7.00	1.00
	SD	0.629	0.250	0.479	1.031	0.655	0.802
	(SE)	( 0.315)	( 0.125)	( 0.239)	( 0.515)	( 0.231)	( 0.283)
	Min,	6.5,	1.0,	6.0,	-0.5,	6.0,	-0.5,
	Max	8.0	1.5	7.0	1.5	8.0	1.5
Week 112	n	4	4	4	4	8	8
	Mean	6.88	0.63	6.50	0.25	6.69	0.44
	Median	7.00	0.50	6.50	0.25	6.75	0.50
	SD	0.629	0.750	0.408	1.190	0.530	0.943
	(SE)	( 0.315)	( 0.375)	( 0.204)	( 0.595)	( 0.188)	( 0.333)
	Min,	6.0,	0.0,	6.0,	-1.0,	6.0,	-1.0,
	Max	7.5	1.5	7.0	1.5	7.5	1.5
Week 116	n	4	4	4	4	8	8
	Mean	7.00	0.75	7.13	0.88	7.06	0.81
	Median	7.00	0.75	7.00	0.75	7.00	0.75
	SD	0.408	0.645	0.629	1.250	0.496	0.923
	(SE)	( 0.204)	( 0.323)	( 0.315)	( 0.625)	( 0.175)	( 0.325)
	Min,	6.5,	0.0,	6.5,	-0.5,	6.5,	-0.5,
	Max	7.5	1.5	8.0	2.5	8.0	2.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	4	4	4	4	8	8
	Mean	6.88	0.63	6.63	0.38	6.75	0.50
	Median	7.00	0.50	6.50	0.25	6.75	0.50
	SD	0.629	0.250	0.629	0.479	0.598	0.378
	(SE)	( 0.315)	( 0.125)	( 0.315)	( 0.239)	( 0.211)	( 0.134)
	Min, Max	6.0, 7.5	0.5, 1.0	6.0, 7.5	0.0, 1.0	6.0, 7.5	0.0, 1.0
Week 124	n	4	4	4	4	8	8
	Mean	6.50	0.25	6.38	0.13	6.44	0.19
	Median	6.50	0.50	6.25	0.00	6.25	0.50
	SD	0.577	0.866	0.479	1.109	0.496	0.923
	(SE)	( 0.289)	( 0.433)	( 0.239)	( 0.554)	( 0.175)	( 0.326)
	Min, Max	6.0, 7.0	-1.0, 1.0	6.0, 7.0	-1.0, 1.5	6.0, 7.0	-1.0, 1.5
Week 128	n	4	4	4	4	8	8
	Mean	7.00	0.75	6.13	-0.13	6.56	0.31
	Median	7.00	0.50	6.00	0.00	6.50	0.25
	SD	0.408	0.957	0.250	0.750	0.563	0.923
	(SE)	( 0.204)	( 0.479)	( 0.125)	( 0.375)	( 0.199)	( 0.326)
	Min, Max	6.5, 7.5	0.0, 2.0	6.0, 6.5	-1.0, 0.5	6.0, 7.5	-1.0, 2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	7.13	0.88	6.63	0.38	6.88	0.63
	Median	7.25	1.25	6.75	0.50	7.00	0.75
	SD	0.479	0.946	0.479	0.629	0.518	0.791
	(SE)	( 0.239)	( 0.473)	( 0.239)	( 0.315)	( 0.183)	( 0.280)
	Min, Max	6.5, 7.5	-0.5, 1.5	6.0, 7.0	-0.5, 1.0	6.0, 7.5	-0.5, 1.5
Week 136	n	4	4	4	4	8	8
	Mean	7.25	1.00	6.50	0.25	6.88	0.63
	Median	7.50	0.75	6.25	0.25	6.75	0.50
	SD	0.957	0.707	0.707	0.645	0.876	0.744
	(SE)	( 0.479)	( 0.354)	( 0.354)	( 0.323)	( 0.310)	( 0.263)
	Min, Max	6.0, 8.0	0.5, 2.0	6.0, 7.5	-0.5, 1.0	6.0, 8.0	-0.5, 2.0
Week 140	n	4	4	4	4	8	8
	Mean	6.75	0.50	6.75	0.50	6.75	0.50
	Median	6.50	0.75	7.00	0.50	6.75	0.50
	SD	0.500	0.707	0.500	0.816	0.463	0.707
	(SE)	( 0.250)	( 0.354)	( 0.250)	( 0.408)	( 0.164)	( 0.250)
	Min, Max	6.5, 7.5	-0.5, 1.0	6.0, 7.0	-0.5, 1.5	6.0, 7.5	-0.5, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	4	4	4	4	8	8
	Mean	7.00	0.75	6.88	0.63	6.94	0.69
	Median	7.00	0.75	7.00	1.00	7.00	0.75
	SD	0.408	0.645	0.250	1.181	0.320	0.884
	(SE)	( 0.204)	( 0.323)	( 0.125)	( 0.591)	( 0.113)	( 0.313)
	Min, Max	6.5, 7.5	0.0, 1.5	6.5, 7.0	-1.0, 1.5	6.5, 7.5	-1.0, 1.5
Week 148	n	4	4	4	4	8	8
	Mean	6.88	0.63	6.38	0.13	6.63	0.38
	Median	7.00	0.75	6.25	0.25	6.50	0.50
	SD	0.750	0.854	0.479	0.479	0.641	0.694
	(SE)	( 0.375)	( 0.427)	( 0.239)	( 0.239)	( 0.227)	( 0.245)
	Min, Max	6.0, 7.5	-0.5, 1.5	6.0, 7.0	-0.5, 0.5	6.0, 7.5	-0.5, 1.5
Week 152	n	2	2	4	4	6	6
	Mean	6.00	0.00	6.75	0.50	6.50	0.33
	Median	6.00	0.00	6.75	0.25	6.00	0.25
	SD	0.000	0.707	0.866	1.080	0.775	0.931
	(SE)	( 0.000)	( 0.500)	( 0.433)	( 0.540)	( 0.316)	( 0.380)
	Min, Max	6.0, 6.0	-0.5, 0.5	6.0, 7.5	-0.5, 2.0	6.0, 7.5	-0.5, 2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	4	4	4	4	8	8
	Mean	6.75	0.50	6.00	-0.25	6.38	0.13
	Median	6.75	0.50	6.00	0.00	6.00	0.50
	SD	0.866	0.816	0.000	0.957	0.694	0.916
	(SE)	( 0.433)	( 0.408)	( 0.000)	( 0.479)	( 0.245)	( 0.324)
	Min, Max	6.0, 7.5	-0.5, 1.5	6.0, 6.0	-1.5, 0.5	6.0, 7.5	-1.5, 1.5
Week 160	n	4	4	4	4	8	8
	Mean	6.88	0.63	6.63	0.38	6.75	0.50
	Median	7.00	0.75	6.50	1.00	6.75	1.00
	SD	0.250	0.479	0.629	1.250	0.463	0.886
	(SE)	( 0.125)	( 0.239)	( 0.315)	( 0.625)	( 0.164)	( 0.313)
	Min, Max	6.5, 7.0	0.0, 1.0	6.0, 7.5	-1.5, 1.0	6.0, 7.5	-1.5, 1.0
Week 164	n	4	4	4	4	8	8
	Mean	6.75	0.50	6.25	0.00	6.50	0.25
	Median	7.00	0.50	6.25	0.00	6.50	0.50
	SD	0.500	0.408	0.289	0.913	0.463	0.707
	(SE)	( 0.250)	( 0.204)	( 0.144)	( 0.456)	( 0.164)	( 0.250)
	Min, Max	6.0, 7.0	0.0, 1.0	6.0, 6.5	-1.0, 1.0	6.0, 7.0	-1.0, 1.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	4	4	4	4	8	8
	Mean	7.00	0.75	6.63	0.38	6.81	0.56
	Median	7.25	0.75	6.50	0.25	6.75	0.75
	SD	0.707	0.289	0.629	1.377	0.651	0.943
	(SE)	( 0.354)	( 0.144)	( 0.315)	( 0.688)	( 0.230)	( 0.333)
	Min, Max	6.0, 7.5	0.5, 1.0	6.0, 7.5	-1.0, 2.0	6.0, 7.5	-1.0, 2.0
Week 172	n	4	4	4	4	8	8
	Mean	6.13	-0.13	6.88	0.63	6.50	0.25
	Median	6.00	0.00	6.75	0.50	6.25	0.25
	SD	0.250	0.629	0.854	1.436	0.707	1.102
	(SE)	( 0.125)	( 0.315)	( 0.427)	( 0.718)	( 0.250)	( 0.390)
	Min, Max	6.0, 6.5	-1.0, 0.5	6.0, 8.0	-1.0, 2.5	6.0, 8.0	-1.0, 2.5
Week 176	n	4	4	4	4	8	8
	Mean	6.13	-0.13	6.13	-0.13	6.13	-0.13
	Median	6.00	0.00	6.00	-0.25	6.00	-0.25
	SD	0.750	1.109	0.629	1.250	0.641	1.094
	(SE)	( 0.375)	( 0.554)	( 0.315)	( 0.625)	( 0.227)	( 0.387)
	Min, Max	5.5, 7.0	-1.5, 1.0	5.5, 7.0	-1.5, 1.5	5.5, 7.0	-1.5, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	4	4	4	4	8	8
	Mean	7.38	1.13	6.75	0.50	7.06	0.81
	Median	7.50	1.25	7.00	0.50	7.00	1.25
	SD	0.250	0.479	0.500	1.155	0.496	0.884
	(SE)	( 0.125)	( 0.239)	( 0.250)	( 0.577)	( 0.175)	( 0.313)
	Min,	7.0,	0.5,	6.0,	-0.5,	6.0,	-0.5,
	Max	7.5	1.5	7.0	1.5	7.5	1.5
Week 184	n	4	4	4	4	8	8
	Mean	6.88	0.63	6.75	0.50	6.81	0.56
	Median	7.00	0.50	6.75	0.25	7.00	0.50
	SD	0.629	0.629	0.645	0.707	0.594	0.623
	(SE)	( 0.315)	( 0.315)	( 0.323)	( 0.354)	( 0.210)	( 0.220)
	Min,	6.0,	0.0,	6.0,	0.0,	6.0,	0.0,
	Max	7.5	1.5	7.5	1.5	7.5	1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Urine Cystatin C (ug/L)							
Baseline <sup>1</sup>	n	3		3		6	
	Mean	10.833		41.500		26.167	
	Median	7.400		60.000		13.200	
	SD	7.1023		34.6735		27.9859	
	(SE)	( 4.1005)		( 20.0187)		( 11.4252)	
	Min, Max	6.10, 19.00		1.50, 63.00		1.50, 63.00	
Week 2	n	3	3	4	3	7	6
	Mean	24.333	13.500	82.500	62.500	57.571	38.000
	Median	21.000	11.600	59.500	43.500	33.000	19.250
	SD	7.5719	12.5583	77.1341	63.1803	62.9334	48.7861
	(SE)	( 4.3716)	( 7.2505)	( 38.5670)	( 36.4772)	( 23.7866)	( 19.9168)
	Min, Max	19.00, 33.00	2.00, 26.90	18.00, 193.00	11.00, 133.00	18.00, 193.00	2.00, 133.00
Week 4	n	4	3	3	2	7	5
	Mean	15.150	7.433	11.200	-16.050	13.457	-1.960
	Median	11.900	11.900	2.400	-16.050	5.800	11.900
	SD	13.4535	20.7635	16.2923	63.0032	13.5439	37.0588
	(SE)	( 6.7268)	( 11.9878)	( 9.4064)	( 44.5500)	( 5.1191)	( 16.5732)
	Min, Max	3.80, 33.00	-15.20, 25.60	1.20, 30.00	-60.60, 28.50	1.20, 33.00	-60.60, 28.50

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 6	n	4	3	3	2	7	5
	Mean	51.925	57.833	46.133	5.500	49.443	36.900
	Median	61.500	62.000	48.000	5.500	48.000	35.900
	SD	38.4364	20.1753	40.8320	28.9914	36.1111	35.1466
	(SE)	( 19.2182)	( 11.6482)	( 23.5744)	( 20.5000)	( 13.6487)	( 15.7180)
	Min, Max	1.70, 83.00	35.90, 75.60	4.40, 86.00	-15.00, 26.00	1.70, 86.00	-15.00, 75.60
Week 8	n	4	3	4	3	8	6
	Mean	13.025	3.600	41.750	1.167	27.388	2.383
	Median	14.400	13.600	44.500	-8.000	23.500	2.800
	SD	9.0393	17.5810	11.9548	20.3613	18.2214	17.0659
	(SE)	( 4.5197)	( 10.1504)	( 5.9774)	( 11.7556)	( 6.4422)	( 6.9671)
	Min, Max	2.30, 21.00	-16.70, 13.90	26.00, 52.00	-13.00, 24.50	2.30, 52.00	-16.70, 24.50
Week 10	n	4	3	4	3	8	6
	Mean	12.925	1.733	69.750	48.167	41.338	24.950
	Median	14.500	-4.000	62.000	33.500	18.000	21.300
	SD	8.0967	10.2788	60.0299	29.3868	49.9508	32.1638
	(SE)	( 4.0483)	( 5.9345)	( 30.0149)	( 16.9665)	( 17.6603)	( 13.1308)
	Min, Max	1.70, 21.00	-4.40, 13.60	10.00, 145.00	29.00, 82.00	1.70, 145.00	-4.40, 82.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mc/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	3	4	3	8	6
	Mean	27.550	25.500	32.745	-2.507	30.148	11.497
	Median	25.000	22.600	7.495	-0.510	17.000	18.250
	SD	24.1276	13.2895	55.1786	55.5319	39.5229	39.2361
	(SE)	( 12.0638)	( 7.6727)	( 27.5893)	( 32.0614)	( 13.9735)	( 16.0181)
	Min, Max	1.20, 59.00	13.90, 40.00	0.99, 115.00	-59.01, 52.00	0.99, 115.00	-59.01, 52.00
Week 15	n	4	3	3	3	7	6
	Mean	23.525	18.967	18.093	-23.407	21.197	-2.220
	Median	5.500	0.200	3.300	-10.000	4.700	-1.550
	SD	36.9950	35.5790	27.6563	33.9566	30.7848	38.8100
	(SE)	( 18.4975)	( 20.5415)	( 15.9674)	( 19.6049)	( 11.6355)	( 15.8441)
	Min, Max	4.10, 79.00	-3.30, 60.00	0.98, 50.00	-62.02, 1.80	0.98, 79.00	-62.02, 60.00
Week 18	n	4	3	4	3	8	6
	Mean	33.200	31.967	19.225	-16.433	26.213	7.767
	Median	15.700	19.600	5.600	1.000	6.150	3.700
	SD	45.2628	43.1986	29.9655	34.9763	36.3132	44.0290
	(SE)	( 22.6314)	( 24.9408)	( 14.9827)	( 20.1936)	( 12.8387)	( 17.9748)
	Min, Max	2.40, 99.00	-3.70, 80.00	1.70, 64.00	-56.70, 6.40	1.70, 99.00	-56.70, 80.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	3	3	3	7	6
	Mean	52.745	59.167	51.667	10.167	52.283	34.667
	Median	60.500	70.000	36.000	-24.000	42.000	52.950
	SD	39.9951	20.1654	34.2977	68.9245	34.5289	52.7560
	(SE)	( 19.9975)	( 11.6425)	( 19.8018)	( 39.7936)	( 13.0507)	( 21.5375)
	Min, Max	0.98, 89.00	35.90, 71.60	28.00, 91.00	-35.00, 89.50	0.98, 91.00	-35.00, 89.50
Week 24	n	4	3	4	3	8	6
	Mean	49.175	54.167	23.275	-14.133	36.225	20.017
	Median	63.000	52.900	11.500	1.000	35.500	29.250
	SD	31.9435	6.8879	27.2721	34.7650	30.7852	43.6106
	(SE)	( 15.9718)	( 3.9767)	( 13.6361)	( 20.0716)	( 10.8842)	( 17.8040)
	Min, Max	1.70, 69.00	48.00, 61.60	6.10, 64.00	-53.90, 10.50	1.70, 69.00	-53.90, 61.60
Week 25	n	4	3	4	3	8	6
	Mean	32.000	23.167	42.650	-11.633	37.325	5.767
	Median	24.000	15.900	40.500	-28.000	29.000	13.750
	SD	19.5448	16.4512	30.4624	52.8848	24.3683	39.8784
	(SE)	( 9.7724)	( 9.4981)	( 15.2312)	( 30.5331)	( 8.6155)	( 16.2803)
	Min, Max	19.00, 61.00	11.60, 42.00	8.60, 81.00	-54.40, 47.50	8.60, 81.00	-54.40, 47.50

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	3	4	3	8	6
	Mean	69.000	72.833	38.250	-0.833	53.625	36.000
	Median	75.000	82.000	39.500	-3.000	50.500	31.200
	SD	36.5148	22.7781	17.8022	15.3650	31.2636	43.9318
	(SE)	( 18.2574)	( 13.1510)	( 8.9011)	( 8.8710)	( 11.0533)	( 17.9351)
	Min, Max	25.00, 101.00	46.90, 89.60	17.00, 57.00	-15.00, 15.50	17.00, 101.00	-15.00, 89.60
Week 32	n	4	3	4	3	8	6
	Mean	72.725	85.167	38.250	4.167	55.488	44.667
	Median	84.000	83.900	36.500	1.000	59.500	43.550
	SD	49.7886	15.2395	24.8244	11.0943	40.8176	45.9394
	(SE)	( 24.8943)	( 8.7985)	( 12.4122)	( 6.4053)	( 14.4312)	( 18.7547)
	Min, Max	2.90, 120.00	70.60, 101.00	16.00, 64.00	-5.00, 16.50	2.90, 120.00	-5.00, 101.00
Week 36	n	4	3	4	3	8	6
	Mean	58.750	61.833	54.475	25.467	56.613	43.650
	Median	61.000	59.900	44.500	63.000	61.000	61.450
	SD	32.6126	25.8543	56.2355	71.6031	42.6189	52.1051
	(SE)	( 16.3063)	( 14.9270)	( 28.1178)	( 41.3401)	( 15.0681)	( 21.2718)
	Min, Max	17.00, 96.00	37.00, 88.60	2.90, 126.00	-57.10, 70.50	2.90, 126.00	-57.10, 88.60

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	3	4	3	8	6
	Mean	44.250	38.833	53.200	-10.233	48.725	14.300
	Median	28.000	21.900	45.450	1.400	28.000	19.750
	SD	34.5290	33.1232	59.4443	42.2682	45.2577	43.3100
	(SE)	( 17.2645)	( 19.1237)	( 29.7221)	( 24.4036)	( 16.0010)	( 17.6813)
	Min,	25.00,	17.60,	2.90,	-57.10,	2.90,	-57.10,
	Max	96.00	77.00	119.00	25.00	119.00	77.00
Week 44	n	4	3	4	3	8	6
	Mean	50.975	56.167	41.250	-14.833	46.113	20.667
	Median	62.000	62.900	28.500	-31.000	43.500	28.750
	SD	33.3147	17.7832	29.4208	31.5291	29.5575	45.1268
	(SE)	( 16.6573)	( 10.2672)	( 14.7104)	( 18.2033)	( 10.4501)	( 18.4230)
	Min,	2.90,	36.00,	23.00,	-35.00,	2.90,	-35.00,
	Max	77.00	69.60	85.00	21.50	85.00	69.60
Week 48	n	4	3	3	3	7	6
	Mean	29.600	21.967	60.333	18.833	42.771	20.400
	Median	31.500	24.000	41.000	39.500	41.000	31.300
	SD	17.7831	17.7376	46.1447	47.9644	33.7308	32.3887
	(SE)	( 8.8916)	( 10.2408)	( 26.6417)	( 27.6923)	( 12.7490)	( 13.2226)
	Min,	9.40,	3.30,	27.00,	-36.00,	9.40,	-36.00,
	Max	46.00	38.60	113.00	53.00	113.00	53.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	3	4	3	8	6
	Mean	24.200	20.467	48.075	-1.400	36.138	9.533
	Median	18.950	26.600	57.000	13.000	38.000	19.800
	SD	25.6454	20.3070	31.9388	50.6590	29.6969	36.5366
	(SE)	( 12.8227)	( 11.7242)	( 15.9694)	( 29.2480)	( 10.4995)	( 14.9160)
	Min,	2.90,	-2.20,	5.30,	-57.70,	2.90,	-57.70,
	Max	56.00	37.00	73.00	40.50	73.00	40.50
Week 56	n	4	3	3	2	7	5
	Mean	44.725	47.833	66.667	50.750	54.129	49.000
	Median	48.000	50.000	81.000	50.750	69.000	50.000
	SD	36.0421	25.9180	25.6970	42.0729	31.7361	27.9456
	(SE)	( 18.0211)	( 14.9638)	( 14.8361)	( 29.7500)	( 11.9951)	( 12.4976)
	Min,	2.90,	20.90,	37.00,	21.00,	2.90,	20.90,
	Max	80.00	72.60	82.00	80.50	82.00	80.50
Week 60	n	4	3	4	3	8	6
	Mean	64.975	74.833	117.750	85.167	91.363	80.000
	Median	70.000	62.000	57.000	21.500	70.000	57.450
	SD	47.7926	30.4507	156.9063	178.7179	111.0222	114.7997
	(SE)	( 23.8963)	( 17.5807)	( 78.4531)	( 103.1828)	( 39.2523)	( 46.8668)
	Min,	2.90,	52.90,	10.00,	-53.00,	2.90,	-53.00,
	Max	117.00	109.60	347.00	287.00	347.00	287.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	4	3	4	3	8	6
	Mean	21.725	17.167	48.700	4.767	35.213	10.967
	Median	25.000	14.000	29.450	1.400	25.000	11.800
	SD	14.7706	9.5521	61.5225	66.6138	43.8583	43.0997
	(SE)	( 7.3853)	( 5.5149)	( 30.7613)	( 38.4595)	( 15.5063)	( 17.5954)
	Min,	2.90,	9.60,	2.90,	-60.10,	2.90,	-60.10,
	Max	34.00	27.90	133.00	73.00	133.00	73.00
Week 68	n	4	3	4	3	8	6
	Mean	13.325	0.933	112.200	102.433	62.763	51.683
	Median	11.700	-3.200	40.000	61.500	17.500	8.200
	SD	11.2598	16.9816	170.4329	185.5184	123.6787	130.2799
	(SE)	( 5.6299)	( 9.8043)	( 85.2164)	( 107.1091)	( 43.7270)	( 53.1865)
	Min,	2.90,	-13.60,	3.80,	-59.20,	2.90,	-59.20,
	Max	27.00	19.60	365.00	305.00	365.00	305.00
Week 72	n	4	3	4	3	8	6
	Mean	28.500	14.167	46.225	16.467	37.363	15.317
	Median	27.000	14.900	24.500	36.500	27.000	15.250
	SD	8.2260	1.9088	59.7646	68.7743	40.6145	43.5317
	(SE)	( 4.1130)	( 1.1020)	( 29.8823)	( 39.7069)	( 14.3594)	( 17.7717)
	Min,	21.00,	12.00,	2.90,	-60.10,	2.90,	-60.10,
	Max	39.00	15.60	133.00	73.00	133.00	73.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	0	0	0	0
	Mean						
	Median						
	SD						
	(SE)						
	Min,						
	Max						
Week 76	n	4	3	4	3	8	6
	Mean	8.950	0.133	39.250	-13.167	24.100	-6.517
	Median	8.450	-3.000	33.000	-13.000	17.500	-3.100
	SD	7.0335	5.6012	25.5131	30.7503	23.7166	21.0677
	(SE)	( 3.5167)	( 3.2338)	( 12.7565)	( 17.7537)	( 8.3851)	( 8.6009)
	Min,	2.90,	-3.20,	19.00,	-44.00,	2.90,	-44.00,
	Max	16.00	6.60	72.00	17.50	72.00	17.50
Week 80	n	4	3	4	3	8	6
	Mean	7.900	-2.033	26.400	-19.633	17.150	-10.833
	Median	3.500	-4.300	29.000	-17.000	11.600	-10.650
	SD	10.2013	16.6164	20.4509	21.1732	17.9341	19.5625
	(SE)	( 5.1007)	( 9.5935)	( 10.2255)	( 12.2243)	( 6.3407)	( 7.9863)
	Min,	1.60,	-17.40,	1.60,	-42.00,	1.60,	-42.00,
	Max	23.00	15.60	46.00	0.10	46.00	15.60

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	4	3	4	3	8	6
	Mean	28.450	26.500	24.400	-26.967	26.425	-0.233
	Median	34.500	30.600	21.000	-50.000	30.000	19.750
	SD	18.4357	12.9464	22.7092	47.3561	19.2708	42.6813
	(SE)	( 9.2179)	( 7.4746)	( 11.3546)	( 27.3411)	( 6.8133)	( 17.4246)
	Min, Max	1.80, 43.00	12.00, 36.90	1.60, 54.00	-58.40, 27.50	1.60, 54.00	-58.40, 36.90
Week 88	n	4	3	4	3	8	6
	Mean	33.250	24.833	32.400	-18.300	32.825	3.267
	Median	35.500	26.000	34.000	-3.000	35.500	5.550
	SD	19.7379	22.6725	30.4057	37.8453	23.7358	36.5605
	(SE)	( 9.8689)	( 13.0900)	( 15.2029)	( 21.8500)	( 8.3919)	( 14.9258)
	Min, Max	9.00, 53.00	1.60, 46.90	1.60, 60.00	-61.40, 9.50	1.60, 60.00	-61.40, 46.90
Week 92	n	4	3	4	3	8	6
	Mean	38.150	39.500	27.400	-15.300	32.775	12.100
	Median	41.500	44.900	21.500	-48.000	31.500	28.950
	SD	28.4597	24.2551	27.8659	68.5709	26.7008	54.9274
	(SE)	( 14.2299)	( 14.0037)	( 13.9329)	( 39.5894)	( 9.4401)	( 22.4240)
	Min, Max	1.60, 68.00	13.00, 60.60	1.60, 65.00	-61.40, 63.50	1.60, 68.00	-61.40, 63.50

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	3	4	3	8	6
	Mean	39.150	40.833	45.500	8.167	42.325	24.500
	Median	43.500	51.900	46.500	0.000	45.500	17.250
	SD	30.0037	27.0545	18.7350	14.1451	23.4043	26.3238
	(SE)	( 15.0019)	( 15.6199)	( 9.3675)	( 8.1667)	( 8.2747)	( 10.7467)
	Min,	1.60,	10.00,	26.00,	0.00,	1.60,	0.00,
	Max	68.00	60.60	63.00	24.50	68.00	60.60
Week 100	n	4	3	4	3	8	6
	Mean	60.000	58.500	31.500	-23.500	45.750	17.500
	Median	56.500	58.600	20.000	-42.000	39.500	30.700
	SD	27.1662	17.5502	27.1968	38.2655	29.4170	52.2121
	(SE)	( 13.5831)	( 10.1326)	( 13.5984)	( 22.0926)	( 10.4005)	( 21.3155)
	Min,	32.00,	40.90,	14.00,	-49.00,	14.00,	-49.00,
	Max	95.00	76.00	72.00	20.50	95.00	76.00
Week 104	n	4	3	4	3	8	6
	Mean	27.550	23.133	20.700	-21.233	24.125	0.950
	Median	14.950	13.600	14.100	-53.800	14.950	8.200
	SD	30.2054	26.4230	23.2382	63.1034	25.2161	49.6247
	(SE)	( 15.1027)	( 15.2553)	( 11.6191)	( 36.4328)	( 8.9153)	( 20.2592)
	Min,	8.30,	2.80,	1.60,	-61.40,	1.60,	-61.40,
	Max	72.00	53.00	53.00	51.50	72.00	53.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	3	4	3	8	6
	Mean	50.600	55.167	18.400	-21.967	34.500	16.600
	Median	44.000	54.900	15.500	-19.000	21.500	17.050
	SD	45.9272	35.7007	16.4349	38.0369	36.2766	53.6041
	(SE)	( 22.9636)	( 20.6118)	( 8.2175)	( 21.9606)	( 12.8257)	( 21.8838)
	Min,	4.40,	19.60,	1.60,	-61.40,	1.60,	-61.40,
	Max	110.00	91.00	41.00	14.50	110.00	91.00
Week 112	n	4	3	4	3	8	6
	Mean	23.900	20.500	37.575	-32.400	30.738	-5.950
	Median	25.500	28.900	12.850	-57.300	19.500	9.250
	SD	18.6880	20.6255	57.7937	46.7238	40.4299	43.3928
	(SE)	( 9.3440)	( 11.9081)	( 28.8968)	( 26.9760)	( 14.2941)	( 17.7150)
	Min,	1.60,	-3.00,	1.60,	-61.40,	1.60,	-61.40,
	Max	43.00	35.60	123.00	21.50	123.00	35.60
Week 116	n	4	3	4	3	8	6
	Mean	21.900	17.833	31.275	-4.467	26.588	6.683
	Median	27.500	17.600	31.500	-11.000	27.500	14.800
	SD	13.7855	5.9534	26.2381	57.9767	20.0400	38.8315
	(SE)	( 6.8927)	( 3.4372)	( 13.1190)	( 33.4729)	( 7.0852)	( 15.8529)
	Min,	1.60,	12.00,	4.10,	-58.90,	1.60,	-58.90,
	Max	31.00	23.90	58.00	56.50	58.00	56.50

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	4	3	4	3	8	6
	Mean	47.500	26.167	51.775	9.200	49.638	17.683
	Median	45.000	25.600	45.500	34.500	45.500	30.050
	SD	25.7876	24.4549	42.1426	55.9211	32.4248	39.7045
	(SE)	( 12.8938)	( 14.1191)	( 21.0713)	( 32.2861)	( 11.4639)	( 16.2093)
	Min, Max	21.00, 79.00	2.00, 50.90	8.10, 108.00	-54.90, 48.00	8.10, 108.00	-54.90, 50.90
Week 124	n	4	3	4	3	8	6
	Mean	34.250	29.500	47.500	13.833	40.875	21.667
	Median	18.000	13.900	26.500	27.500	22.000	20.700
	SD	36.6458	35.3809	52.8804	60.1754	42.7098	44.9754
	(SE)	( 18.3229)	( 20.4272)	( 26.4402)	( 34.7423)	( 15.1002)	( 18.3611)
	Min, Max	12.00, 89.00	4.60, 70.00	11.00, 126.00	-52.00, 66.00	11.00, 126.00	-52.00, 70.00
Week 128	n	4	3	4	3	8	6
	Mean	27.050	24.700	93.000	55.500	60.025	40.100
	Median	19.800	31.900	85.500	30.000	53.000	30.950
	SD	31.6823	39.0017	51.0882	94.8565	52.8341	67.0235
	(SE)	( 15.8412)	( 22.5176)	( 25.5441)	( 54.7654)	( 18.6797)	( 27.3622)
	Min, Max	1.60, 67.00	-17.40, 59.60	39.00, 162.00	-24.00, 160.50	1.60, 162.00	-24.00, 160.50

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	3	4	3	8	6
	Mean	48.650	53.500	64.750	29.167	56.700	41.333
	Median	48.500	67.600	57.500	29.500	57.500	41.250
	SD	44.1975	45.1332	35.5563	24.0017	38.1191	34.9696
	(SE)	( 22.0988)	( 26.0577)	( 17.7781)	( 13.8574)	( 13.4771)	( 14.2763)
	Min, Max	1.60, 96.00	3.00, 89.90	31.00, 113.00	5.00, 53.00	1.60, 113.00	3.00, 89.90
Week 136	n	4	3	4	3	8	6
	Mean	27.550	25.367	60.000	17.167	43.775	21.267
	Median	26.300	43.600	63.500	31.000	53.500	37.300
	SD	30.0339	37.1707	28.4605	52.6316	32.1650	40.9984
	(SE)	( 15.0170)	( 21.4605)	( 14.2302)	( 30.3869)	( 11.3720)	( 16.7375)
	Min, Max	1.60, 56.00	-17.40, 49.90	22.00, 91.00	-41.00, 61.50	1.60, 91.00	-41.00, 61.50
Week 140	n	4	3	4	3	8	6
	Mean	31.650	30.833	43.750	8.500	37.700	19.667
	Median	40.000	27.600	30.000	-28.000	33.500	26.800
	SD	20.5805	7.0316	30.9664	69.3704	25.1857	45.7636
	(SE)	( 10.2902)	( 4.0597)	( 15.4832)	( 40.0510)	( 8.9045)	( 18.6829)
	Min, Max	1.60, 45.00	26.00, 38.90	25.00, 90.00	-35.00, 88.50	1.60, 90.00	-35.00, 88.50

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 144	n	4	3	4	3	8	6
	Mean	9.375	1.133	246.750	-12.500	128.063	-5.683
	Median	8.450	2.600	35.500	-34.000	17.500	-4.750
	SD	7.2940	12.5644	435.6293	46.1709	312.1749	31.1706
	(SE)	( 3.6470)	( 7.2540)	( 217.8147)	( 26.6568)	( 110.3705)	( 12.7253)
	Min,	1.60,	-12.10,	16.00,	-44.00,	1.60,	-44.00,
	Max	19.00	12.90	900.00	40.50	900.00	40.50

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg			Eteplirsen for 184 Weeks			
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Urine KIM-1 (ug/L)							
Baseline <sup>1</sup>	n	4		4		8	
	Mean	0.0943		0.3420		0.2181	
	Median	0.0180		0.3260		0.0460	
	SD	0.15721		0.35490		0.28655	
	(SE)	( 0.07860)		( 0.17745)		( 0.10131)	
	Min, Max	0.011, 0.330		0.006, 0.710		0.006, 0.710	
Week 2	n	4	4	4	4	8	8
	Mean	0.1330	0.0388	0.4765	0.1345	0.3048	0.0866
	Median	0.0475	0.0295	0.5250	0.1000	0.2180	0.0700
	SD	0.19927	0.04495	0.31864	0.09887	0.30699	0.08760
	(SE)	( 0.09964)	( 0.02248)	( 0.15932)	( 0.04943)	( 0.10854)	( 0.03097)
	Min, Max	0.007, 0.430	-0.004, 0.100	0.086, 0.770	0.060, 0.278	0.007, 0.770	-0.004, 0.278
Week 4	n	4	4	4	4	8	8
	Mean	0.1250	0.0308	0.1495	-0.1925	0.1373	-0.0809
	Median	0.0755	0.0270	0.0840	-0.2390	0.0790	0.0215
	SD	0.13237	0.03943	0.16220	0.44283	0.13768	0.31456
	(SE)	( 0.06618)	( 0.01972)	( 0.08110)	( 0.22142)	( 0.04868)	( 0.11121)
	Min, Max	0.029, 0.320	-0.010, 0.079	0.040, 0.390	-0.610, 0.318	0.029, 0.390	-0.610, 0.318

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 6	n	4	4	4	4	8	8
	Mean	0.5695	0.4753	0.5235	0.1815	0.5465	0.3284
	Median	0.1250	0.1070	0.3885	0.0305	0.1250	0.0650
	SD	0.95498	0.79793	0.62503	0.36161	0.74758	0.59461
	(SE)	( 0.47749)	( 0.39897)	( 0.31251)	( 0.18080)	( 0.26431)	( 0.21023)
	Min,	0.028,	0.017,	0.017,	-0.055,	0.017,	-0.055,
	Max	2.000	1.670	1.300	0.720	2.000	1.670
Week 8	n	4	4	4	4	8	8
	Mean	0.0993	0.0050	14.0050	13.6630	7.0521	6.8340
	Median	0.0855	0.0205	0.4200	0.1760	0.1850	0.0645
	SD	0.07433	0.10724	27.33059	27.08484	19.37465	19.17544
	(SE)	( 0.03716)	( 0.05362)	( 13.66529)	( 13.54242)	( 6.84997)	( 6.77954)
	Min,	0.036,	-0.140,	0.180,	0.010,	0.036,	-0.140,
	Max	0.190	0.119	55.000	54.290	55.000	54.290
Week 10	n	4	4	4	4	8	8
	Mean	0.1523	0.0580	0.6750	0.3330	0.4136	0.1955
	Median	0.0940	0.0610	0.7350	0.3440	0.2700	0.1215
	SD	0.17867	0.05462	0.45654	0.16805	0.42554	0.18705
	(SE)	( 0.08933)	( 0.02731)	( 0.22827)	( 0.08403)	( 0.15045)	( 0.06613)
	Min,	0.011,	-0.009,	0.130,	0.124,	0.011,	-0.009,
	Max	0.410	0.119	1.100	0.520	1.100	0.520

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	4	4	4	4	8	8
	Mean	0.2320	0.1378	0.4135	0.0715	0.3228	0.1046
	Median	0.0450	0.0315	0.2200	0.0230	0.0805	0.0315
	SD	0.38545	0.22854	0.54076	0.31429	0.44543	0.25685
	(SE)	( 0.19272)	( 0.11427)	( 0.27038)	( 0.15714)	( 0.15748)	( 0.09081)
	Min, Max	0.028, 0.810	0.008, 0.480	0.014, 1.200	-0.250, 0.490	0.014, 1.200	-0.250, 0.490
Week 15	n	4	4	4	4	8	8
	Mean	0.2763	0.1820	0.1060	-0.2360	0.1911	-0.0270
	Median	0.0370	0.0210	0.0300	-0.1355	0.0335	0.0180
	SD	0.48251	0.32534	0.16284	0.32493	0.34558	0.37488
	(SE)	( 0.24125)	( 0.16267)	( 0.08142)	( 0.16247)	( 0.12218)	( 0.13254)
	Min, Max	0.031, 1.000	0.016, 0.670	0.014, 0.350	-0.696, 0.023	0.014, 1.000	-0.696, 0.670
Week 18	n	4	4	4	4	8	8
	Mean	0.2673	0.1730	0.1735	-0.1685	0.2204	0.0023
	Median	0.0485	0.0340	0.0730	-0.1030	0.0495	0.0180
	SD	0.44186	0.28472	0.24009	0.22364	0.33300	0.29916
	(SE)	( 0.22093)	( 0.14236)	( 0.12005)	( 0.11182)	( 0.11773)	( 0.10577)
	Min, Max	0.042, 0.930	0.024, 0.600	0.018, 0.530	-0.480, 0.012	0.018, 0.930	-0.480, 0.600

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	4	4	4	4	8	8
	Mean	0.4023	0.3080	0.3603	0.0182	0.3813	0.1631
	Median	0.0905	0.0725	0.3600	-0.0575	0.1950	0.0380
	SD	0.66601	0.50898	0.27685	0.44186	0.47271	0.46764
	(SE)	( 0.33300)	( 0.25449)	( 0.13843)	( 0.22093)	( 0.16713)	( 0.16533)
	Min,	0.028,	0.017,	0.031,	-0.430,	0.028,	-0.430,
	Max	1.400	1.070	0.690	0.618	1.400	1.070
Week 24	n	4	4	4	4	8	8
	Mean	0.1900	0.0958	0.1355	-0.2065	0.1628	-0.0554
	Median	0.0975	0.0795	0.0565	-0.1595	0.0800	0.0340
	SD	0.22857	0.07427	0.17689	0.27758	0.19144	0.24797
	(SE)	( 0.11429)	( 0.03714)	( 0.08844)	( 0.13879)	( 0.06768)	( 0.08767)
	Min,	0.035,	0.024,	0.029,	-0.551,	0.029,	-0.551,
	Max	0.530	0.200	0.400	0.044	0.530	0.200
Week 25	n	4	4	4	4	8	8
	Mean	0.2270	0.1328	0.2648	-0.0773	0.2459	0.0278
	Median	0.1260	0.1125	0.3050	0.0140	0.2300	0.1125
	SD	0.23922	0.09089	0.12062	0.42908	0.17655	0.30829
	(SE)	( 0.11961)	( 0.04544)	( 0.06031)	( 0.21454)	( 0.06242)	( 0.10900)
	Min,	0.076,	0.056,	0.089,	-0.621,	0.076,	-0.621,
	Max	0.580	0.250	0.360	0.284	0.580	0.284

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	4	4	4	4	8	8
	Mean	0.5545	0.4603	0.3775	0.0355	0.4660	0.2479
	Median	0.2100	0.1965	0.3300	0.1090	0.2300	0.1460
	SD	0.76619	0.61005	0.22232	0.20154	0.53078	0.47797
	(SE)	( 0.38309)	( 0.30503)	( 0.11116)	( 0.10077)	( 0.18766)	( 0.16899)
	Min,	0.098,	0.078,	0.190,	-0.260,	0.098,	-0.260,
	Max	1.700	1.370	0.660	0.184	1.700	1.370
Week 32	n	4	4	4	4	8	8
	Mean	0.3398	0.2455	0.2948	-0.0473	0.3173	0.0991
	Median	0.1650	0.1470	0.3250	-0.0535	0.2100	0.0965
	SD	0.44498	0.28979	0.17753	0.19550	0.31456	0.27723
	(SE)	( 0.22249)	( 0.14490)	( 0.08877)	( 0.09775)	( 0.11121)	( 0.09802)
	Min,	0.029,	0.018,	0.069,	-0.250,	0.029,	-0.250,
	Max	1.000	0.670	0.460	0.168	1.000	0.670
Week 36	n	4	4	4	4	8	8
	Mean	0.2650	0.1708	0.3528	0.0107	0.3089	0.0908
	Median	0.1400	0.1245	0.3295	0.0215	0.1400	0.1070
	SD	0.27037	0.11381	0.31130	0.40989	0.27397	0.29132
	(SE)	( 0.13519)	( 0.05690)	( 0.15565)	( 0.20495)	( 0.09686)	( 0.10300)
	Min,	0.110,	0.094,	0.082,	-0.498,	0.082,	-0.498,
	Max	0.670	0.340	0.670	0.498	0.670	0.498

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	4	4	4	4	8	8
	Mean	0.5618	0.4675	0.1633	-0.1788	0.3625	0.1444
	Median	0.1350	0.1195	0.1380	-0.1880	0.1350	0.0755
	SD	0.89282	0.73591	0.14003	0.33941	0.62881	0.63308
	(SE)	( 0.44641)	( 0.36796)	( 0.07001)	( 0.16970)	( 0.22232)	( 0.22383)
	Min,	0.077,	0.061,	0.037,	-0.543,	0.037,	-0.543,
	Max	1.900	1.570	0.340	0.204	1.900	1.570
Week 44	n	4	4	4	4	8	8
	Mean	0.2278	0.1335	0.3575	0.0155	0.2926	0.0745
	Median	0.1300	0.1120	0.3300	0.0890	0.3000	0.1120
	SD	0.27305	0.12098	0.08016	0.34089	0.19878	0.24506
	(SE)	( 0.13652)	( 0.06049)	( 0.04008)	( 0.17045)	( 0.07028)	( 0.08664)
	Min,	0.021,	0.010,	0.300,	-0.410,	0.021,	-0.410,
	Max	0.630	0.300	0.470	0.294	0.630	0.300
Week 48	n	4	4	3	3	7	7
	Mean	0.2433	0.1490	0.7067	0.2527	0.4419	0.1934
	Median	0.0910	0.0775	0.4100	0.3380	0.3100	0.0840
	SD	0.31806	0.16124	0.60252	0.61446	0.48265	0.37673
	(SE)	( 0.15903)	( 0.08062)	( 0.34787)	( 0.35476)	( 0.18242)	( 0.14239)
	Min,	0.071,	0.051,	0.310,	-0.400,	0.071,	-0.400,
	Max	0.720	0.390	1.400	0.820	1.400	0.820

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	4	4	4	4	8	8
	Mean	0.1473	0.0530	0.3200	-0.0220	0.2336	0.0155
	Median	0.0405	0.0270	0.3150	0.0770	0.1850	0.0270
	SD	0.22905	0.07329	0.16633	0.40234	0.20705	0.27071
	(SE)	( 0.11453)	( 0.03664)	( 0.08317)	( 0.20117)	( 0.07320)	( 0.09571)
	Min,	0.018,	-0.002,	0.140,	-0.570,	0.018,	-0.570,
	Max	0.490	0.160	0.510	0.328	0.510	0.328
Week 56	n	4	4	3	3	7	7
	Mean	0.2628	0.1685	0.4667	0.2473	0.3501	0.2023
	Median	0.0815	0.0635	0.6100	0.1340	0.1400	0.0940
	SD	0.39273	0.23628	0.28361	0.25375	0.34031	0.22617
	(SE)	( 0.19636)	( 0.11814)	( 0.16374)	( 0.14650)	( 0.12862)	( 0.08548)
	Min,	0.038,	0.027,	0.140,	0.070,	0.038,	0.027,
	Max	0.850	0.520	0.650	0.538	0.850	0.538
Week 60	n	4	4	4	4	8	8
	Mean	0.2625	0.1683	0.4075	0.0655	0.3350	0.1169
	Median	0.1135	0.0955	0.2300	0.1910	0.1850	0.1510
	SD	0.35396	0.19814	0.39677	0.41786	0.35661	0.30769
	(SE)	( 0.17698)	( 0.09907)	( 0.19838)	( 0.20893)	( 0.12608)	( 0.10878)
	Min,	0.033,	0.022,	0.170,	-0.540,	0.033,	-0.540,
	Max	0.790	0.460	1.000	0.420	1.000	0.460

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 64	n	4	4	4	4	8	8
	Mean	0.4615	0.3673	0.5740	0.2320	0.5178	0.2996
	Median	0.1250	0.1070	0.3650	0.3260	0.1950	0.1490
	SD	0.69248	0.53527	0.63900	0.65739	0.61978	0.55967
	(SE)	( 0.34624)	( 0.26764)	( 0.31950)	( 0.32869)	( 0.21912)	( 0.19787)
	Min,	0.096,	0.085,	0.066,	-0.644,	0.066,	-0.644,
	Max	1.500	1.170	1.500	0.920	1.500	1.170
Week 68	n	4	4	4	4	8	8
	Mean	0.1923	0.0980	1.1850	0.8430	0.6886	0.4705
	Median	0.1525	0.0745	0.4900	0.4510	0.2600	0.1445
	SD	0.16207	0.07655	1.62492	1.53149	1.19349	1.07995
	(SE)	( 0.08104)	( 0.03828)	( 0.81246)	( 0.76575)	( 0.42196)	( 0.38182)
	Min,	0.054,	0.034,	0.160,	-0.550,	0.054,	-0.550,
	Max	0.410	0.209	3.600	3.020	3.600	3.020
Week 72	n	4	4	4	4	8	8
	Mean	0.2600	0.1658	0.5320	0.1900	0.3960	0.1779
	Median	0.1850	0.1650	0.4650	0.3060	0.2250	0.1660
	SD	0.21924	0.09104	0.47301	0.53263	0.37098	0.35398
	(SE)	( 0.10962)	( 0.04552)	( 0.23650)	( 0.26632)	( 0.13116)	( 0.12515)
	Min,	0.100,	0.084,	0.098,	-0.520,	0.098,	-0.520,
	Max	0.570	0.249	1.100	0.668	1.100	0.668

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	0	0	0	0
	Mean						
	Median						
	SD						
	(SE)						
	Min,						
	Max						
Week 76	n	4	4	4	4	8	8
	Mean	0.1745	0.0803	0.5150	0.1730	0.3448	0.1266
	Median	0.1150	0.0950	0.3950	0.3090	0.3700	0.1020
	SD	0.17421	0.03598	0.25775	0.30988	0.27314	0.21016
	(SE)	( 0.08710)	( 0.01799)	( 0.12887)	( 0.15494)	( 0.09657)	( 0.07430)
	Min,	0.038,	0.027,	0.370,	-0.290,	0.038,	-0.290,
	Max	0.430	0.104	0.900	0.364	0.900	0.364
Week 80	n	4	4	4	4	8	8
	Mean	0.0750	-0.0193	0.3378	-0.0042	0.2064	-0.0117
	Median	0.0695	0.0195	0.3500	-0.0655	0.1125	-0.0250
	SD	0.05060	0.11767	0.25550	0.19114	0.22091	0.14716
	(SE)	( 0.02530)	( 0.05884)	( 0.12775)	( 0.09557)	( 0.07810)	( 0.05203)
	Min,	0.021,	-0.190,	0.021,	-0.160,	0.021,	-0.190,
	Max	0.140	0.074	0.630	0.274	0.630	0.274

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 84	n	4	4	4	4	8	8
	Mean	0.2758	0.1815	0.3015	-0.0405	0.2886	0.0705
	Median	0.0720	0.0540	0.3400	-0.0180	0.1900	0.0540
	SD	0.43669	0.27956	0.18557	0.46202	0.31092	0.37291
	(SE)	( 0.21834)	( 0.13978)	( 0.09278)	( 0.23101)	( 0.10993)	( 0.13184)
	Min,	0.029,	0.018,	0.046,	-0.534,	0.029,	-0.534,
	Max	0.930	0.600	0.480	0.408	0.930	0.600
Week 88	n	4	4	4	4	8	8
	Mean	0.2785	0.1843	0.3860	0.0440	0.3323	0.1141
	Median	0.1350	0.1195	0.2900	0.2510	0.2250	0.1835
	SD	0.35090	0.19680	0.37441	0.47595	0.34081	0.34540
	(SE)	( 0.17545)	( 0.09840)	( 0.18721)	( 0.23798)	( 0.12049)	( 0.12212)
	Min,	0.044,	0.028,	0.044,	-0.666,	0.044,	-0.666,
	Max	0.800	0.470	0.920	0.340	0.920	0.470
Week 92	n	4	4	4	4	8	8
	Mean	0.4125	0.3183	0.5003	0.1583	0.4564	0.2383
	Median	0.1200	0.1065	0.2400	-0.0530	0.1600	0.1065
	SD	0.59169	0.43457	0.67524	0.92039	0.58961	0.67179
	(SE)	( 0.29584)	( 0.21729)	( 0.33762)	( 0.46020)	( 0.20846)	( 0.23751)
	Min,	0.110,	0.090,	0.021,	-0.689,	0.021,	-0.689,
	Max	1.300	0.970	1.500	1.428	1.500	1.428

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	4	4	4	4	8	8
	Mean	0.3480	0.2538	0.4875	0.1455	0.4178	0.1996
	Median	0.1800	0.1620	0.4750	0.1420	0.3550	0.1620
	SD	0.44053	0.28591	0.17231	0.19807	0.31852	0.23494
	(SE)	( 0.22027)	( 0.14296)	( 0.08616)	( 0.09904)	( 0.11262)	( 0.08306)
	Min,	0.032,	0.021,	0.300,	-0.040,	0.032,	-0.040,
	Max	1.000	0.670	0.700	0.338	1.000	0.670
Week 100	n	4	4	4	4	8	8
	Mean	0.7425	0.6483	0.3775	0.0355	0.5600	0.3419
	Median	0.2200	0.2065	0.3850	0.0440	0.3350	0.2065
	SD	1.10774	0.95131	0.06702	0.40529	0.75225	0.75202
	(SE)	( 0.55387)	( 0.47566)	( 0.03351)	( 0.20264)	( 0.26596)	( 0.26588)
	Min,	0.130,	0.110,	0.290,	-0.340,	0.130,	-0.340,
	Max	2.400	2.070	0.450	0.394	2.400	2.070
Week 104	n	4	4	4	4	8	8
	Mean	0.4578	0.3635	0.3525	0.0105	0.4051	0.1870
	Median	0.0945	0.0810	0.1650	-0.1380	0.1400	0.0810
	SD	0.76219	0.60540	0.39886	0.64792	0.56597	0.61041
	(SE)	( 0.38109)	( 0.30270)	( 0.19943)	( 0.32396)	( 0.20010)	( 0.21581)
	Min,	0.042,	0.022,	0.130,	-0.560,	0.042,	-0.560,
	Max	1.600	1.270	0.950	0.878	1.600	1.270

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	4	4	4	4	8	8
	Mean	0.6398	0.5455	0.2750	-0.0670	0.4574	0.2393
	Median	0.1450	0.1295	0.2300	0.0920	0.1800	0.1295
	SD	1.04118	0.88432	0.23014	0.40467	0.72478	0.71591
	(SE)	( 0.52059)	( 0.44216)	( 0.11507)	( 0.20234)	( 0.25625)	( 0.25311)
	Min, Max	0.069, 2.200	0.053, 1.870	0.050, 0.590	-0.660, 0.208	0.050, 2.200	-0.660, 1.870
Week 112	n	4	4	4	4	8	8
	Mean	0.1870	0.0928	0.2673	-0.0747	0.2271	0.0090
	Median	0.1045	0.0865	0.2140	-0.1120	0.1090	0.0865
	SD	0.21862	0.06805	0.26935	0.61326	0.23112	0.41374
	(SE)	( 0.10931)	( 0.03402)	( 0.13468)	( 0.30663)	( 0.08171)	( 0.14628)
	Min, Max	0.029, 0.510	0.018, 0.180	0.021, 0.620	-0.689, 0.614	0.021, 0.620	-0.689, 0.614
Week 116	n	4	4	4	4	8	8
	Mean	0.4138	0.3195	0.5125	0.1705	0.4631	0.2450
	Median	0.0605	0.0425	0.4500	0.3170	0.1850	0.1305
	SD	0.72428	0.56709	0.40111	0.51289	0.54457	0.50686
	(SE)	( 0.36214)	( 0.28354)	( 0.20056)	( 0.25645)	( 0.19254)	( 0.17920)
	Min, Max	0.034, 1.500	0.023, 1.170	0.150, 1.000	-0.560, 0.608	0.034, 1.500	-0.560, 1.170

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	4	4	4	4	8	8
	Mean	0.2630	0.1688	0.4200	0.0780	0.3415	0.1234
	Median	0.2150	0.0680	0.3000	0.1960	0.2900	0.0970
	SD	0.22354	0.24910	0.37211	0.37503	0.29631	0.29870
	(SE)	( 0.11177)	( 0.12455)	( 0.18606)	( 0.18752)	( 0.10476)	( 0.10561)
	Min,	0.072,	0.000,	0.120,	-0.460,	0.072,	-0.460,
	Max	0.550	0.539	0.960	0.380	0.960	0.539
Week 124	n	4	4	4	4	8	8
	Mean	0.4953	0.4010	0.7625	0.4205	0.6289	0.4108
	Median	0.1800	0.1645	0.4150	0.2710	0.3250	0.2115
	SD	0.74908	0.59599	0.90511	0.80492	0.78229	0.65575
	(SE)	( 0.37454)	( 0.29799)	( 0.45256)	( 0.40246)	( 0.27658)	( 0.23184)
	Min,	0.021,	0.005,	0.120,	-0.380,	0.021,	-0.380,
	Max	1.600	1.270	2.100	1.520	2.100	1.520
Week 128	n	4	4	4	4	8	8
	Mean	0.0605	-0.0338	0.8325	0.4905	0.4465	0.2284
	Median	0.0590	0.0245	0.6800	0.3470	0.2850	0.0600
	SD	0.03117	0.15894	0.46807	0.67592	0.51439	0.53400
	(SE)	( 0.01559)	( 0.07947)	( 0.23404)	( 0.33796)	( 0.18186)	( 0.18880)
	Min,	0.024,	-0.268,	0.470,	-0.160,	0.024,	-0.268,
	Max	0.100	0.084	1.500	1.428	1.500	1.428

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point		Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	4	4	4	4	8	8
	Mean	0.1968	0.1025	0.5050	0.1630	0.3509	0.1328
	Median	0.1900	0.0870	0.4200	0.1560	0.2250	0.1160
	SD	0.14999	0.09038	0.38872	0.20801	0.31866	0.15195
	(SE)	( 0.07499)	( 0.04519)	( 0.19436)	( 0.10400)	( 0.11266)	( 0.05372)
	Min,	0.027,	0.016,	0.180,	-0.080,	0.027,	-0.080,
	Max	0.380	0.220	1.000	0.420	1.000	0.420
Week 136	n	4	4	4	4	8	8
	Mean	0.0708	-0.0235	0.5550	0.2130	0.3129	0.0948
	Median	0.0760	0.0235	0.5100	0.3370	0.2250	0.0635
	SD	0.04135	0.14227	0.23629	0.40388	0.30276	0.30751
	(SE)	( 0.02067)	( 0.07113)	( 0.11815)	( 0.20194)	( 0.10704)	( 0.10872)
	Min,	0.021,	-0.231,	0.340,	-0.370,	0.021,	-0.370,
	Max	0.110	0.090	0.860	0.548	0.860	0.548
Week 140	n	4	4	4	4	8	8
	Mean	0.4065	0.3123	0.5125	0.1705	0.4595	0.2414
	Median	0.0995	0.0815	0.4300	0.0820	0.2950	0.0815
	SD	0.66321	0.50611	0.31202	0.53036	0.48316	0.48587
	(SE)	( 0.33161)	( 0.25306)	( 0.15601)	( 0.26518)	( 0.17082)	( 0.17178)
	Min,	0.027,	0.016,	0.240,	-0.360,	0.027,	-0.360,
	Max	1.400	1.070	0.950	0.878	1.400	1.070

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.1  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Time Point	Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 184 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 144	n	4	4	4	4	8	8
	Mean	0.0955	0.0012	0.4275	0.0855	0.2615	0.0434
	Median	0.0505	0.0190	0.3900	0.0090	0.2550	0.0190
	SD	0.11056	0.04881	0.18246	0.50910	0.22583	0.33783
	(SE)	( 0.05528)	( 0.02440)	( 0.09123)	( 0.25455)	( 0.07984)	( 0.11944)
	Min,	0.021,	-0.070,	0.250,	-0.350,	0.021,	-0.350,
	Max	0.260	0.037	0.680	0.674	0.680	0.674

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:24

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Specific Gravity						
Week 1	n	2	2		4	
	Mean	1.0070	1.0035		1.0053	
	Median	1.0070	1.0035		1.0045	
	SD	0.00566	0.00354		0.00435	
	(SE)	( 0.00400)	( 0.00250)		( 0.00217)	
	Min,	1.003,	1.001,		1.001,	
	Max	1.011	1.006		1.011	
Week 2	n	2	2		4	
	Mean	1.0100	1.0025		1.0063	
	Median	1.0100	1.0025		1.0045	
	SD	0.00566	0.00071		0.00544	
	(SE)	( 0.00400)	( 0.00050)		( 0.00272)	
	Min,	1.006,	1.002,		1.002,	
	Max	1.014	1.003		1.014	
Week 4	n	2	2		4	
	Mean	1.0120	1.0105		1.0113	
	Median	1.0120	1.0105		1.0110	
	SD	0.00424	0.00354		0.00330	
	(SE)	( 0.00300)	( 0.00250)		( 0.00165)	
	Min,	1.009,	1.008,		1.008,	
	Max	1.015	1.013		1.015	

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4	
	Mean	1.0110		1.0035		1.0073	
	Median	1.0110		1.0035		1.0050	
	SD	0.00990		0.00354		0.00746	
	(SE)	( 0.00700)		( 0.00250)		( 0.00373)	
	Min,	1.004,		1.001,		1.001,	
	Max	1.018		1.006		1.018	
Week 8	n	2		2		4	
	Mean	1.0220		1.0115		1.0168	
	Median	1.0220		1.0115		1.0155	
	SD	0.00424		0.00071		0.00655	
	(SE)	( 0.00300)		( 0.00050)		( 0.00328)	
	Min,	1.019,		1.011,		1.011,	
	Max	1.025		1.012		1.025	
Week 10	n	2		2		4	
	Mean	1.0140		1.0025		1.0083	
	Median	1.0140		1.0025		1.0055	
	SD	0.00849		0.00071		0.00826	
	(SE)	( 0.00600)		( 0.00050)		( 0.00413)	
	Min,	1.008,		1.002,		1.002,	
	Max	1.020		1.003		1.020	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2	2		4	
	Mean	1.0075	1.0040		1.0058	
	Median	1.0075	1.0040		1.0055	
	SD	0.00212	0.00141		0.00250	
	(SE)	( 0.00150)	( 0.00100)		( 0.00125)	
	Min,	1.006,	1.003,		1.003,	
	Max	1.009	1.005		1.009	
Week 15	n	2	2		4	
	Mean	1.0135	1.0030		1.0083	
	Median	1.0135	1.0030		1.0030	
	SD	0.01626	0.00000		0.01118	
	(SE)	( 0.01150)	( 0.00000)		( 0.00559)	
	Min,	1.002,	1.003,		1.002,	
	Max	1.025	1.003		1.025	
Week 18	n	2	2		4	
	Mean	1.0180	1.0035		1.0108	
	Median	1.0180	1.0035		1.0100	
	SD	0.00283	0.00071		0.00854	
	(SE)	( 0.00200)	( 0.00050)		( 0.00427)	
	Min,	1.016,	1.003,		1.003,	
	Max	1.020	1.004		1.020	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	1.0165		1.0065		1.0115	
	Median	1.0165		1.0065		1.0115	
	SD	0.00071		0.00071		0.00580	
	(SE)	( 0.00050)		( 0.00050)		( 0.00290)	
	Min,	1.016,		1.006,		1.006,	
	Max	1.017		1.007		1.017	
Week 24	n	2		2		4	
	Mean	1.0125		1.0040		1.0083	
	Median	1.0125		1.0040		1.0060	
	SD	0.00919		0.00283		0.00741	
	(SE)	( 0.00650)		( 0.00200)		( 0.00371)	
	Min,	1.006,		1.002,		1.002,	
	Max	1.019		1.006		1.019	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	1.0145		1.0060		1.0103	
	Median	1.0145		1.0060		1.0070	
	SD	0.01344		0.00424		0.00950	
	(SE)	( 0.00950)		( 0.00300)		( 0.00475)	
	Min,	1.005,		1.003,		1.003,	
	Max	1.024		1.009		1.024	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	1.0160	0.0015	1.0045	-0.0015	1.0103	0.0000
	Median	1.0160	0.0015	1.0045	-0.0015	1.0095	-0.0015
	SD	0.00283	0.01061	0.00071	0.00495	0.00685	0.00698
	(SE)	( 0.00200)	( 0.00750)	( 0.00050)	( 0.00350)	( 0.00342)	( 0.00349)
	Min,	1.014,	-0.006,	1.004,	-0.005,	1.004,	-0.006,
	Max	1.018	0.009	1.005	0.002	1.018	0.009
Week 32	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0100	0.0040	1.0125	0.0023
	Median	1.0150	0.0005	1.0100	0.0040	1.0125	0.0040
	SD	0.00000	0.01344	0.00000	0.00424	0.00289	0.00838
	(SE)	( 0.00000)	( 0.00950)	( 0.00000)	( 0.00300)	( 0.00144)	( 0.00419)
	Min,	1.015,	-0.009,	1.010,	0.001,	1.010,	-0.009,
	Max	1.015	0.010	1.010	0.007	1.015	0.010
Week 36	n	2	2	2	2	4	4
	Mean	1.0250	0.0105	1.0150	0.0090	1.0200	0.0098
	Median	1.0250	0.0105	1.0150	0.0090	1.0200	0.0090
	SD	0.00000	0.01344	0.00000	0.00424	0.00577	0.00818
	(SE)	( 0.00000)	( 0.00950)	( 0.00000)	( 0.00300)	( 0.00289)	( 0.00409)
	Min,	1.025,	0.001,	1.015,	0.006,	1.015,	0.001,
	Max	1.025	0.020	1.015	0.012	1.025	0.020

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	1.0225	0.0080	1.0100	0.0040	1.0163	0.0060
	Median	1.0225	0.0080	1.0100	0.0040	1.0150	0.0040
	SD	0.00354	0.00990	0.00000	0.00424	0.00750	0.00663
	(SE)	( 0.00250)	( 0.00700)	( 0.00000)	( 0.00300)	( 0.00375)	( 0.00332)
	Min,	1.020,	0.001,	1.010,	0.001,	1.010,	0.001,
	Max	1.025	0.015	1.010	0.007	1.025	0.015
Week 44	n	2	2	2	2	4	4
	Mean	1.0225	0.0080	1.0125	0.0065	1.0175	0.0073
	Median	1.0225	0.0080	1.0125	0.0065	1.0175	0.0080
	SD	0.01061	0.00283	0.01061	0.01485	0.01041	0.00877
	(SE)	( 0.00750)	( 0.00200)	( 0.00750)	( 0.01050)	( 0.00520)	( 0.00439)
	Min,	1.015,	0.006,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.030	0.010	1.020	0.017	1.030	0.017
Week 48	n	2	2	2	2	4	4
	Mean	1.0200	0.0055	1.0125	0.0065	1.0163	0.0060
	Median	1.0200	0.0055	1.0125	0.0065	1.0175	0.0055
	SD	0.00707	0.00636	0.01061	0.01485	0.00854	0.00935
	(SE)	( 0.00500)	( 0.00450)	( 0.00750)	( 0.01050)	( 0.00427)	( 0.00467)
	Min,	1.015,	0.001,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.025	0.010	1.020	0.017	1.025	0.017

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0075	0.0015	1.0113	0.0010
	Median	1.0150	0.0005	1.0075	0.0015	1.0100	0.0015
	SD	0.00707	0.00636	0.00354	0.00071	0.00629	0.00374
	(SE)	( 0.00500)	( 0.00450)	( 0.00250)	( 0.00050)	( 0.00315)	( 0.00187)
	Min,	1.010,	-0.004,	1.005,	0.001,	1.005,	-0.004,
	Max	1.020	0.005	1.010	0.002	1.020	0.005
Week 56	n	2	2	2	2	4	4
	Mean	1.0225	0.0080	1.0075	0.0015	1.0150	0.0048
	Median	1.0225	0.0080	1.0075	0.0015	1.0150	0.0015
	SD	0.00354	0.01697	0.00354	0.00071	0.00913	0.01050
	(SE)	( 0.00250)	( 0.01200)	( 0.00250)	( 0.00050)	( 0.00456)	( 0.00525)
	Min,	1.020,	-0.004,	1.005,	0.001,	1.005,	-0.004,
	Max	1.025	0.020	1.010	0.002	1.025	0.020
Week 60	n	2	2	2	2	4	4
	Mean	1.0125	-0.0020	1.0075	0.0015	1.0100	-0.0003
	Median	1.0125	-0.0020	1.0075	0.0015	1.0075	-0.0020
	SD	0.01061	0.00283	0.00354	0.00778	0.00707	0.00519
	(SE)	( 0.00750)	( 0.00200)	( 0.00250)	( 0.00550)	( 0.00354)	( 0.00259)
	Min,	1.005,	-0.004,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.020	0.000	1.010	0.007	1.020	0.007

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	1	1	2	2	3	3
	Mean	1.0150	-0.0090	1.0050	-0.0010	1.0083	-0.0037
	Median	1.0150	-0.0090	1.0050	-0.0010	1.0050	-0.0040
	SD			0.00000	0.00424	0.00577	0.00551
	(SE)			( 0.00000)	( 0.00300)	( 0.00333)	( 0.00318)
	Min, Max	1.015, 1.015	-0.009, -0.009	1.005, 1.005	-0.004, 0.002	1.005, 1.015	-0.009, 0.002
Week 68	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0200	0.0140	1.0188	0.0085
	Median	1.0175	0.0030	1.0200	0.0140	1.0175	0.0110
	SD	0.00354	0.01697	0.01414	0.00990	0.00854	0.01300
	(SE)	( 0.00250)	( 0.01200)	( 0.01000)	( 0.00700)	( 0.00427)	( 0.00650)
	Min, Max	1.015, 1.020	-0.009, 0.015	1.010, 1.030	0.007, 0.021	1.010, 1.030	-0.009, 0.021
Week 72	n	2	2	0	0	2	2
	Mean	1.0250	0.0105			1.0250	0.0105
	Median	1.0250	0.0105			1.0250	0.0105
	SD	0.00707	0.00636			0.00707	0.00636
	(SE)	( 0.00500)	( 0.00450)			( 0.00500)	( 0.00450)
	Min, Max	1.020, 1.030	0.006, 0.015			1.020, 1.030	0.006, 0.015

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			1.0100	0.0010	1.0100	0.0010
	Median			1.0100	0.0010	1.0100	0.0010
	SD						
	(SE)						
	Min, Max			1.010, 1.010	0.001, 0.001	1.010, 1.010	0.001, 0.001
Week 76	n	2	2	2	2	4	4
	Mean	1.0225	0.0080	1.0050	-0.0010	1.0138	0.0035
	Median	1.0225	0.0080	1.0050	-0.0010	1.0125	-0.0010
	SD	0.00354	0.01697	0.00000	0.00424	0.01031	0.01136
	(SE)	( 0.00250)	( 0.01200)	( 0.00000)	( 0.00300)	( 0.00515)	( 0.00568)
	Min, Max	1.020, 1.025	-0.004, 0.020	1.005, 1.005	-0.004, 0.002	1.005, 1.025	-0.004, 0.020
Week 80	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0075	0.0015	1.0125	0.0023
	Median	1.0175	0.0030	1.0075	0.0015	1.0125	0.0015
	SD	0.00354	0.01697	0.00354	0.00071	0.00645	0.00984
	(SE)	( 0.00250)	( 0.01200)	( 0.00250)	( 0.00050)	( 0.00323)	( 0.00492)
	Min, Max	1.015, 1.020	-0.009, 0.015	1.005, 1.010	0.001, 0.002	1.005, 1.020	-0.009, 0.015

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 84	n	2	2	2	2	4	4
	Mean	1.0125	-0.0020	1.0050	-0.0010	1.0088	-0.0015
	Median	1.0125	-0.0020	1.0050	-0.0010	1.0075	-0.0010
	SD	0.00354	0.00990	0.00000	0.00424	0.00479	0.00624
	(SE)	( 0.00250)	( 0.00700)	( 0.00000)	( 0.00300)	( 0.00239)	( 0.00312)
	Min,	1.010,	-0.009,	1.005,	-0.004,	1.005,	-0.009,
	Max	1.015	0.005	1.005	0.002	1.015	0.005
Week 88	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0050	-0.0010	1.0100	-0.0003
	Median	1.0150	0.0005	1.0050	-0.0010	1.0050	0.0005
	SD	0.01414	0.00071	0.00000	0.00424	0.01000	0.00263
	(SE)	( 0.01000)	( 0.00050)	( 0.00000)	( 0.00300)	( 0.00500)	( 0.00131)
	Min,	1.005,	0.000,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.025	0.001	1.005	0.002	1.025	0.002
Week 92	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0075	0.0015	1.0113	0.0010
	Median	1.0150	0.0005	1.0075	0.0015	1.0100	0.0015
	SD	0.00707	0.00636	0.00354	0.00071	0.00629	0.00374
	(SE)	( 0.00500)	( 0.00450)	( 0.00250)	( 0.00050)	( 0.00315)	( 0.00187)
	Min,	1.010,	-0.004,	1.005,	0.001,	1.005,	-0.004,
	Max	1.020	0.005	1.010	0.002	1.020	0.005

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0075	0.0015	1.0125	0.0023
	Median	1.0175	0.0030	1.0075	0.0015	1.0075	0.0030
	SD	0.01768	0.00424	0.00354	0.00778	0.01190	0.00519
	(SE)	( 0.01250)	( 0.00300)	( 0.00250)	( 0.00550)	( 0.00595)	( 0.00259)
	Min,	1.005,	0.000,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.030	0.006	1.010	0.007	1.030	0.007
Week 100	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0100	0.0040	1.0125	0.0023
	Median	1.0150	0.0005	1.0100	0.0040	1.0125	0.0040
	SD	0.00000	0.01344	0.00000	0.00424	0.00289	0.00838
	(SE)	( 0.00000)	( 0.00950)	( 0.00000)	( 0.00300)	( 0.00144)	( 0.00419)
	Min,	1.015,	-0.009,	1.010,	0.001,	1.010,	-0.009,
	Max	1.015	0.010	1.010	0.007	1.015	0.010
Week 104	n	2	2	2	2	4	4
	Mean	1.0050	-0.0095	1.0100	0.0040	1.0075	-0.0028
	Median	1.0050	-0.0095	1.0100	0.0040	1.0075	0.0005
	SD	0.00000	0.01344	0.00000	0.00424	0.00289	0.01127
	(SE)	( 0.00000)	( 0.00950)	( 0.00000)	( 0.00300)	( 0.00144)	( 0.00563)
	Min,	1.005,	-0.019,	1.010,	0.001,	1.005,	-0.019,
	Max	1.005	0.000	1.010	0.007	1.010	0.007

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0125	0.0065	1.0138	0.0035
	Median	1.0150	0.0005	1.0125	0.0065	1.0150	0.0065
	SD	0.00707	0.02051	0.01061	0.00636	0.00750	0.01287
	(SE)	( 0.00500)	( 0.01450)	( 0.00750)	( 0.00450)	( 0.00375)	( 0.00644)
	Min,	1.010,	-0.014,	1.005,	0.002,	1.005,	-0.014,
	Max	1.020	0.015	1.020	0.011	1.020	0.015
Week 112	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0050	-0.0010	1.0100	-0.0002
	Median	1.0150	0.0005	1.0050	-0.0010	1.0100	-0.0010
	SD	0.00000	0.01344	0.00000	0.00424	0.00577	0.00818
	(SE)	( 0.00000)	( 0.00950)	( 0.00000)	( 0.00300)	( 0.00289)	( 0.00409)
	Min,	1.015,	-0.009,	1.005,	-0.004,	1.005,	-0.009,
	Max	1.015	0.010	1.005	0.002	1.015	0.010
Week 116	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0075	0.0015	1.0125	0.0022
	Median	1.0175	0.0030	1.0075	0.0015	1.0100	0.0015
	SD	0.01061	0.02404	0.00354	0.00778	0.00866	0.01461
	(SE)	( 0.00750)	( 0.01700)	( 0.00250)	( 0.00550)	( 0.00433)	( 0.00731)
	Min,	1.010,	-0.014,	1.005,	-0.004,	1.005,	-0.014,
	Max	1.025	0.020	1.010	0.007	1.025	0.020

<sup>3</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 120	n	2	2	2	2	4	4
	Mean	1.0100	-0.0045	1.0175	0.0115	1.0138	0.0035
	Median	1.0100	-0.0045	1.0175	0.0115	1.0100	0.0060
	SD	0.00000	0.01344	0.01061	0.00636	0.00750	0.01261
	(SE)	( 0.00000)	( 0.00950)	( 0.00750)	( 0.00450)	( 0.00375)	( 0.00630)
	Min,	1.010,	-0.014,	1.010,	0.007,	1.010,	-0.014,
	Max	1.010	0.005	1.025	0.016	1.025	0.016
Week 124	n	2	2	2	2	4	4
	Mean	1.0200	0.0055	1.0100	0.0040	1.0150	0.0048
	Median	1.0200	0.0055	1.0100	0.0040	1.0175	0.0040
	SD	0.00000	0.01344	0.00707	0.01131	0.00707	0.01018
	(SE)	( 0.00000)	( 0.00950)	( 0.00500)	( 0.00800)	( 0.00354)	( 0.00509)
	Min,	1.020,	-0.004,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.020	0.015	1.015	0.012	1.020	0.015
Week 128	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0125	0.0065	1.0138	0.0035
	Median	1.0150	0.0005	1.0125	0.0065	1.0125	0.0055
	SD	0.00707	0.00636	0.00354	0.00071	0.00479	0.00507
	(SE)	( 0.00500)	( 0.00450)	( 0.00250)	( 0.00050)	( 0.00239)	( 0.00253)
	Min,	1.010,	-0.004,	1.010,	0.006,	1.010,	-0.004,
	Max	1.020	0.005	1.015	0.007	1.020	0.007

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0075	0.0015	1.0113	0.0010
	Median	1.0150	0.0005	1.0075	0.0015	1.0100	0.0015
	SD	0.00707	0.00636	0.00354	0.00071	0.00629	0.00374
	(SE)	( 0.00500)	( 0.00450)	( 0.00250)	( 0.00050)	( 0.00315)	( 0.00187)
	Min,	1.010,	-0.004,	1.005,	0.001,	1.005,	-0.004,
	Max	1.020	0.005	1.010	0.002	1.020	0.005
Week 136	n	2	2	2	2	4	4
	Mean	1.0225	0.0080	1.0075	0.0015	1.0150	0.0048
	Median	1.0225	0.0080	1.0075	0.0015	1.0150	0.0015
	SD	0.00354	0.00990	0.00354	0.00071	0.00913	0.00685
	(SE)	( 0.00250)	( 0.00700)	( 0.00250)	( 0.00050)	( 0.00456)	( 0.00342)
	Min,	1.020,	0.001,	1.005,	0.001,	1.005,	0.001,
	Max	1.025	0.015	1.010	0.002	1.025	0.015
Week 140	n	2	2	2	2	4	4
	Mean	1.0150	0.0005	1.0075	0.0015	1.0113	0.0010
	Median	1.0150	0.0005	1.0075	0.0015	1.0100	0.0005
	SD	0.00707	0.00636	0.00354	0.00778	0.00629	0.00583
	(SE)	( 0.00500)	( 0.00450)	( 0.00250)	( 0.00550)	( 0.00315)	( 0.00292)
	Min,	1.010,	-0.004,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.020	0.005	1.010	0.007	1.020	0.007

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	1.0200	0.0055	1.0075	0.0015	1.0138	0.0035
	Median	1.0200	0.0055	1.0075	0.0015	1.0150	0.0015
	SD	0.00000	0.01344	0.00354	0.00778	0.00750	0.00926
	(SE)	( 0.00000)	( 0.00950)	( 0.00250)	( 0.00550)	( 0.00375)	( 0.00463)
	Min,	1.020,	-0.004,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.020	0.015	1.010	0.007	1.020	0.015
Week 148	n	2	2	2	2	4	4
	Mean	1.0125	-0.0020	1.0075	0.0015	1.0100	-0.0003
	Median	1.0125	-0.0020	1.0075	0.0015	1.0075	0.0005
	SD	0.01061	0.00283	0.00354	0.00071	0.00707	0.00263
	(SE)	( 0.00750)	( 0.00200)	( 0.00250)	( 0.00050)	( 0.00354)	( 0.00131)
	Min,	1.005,	-0.004,	1.005,	0.001,	1.005,	-0.004,
	Max	1.020	0.000	1.010	0.002	1.020	0.002
Week 152	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0100	0.0040	1.0138	0.0035
	Median	1.0175	0.0030	1.0100	0.0040	1.0100	0.0030
	SD	0.01061	0.00283	0.00000	0.00424	0.00750	0.00300
	(SE)	( 0.00750)	( 0.00200)	( 0.00000)	( 0.00300)	( 0.00375)	( 0.00150)
	Min,	1.010,	0.001,	1.010,	0.001,	1.010,	0.001,
	Max	1.025	0.005	1.010	0.007	1.025	0.007

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	1.0075	-0.0070	1.0100	0.0040	1.0088	-0.0015
	Median	1.0075	-0.0070	1.0100	0.0040	1.0075	0.0010
	SD	0.00354	0.00990	0.00707	0.00283	0.00479	0.00870
	(SE)	( 0.00250)	( 0.00700)	( 0.00500)	( 0.00200)	( 0.00239)	( 0.00435)
	Min,	1.005,	-0.014,	1.005,	0.002,	1.005,	-0.014,
	Max	1.010	0.000	1.015	0.006	1.015	0.006
Week 160	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0075	0.0015	1.0125	0.0023
	Median	1.0175	0.0030	1.0075	0.0015	1.0125	0.0015
	SD	0.00354	0.01697	0.00354	0.00071	0.00645	0.00984
	(SE)	( 0.00250)	( 0.01200)	( 0.00250)	( 0.00050)	( 0.00323)	( 0.00492)
	Min,	1.015,	-0.009,	1.005,	0.001,	1.005,	-0.009,
	Max	1.020	0.015	1.010	0.002	1.020	0.015
Week 164	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0100	0.0040	1.0138	0.0035
	Median	1.0175	0.0030	1.0100	0.0040	1.0150	0.0040
	SD	0.00354	0.00990	0.00707	0.00283	0.00629	0.00597
	(SE)	( 0.00250)	( 0.00700)	( 0.00500)	( 0.00200)	( 0.00315)	( 0.00299)
	Min,	1.015,	-0.004,	1.005,	0.002,	1.005,	-0.004,
	Max	1.020	0.010	1.015	0.006	1.020	0.010

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0075	0.0015	1.0125	0.0023
	Median	1.0175	0.0030	1.0075	0.0015	1.0125	0.0015
	SD	0.00354	0.01697	0.00354	0.00071	0.00645	0.00984
	(SE)	( 0.00250)	( 0.01200)	( 0.00250)	( 0.00050)	( 0.00323)	( 0.00492)
	Min,	1.015,	-0.009,	1.005,	0.001,	1.005,	-0.009,
	Max	1.020	0.015	1.010	0.002	1.020	0.015
Week 172	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0050	-0.0010	1.0113	0.0010
	Median	1.0175	0.0030	1.0050	-0.0010	1.0100	-0.0010
	SD	0.00354	0.00990	0.00000	0.00424	0.00750	0.00663
	(SE)	( 0.00250)	( 0.00700)	( 0.00000)	( 0.00300)	( 0.00375)	( 0.00332)
	Min,	1.015,	-0.004,	1.005,	-0.004,	1.005,	-0.004,
	Max	1.020	0.010	1.005	0.002	1.020	0.010
Week 176	n	2	2	2	2	4	4
	Mean	1.0125	-0.0020	1.0175	0.0115	1.0150	0.0048
	Median	1.0125	-0.0020	1.0175	0.0115	1.0125	0.0085
	SD	0.00354	0.01697	0.01061	0.00636	0.00707	0.01305
	(SE)	( 0.00250)	( 0.01200)	( 0.00750)	( 0.00450)	( 0.00354)	( 0.00652)
	Min,	1.010,	-0.014,	1.010,	0.007,	1.010,	-0.014,
	Max	1.015	0.010	1.025	0.016	1.025	0.016

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 180	n	2	2	2	2	4	4
	Mean	1.0175	0.0030	1.0075	0.0015	1.0125	0.0023
	Median	1.0175	0.0030	1.0075	0.0015	1.0075	0.0015
	SD	0.01768	0.03111	0.00354	0.00071	0.01190	0.01799
	(SE)	( 0.01250)	( 0.02200)	( 0.00250)	( 0.00050)	( 0.00595)	( 0.00899)
	Min,	1.005,	-0.019,	1.005,	0.001,	1.005,	-0.019,
	Max	1.030	0.025	1.010	0.002	1.030	0.025
Week 184	n	2	2	2	2	4	4
	Mean	1.0125	-0.0020	1.0200	0.0140	1.0163	0.0060
	Median	1.0125	-0.0020	1.0200	0.0140	1.0125	0.0085
	SD	0.00354	0.01697	0.01414	0.00990	0.00946	0.01463
	(SE)	( 0.00250)	( 0.01200)	( 0.01000)	( 0.00700)	( 0.00473)	( 0.00731)
	Min,	1.010,	-0.014,	1.010,	0.007,	1.010,	-0.014,
	Max	1.015	0.010	1.030	0.021	1.030	0.021

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
pH						
Week 1	n	2	2		4	
	Mean	6.50	6.50		6.50	
	Median	6.50	6.50		6.50	
	SD	0.707	0.707		0.577	
	(SE)	( 0.500)	( 0.500)		( 0.289)	
	Min, Max	6.0, 7.0	6.0, 7.0		6.0, 7.0	
Week 2	n	2	2		4	
	Mean	6.75	6.00		6.38	
	Median	6.75	6.00		6.50	
	SD	0.354	0.707		0.629	
	(SE)	( 0.250)	( 0.500)		( 0.315)	
	Min, Max	6.5, 7.0	5.5, 6.5		5.5, 7.0	
Week 4	n	2	2		4	
	Mean	6.50	5.75		6.13	
	Median	6.50	5.75		5.75	
	SD	1.414	0.354		0.946	
	(SE)	( 1.000)	( 0.250)		( 0.473)	
	Min, Max	5.5, 7.5	5.5, 6.0		5.5, 7.5	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4
	Mean	6.25		6.50		6.38
	Median	6.25		6.50		6.50
	SD	1.061		0.707		0.750
	(SE)	( 0.750)		( 0.500)		( 0.375)
	Min,	5.5,		6.0,		5.5,
	Max	7.0		7.0		7.0
Week 8	n	2		2		4
	Mean	6.00		6.75		6.38
	Median	6.00		6.75		6.00
	SD	0.000		1.061		0.750
	(SE)	( 0.000)		( 0.750)		( 0.375)
	Min,	6.0,		6.0,		6.0,
	Max	6.0		7.5		7.5
Week 10	n	2		2		4
	Mean	6.00		6.25		6.13
	Median	6.00		6.25		6.25
	SD	0.707		0.354		0.479
	(SE)	( 0.500)		( 0.250)		( 0.239)
	Min,	5.5,		6.0,		5.5,
	Max	6.5		6.5		6.5

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2	2		4	
	Mean	6.00	6.50		6.25	
	Median	6.00	6.50		6.50	
	SD	0.707	0.000		0.500	
	(SE)	( 0.500)	( 0.000)		( 0.250)	
	Min,	5.5,	6.5,		5.5,	
	Max	6.5	6.5		6.5	
Week 15	n	2	2		4	
	Mean	6.50	5.75		6.13	
	Median	6.50	5.75		6.50	
	SD	0.000	1.061		0.750	
	(SE)	( 0.000)	( 0.750)		( 0.375)	
	Min,	6.5,	5.0,		5.0,	
	Max	6.5	6.5		6.5	
Week 18	n	2	2		4	
	Mean	7.00	6.75		6.88	
	Median	7.00	6.75		6.75	
	SD	2.121	1.061		1.377	
	(SE)	( 1.500)	( 0.750)		( 0.688)	
	Min,	5.5,	6.0,		5.5,	
	Max	8.5	7.5		8.5	

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	6.25		6.00		6.13	
	Median	6.25		6.00		6.00	
	SD	1.061		0.000		0.629	
	(SE)	( 0.750)		( 0.000)		( 0.315)	
	Min, Max	5.5, 7.0		6.0, 6.0		5.5, 7.0	
Week 24	n	2		2		4	
	Mean	6.00		6.75		6.38	
	Median	6.00		6.75		6.50	
	SD	0.707		0.354		0.629	
	(SE)	( 0.500)		( 0.250)		( 0.315)	
	Min, Max	5.5, 6.5		6.5, 7.0		5.5, 7.0	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	6.25		6.25		6.25	
	Median	6.25		6.25		6.25	
	SD	0.354		0.354		0.289	
	(SE)	( 0.250)		( 0.250)		( 0.144)	
	Min, Max	6.0, 6.5		6.0, 6.5		6.0, 6.5	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	6.25	0.00	6.50	0.25	6.38	0.13
	Median	6.25	0.00	6.50	0.25	6.25	0.00
	SD	0.354	0.000	0.707	0.354	0.479	0.250
	(SE)	( 0.250)	( 0.000)	( 0.500)	( 0.250)	( 0.239)	( 0.125)
	Min, Max	6.0, 6.5	0.0, 0.0	6.0, 7.0	0.0, 0.5	6.0, 7.0	0.0, 0.5
Week 32	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.00	0.75	6.75	0.50
	Median	6.50	0.25	7.00	0.75	6.50	0.50
	SD	0.000	0.354	0.707	0.354	0.500	0.408
	(SE)	( 0.000)	( 0.250)	( 0.500)	( 0.250)	( 0.250)	( 0.204)
	Min, Max	6.5, 6.5	0.0, 0.5	6.5, 7.5	0.5, 1.0	6.5, 7.5	0.0, 1.0
Week 36	n	2	2	2	2	4	4
	Mean	6.25	0.00	7.00	0.75	6.63	0.38
	Median	6.25	0.00	7.00	0.75	6.75	0.25
	SD	0.354	0.000	0.000	0.354	0.479	0.479
	(SE)	( 0.250)	( 0.000)	( 0.000)	( 0.250)	( 0.239)	( 0.239)
	Min, Max	6.0, 6.5	0.0, 0.0	7.0, 7.0	0.5, 1.0	6.0, 7.0	0.0, 1.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.00	0.75	6.75	0.50
	Median	6.50	0.25	7.00	0.75	6.75	0.50
	SD	0.000	0.354	0.000	0.354	0.289	0.408
	(SE)	( 0.000)	( 0.250)	( 0.000)	( 0.250)	( 0.144)	( 0.204)
	Min, Max	6.5, 6.5	0.0, 0.5	7.0, 7.0	0.5, 1.0	6.5, 7.0	0.0, 1.0
Week 44	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.25	1.00	6.88	0.63
	Median	6.50	0.25	7.25	1.00	7.00	0.75
	SD	0.707	0.354	0.354	0.000	0.629	0.479
	(SE)	( 0.500)	( 0.250)	( 0.250)	( 0.000)	( 0.315)	( 0.239)
	Min, Max	6.0, 7.0	0.0, 0.5	7.0, 7.5	1.0, 1.0	6.0, 7.5	0.0, 1.0
Week 48	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.50	1.25	7.00	0.75
	Median	6.50	0.25	7.50	1.25	6.75	0.50
	SD	0.707	0.354	1.414	1.061	1.080	0.866
	(SE)	( 0.500)	( 0.250)	( 1.000)	( 0.750)	( 0.540)	( 0.433)
	Min, Max	6.0, 7.0	0.0, 0.5	6.5, 8.5	0.5, 2.0	6.0, 8.5	0.0, 2.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	7.00	0.75	7.75	1.50	7.38	1.13
	Median	7.00	0.75	7.75	1.50	7.75	1.50
	SD	1.414	1.061	0.354	0.000	0.946	0.750
	(SE)	( 1.000)	( 0.750)	( 0.250)	( 0.000)	( 0.473)	( 0.375)
	Min, Max	6.0, 8.0	0.0, 1.5	7.5, 8.0	1.5, 1.5	6.0, 8.0	0.0, 1.5
Week 56	n	2	2	2	2	4	4
	Mean	7.25	1.00	7.75	1.50	7.50	1.25
	Median	7.25	1.00	7.75	1.50	7.75	1.50
	SD	1.061	1.414	0.354	0.000	0.707	0.866
	(SE)	( 0.750)	( 1.000)	( 0.250)	( 0.000)	( 0.354)	( 0.433)
	Min, Max	6.5, 8.0	0.0, 2.0	7.5, 8.0	1.5, 1.5	6.5, 8.0	0.0, 2.0
Week 60	n	2	2	2	2	4	4
	Mean	7.00	0.75	7.50	1.25	7.25	1.00
	Median	7.00	0.75	7.50	1.25	7.25	1.25
	SD	0.707	1.061	0.707	0.354	0.645	0.707
	(SE)	( 0.500)	( 0.750)	( 0.500)	( 0.250)	( 0.323)	( 0.354)
	Min, Max	6.5, 7.5	0.0, 1.5	7.0, 8.0	1.0, 1.5	6.5, 8.0	0.0, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	1	1	2	2	3	3
	Mean	7.50	1.50	7.25	1.00	7.33	1.17
	Median	7.50	1.50	7.25	1.00	7.50	1.00
	SD			0.354	0.000	0.289	0.289
	(SE)			( 0.250)	( 0.000)	( 0.167)	( 0.167)
	Min, Max	7.5, 7.5	1.5, 1.5	7.0, 7.5	1.0, 1.0	7.0, 7.5	1.0, 1.5
Week 68	n	2	2	2	2	4	4
	Mean	6.25	0.00	6.75	0.50	6.50	0.25
	Median	6.25	0.00	6.75	0.50	6.50	0.50
	SD	0.354	0.707	0.354	0.000	0.408	0.500
	(SE)	( 0.250)	( 0.500)	( 0.250)	( 0.000)	( 0.204)	( 0.250)
	Min, Max	6.0, 6.5	-0.5, 0.5	6.5, 7.0	0.5, 0.5	6.0, 7.0	-0.5, 0.5
Week 72	n	2	2	0	0	2	2
	Mean	6.75	0.50			6.75	0.50
	Median	6.75	0.50			6.75	0.50
	SD	1.061	1.414			1.061	1.414
	(SE)	( 0.750)	( 1.000)			( 0.750)	( 1.000)
	Min, Max	6.0, 7.5	-0.5, 1.5			6.0, 7.5	-0.5, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			6.50	0.50	6.50	0.50
	Median			6.50	0.50	6.50	0.50
	SD						
	(SE)						
	Min, Max			6.5, 6.5	0.5, 0.5	6.5, 6.5	0.5, 0.5
Week 76	n	2	2	2	2	4	4
	Mean	7.00	0.75	7.25	1.00	7.13	0.88
	Median	7.00	0.75	7.25	1.00	7.25	1.00
	SD	1.414	1.768	0.354	0.000	0.854	1.031
	(SE)	( 1.000)	( 1.250)	( 0.250)	( 0.000)	( 0.427)	( 0.515)
	Min, Max	6.0, 8.0	-0.5, 2.0	7.0, 7.5	1.0, 1.0	6.0, 8.0	-0.5, 2.0
Week 80	n	2	2	2	2	4	4
	Mean	6.75	0.50	6.75	0.50	6.75	0.50
	Median	6.75	0.50	6.75	0.50	6.75	0.50
	SD	1.061	1.414	0.354	0.000	0.645	0.816
	(SE)	( 0.750)	( 1.000)	( 0.250)	( 0.000)	( 0.323)	( 0.408)
	Min, Max	6.0, 7.5	-0.5, 1.5	6.5, 7.0	0.5, 0.5	6.0, 7.5	-0.5, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.25	1.00	7.00	0.75
	Median	6.75	0.50	7.25	1.00	7.00	1.00
	SD	0.354	0.707	0.354	0.000	0.408	0.500
	(SE)	( 0.250)	( 0.500)	( 0.250)	( 0.000)	( 0.204)	( 0.250)
	Min, Max	6.5, 7.0	0.0, 1.0	7.0, 7.5	1.0, 1.0	6.5, 7.5	0.0, 1.0
Week 88	n	2	2	2	2	4	4
	Mean	7.50	1.25	7.25	1.00	7.38	1.13
	Median	7.50	1.25	7.25	1.00	7.25	1.00
	SD	0.707	1.061	0.354	0.000	0.479	0.629
	(SE)	( 0.500)	( 0.750)	( 0.250)	( 0.000)	( 0.239)	( 0.315)
	Min, Max	7.0, 8.0	0.5, 2.0	7.0, 7.5	1.0, 1.0	7.0, 8.0	0.5, 2.0
Week 92	n	2	2	2	2	4	4
	Mean	7.25	1.00	7.50	1.25	7.38	1.13
	Median	7.25	1.00	7.50	1.25	7.50	1.25
	SD	0.354	0.707	0.000	0.354	0.250	0.479
	(SE)	( 0.250)	( 0.500)	( 0.000)	( 0.250)	( 0.125)	( 0.239)
	Min, Max	7.0, 7.5	0.5, 1.5	7.5, 7.5	1.0, 1.5	7.0, 7.5	0.5, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.25	1.00	7.00	0.75
	Median	6.75	0.50	7.25	1.00	7.00	1.00
	SD	0.354	0.707	0.354	0.000	0.408	0.500
	(SE)	( 0.250)	( 0.500)	( 0.250)	( 0.000)	( 0.204)	( 0.250)
	Min, Max	6.5, 7.0	0.0, 1.0	7.0, 7.5	1.0, 1.0	6.5, 7.5	0.0, 1.0
Week 100	n	2	2	2	2	4	4
	Mean	6.25	0.00	7.00	0.75	6.63	0.38
	Median	6.25	0.00	7.00	0.75	6.50	0.50
	SD	0.354	0.707	0.707	0.354	0.629	0.629
	(SE)	( 0.250)	( 0.500)	( 0.500)	( 0.250)	( 0.315)	( 0.315)
	Min, Max	6.0, 6.5	-0.5, 0.5	6.5, 7.5	0.5, 1.0	6.0, 7.5	-0.5, 1.0
Week 104	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.50	1.25	7.00	0.75
	Median	6.50	0.25	7.50	1.25	7.00	0.75
	SD	0.000	0.354	0.000	0.354	0.577	0.645
	(SE)	( 0.000)	( 0.250)	( 0.000)	( 0.250)	( 0.289)	( 0.323)
	Min, Max	6.5, 6.5	0.0, 0.5	7.5, 7.5	1.0, 1.5	6.5, 7.5	0.0, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.50	1.25	7.13	0.88
	Median	6.75	0.50	7.50	1.25	7.50	1.25
	SD	1.061	1.414	0.000	0.354	0.750	0.946
	(SE)	( 0.750)	( 1.000)	( 0.000)	( 0.250)	( 0.375)	( 0.473)
	Min, Max	6.0, 7.5	-0.5, 1.5	7.5, 7.5	1.0, 1.5	6.0, 7.5	-0.5, 1.5
Week 112	n	2	2	2	2	4	4
	Mean	7.00	0.75	7.25	1.00	7.13	0.88
	Median	7.00	0.75	7.25	1.00	7.25	1.00
	SD	0.707	1.061	0.354	0.000	0.479	0.629
	(SE)	( 0.500)	( 0.750)	( 0.250)	( 0.000)	( 0.239)	( 0.315)
	Min, Max	6.5, 7.5	0.0, 1.5	7.0, 7.5	1.0, 1.0	6.5, 7.5	0.0, 1.5
Week 116	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.00	0.75	6.88	0.63
	Median	6.75	0.50	7.00	0.75	7.00	0.75
	SD	1.061	1.414	0.000	0.354	0.629	0.854
	(SE)	( 0.750)	( 1.000)	( 0.000)	( 0.250)	( 0.315)	( 0.427)
	Min, Max	6.0, 7.5	-0.5, 1.5	7.0, 7.0	0.5, 1.0	6.0, 7.5	-0.5, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.25	1.00	7.00	0.75
	Median	6.75	0.50	7.25	1.00	7.00	0.75
	SD	0.354	0.000	0.354	0.000	0.408	0.289
	(SE)	( 0.250)	( 0.000)	( 0.250)	( 0.000)	( 0.204)	( 0.144)
	Min, Max	6.5, 7.0	0.5, 0.5	7.0, 7.5	1.0, 1.0	6.5, 7.5	0.5, 1.0
Week 124	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.50	1.25	7.13	0.88
	Median	6.75	0.50	7.50	1.25	7.00	0.75
	SD	0.354	0.000	0.707	0.354	0.629	0.479
	(SE)	( 0.250)	( 0.000)	( 0.500)	( 0.250)	( 0.315)	( 0.239)
	Min, Max	6.5, 7.0	0.5, 0.5	7.0, 8.0	1.0, 1.5	6.5, 8.0	0.5, 1.5
Week 128	n	2	2	2	2	4	4
	Mean	6.25	0.00	7.75	1.50	7.00	0.75
	Median	6.25	0.00	7.75	1.50	7.00	0.75
	SD	0.354	0.000	0.354	0.000	0.913	0.866
	(SE)	( 0.250)	( 0.000)	( 0.250)	( 0.000)	( 0.456)	( 0.433)
	Min, Max	6.0, 6.5	0.0, 0.0	7.5, 8.0	1.5, 1.5	6.0, 8.0	0.0, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 132	n	2	2	2	2	4	4
	Mean	7.25	1.00	6.75	0.50	7.00	0.75
	Median	7.25	1.00	6.75	0.50	7.00	0.50
	SD	0.354	0.707	0.354	0.000	0.408	0.500
	(SE)	( 0.250)	( 0.500)	( 0.250)	( 0.000)	( 0.204)	( 0.250)
	Min, Max	7.0, 7.5	0.5, 1.5	6.5, 7.0	0.5, 0.5	6.5, 7.5	0.5, 1.5
Week 136	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.25	1.00	7.00	0.75
	Median	6.75	0.50	7.25	1.00	7.00	1.00
	SD	0.354	0.707	0.354	0.000	0.408	0.500
	(SE)	( 0.250)	( 0.500)	( 0.250)	( 0.000)	( 0.204)	( 0.250)
	Min, Max	6.5, 7.0	0.0, 1.0	7.0, 7.5	1.0, 1.0	6.5, 7.5	0.0, 1.0
Week 140	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.50	1.25	7.13	0.88
	Median	6.75	0.50	7.50	1.25	7.00	1.00
	SD	0.354	0.707	0.707	0.354	0.629	0.629
	(SE)	( 0.250)	( 0.500)	( 0.500)	( 0.250)	( 0.315)	( 0.315)
	Min, Max	6.5, 7.0	0.0, 1.0	7.0, 8.0	1.0, 1.5	6.5, 8.0	0.0, 1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 144	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.25	1.00	6.88	0.63
	Median	6.50	0.25	7.25	1.00	6.75	0.75
	SD	0.000	0.354	0.354	0.000	0.479	0.479
	(SE)	( 0.000)	( 0.250)	( 0.250)	( 0.000)	( 0.239)	( 0.239)
	Min, Max	6.5, 6.5	0.0, 0.5	7.0, 7.5	1.0, 1.0	6.5, 7.5	0.0, 1.0
Week 148	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.75	1.50	7.13	0.88
	Median	6.50	0.25	7.75	1.50	7.25	1.00
	SD	0.707	0.354	0.354	0.000	0.854	0.750
	(SE)	( 0.500)	( 0.250)	( 0.250)	( 0.000)	( 0.427)	( 0.375)
	Min, Max	6.0, 7.0	0.0, 0.5	7.5, 8.0	1.5, 1.5	6.0, 8.0	0.0, 1.5
Week 152	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.00	0.75	6.75	0.50
	Median	6.50	0.25	7.00	0.75	6.50	0.50
	SD	0.000	0.354	0.707	0.354	0.500	0.408
	(SE)	( 0.000)	( 0.250)	( 0.500)	( 0.250)	( 0.250)	( 0.204)
	Min, Max	6.5, 6.5	0.0, 0.5	6.5, 7.5	0.5, 1.0	6.5, 7.5	0.0, 1.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 156	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.50	1.25	7.00	0.75
	Median	6.50	0.25	7.50	1.25	7.00	0.75
	SD	0.000	0.354	0.000	0.354	0.577	0.645
	(SE)	( 0.000)	( 0.250)	( 0.000)	( 0.250)	( 0.289)	( 0.323)
	Min,	6.5,	0.0,	7.5,	1.0,	6.5,	0.0,
	Max	6.5	0.5	7.5	1.5	7.5	1.5
Week 160	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.75	1.50	7.25	1.00
	Median	6.75	0.50	7.75	1.50	7.25	1.25
	SD	1.061	1.414	1.061	0.707	1.041	1.080
	(SE)	( 0.750)	( 1.000)	( 0.750)	( 0.500)	( 0.520)	( 0.540)
	Min,	6.0,	-0.5,	7.0,	1.0,	6.0,	-0.5,
	Max	7.5	1.5	8.5	2.0	8.5	2.0
Week 164	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.75	1.50	7.13	0.88
	Median	6.50	0.25	7.75	1.50	7.00	1.00
	SD	0.000	0.354	0.354	0.000	0.750	0.750
	(SE)	( 0.000)	( 0.250)	( 0.250)	( 0.000)	( 0.375)	( 0.375)
	Min,	6.5,	0.0,	7.5,	1.5,	6.5,	0.0,
	Max	6.5	0.5	8.0	1.5	8.0	1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 168	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.50	1.25	7.13	0.88
	Median	6.75	0.50	7.50	1.25	7.25	1.00
	SD	0.354	0.707	0.000	0.354	0.479	0.629
	(SE)	( 0.250)	( 0.500)	( 0.000)	( 0.250)	( 0.239)	( 0.315)
	Min, Max	6.5, 7.0	0.0, 1.0	7.5, 7.5	1.0, 1.5	6.5, 7.5	0.0, 1.5
Week 172	n	2	2	2	2	4	4
	Mean	6.25	0.00	7.25	1.00	6.75	0.50
	Median	6.25	0.00	7.25	1.00	6.75	0.75
	SD	0.354	0.707	0.354	0.000	0.645	0.707
	(SE)	( 0.250)	( 0.500)	( 0.250)	( 0.000)	( 0.323)	( 0.354)
	Min, Max	6.0, 6.5	-0.5, 0.5	7.0, 7.5	1.0, 1.0	6.0, 7.5	-0.5, 1.0
Week 176	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.00	0.75	6.88	0.63
	Median	6.75	0.50	7.00	0.75	6.75	0.75
	SD	0.354	0.707	0.707	0.354	0.479	0.479
	(SE)	( 0.250)	( 0.500)	( 0.500)	( 0.250)	( 0.239)	( 0.239)
	Min, Max	6.5, 7.0	0.0, 1.0	6.5, 7.5	0.5, 1.0	6.5, 7.5	0.0, 1.0

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 180	n	2	2	2	2	4	4
	Mean	6.50	0.25	7.25	1.00	6.88	0.63
	Median	6.50	0.25	7.25	1.00	6.75	0.75
	SD	0.707	1.061	1.061	0.707	0.854	0.854
	(SE)	( 0.500)	( 0.750)	( 0.750)	( 0.500)	( 0.427)	( 0.427)
	Min,	6.0,	-0.5,	6.5,	0.5,	6.0,	-0.5,
	Max	7.0	1.0	8.0	1.5	8.0	1.5
Week 184	n	2	2	2	2	4	4
	Mean	6.75	0.50	7.25	1.00	7.00	0.75
	Median	6.75	0.50	7.25	1.00	6.75	0.50
	SD	0.354	0.000	1.061	0.707	0.707	0.500
	(SE)	( 0.250)	( 0.000)	( 0.750)	( 0.500)	( 0.354)	( 0.250)
	Min,	6.5,	0.5,	6.5,	0.5,	6.5,	0.5,
	Max	7.0	0.5	8.0	1.5	8.0	1.5

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Urine Cystatin C (ug/L)						
Week 1	n	2	2		4	
	Mean	6.500	1.300		3.900	
	Median	6.500	1.300		1.700	
	SD	6.3640	0.1414		4.7455	
	(SE)	( 4.5000)	( 0.1000)		( 2.3728)	
	Min, Max	2.00, 11.00	1.20, 1.40		1.20, 11.00	
Week 2	n	2	1		3	
	Mean	39.050	1.500		26.533	
	Median	39.050	1.500		8.100	
	SD	43.7699			37.7876	
	(SE)	( 30.9500)			( 21.8167)	
	Min, Max	8.10, 70.00	1.50, 1.50		1.50, 70.00	
Week 4	n	2	2		4	
	Mean	34.000	16.500		25.250	
	Median	34.000	16.500		24.500	
	SD	7.0711	4.9497		11.2657	
	(SE)	( 5.0000)	( 3.5000)		( 5.6329)	
	Min, Max	29.00, 39.00	13.00, 20.00		13.00, 39.00	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		1		3	
	Mean	32.900		0.700		22.167	
	Median	32.900		0.700		6.800	
	SD	36.9110				32.0441	
	(SE)	( 26.1000)				( 18.5007)	
	Min,	6.80,		0.70,		0.70,	
	Max	59.00		0.70		59.00	
Week 8	n	2		2		4	
	Mean	149.000		25.500		87.250	
	Median	149.000		25.500		37.500	
	SD	149.9066		9.1924		112.2627	
	(SE)	( 106.0000)		( 6.5000)		( 56.1314)	
	Min,	43.00,		19.00,		19.00,	
	Max	255.00		32.00		255.00	
Week 10	n	2		2		4	
	Mean	95.850		4.300		50.075	
	Median	95.850		4.300		8.300	
	SD	121.8345		3.6770		88.0124	
	(SE)	( 86.1500)		( 2.6000)		( 44.0062)	
	Min,	9.70,		1.70,		1.70,	
	Max	182.00		6.90		182.00	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4	
	Mean	19.500		3.650		11.575	
	Median	19.500		3.650		12.550	
	SD	0.7071		3.4648		9.3760	
	(SE)	( 0.5000)		( 2.4500)		( 4.6880)	
	Min,	19.00,		1.20,		1.20,	
	Max	20.00		6.10		20.00	
Week 15	n	2		1		3	
	Mean	77.700		1.600		52.333	
	Median	77.700		1.600		5.400	
	SD	102.2476				84.6032	
	(SE)	( 72.3000)				( 48.8457)	
	Min,	5.40,		1.60,		1.60,	
	Max	150.00		1.60		150.00	
Week 18	n	2		1		3	
	Mean	70.500		12.000		51.000	
	Median	70.500		12.000		49.000	
	SD	30.4056				40.0375	
	(SE)	( 21.5000)				( 23.1157)	
	Min,	49.00,		12.00,		12.00,	
	Max	92.00		12.00		92.00	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4	
	Mean	106.500		10.500		58.500	
	Median	106.500		10.500		35.500	
	SD	72.8320		7.7782		69.7161	
	(SE)	( 51.5000)		( 5.5000)		( 34.8580)	
	Min,	55.00,		5.00,		5.00,	
	Max	158.00		16.00		158.00	
Week 24	n	2		1		3	
	Mean	40.500		15.000		32.000	
	Median	40.500		15.000		30.000	
	SD	14.8492				18.0831	
	(SE)	( 10.5000)				( 10.4403)	
	Min,	30.00,		15.00,		15.00,	
	Max	51.00		15.00		51.00	
Baseline <sup>1</sup>	n	2		2		4	
	Mean	53.100		9.350		31.225	
	Median	53.100		9.350		10.600	
	SD	67.7408		9.4045		46.8733	
	(SE)	( 47.9000)		( 6.6500)		( 23.4367)	
	Min,	5.20,		2.70,		2.70,	
	Max	101.00		16.00		101.00	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	63.000	9.900	12.300	2.950	37.650	6.425
	Median	63.000	9.900	12.300	2.950	36.000	2.950
	SD	11.3137	79.0545	6.6468	2.7577	30.2361	45.8459
	(SE)	( 8.0000)	( 55.9000)	( 4.7000)	( 1.9500)	( 15.1181)	( 22.9229)
	Min, Max	55.00, 71.00	-46.00, 65.80	7.60, 17.00	1.00, 4.90	7.60, 71.00	-46.00, 65.80
Week 32	n	2	2	2	2	4	4
	Mean	68.000	14.900	6.000	-3.350	37.000	5.775
	Median	68.000	14.900	6.000	-3.350	16.050	-3.350
	SD	63.6396	131.3804	4.3841	5.0205	51.3589	76.6357
	(SE)	( 45.0000)	( 92.9000)	( 3.1000)	( 3.5500)	( 25.6795)	( 38.3178)
	Min, Max	23.00, 113.00	-78.00, 107.80	2.90, 9.10	-6.90, 0.20	2.90, 113.00	-78.00, 107.80
Week 36	n	2	2	2	2	4	4
	Mean	132.500	79.400	17.000	7.650	74.750	43.525
	Median	132.500	79.400	17.000	7.650	40.000	7.650
	SD	101.1163	168.8571	2.8284	6.5761	88.6430	105.9938
	(SE)	( 71.5000)	( 119.4000)	( 2.0000)	( 4.6500)	( 44.3215)	( 52.9969)
	Min, Max	61.00, 204.00	-40.00, 198.80	15.00, 19.00	3.00, 12.30	15.00, 204.00	-40.00, 198.80

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	66.500	13.400	9.700	0.350	38.100	6.875
	Median	66.500	13.400	9.700	0.350	37.000	0.350
	SD	9.1924	76.9332	6.0811	15.4856	33.4052	45.9305
	(SE)	( 6.5000)	( 54.4000)	( 4.3000)	( 10.9500)	( 16.7026)	( 22.9652)
	Min, Max	60.00, 73.00	-41.00, 67.80	5.40, 14.00	-10.60, 11.30	5.40, 73.00	-41.00, 67.80
Week 44	n	2	2	2	2	4	4
	Mean	86.000	32.900	34.450	25.100	60.225	29.000
	Median	86.000	32.900	34.450	25.100	57.000	32.900
	SD	53.7401	14.0007	44.6184	54.0230	50.1205	32.5338
	(SE)	( 38.0000)	( 9.9000)	( 31.5500)	( 38.2000)	( 25.0603)	( 16.2669)
	Min, Max	48.00, 124.00	23.00, 42.80	2.90, 66.00	-13.10, 63.30	2.90, 124.00	-13.10, 63.30
Week 48	n	2	2	2	2	4	4
	Mean	67.500	14.400	34.450	25.100	50.975	19.750
	Median	67.500	14.400	34.450	25.100	62.500	20.350
	SD	12.0208	55.7200	44.6184	54.0230	32.8004	45.2316
	(SE)	( 8.5000)	( 39.4000)	( 31.5500)	( 38.2000)	( 16.4002)	( 22.6158)
	Min, Max	59.00, 76.00	-25.00, 53.80	2.90, 66.00	-13.10, 63.30	2.90, 76.00	-25.00, 63.30

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	47.500	-5.600	7.950	-1.400	27.725	-3.500
	Median	47.500	-5.600	7.950	-1.400	28.000	-1.400
	SD	6.3640	61.3769	7.1418	2.2627	23.4926	35.5428
	(SE)	( 4.5000)	( 43.4000)	( 5.0500)	( 1.6000)	( 11.7463)	( 17.7714)
	Min, Max	43.00, 52.00	-49.00, 37.80	2.90, 13.00	-3.00, 0.20	2.90, 52.00	-49.00, 37.80
Week 56	n	2	2	2	2	4	4
	Mean	54.000	0.900	2.900	-6.450	28.450	-2.775
	Median	54.000	0.900	2.900	-6.450	13.950	-6.450
	SD	41.0122	108.7530	0.0000	9.4045	37.8295	63.1656
	(SE)	( 29.0000)	( 76.9000)	( 0.0000)	( 6.6500)	( 18.9147)	( 31.5828)
	Min, Max	25.00, 83.00	-76.00, 77.80	2.90, 2.90	-13.10, 0.20	2.90, 83.00	-76.00, 77.80
Week 60	n	2	2	2	2	4	4
	Mean	16.400	-36.700	12.450	3.100	14.425	-16.800
	Median	16.400	-36.700	12.450	3.100	15.400	-4.750
	SD	10.7480	56.9928	13.5057	22.9103	10.2230	42.2575
	(SE)	( 7.6000)	( 40.3000)	( 9.5500)	( 16.2000)	( 5.1115)	( 21.1288)
	Min, Max	8.80, 24.00	-77.00, 3.60	2.90, 22.00	-13.10, 19.30	2.90, 24.00	-77.00, 19.30

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 64	n	2	2	2	2	4	4
	Mean	15.800	-37.300	2.900	-6.450	9.350	-21.875
	Median	15.800	-37.300	2.900	-6.450	5.250	-6.450
	SD	11.5966	79.3374	0.0000	9.4045	10.0148	49.4456
	(SE)	( 8.2000)	( 56.1000)	( 0.0000)	( 6.6500)	( 5.0074)	( 24.7228)
	Min, Max	7.60, 24.00	-93.40, 18.80	2.90, 2.90	-13.10, 0.20	2.90, 24.00	-93.40, 18.80
Week 68	n	2	2	2	2	4	4
	Mean	67.000	13.900	31.600	22.250	49.300	18.075
	Median	67.000	13.900	31.600	22.250	37.500	22.250
	SD	65.0538	132.7947	31.6784	22.2739	46.5069	77.8894
	(SE)	( 46.0000)	( 93.9000)	( 22.4000)	( 15.7500)	( 23.2535)	( 38.9447)
	Min, Max	21.00, 113.00	-80.00, 107.80	9.20, 54.00	6.50, 38.00	9.20, 113.00	-80.00, 107.80
Week 72	n	2	2	0	0	2	2
	Mean	66.500	13.400			66.500	13.400
	Median	66.500	13.400			66.500	13.400
	SD	19.0919	86.8327			19.0919	86.8327
	(SE)	( 13.5000)	( 61.4000)			( 13.5000)	( 61.4000)
	Min, Max	53.00, 80.00	-48.00, 74.80			53.00, 80.00	-48.00, 74.80

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			2.900	-13.100	2.900	-13.100
	Median			2.900	-13.100	2.900	-13.100
	SD						
	(SE)						
	Min, Max			2.90, 2.90	-13.10, -13.10	2.90, 2.90	-13.10, -13.10
Week 76	n	2	2	2	2	4	4
	Mean	35.800	-17.300	2.900	-6.450	19.350	-11.875
	Median	35.800	-17.300	2.900	-6.450	5.750	-6.450
	SD	38.4666	106.2074	0.0000	9.4045	29.2238	61.8767
	(SE)	( 27.2000)	( 75.1000)	( 0.0000)	( 6.6500)	( 14.6119)	( 30.9384)
	Min, Max	8.60, 63.00	-92.40, 57.80	2.90, 2.90	-13.10, 0.20	2.90, 63.00	-92.40, 57.80
Week 80	n	2	2	2	2	4	4
	Mean	49.900	-3.200	4.250	-5.100	27.075	-4.150
	Median	49.900	-3.200	4.250	-5.100	4.350	-5.100
	SD	68.0237	135.7645	3.7477	5.6569	47.3469	78.4594
	(SE)	( 48.1000)	( 96.0000)	( 2.6500)	( 4.0000)	( 23.6735)	( 39.2297)
	Min, Max	1.80, 98.00	-99.20, 92.80	1.60, 6.90	-9.10, -1.10	1.60, 98.00	-99.20, 92.80

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 84	n	2	2	2	2	4	4
	Mean	24.400	-28.700	1.600	-7.750	13.000	-18.225
	Median	24.400	-28.700	1.600	-7.750	5.200	-7.750
	SD	22.0617	89.8026	0.0000	9.4045	18.3172	53.5159
	(SE)	( 15.6000)	( 63.5000)	( 0.0000)	( 6.6500)	( 9.1586)	( 26.7579)
	Min,	8.80,	-92.20,	1.60,	-14.40,	1.60,	-92.20,
	Max	40.00	34.80	1.60	-1.10	40.00	34.80
Week 88	n	2	2	2	2	4	4
	Mean	15.200	-37.900	1.600	-7.750	8.400	-22.825
	Median	15.200	-37.900	1.600	-7.750	4.500	-7.750
	SD	11.0309	56.7100	0.0000	9.4045	10.1101	37.4766
	(SE)	( 7.8000)	( 40.1000)	( 0.0000)	( 6.6500)	( 5.0550)	( 18.7383)
	Min,	7.40,	-78.00,	1.60,	-14.40,	1.60,	-78.00,
	Max	23.00	2.20	1.60	-1.10	23.00	2.20
Week 92	n	2	2	2	2	4	4
	Mean	17.000	-36.100	15.800	6.450	16.400	-14.825
	Median	17.000	-36.100	15.800	6.450	17.000	4.350
	SD	2.8284	64.9124	20.0818	10.6773	11.7292	45.2332
	(SE)	( 2.0000)	( 45.9000)	( 14.2000)	( 7.5500)	( 5.8646)	( 22.6166)
	Min,	15.00,	-82.00,	1.60,	-1.10,	1.60,	-82.00,
	Max	19.00	9.80	30.00	14.00	30.00	14.00

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	77.000	23.900	1.600	-7.750	39.300	8.075
	Median	77.000	23.900	1.600	-7.750	6.300	2.350
	SD	93.3381	25.5973	0.0000	9.4045	69.2752	24.1204
	(SE)	( 66.0000)	( 18.1000)	( 0.0000)	( 6.6500)	( 34.6376)	( 12.0602)
	Min,	11.00,	5.80,	1.60,	-14.40,	1.60,	-14.40,
	Max	143.00	42.00	1.60	-1.10	143.00	42.00
Week 100	n	2	2	2	2	4	4
	Mean	95.500	42.400	4.850	-4.500	50.175	18.950
	Median	95.500	42.400	4.850	-4.500	37.500	-4.500
	SD	38.8909	106.6317	3.0406	6.3640	56.9771	67.3558
	(SE)	( 27.5000)	( 75.4000)	( 2.1500)	( 4.5000)	( 28.4885)	( 33.6779)
	Min,	68.00,	-33.00,	2.70,	-9.00,	2.70,	-33.00,
	Max	123.00	117.80	7.00	0.00	123.00	117.80
Week 104	n	2	2	2	2	4	4
	Mean	6.250	-46.850	11.250	1.900	8.750	-22.475
	Median	6.250	-46.850	11.250	1.900	8.150	1.900
	SD	5.0205	72.7613	6.7175	2.6870	5.6371	50.5898
	(SE)	( 3.5500)	( 51.4500)	( 4.7500)	( 1.9000)	( 2.8185)	( 25.2949)
	Min,	2.70,	-98.30,	6.50,	0.00,	2.70,	-98.30,
	Max	9.80	4.60	16.00	3.80	16.00	4.60

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 108	n	2	2	2	2	4	4
	Mean	57.950	4.850	39.300	29.950	48.625	17.400
	Median	57.950	4.850	39.300	29.950	39.950	29.950
	SD	77.8525	145.5933	53.3159	43.9113	55.5320	88.9862
	(SE)	( 55.0500)	( 102.9500)	( 37.7000)	( 31.0500)	( 27.7660)	( 44.4931)
	Min,	2.90,	-98.10,	1.60,	-1.10,	1.60,	-98.10,
	Max	113.00	107.80	77.00	61.00	113.00	107.80
Week 112	n	2	2	2	2	4	4
	Mean	28.900	-24.200	2.850	-6.500	15.875	-15.350
	Median	28.900	-24.200	2.850	-6.500	5.950	-6.500
	SD	29.8399	97.5807	1.7678	7.6368	22.8921	57.4271
	(SE)	( 21.1000)	( 69.0000)	( 1.2500)	( 5.4000)	( 11.4461)	( 28.7135)
	Min,	7.80,	-93.20,	1.60,	-11.90,	1.60,	-93.20,
	Max	50.00	44.80	4.10	-1.10	50.00	44.80
Week 116	n	2	2	2	2	4	4
	Mean	50.600	-2.500	4.700	-4.650	27.650	-3.575
	Median	50.600	-2.500	4.700	-4.650	7.000	-4.650
	SD	62.7911	130.5319	4.3841	13.7886	44.9768	75.7921
	(SE)	( 44.4000)	( 92.3000)	( 3.1000)	( 9.7500)	( 22.4884)	( 37.8961)
	Min,	6.20,	-94.80,	1.60,	-14.40,	1.60,	-94.80,
	Max	95.00	89.80	7.80	5.10	95.00	89.80

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	12.000	-41.100	87.550	78.200	49.775	18.550
	Median	12.000	-41.100	87.550	78.200	13.550	9.600
	SD	9.8995	77.6403	112.3593	102.9547	78.3803	101.4235
	(SE)	( 7.0000)	( 54.9000)	( 79.4500)	( 72.8000)	( 39.1901)	( 50.7118)
	Min,	5.00,	-96.00,	8.10,	5.40,	5.00,	-96.00,
	Max	19.00	13.80	167.00	151.00	167.00	151.00
Week 124	n	2	2	2	2	4	4
	Mean	56.500	3.400	1.650	-7.700	29.075	-2.150
	Median	56.500	3.400	1.650	-7.700	7.850	-7.700
	SD	60.1041	127.8449	0.0707	9.4752	46.9788	74.2907
	(SE)	( 42.5000)	( 90.4000)	( 0.0500)	( 6.7000)	( 23.4894)	( 37.1453)
	Min,	14.00,	-87.00,	1.60,	-14.40,	1.60,	-87.00,
	Max	99.00	93.80	1.70	-1.00	99.00	93.80
Week 128	n	2	2	2	2	4	4
	Mean	25.450	-27.650	13.200	3.850	19.325	-11.900
	Median	25.450	-27.650	13.200	3.850	13.950	3.350
	SD	23.4052	44.3356	8.2024	1.2021	15.9703	31.4077
	(SE)	( 16.5500)	( 31.3500)	( 5.8000)	( 0.8500)	( 7.9851)	( 15.7039)
	Min,	8.90,	-59.00,	7.40,	3.00,	7.40,	-59.00,
	Max	42.00	3.70	19.00	4.70	42.00	4.70

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 132	n	2	2	2	2	4	4
	Mean	12.750	-40.350	2.600	-6.750	7.675	-23.550
	Median	12.750	-40.350	2.600	-6.750	4.100	-6.750
	SD	10.2530	57.4878	0.1414	9.5459	8.3300	38.8370
	(SE)	( 7.2500)	( 40.6500)	( 0.1000)	( 6.7500)	( 4.1650)	( 19.4185)
	Min,	5.50,	-81.00,	2.50,	-13.50,	2.50,	-81.00,
	Max	20.00	0.30	2.70	0.00	20.00	0.30
Week 136	n	2	2	2	2	4	4
	Mean	72.000	18.900	6.850	-2.500	39.425	8.200
	Median	72.000	18.900	6.850	-2.500	22.000	-2.500
	SD	56.5685	124.3094	7.2832	2.1213	49.9919	72.8361
	(SE)	( 40.0000)	( 87.9000)	( 5.1500)	( 1.5000)	( 24.9959)	( 36.4180)
	Min,	32.00,	-69.00,	1.70,	-4.00,	1.70,	-69.00,
	Max	112.00	106.80	12.00	-1.00	112.00	106.80
Week 140	n	2	2	2	2	4	4
	Mean	25.500	-27.600	2.900	-6.450	14.200	-17.025
	Median	25.500	-27.600	2.900	-6.450	12.600	-6.450
	SD	6.3640	74.1048	1.8385	11.2430	13.5971	44.9639
	(SE)	( 4.5000)	( 52.4000)	( 1.3000)	( 7.9500)	( 6.7985)	( 22.4819)
	Min,	21.00,	-80.00,	1.60,	-14.40,	1.60,	-80.00,
	Max	30.00	24.80	4.20	1.50	30.00	24.80

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 144	n	2	2	2	2	4	4
	Mean	102.000	48.900	4.100	-5.250	53.050	21.825
	Median	102.000	48.900	4.100	-5.250	14.900	-5.250
	SD	108.8944	176.6353	0.9899	8.4146	84.5446	106.7755
	(SE)	( 77.0000)	( 124.9000)	( 0.7000)	( 5.9500)	( 42.2723)	( 53.3878)
	Min,	25.00,	-76.00,	3.40,	-11.20,	3.40,	-76.00,
	Max	179.00	173.80	4.80	0.70	179.00	173.80

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Urine KIM-1 (ug/L)						
Week 1	n	2	2		4	
	Mean	0.1485	0.0370		0.0928	
	Median	0.1485	0.0370		0.0410	
	SD	0.15768	0.01131		0.11169	
	(SE)	( 0.11150)	( 0.00800)		( 0.05585)	
	Min, Max	0.037, 0.260	0.029, 0.045		0.029, 0.260	
Week 2	n	2	2		4	
	Mean	0.3150	0.0545		0.1848	
	Median	0.3150	0.0545		0.1320	
	SD	0.17678	0.02758		0.18246	
	(SE)	( 0.12500)	( 0.01950)		( 0.09123)	
	Min, Max	0.190, 0.440	0.035, 0.074		0.035, 0.440	
Week 4	n	2	2		4	
	Mean	0.3200	0.1600		0.2400	
	Median	0.3200	0.1600		0.1600	
	SD	0.31113	0.07071		0.20607	
	(SE)	( 0.22000)	( 0.05000)		( 0.10304)	
	Min, Max	0.100, 0.540	0.110, 0.210		0.100, 0.540	

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 6	n	2		2		4
	Mean	0.4130		0.0700		0.2415
	Median	0.4130		0.0700		0.0830
	SD	0.51902		0.07071		0.36149
	(SE)	( 0.36700)		( 0.05000)		( 0.18075)
	Min,	0.046,		0.020,		0.020,
	Max	0.780		0.120		0.780
Week 8	n	2		2		4
	Mean	0.7750		0.1950		0.4850
	Median	0.7750		0.1950		0.4650
	SD	0.09192		0.03536		0.33966
	(SE)	( 0.06500)		( 0.02500)		( 0.16983)
	Min,	0.710,		0.170,		0.170,
	Max	0.840		0.220		0.840
Week 10	n	2		2		4
	Mean	0.4150		0.0350		0.2250
	Median	0.4150		0.0350		0.1355
	SD	0.26163		0.00849		0.26641
	(SE)	( 0.18500)		( 0.00600)		( 0.13320)
	Min,	0.230,		0.029,		0.029,
	Max	0.600		0.041		0.600

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 12	n	2		2		4
	Mean	0.2800		0.0365		0.1583
	Median	0.2800		0.0365		0.0945
	SD	0.21213		0.03182		0.18735
	(SE)	( 0.15000)		( 0.02250)		( 0.09368)
	Min,	0.130,		0.014,		0.014,
	Max	0.430		0.059		0.430
Week 15	n	2		2		4
	Mean	0.4675		0.0285		0.2480
	Median	0.4675		0.0285		0.0395
	SD	0.59751		0.00778		0.42809
	(SE)	( 0.42250)		( 0.00550)		( 0.21405)
	Min,	0.045,		0.023,		0.023,
	Max	0.890		0.034		0.890
Week 18	n	2		2		4
	Mean	0.3050		0.0330		0.1690
	Median	0.3050		0.0330		0.1455
	SD	0.07778		0.01131		0.16346
	(SE)	( 0.05500)		( 0.00800)		( 0.08173)
	Min,	0.250,		0.025,		0.025,
	Max	0.360		0.041		0.360

\*Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen					
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 21	n	2		2		4
	Mean	0.3850		0.0715		0.2283
	Median	0.3850		0.0715		0.2140
	SD	0.04950		0.00919		0.18332
	(SE)	( 0.03500)		( 0.00650)		( 0.09166)
	Min,	0.350,		0.065,		0.065,
	Max	0.420		0.078		0.420
Week 24	n	2		2		4
	Mean	0.1590		0.0320		0.0955
	Median	0.1590		0.0320		0.0745
	SD	0.08627		0.02687		0.08999
	(SE)	( 0.06100)		( 0.01900)		( 0.04499)
	Min,	0.098,		0.013,		0.013,
	Max	0.220		0.051		0.220
Baseline <sup>1</sup>	n	2		2		4
	Mean	0.2405		0.0635		0.1520
	Median	0.2405		0.0635		0.0635
	SD	0.28214		0.01485		0.19248
	(SE)	( 0.19950)		( 0.01050)		( 0.09624)
	Min,	0.041,		0.053,		0.041,
	Max	0.440		0.074		0.440

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 28	n	2	2	2	2	4	4
	Mean	0.6850	0.4445	0.1850	0.1215	0.4350	0.2830
	Median	0.6850	0.4445	0.1850	0.1215	0.3100	0.2630
	SD	0.44548	0.16334	0.09192	0.10677	0.39026	0.21788
	(SE)	( 0.31500)	( 0.11550)	( 0.06500)	( 0.07550)	( 0.19513)	( 0.10894)
	Min,	0.370,	0.329,	0.120,	0.046,	0.120,	0.046,
	Max	1.000	0.560	0.250	0.197	1.000	0.560
Week 32	n	2	2	2	2	4	4
	Mean	0.4000	0.1595	0.0940	0.0305	0.2470	0.0950
	Median	0.4000	0.1595	0.0940	0.0305	0.1900	0.0305
	SD	0.18385	0.46598	0.02263	0.00778	0.20652	0.27919
	(SE)	( 0.13000)	( 0.32950)	( 0.01600)	( 0.00550)	( 0.10326)	( 0.13960)
	Min,	0.270,	-0.170,	0.078,	0.025,	0.078,	-0.170,
	Max	0.530	0.489	0.110	0.036	0.530	0.489
Week 36	n	2	2	2	2	4	4
	Mean	0.7000	0.4595	0.1850	0.1215	0.4425	0.2905
	Median	0.7000	0.4595	0.1850	0.1215	0.3850	0.2585
	SD	0.16971	0.11243	0.00707	0.02192	0.31309	0.20605
	(SE)	( 0.12000)	( 0.07950)	( 0.00500)	( 0.01550)	( 0.15654)	( 0.10302)
	Min,	0.580,	0.380,	0.180,	0.106,	0.180,	0.106,
	Max	0.820	0.539	0.190	0.137	0.820	0.539

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 40	n	2	2	2	2	4	4
	Mean	0.6500	0.4095	0.1385	0.0750	0.3943	0.2423
	Median	0.6500	0.4095	0.1385	0.0750	0.3050	0.2580
	SD	0.33941	0.05728	0.08697	0.10182	0.35796	0.20456
	(SE)	( 0.24000)	( 0.04050)	( 0.06150)	( 0.07200)	( 0.17898)	( 0.10228)
	Min,	0.410,	0.369,	0.077,	0.003,	0.077,	0.003,
	Max	0.890	0.450	0.200	0.147	0.890	0.450
Week 44	n	2	2	2	2	4	4
	Mean	0.6700	0.4295	0.1445	0.0810	0.4073	0.2553
	Median	0.6700	0.4295	0.1445	0.0810	0.2450	0.1980
	SD	0.60811	0.32598	0.14920	0.16405	0.47195	0.29133
	(SE)	( 0.43000)	( 0.23050)	( 0.10550)	( 0.11600)	( 0.23598)	( 0.14567)
	Min,	0.240,	0.199,	0.039,	-0.035,	0.039,	-0.035,
	Max	1.100	0.660	0.250	0.197	1.100	0.660
Week 48	n	2	2	2	2	4	4
	Mean	0.7400	0.4995	0.1625	0.0990	0.4513	0.2993
	Median	0.7400	0.4995	0.1625	0.0990	0.2700	0.2230
	SD	0.65054	0.36840	0.13789	0.15274	0.50850	0.32632
	(SE)	( 0.46000)	( 0.26050)	( 0.09750)	( 0.10800)	( 0.25425)	( 0.16316)
	Min,	0.280,	0.239,	0.065,	-0.009,	0.065,	-0.009,
	Max	1.200	0.760	0.260	0.207	1.200	0.760

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 52	n	2	2	2	2	4	4
	Mean	0.4750	0.2345	0.0930	0.0295	0.2840	0.1320
	Median	0.4750	0.2345	0.0930	0.0295	0.1450	0.0875
	SD	0.44548	0.16334	0.05233	0.03748	0.34015	0.15287
	(SE)	( 0.31500)	( 0.11550)	( 0.03700)	( 0.02650)	( 0.17008)	( 0.07644)
	Min,	0.160,	0.119,	0.056,	0.003,	0.056,	0.003,
	Max	0.790	0.350	0.130	0.056	0.790	0.350
Week 56	n	2	2	2	2	4	4
	Mean	0.3250	0.0845	0.0570	-0.0065	0.1910	0.0390
	Median	0.3250	0.0845	0.0570	-0.0065	0.1925	-0.0065
	SD	0.00707	0.28921	0.01131	0.02616	0.15492	0.17569
	(SE)	( 0.00500)	( 0.20450)	( 0.00800)	( 0.01850)	( 0.07746)	( 0.08785)
	Min,	0.320,	-0.120,	0.049,	-0.025,	0.049,	-0.120,
	Max	0.330	0.289	0.065	0.012	0.330	0.289
Week 60	n	2	2	2	2	4	4
	Mean	0.2445	0.0040	0.1735	0.1100	0.2090	0.0570
	Median	0.2445	0.0040	0.1735	0.1100	0.1795	0.0155
	SD	0.23405	0.04808	0.15061	0.16546	0.16584	0.11680
	(SE)	( 0.16550)	( 0.03400)	( 0.10650)	( 0.11700)	( 0.08292)	( 0.05840)
	Min,	0.079,	-0.030,	0.067,	-0.007,	0.067,	-0.030,
	Max	0.410	0.038	0.280	0.227	0.410	0.227

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 64	n	2	2	2	2	4	4
	Mean	0.2900	0.0495	0.1200	0.0565	0.2050	0.0530
	Median	0.2900	0.0495	0.1200	0.0565	0.1650	0.0565
	SD	0.11314	0.16900	0.00000	0.01485	0.11790	0.09803
	(SE)	( 0.08000)	( 0.11950)	( 0.00000)	( 0.01050)	( 0.05895)	( 0.04902)
	Min,	0.210,	-0.070,	0.120,	0.046,	0.120,	-0.070,
	Max	0.370	0.169	0.120	0.067	0.370	0.169
Week 68	n	2	2	2	2	4	4
	Mean	0.6700	0.4295	0.6300	0.5665	0.6500	0.4980
	Median	0.6700	0.4295	0.6300	0.5665	0.6300	0.5665
	SD	0.35355	0.63569	0.22627	0.21142	0.24345	0.39479
	(SE)	( 0.25000)	( 0.44950)	( 0.16000)	( 0.14950)	( 0.12172)	( 0.19739)
	Min,	0.420,	-0.020,	0.470,	0.417,	0.420,	-0.020,
	Max	0.920	0.879	0.790	0.716	0.920	0.879
Week 72	n	2	2	0	0	2	2
	Mean	0.8550	0.6145			0.8550	0.6145
	Median	0.8550	0.6145			0.8550	0.6145
	SD	0.34648	0.06435			0.34648	0.06435
	(SE)	( 0.24500)	( 0.04550)			( 0.24500)	( 0.04550)
	Min,	0.610,	0.569,			0.610,	0.569,
	Max	1.100	0.660			1.100	0.660

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 73	n	0	0	1	1	1	1
	Mean			0.2100	0.1360	0.2100	0.1360
	Median			0.2100	0.1360	0.2100	0.1360
	SD						
	(SE)						
	Min, Max			0.210, 0.210	0.136, 0.136	0.210, 0.210	0.136, 0.136
Week 76	n	2	2	2	2	4	4
	Mean	0.3800	0.1395	0.1165	0.0530	0.2483	0.0963
	Median	0.3800	0.1395	0.1165	0.0530	0.2700	0.0530
	SD	0.01414	0.26799	0.07566	0.09051	0.15849	0.17078
	(SE)	( 0.01000)	( 0.18950)	( 0.05350)	( 0.06400)	( 0.07924)	( 0.08539)
	Min, Max	0.370, 0.390	-0.050, 0.329	0.063, 0.170	-0.011, 0.117	0.063, 0.390	-0.050, 0.329
Week 80	n	2	2	2	2	4	4
	Mean	0.4750	0.2345	0.0745	0.0110	0.2748	0.1228
	Median	0.4750	0.2345	0.0745	0.0110	0.1825	0.0110
	SD	0.27577	0.55791	0.01485	0.00000	0.28087	0.34699
	(SE)	( 0.19500)	( 0.39450)	( 0.01050)	( 0.00000)	( 0.14044)	( 0.17350)
	Min, Max	0.280, 0.670	-0.160, 0.629	0.064, 0.085	0.011, 0.011	0.064, 0.670	-0.160, 0.629

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 84	n	2	2	2	2	4	4
	Mean	0.3850	0.1445	0.0570	-0.0065	0.2210	0.0690
	Median	0.3850	0.1445	0.0570	-0.0065	0.2100	-0.0015
	SD	0.04950	0.23264	0.01838	0.03323	0.19181	0.16127
	(SE)	( 0.03500)	( 0.16450)	( 0.01300)	( 0.02350)	( 0.09590)	( 0.08064)
	Min,	0.350,	-0.020,	0.044,	-0.030,	0.044,	-0.030,
	Max	0.420	0.309	0.070	0.017	0.420	0.309
Week 88	n	2	2	2	2	4	4
	Mean	0.5145	0.2740	0.0300	-0.0335	0.2723	0.1203
	Median	0.5145	0.2740	0.0300	-0.0335	0.0490	-0.0070
	SD	0.64417	0.36204	0.01273	0.00212	0.46543	0.27425
	(SE)	( 0.45550)	( 0.25600)	( 0.00900)	( 0.00150)	( 0.23271)	( 0.13712)
	Min,	0.059,	0.018,	0.021,	-0.035,	0.021,	-0.035,
	Max	0.970	0.530	0.039	-0.032	0.970	0.530
Week 92	n	2	2	2	2	4	4
	Mean	0.3400	0.0995	0.1535	0.0900	0.2468	0.0948
	Median	0.3400	0.0995	0.1535	0.0900	0.1850	0.0995
	SD	0.29698	0.01485	0.12233	0.10748	0.21443	0.06288
	(SE)	( 0.21000)	( 0.01050)	( 0.08650)	( 0.07600)	( 0.10722)	( 0.03144)
	Min,	0.130,	0.089,	0.067,	0.014,	0.067,	0.014,
	Max	0.550	0.110	0.240	0.166	0.550	0.166

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 96	n	2	2	2	2	4	4
	Mean	0.7300	0.4895	0.0810	0.0175	0.4055	0.2535
	Median	0.7300	0.4895	0.0810	0.0175	0.1400	0.0930
	SD	0.80610	0.52397	0.05515	0.07000	0.59834	0.40916
	(SE)	( 0.57000)	( 0.37050)	( 0.03900)	( 0.04950)	( 0.29917)	( 0.20458)
	Min,	0.160,	0.119,	0.042,	-0.032,	0.042,	-0.032,
	Max	1.300	0.860	0.120	0.067	1.300	0.860
Week 100	n	2	2	2	2	4	4
	Mean	1.6000	1.3595	0.0790	0.0155	0.8395	0.6875
	Median	1.6000	1.3595	0.0790	0.0155	0.7550	0.4980
	SD	0.28284	0.56498	0.04384	0.02899	0.89356	0.84190
	(SE)	( 0.20000)	( 0.39950)	( 0.03100)	( 0.02050)	( 0.44678)	( 0.42095)
	Min,	1.400,	0.960,	0.048,	-0.005,	0.048,	-0.005,
	Max	1.800	1.759	0.110	0.036	1.800	1.759
Week 104	n	2	2	2	2	4	4
	Mean	0.1550	-0.0855	0.2550	0.1915	0.2050	0.0530
	Median	0.1550	-0.0855	0.2550	0.1915	0.2050	0.1475
	SD	0.02121	0.30335	0.02121	0.03606	0.06028	0.23808
	(SE)	( 0.01500)	( 0.21450)	( 0.01500)	( 0.02550)	( 0.03014)	( 0.11904)
	Min,	0.140,	-0.300,	0.240,	0.166,	0.140,	-0.300,
	Max	0.170	0.129	0.270	0.217	0.270	0.217

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 108	n	2	2	2	2	4	4
	Mean	0.5050	0.2645	0.4195	0.3560	0.4623	0.3103
	Median	0.5050	0.2645	0.4195	0.3560	0.5050	0.3275
	SD	0.30406	0.58619	0.55225	0.53740	0.36731	0.46217
	(SE)	( 0.21500)	( 0.41450)	( 0.39050)	( 0.38000)	( 0.18365)	( 0.23108)
	Min,	0.290,	-0.150,	0.029,	-0.024,	0.029,	-0.150,
	Max	0.720	0.679	0.810	0.736	0.810	0.736
Week 112	n	2	2	2	2	4	4
	Mean	0.2950	0.0545	0.0605	-0.0030	0.1778	0.0258
	Median	0.2950	0.0545	0.0605	-0.0030	0.1430	-0.0030
	SD	0.10607	0.38820	0.00778	0.02263	0.14866	0.22695
	(SE)	( 0.07500)	( 0.27450)	( 0.00550)	( 0.01600)	( 0.07433)	( 0.11347)
	Min,	0.220,	-0.220,	0.055,	-0.019,	0.055,	-0.220,
	Max	0.370	0.329	0.066	0.013	0.370	0.329
Week 116	n	2	2	2	2	4	4
	Mean	0.4850	0.2445	0.0760	0.0125	0.2805	0.1285
	Median	0.4850	0.2445	0.0760	0.0125	0.1950	0.0125
	SD	0.28991	0.57205	0.04808	0.06293	0.29077	0.35825
	(SE)	( 0.20500)	( 0.40450)	( 0.03400)	( 0.04450)	( 0.14539)	( 0.17912)
	Min,	0.280,	-0.160,	0.042,	-0.032,	0.042,	-0.160,
	Max	0.690	0.649	0.110	0.057	0.690	0.649

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point		Placebo to Eteplirsen					
		30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks	
		Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline
Week 120	n	2	2	2	2	4	4
	Mean	0.1950	-0.0455	0.4245	0.3610	0.3098	0.1578
	Median	0.1950	-0.0455	0.4245	0.3610	0.1950	0.0625
	SD	0.09192	0.19021	0.47447	0.45962	0.30889	0.37089
	(SE)	( 0.06500)	( 0.13450)	( 0.33550)	( 0.32500)	( 0.15445)	( 0.18544)
	Min,	0.130,	-0.180,	0.089,	0.036,	0.089,	-0.180,
	Max	0.260	0.089	0.760	0.686	0.760	0.686
Week 124	n	2	2	2	2	4	4
	Mean	0.4550	0.2145	0.0440	-0.0195	0.2495	0.0975
	Median	0.4550	0.2145	0.0440	-0.0195	0.2535	0.0220
	SD	0.02121	0.26092	0.03253	0.04738	0.23835	0.20419
	(SE)	( 0.01500)	( 0.18450)	( 0.02300)	( 0.03350)	( 0.11917)	( 0.10210)
	Min,	0.440,	0.030,	0.021,	-0.053,	0.021,	-0.053,
	Max	0.470	0.399	0.067	0.014	0.470	0.399
Week 128	n	2	2	2	2	4	4
	Mean	0.4100	0.1695	0.0985	0.0350	0.2543	0.1023
	Median	0.4100	0.1695	0.0985	0.0350	0.1000	0.0530
	SD	0.48083	0.19870	0.04455	0.05940	0.33177	0.14271
	(SE)	( 0.34000)	( 0.14050)	( 0.03150)	( 0.04200)	( 0.16589)	( 0.07136)
	Min,	0.070,	0.029,	0.067,	-0.007,	0.067,	-0.007,
	Max	0.750	0.310	0.130	0.077	0.750	0.310

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 132	n	2	2	2	2	4	4
	Mean	0.1340	-0.1065	0.0505	-0.0130	0.0923	-0.0598
	Median	0.1340	-0.1065	0.0505	-0.0130	0.0505	-0.0195
	SD	0.13576	0.14637	0.01768	0.03253	0.09259	0.10202
	(SE)	( 0.09600)	( 0.10350)	( 0.01250)	( 0.02300)	( 0.04629)	( 0.05101)
	Min,	0.038,	-0.210,	0.038,	-0.036,	0.038,	-0.210,
	Max	0.230	-0.003	0.063	0.010	0.230	0.010
Week 136	n	2	2	2	2	4	4
	Mean	0.5500	0.3095	0.0600	-0.0035	0.3050	0.1530
	Median	0.5500	0.3095	0.0600	-0.0035	0.3095	0.0825
	SD	0.04243	0.23971	0.05515	0.04031	0.28574	0.22880
	(SE)	( 0.03000)	( 0.16950)	( 0.03900)	( 0.02850)	( 0.14287)	( 0.11440)
	Min,	0.520,	0.140,	0.021,	-0.032,	0.021,	-0.032,
	Max	0.580	0.479	0.099	0.025	0.580	0.479
Week 140	n	2	2	2	2	4	4
	Mean	0.3100	0.0695	0.0445	-0.0190	0.1773	0.0253
	Median	0.3100	0.0695	0.0445	-0.0190	0.1240	0.0075
	SD	0.18385	0.09829	0.03323	0.04808	0.18743	0.08125
	(SE)	( 0.13000)	( 0.06950)	( 0.02350)	( 0.03400)	( 0.09372)	( 0.04063)
	Min,	0.180,	0.000,	0.021,	-0.053,	0.021,	-0.053,
	Max	0.440	0.139	0.068	0.015	0.440	0.139

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.1.2  
 Summary and Change from Baseline of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Time Point	Placebo to Eteplirsen						
	30 mg/kg		50 mg/kg		Eteplirsen for 160 Weeks		
	Observed	Change from Baseline	Observed	Change from Baseline	Observed	Change from Baseline	
Week 144	n	2	2	2	2	4	4
	Mean	0.7450	0.5045	0.1145	0.0510	0.4298	0.2778
	Median	0.7450	0.5045	0.1145	0.0510	0.2650	0.0510
	SD	0.50205	0.78418	0.03606	0.02121	0.46579	0.52315
	(SE)	( 0.35500)	( 0.55450)	( 0.02550)	( 0.01500)	( 0.23289)	( 0.26157)
	Min,	0.390,	-0.050,	0.089,	0.036,	0.089,	-0.050,
	Max	1.100	1.059	0.140	0.066	1.100	1.059

<sup>1</sup>Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_lab.sas, Date/time of run: 06APR2015: 9:25

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.2.1  
 Shift Table of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Treatment Group	Baseline (Pre-Dose)	Week 184		
		Low	Normal	High
Specific Gravity				
30 mg/kg (N=4)	Low	0	2 (50.0%)	0
	Normal	0	0	0
	High	0	0	0
50 mg/kg (N=4)	Low	0	0	0
	Normal	0	2 (50.0%)	0
	High	0	0	0
Eteplirsen for 184 Weeks (N=8)	Low	0	2 (25.0%)	0
	Normal	0	2 (25.0%)	0
	High	0	0	0

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sftlab.sas, Date/time of run: 06APR2015: 9:26  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.2.1  
 Shift Table of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Treatment Group	Baseline (Pre-Dose)	Week 184		
		Low	Normal	High
pH				
30 mg/kg (N=4)	Low	0	0	0
	Normal	0	4 (100.0%)	0
	High	0	0	0
50 mg/kg (N=4)	Low	0	0	0
	Normal	0	4 (100.0%)	0
	High	0	0	0
Eteplirsen for 184 Weeks (N=8)	Low	0	0	0
	Normal	0	8 (100.0%)	0
	High	0	0	0

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sftlab.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.2.2  
 Shift Table of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Treatment Group	Baseline (Pre-Dose)	Week 160		
		Low	Normal	High
Specific Gravity				
Placebo to 30 mg/kg (N=2)	Low	0	1 (50.0%)	0
	Normal	0	1 (50.0%)	0
	High	0	0	0
Placebo to 50 mg/kg (N=2)	Low	0	1 (50.0%)	0
	Normal	0	0	0
	High	0	0	0
Placebo to Eteplirsen for 160 Weeks (N=4)	Low	0	2 (50.0%)	0
	Normal	0	1 (25.0%)	0
	High	0	0	0

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sftlab.sas, Date/time of run: 06APR2015: 9:26

Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.2.2  
 Shift Table of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Treatment Group	Baseline (Pre-Dose)	Week 160		
		Low	Normal	High
pH				
Placebo to 30 mg/kg (N=2)	Low	0	0	0
	Normal	0	2 (100.0%)	0
	High	0	0	0
Placebo to 50 mg/kg (N=2)	Low	0	0	0
	Normal	0	1 (50.0%)	1 (50.0%)
	High	0	0	0
Placebo to Eteplirsen for 160 Weeks (N=4)	Low	0	0	0
	Normal	0	3 (75.0%)	1 (25.0%)
	High	0	0	0

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sftlab.sas, Date/time of run: 06APR2015: 9:26  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.3.1  
 Summary of Treatment Emergent Markedly Abnormal Results of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter (Units)	Pre-defined change from Baseline (pre-dose)	Visit	Eteplirsen		
			30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Specific Gravity	Decrease of 0.018 or more	Week 4	0	1 ( 25.0%)	1 ( 12.5%)
		Overall	0	1 ( 25.0%)	1 ( 12.5%)
Specific Gravity	Increase of 0.017 or more	Week 2	0	1 ( 25.0%)	1 ( 12.5%)
		Week 8	0	1 ( 25.0%)	1 ( 12.5%)
		Week 10	1 ( 25.0%)	0	1 ( 12.5%)
		Week 15	0	1 ( 25.0%)	1 ( 12.5%)
		Week 18	0	1 ( 25.0%)	1 ( 12.5%)
		Week 21	0	1 ( 25.0%)	1 ( 12.5%)
		Week 25	0	1 ( 25.0%)	1 ( 12.5%)
		Week 32	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
		Week 36	3 ( 75.0%)	2 ( 50.0%)	5 ( 62.5%)
		Week 40	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 44	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
		Week 48	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 52	0	1 ( 25.0%)	1 ( 12.5%)
		Week 56	1 ( 25.0%)	2 ( 50.0%)	3 ( 37.5%)
		Week 60	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
		Week 64	0	1 ( 25.0%)	1 ( 12.5%)
		Week 68	1 ( 25.0%)	2 ( 50.0%)	3 ( 37.5%)
		Week 72	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 76	0	1 ( 25.0%)	1 ( 12.5%)
		Week 80	0	1 ( 25.0%)	1 ( 12.5%)
Week 84	0	1 ( 25.0%)	1 ( 12.5%)		
Week 88	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)		
Week 92	0	2 ( 50.0%)	2 ( 25.0%)		
Week 96	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)		

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_ablab.sas, Date/time of run: 06APR2015: 9:22  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.3.1  
 Summary of Treatment Emergent Markedly Abnormal Results of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter (Units)	Pre-defined change from Baseline (pre-dose)	Visit	Eteplirsen		
			30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Specific Gravity	Increase of 0.017 or more	Week 100	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 104	0	2 ( 50.0%)	2 ( 25.0%)
		Week 108	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
		Week 112	0	1 ( 25.0%)	1 ( 12.5%)
		Week 120	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 124	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)
		Week 128	1 ( 25.0%)	2 ( 50.0%)	3 ( 37.5%)
		Week 132	0	1 ( 25.0%)	1 ( 12.5%)
		Week 136	1 ( 25.0%)	2 ( 50.0%)	3 ( 37.5%)
		Week 140	0	2 ( 50.0%)	2 ( 25.0%)
		Week 144	0	1 ( 25.0%)	1 ( 12.5%)
		Week 148	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
		Week 152	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 156	0	2 ( 50.0%)	2 ( 25.0%)
		Week 160	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)
		Week 164	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 168	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 172	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
		Week 176	2 ( 50.0%)	1 ( 25.0%)	3 ( 37.5%)
		Week 180	0	2 ( 50.0%)	2 ( 25.0%)
Week 184	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)		
		Overall	4 (100.0%)	2 ( 50.0%)	6 ( 75.0%)

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_ablab.sas, Date/time of run: 06APR2015: 9:22  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.3.1  
 Summary of Treatment Emergent Markedly Abnormal Results of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter (Units)	Pre-defined change from Baseline (pre-dose)	Visit	Eteplirsen			
			30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)	
pH	Decrease of 2.0 or more	Week 6	0	1 ( 25.0%)	1 ( 12.5%)	
		Week 15	0	1 ( 25.0%)	1 ( 12.5%)	
		Week 18	1 ( 25.0%)	0	1 ( 12.5%)	
		Week 21	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)	
		Week 24	1 ( 25.0%)	0	1 ( 12.5%)	
		Week 28	0	1 ( 25.0%)	1 ( 12.5%)	
		Overall	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)	
		Increase of 2.0 or more	Week 6	0	1 ( 25.0%)	1 ( 12.5%)
			Week 12	0	1 ( 25.0%)	1 ( 12.5%)
			Week 24	0	1 ( 25.0%)	1 ( 12.5%)
	Week 32		0	1 ( 25.0%)	1 ( 12.5%)	
	Week 36		0	1 ( 25.0%)	1 ( 12.5%)	
	Week 44		1 ( 25.0%)	0	1 ( 12.5%)	
	Week 52		0	1 ( 25.0%)	1 ( 12.5%)	
	Week 60		1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)	
	Week 64		1 ( 25.0%)	0	1 ( 12.5%)	
	Week 72		0	2 ( 50.0%)	2 ( 25.0%)	
	Week 80	1 ( 25.0%)	0	1 ( 12.5%)		
	Week 84	1 ( 25.0%)	0	1 ( 12.5%)		
	Week 92	1 ( 25.0%)	0	1 ( 12.5%)		
Week 100	1 ( 25.0%)	0	1 ( 12.5%)			
Week 116	0	1 ( 25.0%)	1 ( 12.5%)			
Week 128	1 ( 25.0%)	0	1 ( 12.5%)			
Week 136	1 ( 25.0%)	0	1 ( 12.5%)			
Week 152	0	1 ( 25.0%)	1 ( 12.5%)			
Week 168	0	1 ( 25.0%)	1 ( 12.5%)			

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_ablab.sas, Date/time of run: 06APR2015: 9:22  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.3.1  
 Summary of Treatment Emergent Markedly Abnormal Results of Quantitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter (Units)	Pre-defined change from Baseline (pre-dose)	Visit	Eteplirsen		
			30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
pH	Increase of 2.0 or more	Week 172	0	1 ( 25.0%)	1 ( 12.5%)
		Overall	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_ablab.sas, Date/time of run: 06APR2015: 9:22  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.1.3.2  
 Summary of Treatment Emergent Markedly Abnormal Results of Quantitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter (Units)	Pre-defined change from Baseline (pre-dose)	Visit	Placebo to Eteplirsen		
			30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Specific Gravity	Decrease of 0.018 or more	Week 104	1 ( 50.0%)	0	1 ( 25.0%)
		Week 180	1 ( 50.0%)	0	1 ( 25.0%)
		Overall	1 ( 50.0%)	0	1 ( 25.0%)
	Increase of 0.017 or more	Week 36	1 ( 50.0%)	0	1 ( 25.0%)
		Week 44	0	1 ( 50.0%)	1 ( 25.0%)
		Week 48	0	1 ( 50.0%)	1 ( 25.0%)
		Week 56	1 ( 50.0%)	0	1 ( 25.0%)
		Week 68	0	1 ( 50.0%)	1 ( 25.0%)
		Week 76	1 ( 50.0%)	0	1 ( 25.0%)
		Week 116	1 ( 50.0%)	0	1 ( 25.0%)
		Week 180	1 ( 50.0%)	0	1 ( 25.0%)
		Week 184	0	1 ( 50.0%)	1 ( 25.0%)
		Overall	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
pH	Decrease of 2.0 or more	No Subjects Met Criteria			
	Increase of 2.0 or more	Week 48	0	1 ( 50.0%)	1 ( 25.0%)
		Week 56	1 ( 50.0%)	0	1 ( 25.0%)
		Week 76	1 ( 50.0%)	0	1 ( 25.0%)
		Week 88	1 ( 50.0%)	0	1 ( 25.0%)
		Week 160	0	1 ( 50.0%)	1 ( 25.0%)
		Overall	1 ( 50.0%)	1 ( 50.0%)	2 ( 50.0%)

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_ablab.sas, Date/time of run: 06APR2015: 9:22  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Protein	mg/dL	Week 0	Negative	3 ( 75.0%)	3 ( 75.0%)	6 ( 75.0%)
			Trace	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)
		Week 1	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			30	0	1 ( 25.0%)	1 ( 12.5%)
		Week 2	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 4	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 6	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 8	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 10	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 12	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 15	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 16	30	0	1 ( 25.0%)	1 ( 12.5%)
Week 18	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)		
Week 21	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)		
Week 24	Negative	4 (100.0%)	2 ( 50.0%)	6 ( 75.0%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Protein	mg/dL	Week 24	Trace	0	2 ( 50.0%)	2 ( 25.0%)
		Week 25	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 28	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 32	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 36	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 40	Negative	3 ( 75.0%)	3 ( 75.0%)	6 ( 75.0%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
			1+	1 ( 25.0%)	0	1 ( 12.5%)
		Week 44	Negative	3 ( 75.0%)	4 (100.0%)	7 ( 87.5%)
			1+	1 ( 25.0%)	0	1 ( 12.5%)
Week 48	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)		
Week 52	Negative	3 ( 75.0%)	4 (100.0%)	7 ( 87.5%)		
	2+	1 ( 25.0%)	0	1 ( 12.5%)		
Week 56	Negative	3 ( 75.0%)	3 ( 75.0%)	6 ( 75.0%)		
	1+	1 ( 25.0%)	0	1 ( 12.5%)		
Week 58	Negative	1 ( 25.0%)	0	1 ( 12.5%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25

Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Protein	mg/dL	Week 60	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 64	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 68	Negative	4 (100.0%)	2 ( 50.0%)	6 ( 75.0%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
			1+	0	1 ( 25.0%)	1 ( 12.5%)
			2+	0	1 ( 25.0%)	1 ( 12.5%)
		Week 72	Negative	4 (100.0%)	2 ( 50.0%)	6 ( 75.0%)
			Trace	0	2 ( 50.0%)	2 ( 25.0%)
		Week 76	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
			1+	0	1 ( 25.0%)	1 ( 12.5%)
Week 80	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)		
Week 84	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)		
Week 88	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)		
	Trace	0	1 ( 25.0%)	1 ( 12.5%)		
Week 89	Negative	0	1 ( 25.0%)	1 ( 12.5%)		
Week 92	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Protein	mg/dL	Week 95	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 96	Negative	4 (100.0%)	2 ( 50.0%)	6 ( 75.0%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
			1+	0	1 ( 25.0%)	1 ( 12.5%)
		Week 97	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 99	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 100	Negative	3 ( 75.0%)	4 (100.0%)	7 ( 87.5%)
			Trace	1 ( 25.0%)	0	1 ( 12.5%)
		Week 104	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 108	Negative	2 ( 50.0%)	4 (100.0%)	6 ( 75.0%)
			1+	2 ( 50.0%)	0	2 ( 25.0%)
		Week 112	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 116	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 120	Negative	3 ( 75.0%)	3 ( 75.0%)	6 ( 75.0%)
Trace	1 ( 25.0%)		1 ( 25.0%)	2 ( 25.0%)		
Week 124	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)		
	Trace	0	1 ( 25.0%)	1 ( 12.5%)		
Week 128	Negative	2 ( 50.0%)	4 (100.0%)	6 ( 75.0%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Protein	mg/dL	Week 128	1+	2 ( 50.0%)	0	2 ( 25.0%)
		Week 132	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 136	Negative Trace	2 ( 50.0%) 2 ( 50.0%)	3 ( 75.0%) 1 ( 25.0%)	5 ( 62.5%) 3 ( 37.5%)
		Week 140	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 144	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 148	Negative Trace	2 ( 50.0%) 2 ( 50.0%)	2 ( 50.0%) 2 ( 50.0%)	4 ( 50.0%) 4 ( 50.0%)
		Week 152	Negative	2 ( 50.0%)	4 (100.0%)	6 ( 75.0%)
		Week 153	Negative	2 ( 50.0%)	0	2 ( 25.0%)
		Week 156	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 160	Negative Trace	4 (100.0%) 0	2 ( 50.0%) 2 ( 50.0%)	6 ( 75.0%) 2 ( 25.0%)
		Week 164	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen

Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25

Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen				
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)		
Urine Protein	mg/dL	Week 168	Negative	2 ( 50.0%)	2 ( 50.0%)	4 ( 50.0%)		
			Trace	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)		
			1+	1 ( 25.0%)	1 ( 25.0%)	2 ( 25.0%)		
		Week 172	Negative	4 (100.0%)	2 ( 50.0%)	6 ( 75.0%)		
			Trace	0	1 ( 25.0%)	1 ( 12.5%)		
			1+	0	1 ( 25.0%)	1 ( 12.5%)		
		Week 176	Negative	3 ( 75.0%)	4 (100.0%)	7 ( 87.5%)		
			Trace	1 ( 25.0%)	0	1 ( 12.5%)		
		Week 180	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)		
			Trace	0	1 ( 25.0%)	1 ( 12.5%)		
		Week 184	Negative	4 (100.0%)	2 ( 50.0%)	6 ( 75.0%)		
			Trace	0	2 ( 50.0%)	2 ( 25.0%)		
		Urine Glucose	mg/dL	Week 0	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
				Week 1	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
				Week 2	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
Week 4	Negative			4 (100.0%)	4 (100.0%)	8 (100.0%)		
Week 6	Negative			4 (100.0%)	4 (100.0%)	8 (100.0%)		
Week 8	Negative			4 (100.0%)	4 (100.0%)	8 (100.0%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Glucose	mg/dL	Week 10	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 12	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 15	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 16	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 18	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 21	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 24	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 25	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 28	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 32	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 36	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 40	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 44	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 48	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 52	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Glucose	mg/dL	Week 56	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
		Week 58	Negative	1 ( 25.0%)	0	1 ( 12.5%)
		Week 60	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 64	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 68	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 72	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 76	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 80	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 84	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 88	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 89	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 92	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 95	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 96	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 97	Negative	0	1 ( 25.0%)	1 ( 12.5%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Glucose	mg/dL	Week 99	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 100	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 104	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 108	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 112	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 116	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 120	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 124	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 128	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 132	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 136	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 140	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 144	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 148	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
Week 152	Negative	2 ( 50.0%)	4 (100.0%)	6 ( 75.0%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Glucose	mg/dL	Week 153	Negative	2 ( 50.0%)	0	2 ( 25.0%)
		Week 156	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 160	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 164	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 168	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 172	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 176	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 180	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 184	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
Urine Ketones	mg/dL	Week 0	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 1	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 2	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 4	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 6	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Ketones	mg/dL	Week 8	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 10	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 12	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 15	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 16	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 18	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 21	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 24	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 25	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 28	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 32	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 36	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 40	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 44	Negative 1+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Ketones	mg/dL	Week 48	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 52	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 56	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
		Week 58	Negative	1 ( 25.0%)	0	1 ( 12.5%)
		Week 60	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 64	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 68	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 72	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 76	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 80	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 84	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 88	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 89	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 92	Negative Trace	3 ( 75.0%) 1 ( 25.0%)	4 (100.0%) 0	7 ( 87.5%) 1 ( 12.5%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Ketones	mg/dL	Week 95	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 96	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 97	1+	0	1 ( 25.0%)	1 ( 12.5%)
		Week 99	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 100	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 104	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 108	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 112	Negative 1+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 116	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 120	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 124	Negative 1+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 128	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 132	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 136	Negative	3 ( 75.0%)	4 (100.0%)	7 ( 87.5%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Ketones	mg/dL	Week 136	Trace	1 ( 25.0%)	0	1 ( 12.5%)
		Week 140	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 144	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 148	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 152	Negative	2 ( 50.0%)	4 (100.0%)	6 ( 75.0%)
		Week 153	Negative	2 ( 50.0%)	0	2 ( 25.0%)
		Week 156	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 160	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
			Trace	0	1 ( 25.0%)	1 ( 12.5%)
		Week 164	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 168	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 172	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
Week 176	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)		
Week 180	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)		
	1+	0	1 ( 25.0%)	1 ( 12.5%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Ketones	mg/dL	Week 184	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
Urine Hemoglobin		Week 0	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 1	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 2	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 4	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 6	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 8	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 10	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 12	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 15	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 16	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 18	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 21	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 24	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Hemoglobin		Week 25	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 28	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 32	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 36	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 40	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 44	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 48	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 52	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 56	Negative	4 (100.0%)	3 ( 75.0%)	7 ( 87.5%)
		Week 58	Negative	1 ( 25.0%)	0	1 ( 12.5%)
		Week 60	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 64	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 68	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 72	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Hemoglobin		Week 76	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 80	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 84	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 88	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 89	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 92	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 95	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 96	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 97	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 99	Negative	0	1 ( 25.0%)	1 ( 12.5%)
		Week 100	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 104	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 108	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 112	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Hemoglobin		Week 116	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 120	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 124	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 128	Negative 1+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 132	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 136	Negative 1+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 140	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 144	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 148	Negative 1+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 152	Negative 1+	2 ( 50.0%) 0	3 ( 75.0%) 1 ( 25.0%)	5 ( 62.5%) 1 ( 12.5%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.1  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Eteplirsen		
				30 mg/kg (N=4)	50 mg/kg (N=4)	Eteplirsen for 184 Weeks (N=8)
Urine Hemoglobin		Week 153	Negative	2 ( 50.0%)	0	2 ( 25.0%)
		Week 156	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 160	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 164	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 168	Negative Trace	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 172	Negative 1+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 176	Negative 2+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)
		Week 180	Negative	4 (100.0%)	4 (100.0%)	8 (100.0%)
		Week 184	Negative 1+	4 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)	7 ( 87.5%) 1 ( 12.5%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Protein	mg/dL	Week 0	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
			Trace	1 ( 50.0%)	0	1 ( 25.0%)
		Week 1	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 2	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 4	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 6	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 8	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
			30	1 ( 50.0%)	0	1 ( 25.0%)
		Week 10	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
			Trace	1 ( 50.0%)	0	1 ( 25.0%)
		Week 12	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 15	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
			Trace	1 ( 50.0%)	0	1 ( 25.0%)
		Week 18	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
Trace	1 ( 50.0%)		0	1 ( 25.0%)		
Week 21	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)		
Week 24	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Protein	mg/dL	Week 25	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 28	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 32	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 36	Negative Trace	1 ( 50.0%) 1 ( 50.0%)	2 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)
		Week 40	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 44	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 48	Negative Trace	2 (100.0%) 0	1 ( 50.0%) 1 ( 50.0%)	3 ( 75.0%) 1 ( 25.0%)
		Week 52	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 56	Negative Trace	1 ( 50.0%) 1 ( 50.0%)	2 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)
		Week 60	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 63	Negative	1 ( 50.0%)	0	1 ( 25.0%)
		Week 64	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
		Week 68	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Protein	mg/dL	Week 72	Negative	1 ( 50.0%)	0	1 ( 25.0%)
			Trace	1 ( 50.0%)	0	1 ( 25.0%)
		Week 73	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 74	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 76	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 77	Negative	1 ( 50.0%)	0	1 ( 25.0%)
		Week 80	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 84	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
			Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
		Week 88	Trace	1 ( 50.0%)	0	1 ( 25.0%)
			Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 92	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 96	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
			Trace	1 ( 50.0%)	0	1 ( 25.0%)
Week 100	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)		
Week 104	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)		
Week 108	Negative	2 (100.0%)	1 ( 50.0%)	3 ( 75.0%)		
	Trace	0	1 ( 50.0%)	1 ( 25.0%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Protein	mg/dL	Week 112	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 116	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 120	Negative	2 (100.0%)	1 ( 50.0%)	3 ( 75.0%)
			Trace	0	1 ( 50.0%)	1 ( 25.0%)
		Week 124	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 128	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 131	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 132	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
			Trace	1 ( 50.0%)	0	1 ( 25.0%)
		Week 135	1+	0	1 ( 50.0%)	1 ( 25.0%)
		Week 136	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
			Trace	1 ( 50.0%)	0	1 ( 25.0%)
		Week 140	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 144	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
Week 148	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)		
Week 152	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)		

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Protein	mg/dL	Week 156	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 159	Trace	0	1 ( 50.0%)	1 ( 25.0%)
		Week 160	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 164	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 168	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 172	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 176	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 180	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 184	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
Urine Glucose	mg/dL	Week 0	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 1	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 2	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 4	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 6	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 8	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Glucose	mg/dL	Week 10	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 12	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 15	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 18	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 21	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 24	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 25	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 28	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 32	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 36	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 40	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 44	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 48	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 52	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 56	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsén for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsén		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsén for 160 Weeks (N=4)
Urine Glucose	mg/dL	Week 60	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 63	Negative	1 ( 50.0%)	0	1 ( 25.0%)
		Week 64	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
		Week 68	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 72	Negative	2 (100.0%)	0	2 ( 50.0%)
		Week 73	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 74	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 76	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 77	Negative	1 ( 50.0%)	0	1 ( 25.0%)
		Week 80	Negative Trace	2 (100.0%) 0	1 ( 50.0%) 1 ( 50.0%)	3 ( 75.0%) 1 ( 25.0%)
		Week 84	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 88	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 92	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 96	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsén  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Glucose	mg/dL	Week 100	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 104	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 108	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 112	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 116	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 120	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 124	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 128	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 131	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 132	Negative 2+	2 (100.0%) 0	1 ( 50.0%) 1 ( 50.0%)	3 ( 75.0%) 1 ( 25.0%)
		Week 135	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 136	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 140	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 144	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Glucose	mg/dL	Week 148	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 152	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 156	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 159	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 160	Negative	2 (100.0%)	1 ( 50.0%)	3 ( 75.0%)
			Trace	0	1 ( 50.0%)	1 ( 25.0%)
		Week 164	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 168	Negative	2 (100.0%)	1 ( 50.0%)	3 ( 75.0%)
			Trace	0	1 ( 50.0%)	1 ( 25.0%)
		Week 172	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 176	Negative	2 (100.0%)	1 ( 50.0%)	3 ( 75.0%)
			Trace	0	1 ( 50.0%)	1 ( 25.0%)
		Week 180	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
Week 184	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)		
Urine Ketones	mg/dL	Week 0	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 1	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Ketones	mg/dL	Week 2	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 4	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 6	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 8	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 10	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 12	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 15	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 18	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 21	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 24	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 25	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 28	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 32	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 36	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 40	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Ketones	mg/dL	Week 44	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 48	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 52	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 56	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 60	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 63	Negative	1 ( 50.0%)	0	1 ( 25.0%)
		Week 64	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
		Week 68	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 72	Negative	2 (100.0%)	0	2 ( 50.0%)
		Week 73	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 74	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 76	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 77	Negative	1 ( 50.0%)	0	1 ( 25.0%)
		Week 80	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 84	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Ketones	mg/dL	Week 88	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 92	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 96	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 100	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 104	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 108	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 112	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 116	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 120	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 124	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 128	Negative Trace	1 ( 50.0%) 1 ( 50.0%)	2 (100.0%) 0	3 ( 75.0%) 1 ( 25.0%)
		Week 131	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 132	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 135	Negative	0	1 ( 50.0%)	1 ( 25.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Ketones	mg/dL	Week 136	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 140	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 144	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 148	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 152	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 156	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 159	Negative	0	1 (50.0%)	1 (25.0%)
		Week 160	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 164	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 168	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 172	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 176	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 180	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 184	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
Urine Hemoglobin		Week 0	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/Time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Hemoglobin		Week 1	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 2	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 4	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 6	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 8	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 10	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 12	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 15	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 18	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 21	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 24	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 25	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 28	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 32	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 36	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4



Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Hemoglobin		Week 40	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 44	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 48	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 52	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 56	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 60	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 63	Negative	1 ( 50.0%)	0	1 ( 25.0%)
		Week 64	Negative	1 ( 50.0%)	2 (100.0%)	3 ( 75.0%)
		Week 68	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 72	Negative	2 (100.0%)	0	2 ( 50.0%)
		Week 73	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 74	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 76	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 77	Negative	1 ( 50.0%)	0	1 ( 25.0%)
		Week 80	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Hemoglobin		Week 84	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 88	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 92	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 96	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 100	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 104	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 108	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 112	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 116	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 120	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 124	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 128	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 131	Negative	0	1 ( 50.0%)	1 ( 25.0%)
		Week 132	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 135	Negative	0	1 ( 50.0%)	1 ( 25.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.1.2  
 Summary of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Parameter	Unit	Time Point	Result	Placebo to Eteplirsen		
				30 mg/kg (N=2)	50 mg/kg (N=2)	Eteplirsen for 160 Weeks (N=4)
Urine Hemoglobin		Week 136	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 140	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 144	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 148	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 152	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 156	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 159	Negative	0	1 (50.0%)	1 (25.0%)
		Week 160	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 164	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 168	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 172	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 176	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 180	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)
		Week 184	Negative	2 (100.0%)	2 (100.0%)	4 (100.0%)

Baseline is the last non-missing assessment prior to dosing with Eteplirsen  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_purin.sas, Date/time of run: 06APR2015: 9:25  
 Reference listing: 16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.2.1  
 Shift Table of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Treatment Group	Baseline (Pre-Dose)	Week 184	
		Normal	Abnormal
Urine Protein (mg/dL)			
30 mg/kg (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0
50 mg/kg (N=4)	Normal	3 (75.0%)	0
	Abnormal	1 (25.0%)	0
Eteplirsen for 184 Weeks (N=8)	Normal	7 (87.5%)	0
	Abnormal	1 (12.5%)	0
Urine Glucose (mg/dL)			
30 mg/kg (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0
50 mg/kg (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0
Eteplirsen for 184 Weeks (N=8)	Normal	8 (100.0%)	0
	Abnormal	0	0

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sftpurin.sas, Date/time of run: 06APR2015: 9:26  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.2.1  
 Shift Table of Qualitative Urinalysis Laboratory Parameters  
 Eteplirsen for 184 Weeks  
 Safety Population

Treatment Group	Baseline (Pre-Dose)	Week 184	
		Normal	Abnormal
Urine Ketones (mg/dL)			
30 mg/kg (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0
50 mg/kg (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0
Eteplirsen for 184 Weeks (N=8)	Normal	8 (100.0%)	0
	Abnormal	0	0
Urine Hemoglobin			
30 mg/kg (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0
50 mg/kg (N=4)	Normal	3 (75.0%)	1 (25.0%)
	Abnormal	0	0
Eteplirsen for 184 Weeks (N=8)	Normal	7 (87.5%)	1 (12.5%)
	Abnormal	0	0

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sftpurin.sas, Date/time of run: 06APR2015: 9:26  
 Reference listing: L.16.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.2.2  
 Shift Table of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Treatment Group	Baseline (Pre-Dose)	Week 160	
		Normal	Abnormal
Urine Protein (mg/dL)			
Placebo to 30 mg/kg (N=2)	Normal	2 (100.0%)	0
	Abnormal	0	0
Placebo to 50 mg/kg (N=2)	Normal	2 (100.0%)	0
	Abnormal	0	0
Placebo to Eteplirsen for 160 Weeks (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0
Urine Glucose (mg/dL)			
Placebo to 30 mg/kg (N=2)	Normal	2 (100.0%)	0
	Abnormal	0	0
Placebo to 50 mg/kg (N=2)	Normal	2 (100.0%)	0
	Abnormal	0	0
Placebo to Eteplirsen for 160 Weeks (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sftpurin.sas, Date/time of run: 06APR2015: 9:26  
 Reference listing: L.1b.2.8.1.1.4

Sarepta, Inc.  
 4658-us-201 & 4658-us-202  
 Week 185 Safety Analysis

Table 14.3.4.4.2.2.2  
 Shift Table of Qualitative Urinalysis Laboratory Parameters  
 Placebo to Eteplirsen for 160 Weeks  
 Safety Population

Treatment Group	Baseline (Pre-Dose)	Week 160	
		Normal	Abnormal
Urine Ketones (mg/dL)			
Placebo to 30 mg/kg (N=2)	Normal	2 (100.0%)	0
	Abnormal	0	0
Placebo to 50 mg/kg (N=2)	Normal	2 (100.0%)	0
	Abnormal	0	0
Placebo to Eteplirsen for 160 Weeks (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0
Urine Hemoglobin			
Placebo to 30 mg/kg (N=2)	Normal	2 (100.0%)	0
	Abnormal	0	0
Placebo to 50 mg/kg (N=2)	Normal	2 (100.0%)	0
	Abnormal	0	0
Placebo to Eteplirsen for 160 Weeks (N=4)	Normal	4 (100.0%)	0
	Abnormal	0	0

Baseline is the last non-missing assessment prior to dosing with Eteplirsen.  
 Source: P:\Sarepta\DMD\202\Programs\Analysis\Production\Tables\t\_sftpurin.sas, Date/time of run: 06APR2015: 9:26  
 Reference listing: L.16.2.8.1.1.4

FULLY REDACTED PAGES WITHHELD IN FULL FOLLOWING THIS PAGE. SEE BATES-NUMBERS ON BOTTOM OF PAGES TO IDENTIFY RANGE OF PAGES WITHHELD IN FULL.